RESULT_COUNT: 2302,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
LLY,LLY:US,BBG000BNBDC2,Governor says change-resistant Indiana should think globally,2017-10-21 13:56:56 +0000,http://finance.yahoo.com/r/3bf6cbde-b153-3ab2-9296-6ab9631e9a96/governor-says-change-resistant-indiana-135458899.html?.tsrc=rss,"INDIANAPOLIS (AP) — Factory work dwindled as companies moved operations overseas. Indiana, a manufacturing powerhouse where you once could get a good-paying job even without a high school education, was falling behind."
LLY,LLY:US,BBG000BNBDC2,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday,2017-10-20 17:44:55 +0000,https://finance.yahoo.com/news/upcoming-earnings-heavy-equipment-maker-174455532.html?.tsrc=rss,The earnings parade continues with Caterpillar Inc. (NYSE: CAT ) and Eli Lilly & Co (NYSE: LLY ) scheduled to report early next week. Both companies are expected to release results before market open on ...
LLY,LLY:US,BBG000BNBDC2,Earnings Preview: Caterpillar And Eli Lilly Report on Tuesday,2017-10-20 17:17:00 +0000,http://finance.yahoo.com/r/b2b766f4-30a4-3274-8727-6e832390a006/earnings-preview-caterpillar-and-eli-lilly-report-on-tuesday?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Heavy-equipment maker Caterpillar and pharma company Eli Lilly & Co. report earnings before the open on Tues., Oct. 24. Here’s a look at what might be expected."
LLY,LLY:US,BBG000BNBDC2,iShares U.S. Healthcare ETF Experiences Big Inflow,2017-10-20 16:02:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OF0xHcg09LQ/ishares-us-healthcare-etf-experiences-big-inflow-cm862600,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 52 8 million dollar inflow that s a 2 4 increase week over week in
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling",2017-10-20 15:14:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-gagVZGWJ0M/pharma-stock-roundup-beat-raise-quarter-from-jj-allergan-hit-by-restasis-ruling-cm862525,Johnson amp Johnson JNJ kicked off third quarter earnings season for the pharmaceutical sector on a strong note with the company beating on both earnings and revenues While focus remained on J amp J s strong earnings results companies like Allergan AGN were also in the news regarding
LLY,LLY:US,BBG000BNBDC2,Featured Company News - Eli Lilly Joins Hands with Germany's CureVac To Develop Cancer Vaccines Using mRNA Technology,2017-10-20 11:00:00 +0000,https://finance.yahoo.com/news/featured-company-news-eli-lilly-110000019.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Eli Lilly and Co. (NYSE: LLY ), following which we have published ..."
LLY,LLY:US,BBG000BNBDC2,China Biotech Promise Struggles to Keep Foreign Innovators,2017-10-19 21:00:01 +0000,http://finance.yahoo.com/r/ce149f4c-17cc-3252-86a1-69dd10196b1f/china-s-biotech-promise-is-struggling-to-keep-foreign-innovators?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back."
LLY,LLY:US,BBG000BNBDC2,"Ken Langone on Black Monday Crash, Regulatory Landscape",2017-10-19 18:13:12 +0000,https://finance.yahoo.com/video/ken-langone-black-monday-crash-181312938.html?.tsrc=rss,"Oct.19 -- Ken Langone, chairman at Invemed Associates and co-founder at Home Depot, recounts his experience during the Black Monday market crash in 1987 and the future of financial regulation. He speaks with Bloomberg's Jason Kelly from the Robin Hood Investors Conference on &quot;Bloomberg Markets.&quot;"
LLY,LLY:US,BBG000BNBDC2,Teva Submits BLA to FDA for Migraine Candidate Fremanezumab,2017-10-19 15:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TSq-mlfqWs/teva-submits-bla-to-fda-for-migraine-candidate-fremanezumab-cm861987,Teva Pharmaceutical Industries Ltd TEVA announced the submission of a biologics license application BLA to the FDA seeking approval for its monoclonal antibody candidate fremanezumab as a preventive treatment for migraine The BLA submission was supported by positive data from two
LLY,LLY:US,BBG000BNBDC2,Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?,2017-10-19 15:48:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaIZlcm4bl8/can-immunogens-key-pipeline-cancer-candidate-drive-growth-cm861945,On Oct 18 2017 we issued an updated report on ImmunoGen Inc IMGN ImmunoGen is a development stage biotechnology company focused on developing targeted cancer therapeutics using its proprietary antibody drug conjugate ADC technology ImmunoGen has made significant progress with
LLY,LLY:US,BBG000BNBDC2,Novartis Reports Positive Results on Thrombocytopenia Drug,2017-10-19 14:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7zIrLHnOVhE/novartis-reports-positive-results-on-thrombocytopenia-drug-cm861901,Novartis AG NVS announced encouraging results on Revolade from the EXTEND study The open label extension study from four trials TRA100773A TRA100773B TRA102537 RAISE and TRA108057 REPEAT showed long term disease control in chronic persistent immune thrombocytopenia ITP patients
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug,2017-10-19 07:32:41 +0000,https://finance.yahoo.com/news/novo-nordisk-takes-aim-eli-073241119.html?.tsrc=rss,"WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo  Nordisk will take aim at Eli Lilly in the  growing diabetes market after an advisory panel to the U.S. Food  and Drug Administration (FDA) gave the green light to its  semaglutide drug.  Shares in Novo Nordisk rose almost 3 percent in early  trading on Thursday, after the panel late on Wednesday concluded  semaglutide is effective, reasonably safe and should be approved  by the FDA.  The panel voted 16-0 with one abstention in favor of the  drug being approved."
LLY,LLY:US,BBG000BNBDC2,What to Expect from Big Pharmas After J&J's Solid Q3 Results?,2017-10-18 22:52:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e4YHAAqtt4s/what-to-expect-from-big-pharmas-after-jjs-solid-q3-results-cm861641,Johnson amp Johnson JNJ was the first large cap pharma stock to report its earnings results for this season on Oct 17 J amp J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook Shares of J amp J were up
LLY,LLY:US,BBG000BNBDC2,What to Expect from Big Pharmas After J&J&apos;s Solid Q3 Results?,2017-10-18 20:21:08 +0000,https://finance.yahoo.com/news/expect-big-pharmas-j-j-202108992.html?.tsrc=rss,"Large-cap pharmas are expected to report encouraging third-quarter results, following J&J&apos;s earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter."
LLY,LLY:US,BBG000BNBDC2,Behind Eli Lilly’s Performance in 3Q17,2017-10-18 14:39:48 +0000,http://finance.yahoo.com/r/823206b4-a435-3f39-9b7d-6d5bee0a41d0/behind-eli-lillys-performance-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,LLY stock rose ~4.5% in 3Q17 and has risen 17.7% YTD (year-to-date) as of October 16.
LLY,LLY:US,BBG000BNBDC2,Understanding Eli Lilly’s Position in Neurology Drugs after 1H17,2017-10-18 14:37:25 +0000,http://finance.yahoo.com/r/5bb0872e-72fc-350b-b7a8-a4579329c271/understanding-eli-lillys-position-in-neurology-drugs-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly's (LLY) Cymbalta reported revenues of around $381.2 million, compared with $435.2 million in 1H16."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?,2017-10-18 13:54:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5bnIzrtRjhE/eli-lilly-lly-to-report-q3-earnings-whats-in-store-cm861192,Eli Lilly and Company LLY will report third quarter 2017 results on Oct 24 before the market opens Last quarter the company delivered a positive earnings surprise of 6 73 Lilly s shares have risen 17 this year so far while the industry recorded an increase of 18 2 Lilly
LLY,LLY:US,BBG000BNBDC2,Inside Eli Lilly’s Endocrinology Franchise Positioned after 1H17,2017-10-18 13:06:57 +0000,http://finance.yahoo.com/r/d790a50a-4bf3-3feb-b35d-2246de1fde78/inside-eli-lillys-endocrinology-franchise-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly’s (LLY) Humalog reported revenues of around $1.39 million, compared with $1.31 million in 1H16."
LLY,LLY:US,BBG000BNBDC2,10 Stunning Numbers You Need to Know About Breast Cancer,2017-10-18 12:33:00 +0000,https://finance.yahoo.com/news/10-stunning-numbers-know-breast-123300002.html?.tsrc=rss,There&apos;s more good news than you might think.
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-10-18 12:01:14 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120114340.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) to Report Q3 Earnings: What&apos;s in Store?,2017-10-18 11:42:11 +0000,https://finance.yahoo.com/news/eli-lilly-lly-report-q3-114211489.html?.tsrc=rss,"Eli Lilly and Company&apos;s (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let&apos;s see if these along with its older products lead the company to an earnings beat."
LLY,LLY:US,BBG000BNBDC2,"Why Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018",2017-10-18 11:36:54 +0000,http://finance.yahoo.com/r/f4e3d9b2-dc33-3c7b-88e6-9bbc303e61cb/why-eli-lillys-basaglar-jardiance-and-trajenta-could-witness-steady-growth-in-2018?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly's (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to collaborate with Germany's CureVac on cancer vaccines,2017-10-18 10:45:30 +0000,https://finance.yahoo.com/news/eli-lilly-collaborate-germanys-curevac-104530407.html?.tsrc=rss,"U.S. drugmaker Eli Lilly and Co  said on Wednesday it will collaborate with CureVac AG on  development of up to five immunotherapy cancer vaccines using  the German company's messenger RNA (mRNA) technology.  Under terms of the deal, CureVac will receive $50 million up  front and Lilly will take an equity stake in CureVac worth about  $53 million (45 million euros)."
LLY,LLY:US,BBG000BNBDC2,Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines,2017-10-18 10:45:00 +0000,https://finance.yahoo.com/news/lilly-curevac-announce-global-collaboration-104500058.html?.tsrc=rss,"INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology.  The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response."
LLY,LLY:US,BBG000BNBDC2,Wall Street Poised To Surge At Opening,2017-10-18 07:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aSLuV89Xm-8/wall-street-poised-to-surge-at-opening-20171018-00435,Wall Street Poised To Surge At Opening
LLY,LLY:US,BBG000BNBDC2,"Lilly, CureVac In Global Collaboration To Develop MRNA Cancer Vaccines",2017-10-18 07:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qvMG2CGYnec/lilly-curevac-in-global-collaboration-to-develop-mrna-cancer-vaccines-20171018-00345,"Lilly, CureVac In Global Collaboration To Develop MRNA Cancer Vaccines"
LLY,LLY:US,BBG000BNBDC2,3 Things You Won't Learn by Focusing on Johnson & Johnson's Headline Figures in Its Q3 Report,2017-10-18 02:49:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qP9oevea42Q/3-things-you-wont-learn-by-focusing-on-johnson-johnsons-headline-figures-in-its-q3-report-cm861080,Johnson amp Johnson NYSE JNJ often kicks things off for the healthcare sector with the release of its quarterly earnings and once again the largest healthcare company by market cap surpassed Wall Street s loftiest expectations Johnson amp Johnson s Q3 by the
LLY,LLY:US,BBG000BNBDC2,Trump favors ex-pharma executive Azar for health secretary -Politico,2017-10-17 22:27:54 +0000,https://finance.yahoo.com/news/trump-favors-ex-pharma-executive-222754238.html?.tsrc=rss,"U.S. President Donald Trump is leaning toward naming former pharmaceutical industry executive Alex Azar as his pick to lead the Department of Health and Human Services, Politico reported on Tuesday, citing ..."
LLY,LLY:US,BBG000BNBDC2,This hot trade is about to get even hotter: Trader,2017-10-17 21:00:00 +0000,https://finance.yahoo.com/video/hot-trade-even-hotter-trader-210000526.html?.tsrc=rss,The “Fast Money” traders discuss the health care sector seeing a pop and where it could go from here.
LLY,LLY:US,BBG000BNBDC2,How Allergan's 'Public Relations Backlash' Deepened This Week,2017-10-17 20:50:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MS0e4TAnYTc/how-allergans-public-relations-backlash-deepened-this-week-cm860847,Allergan AGN was already facing a public relations backlash after transferring patent rights for its Restasis eye medication to a Native American tribe when a judge on Monday then invalidated four of those patents ibd display video id 2326965 width 50 float
LLY,LLY:US,BBG000BNBDC2,"Daily Dividend Report: CTAS, CIT, LLY, MS, SO, LLL",2017-10-17 18:49:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cIhs7jFj9io/daily-dividend-report-ctas-cit-lly-ms-so-lll-cm860874,Cintas Corporation CTAS approved a 1 62 per share annual dividend at its meeting today representing a 21 8 increase over last year s annual dividend of 1 33 per share This dividend is payable on December 8 2017 to shareholders of record as of November 10 2017 CIT Group
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly’s Taltz Is Positioned after 1H17,2017-10-17 14:36:48 +0000,http://finance.yahoo.com/r/5220c9c8-e9d1-3044-aa3d-5d50fd3b5093/how-eli-lillys-taltz-is-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly’s (LLY) Taltz reported revenues of ~$235.3 million, compared with $19.3 million in 1H16."
LLY,LLY:US,BBG000BNBDC2,Positioning Eli Lilly’s Cardiovascular Franchise Positioned after 1H17,2017-10-17 13:07:02 +0000,http://finance.yahoo.com/r/c056958f-7c8c-39f4-814a-9a4d2c016145/positioning-eli-lillys-cardiovascular-franchise-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly’s (LLY) Adcirca reported revenues of around $43.9 million, compared with $41.1 million in 1H16."
LLY,LLY:US,BBG000BNBDC2,Lilly Declares Fourth-Quarter 2017 Dividend,2017-10-16 18:45:00 +0000,https://finance.yahoo.com/news/lilly-declares-fourth-quarter-2017-184500200.html?.tsrc=rss,"INDIANAPOLIS , Oct. 16, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding common ..."
LLY,LLY:US,BBG000BNBDC2,The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad,2017-10-16 14:58:00 +0000,http://finance.yahoo.com/r/f26f5cf6-5eba-3c51-bb21-d0403b473077/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny."
LLY,LLY:US,BBG000BNBDC2,This Could Be Eli Lilly’s Long-Term Growth Driver,2017-10-16 14:38:27 +0000,http://finance.yahoo.com/r/27b94a56-346f-39af-95b7-007ea66d3003/this-could-be-eli-lillys-long-term-growth-driver?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines."
LLY,LLY:US,BBG000BNBDC2,Inside Eli Lilly’s Oncology Portfolio: Key Updates,2017-10-16 13:07:56 +0000,http://finance.yahoo.com/r/7a82a839-7dcf-33b5-9a7a-7405bde76982/inside-eli-lillys-oncology-portfolio-key-updates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly’s (LLY) Alimta reported revenues of around $1.0 billion, compared with $1.2 billion in 1H16."
LLY,LLY:US,BBG000BNBDC2,Gauging Eli Lilly’s Position with Cyramza after 1H17,2017-10-16 11:38:46 +0000,http://finance.yahoo.com/r/c72ca071-c89c-3b39-8062-03811530b34f/gauging-eli-lillys-position-with-cyramza-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly’s (LLY) Cyramza reported revenues of around $357.5 million, compared with $278.0 million in 1H16."
LLY,LLY:US,BBG000BNBDC2,Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis,2017-10-16 10:45:00 +0000,https://finance.yahoo.com/news/rapidly-progressing-advanced-non-small-104500150.html?.tsrc=rss,"Data presented at 18th World Conference on Lung Cancer INDIANAPOLIS , Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA ® (ramucirumab) ..."
LLY,LLY:US,BBG000BNBDC2,5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings,2017-10-13 20:14:08 +0000,https://finance.yahoo.com/news/5-large-cap-drug-stocks-201408113.html?.tsrc=rss,The pharma/biotech sector has a number of things going in its favor.
LLY,LLY:US,BBG000BNBDC2,This Could Boost Eli Lilly’s Revenue Growth in 2018,2017-10-13 19:06:25 +0000,http://finance.yahoo.com/r/d65abf1b-17a1-3678-bfbe-9a010a2b5e61/this-could-boost-eli-lillys-revenue-growth-in-2018?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In September, the FDA approved Eli Lilly's (LLY) Verzenio-fulvestrant combination therapy for the treatment of women with hormone receptor-positive or HR+."
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly Is Positioned after 1H17,2017-10-13 17:35:56 +0000,http://finance.yahoo.com/r/5d16a26c-fe91-37e0-9e9d-0a73070399dd/how-eli-lilly-is-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Eli Lilly (LLY) generated revenues of around $11.0 billion, compared with $10.3 billion in 1H16."
LLY,LLY:US,BBG000BNBDC2,Cancer Space Update: Lung & Breast Cancer Studies in Focus,2017-10-13 17:12:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICWbxtpsd28/cancer-space-update-lung-breast-cancer-studies-in-focus-cm859512,Major news in the cancer segment this week was the failure of Eli Lilly and Company s LLY newly approved breast cancer drug Verzenio in a pivotal lung cancer study With this latest failure Lilly joins the list of large pharma companies who have failed in their respective lung cancer
LLY,LLY:US,BBG000BNBDC2,Behind Eli Lilly’s October Analyst Recommendations,2017-10-13 15:42:53 +0000,http://finance.yahoo.com/r/fa09096b-4083-327b-94d1-3541f5315994/behind-eli-lillys-october-analyst-recommendations?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”"
LLY,LLY:US,BBG000BNBDC2,Lilly's Verzenio Gets Priority Review in First-Line Setting,2017-10-13 15:18:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tVSPlx-Kjjw/lillys-verzenio-gets-priority-review-in-first-line-setting-cm859350,Eli Lilly and Company LLY announced that the FDA has granted priority review to its new drug application NDA for Verzenio abemaciclib This drug is looking forward to get approved for the first line treatment of advanced breast cancer Markedly the NDA was based upon the positive
LLY,LLY:US,BBG000BNBDC2,Cancer Space Update: Lung & Breast Cancer Studies in Focus,2017-10-13 15:18:03 +0000,https://finance.yahoo.com/news/cancer-space-lung-breast-cancer-151803744.html?.tsrc=rss,"While Lilly announced failure of a lung cancer study, AstraZeneca&apos;s Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback",2017-10-13 14:20:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o-6IHur8DDQ/pharma-stock-roundup-pfizer-mulls-options-for-consumer-healthcare-llys-pipeline-setback-cm859307,Companies like Pfizer PFE Merck MRK and Eli Lilly LLY were in the news this week while Pfizer is mulling strategic options for its Consumer Healthcare business Merck said that it will not file its CETP inhibitor Recap of the Week s Most Important Stories Pfizer to
LLY,LLY:US,BBG000BNBDC2,IDEX (IEX) To Report Q3 Earnings: What's in the Cards?,2017-10-13 13:18:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bjxqOp_rvIg/idex-iex-to-report-q3-earnings-whats-in-the-cards-cm859236,Industrial goods manufacturer IDEX Corporation IEX is scheduled to report third quarter 2017 results after the closing bell on Oct 16 In the last reported quarter adjusted earnings beat the Zacks Consensus Estimate by 2 cents IDEX s earnings track record has been quite healthy having
LLY,LLY:US,BBG000BNBDC2,Lilly&apos;s Verzenio Gets Priority Review in First-Line Setting,2017-10-13 13:02:01 +0000,https://finance.yahoo.com/news/lilly-apos-verzenio-gets-priority-130201938.html?.tsrc=rss,Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY&apos;s Pipeline Setback",2017-10-13 12:06:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-pfizer-mulls-120612619.html?.tsrc=rss,Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won&apos;t be seeking approval for its CETP inhibitor.
LLY,LLY:US,BBG000BNBDC2,Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib,2017-10-12 21:12:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qr7zJU-LYcg/merck-will-not-seek-approval-for-cetp-inhibitor-anacetrapib-cm859055,Merck amp Co Inc MRK announced that it is not going ahead with filing the regulatory applications seeking approval for anacetrapib a cholesteryl ester transfer protein CETP inhibitor that it had developed for cholesterol management The stock was down more than 1 on Wednesday Merck
LLY,LLY:US,BBG000BNBDC2,Featured Company News – Eli Lilly Announces That Verzenio Failed To Meet Primary Endpoint of Overall Survival in Phase-3 JUNIPER Study,2017-10-12 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-eli-lilly-114000769.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Eli Lilly and Co. (NYSE: LLY ) (""Eli Lilly""), following ..."
LLY,LLY:US,BBG000BNBDC2,FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer,2017-10-12 10:45:00 +0000,https://finance.yahoo.com/news/fda-grants-priority-review-potential-104500296.html?.tsrc=rss,"INDIANAPOLIS , Oct. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug ..."
LLY,LLY:US,BBG000BNBDC2,Lilly's Verzenio Gets FDA Priority Review Designation For Advanced Breast Cancer,2017-10-12 06:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OnJ2yWStNXM/lillys-verzenio-gets-fda-priority-review-designation-for-advanced-breast-cancer-20171012-00287,Lilly's Verzenio Gets FDA Priority Review Designation For Advanced Breast Cancer
LLY,LLY:US,BBG000BNBDC2,Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study,2017-10-11 17:13:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nWsQzJD0NC0/lillys-lly-verzenio-fails-in-phase-iii-lung-cancer-study-cm858308,The series of setbacks continues for Eli Lilly and Company LLY as the company announced that its phase III JUNIPER study failed to meet the primary endpoint The study was evaluating Verzenio in advanced non small lung cancer NSCLC with KRAS mutation Shares fell 1 on Tuesday after
LLY,LLY:US,BBG000BNBDC2,Seattle Genetics Begins Phase II Study of Cancer Candidate,2017-10-11 16:13:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jq9-dFauDFg/seattle-genetics-begins-phase-ii-study-of-cancer-candidate-cm858181,Seattle Genetics Inc SGEN and Astellas Pharma Inc announced the initiation of a phase II study EV 201 of enfortumab vedotin The study will evaluate patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor CPI
LLY,LLY:US,BBG000BNBDC2,Lilly&apos;s (LLY) Verzenio Fails in Phase III Lung Cancer Study,2017-10-11 14:40:02 +0000,https://finance.yahoo.com/news/lilly-apos-lly-verzenio-fails-144002732.html?.tsrc=rss,"Lilly&apos;s breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients."
LLY,LLY:US,BBG000BNBDC2,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4",2017-10-11 01:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EzjObddRtQY/cry-opens-wallet-llys-juniper-flops-mdxg-catches-eyes-rnn-awaits-data-in-q4-20171011-00020,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4"
LLY,LLY:US,BBG000BNBDC2,"Health Care Sector Update for 10/10/2017: AKCA,ROKA,LLY",2017-10-10 20:30:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1NSkT5IxmHc/health-care-sector-update-for-10102017-akcarokally-cm857786,Top Health Care StocksTop Health Care Stocks JNJ 0 30 JNJ 0 30 PFE 0 72 PFE 0 72 ABT 1 27 ABT 1 27 MRK 0 10 MRK 0 10 AMGN 0 11 AMGN 0 11 Health care stocks were narrowly higher late Tuesday with the NYSE Health Care Index climbing less than 0 1 while shares of health care
LLY,LLY:US,BBG000BNBDC2,Closing Bell: LIVE MARKETS BLOG,2017-10-10 20:03:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/closing-bell-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The Dow closed at a new record Tuesday.
LLY,LLY:US,BBG000BNBDC2,Monday Night Football Posts Lowest Ratings of the Season: LIVE MARKETS BLOG,2017-10-10 18:55:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/monday-night-football-posts-lowest-ratings-season-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The Vikings beat the Bears in a snoozefest Monday night.
LLY,LLY:US,BBG000BNBDC2,"Health Care Sector Update for 10/10/2017: KALV,ROKA,LLY, MRK",2017-10-10 18:11:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/70uXiwQKQEA/health-care-sector-update-for-10102017-kalvrokally-mrk-cm857714,Top Health Care StocksTop Health Care Stocks JNJ 0 36 JNJ 0 36 PFE 0 04 PFE 0 04 ABT 0 89 ABT 0 89 MRK 0 12 MRK 0 12 AMGN 0 37 AMGN 0 37 Health care stocks were little changed with the NYSE Health Care Index dropping less than 0 1 while shares of health care companies in
LLY,LLY:US,BBG000BNBDC2,Lilly's breast cancer drug fails to help lung patients,2017-10-10 17:05:19 +0000,https://finance.yahoo.com/news/lillys-lung-cancer-drug-fails-113139010.html?.tsrc=rss,"Eli Lilly and Co said its  recently approved breast cancer drug failed to meet a late-stage  trial's main goal of improving overall survival in patients with  non-small cell lung cancer.  The news comes as a blow to the drugmaker, which has  suffered setbacks on two potential blockbuster treatments over  the past year - the delay of a rheumatoid arthritis drug, as  well as the failure of an experimental Alzheimer's treatment.  A positive data in lung cancer patients would have given the  drug, Verzenio, a competitive edge over rival breast cancer  treatments such as Pfizer Inc's Ibrance and Novartis AG  Kisqali."
LLY,LLY:US,BBG000BNBDC2,"NFL Caves to Trump, Considers Regulating Anthem Protest: LIVE MARKETS BLOG",2017-10-10 16:45:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/nfl-caves-trump-considers-regulating-anthem-protest-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,NFL Commissioner Roger Goodell sent a letter to NFL teams Tuesday.
LLY,LLY:US,BBG000BNBDC2,Trian to Contest P&G Vote :LIVE MARKETS BLOG,2017-10-10 16:45:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/trian-contest-pg-vote-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Peltz said the vote was too close to call ahead of P&G's announcement
LLY,LLY:US,BBG000BNBDC2,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 16:17:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wP2vD6cg5FA/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings-cm857590,Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses So far this year the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index are up 25 6 and 14 6 respectively With investors being more
LLY,LLY:US,BBG000BNBDC2,P&G Will Listen to Peltz as Company's Largest Shareholder :LIVE MARKETS BLOG,2017-10-10 15:52:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/pg-will-listen-peltz-companys-largest-shareholder-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,P&G CEO says relationship with Peltz has been respectful.
LLY,LLY:US,BBG000BNBDC2,Retirees and Legacy Investors Are Unhappy With P&G Peltz Says :LIVE MARKETS BLOG,2017-10-10 14:50:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/retirees-and-legacy-investors-are-unhappy-pg-peltz-says-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Peltz lost a narrow vote to be put on P&G's board.
LLY,LLY:US,BBG000BNBDC2,7 Catalysts For Eli Lilly Over The Next Year,2017-10-10 14:33:36 +0000,https://finance.yahoo.com/news/7-catalysts-eli-lilly-over-143336236.html?.tsrc=rss,Credit Suisse in a note Monday listed seven catalysts for Eli Lilly and Co (NYSE: LLY ) shares over the coming year even as it downgraded the shares of the company on the pretext that there are limited ...
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Loses Some Luster,2017-10-10 14:20:00 +0000,http://finance.yahoo.com/r/6a33b928-2e75-3f3c-94bf-634c4b36cf39/eli-lilly-loses-some-luster-1507645242?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse’s Vamil Divan published a note late Monday that lowered his rating on Eli Lilly & Co. (LLY) from Outperform to Neutral, citing among other concerns a full valuation and a lack of catalysts capable of lifting the stock price higher after it had already climbed 18% since the start of the year.  Then this morning, the U.S. pharmaceutical giant announced that the breast cancer treatment Verzenio, which received FDA approval last month, had flopped in a late-stage study testing it on lung cancer.  It marks the latest pipeline disappointment for Lilly after big setbacks earlier this year with potential blockbuster drugs for rheumatoid arthritis and Alzheimer’s. Now at $86.51 a sahre, Lilly's stock has pared earlier losses."
LLY,LLY:US,BBG000BNBDC2,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 14:01:02 +0000,https://finance.yahoo.com/news/5-pharma-biotech-stocks-could-140102820.html?.tsrc=rss,Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
LLY,LLY:US,BBG000BNBDC2,"P&G Vote May Be Too Close to Call Today, Peltz Says: LIVE MARKETS BLOG",2017-10-10 13:57:00 +0000,http://finance.yahoo.com/r/7ed140f3-64e7-3635-a8f2-fc5b0e78ae9c/pg-vote-may-be-too-close-call-today-peltz-says-live-markets-blog?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Shareholders are voting on whether to give Nelson Peltz a seat on P&G's board.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's stock sinks after disappointing results from late-stage trial of cancer treatment,2017-10-10 12:41:09 +0000,http://finance.yahoo.com/r/8134216b-61c0-3250-b183-f24496d5e5a7/Story.aspx?guid=4EB7DB68-7EA2-498F-A43E-BA89381A8213&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Eli Lilly & Co. sank 4.2% in premarket trade Tuesday, after disappointing drug trial results. The company said earlier that a phase 3 trial of its lung cancer treatment Verzenio failed to meet ..."
LLY,LLY:US,BBG000BNBDC2,Lilly's lung cancer drug fails late-stage study,2017-10-10 10:58:55 +0000,https://finance.yahoo.com/news/lillys-lung-cancer-drug-fails-105855714.html?.tsrc=rss,"Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study. Lilly's abemaciclib, however, ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer",2017-10-10 10:45:00 +0000,https://finance.yahoo.com/news/lilly-reports-topline-results-phase-104500815.html?.tsrc=rss,"INDIANAPOLIS , Oct. 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Verzenio Phase 3 JUNIPER Study Fails To Meet Primary Endpoint,2017-10-10 07:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pmUoryGMHrU/eli-lilly-verzenio-phase-3-juniper-study-fails-to-meet-primary-endpoint-20171010-00316,Eli Lilly: Verzenio Phase 3 JUNIPER Study Fails To Meet Primary Endpoint
LLY,LLY:US,BBG000BNBDC2,Cancer Space Last Week Update: Pipeline Expansion in Focus,2017-10-09 16:54:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aaBxM7el674/cancer-space-last-week-update-pipeline-expansion-in-focus-cm857054,There was not much activity in the cancer space last week Notable among them was an immuno oncology partnership deal signed between Amgen and CytomX for developing t Cell based therapy for cancer and acquisition of a late stage prostate cancer candidate by Endocyte Also the FDA
LLY,LLY:US,BBG000BNBDC2,Cancer Space Last Week Update: Pipeline Expansion in Focus,2017-10-09 14:13:02 +0000,https://finance.yahoo.com/news/cancer-space-last-week-pipeline-141302097.html?.tsrc=rss,"Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office."
LLY,LLY:US,BBG000BNBDC2,New Drugs Approved In September,2017-10-09 05:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AMA7U9Q5EXE/new-drugs-approved-in-september-20171009-00181,New Drugs Approved In September
LLY,LLY:US,BBG000BNBDC2,It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now,2017-10-08 13:00:00 +0000,https://finance.yahoo.com/news/brutal-search-treatment-alzheimer-where-130000007.html?.tsrc=rss,The search for an Alzheimer's disease treatment has been unsuccessful for the past 14 years...
LLY,LLY:US,BBG000BNBDC2,It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now,2017-10-08 13:00:00 +0000,https://www.yahoo.com/lifestyle/brutal-search-treatment-alzheimer-where-130000007.html?.tsrc=rss,The search for an Alzheimer's disease treatment has been unsuccessful for the past 14 years...
LLY,LLY:US,BBG000BNBDC2,No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock,2017-10-06 22:55:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TWZDFp5rr5c/no-side-effects-to-this-bullish-trade-on-celgene-corporation-celg-stock-cm856576,InvestorPlace Stock Market News Stock Advice amp Trading Tips Yesterday Celgene Corporation NASDAQ CELG caught a downgrade and the stock fell 4 on the headline Money fled to Biogen Inc NASDAQ BIIB which caught the opposing upgrade Source Wikimedia
LLY,LLY:US,BBG000BNBDC2,FDA: Drug shortages possible due to Puerto Rico power outage,2017-10-06 22:27:58 +0000,http://finance.yahoo.com/r/73f8aa97-d6e4-3121-9d9b-2bf8b6ef12d1/fda-drug-shortages-possible-due-211242921.html?.tsrc=rss,The Food and Drug Administration on Friday warned that U.S. drug shortages are possible because power outages in Puerto Rico have stopped or limited production at many medicine factories there.
LLY,LLY:US,BBG000BNBDC2,FDA: Drug shortages possible due to Puerto Rico power outage,2017-10-06 22:27:58 +0000,https://finance.yahoo.com/news/fda-drug-shortages-possible-due-211242921.html?.tsrc=rss,The Food and Drug Administration on Friday warned that U.S. drug shortages are possible because power outages in Puerto Rico have stopped or limited production at many medicine factories there. Nearly ...
LLY,LLY:US,BBG000BNBDC2,Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer,2017-10-06 17:00:00 +0000,https://finance.yahoo.com/news/lilly-monarch-3-study-published-170000455.html?.tsrc=rss,"- Verzenio, used in combination with a nonsteroidal aromatase inhibitor (NSAI), reduced the risk of progression or death by 46 percent in patients with HR+, HER2- advanced breast cancer - Results showed ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute,2017-10-06 14:45:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/anQgQDkKhIA/lilly-wins-favorable-ruling-from-us-pto-in-alimta-dispute-cm856174,Eli Lilly amp Company LLY announced that it has received a favorable ruling from the U S Patent and Trademark Office PTO in a dispute related to the vitamin regimen patent on its key cancer drug Alimta pemetrexed disodium In an inter partes review IPR ruling the U S PTO
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal",2017-10-06 14:44:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7icxbt800Go/pharma-stock-roundup-mylan-up-teva-down-on-copaxone-news-lawmakers-question-allergan-deal-cm856152,This week companies like Allergan AGN Teva TEVA and Mylan MYL were in the limelight While Mylan and Teva were in the news related to the FDA approval of Mylan s generic versions of Teva s top selling branded drug Copaxone Allergan is under fire for its agreement with the Saint Regis
LLY,LLY:US,BBG000BNBDC2,No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock,2017-10-06 13:37:37 +0000,https://finance.yahoo.com/news/no-side-effects-bullish-trade-133737087.html?.tsrc=rss,"Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline.  To do this, I use CELG options instead of trading its underlying equity.  Click to Enlarge Fundamentally, Celgene is not cheap."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal",2017-10-06 13:07:01 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-mylan-teva-130701395.html?.tsrc=rss,The FDA approval of Mylan&apos;s (MYL) generic version of Teva&apos;s Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
LLY,LLY:US,BBG000BNBDC2,Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute,2017-10-06 12:50:12 +0000,https://finance.yahoo.com/news/lilly-wins-favorable-ruling-u-125012937.html?.tsrc=rss,"Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta."
LLY,LLY:US,BBG000BNBDC2,4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3,2017-10-05 22:48:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UI_qjrHImVg/4-large-cap-drug-stocks-to-buy-on-solid-momentum-ahead-of-q3-cm856013,The pharmaceutical sector has been grabbing investors attention of late with the NYSE ARCA Pharmaceutical Index gaining 13 1 and the Large Cap Pharmaceuticals 160 industry 20 7 year to date outpacing 14 7 gain for the S amp P 500 New drug approvals and tax reforms are expected to provide
LLY,LLY:US,BBG000BNBDC2,Lilly wins Alimta patent dispute in US,2017-10-05 20:43:51 +0000,https://finance.yahoo.com/news/lilly-wins-alimta-patent-dispute-204351419.html?.tsrc=rss,"The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co in a patent dispute over its cancer drug Alimta with Neptune Generics LLC and Sandoz Inc. Alimta, Lilly's top-selling oncology treatment, ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly defeats challenge to Alimta cancer drug patent,2017-10-05 20:36:45 +0000,https://finance.yahoo.com/news/eli-lilly-defeats-challenge-alimta-203645745.html?.tsrc=rss,"A federal patent review board on Thursday  rejected a challenge to a patent covering Eli Lilly and Co's  Alimta drug to treat some lung cancers and mesothelioma.  The U.S. Patent Trial and Appeal Board said Neptune Generics  LLC and other companies failed to show it was more likely than  not that 22 claims underlying the Lilly patent could not be  patented.  Alimta is Lilly's third biggest-selling drug, accounting for  $2.28 billion of the Indianapolis-based company's $21.22 billion  of revenue last year, a regulatory filing shows."
LLY,LLY:US,BBG000BNBDC2,U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent,2017-10-05 20:13:00 +0000,https://finance.yahoo.com/news/u-patent-trademark-office-rules-201300212.html?.tsrc=rss,"INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection).  In the inter partes review (IPR) proceedings initiated by Neptune Generics, LLC and Sandoz Inc., the U.S. PTO found that the claims of the vitamin regimen patent are valid.  If the patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022, preventing marketing of generic products for as long as the patent remains in force."
LLY,LLY:US,BBG000BNBDC2,Additional Delivery of Insulin Ready for Distribution in Puerto Rico,2017-10-05 19:48:00 +0000,https://finance.yahoo.com/news/additional-delivery-insulin-ready-distribution-194800786.html?.tsrc=rss,"The delivery by Eli Lilly and Company (LLY) includes 3,000 vials for humanitarian distribution and enough commercial insulin to help re-stock operational pharmacies.  Lilly's humanitarian donation now includes 5,400 insulin pens and vials since Hurricane Maria struck Puerto Rico on September 20."
LLY,LLY:US,BBG000BNBDC2,Changes in GlaxoSmithKline’s Valuation,2017-10-05 14:38:09 +0000,http://finance.yahoo.com/r/30acc338-c42a-3243-bd25-150cdfddf12a/changes-in-glaxosmithklines-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x."
LLY,LLY:US,BBG000BNBDC2,Changes in Eli Lilly’s Valuation,2017-10-05 11:37:42 +0000,http://finance.yahoo.com/r/3c55f325-212b-374e-857f-8d43170d3572/changes-in-eli-lillys-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On September 28, 2017, Eli Lilly was trading at a forward PE multiple of ~18.7x compared to the industry average of ~16.6x."
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s Elanco,2017-10-04 14:38:00 +0000,http://finance.yahoo.com/r/73863414-1367-302c-8efe-75ce25442e92/quarterly-performance-of-eli-lillys-elanco?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Elanco includes food animal products as well as companion animal products. Its revenues fell ~9.0% to $784.8 million in 2Q17 compared to $859.8 million in 2Q16.
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s Neuroscience Products,2017-10-04 13:07:44 +0000,http://finance.yahoo.com/r/516194ae-085a-3cd5-a016-1e0452b0bfe2/quarterly-performance-of-eli-lillys-neuroscience-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Strattera, a drug for attention-deficit/hyperactivity disorder, reported a 17.0% fall in revenues to $186.6 million in 2Q17 compared to $224.6 million in 2Q16."
LLY,LLY:US,BBG000BNBDC2,Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes,2017-10-04 13:00:00 +0000,https://finance.yahoo.com/news/humalog-junior-kwikpen-now-available-130000111.html?.tsrc=rss,"INDIANAPOLIS, Oct. 4, 2017 /PRNewswire/ -- Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and delivery options Eli Lilly and Company (LLY) offers for people with type 1 or type 2 diabetes.  Humalog Junior KwikPen is the only prefilled, disposable half-unit insulin pen."
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s Cardiovascular Products,2017-10-04 11:40:16 +0000,http://finance.yahoo.com/r/6b40a192-ff8c-3467-aa54-65148360d271/quarterly-performance-of-eli-lillys-cardiovascular-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Effient's revenues rose 6.0% to $142.9 million in 2Q17 compared to $135.1 million in 2Q16.
LLY,LLY:US,BBG000BNBDC2,Why This Biotech Suffered A 2-Day Headache On Rare-Disease Trial,2017-10-03 20:54:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yawyer5s1Cc/why-this-biotech-suffered-a-2-day-headache-on-rare-disease-trial-cm854795,Biohaven Pharmaceuticals BHVN continued its two day free fall Tuesday after its rare disease drug failed in a trial 160 prompting at least two analysts to downgrade the stock ibd display video id 2326102 width 50 float left autostart true By the closing bell on the
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson Files sNDA for Label Expansion of Invokana,2017-10-03 16:57:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uCBMaTfjmoI/johnson-johnson-files-snda-for-label-expansion-of-invokana-cm854650,Johnson amp Johnson s JNJ announced that it has submitted a supplemental new drug application sNDA to the FDA for the label expansion of its diabetes drug Invokana to include the cardiovascular indication based on data from a large CANVAS outcomes program The application to
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson Files sNDA for Label Expansion of Invokana,2017-10-03 14:59:02 +0000,https://finance.yahoo.com/news/johnson-johnson-files-snda-label-145902472.html?.tsrc=rss,Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s Endocrine Franchise,2017-10-03 14:40:05 +0000,http://finance.yahoo.com/r/b2ebb796-36fd-30c9-a28a-cd38e2d13a94/quarterly-performance-of-eli-lillys-endocrine-franchise?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Humalog, the meal-time insulin products portfolio, reported sales of $678.4 million in 2Q17."
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s Oncology Products,2017-10-03 13:08:50 +0000,http://finance.yahoo.com/r/4b8eccef-e3b4-3d73-afb9-e640c481dc32/quarterly-performance-of-eli-lillys-oncology-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Alimta, a chemotherapy drug for the treatment of advanced non-small cell lung cancer, reported a 12.0% fall in revenues to $532.9 million in 2Q17 compared to $607.1 million for 2Q16."
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s New Products,2017-10-03 11:42:27 +0000,http://finance.yahoo.com/r/d42258bb-1025-3e73-9ed3-840d8d134b62/quarterly-performance-of-eli-lillys-new-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16."
LLY,LLY:US,BBG000BNBDC2,Lilly (LLY) Makes Leadership Changes to Executive Positions,2017-10-03 00:46:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hcx-ogTJGDQ/lilly-lly-makes-leadership-changes-to-executive-positions-cm854291,Eli Lilly and Company LLY announced a number of leadership changes in order to focus on bringing newer drugs to the market In this regard the company promoted Josh Smiley to the post of Chief Financial Officer CFO effective Jan 1 2018 In June 2017 the company announced that its
LLY,LLY:US,BBG000BNBDC2,Lilly (LLY) Makes Leadership Changes to Executive Positions,2017-10-02 22:19:10 +0000,https://finance.yahoo.com/news/lilly-lly-makes-leadership-changes-221910705.html?.tsrc=rss,Eli Lilly and Company (LLY) makes some executive appointments for various departments.
LLY,LLY:US,BBG000BNBDC2,Quarterly Performance of Eli Lilly’s Business Segments,2017-10-02 19:06:13 +0000,http://finance.yahoo.com/r/62839a75-16e6-376a-8291-1586d89b6868/quarterly-performance-of-eli-lillys-business-segments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The human pharmaceutical segment reported a 10.9% rise in revenues to $5.0 billion in 2Q17 compared to 2Q16.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Quarterly Revenues and Estimates,2017-10-02 17:36:21 +0000,http://finance.yahoo.com/r/036015eb-33de-3aa3-b1e5-fa50abb8b53b/eli-lillys-quarterly-revenues-and-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) reported growth of 8.0% in its 2Q17 revenues to $5.8 billion compared to 2Q16. Analysts estimate revenues of $5.5 billion for 3Q17, a 6.1% rise compared to 3Q16."
LLY,LLY:US,BBG000BNBDC2,Radius (RDUS) Enrols First Patient in Breast Cancer Study,2017-10-02 15:51:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oaRn-WTqtpM/radius-rdus-enrols-first-patient-in-breast-cancer-study-cm853917,Radius Health Inc RDUS announced that the first patient has been enroled in the phase I study on pipeline candidate RAD140 RAD140 is a nonsteroidal selective androgen receptor modulator SARM which is being evaluated for the treatment of hormone receptor positive breast cancer The phase
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Recent Developments after 2Q17,2017-10-02 15:43:59 +0000,http://finance.yahoo.com/r/0f5c60c8-c158-3a88-bf7f-ec03e8111c03/eli-lillys-recent-developments-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On September 25, 2017, Geisinger entered into an agreement with Boehringer Ingelheim on behalf of Eli Lilly to develop a risk-prediction model for three serious health consequences associated with type ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement,2017-10-02 14:00:00 +0000,https://finance.yahoo.com/news/lilly-confirms-date-conference-call-140000080.html?.tsrc=rss,"INDIANAPOLIS, Oct. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017.  Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 9 a.m. Eastern time."
LLY,LLY:US,BBG000BNBDC2,These Are the Top 5 Stocks the Smart Money Is Selling,2017-10-02 13:00:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qKvPh-MiuU8/these-are-the-top-5-stocks-the-smart-money-is-selling-cm853686,When the smart money moves into a stock investors may want to take notice because it just might signal the start of an upswing in its value Similarly when the smart money withdraws its money from a holding you may want to pay attention because it may see problems others
LLY,LLY:US,BBG000BNBDC2,"Corporate News Blog - Eli Lilly Declares New Appointments for Senior Leadership in Finance, Research & Development, and Manufacturing",2017-10-02 11:40:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-eli-lilly-114000390.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Eli Lilly and Co. (NYSE: LLY ) (""Lilly""), following which we ..."
LLY,LLY:US,BBG000BNBDC2,These Are the Top 5 Stocks the Smart Money Is Selling,2017-10-02 11:33:00 +0000,http://finance.yahoo.com/r/c579833a-dc40-3276-8388-7a697d5f6762/these-are-the-top-5-stocks-the-smart-money-is-sell.aspx?yptr=yahoo&.tsrc=rss,"When the smart money exits a position, it should give you a noodle point about why they&apos;re selling."
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Names Joshua Smiley CFO,2017-09-30 04:31:49 +0000,http://finance.yahoo.com/r/bfcfff5f-6767-32a8-8db5-32df8bbfbd66/eli-lilly-names-joshua-smiley-cfo-1506687112?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Eli Lilly named a new finance chief and announced a number of other executive changes, as the drugmaker contends with layoffs and patent expirations."
LLY,LLY:US,BBG000BNBDC2,Must-Know Changes to Bristol-Myers Squibb’s Valuation,2017-09-29 14:40:15 +0000,http://finance.yahoo.com/r/5291550d-982b-3297-9fe7-e6b51ab4ffff/must-know-changes-to-bristol-myers-squibbs-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises."
LLY,LLY:US,BBG000BNBDC2,"Lilly names new CFO, replaces head of R&D in management shakeup",2017-09-29 14:26:14 +0000,https://finance.yahoo.com/news/lilly-names-cfo-replaces-head-142614764.html?.tsrc=rss,"Eli Lilly and Co named  a new chief financial officer and replaced the head of its  research and development arm, among other changes to its top  management on Friday, weeks after the drugmaker announced  layoffs to cut costs.  Company Treasurer Josh Smiley will become CFO on Jan. 1 to  replace Derica Rice who announced his retirement in June.  Dan Skovronsky, a senior vice-president, will become  president of R&D arm Lilly Research Labs on June 1, 2018, taking  the place of Jan Lundberg, who will retire."
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Names Joshua Smiley CFO,2017-09-29 12:14:01 +0000,http://finance.yahoo.com/r/bfcfff5f-6767-32a8-8db5-32df8bbfbd66/eli-lilly-names-joshua-smiley-cfo-1506687112?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Eli Lilly named a new finance chief and announced a number of other executive changes, as the drugmaker contends with layoffs and patent expirations."
LLY,LLY:US,BBG000BNBDC2,"Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing",2017-09-29 10:45:00 +0000,https://finance.yahoo.com/news/lilly-announces-senior-leadership-appointments-104500745.html?.tsrc=rss,"INDIANAPOLIS, Sept. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018.  Josh Smiley has been promoted to senior vice president and chief financial officer and will become a member of Lilly's executive committee, effective January 1, 2018.  Lilly announced in June that Derica Rice, Lilly's current CFO, would retire at year-end."
LLY,LLY:US,BBG000BNBDC2,Lilly Promotes Josh Smiley To SVP And CFO,2017-09-29 06:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OHqW8n977ZE/lilly-promotes-josh-smiley-to-svp-and-cfo-20170929-00240,Lilly Promotes Josh Smiley To SVP And CFO
LLY,LLY:US,BBG000BNBDC2,FDA approves Lilly pill for common advanced breast cancer,2017-09-28 22:20:32 +0000,https://finance.yahoo.com/news/fda-approves-lilly-pill-common-212719861.html?.tsrc=rss,U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body. Eli Lilly's Verzenio was approved Thursday by the Food and Drug ...
LLY,LLY:US,BBG000BNBDC2,FDA approves Lilly pill for common advanced breast cancer,2017-09-28 22:20:32 +0000,http://finance.yahoo.com/r/7f786f66-8f38-3404-b721-6de4884093e2/fda-approves-lilly-pill-common-212719861.html?.tsrc=rss,U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body.
LLY,LLY:US,BBG000BNBDC2,FDA Okays Lilly's Breast Cancer Drug Verzenio,2017-09-28 21:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mjjtqos2a7w/fda-okays-lillys-breast-cancer-drug-verzenio-20170928-01381,FDA Okays Lilly's Breast Cancer Drug Verzenio
LLY,LLY:US,BBG000BNBDC2,Eli Lilly wins U.S. approval for breast cancer drug,2017-09-28 20:41:36 +0000,https://finance.yahoo.com/news/eli-lilly-wins-u-approval-183549014.html?.tsrc=rss,"The U.S. Food and Drug Administration  said on Thursday it approved an Eli Lilly and Co drug to  treat advanced breast cancer that has progressed following prior  treatment.  The drug, abemaciclib, which will be sold under the brand  name Verzenio, will carry a list price before any discounts or  rebates of about $10,948 per month, Lilly said.  Verzenio belongs to a newer class of oral medicines called  CDK 4/6 inhibitors that block cancer cells' ability to divide  and proliferate."
LLY,LLY:US,BBG000BNBDC2,"Noteworthy ETF Outflows: OEF, LLY, PYPL, BK",2017-09-28 16:43:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K-sKrjTi2Tc/noteworthy-etf-outflows-oef-lly-pypl-bk-cm852654,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares S amp P 100 ETF Symbol OEF where we have detected an approximate 22 2 million dollar outflow that s a 0 5 decrease week over week from 44 100 000
LLY,LLY:US,BBG000BNBDC2,YieldBoost LLY To 5.4% Using Options,2017-09-28 16:42:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GzPI7CZxnww/yieldboost-lly-to-54-using-options-cm852645,Shareholders of Lilly Eli amp Co Symbol LLY looking to boost their income beyond the stock s 2 5 annualized dividend yield can sell the January 2019 covered call at the 95 strike and collect the premium based on the 3 30 bid which annualizes to an additional 3 rate of return against
LLY,LLY:US,BBG000BNBDC2,Elanco Celebrates 10 Years of Volunteerism During Global Day of Service,2017-09-28 12:05:00 +0000,https://finance.yahoo.com/news/elanco-celebrates-10-years-volunteerism-120500592.html?.tsrc=rss,"An estimated 3,000 global Elanco employees will volunteer in one of 240 projects in more than 40 countries around the world.  GREENFIELD, Ind., Sept. 28, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), will celebrate its 10th year of giving back to local communities around the world during Global Day of Service on Thursday, Sept. 28.  Day of Service is one of the largest single-day corporate volunteer programs in the world."
LLY,LLY:US,BBG000BNBDC2,Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron,2017-09-27 20:43:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s91TmB0uU6c/galapagos-pops-after-eczema-drug-shows-promise-vs-regeneron-cm852063,Galapagos GLPG popped Wednesday after its eczema drug compared favorably with potential blockbuster Dupixent from Regeneron Pharmaceuticals REGN and Sanofi SNY in a Phase 1 trial ibd display video id 2322091 width 50 float left autostart true
LLY,LLY:US,BBG000BNBDC2,"Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe",2017-09-27 16:00:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/twUguu-DHPc/nektars-lead-drugs-drive-growth-partner-reliance-a-woe-cm851890,On Sep 26 2017 we issued an updated report on Nektar Therapeutics NKTR a biopharmaceutical company focused on developing treatments utilizing PEGylation and advanced polymer conjugate technology platforms The company s portfolio comprises two drugs Movantik for opioid
LLY,LLY:US,BBG000BNBDC2,Pharmaceuticals: A Solid End To 2017,2017-09-27 14:17:00 +0000,http://finance.yahoo.com/r/24d1b53d-e0ff-3ddd-a09a-dc98cfac66af/pharmaceuticals-a-solid-end-to-2017-1506521852?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Pharmaceutical stocks have had a pretty decent year, with the SPDR S&P Pharmaceuticals ETF(XPH) up 7.5%, although the performance of individual stocks was a bit mixed. Looking at head to the last quarter ..."
LLY,LLY:US,BBG000BNBDC2,What Happened to Allergan’s Valuation after 2Q17?,2017-09-27 11:37:12 +0000,http://finance.yahoo.com/r/08cec61f-6888-3ef7-a419-b673d64a59e6/what-happened-to-allergans-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 21 analysts tracking Allergan stock, 14 recommend a “buy,” and seven analysts recommend a “hold.” None recommends a “sell.”"
LLY,LLY:US,BBG000BNBDC2,Bullish Pattern Showing for Eli Lilly: Cramer's 'Off the Charts',2017-09-27 11:01:00 +0000,http://finance.yahoo.com/r/a6745e9d-5368-3ffa-85c4-0f78d55dac52/bullish-pattern-showing-for-eli-lilly-cramer-s-off-the-charts.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Shares of the pharma giant could be ready for a big upside move.
LLY,LLY:US,BBG000BNBDC2,Cramer's charts diagnose a potential breakout for shares ...,2017-09-26 23:13:00 +0000,https://finance.yahoo.com/video/cramers-charts-diagnose-potential-breakout-231300878.html?.tsrc=rss,"Jim Cramer reviews Eli Lilly's stock charts with technician Tim Collins, who predicts more upside for the pharmaceutical stock."
LLY,LLY:US,BBG000BNBDC2,Cramer charts: Potential breakout for Eli Lilly,2017-09-26 23:07:00 +0000,https://finance.yahoo.com/video/cramer-charts-potential-breakout-eli-230700104.html?.tsrc=rss,"Jim Cramer reviews Eli Lilly's stock charts with technician Tim Collins, who predicts more upside for the pharmaceutical stock."
LLY,LLY:US,BBG000BNBDC2,Cramer Remix: Why Apple is the Muhammad Ali of stocks,2017-09-26 23:05:00 +0000,https://finance.yahoo.com/video/cramer-remix-why-apple-muhammad-230500017.html?.tsrc=rss,"Jim Cramer compares the “Greatest Of All Time,” Muhammad Ali, to Apple, naming the company the “Greatest Stock Of All Time.”"
LLY,LLY:US,BBG000BNBDC2,Cramer Remix: Why Apple is the Muhammad Ali of stocks,2017-09-26 23:00:29 +0000,http://finance.yahoo.com/r/9f516667-54ff-3fa0-9bf2-f5e96076a5d2/104732640?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104732640&yptr=yahoo&.tsrc=rss,"Jim Cramer compares the “Greatest Of All Time,” Muhammad Ali, to Apple, naming the company the “Greatest Stock Of All Time.”"
LLY,LLY:US,BBG000BNBDC2,Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why,2017-09-26 19:53:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7HML62lfthA/axovant-sciences-axon-stock-crashed-over-70-heres-why-cm851325,On Tuesday shares of biopharmaceutical company Axovant Sciences Ltd AXON have crashed and the stock is currently down over 70 to 6 72 per share in late morning trading after it said that its experimental Alzheimer s drug failed a key late stage trial The drug called intepirdine was
LLY,LLY:US,BBG000BNBDC2,Axovant Sciences (AXON) Stock Crashed Over 70%: Here&apos;s Why,2017-09-26 17:27:05 +0000,https://finance.yahoo.com/news/axovant-sciences-axon-stock-crashed-172705119.html?.tsrc=rss,"On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer&apos;s drug failed a key late-stage trial."
LLY,LLY:US,BBG000BNBDC2,3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day,2017-09-26 15:56:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J3oN8-iprTw/3-heart-disease-focused-stocks-to-buy-ahead-of-world-heart-day-cm851047,World Heart Day is observed every year on September 29 to raise awareness across the world about cardiovascular CV diseases CV diseases more commonly known as heart disease or stroke are basically diseases of the heart or blood vessels According to the World Heart Federation CV
LLY,LLY:US,BBG000BNBDC2,J&J's Arthritis Candidate Sirukumab Denied FDA Approval,2017-09-26 13:57:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E_YDM-Zy_KQ/jjs-arthritis-candidate-sirukumab-denied-fda-approval-cm850880,Johnson amp Johnson JNJ announced that the FDA has denied approval to its investigational rheumatoid arthritis RA treatment sirukumab an IL 6 inhibitor for want of additional safety data The FDA issued a complete response letter CRL for J amp J s Biologics License Application BLA
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs",2017-09-26 12:50:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IavOpd2pqmg/pharma-stock-roundup-jj-drug-gets-crl-label-expansion-for-merck-and-bmy-drugs-cm850815,Key highlights in the pharma sector include a complete response letter CRL from the FDA for Johnson amp Johnson s JNJ investigational rheumatoid arthritis RA treatment and FDA approval for Merck s MRK and Bristol Myers Squibb s BMY cancer drugs Recap of the Week s Most
LLY,LLY:US,BBG000BNBDC2,J&J&apos;s Arthritis Candidate Sirukumab Denied FDA Approval,2017-09-26 11:12:11 +0000,https://finance.yahoo.com/news/j-j-apos-arthritis-candidate-111211917.html?.tsrc=rss,"J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data."
LLY,LLY:US,BBG000BNBDC2,Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer,2017-09-25 16:52:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U-h_hQ6nFig/mercks-keytruda-gets-fda-nod-for-advanced-gastric-cancer-cm850454,Merck amp Co Inc MRK announced that the FDA has approved its anti PD 1 therapy Keytruda as a monotherapy for third line treatment of advanced gastric or gastroesophageal junction adenocarcinoma Keytruda is already approved for many types of cancers and treatment settings including
LLY,LLY:US,BBG000BNBDC2,"Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death",2017-09-25 12:30:00 +0000,https://finance.yahoo.com/news/geisinger-boehringer-ingelheim-collaborate-create-123000062.html?.tsrc=rss,"DANVILLE, Pa., RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (LLY), today announced a major collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes that have long-term impact and cost-of-care implications: cardiovascular death, kidney failure and hospitalization for heart failure.  The new model will allow healthcare professionals to predict which adults with type 2 diabetes are most at risk for developing these serious – and costly – health consequences."
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-09-25 12:00:48 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120048043.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,"Geisinger, Boehringer Ingelheim Announce Collaboration - Quick Facts",2017-09-25 08:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qtjTbLKbTE8/geisinger-boehringer-ingelheim-announce-collaboration--quick-facts-20170925-00604,"Geisinger, Boehringer Ingelheim Announce Collaboration - Quick Facts"
LLY,LLY:US,BBG000BNBDC2,AstraZeneca Stock Upgraded: What You Need to Know,2017-09-22 19:18:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I9VQ8FwhS0Y/astrazeneca-stock-upgraded-what-you-need-to-know-cm849759,Every day Wall Street analysts upgrade some stocks downgrade others and initiate coverage on a few more But do these analysts even know what they re talking about Today we re taking one high profile Wall Street pick and putting it under the microscope Shares of U
LLY,LLY:US,BBG000BNBDC2,AstraZeneca Stock Upgraded: What You Need to Know,2017-09-22 17:08:19 +0000,http://finance.yahoo.com/r/7e1d49e2-80bd-33e4-a0ab-886776a4edf3/astrazeneca-stock-upgraded-what-you-need-to-know.aspx?yptr=yahoo&.tsrc=rss,Bernstein sees opportunity in a buyout target.
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-09-22 12:01:02 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120102589.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-09-21 12:01:05 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120105038.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,What Analysts Recommend for Zoetis and Peers in September 2017,2017-09-20 12:08:20 +0000,http://finance.yahoo.com/r/014831c7-2919-3049-b1e3-f691eb3d55db/analysts-recommendations-zoetis-peers-september-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Zoetis reported revenues close to $1.3 billion, which is year-over-year (or YoY) growth of about 5% and YoY operational growth of around 6%."
LLY,LLY:US,BBG000BNBDC2,"Notable ETF Inflow Detected - VONG, GOOG, PEP, LLY",2017-09-19 16:38:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/30ouxss9Whk/notable-etf-inflow-detected-vong-goog-pep-lly-cm847823,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Russell 1000 Growth ETF Symbol VONG where we have detected an approximate 121 5 million dollar inflow that s a 10 1 increase week over week
LLY,LLY:US,BBG000BNBDC2,"Health Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD",2017-09-18 20:36:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L8MIskxQnAY/health-care-sector-update-for-09182017-clvsllyitusaemd-cm847389,Top Health Care StocksTop Health Care Stocks JNJ 0 74 JNJ 0 74 PFE 0 35 PFE 0 35 ABT 0 56 ABT 0 56 MRK 0 30 MRK 0 30 AMGN 0 46 AMGN 0 46 Health care stocks were ending little changed this afternoon with the NYSE Health Care Index rising less than 0 1 while shares of health
LLY,LLY:US,BBG000BNBDC2,[$$] 4 Buys in a Watchful Market,2017-09-16 03:34:00 +0000,http://finance.yahoo.com/r/bd6320d3-1f1d-32eb-b49e-730f74240161/4-buys-in-a-watchful-market-1505532898?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly • LLY-NYSE  Long-Term Buy • Price $82.17 on Sept. 12  by Hilliard Lyons  At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib.  As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Still Looking for Lower Prices,2017-09-15 17:45:00 +0000,http://finance.yahoo.com/r/f8a0cf4a-3122-3152-bc6c-22d63fe3c2cf/eli-lilly-still-looking-lower-prices?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The charts don't look positive for drug company Eli Lilly.
LLY,LLY:US,BBG000BNBDC2,"Why Amgen, Lilly, J&J Are Interested In These Small Biotechs",2017-09-15 17:18:04 +0000,http://finance.yahoo.com/r/bb7093cc-a209-3c81-b12b-373b56f01c80/why-amgen-lilly-jj-are-interested-in-these-small-biotechs?src=A00220&yptr=yahoo&.tsrc=rss,"Theravance and Exelixis tick off most of the acquisition boxes for Big Pharma, an analyst said Friday."
LLY,LLY:US,BBG000BNBDC2,Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study,2017-09-15 15:41:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GptKyODlHc8/lillyincytes-baricitinib-meets-endpoint-in-eczema-study-cm846253,Eli Lilly and Company LLY and partner Incyte Corporation INCY announced that its pipeline candidate baricitinib met the primary endpoint in a phase II study in patients with moderate to severe atopic dermatitis AD a type of eczema So far this year Lilly s shares have underperformed
LLY,LLY:US,BBG000BNBDC2,Lilly/Incyte&apos;s Baricitinib Meets Endpoint in Eczema Study,2017-09-15 13:51:01 +0000,https://finance.yahoo.com/news/lilly-incyte-apos-baricitinib-meets-135101219.html?.tsrc=rss,Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
LLY,LLY:US,BBG000BNBDC2,Why New Generic Products Could Boost TEVA’s Revenue Growth,2017-09-15 13:07:33 +0000,http://finance.yahoo.com/r/c8276737-a1db-317d-b140-72f5ce069f9c/why-new-generic-products-could-boost-tevas-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In August 2017, Teva Pharmaceutical (TEVA) launched the generic version of Eli Lilly’s (LLY) Axiron."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO",2017-09-15 12:38:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nEtZLBtU3oM/pharma-stock-roundup-achillion-slumps-on-end-of-hcv-deal-teva-gets-a-new-ceo-cm846148,Several important developments were reported this week with key highlights including the termination of a hepatitis C virus deal the approval of the first cancer biosimilar in the United States and the presentation of data by companies like Pfizer PFE and Bristol Myers Squibb BMY among
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO",2017-09-15 10:52:10 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-achillion-slumps-105210457.html?.tsrc=rss,Key highlights this week include Teva&apos;s (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
LLY,LLY:US,BBG000BNBDC2,4 Biotech Stocks That Show Promise on Sustainable Growth,2017-09-14 23:35:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DUmN8t894cM/4-biotech-stocks-that-show-promise-on-sustainable-growth-cm846030,Within the Medical sector biotech stocks have performed well in the first half of the year despite challenges like rising competition pipeline setbacks slowdown in growth of mature products and generic competition for certain key drugs The sector recovered from the pricing controversy of
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2017 (record date) : By the numbers : September 14, 2017",2017-09-14 19:17:21 +0000,http://finance.yahoo.com/r/a382fb04-caa1-3b36-923f-37ad5cfe5571/eli-lilly-co-lly-us-dividend-analysis-august-15th-2017-record-date-by-the-numbers-september-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing Eli Lilly & Co. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Roche Holding Ltd Genusssch., Amgen Inc. and Novartis AG Sponsored ADR (JNJ-US, MRK-US, PFE-US, BMY-US, ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,Lilly/Incyte pill beats placebo in mid-stage eczema trial,2017-09-14 18:49:16 +0000,https://finance.yahoo.com/news/lilly-incyte-pill-beats-placebo-184916406.html?.tsrc=rss,"Eli Lilly and Co and Incyte Corp  on Thursday said a mid-stage trial of their oral drug  baricitinib showed that at the highest dose it worked better  than placebo for people with moderate-to-severe atopic  dermatitis.  The finding could be a boost for the drug's prospects, which  suffered a setback earlier this year after U.S. regulators  turned down an application for its use in rheumatoid arthritis,  saying that more data was needed.  Baricitinib, in a class of drugs known as Jak inhibitors, is  sold in the European Union under the brand name Olumiant for  treating rheumatoid arthritis."
LLY,LLY:US,BBG000BNBDC2,"US stocks are mixed as energy companies rise, retailers dip",2017-09-14 16:20:14 +0000,http://finance.yahoo.com/r/8a8645e4-f46e-3ad9-a35a-5e94b73d42d6/us-stocks-dip-record-run-143116694.html?.tsrc=rss,"NEW YORK (AP) — U.S. stocks are mixed Thursday after finishing at record highs the last two days. Companies that sell everything from clothes to groceries are slipping after the government said prices paid by consumers jumped in August. That could be a sign inflation is increasing, which would push the Federal Reserve to raise interest rates at a faster pace and slow the economy down. Health care and energy companies are rising."
LLY,LLY:US,BBG000BNBDC2,Lilly/Incyte pill beats placebo in mid-stage eczema trial,2017-09-14 15:35:18 +0000,https://finance.yahoo.com/news/lilly-incyte-pill-beats-placebo-130000312.html?.tsrc=rss,"Eli Lilly and Co and Incyte Corp  on Thursday said a mid-stage trial of their oral drug  baricitinib showed that at the highest dose it worked better  than placebo for people with moderate-to-severe atopic  dermatitis.  The finding could be a boost for the drug's prospects, which  suffered a setback earlier this year after U.S. regulators  turned down an application for its use in rheumatoid arthritis,  saying that more data was needed.  Baricitinib, in a class of drugs known as Jak inhibitors, is  sold in the European Union under the brand name Olumiant for  treating rheumatoid arthritis."
LLY,LLY:US,BBG000BNBDC2,Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,2017-09-14 13:00:00 +0000,https://finance.yahoo.com/news/baricitinib-meets-primary-endpoint-phase-130000044.html?.tsrc=rss,- Results presented at EADV show baricitinib significantly improved clinical and patient-reported outcomes compared to placebo in moderate-to-severe atopic dermatitis patients - Improvements seen as early ...
LLY,LLY:US,BBG000BNBDC2,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib,2017-09-14 09:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KTWtKkhO53o/lilly-announces-new-safety-and-efficacy-data-from-phase-2-study-of-baricitinib-20170914-00684,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib
LLY,LLY:US,BBG000BNBDC2,Astra's Farxiga results may open up type 1 diabetes opportunity,2017-09-14 07:30:02 +0000,https://finance.yahoo.com/news/astras-farxiga-results-may-open-073002268.html?.tsrc=rss,"AstraZeneca's Farxiga  was shown to help type-1 diabetics when added to standard  insulin therapy, possibly opening up a additional market  opportunity for the type-2 diabetes drug, the British drugmaker  said in a statement on Thursday.  Adding Farxiga, also known as dapagliflozin, helped reduce  excess glucose levels in the blood, led to some weight loss and  allowed patients to lower their insulin dose, when compared to a  control group that received insulin only, the group said, citing  interim results from a late-stage trial."
LLY,LLY:US,BBG000BNBDC2,Is Lilly Headed for the Valley?,2017-09-13 19:44:00 +0000,http://finance.yahoo.com/r/7773f79f-917f-3665-9a28-994b3320c98f/lilly-headed-valley?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The path of least resistance for LLY is lower.
LLY,LLY:US,BBG000BNBDC2,Array's NDAs for Melanoma Combo Accepted for Review by FDA,2017-09-13 16:39:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-x6R-Qh33tw/arrays-ndas-for-melanoma-combo-accepted-for-review-by-fda-cm845165,Array BioPharma ARRY announced that the FDA has accepted for review its two New Drug Applications NDAs seeking approval for the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily COMBO450 to treat patients with BRAF mutant advanced unresectable or
LLY,LLY:US,BBG000BNBDC2,Drug Companies Tie Costs to Outcomes,2017-09-13 04:34:55 +0000,http://finance.yahoo.com/r/6e2ea8d9-1a63-34c9-8fc8-a99b31267795/drug-companies-tie-costs-to-outcomes-1505268421?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,But early signs show little evidence that the plans lower prices.
LLY,LLY:US,BBG000BNBDC2,1 Stock for General Electric Shareholders Now That Buffett Has Sold,2017-09-13 02:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3W29F-HW3O0/1-stock-for-general-electric-shareholders-now-that-buffett-has-sold-cm844691,Shareholders of General Electric NYSE GE 160 who were disillusioned following the announcement that Berkshire Hathaway NYSE BRK A NYSE BRK B has sold all of its remaining stake in the company should take heart There s more than one fish in the investment sea That
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : September 12, 2017",2017-09-12 23:46:39 +0000,http://finance.yahoo.com/r/e160c7ba-f23f-35b3-be98-d8e8e390a518/eli-lilly-co-value-analysis-nyselly-september-12-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Eli Lilly & Co. a score of 59. Our analysis is based on comparing Eli Lilly & Co. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Roche Holding Ltd ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,AbbVie's RA Candidate Meets Primary Endpoint in Phase III,2017-09-12 16:38:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dJzLP19PRKo/abbvies-ra-candidate-meets-primary-endpoint-in-phase-iii-cm844374,AbbVie s ABBV shares increased almost 2 after the company announced that its oral JAK 1 selective inhibitor upadacitinib ABT 494 met primary endpoints in a phase III study for treatment of patients with rheumatoid arthritis RA In fact AbbVie s shares have rallied 38 9
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Present At Morgan Stanley Global Conference; Webcast At 12:55 PM ET,2017-09-12 11:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FNVTOjQYPKo/eli-lilly-to-present-at-morgan-stanley-global-conference-webcast-at-1255-pm-et-20170912-01044,Eli Lilly To Present At Morgan Stanley Global Conference; Webcast At 12:55 PM ET
LLY,LLY:US,BBG000BNBDC2,Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control,2017-09-12 10:59:00 +0000,https://finance.yahoo.com/news/jardiance-empagliflozin-tablets-reduced-risk-105900164.html?.tsrc=rss,"RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 12, 2017 /PRNewswire/ -- New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study.  A reduction in cardiovascular death was also seen when Jardiance was added to common first and second-line diabetes medications, such as metformin or sulfonylurea."
LLY,LLY:US,BBG000BNBDC2,Lilly: Jardiance Tablets Reduces Cardiovascular Death Risks In Type 2 Diabetes,2017-09-12 07:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DRbQ6n_MRDs/lilly-jardiance-tablets-reduces-cardiovascular-death-risks-in-type-2-diabetes-20170912-00422,Lilly: Jardiance Tablets Reduces Cardiovascular Death Risks In Type 2 Diabetes
LLY,LLY:US,BBG000BNBDC2,Array BioPharma And Others Shine At The ESMO 2017 Congress,2017-09-11 17:30:48 +0000,https://finance.yahoo.com/news/array-biopharma-others-shine-esmo-173048019.html?.tsrc=rss,"The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference. Here’s a breakdown of the highlights. ..."
LLY,LLY:US,BBG000BNBDC2,AbbVie says deaths in arthritis trial not linked to drug,2017-09-11 15:16:49 +0000,https://finance.yahoo.com/news/abbvie-reports-two-patient-deaths-133045534.html?.tsrc=rss,"AbbVie Inc said on Monday two  patients died in a late-stage trial of its rheumatoid arthritis  drug but that the deaths were not linked to the drug, which met  the study's main goals.  The trial was evaluating two doses of the drug upadacitinib  - 15 mg and 30 mg - in patients with moderate to severe  rheumatoid arthritis, who did not adequately respond to or were  intolerant to other anti-rheumatic drugs.  Upadacitinib, a once-daily pill, belongs to a class of drugs  known as JAK inhibitors, which block inflammation-causing  enzymes called Janus kinases and are being used to treat  rheumatoid arthritis among other diseases."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : September 11, 2017",2017-09-11 13:03:18 +0000,http://finance.yahoo.com/r/193440e3-0e9d-3527-b8dc-d7fcac7ccffa/eli-lilly-co-breached-its-50-day-moving-average-in-a-bullish-manner-lly-us-september-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Eli Lilly & Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress,2017-09-11 13:00:00 +0000,https://finance.yahoo.com/news/lilly-present-data-olumiant-baricitinib-130000146.html?.tsrc=rss,"Lilly will showcase 18 abstracts, including data for Olumiant in atopic dermatitis and Taltz in psoriatic diseases INDIANAPOLIS , Sept. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced ..."
LLY,LLY:US,BBG000BNBDC2,Corporate News Blog - Eli Lilly's Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 Study,2017-09-11 11:20:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-eli-lillys-112000819.html?.tsrc=rss,"Research Desk Line-up: Tonix Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 11 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Eli ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly takes on Pfizer, Novartis with new breast cancer drug data",2017-09-10 08:19:36 +0000,https://finance.yahoo.com/news/lilly-takes-pfizer-novartis-breast-081936133.html?.tsrc=rss,"NEW YORK/MADRID, Sept 10 (Reuters) - Eli Lilly  staked its claim for a slice of sales in a new class of breast  cancer drugs on Sunday as clinical data showed adding its  medicine abemaciclib to standard therapy reduced the risk of  disease progression by 46 percent.  Experts at the European Society for Medical Oncology (ESMO)  congress in Madrid said the experimental drug's efficacy was  comparable to that of rival drugs from Pfizer and  Novartis already on the market."
LLY,LLY:US,BBG000BNBDC2,Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer,2017-09-10 06:26:00 +0000,https://finance.yahoo.com/news/lilly-builds-upon-body-clinical-062600680.html?.tsrc=rss,"Randomized, placebo-controlled study confirms ramucirumab, in combination with docetaxel, significantly extended progression-free survival (PFS) in patients with platinum-refractory advanced urothelial ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Breast Cancer Drug Results May Challenge Pfizer Pill,2017-09-09 22:05:00 +0000,http://finance.yahoo.com/r/ea8fe05b-9e2f-351d-a60c-2390ce60989b/lilly-breast-cancer-drug-results-may-challenge-pfizer-pill?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co.’s experimental breast cancer drug abemaciclib, when combined with standard therapy, slowed the progression of the tumor in patients with an advanced form of the disease."
LLY,LLY:US,BBG000BNBDC2,Lilly drug cuts risk of advanced breast cancer progression -study,2017-09-09 22:05:00 +0000,https://finance.yahoo.com/news/lilly-drug-cuts-risk-advanced-220500170.html?.tsrc=rss,"An experimental Eli Lilly and Co  drug taken with  standard therapy reduced the risk of disease  progression by 46 percent versus standard therapy alone in women  not previously treated for advanced breast cancer, according to  interim data from a late stage study presented at a medical  meeting.  Adding the drug, abemaciclib, led to significant tumor  shrinkage in 59 percent of patients compared with 44 percent for  the control group in the ongoing study dubbed Monarch-3,  researchers reported.  For the study's main goal of progression-free survival  (PFS), women who received standard endocrine therapy of  letrozole or anastrazole on average went 14.7 months before  disease worsening."
LLY,LLY:US,BBG000BNBDC2,IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine,2017-09-09 12:00:00 +0000,https://finance.yahoo.com/news/ihc-2017-lillys-lasmiditan-significantly-120000804.html?.tsrc=rss,"INDIANAPOLIS, Sept. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant improvements compared to placebo in the Phase 3 SPARTAN study.  ""The data presented today demonstrate lasmiditan's potential to reduce pain and provide freedom from the most bothersome symptoms associated with migraine,"" said Christi Shaw, president of Lilly Bio-Medicines."
LLY,LLY:US,BBG000BNBDC2,Array Resumes Trades After Unveiling Data In Colon Cancer Trial,2017-09-08 20:35:43 +0000,http://finance.yahoo.com/r/4bc470db-f522-37cd-b744-a9942aa809b6/array-halted-pending-news-ahead-of-key-data-in-cancer-trials-2?src=A00220&yptr=yahoo&.tsrc=rss,Array shares were halted early Friday pending news likely tied to data regarding its Phase 3 trials in colon cancer and melanoma.
LLY,LLY:US,BBG000BNBDC2,"Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth",2017-09-08 15:55:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ELjzSz_DaM/lilly-to-cut-3500-jobs-to-invest-in-new-drugs-and-growth-cm842928,Eli Lilly amp Company LLY announced plans on Thursday to reduce its global workforce by approximately 3 500 positions These initiatives are expected to amass annualized savings of approximately 500 million beginning 2018 The drug giant plans to invest the savings in new drugs and
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018",2017-09-08 13:54:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gWEYvBsFK_k/pharma-stock-roundup-lilly-to-cut-jobs-streamline-operations-nvs-ceo-to-step-down-in-2018-cm842878,There were quite a few important developments this week with Eli Lilly and Company LLY announcing that it is streamlining its operations and cutting down its workforce as it focuses on developing new medicines and improving its cost structure Meanwhile Novartis NVS announced that its CEO
LLY,LLY:US,BBG000BNBDC2,"Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth",2017-09-08 13:54:01 +0000,https://finance.yahoo.com/news/lilly-cut-3-500-jobs-135401853.html?.tsrc=rss,"Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018",2017-09-08 12:25:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-lilly-cut-122512134.html?.tsrc=rss,Key highlights this week include Eli Lilly and Company&apos;s (LLY) decision to cut the work force and streamline operations and Merck&apos;s efforts to strengthen its immune-oncology franchise.
LLY,LLY:US,BBG000BNBDC2,Understanding Merck’s Valuation after 2Q17,2017-09-08 11:38:13 +0000,http://finance.yahoo.com/r/63146f08-0644-3585-80c9-23825ddc23cc/understanding-mercks-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective",2017-09-08 11:15:38 +0000,http://finance.yahoo.com/r/492af4cb-9d16-389b-8535-7d7b1a955349/Story.aspx?guid=4D91B023-19EA-422B-A4AD-5786020AC841&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said early Friday that its migraine prevention drug had positive results in a late-stage, 12-month open-label study. The therapy, galcanezumab, showed a positive safety and tolerability ..."
LLY,LLY:US,BBG000BNBDC2,IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine,2017-09-08 10:45:00 +0000,https://finance.yahoo.com/news/ihc-2017-lillys-galcanezumab-demonstrates-104500282.html?.tsrc=rss,"INDIANAPOLIS, Sept. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive safety and tolerability profile in patients with migraine, consistent with previous studies.  Detailed results from a 12-month, open-label Phase 3 study will be presented today at the 18th Congress of the International Headache Society (IHC) in Vancouver.  Over the 12-month treatment period, galcanezumab was also associated with a statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)."
LLY,LLY:US,BBG000BNBDC2,Wall Street To Reflect Worries On Natural Disasters,2017-09-08 07:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/inj9Btkunmw/wall-street-to-reflect-worries-on-natural-disasters-20170908-00284,Wall Street To Reflect Worries On Natural Disasters
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study,2017-09-08 06:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QP14QkgsYCY/eli-lilly-galcanezumab-shows-positive-safety-results-in-12month-phase-3-study-20170908-00199,Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study
LLY,LLY:US,BBG000BNBDC2,"[$$] Eli Lilly to Cut 8% of Jobs, Invest More on New Drugs",2017-09-08 05:05:45 +0000,http://finance.yahoo.com/r/1a3f2c03-78db-3f71-b052-cf24266a0c2c/eli-lilly-to-cut-8-of-global-workforce-or-3-500-jobs-1504790131?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Eli Lilly plans to cut its global workforce by about 8% and close several facilities, a step it said it needs to make to lower costs and raise investment in new drugs as the company faces patent expirations ..."
LLY,LLY:US,BBG000BNBDC2,PRESS DIGEST - Wall Street Journal - Sept 8,2017-09-08 03:58:57 +0000,https://finance.yahoo.com/news/press-digest-wall-street-journal-035857908.html?.tsrc=rss,"The following are the top stories in the  Wall Street Journal.  - Amazon.com Inc on Thursday launched an  plan to  establish a second corporate headquarters in North America,  creating up to 50,000 high-paying jobs, many in software  development and most of them new.  - President Donald Trump signaled he was open to making more  deals with Democrats in Congress despite anger from fellow  Republicans over a bipartisan agreement that passed the Senate  Thursday."
LLY,LLY:US,BBG000BNBDC2,"[$$] Eli Lilly to Cut Jobs, Invest More on New Drugs",2017-09-08 00:14:29 +0000,http://finance.yahoo.com/r/1a3f2c03-78db-3f71-b052-cf24266a0c2c/eli-lilly-to-cut-8-of-global-workforce-or-3-500-jobs-1504790131?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Eli Lilly plans to cut its global workforce by about 8% and close several facilities, a step it said it needs to make to lower costs and raise investment in new drugs as the company faces patent expirations ..."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Co (LLY) Layoffs: Drugmaker to Cut 3,500 Jobs",2017-09-07 20:53:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2qg0h_Pa0sc/eli-lilly-and-co-lly-layoffs-drugmaker-to-cut-3500-jobs-cm842624,InvestorPlace Stock Market News Stock Advice amp Trading Tips Eli Lilly and Co NYSE LLY is planning to lay off employees in an effort to save money Source Paul Sableman via Flickr Eli Lilly and Co says that the layoffs will mostly come from its voluntary retirement
LLY,LLY:US,BBG000BNBDC2,"Hurricane Irma, a Debt Deal and Disney Cause Wall Street Waves",2017-09-07 20:05:00 +0000,http://finance.yahoo.com/r/70084a8b-c8d8-393e-bef9-8acd69aa6057/hurricane-irma-a-debt-deal-and-disney-cause-wall-street-waves.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Hurricane Irma and disappointing Disney guidance caused market waves. Here's where stocks ended Thursday.
LLY,LLY:US,BBG000BNBDC2,Hurricane Irma Bears Down on Equities and Disney Slide Hits Dow,2017-09-07 18:56:00 +0000,http://finance.yahoo.com/r/bb2c411e-3fd3-3920-b569-0063042bcc9d/hurricane-irma-prep-harvey-recovery-send-stocks-seesawing.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Stocks are mixed after Wednesday's gains. Here's where stocks are trading Thursday afternoon.
LLY,LLY:US,BBG000BNBDC2,"[$$] Eli Lilly cuts 3,500 jobs as focus turns to costs",2017-09-07 17:51:38 +0000,"http://finance.yahoo.com/r/29d38661-35ad-34c9-83b5-31b515e8579e/e4e62632-93f0-11e7-a9e6-11d2f0ebb7f0,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","US pharmaceutical group Eli Lilly will make job cuts and close sites as part of an effort to lower costs, streamline operations and invest in new medicines. The Indiana-based company said on Thursday that ..."
LLY,LLY:US,BBG000BNBDC2,Lilly to lay off 8 percent of employees in bid to cut costs,2017-09-07 16:35:44 +0000,https://finance.yahoo.com/news/lilly-cut-8-percent-jobs-134449349.html?.tsrc=rss,"Lilly will cut about 3,500 positions around the world, resulting in yearly savings of about $500 million, beginning in 2018.  Lilly's operating margins have lagged behind those of the company's rivals, according to Morningstar analyst Damien Conover.  Lilly expects charges of about $1.2 billion before tax, or $0.80 per share after tax."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Co (LLY) Layoffs: Drugmaker to Cut 3,500 Jobs",2017-09-07 16:25:31 +0000,https://finance.yahoo.com/news/eli-lilly-co-lly-layoffs-162531712.html?.tsrc=rss,"Eli Lilly and Co says that the layoffs will mostly come from its voluntary retirement offer made today.  This offer will be available to select U.S. employees until Dec. 31, 2017 and will include enhanced retirement benefits.  Eli Lilly and Co notes that the layoffs will include it eliminating 3,500 positions."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: Need to free up resources for new investme...,2017-09-07 15:18:00 +0000,https://finance.yahoo.com/video/eli-lilly-ceo-free-resources-151800258.html?.tsrc=rss,CNBC's Meg Tirrell reports on comments from the CEO of Eli Lilly following the pharmaceutical giant's announcement of global job cuts.
LLY,LLY:US,BBG000BNBDC2,"Hurricane Irma Prep, Harvey Recovery Set Wall Street on Edge",2017-09-07 14:42:00 +0000,http://finance.yahoo.com/r/51bc558c-ceb1-3b1f-9b49-e27b8a70415f/stocks-higher-as-ecb-holds-rates-u-s-jobless-claims-surge.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Stocks fluctuate after Wednesday's gains. Here's where stocks are trading at the market open on Thursday.
LLY,LLY:US,BBG000BNBDC2,Drugmaker Lilly to trim workforce by nearly 9 percent,2017-09-07 14:31:43 +0000,https://finance.yahoo.com/news/drugmaker-lilly-trim-workforce-nearly-135654841.html?.tsrc=rss,"Eli Lilly will slash its global workforce by nearly 9 percent as the drugmaker closes some research sites and pushes to trim fixed costs. The Indianapolis company said Thursday it will cut about 3,500 ..."
LLY,LLY:US,BBG000BNBDC2,Drugmaker Lilly to trim workforce by nearly 9 percent,2017-09-07 13:56:54 +0000,http://finance.yahoo.com/r/928073c1-1f3a-3dd2-80c1-6396bdfd95f4/drugmaker-lilly-trim-workforce-nearly-135654841.html?.tsrc=rss,INDIANAPOLIS (AP) — Eli Lilly will slash its global workforce by nearly 9 percent as the drugmaker closes some research sites and pushes to trim fixed costs.
LLY,LLY:US,BBG000BNBDC2,Lilly to cut 8 pct jobs as it works to reduce costs,2017-09-07 13:47:55 +0000,https://finance.yahoo.com/news/lilly-cut-8-pct-jobs-134755382.html?.tsrc=rss,"Eli Lilly and Co said on Thursday  it would lay off about 8 percent of its employees as the  drugmaker, which delayed development of a potential blockbuster  rheumatoid arthritis drug earlier this year, works to cut costs.  Lilly said it would cut about 3,500 positions around the  world, resulting in yearly savings of about $500 million,  beginning in 2018.  Shares of Lilly rose 41 cents, or 0.5 percent, to $80.92."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly to cut 3,500 jobs after part of cost cutting plan",2017-09-07 13:31:21 +0000,http://finance.yahoo.com/r/69a29b64-b8ae-3115-a37f-7163f20f391d/Story.aspx?guid=2B7A2F5B-A274-4EDD-ADD0-86147D0C4CFB&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said it will cut about 3,500 jobs, or about 8.3% of its global workforce, as part of a streamlining plan aimed at cutting costs by $500 million a year. The drug giant expects most of the ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly to cut 8 pct jobs, focus on developing new medicines",2017-09-07 13:29:42 +0000,https://finance.yahoo.com/news/lilly-cut-8-pct-jobs-132942290.html?.tsrc=rss,"Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees to focus on developing new medicines and cut costs. The drugmaker said the workforce reduction, including those from ..."
LLY,LLY:US,BBG000BNBDC2,"Drugmaker Eli Lilly Will Cut 3,500 Jobs",2017-09-07 13:22:18 +0000,http://finance.yahoo.com/r/e500271c-2bb6-3b7b-acd7-bcb623ee2f41/lilly-to-cut-3-500-jobs-close-sites-as-drugmaker-streamlines?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. plans to cut 8.5 percent of its workforce in a bid to free up resources to fund new drugs, amid acute pricing pressure for some of its biggest products."
LLY,LLY:US,BBG000BNBDC2,"Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth",2017-09-07 13:15:00 +0000,https://finance.yahoo.com/news/lilly-takes-steps-streamline-business-131500614.html?.tsrc=rss,"INDIANAPOLIS, Sept. 7, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines and to improve its cost structure.  With the streamlining efforts announced, the company expects annualized savings of approximately $500 million that will begin to be realized in 2018.  ""We have an abundance of opportunities—eight medicines launched in the past four years and the potential for two more by the end of next year,"" said David A. Ricks, Lilly's chairman and chief executive officer."
LLY,LLY:US,BBG000BNBDC2,"Lilly Plans To Cut About 3,500 Jobs Globally",2017-09-07 09:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0i7EPCEdQdc/lilly-plans-to-cut-about-3500-jobs-globally-20170907-00878,"Lilly Plans To Cut About 3,500 Jobs Globally"
LLY,LLY:US,BBG000BNBDC2,Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand,2017-09-06 21:36:41 +0000,http://finance.yahoo.com/r/ac5a5145-cbe0-32ea-8be0-6775333230bf/captisol-enabled-prexasertib-may-prove-major-growth-driver-ligand-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic ..."
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks Worth a Look on Promising Cancer Pipeline,2017-09-06 16:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KlT1ZASm774/4-drug-stocks-worth-a-look-on-promising-cancer-pipeline-cm841764,Cancer is the second most common cause of death in the U S preceded only by heart disease The traditional cancer treatments include surgery radiation and chemotherapy However immunotherapy gene therapy and other new novel therapies are being developed to improve supplement or
LLY,LLY:US,BBG000BNBDC2,Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer,2017-09-06 16:52:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g6PGdb900_Q/mercks-mrk-keytruda-gets-eu-approval-for-bladder-cancer-cm841692,Merck amp Co Inc MRK announced that its anti PD 1 therapy Keytruda has received approval from the European Commission EC for the first and second line treatment of certain patients with locally advanced or metastatic urothelial carcinoma a type of bladder cancer Keytruda has
LLY,LLY:US,BBG000BNBDC2,Here's Why Novo Nordisk A/S Gained 12% in August,2017-09-06 15:52:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5qxEZIwi8n4/heres-why-novo-nordisk-as-gained-12-in-august-cm841573,What happened Shares of Danish pharma giant Novo Nordisk A S NYSE NVO 160 rose 11 7 in August according to data from S amp P Global Market Intelligence Investors were relieved to see that the 160 sales stall the company had warned about last summer never
LLY,LLY:US,BBG000BNBDC2,Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC),2017-09-06 10:45:00 +0000,https://finance.yahoo.com/news/lilly-present-data-galcanezumab-lasmiditan-104500381.html?.tsrc=rss,"INDIANAPOLIS , Sept. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for migraine, at ..."
LLY,LLY:US,BBG000BNBDC2,Asian Markets Mostly Lower,2017-09-05 23:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wAA1OVbjHww/asian-markets-mostly-lower-20170905-01623,Asian Markets Mostly Lower
LLY,LLY:US,BBG000BNBDC2,Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018,2017-09-05 22:49:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ol9pgMfBBQM/narasimhan-to-replace-jimenez-as-novartis-nvs-ceo-in-2018-cm841279,Novartis AG NVS announced that its Chief Executive Officer CEO Joseph Jimenez will step down from his position in 2018 Vasant Narasimhan M D Global Head of Drug Development and Chief Medical Officer will replace him effective Feb 1 2018 Narasimhan is a member of the Executive
LLY,LLY:US,BBG000BNBDC2,Australian Market Declines,2017-09-05 21:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SiDZYm8gPsg/australian-market-declines-20170905-01606,Australian Market Declines
LLY,LLY:US,BBG000BNBDC2,The Key Reason Incyte Corporation Added $850 Million in Market Cap in August,2017-09-05 16:50:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BR0CK5h-V34/the-key-reason-incyte-corporation-added-850-million-in-market-cap-in-august-cm841083,What happened Shares of Incyte NASDAQ INCY a large cap biotech company primarily focused on developing therapies to treat cancer and inflammatory diseases tacked on more than 4 per share or 850 million in total market cap during the month of August according to S amp
LLY,LLY:US,BBG000BNBDC2,The Key Reason Incyte Corporation Added $850 Million in Market Cap in August,2017-09-05 14:46:00 +0000,http://finance.yahoo.com/r/67f3ef89-f1b4-3640-922e-25a7caa0809a/the-key-reason-incyte-corporation-added-850-millio.aspx?yptr=yahoo&.tsrc=rss,An update on bariticinib&apos;s review timeline has Wall Street rightly excited.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings,2017-09-05 13:06:30 +0000,http://finance.yahoo.com/r/a44f3500-63f2-3206-a0a5-24d8d9f6d8cb/eli-lilly-co-s-recent-developments-after-its-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology."
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly & Co.’s Elanco in 2Q17,2017-09-05 11:36:36 +0000,http://finance.yahoo.com/r/be89281a-c7cf-3dab-b0bb-2f6933974497/performance-of-eli-lilly-co-s-elanco-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Elanco reported revenues of $784.8 million during 2Q17, a 9.0% decline in revenues compared to $859.8 million during 2Q16."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Cardiovascular Products in 2Q17,2017-09-04 14:36:44 +0000,http://finance.yahoo.com/r/8398990c-6ca1-3765-a19a-8cc65752efa9/eli-lillys-cardiovascular-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company's total revenues.
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Neuroscience Products in 2Q17,2017-09-04 13:06:46 +0000,http://finance.yahoo.com/r/262890cf-e39c-3b6d-80d6-a42bfb0d0d72/performance-of-eli-lillys-neuroscience-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Cymbalta's sales totaled $206.6 million during 2Q17, a 13.0% decline compared to sales of $236.5 million in 2Q16."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Oncology Products in 2Q17,2017-09-04 11:36:52 +0000,http://finance.yahoo.com/r/9ae2d6a9-cc07-347a-bd0a-adc427bbe940/eli-lillys-oncology-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Alimta's sales totaled $532.9 million during 2Q17, a 12.0% decrease compared to $607.1 million for 2Q16."
LLY,LLY:US,BBG000BNBDC2,Learn From My Portfolio Mistakes: Cramer's 'Mad Money' Recap (Friday 9/1/17),2017-09-01 23:01:00 +0000,http://finance.yahoo.com/r/46d16d2b-4021-3ee9-9725-99d7ed03c025/learn-from-my-portfolio-mistakes-cramer-s-mad-money-recap-friday-9-1-17-.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Jim Cramer has learned -- sometimes the hard way -- what works and what doesn't at Action Alerts PLUS. Here's how his thinking can help you profit.
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. Pfizer Inc.,2017-09-01 19:49:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v6omtrCe_NM/better-buy-eli-lilly-and-company-vs-pfizer-inc-cm840443,Two of the biggest pharmaceutical companies in the world have been around since the 19th century Eli Lilly and Company NYSE LLY was founded in 1876 while Pfizer Inc NYSE PFE began operations even earlier in 1849 Overall Pfizer stock has been the better investment That
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. Pfizer Inc.,2017-09-01 18:41:00 +0000,http://finance.yahoo.com/r/be55ce5f-e0c6-3891-9dbd-6b9b822f9f62/better-buy-eli-lilly-and-company-vs-pfizer.aspx?yptr=yahoo&.tsrc=rss,How do Eli Lilly and Pfizer fare in a head-to-head matchup between the two big pharma stocks?
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Endocrine Franchise in 2Q17,2017-09-01 14:37:34 +0000,http://finance.yahoo.com/r/bf47f0ee-acec-305f-99f3-9b99a8400c94/performance-of-eli-lillys-endocrine-franchise-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Forteo is used for the treatment of osteoporosis. Forteo's sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update",2017-09-01 13:54:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O-ksqXE2hTc/pharma-stock-roundup-novartis-car-t-drug-gets-fda-nod-lilly-gives-baricitinib-update-cm840130,It was a historic week not just for Novartis NVS but also for the medical community and patients with the FDA giving its nod to the first gene therapy in the United States Novartis Kymriah This marks the beginning of a new era for the treatment of cancer and other serious and life
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s New Products in 2Q17,2017-09-01 13:08:25 +0000,http://finance.yahoo.com/r/dfa7ee31-f445-3d60-bd17-9bfd6603f78a/eli-lillys-new-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Trulicity's sales totaled $480.2 million during 2Q17, representing growth exceeding 100% compared to $201.3 million during 2Q16."
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-09-01 12:00:55 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120055698.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Business Segments in 2Q17,2017-09-01 11:38:40 +0000,http://finance.yahoo.com/r/5cb4abde-2154-3b5b-9ee8-a0ff22a83c25/performance-of-eli-lillys-business-segments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues."
LLY,LLY:US,BBG000BNBDC2,How United Therapeutics’ Adcirca and Tyvaso Are Positioned in 3Q17,2017-09-01 11:37:19 +0000,http://finance.yahoo.com/r/ed68c9cb-d716-333a-8fc6-413f40acd658/how-united-therapeutics-adcirca-and-tyvaso-are-positioned-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, United Therapeutics’ (UTHR) Adcirca generated revenues of around $120.6 million."
LLY,LLY:US,BBG000BNBDC2,"Bristol-Myers Squibb, Pfizer, Abbott Are on the Move: Buy These Target Prices",2017-09-01 00:11:00 +0000,http://finance.yahoo.com/r/c1a13695-f358-3adc-9a14-7d7b6a3efea7/eli-lilly-pfizer-abbott-are-big-pharma-on-the-move-buy-these-target-prices.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Check out these three big movers today.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Revenues in 2Q17,2017-08-31 20:36:06 +0000,http://finance.yahoo.com/r/be01a114-2bbb-3c8d-95f7-7e0a2a8513a0/eli-lilly-co-s-revenues-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. (LLY) reported revenues of ~$5.8 billion during 2Q17, reflecting 8.0% growth compared to its revenues in 2Q16."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Valuations after Its 2Q17 Earnings,2017-08-31 19:02:29 +0000,http://finance.yahoo.com/r/3c187d36-78e5-35ef-a953-453f81dbec46/eli-lillys-valuations-after-its-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of ..."
LLY,LLY:US,BBG000BNBDC2,Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected,2017-08-31 16:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HANSn7KYG40/lillyincyte-to-re-file-baricitinib-nda-faster-than-expected-cm839768,Eli Lilly amp Company LLY and partner Incyte Corporation INCY announced that they will re submit the new drug application NDA for its rheumatoid arthritis RA drug baricitinib much faster than previously expected The NDA is expected to be re submitted in January next year In July
LLY,LLY:US,BBG000BNBDC2,Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected,2017-08-31 15:10:03 +0000,https://finance.yahoo.com/news/lilly-incyte-file-baricitinib-nda-151003842.html?.tsrc=rss,"Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected."
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-08-31 12:00:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120052985.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,The Hot Stocks: Incyte Jumps 11%,2017-08-30 20:58:00 +0000,http://finance.yahoo.com/r/7e20f5f9-f898-3da2-bda3-4fefa8f6d75a/the-hot-stocks-incyte-jumps-11-1504126725?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte (INCY) soared to the top of the S&P 500 today on reports that it--and partner Eli Lilly (LLY)--plans to try to get its rheumatoid arthritis drug approved by the FDA after getting delayed earlier this year.  Incyte gained 11% to $138.27 today, while the S&P 500 rose 0.5% to 2,457.59.  Eli Lilly gained 2.5% to $80.49."
LLY,LLY:US,BBG000BNBDC2,Incyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approval,2017-08-30 19:23:45 +0000,http://finance.yahoo.com/r/e318d3a7-02ad-3008-8fe2-691aaf764b03/Story.aspx?guid=C7176A63-6AB4-447B-82C0-FA4E578E9D09&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Incyte Corp. shares soared 10.1% in extremely heavy Wednesday trade after news that it and Eli Lilly & Co. plan to reapply for approval of rheumatoid arthritis drug baricitinib by the end of January 2018, ..."
LLY,LLY:US,BBG000BNBDC2,Merck: Heartbreak Over A Cholesterol Drug,2017-08-30 15:46:00 +0000,http://finance.yahoo.com/r/c7945d4c-67f3-3280-aac8-18b2e25cb635/merck-heartbreak-over-a-cholesterol-drug-1504108016?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Is it still a good time to buy Merck & Co. (MRK)?  In fact, Merck appears poised to become the leader in the new market for immuno-cancer therapies that use the body’s own defense system to battle malignant cells.  Thanks to underwhelming results from a big study of its experimental cholesterol drug anacetrapib, Merck’s fortunes seem more attached than ever to those cancer drugs."
LLY,LLY:US,BBG000BNBDC2,Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%,2017-08-30 14:52:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bZuu54b7bA4/mercks-cetp-inhibitor-reduces-cardiovascular-risk-by-9-cm839057,Merck amp Co Inc MRK announced detailed data from a large phase III cardiovascular outcomes study REVEAL evaluating anacetrapib a cholesteryl ester transfer protein CETP inhibitor in patients with cardiovascular disease Data from the phase III study showed that anacetrapib and
LLY,LLY:US,BBG000BNBDC2,Lilly lays out faster time frame for FDA drug resubmission,2017-08-30 14:04:19 +0000,http://finance.yahoo.com/r/b770126b-3968-3b97-ad65-20f50672b4c5/lilly-lays-faster-time-frame-140416900.html?.tsrc=rss,INDIANAPOLIS (AP) — Eli Lilly says it will resubmit its potential rheumatoid arthritis treatment to regulators several months faster than expected.
LLY,LLY:US,BBG000BNBDC2,Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers,2017-08-30 13:46:00 +0000,http://finance.yahoo.com/r/aad88e1b-1351-3caf-9d12-0a5e4370009d/otonomy-shares-fall-on-disappointing-phase-3-data-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.
LLY,LLY:US,BBG000BNBDC2,Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018,2017-08-30 10:45:00 +0000,https://finance.yahoo.com/news/lilly-file-baricitinib-resubmission-u-104500221.html?.tsrc=rss,"INDIANAPOLIS , Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) ..."
LLY,LLY:US,BBG000BNBDC2,Wall Street To Open In Greener Zone,2017-08-30 07:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qADRvhGq9M4/wall-street-to-open-in-greener-zone-20170830-00323,Wall Street To Open In Greener Zone
LLY,LLY:US,BBG000BNBDC2,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018,2017-08-30 07:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tqEaXVzncOE/lilly-to-resubmit-nda-for-baricitinib-to-fda-before-end-of-january-2018-20170830-00267,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018
LLY,LLY:US,BBG000BNBDC2,Biogen Alzheimer's Drug Shows Promise in Long-Term Study,2017-08-29 17:52:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MV4uBZiaT8g/biogen-alzheimers-drug-shows-promise-in-long-term-study-cm838739,Biogen Inc BIIB announced data from a long term study on its Alzheimer s disease AD candidate aducanumab Data from the study showed a continued benefit in the rate of amyloid decline over a two three year period in patients with prodromal or mild Alzheimer s disease when treated
LLY,LLY:US,BBG000BNBDC2,Bristol-Myers Squibb’s Valuation after 2Q17 Earnings,2017-08-29 17:12:58 +0000,http://finance.yahoo.com/r/6187a854-9ad1-3969-b977-291393c7d80a/bristol-myers-squibbs-valuation-after-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
LLY,LLY:US,BBG000BNBDC2,Anthera's Blisibimod Positive in Phase II Extension Study,2017-08-29 16:53:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GBkXAOpCQTw/antheras-blisibimod-positive-in-phase-ii-extension-study-cm838694,Anthera Pharmaceuticals Inc ANTH announced positive top line data from the extension of a phase II BRIGHT SC study evaluating key pipeline candidate blisibimod for treatment of patients with IgA nephropathy IgAN Notably the BRIGHT SC study is randomized double blind
LLY,LLY:US,BBG000BNBDC2,Biogen Alzheimer&apos;s Drug Shows Promise in Long-Term Study,2017-08-29 15:29:03 +0000,https://finance.yahoo.com/news/biogen-alzheimer-apos-drug-shows-152903612.html?.tsrc=rss,"Biogen (BIIB) announced data from a long-term study on its Alzheimer&apos;s disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline."
LLY,LLY:US,BBG000BNBDC2,New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress,2017-08-29 10:45:00 +0000,https://finance.yahoo.com/news/phase-3-data-abemaciclib-ramucirumab-104500205.html?.tsrc=rss,"First presentations of MONARCH 3, a Phase 3 study of abemaciclib as initial treatment for advanced breast cancer, and RANGE, a Phase 3 study of ramucirumab for the treatment of platinum-refractory urothelial ..."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly To Present Data From Phase 3 Studies Of Abemaciclib, Ramucirumab",2017-08-29 07:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IzozDGVlHzA/eli-lilly-to-present-data-from-phase-3-studies-of-abemaciclib-ramucirumab-20170829-00321,"Eli Lilly To Present Data From Phase 3 Studies Of Abemaciclib, Ramucirumab"
LLY,LLY:US,BBG000BNBDC2,A Look at Johnson & Johnson’s Post-2Q17 Valuation,2017-08-28 18:59:09 +0000,http://finance.yahoo.com/r/6d6410be-034a-38e1-a1b0-341a26fef7ac/a-look-at-johnson-johnsons-post-2q17-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed ..."
LLY,LLY:US,BBG000BNBDC2,Lilly to Participate in Morgan Stanley Global Healthcare Conference,2017-08-28 18:00:00 +0000,https://finance.yahoo.com/news/lilly-participate-morgan-stanley-global-180000647.html?.tsrc=rss,"INDIANAPOLIS , Aug. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 . Derica Rice , Lilly's executive ..."
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's Victoza Gets FDA Nod for Label Expansion,2017-08-28 12:50:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0hkU92WXDXE/novo-nordisks-victoza-gets-fda-nod-for-label-expansion-cm837706,Novo Nordisk A S NVO shares gained 1 1 on Friday after it announced that the FDA has approved the label expansion of Victoza The drug is now approved as a treatment to reduce the risk of major adverse cardiovascular CV events including heart attack stroke and CV death in adults with
LLY,LLY:US,BBG000BNBDC2,FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk,2017-08-25 19:51:58 +0000,https://finance.yahoo.com/news/fda-clears-novo-nordisks-diabetes-191429121.html?.tsrc=rss,"Novo Nordisk  said on  Friday the U.S. Food and Drug Administration (FDA) approved an  expanded use of its diabetes drug to reduce the risk of  cardiovascular events such as heart attack and stroke.  This is the first time the FDA has cleared a diabetes drug  for reducing risks of heart attack, stroke and cardiovascular  deaths in patients with type 2 diabetes, the company said in a  statement."
LLY,LLY:US,BBG000BNBDC2,Steven Cohen Plunges Into Opioid Replacement Maker Pacira,2017-08-25 17:38:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W_ltYRVvVhk/steven-cohen-plunges-into-opioid-replacement-maker-pacira-cm837322,Steven Cohen Trades Portfolio founder of Point72 Asset Management made a 1098 increase to his holding of Pacira Pharmaceuticals PCRX he revealed this week Steven Cohen Trades Portfolio founder of Point72 Asset Management made a 1098 increase to his holding of
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug",2017-08-25 13:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8O4vBBSNiU/pharma-stock-roundup-roche-drug-gets-priority-review-eu-nod-for-novartis-drug-cm836996,Key news this week include priority review for Roche s RHHBY experimental hemophilia A drug and EU approval for Novartis NVS advanced breast cancer drug Meanwhile deals involving companies like AstraZeneca plc AZN and Eli Lilly and Company LLY were also announced this week Recap of
LLY,LLY:US,BBG000BNBDC2,Pharma Stocks That Could Move On New Data,2017-08-25 13:18:00 +0000,http://finance.yahoo.com/r/a7efbd61-1b8f-31b6-9135-c1324fe4dbf1/pharma-stocks-that-could-move-on-new-data-1503667101?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Jefferies’ Jeffrey Holford and his team take a look at the pharmaceutical sector, writing that AbbVie (ABBV) is still their top pick in the U.S., and parse how companies are positioned ahead of the upcoming European ..."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug",2017-08-25 11:22:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-roche-drug-112211459.html?.tsrc=rss,It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
LLY,LLY:US,BBG000BNBDC2,Analysts’ Recommendations for Merck in August 2017,2017-08-23 21:05:58 +0000,http://finance.yahoo.com/r/cc44b748-6ee5-3993-b00b-43ddf1ef1466/analysts-recommendations-for-merck-in-august-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 21 analysts tracking Merck in August 2017, three analysts recommended a “strong buy,” and ten analysts recommended a “buy.” Seven analysts recommended a ""hold,"" and one analyst recommended ..."
LLY,LLY:US,BBG000BNBDC2,Incyte Had These Key Collaborations and Developments in 2Q17,2017-08-23 15:53:09 +0000,http://finance.yahoo.com/r/d44557c7-fd8b-305b-a230-e06f99622b1d/incyte-had-these-key-collaborations-and-developments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets."
LLY,LLY:US,BBG000BNBDC2,Behind Incyte’s 2Q17 Product Portfolio,2017-08-23 11:37:35 +0000,http://finance.yahoo.com/r/0bacd429-0f0b-3652-9874-9a31ff34327b/behind-incytes-2q17-product-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.
LLY,LLY:US,BBG000BNBDC2,"[$$] Eli Lilly, Topas Therapeutics Join Together in Autoimmune Disease Alliance",2017-08-22 22:53:46 +0000,http://finance.yahoo.com/r/4fe42423-1fe3-3a8f-be23-48c218dc3088/eli-lilly-topas-therapeutics-join-together-in-autoimmune-disease-alliance-1503442424?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Topas Therapeutics GmbH, which last year sold venture firms on its technology for developing autoimmune-disease treatments, has now won over a large pharmaceutical company."
LLY,LLY:US,BBG000BNBDC2,Understanding Incyte’s 2Q17 Revenue Stream,2017-08-22 18:05:53 +0000,http://finance.yahoo.com/r/c5b7b710-8803-38ec-972c-961e8e32b384/understanding-incytes-2q17-revenue-stream?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
LLY,LLY:US,BBG000BNBDC2,3 Most Promising Cancer Drugs in Late-Stage Development,2017-08-22 12:38:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6xD44vzVHVs/3-most-promising-cancer-drugs-in-late-stage-development-cm835114,Progress marches on in the fight against cancer While more biosimilars 160 are becoming available for top cancer drugs of the past biopharmaceutical companies are developing newer and more powerful treatments Market research firm EvaluatePharma evaluated all of the
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-08-22 12:00:31 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120031774.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,3 Most Promising Cancer Drugs in Late-Stage Development,2017-08-22 11:23:00 +0000,http://finance.yahoo.com/r/02493484-59aa-3b65-a97f-cd2369e2d302/3-most-promising-cancer-drugs-in-late-stage-develo.aspx?yptr=yahoo&.tsrc=rss,"Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates."
LLY,LLY:US,BBG000BNBDC2,Zoetis (ZTS) Poised to Grow on Companion Animal Portfolio,2017-08-22 00:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xa07Swiu8D4/zoetis-zts-poised-to-grow-on-companion-animal-portfolio-cm835040,We issued an updated report on Zoetis Inc ZTS on Aug 18 Zoetis boasts a robust and diversified product portfolio The company s business is divided into five categories anti infectives vaccines parasiticides medicated feed additives and other pharmaceuticals Zoetis markets its
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Can Sales Grow Without M&A?,2017-08-18 20:47:00 +0000,http://finance.yahoo.com/r/57eeb2b2-3443-345b-aa86-02c716d3a601/eli-lilly-can-sales-grow-without-m-a-1503088068?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Can Eli Lilly (LLY) deliver the revenue growth it promised Wall Street?  It was last summer when the drug maker set a target for 5% average annual sales growth for the five-year period ending in 2020.  Now, Morgan Stanley David Risinger says Lilly can hit its growth goal, but only if it makes some acquisitions."
LLY,LLY:US,BBG000BNBDC2,Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017,2017-08-18 14:38:09 +0000,http://finance.yahoo.com/r/c64989ee-5d48-3ff0-817c-46e32c859820/opdivo-could-drive-bristol-myers-squibbs-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis."
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's Semaglutide Shows Remarkable Results in Study,2017-08-18 00:37:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zQgyFW0AMdA/novo-nordisks-semaglutide-shows-remarkable-results-in-study-cm833671,Novo Nordisk NVO announced results from SUSTAIN 7 study which showed that people with type II diabetes who are treated with once weekly semaglutide experienced superior reduction in HbA1c and body weight compared with treatment with Eli Lilly and Co s LLY Trulicity dulaglutide 160
LLY,LLY:US,BBG000BNBDC2,LLY Makes Notable Cross Below Critical Moving Average,2017-08-17 16:36:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CRyoxeFfhNY/lly-makes-notable-cross-below-critical-moving-average-cm833358,In trading on Thursday shares of Lilly Eli amp Co Symbol LLY crossed below their 200 day moving average of 79 22 changing hands as low as 78 65 per share Lilly Eli amp Co shares are currently trading off about 1 5 on the day The chart below shows the one year performance of
LLY,LLY:US,BBG000BNBDC2,"XLV, LLY, TMO, AET: ETF Outflow Alert",2017-08-17 16:34:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eMG4iGgdcjY/xlv-lly-tmo-aet-etf-outflow-alert-cm833350,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 39 7 million dollar outflow that s a 0 2 decrease week over week
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Will A New Rival Hobble Its Top Growth Driver?,2017-08-17 16:17:00 +0000,http://finance.yahoo.com/r/d2102cf5-0cbd-3903-ae18-378d8f0815aa/eli-lilly-will-a-new-rival-hobble-its-top-growth-driver-1502986651?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The Danish drug maker is the world’s largest manufacturer of insulin.  Late yesterday, the company unveiled data from the Sustain-7 trial that shows its diabetes treatment semaglutide bested a competing treatment made by Eli Lilly (LLY) in controlling blood sugar levels and aiding in weight loss.  Evercore ISI’s Umer Raffat called it a “best case outcome” for Novo Nordisk."
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's diabetes drug succeeds in key trial (Aug 16),2017-08-17 15:12:28 +0000,https://finance.yahoo.com/news/novo-nordisks-diabetes-drug-succeeds-151228406.html?.tsrc=rss,"Novo Nordisk A/S said on  Wednesday its diabetes drug met the main goal of reducing  glucose levels in patients in a key late-stage trial, setting  the stage for it to become the new standard therapy for type 2  diabetes.  The 40-week trial tested two dosages of Novo's once-weekly  drug, semaglutide, in addition to initial standard-of-care  therapy metformin, against Eli Lilly and Co's  dulaglutide plus metformin.  Novo Nordisk said semaglutide was statistically significant  in reducing glucose levels and body weight in about 1,200  patients suffering with type 2 diabetes, when compared with  dulaglutide."
LLY,LLY:US,BBG000BNBDC2,IYH's Underlying Holdings Imply 10% Gain Potential,2017-08-17 14:36:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3XkMWDOJNWE/iyhs-underlying-holdings-imply-10-gain-potential-cm833214,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's diabetes drug succeeds in key trial,2017-08-17 04:44:57 +0000,https://finance.yahoo.com/news/novo-nordisks-diabetes-drug-succeeds-044457488.html?.tsrc=rss,"Novo Nordisk A/S said on  Wednesday its diabetes drug met the main goal of reducing  glucose levels in patients in a key late-stage trial, setting  the stage for it to become the new standard therapy for type 2  diabetes.  The 40-week trial tested two dosages of Novo's once-weekly  drug, semaglutide, in addition to initial standard-of-care  therapy metformin, against Eli Lilly and Co's  dulaglutide plus metformin.  Novo Nordisk said its drug was statistically significant in  reducing glucose levels and lowering body weight in about 1,200  patients suffering from type 2 diabetes, when compared with  dulaglutide."
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's diabetes drug succeeds in key trial,2017-08-16 21:31:19 +0000,https://finance.yahoo.com/news/novo-nordisks-diabetes-drug-succeeds-213119886.html?.tsrc=rss,"Novo Nordisk A/S said on  Wednesday its diabetes drug met the main goal of reducing  glucose levels in patients in a key late-stage trial, setting  the stage for it to become the new standard therapy for type 2  diabetes.  The 40-week trial tested two dosages of Novo's once-weekly  drug, semaglutide, in addition to initial standard-of-care  therapy metformin, against Eli Lilly and Co's  dulaglutide plus metformin.  Novo Nordisk said semaglutide was statistically significant  in reducing glucose levels and body weight in about 1,200  patients suffering with type 2 diabetes, when compared with  dulaglutide."
LLY,LLY:US,BBG000BNBDC2,Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock,2017-08-16 18:30:11 +0000,https://finance.yahoo.com/news/goldman-sachs-bet-biogen-potential-183011242.html?.tsrc=rss,Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-08-16 12:00:33 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120033816.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,"ETFs with exposure to Eli Lilly & Co. : August 14, 2017",2017-08-14 20:48:53 +0000,http://finance.yahoo.com/r/6fdde28f-9783-3047-977f-fdcec05d78c3/etfs-with-exposure-to-eli-lilly-co-august-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Eli Lilly & Co. Here are 5 ETFs with the largest exposure to LLY-US. Comparing the performance and risk of Eli Lilly & Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,What Trump has done to lower the ‘RIPOFF DRUG PRICES’ he’s decrying,2017-08-14 18:20:36 +0000,https://finance.yahoo.com/news/trump-done-lower-ripoff-drug-prices-hes-decrying-182036675.html?.tsrc=rss,"Trump has decried these price hikes since the campaign.  President Donald Trump blasted Merck CEO Kenneth C. Frazier on Monday morning after Frazier announced he was leaving the President’s manufacturing council following Trump’s equivocal response to the neo-Nazi and white nationalist rally in Charlottesville, Virginia.  In March, Democratic Representatives Elijah Cummings (MD) and Peter Welch (VT) met with Trump to discuss their bill that would help lower prescription drug prices by allowing regulated drug importation and Medicare’s ability to negotiate wholesale prices for wholesale drugs, instead of retail prices."
LLY,LLY:US,BBG000BNBDC2,Will Nektar's (NKTR) Candidates Enhance Growth in 2017?,2017-08-14 16:37:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GbYUD-GBKAw/will-nektars-nktr-candidates-enhance-growth-in-2017-cm831733,On Aug 11 2017 we issued an updated report on Nektar Therapeutics NKTR a biopharmaceutical company focused on development of treatments by utilizing PEGylation and advanced polymer conjugate technology platforms Nektar s shares have significantly outperformed the industry so far
LLY,LLY:US,BBG000BNBDC2,Will Nektar&apos;s (NKTR) Candidates Enhance Growth in 2017?,2017-08-14 14:56:02 +0000,https://finance.yahoo.com/news/nektar-apos-nktr-candidates-enhance-145602276.html?.tsrc=rss,"Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology."
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-08-14 12:00:19 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120019318.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,Edited Transcript of LLY earnings conference call or presentation 25-Jul-17 1:00pm GMT,2017-08-13 08:06:06 +0000,https://finance.yahoo.com/news/edited-transcript-lly-earnings-conference-225002126.html?.tsrc=rss,Q2 2017 Eli Lilly and Co Earnings Call
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-08-12 12:00:28 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120028117.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,Pfizer’s Valuation after 2Q17 Earnings,2017-08-11 19:59:09 +0000,http://finance.yahoo.com/r/278f9d57-73ba-3f43-89ae-52dab407cb1b/pfizers-valuation-after-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16."
LLY,LLY:US,BBG000BNBDC2,"Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag",2017-08-11 19:35:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xitXTGiEMAc/nektars-nktr-shares-fall-post-wider-q2-loss-revenues-lag-cm831095,Nektar Therapeutics NKTR shares have declined almost 9 since Aug 8 after the company reported second quarter results The biotech reported a wider than expected loss while sales missed estimates Nektar s second quarter 2017 loss of 39 cents per share was wider than the Zacks
LLY,LLY:US,BBG000BNBDC2,"Nektar&apos;s (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag",2017-08-11 17:09:05 +0000,https://finance.yahoo.com/news/nektar-apos-nktr-shares-fall-170905616.html?.tsrc=rss,"Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues."
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global",2017-08-11 14:40:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A1HUREVoDoo/the-zacks-analyst-blog-highlights-eli-lilly-halliburton-monster-beverage-huntington-bancshares-and-liberty-global-cm830897,For Immediate Release Chicago IL August 11 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global",2017-08-11 12:12:12 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-121212783.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares and Liberty Global"
LLY,LLY:US,BBG000BNBDC2,See what the IHS Markit Score report has to say about Eli Lilly And Co.,2017-08-11 12:01:13 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120113285.html?.tsrc=rss,Eli Lilly And Co NYSE:LLY
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Eli Lilly, Halliburton & Monster Beverage",2017-08-11 05:35:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3wJCE9riJ6c/top-research-reports-for-eli-lilly-halliburton-monster-beverage-cm830671,Thursday August 10 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Eli Lilly LLY Halliburton HAL and Monster Beverage MNST These research reports have been hand
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Eli Lilly, Halliburton & Monster Beverage",2017-08-10 22:07:10 +0000,https://finance.yahoo.com/news/top-research-reports-eli-lilly-220710684.html?.tsrc=rss,"Top Research Reports for Eli Lilly, Halliburton & Monster Beverage"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 11, 2017",2017-08-10 14:03:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YgcRCna-n-Y/eli-lilly-and-company-lly-ex-dividend-date-scheduled-for-august-11-2017-cm830061,Eli Lilly and Company LLY will begin trading ex dividend on August 11 2017 A cash dividend payment of 0 52 per share is scheduled to be paid on September 08 2017 Shareholders who purchased LLY prior to the ex dividend date are eligible for the cash dividend payment This marks the
LLY,LLY:US,BBG000BNBDC2,"Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up",2017-08-09 16:38:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bXDhaBoqbxY/celldex-cldx-q2-loss-narrows-revenues-beat-shares-up-cm829529,Celldex Therapeutics Inc CLDX incurred second quarter 2017 loss of 23 cents per share which was narrower than the Zacks Consensus Estimate of a loss of 25 cents as well as the year ago loss of 32 cents per share Lower costs and higher revenues led to the narrower loss in the quarter
LLY,LLY:US,BBG000BNBDC2,"Ex-Dividend Reminder: Otter Tail, Eli Lilly and Teleflex",2017-08-09 15:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kIaVXbdC4CE/ex-dividend-reminder-otter-tail-eli-lilly-and-teleflex-cm829417,Looking at the universe of stocks we cover at Dividend Channel on 8 11 17 Otter Tail Corp Symbol OTTR Lilly Eli amp Co Symbol LLY and Teleflex Incorporated Symbol TFX will all trade ex dividend for their respective upcoming dividends Otter Tail Corp will pay its
LLY,LLY:US,BBG000BNBDC2,CVS Health's dull Q3 forecast overshadows profit beat,2017-08-08 16:29:07 +0000,https://finance.yahoo.com/news/cvs-healths-profit-beats-higher-114026935.html?.tsrc=rss,CVS Health Corp forecast current quarter profit below Wall Street estimates and said it has been ordered to cooperate with investigations into possible false claims submitted to a government healthcare ...
LLY,LLY:US,BBG000BNBDC2,Here's Why Array BioPharma Inc. Fell 13.7% in July,2017-08-07 21:36:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s9STc1HU2IA/heres-why-array-biopharma-inc-fell-137-in-july-cm828363,What happened Shares of Array BioPharma NASDAQ ARRY a cancer focused clinical stage biotech dropped nearly 14 in July according to data from S amp P Global Market Intelligence So what Here s a review of the two company announcements made during the
LLY,LLY:US,BBG000BNBDC2,"IWV, PEP, UNP, LLY: ETF Outflow Alert",2017-08-07 16:37:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sDlgrGTZrcU/iwv-pep-unp-lly-etf-outflow-alert-cm828163,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 3000 ETF Symbol IWV where we have detected an approximate 43 9 million dollar outflow that s a 0 6 decrease week over week from 53 650 000
LLY,LLY:US,BBG000BNBDC2,Q2 Earnings Fail to Impress Pharma ETF,2017-08-07 15:42:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7wKlBEenEnM/q2-earnings-fail-to-impress-pharma-etf-cm828073,Total earnings for 83 3 of the total healthcare market capitalization are up 6 on revenue growth of 4 1 Though earnings growth is weak compared with many other sectors earnings and revenue beat ratios of 85 and 70 respectively are particularly encouraging In fact healthcare is
LLY,LLY:US,BBG000BNBDC2,Can CVS Health Corp (CVS) Stock Stop Infuriating the Bulls?,2017-08-07 14:50:38 +0000,https://finance.yahoo.com/news/cvs-health-corp-cvs-stock-145038901.html?.tsrc=rss,"CVS Health Corp (NYSE:CVS) is one of the few stocks I have lost money on during the current bull market.  The balance sheet took a hit in 2015 when it took over Target Corporation (NYSE:TGT) pharmacies as part of a $1.9 billion deal, and bought Omnicare, a pharmacy for nursing homes, for $12.9 billion.  Despite this, CVS stock now is worth one-third less than it did when the deals went down."
LLY,LLY:US,BBG000BNBDC2,Q2 Earnings Fail to Impress Pharma ETF,2017-08-07 13:45:01 +0000,https://finance.yahoo.com/news/q2-earnings-fail-impress-pharma-134501496.html?.tsrc=rss,The string of earnings beat failed to boost pharma ETFs.
LLY,LLY:US,BBG000BNBDC2,"Featured Company News - Eli Lilly Achieves Positive Results for Second Phase-3 Study of Lasmiditan, an Acute Migraine Treatment",2017-08-07 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-eli-lilly-114000004.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / August 7, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Eli Lilly & Co. (NYSE: LLY ) (""Eli Lilly""), following ..."
LLY,LLY:US,BBG000BNBDC2,Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses,2017-08-04 22:01:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/libsZKVcRFE/radius-rdus-q2-loss-wider-than-expected-on-higher-expenses-cm827562,Radius Health Inc RDUS posted a loss of 1 58 per share in the second quarter of 2017 wider than the loss of 1 01 per share in the year ago quarter and wider than the Zacks Consensus Estimate loss of 1 35 The year over year increase in net loss was attributable to an increase in
LLY,LLY:US,BBG000BNBDC2,"[$$] CVS Formulary Changes Boost JNJ, Pfizer; Hurt Lilly",2017-08-04 15:13:00 +0000,http://finance.yahoo.com/r/a0bb1d20-316b-3806-b496-83916105154f/cvs-formulary-changes-boost-jnj-pfizer-hurt-lilly-1501859632?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse  CVS Health has released its 2018 Formulary Strategy, including the list of drugs that will be removed from the Standard Control Formulary.  As compared to the Express Scripts Holding (ESRX) 2018 National Formulary List that was released earlier this week, the list from CVS (CVS) has some changes that will likely be more impactful to the stocks in our coverage.  The most notable shift we see in CVS’ 2018 formulary is in the diabetes space, where Eli Lilly’s (LLY) SGLT-2 inhibitor Jardiance is being dropped from the Standard Control Formulary and Johnson & Johnson’s (JNJ) Invokana is being added back as a Preferred drug for 2018."
LLY,LLY:US,BBG000BNBDC2,Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring,2017-08-04 14:43:00 +0000,http://finance.yahoo.com/r/bd89cb5e-38d9-3055-9278-f07f1a700619/biotech-movers-buzz-on-potential-suitors-sends-united-therapeutics-stock-soaring.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals",2017-08-04 14:02:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ORWtwFM3l7Q/pharma-stock-roundup-mixed-2q-results-from-pfizer-bristol-myers-announces-io-deals-cm827183,This week companies like Pfizer PFE Allergan AGN and Teva TEVA reported second quarter results While Pfizer reported a mixed quarter Allergan topped expectations Teva however had a tough quarter Meanwhile Bristol Myers BMY announced immune oncology IO focused deals including
LLY,LLY:US,BBG000BNBDC2,Lilly's acute migraine drug succeeds in late-stage study,2017-08-04 13:43:57 +0000,https://finance.yahoo.com/news/lillys-acute-migraine-drug-succeeds-111827565.html?.tsrc=rss,"Drugmaker Eli Lilly and Co said on  Friday its acute migraine drug lasmiditan succeeded in a key  late-stage study, setting the stage for U.S. regulatory  approval.  About 40 million Americans suffer from migraine - intense  headaches characterized by throbbing pain and sensitivity to  light and nausea.  The size of the migraine market is expected to balloon to  more than $10 billion in 2025 from $3 billion in 2015 in the  United States and other developed countries, healthcare research  firm Decision Resources Group said last year."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Stock Rises on Positive Migraine Pill Test Results,2017-08-04 13:01:00 +0000,http://finance.yahoo.com/r/f031d862-baaa-31fa-8038-98efc7c854f8/eli-lilly-stock-rises-on-positive-migraine-pill-test-results.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,A majority of the test subjects were migraine pain-free two hours after the drug was administered.
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals",2017-08-04 12:47:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-mixed-2q-124712684.html?.tsrc=rss,Pfizer&apos;s (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
LLY,LLY:US,BBG000BNBDC2,"Early movers: ADP, WCG, F, NWL, VIAB, PBPB, LLY, GPRO & more",2017-08-04 11:53:09 +0000,https://finance.yahoo.com/news/early-movers-adp-wcg-f-115309995.html?.tsrc=rss,These are the stocks posting the largest moves before the bell.
LLY,LLY:US,BBG000BNBDC2,"Early movers: ADP, WCG, F, NWL, VIAB, PBPB, LLY, GPRO & more",2017-08-04 11:53:09 +0000,http://finance.yahoo.com/r/b94b2cc0-9223-3f5a-88e0-b88f1ca2a87e/104633163?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104633163&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
LLY,LLY:US,BBG000BNBDC2,CORRECTED: Eli Lilly & Co. says its migraine drug met primary endpoint in late-stage trial,2017-08-04 11:50:41 +0000,http://finance.yahoo.com/r/64a4b8d4-71c3-3b19-92a6-9abc829cf303/Story.aspx?guid=A992C4F3-A02D-4463-A818-C6F15252C9BA&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. said early Friday that its migraine drug lasmiditan met its primary endpoint and a key secondary endpoint in a late-stage clinical trial. The company plans to submit for Food and Drug Administration ...
LLY,LLY:US,BBG000BNBDC2,Lilly's acute migraine drug succeeds in late-stage study,2017-08-04 10:58:45 +0000,https://finance.yahoo.com/news/lillys-acute-migraine-drug-succeeds-104852178.html?.tsrc=rss,"Eli Lilly and Co said on Friday  its acute migraine drug, lasmiditan, induced a statistically  significant improvement in pain relief against a placebo in a  late-stage study.  The trial tested three doses of the oral drug against a  placebo.  Patients in the trial had an average of more than five  migraine attacks per month."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine,2017-08-04 10:45:00 +0000,https://finance.yahoo.com/news/lilly-announces-positive-results-second-104500788.html?.tsrc=rss,"INDIANAPOLIS, Aug. 4, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase 3 study.  At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo.  Lasmiditan also met the key secondary endpoint for SPARTAN across all three studied doses, with a statistically significantly greater percentage of patients free of their most bothersome symptom (MBS) compared with placebo at two hours following the first dose."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study,2017-08-04 06:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/33XqMgX5Nmw/eli-lilly-lasmiditan-meets-primary-endpoint-in-second-phase-3-study-20170804-00269,Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : August 3, 2017",2017-08-03 13:56:11 +0000,http://finance.yahoo.com/r/46bb6ed1-4336-33be-95f3-c5356b31d908/eli-lilly-co-breached-its-50-day-moving-average-in-a-bearish-manner-lly-us-august-3-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Eli Lilly & Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,Drugmakers Hunt for Patients in India’s Remote Corners,2017-08-02 16:00:01 +0000,http://finance.yahoo.com/r/90dfba7d-eae3-354d-8063-598701d45534/drug-giants-are-hunting-for-patients-in-india-s-remote-corners?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"First, foreign food brands flooded India with chips, cookies and soft drinks that fundamentally changed the nation’s eating habits. Now, Big Pharma wants to cash in on an upsurge in cases of diabetes and ..."
LLY,LLY:US,BBG000BNBDC2,How BMY Is Valued following Its 2Q17 Earnings,2017-08-02 11:37:01 +0000,http://finance.yahoo.com/r/024deee5-cd23-3f8c-8c34-d96b3e1e2b0f/how-bmy-is-valued-following-its-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb (BMY) met Wall Street analysts’ consensus estimate for earnings per share (or EPS) in 2Q17, reporting EPS of $0.74."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Valuation after 2Q17 Earnings Release,2017-08-02 11:35:56 +0000,http://finance.yahoo.com/r/692b92c6-c691-3256-a106-cddd80d7e3ab/eli-lillys-valuation-after-2q17-earnings-release?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, Eli Lilly (LLY) surpassed analysts’ EPS estimate of $1.05 and reported EPS of $1.11. Analysts are estimating EPS of $1.03 for 3Q17."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Major Developments in 2Q17,2017-08-01 14:36:13 +0000,http://finance.yahoo.com/r/1e14b3a0-10f7-3ccf-9ecc-00ae41ea2837/eli-lillys-major-developments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly repurchased shares worth $200.0 million and distributed dividends of more than $500.0 million to its shareholders in 2Q17.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Elanco in 2Q17,2017-08-01 13:06:43 +0000,http://finance.yahoo.com/r/de5db30c-92bf-35f8-afe4-3b22019d260e/eli-lillys-elanco-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Elanco's revenues fell 9.0% to $784.8 million during 2Q17 compared to $859.8 million during 2Q16.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly in 2Q17: Performance of Cardiovascular Products,2017-08-01 11:36:58 +0000,http://finance.yahoo.com/r/1ad57de5-0fac-3aa5-a9ef-58057394388c/eli-lilly-in-2q17-performance-of-cardiovascular-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Cialis reported nearly flat revenues at $627.3 million in 2Q17 compared to $630.5 million for 2Q16.
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. :LLY-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017",2017-07-31 17:43:19 +0000,http://finance.yahoo.com/r/988802bf-4e8d-33df-94a9-115ec12a356f/eli-lilly-co-lly-us-earnings-analysis-q2-2017-by-the-numbers-july-31-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Eli Lilly & Co. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Eli Lilly & Co. – Johnson & Johnson, Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc. and Novartis AG Sponsored ADR (JNJ-US, BMY-US, GSK-US, AMGN-US and ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY",2017-07-31 16:58:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EpIjHOlJH7M/drug-stocks-q2-earnings-releases-on-aug-1-pfe-aeri-incy-cm824357,We have already crossed the halfway mark of the second quarter reporting cycle The earning season has shown broad based growth with record earnings this quarter As of Jul 28 2017 286 S amp P 500 members accounting for 68 8 of the index s total market capitalization reported
LLY,LLY:US,BBG000BNBDC2,Eli Lilly in 2Q17: Performance of Neuroscience Products,2017-07-31 14:39:23 +0000,http://finance.yahoo.com/r/0554abbd-a464-3558-98ef-4ded750b9ac3/eli-lilly-in-2q17-performance-of-neuroscience-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Sales of Cymbalta fell ~13.0% to $206.6 million in 2Q17 compared to ~$236.5 million in 2Q16.
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More",2017-07-31 13:58:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6oRUXJ7Xm1g/pharma-stock-roundup-q2-earnings-results-from-merck-lilly-bristol-myers-more-cm824039,Last week several pharma majors reported second quarter results Meanwhile important study data was released by Merck MRK and AstraZeneca AZN Recap of the Week s Most Important Stories A Look at Q2 Earnings Results Big pharma companies like Merck Lilly LLY Glaxo
LLY,LLY:US,BBG000BNBDC2,Eli Lilly in 2Q17: Oncology Products Lose Revenues,2017-07-31 13:10:23 +0000,http://finance.yahoo.com/r/001cf010-9af1-32b8-9818-29e4fad043b4/eli-lilly-in-2q17-oncology-products-lose-revenues?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Alimta sales fell ~12.0% to $532.9 million in 2Q17 compared to $607.1 million in 2Q16.
LLY,LLY:US,BBG000BNBDC2,Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes,2017-07-31 13:00:00 +0000,https://finance.yahoo.com/news/boehringer-ingelheim-lilly-support-american-130000945.html?.tsrc=rss,"RIDGEFIELD, Conn. and INDIANAPOLIS, July 31, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and addressing the latest research advances in the reduction of cardiovascular risk and cardiovascular mortality in people with type 2 diabetes.  Despite recent advances, cardiovascular disease is still the leading cause of death associated with diabetes.  Given that people with diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes, cardiologists are treating more and more of the 30 million adults in the U.S. living with this condition who have experienced a cardiovascular event."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More",2017-07-31 12:06:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-q2-earnings-120612184.html?.tsrc=rss,Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly in 2Q17: Humulin and Endocrine Products,2017-07-31 11:40:34 +0000,http://finance.yahoo.com/r/b51df39e-7f3f-35bc-901c-79e33dbb6938/eli-lilly-in-2q17-humulin-and-endocrine-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly'’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.
LLY,LLY:US,BBG000BNBDC2,3 Biotech Stocks for Enterprising Investors,2017-07-29 11:58:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WT3j0UOo1XU/3-biotech-stocks-for-enterprising-investors-cm823767,The biotech sector isn t for the faint of heart While investors can strike it rich if they get lucky they can also lose a bundle if things don t go according to plan Given the risk it can take a lot of courage to put money to work in the sector Which biotech stocks do we
LLY,LLY:US,BBG000BNBDC2,"Weatherly Asset Management L. P. Buys SPDR Series Trust S&P Biotech, iShares MSCI New ...",2017-07-29 08:56:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tx_8dUVEHP0/weatherly-asset-management-l-p-buys-spdr-series-trust-sp-biotech-ishares-msci-new-cm823759,Weatherly Asset Management L P New Purchases XBI ENZL BHI TSN PEP A BMY AMT IWF WYN Added Positions ROK DIS CGW GOOGL HON CNI T HD PG MSFT Reduced Positions ADBE CAT NFLX DVY IWR QQQ IBM BAX CVS WM Sold Out BHGE FUN
LLY,LLY:US,BBG000BNBDC2,Eli Lilly in 2Q17: Performance of New Products,2017-07-28 21:05:52 +0000,http://finance.yahoo.com/r/e0a1e67f-bd9c-3dc2-be31-93ab42dea6cd/eli-lilly-in-2q17-performance-of-new-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, Basaglar sales were $86.6 million. Of that, $60.0 million was from sales in the US markets, while $27.0 million was from international sales."
LLY,LLY:US,BBG000BNBDC2,"AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact",2017-07-28 20:57:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nO2OGvJekSs/abbvie-abbv-tops-q2-earnings-revenues-outlook-intact-cm823604,AbbVie Inc 160 ABBV reported better than expected results in the second quarter of 2017 The company surpassed both earnings and sales expectations In the year so far AbbVie s shares have rallied 11 8 thus favorably comparing with the industry s increase of 9 9
LLY,LLY:US,BBG000BNBDC2,Dow&apos;s Merck Crushed Keytruda Sales Views By $68 Million,2017-07-28 20:28:35 +0000,http://finance.yahoo.com/r/1e1d7c6f-9328-3b67-9fd3-3cb68207f2a5/dows-merck-tops-sales-views-crushes-profits-forecasts?src=A00220&yptr=yahoo&.tsrc=rss,Dow&apos;s Merck topped sales and adjusted profits expectations for its second quarter.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Business Segments in 2Q17,2017-07-28 19:36:48 +0000,http://finance.yahoo.com/r/0e3115d4-bd6b-3dab-848f-dd6cd3ad1988/eli-lillys-business-segments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Growth for the Human Pharmaceuticals segment in 2Q17 was driven by increased sales of products such as Forteo, Humulin, and Effient."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year,2017-07-28 18:00:43 +0000,http://finance.yahoo.com/r/09c5e157-6330-310e-8189-388991dcff02/eli-lillys-2q17-earnings-rose-8-year-over-year?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly and Company (LLY) released its 2Q17 earnings on July 25, 2017, reporting an 8.0% rise in its top line to $5.8 billion for 2Q17 compared to 2Q16."
LLY,LLY:US,BBG000BNBDC2,"Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View",2017-07-28 17:02:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/udhQPUnt-Ho/merck-mrk-beats-on-q2-earnings-and-sales-keeps-2017-view-cm823416,Merck amp Co Inc MRK reported second quarter 2017 earnings of 1 01 per share which easily beat the Zacks Consensus Estimate of 87 cents by 16 1 Earnings also rose 8 6 from the year ago period Revenues for the quarter increased 1 year over year to 9 93 billion beating the
LLY,LLY:US,BBG000BNBDC2,"Notable ETF Inflow Detected - VHT, LLY, TMO, BIIB",2017-07-28 15:57:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/30OvFeGcSz8/notable-etf-inflow-detected-vht-lly-tmo-biib-cm823222,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Health Care ETF Symbol VHT where we have detected an approximate 33 3 million dollar inflow that s a 0 5 increase week over week in outstanding
LLY,LLY:US,BBG000BNBDC2,Pfizer on the Street: Inside the Analysts’ Recommendations,2017-07-28 13:06:15 +0000,http://finance.yahoo.com/r/f61ecc0e-052d-339a-8f0b-78e5710d90bf/pfizer-on-the-street-inside-the-analysts-recommendations?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"No analyst has recommended any form of ""sell"" for Pfizer stock."
LLY,LLY:US,BBG000BNBDC2,Overhaul Drug R&D? Easier Said Than Done,2017-07-27 18:00:10 +0000,http://finance.yahoo.com/r/a667e4a1-8b4e-3ec0-97d9-a56c7b155f17/eli-lilly-glaxosmithkline-earnings-r-d-overhauls-good-luck?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Both in-house and M&A solutions will be risky and take time to bear fruit.
LLY,LLY:US,BBG000BNBDC2,"Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK",2017-07-27 17:04:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r5d88A5Qm7A/pharma-stocks-to-watch-for-earnings-on-jul-28-abbv-mrk-cm822646,The second quarter reporting cycle is in full swing The quarter undoubtedly is off to a strong start As of Jul 26 2017 171 S amp P 500 members accounting for 44 1 of the index s total market capitalization reported results according to Earnings Preview Total earnings for these
LLY,LLY:US,BBG000BNBDC2,3 Buy-Ranked Stocks That Just Crushed Earnings,2017-07-27 16:03:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qAeU39RHewA/3-buy-ranked-stocks-that-just-crushed-earnings-cm822660,InvestorPlace Stock Market News Stock Advice amp Trading Tips The heart of earnings reason is upon us as numerous companies provide updates on their firm s performance over the past quarter Of course beating revenue and or earnings estimates can positively affect a company
LLY,LLY:US,BBG000BNBDC2,"Diabetes Crisis Continues To Rage, But Biopharma's Response Is Tepid",2017-07-27 11:58:00 +0000,http://finance.yahoo.com/r/cf6f22b2-b083-31fc-a438-ce348986b7d4/diabetes-crisis-continues-to-rage-but-biopharmas-response-is-tepid?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"If you were running an R&D organization, would you use your precious resources to invest in diabetes R&D, or would you look at other important areas like cancer and rare diseases, where the need is great but the ultimate development costs are less?"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: The Competition is Just Too Darn Intense!,2017-07-26 15:23:00 +0000,http://finance.yahoo.com/r/15184f29-2441-375c-88c5-c6b7384db0c6/eli-lilly-the-competition-is-just-too-darn-intense-1501082591?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Yesterday, shares fop Eli Lilly (LLY) dropped 3% after the pharmaceutical giant beat earnings forecasts but said that a new drug application for a rheumatoid arthritis treatment had been delayed. Leerink ..."
LLY,LLY:US,BBG000BNBDC2,Zoetis Investors May Need Patience To See Bull Thesis Play Out,2017-07-26 15:08:54 +0000,https://finance.yahoo.com/news/zoetis-investors-may-patience-see-150854700.html?.tsrc=rss,"After a more than 15-percent gain in Zoetis Inc (NYSE: ZTS ) since the start of 2017, analysts at Deutsche Bank see little incremental upside in the near-term. Gregg Gilbert downgraded Zoetis' stock from ..."
LLY,LLY:US,BBG000BNBDC2,"Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline",2017-07-26 15:04:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sgm9HM4zjag/key-takeaways-from-lillys-lly-q2-call-baricitinib-cancer-pipeline-cm821750,Yesterday big pharma player Eli Lilly and Company LLY reported better than expected second quarter results and raised its outlook for the year However shares were down 3 with investors focusing on the company s update regarding its investigational rheumatoid arthritis RA
LLY,LLY:US,BBG000BNBDC2,"Key Takeaways from Lilly&apos;s (LLY) Q2 Call: Baricitinib, Cancer Pipeline",2017-07-26 13:29:01 +0000,https://finance.yahoo.com/news/key-takeaways-lilly-apos-lly-132901643.html?.tsrc=rss,"Why were Lilly&apos;s (LLY) shares down despite the company delivering a ""beat and raise"" quarter?"
LLY,LLY:US,BBG000BNBDC2,"Featured Company News - Eli Lilly and Nektar Announce Agreement to Co-Develop NKTR-358, the Self-Administered Injection for a Number of Autoimmune Disease",2017-07-26 11:00:00 +0000,https://finance.yahoo.com/news/featured-company-news-eli-lilly-110000438.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / July 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Nektar Therapeutics (NASDAQ: NKTR ) (""Nektar""), following ..."
LLY,LLY:US,BBG000BNBDC2,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX",2017-07-26 02:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TRAnoGhx_E/positive-data-ignites-ttph-mdco-makes-a-good-tango-wait-continues-for-egrx-20170726-00106,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX"
LLY,LLY:US,BBG000BNBDC2,Lilly beats Street 2Q forecasts,2017-07-26 01:39:49 +0000,https://finance.yahoo.com/news/lilly-beats-street-2q-forecasts-103238178.html?.tsrc=rss,"The Indianapolis-based company said it had profit of 95 cents per share. Earnings, adjusted for restructuring costs, came to $1.11 per share. The results topped Wall Street expectations. The average estimate ..."
LLY,LLY:US,BBG000BNBDC2,Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records,2017-07-26 00:00:00 +0000,http://finance.yahoo.com/r/ba747480-0a0f-33d4-95b6-9c68ebc847fa/earnings-wave-pushes-s-amp-p-500-and-nasdaq-to-fresh-records.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Wall Street at records.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug,2017-07-25 20:17:00 +0000,http://finance.yahoo.com/r/4fdc3bb4-8563-3902-a2d0-645d393744da/eli-lilly-shares-lower-after-update-on-rheumatoid-arthritis-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Tumbles On Arthritis Drug Delay,2017-07-25 20:02:36 +0000,http://finance.yahoo.com/r/1845a25d-f5e5-3087-b0aa-160ab732fd3f/eli-lilly-dives-after-q2-sales-come-up-light-though-profits-top?src=A00220&yptr=yahoo&.tsrc=rss,A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO expects a Trump executive order on drug pricing this year,2017-07-25 18:15:57 +0000,https://finance.yahoo.com/news/eli-lilly-ceo-expects-trump-181557797.html?.tsrc=rss,Eli Lilly CEO David Ricks said on an earnings call Tuesday that he hopes a policy includes some of the reforms the industry has pushed for.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO expects a Trump executive order on drug pricing this year,2017-07-25 18:15:57 +0000,http://finance.yahoo.com/r/b390cdfa-86a6-398b-a55c-034cfa92138a/104607918?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104607918&yptr=yahoo&.tsrc=rss,Eli Lilly CEO David Ricks said on an earnings call Tuesday that he hopes a policy includes some of the reforms the industry has pushed for.
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK",2017-07-25 18:03:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LVJd7sECmpI/drug-stocks-q2-earnings-releases-on-jul-26-gild-vrtx-gsk-cm820959,We are entering the peak period of the second quarter reporting cycle this week The quarter undoubtedly is off to a strong start As of Jul 21 2017 97 S amp P 500 members accounting for 28 1 of the index s total market capitalization reported results according to 160 Earnings
LLY,LLY:US,BBG000BNBDC2,3 Buy-Ranked Stocks That Just Crushed Earnings,2017-07-25 17:18:05 +0000,https://finance.yahoo.com/news/3-buy-ranked-stocks-just-171805804.html?.tsrc=rss,"These earnings reports not only demonstrate the past quarter???s solid performance, but they also preview its financial outlook over its next operational quarter."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly beats on earnings as stock dips,2017-07-25 16:55:00 +0000,https://finance.yahoo.com/video/eli-lilly-beats-earnings-stock-165500597.html?.tsrc=rss,CNBC's Meg Tirrell reports on Eli Lilly beating on earnings as the stock dips almost 4% and Biogen pops on an earnings beat.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: What the Heck Just Happened?,2017-07-25 16:10:00 +0000,http://finance.yahoo.com/r/9b6b22f9-d18a-36f2-8733-c66b072aa4d1/eli-lilly-what-the-heck-just-happened-1500999026?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY).  Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion.  Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed."
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed",2017-07-25 16:08:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XznaTXdlKG4/lilly-lly-q2-earnings-top-baricitinib-re-filing-delayed-cm821037,Eli Lilly and Company LLY reported second quarter 2017 adjusted earnings per share of 1 11 which beat the Zacks Consensus Estimate of 1 04 by 6 7 Earnings rose 29 from the year ago quarter backed by volume driven pharma sales growth and higher profits Revenues Beat Quarterly
LLY,LLY:US,BBG000BNBDC2,"Lilly signals long delay for arthritis drug, shares fall",2017-07-25 15:28:35 +0000,https://finance.yahoo.com/news/drugmaker-lillys-second-quarter-profit-110121465.html?.tsrc=rss,"Eli Lilly and Co on Tuesday  outlined a likely multi-year delay for its experimental  rheumatoid arthritis drug with blockbuster sales potential, and  disappointed investors sent its shares down nearly 4 percent.  In a surprise move, the U.S. Food and Drug Administration in  April declined to approve the drug, baricitinib, calling for an  additional clinical study.  Lilly said on Tuesday the FDA was concerned about a small,  but increased number of potentially dangerous blood clots seen  in baricitinib patients in clinical trials."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly beats the Street on earnings, raises outlook",2017-07-25 14:53:00 +0000,https://finance.yahoo.com/video/eli-lilly-beats-street-earnings-145300331.html?.tsrc=rss,CNBC's Meg Tirrell reports the highlights of the pharmaceutical company's quarterly earnings.
LLY,LLY:US,BBG000BNBDC2,"S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq",2017-07-25 14:50:00 +0000,http://finance.yahoo.com/r/a36abb45-cfcf-3126-b286-ac2fab8477f3/s-amp-p-500-hits-intraday-high-but-alphabet-weighs-on-nasdaq.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Stocks are mixed.
LLY,LLY:US,BBG000BNBDC2,"Tuesday&apos;s Earnings Losers: Eli Lilly, Seagate Technology",2017-07-25 14:46:00 +0000,http://finance.yahoo.com/r/91642427-a40e-335c-ade5-618591b7364b/tuesdays-earnings-losers-eli-lilly-seagate-technology?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly fell after telling investors that its rheumatoid arthritis drug will be delayed. Seagate sank to an 8-month low on a big EPS miss.
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed",2017-07-25 14:41:02 +0000,https://finance.yahoo.com/news/lilly-lly-q2-earnings-top-144102208.html?.tsrc=rss,"Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY)'s Seemingly Illogical Reaction To Earnings Beat,2017-07-25 14:28:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JRBCD-8cQk/eli-lilly-llys-seemingly-illogical-reaction-to-earnings-beat-cm820820,"When pharma giant Eli Lilly ( LLY ) released their second quarter results early this morning, they appeared to be positive in every way. Adjusted EPS came in at $1.11, a nice beat of the $1.05 consensus expectation, and sales of $5.82 billion easily outstripped the $5.59 billion that analysts had predicted.  Both of"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO Reiterates 5% Revenue Growth Target,2017-07-25 14:13:23 +0000,https://finance.yahoo.com/video/eli-lilly-ceo-reiterates-5-141323713.html?.tsrc=rss,"Jul.25 -- Dave Ricks, chief executive officer at Eli Lily & Co., talks about a regulatory roadblock for a rheumatoid arthritis drug and potential risks to the company’s revenue growth commitment. He speaks with Bloomberg's David Westin on &quot;Bloomberg Daybreak: Americas.&quot;"
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Tops Q2 Earnings & Sales, Ups View, Stock Falls",2017-07-25 14:06:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zDN_oews37Y/lilly-lly-tops-q2-earnings-sales-ups-view-stock-falls-cm820811,Indianapolis IN based Eli Lilly and Company LLY is a global healthcare company with core products in a number of primary care pharmaceutical markets Lilly generates revenues from its pharmaceutical product and animal health segments The company s portfolio includes Zyprexa schizophrenia
LLY,LLY:US,BBG000BNBDC2,"Stocks to Watch: Alphabet, Caterpillar, Michael Kors, GM, Barnes & Noble",2017-07-25 13:29:09 +0000,http://finance.yahoo.com/r/84a7e7fb-8617-3483-842b-f1adec1478c0/stocks-to-watch-alphabet-caterpillar-michael-kors-gm-barnes-noble-1500989348?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Among the companies with shares expected to trade actively in Tuesday's session are Alphabet, Caterpillar, Michael Kors, General Motors and Barnes & Noble."
LLY,LLY:US,BBG000BNBDC2,Stock Futures Solidly Higher but Alphabet's Earnings Cause Concern,2017-07-25 12:44:00 +0000,http://finance.yahoo.com/r/e2dee9e4-47c2-3141-8419-25302d77e26d/stock-futures-inch-higher-but-alphabet-s-earnings-cause-concern.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Stock futures are higher.
LLY,LLY:US,BBG000BNBDC2,"Early movers: MMM, UTX, DD, CAT, GM, LLY, KORS, C, WMT & more",2017-07-25 12:36:08 +0000,https://finance.yahoo.com/news/early-movers-mmm-utx-dd-123608745.html?.tsrc=rss,These are the stocks posting the largest moves before the bell.
LLY,LLY:US,BBG000BNBDC2,"Early movers: MMM, UTX, DD, CAT, GM, LLY, KORS, C, WMT & more",2017-07-25 12:36:08 +0000,http://finance.yahoo.com/r/a465edc5-5869-3868-9c87-3db9f7bacf3d/104607266?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104607266&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Tops Q2 Earnings & Sales, Ups View, Stock Falls",2017-07-25 12:30:12 +0000,https://finance.yahoo.com/news/lilly-lly-tops-q2-earnings-123012010.html?.tsrc=rss,"Lilly beat estimates for both sales and earnings and raised its 2017 outlook. However, it said the NDA resubmission for its rheumatoid arthritis drug baricitinib will not occur this year."
LLY,LLY:US,BBG000BNBDC2,"As 5 Dow components report earnings, futures take off",2017-07-25 12:17:55 +0000,https://finance.yahoo.com/news/5-dow-components-report-earnings-121755742.html?.tsrc=rss,U.S. stock futures were higher this morning despite pressure coming from a sharp premarket decline in Google-parent Alphabet.
LLY,LLY:US,BBG000BNBDC2,"As 5 Dow components report earnings, futures take off",2017-07-25 12:17:55 +0000,http://finance.yahoo.com/r/98150ff0-90f6-3049-bf6b-be9a421b999f/104607197?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104607197&yptr=yahoo&.tsrc=rss,U.S. stock futures were higher this morning despite pressure coming from a sharp premarket decline in Google-parent Alphabet.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: Strong quarter driven by new products,2017-07-25 11:19:00 +0000,https://finance.yahoo.com/video/eli-lilly-ceo-strong-quarter-111900238.html?.tsrc=rss,"David Ricks, Eli Lilly CEO, talks about the company's quarterly results which beat on the top and bottom line, driven largely by the introduction of new drugs in the marketplace. Also Ricks weighs in on the Democrats' &quot;Better Deal&quot; proposal."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly beats profit and sales expectations; NDA for RA treatment to be delayed,2017-07-25 10:58:24 +0000,http://finance.yahoo.com/r/018e22d1-d60d-3788-80e4-b2bc36c18061/Story.aspx?guid=AE48D431-A7F1-4DB4-947E-B34829782C69&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. reported a second-quarter net profit that rose to $1.01 billion, or 95 cents a share, from $747.7 million, or 71 cents a share, in the same period a year ago. Excluding non-recurring items, ..."
LLY,LLY:US,BBG000BNBDC2,"Earnings Reaction History: Eli Lilly & Co., 27.3% Follow-Through Indicator, 1.4% Sensitive",2017-07-25 10:57:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wBr8Sj_WuGY/earnings-reaction-history-eli-lilly-co-273-follow-through-indicator-14-sensitive-cm820623,Expected Earnings Release 07 25 2017 PremarketExpected Earnings Release 07 25 2017 Premarket Avg Extended Hours Dollar Volume 1 061 675Avg Extended Hours Dollar Volume 1 061 675 Eli Lilly amp Co LLY is due to issue its quarterly earnings report in the upcoming extended
LLY,LLY:US,BBG000BNBDC2,Drugmaker Lilly's profit jumps 35 percent,2017-07-25 10:37:09 +0000,https://finance.yahoo.com/news/drugmaker-lillys-profit-jumps-35-103709446.html?.tsrc=rss,Eli Lilly and Co on Tuesday reported a 35 percent rise in quarterly profit as the U.S. drugmaker benefited from higher sales of its diabetes treatment Trulicity as well as its psoriasis drug Taltz. Net ...
LLY,LLY:US,BBG000BNBDC2,Nasdaq Futures Lag On Google; 4 Stocks Near Buys With Earnings Due,2017-07-25 10:28:27 +0000,http://finance.yahoo.com/r/6bbbbd9a-0e05-3ba5-92f2-a2e5bb63060e/nasdaq-futures-fall-on-google-4-stocks-near-buys-with-earnings-due?src=A00220&yptr=yahoo&.tsrc=rss,Nasdaq futures fell Monday evening as Apple retreated following its Q2 earnings. Four stocks near buy points report earnings Tuesday morning.
LLY,LLY:US,BBG000BNBDC2,Lilly Reports Second-Quarter Results,2017-07-25 10:25:00 +0000,https://finance.yahoo.com/news/lilly-reports-second-quarter-results-102500387.html?.tsrc=rss,"- Second-quarter 2017 revenue increased 8 percent, driven primarily by volume growth from Trulicity, Taltz and other new pharmaceutical products, while operating expenses remained flat. - Second-quarter ..."
LLY,LLY:US,BBG000BNBDC2,Lilly and Incyte Provide Update on Baricitinib,2017-07-25 10:15:00 +0000,https://finance.yahoo.com/news/lilly-incyte-baricitinib-101500123.html?.tsrc=rss,"INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), will be delayed beyond 2017.  The companies will be further discussing the path forward with the agency and evaluating options for resubmission, including the potential for an additional clinical study, as requested by the FDA."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Q2 17 Earnings Conference Call At 9:00 AM ET,2017-07-25 08:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HBp-x4UCtZA/eli-lilly-q2-17-earnings-conference-call-at-900-am-et-20170725-00651,Eli Lilly Q2 17 Earnings Conference Call At 9:00 AM ET
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Raises 2017 Non-GAAP EPS Guidance - Quick Facts,2017-07-25 06:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d1D9kiuxqrg/eli-lilly-raises-2017-nongaap-eps-guidance--quick-facts-20170725-00270,Eli Lilly Raises 2017 Non-GAAP EPS Guidance - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Reports 30% Advance In Q2 Profit,2017-07-25 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OdPYUAolwKA/eli-lilly-and-co-reports-30-advance-in-q2-profit-20170725-00238,Eli Lilly And Co. Reports 30% Advance In Q2 Profit
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Reports 30% Advance In Q2 Profit,2017-07-25 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ttElEhuvTG4/eli-lilly-and-co-reports-30%25-advance-in-q2-profit-20170725-00238,Eli Lilly And Co. Reports 30% Advance In Q2 Profit
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib,2017-07-25 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VhT_ZibysEg/eli-lilly--incyte-issue-update-on-resubmission-of-nda-for-baricitinib-20170725-00237,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib
LLY,LLY:US,BBG000BNBDC2,Could This Small Biotech Break Out On A Tie-Up With Eli Lilly?,2017-07-24 20:29:46 +0000,http://finance.yahoo.com/r/00d525fc-9da8-3edf-b6c3-94e6ac680981/could-this-small-biotech-break-out-on-a-tie-up-with-eli-lilly?src=A00220&yptr=yahoo&.tsrc=rss,Nektar neared a breakout on a deal with Lilly for a drug designed to fight autoimmune and inflammatory conditions.
LLY,LLY:US,BBG000BNBDC2,"Pre-Market Earnings Report for July 25, 2017 :  MMM, MCD, UTX, LLY, DD, CAT, BIIB, GM, KMB, HCA, PCAR, TROW",2017-07-24 20:16:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l4RSMTtytQY/pre-market-earnings-report-for-july-25-2017-mmm-mcd-utx-lly-dd-cat-biib-gm-kmb-hca-pcar-trow-cm820506,The following companies are expected to report earnings prior to market open on 07 25 2017 Visit our Earnings Calendar for a full list of expected earnings releases 3M Company MMM is reporting for the quarter ending June 30 2017 The diversified
LLY,LLY:US,BBG000BNBDC2,"Noteworthy Monday Option Activity: YRCW, K, LLY",2017-07-24 19:56:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qg9kHQbPnig/noteworthy-monday-option-activity-yrcw-k-lly-cm820476,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in YRC Worldwide Inc Symbol YRCW where a total of 2 134 contracts have traded so far representing approximately 213 400 underlying shares That amounts to about 40 6 of YRCW s
LLY,LLY:US,BBG000BNBDC2,FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20),2017-07-24 18:06:39 +0000,https://finance.yahoo.com/news/fda-tentatively-approves-mercks-copycat-180639209.html?.tsrc=rss,"Merck and Co Inc said on  Thursday the U.S. Food and Drug Administration (FDA) tentatively  approved its follow-on biologic version of French drugmaker  Sanofi SA's blockbuster diabetes treatment, Lantus.  Merck's copycat, if launched, would challenge Lantus as a  cheaper alternative that could chip away at the drug's sales,  which reached 5.71 billion euros ($6.6 billion) last year and  represented over a sixth of Sanofi's total sales."
LLY,LLY:US,BBG000BNBDC2,What Analysts Recommend for Eli Lilly ahead of 2Q17 Results,2017-07-24 16:35:43 +0000,http://finance.yahoo.com/r/b6d8a090-af88-3861-95ab-84ec8ea64155/what-analysts-recommend-for-eli-lilly-ahead-of-2q17-results?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly (LLY) surpassed Wall Street analysts’ revenue estimates of $5.21 billion with reported revenues of $5.23 billion during 1Q17.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar,2017-07-24 15:33:42 +0000,http://finance.yahoo.com/r/2f519d6f-1eb0-35ab-b235-3e11f5bc943a/Story.aspx?guid=1F6A19DA-706A-11E7-9E43-ACE49ED3ADD7&siteid=yhoof2&yptr=yahoo&.tsrc=rss,The therapy could treat an underlying disease but is very early in development.
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly Expects 2Q17 Revenue Growth,2017-07-24 15:05:43 +0000,http://finance.yahoo.com/r/db6cac7a-526f-3ad4-b66f-8b375c6c152b/why-eli-lilly-expects-2q17-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As per analysts' estimates, Eli Lilly's (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17."
LLY,LLY:US,BBG000BNBDC2,What Analysts Predict for Eli Lilly’s 2Q17 Earnings,2017-07-24 13:13:43 +0000,http://finance.yahoo.com/r/b41df091-2ba1-30e4-abb8-7af493981136/what-analysts-predict-for-eli-lillys-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, analysts estimate that Eli Lilly will post EPS of $1.05 and revenues of $5.6 billion."
LLY,LLY:US,BBG000BNBDC2,"Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN",2017-07-24 13:05:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/na8HBi0HD_Y/big-pharma-q2-earnings-releases-on-jul-25-lly-biib-amgn-cm820000,The second quarter reporting cycle seems to have gotten off to a good start with an abundance of positive surprises particularly on the revenue front Meanwhile earnings and revenue growth also bettered expectations As of Jul 21 2017 97 S amp P 500 members accounting for 28 1 of
LLY,LLY:US,BBG000BNBDC2,"Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN",2017-07-24 12:16:12 +0000,https://finance.yahoo.com/news/big-pharma-q2-earnings-releases-121612693.html?.tsrc=rss,Three pharma giants are set to report second-quarter results on Jul 25. Let&apos;s see how things are shaping up for this quarter.
LLY,LLY:US,BBG000BNBDC2,Nektar Therapeutics surges 10% on $150 mln Eli Lilly deal,2017-07-24 12:15:08 +0000,http://finance.yahoo.com/r/1f916458-9abb-357e-939a-5e954c08a712/Story.aspx?guid=BF77B343-1734-4AD3-8C9D-9049D0208DFC&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Nektar Therapeutics shares surged as much as 10% in premarket trade Monday after the company announced a $150 million deal with Eli Lilly & Co. to co-develop its immunological therapy NKTR-358. The deal ...
LLY,LLY:US,BBG000BNBDC2,"Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy",2017-07-24 11:30:00 +0000,https://finance.yahoo.com/news/lilly-nektar-therapeutics-announce-alliance-113000678.html?.tsrc=rss,"INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Nektar Therapeutics (NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.  NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory conditions.  NKTR-358 is a potential first-in-class resolution therapeutic that may address an underlying immune system imbalance in patients with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, NKTR-358 may act to bring the immune system back into balance."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358,2017-07-24 07:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/siZPd8N15iI/eli-lilly-agrees-with-nektar-to-codevelop-nktr--358-20170724-00404,Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358
LLY,LLY:US,BBG000BNBDC2,These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet,2017-07-23 13:04:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HIqLPfhEpfU/these-5-drugs-could-be-worth-45-billion-and-theyre-not-even-on-the-market-yet-cm819829,45 billion for five experimental drugs That s how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now The firm calculated the net present value the current value of potential future sales of all the experimental drugs
LLY,LLY:US,BBG000BNBDC2,These 5 Drugs Could Be Worth $45 Billion -- and They&apos;re Not Even on the Market Yet,2017-07-23 11:27:00 +0000,http://finance.yahoo.com/r/cd7be451-95ee-3e17-9e89-8b2c3babf417/these-5-drugs-could-be-worth-45-billion-and-theyre.aspx?yptr=yahoo&.tsrc=rss,"Biogen, Johnson & Johnson, Lilly, AbbVie, and Celgene could have huge winners on their hands in the near future."
LLY,LLY:US,BBG000BNBDC2,Merck's Biosimilar Insulin Gets Tentative FDA Approval,2017-07-21 23:04:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/89oq2wrBoXc/mercks-biosimilar-insulin-gets-tentative-fda-approval-cm819640,Merck MRK announced that the FDA has granted a tentative approval to Lusduna Nexvue the company s biosimilar version of Sanofi s SNY Lantus insulin glargine for treatment of people with type I and type II diabetes Lusduna Nexvue delivers insulin in a pre filled dosing device Note that
LLY,LLY:US,BBG000BNBDC2,2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't,2017-07-21 20:04:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IM7_-ts66fs/2-reasons-incyte-is-a-better-growth-stock-than-exelixis-and-1-reason-it-isnt-cm819529,Exelixis NASDAQ EXEL is without question one of the hottest biotech stocks on the market We re talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70 so far this year Exelixis is simply put a fantastic growth stock But
LLY,LLY:US,BBG000BNBDC2,5 New Breast Cancer Treatments That Are Helping to Save Lives,2017-07-20 23:30:00 +0000,http://finance.yahoo.com/r/fa9ce2cc-dc7b-3464-a331-dbc17fc49825/5-new-breast-cancer-treatments-from-lilly-novartis-and-pfizer-that-could-double-sales-by-2021.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000."
LLY,LLY:US,BBG000BNBDC2,FDA tentatively approves Merck's copycat of Sanofi's Lantus,2017-07-20 16:55:27 +0000,https://finance.yahoo.com/news/fda-tentatively-approves-mercks-copycat-165527005.html?.tsrc=rss,"Merck and Co Inc said on  Thursday the U.S. Food and Drug Administration (FDA) tentatively  approved its biosimilar version of French drugmaker Sanofi SA's  blockbuster diabetes treatment, Lantus.  Merck's copycat, if launched, would challenge Lantus as a  cheaper alternative that could chip away at the drug's sales,  which reached 5.71 billion euros ($6.6 billion) last year and  represented over a sixth of Sanofi's total sales."
LLY,LLY:US,BBG000BNBDC2,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?,2017-07-19 16:08:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bMMoAQYV5F4/can-biogen-biib-keep-the-earnings-streak-alive-in-q2-cm818132,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will report second quarter 2017 results on Jul 25 before the market opens Last quarter the company delivered a positive earnings surprise of 4 63 Biogen s shares have declined 0 4 this year so far while the
LLY,LLY:US,BBG000BNBDC2,Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?,2017-07-19 15:08:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZLiylOsYHhU/is-a-beat-in-the-cards-for-eli-lilly-lly-in-q2-earnings-cm818012,We expect Eli Lilly and Company LLY to beat expectations when it reports second quarter 2017 results on Jul 25 before the market opens Last quarter the company delivered a positive earnings surprise of 2 08 So far this year Lilly s share price has risen 13 8 compared with an increase
LLY,LLY:US,BBG000BNBDC2,Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?,2017-07-19 13:17:01 +0000,https://finance.yahoo.com/news/beat-cards-eli-lilly-lly-131701763.html?.tsrc=rss,"Eli Lilly and Company&apos;s (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let&apos;s see if these along with its older products lead the company to an earnings beat."
LLY,LLY:US,BBG000BNBDC2,Quintiles IMS: A Novel Way To Invest In Biopharma,2017-07-17 22:49:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wZ878-6rxjY/quintiles-ims-a-novel-way-to-invest-in-biopharma-cm817177,By In Sickness and Wealth ByIn Sickness and Wealth Photo credit istockphoto com Photo credit Photo credit istockphoto comistockphoto com By David Lerman amp Jodie Warner By David Lerman amp Jodie WarnerBy David Lerman Jodie Warner
LLY,LLY:US,BBG000BNBDC2,Why Did Radius Health (RDUS) Stock Plummet Today?,2017-07-17 18:47:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Le5X7CtZyuI/why-did-radius-health-rdus-stock-plummet-today-cm817068,Shares of Radius Health RDUS dropped more than 7 8 in early morning trading hours Monday after the company announced that Jesper Høiland a former top ranking executive at Novo Nordisk NVO has been appointed its new president and chief executive officer 160 Høiland joins
LLY,LLY:US,BBG000BNBDC2,5 Pharma and Biotech Stocks Set for Big Q2 Earnings Wins,2017-07-17 15:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sCwc1dCAaVA/5-pharma-and-biotech-stocks-set-for-big-q2-earnings-wins-cm817005,InvestorPlace Stock Market News Stock Advice amp Trading Tips Pharma and biotech 160 stocks have bounced back this year The SPDR S amp P Biotech ETF NYSEARCA XBI has gained 34 in 2017 for example and the 160 iShares NASDAQ Biotechnology
LLY,LLY:US,BBG000BNBDC2,"Amgen FDA Letter Isn't A Surprise (Or A Concern), Says Jefferies",2017-07-17 14:46:00 +0000,http://finance.yahoo.com/r/e0492778-a767-393b-bc16-679eefc660e7/amgen-fda-letter-isnt-a-surprise-or-a-concern-says-jefferies-1500302810?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Amgen (AMGN) announced today that the Food and Drug Administration issued a Complete Response Letter for the Biologics License Application (BLA) for its osteoporosis treatment romosozumab.  Jefferies' Michael Yee and Andrew Tsai reiterated a Buy rating and $195 price target on the stock, writing that the FDA letter was no surprise, given new Phase III data."
LLY,LLY:US,BBG000BNBDC2,"Old National Bancorp  Buys SPDR Select Sector Fund - Energy Select Sector, iShares Core MSCI ...",2017-07-15 15:45:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OSIiluviBkQ/old-national-bancorp-buys-spdr-select-sector-fund-energy-select-sector-ishares-core-msci-cm816528,Old National Bancorp New Purchases CELG STZ XLRE ZTS INTU GVI MCK PCLN NOBL MANH Added Positions XLE IEFA XLK IVV MSFT XLF XLV CMI XLI XLB Reduced Positions AGG XLP PFE AGN GE EEMV DIS VOO COST LLY Sold Out DIA IALB
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.",2017-07-14 13:50:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QAofaLZsNT0/pharma-stock-roundup-fda-panel-votes-for-novartis-car-t-drug-sny-to-buy-vaccines-co-cm816035,It was a busy week for the FDA s Oncologic Drugs Advisory Committee ODAC which reviewed several experimental treatments this week including Novartis NVS CAR T cell drug Meanwhile French pharma giant Sanofi SNY announced it will be acquiring a vaccines company Recap of the Week s
LLY,LLY:US,BBG000BNBDC2,"Novartis stocks drug cabinet with ""Big-3"" arthritis blockbusters",2017-07-14 11:44:30 +0000,https://finance.yahoo.com/news/novartis-stocks-drug-cabinet-big-114430840.html?.tsrc=rss,"Switzerland's Novartis  is stocking up cheaper versions of the world's top-selling  arthritis medicines, hoping a broad portfolio gives it an edge  on rivals with narrower offerings.  Novartis's near-copy of Amgen's Enbrel won European  approval last month."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.",2017-07-14 11:28:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-fda-panel-112811804.html?.tsrc=rss,Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
LLY,LLY:US,BBG000BNBDC2,Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?,2017-07-13 22:48:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uZgTgpaHS0k/can-immunogens-lead-pipeline-cancer-candidate-boost-growth-cm815898,On Jul 12 2017 we issued an updated report on ImmunoGen Inc IMGN ImmunoGen is a development stage biotechnology company focused on developing targeted cancer therapeutics using its proprietary antibody drug conjugate ADC technology The company s shares have significantly
LLY,LLY:US,BBG000BNBDC2,Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back,2017-07-13 18:49:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V5IkRVXtNcM/heres-why-alder-biopharmaceuticals-inc-stock-is-bouncing-back-cm815772,What happened Investors in Alder Biopharmaceuticals NASDAQ ALDR are 160 having another 160 wild 160 day Shares of the clinical stage biopharma rose as much as 15 5 on Thursday after the company released the pricing details of its just announced common stock offering
LLY,LLY:US,BBG000BNBDC2,Lilly Settles Patent Litigation on Cialis with Generic Firms,2017-07-13 15:03:03 +0000,https://finance.yahoo.com/news/lilly-settles-patent-litigation-cialis-150303089.html?.tsrc=rss,Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).
LLY,LLY:US,BBG000BNBDC2,5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings,2017-07-13 13:52:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/36s15LHvYVU/5-pharma-biotech-stocks-that-could-be-big-winners-in-q2-earnings-cm815547,Drug stocks have bounced back this year with the NASDAQ Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18 6 and 10 8 respectively year to date YTD There are several reasons for this improved performance Investors are now more comfortable with the drug
LLY,LLY:US,BBG000BNBDC2,"Private Capital Advisors, Inc. Buys EVINE Live Inc, Arconic Inc, Alphabet Inc, Sells General ...",2017-07-13 13:46:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TpXVIrG0C8U/private-capital-advisors-inc-buys-evine-live-inc-arconic-inc-alphabet-inc-sells-general-cm815481,Private Capital Advisors Inc New Purchases EVLV IBB NVDA TSO SRPT YY AMGN GLYC ADI GDS Added Positions ARNC GOOGL FWONA MRK SBPH BX JNJ DVY CELG JPM Reduced Positions GE BIB CMCSA LLY INTC T RTN FB ADBE V Sold Out
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire",2017-07-13 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-merck-133001965.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire"
LLY,LLY:US,BBG000BNBDC2,5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings,2017-07-13 12:13:12 +0000,https://finance.yahoo.com/news/5-pharma-biotech-stocks-could-121312172.html?.tsrc=rss,Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.
LLY,LLY:US,BBG000BNBDC2,"&quot;Fast Money&quot; final trades: UAL, DAL, and more",2017-07-12 21:59:00 +0000,https://finance.yahoo.com/video/fast-money-final-trades-ual-215900153.html?.tsrc=rss,"The “Fast Money” traders discuss their final trades for the day including United, Delta Airlines, General Electric and Eli Lilly."
LLY,LLY:US,BBG000BNBDC2,InPlay from Briefing.com,2017-07-12 14:56:44 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly settlement will result in Cialis patent expiring as early as 2018, rather than 2020",2017-07-12 14:29:48 +0000,http://finance.yahoo.com/r/f218e7b6-54d5-3e37-86ae-b62749644431/Story.aspx?guid=2A769213-2A4A-4CFB-B121-1D5673AB8C71&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said on Wednesday that as part of a settlement with generic companies over its Cialis patent, the exclusive patent is now expected to end on September 27, 2018 at the earliest, roughly ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation,2017-07-12 14:00:00 +0000,https://finance.yahoo.com/news/lilly-reaches-settlement-agreement-u-140000928.html?.tsrc=rss,"INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis® (tadalafil) unit dose patent.  As part of the agreement, Cialis exclusivity is now expected to end at the earliest on September 27, 2018."
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, NVIDIA, American Express, NIKE and State Street",2017-07-12 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-133001140.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Eli Lilly, NVIDIA, American Express, NIKE and State Street"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017),2017-07-12 13:00:00 +0000,https://finance.yahoo.com/news/eli-lilly-company-present-more-130000834.html?.tsrc=rss,Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)
LLY,LLY:US,BBG000BNBDC2,Lilly Reaches Settlement Deal In US Cialis Patent Litigation,2017-07-12 10:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7MGk-6OUOJw/lilly-reaches-settlement-deal-in-us-cialis-patent-litigation-20170712-00709,Lilly Reaches Settlement Deal In US Cialis Patent Litigation
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Eli Lilly, NVIDIA & AmEx",2017-07-11 23:43:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5_kcRVyKC_g/top-research-reports-for-eli-lilly-nvidia-amex-cm814792,Tuesday July 11 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Eli Lilly LLY NVIDIA NVDA and American Express AXP These research reports have been hand picked
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Eli Lilly, NVIDIA & AmEx",2017-07-11 21:36:09 +0000,https://finance.yahoo.com/news/top-research-reports-eli-lilly-213609570.html?.tsrc=rss,"Top Research Reports for Eli Lilly, NVIDIA & AmEx"
LLY,LLY:US,BBG000BNBDC2,Lilly's Breast Cancer Drug Gets Priority Review Status by FDA,2017-07-11 15:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9YNBGKO0CvQ/lillys-breast-cancer-drug-gets-priority-review-status-by-fda-cm814438,Eli Lilly and Company LLY announced that its new drug application for its pipeline candidate abemaciclib both as a potential monotherapy and combination therapy has been accepted for priority review by the FDA for patients with advanced breast cancer Lilly is looking to get the CDK 4
LLY,LLY:US,BBG000BNBDC2,Lilly&apos;s Breast Cancer Drug Gets Priority Review Status by FDA,2017-07-11 13:44:01 +0000,https://finance.yahoo.com/news/lilly-apos-breast-cancer-drug-134401710.html?.tsrc=rss,"Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer."
LLY,LLY:US,BBG000BNBDC2,"Why Eli Lilly Is Gouging Diabetes Drug Share From Dow&apos;s J&J, Others",2017-07-10 21:33:52 +0000,http://finance.yahoo.com/r/fbfa7161-0b99-39ca-bcc0-8b216ec03617/why-eli-lilly-is-gouging-diabetes-drug-share-from-dows-jj-others?src=A00220&yptr=yahoo&.tsrc=rss,"Eli Lilly is taking share from J&J and Novo Nordisk in two classes of diabetes drugs, an analyst said Monday."
LLY,LLY:US,BBG000BNBDC2,FDA Cranks Up Its Review of Eli Lilly's Advanced Breast Cancer Drug,2017-07-10 16:29:00 +0000,http://finance.yahoo.com/r/88fb0078-341f-3b2a-aa6e-ca0b3a376e29/fda-cranks-up-its-review-of-eli-lilly-s-advanced-breast-cancer-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The FDA has given priority review designation for abemaciclib.
LLY,LLY:US,BBG000BNBDC2,Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK,2017-07-10 13:14:01 +0000,https://finance.yahoo.com/news/lilly-gets-favorable-ruling-alimta-131401094.html?.tsrc=rss,"Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium)."
LLY,LLY:US,BBG000BNBDC2,Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment,2017-07-10 12:00:00 +0000,https://finance.yahoo.com/news/renowned-television-personality-don-francisco-120000203.html?.tsrc=rss,"INDIANAPOLIS and RIDGEFIELD, Conn., July 10, 2017 /PRNewswire/ -- Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos, to help address common misconceptions about type 2 diabetes and insulin treatment.  As part of this partnership, Don Francisco, who is known for his ability to connect with his audiences and inform them of the important issues of the day, will head to cities across the country to share his own personal journey of living with type 2 diabetes.  ""I was diagnosed with type 2 diabetes 16 years ago, and at that time I believed many things about diabetes that weren't correct."
LLY,LLY:US,BBG000BNBDC2,What We Can Expect from Eli Lilly and Company in 2Q17,2017-07-10 11:39:13 +0000,http://finance.yahoo.com/r/d1f42c2a-d043-3179-a4f1-a04fbdabc3be/what-we-can-expect-from-eli-lilly-and-company-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Eli Lilly’s stock price has fallen ~4.4% in 2Q17.…..."
LLY,LLY:US,BBG000BNBDC2,FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer,2017-07-10 10:45:00 +0000,https://finance.yahoo.com/news/fda-grants-priority-review-lillys-104500384.html?.tsrc=rss,"INDIANAPOLIS, July 10, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, and given the NDA a Priority Review designation.  This submission is based on the MONARCH 1 and MONARCH 2 studies, respectively."
LLY,LLY:US,BBG000BNBDC2,Lilly: FDA Files NDA For Abemaciclib For Treatment Of Advanced Breast Cancer,2017-07-10 07:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/16sXPsnM_Xg/lilly-fda-files-nda-for-abemaciclib-for-treatment-of-advanced-breast-cancer-20170710-00286,Lilly: FDA Files NDA For Abemaciclib For Treatment Of Advanced Breast Cancer
LLY,LLY:US,BBG000BNBDC2,[$$] U.K. Court Says Generics Infringe on Lilly’s Alimta Patents,2017-07-10 04:29:28 +0000,http://finance.yahoo.com/r/3fc9692e-6e7f-3a76-b24f-a85827e93d12/u-k-court-says-generics-infringe-on-lillys-alimta-patents-1499439663?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Lilly said the U.K. Supreme Court ruled that a rival’s product infringes on its patents for cancer-treatment drug Alimta in several European countries.
LLY,LLY:US,BBG000BNBDC2,What’s News: Business & Finance,2017-07-10 04:27:03 +0000,http://finance.yahoo.com/r/3e113d04-d84b-336c-a35e-cfd95b58f2b0/whats-news-business-finance-1499658357?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,What’s News: Business & Finance
LLY,LLY:US,BBG000BNBDC2,[$$] U.K. Court Says Generics Infringe on Lilly's Alimta Patents,2017-07-07 16:47:09 +0000,http://finance.yahoo.com/r/3fc9692e-6e7f-3a76-b24f-a85827e93d12/u-k-court-says-generics-infringe-on-lillys-alimta-patents-1499439663?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Lilly said the U.K. Supreme Court ruled that a rival’s product infringes on its patents for cancer-treatment drug Alimta in several European countries.
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court rules in favor of Lilly's Alimta patents,2017-07-07 15:10:26 +0000,https://finance.yahoo.com/news/uk-supreme-court-rules-favor-135018853.html?.tsrc=rss,"Eli Lilly and Co won a years-long  patent dispute with Actavis on Friday after the UK Supreme Court  ruled that the generic drugmaker's versions of Lilly's  top-selling cancer drug Alimta directly infringe on certain  Lilly patents in Britain, France, Italy and Spain.  Teva Pharmaceutical Industries Ltd  owns  the generic versions of Alimta in question after buying Allergan  Plc's generic business Actavis last August."
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court rules in Eli Lilly's favor in drug dispute,2017-07-07 14:05:04 +0000,http://finance.yahoo.com/r/b2e2f91a-1dc3-36b7-8dd2-a2681d9d875c/uk-supreme-court-rules-eli-140504719.html?.tsrc=rss,LONDON (AP) — Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drug-maker Actavis over Lilly's Alimta cancer treatment.
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court rules in Eli Lilly's favor in drug dispute,2017-07-07 14:05:04 +0000,https://finance.yahoo.com/news/uk-supreme-court-rules-eli-140504719.html?.tsrc=rss,Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drug-maker Actavis over Lilly's Alimta cancer treatment. The court announced Friday that Actavis products ...
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents,2017-07-07 14:02:00 +0000,http://finance.yahoo.com/r/6872f3a3-e7ea-3509-8478-c762ce22ce53/uk-supreme-court-rules-in-lilly-s-favor-actavis-infringed-on-european-vitamins-patents.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution."
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court rules in favor of Lilly's Alimta patents,2017-07-07 12:49:50 +0000,https://finance.yahoo.com/news/uk-supreme-court-rules-favor-124950060.html?.tsrc=rss,"Eli Lilly and Co said on Friday  the UK Supreme Court ruled that generic versions of the  company's top-selling cancer drug Alimta sold by Actavis  directly infringe certain Lilly patents in the UK, France, Italy  and Spain.  Alimta, whose chemical name is pemetrexed, is Lilly's  top-selling oncology treatment and generated sales of $2.3  billion last year."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly says UK Supreme Court ruled in its favor on Alimta vitamin regiment patents,2017-07-07 12:06:38 +0000,http://finance.yahoo.com/r/0db2e055-548d-317b-9f2f-6ee4646477fe/Story.aspx?guid=1E2C05D4-444B-4753-8A94-2030742F7277&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said Friday the UK Supreme Court has ruled in its favor in a patent suit with Actavis, which now trades as Allergan Plc . The court found that Actativs's products directly infringe Lilly's ..."
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents,2017-07-07 11:45:00 +0000,https://finance.yahoo.com/news/uk-supreme-court-rules-lillys-114500990.html?.tsrc=rss,"INDIANAPOLIS, July 7, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain.  The UK Supreme Court also affirmed the indirect infringement finding by the UK Court of Appeal."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court,2017-07-07 11:33:13 +0000,http://finance.yahoo.com/r/cfcee8f9-7c34-3e2e-8419-df4602922dd7/elli-lilly-wins-cancer-drug-patent-case-at-u-k-supreme-court-j4ts8kkj?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&trackingId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. won a patent dispute with Actavis at the U.K.’s top court, marking a victory in a long-running legal campaign to defend its third best-selling drug, Alimta, from rival products."
LLY,LLY:US,BBG000BNBDC2,UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents,2017-07-07 07:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iM8XXg_FDoU/uk-supreme-court-rules-in-favor-of-lilly-on-alimta-vitamin-regimen-patents-20170707-00265,UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents
LLY,LLY:US,BBG000BNBDC2,Array (ARRY) Submits NDA for Melanoma Combination Therapy,2017-07-06 23:43:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HpVZ7guwg2E/array-arry-submits-nda-for-melanoma-combination-therapy-cm812759,Array BioPharma ARRY announced that it has submitted two new drug applications NDAs to FDA seeking approval for the combination of binimetinib and encorafenib to treat patients with BRAF mutant advanced unresectable or metastatic melanoma Notably both binimetinib and encorafenib
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement,2017-07-06 18:30:00 +0000,https://finance.yahoo.com/news/lilly-confirms-date-conference-call-183000461.html?.tsrc=rss,"INDIANAPOLIS, July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017.  Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 9 a.m. Eastern time."
LLY,LLY:US,BBG000BNBDC2,Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff,2017-07-06 16:44:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-sw8yUP3Ej0/sanofi-versus-astrazeneca-large-cap-pharma-stock-faceoff-cm812466,After being battered by the drug pricing controversy in 2016 the pharma biotech sector has turned around this year The first half has been pretty strong for companies in this space The sector does have its share of challenges in the form of rising competition high profile pipeline
LLY,LLY:US,BBG000BNBDC2,Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies,2017-07-06 15:46:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fNDHQed2Tbg/merck-falls-as-fda-puts-hold-on-3-keytruda-myeloma-studies-cm812376,Merck amp Co Inc MRK shares were down more than 1 in after hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma a form of blood cancer While the KEYNOTE 183 and KEYNOTE 185 phase
LLY,LLY:US,BBG000BNBDC2,Lilly and Purdue University Announce Strategic Research Collaboration,2017-07-06 12:00:00 +0000,https://finance.yahoo.com/news/lilly-purdue-university-announce-strategic-120000110.html?.tsrc=rss,"INDIANAPOLIS and WEST LAFAYETTE, Ind., July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Purdue University today announced a strategic collaboration to conduct life science research.  The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company.  ""Purdue has enjoyed a long history of engagement with Lilly."
LLY,LLY:US,BBG000BNBDC2,"Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts",2017-07-06 08:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PH85w0-u6JQ/lilly-purdue-university-announce-strategic-research-collaboration--quick-facts-20170706-00464,"Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts"
LLY,LLY:US,BBG000BNBDC2,Incyte & Lilly's Olumiant Gets Marketing Approval in Japan,2017-07-04 13:45:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y32zXwOVkZM/incyte-lillys-olumiant-gets-marketing-approval-in-japan-cm811536,Incyte Corporation INCY and partner Eli Lilly and Company LLY announced that Japan s Ministry of Health Labor and Welfare MHLW granted marketing approval for Olumiant baricitinib 2 mg and 4 mg tablets The drug will be used for treating rheumatoid arthritis RA including the
LLY,LLY:US,BBG000BNBDC2,Incyte & Lilly&apos;s Olumiant Gets Marketing Approval in Japan,2017-07-04 11:53:11 +0000,https://finance.yahoo.com/news/incyte-lilly-apos-olumiant-gets-115311158.html?.tsrc=rss,Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.
LLY,LLY:US,BBG000BNBDC2,Alkermes Presents Phase III Data on Schizophrenia Candidate,2017-07-03 15:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WIXkp83thro/alkermes-presents-phase-iii-data-on-schizophrenia-candidate-cm811221,Alkermes plc ALKS announced positive preliminary top line results from a phase III study ENLIGHTEN 1 evaluating its schizophrenia candidate ALKS 3831 It is a supportive study in the broad clinical development program ENLIGTHEN on ALKS 3831 We note that ALKS 3831 is a once daily
LLY,LLY:US,BBG000BNBDC2,"Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis",2017-07-03 12:00:00 +0000,https://finance.yahoo.com/news/japan-ministry-health-labor-welfare-120000225.html?.tsrc=rss,"INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies.  The Olumiant approval is based on the results of the baricitinib development program, which includes four phase 3 clinical trials enrolling various populations of more than 3,000 moderate-to-severe RA patients worldwide, including more than 500 Japanese patients.  In clinical studies, baricitinib has demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts,2017-07-03 08:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WSLlkvYcl-s/eli-lilly-reports-japan-marketing-approval-for-olumiant--quick-facts-20170703-00283,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Better Buy: Pfizer Inc. vs. Eli Lilly and Company,2017-07-01 19:42:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I7EIw1IwUPE/better-buy-pfizer-inc-vs-eli-lilly-and-company-cm810898,Pfizer NYSE PFE might be more than twice as big as fellow drugmaker Eli Lilly and Company NYSE LLY but Lilly has been the better investment choice for quite a while Lilly stock has outperformed Pfizer over the last 10 years the last five years the last 12 months and so
LLY,LLY:US,BBG000BNBDC2,Better Buy: Pfizer Inc. vs. Eli Lilly and Company,2017-07-01 18:04:00 +0000,http://finance.yahoo.com/r/d34ac086-dfab-3da9-af2d-a35dcf6d26b0/better-buy-pfizer-inc-vs-eli-lilly-and-company.aspx?yptr=yahoo&.tsrc=rss,Which big pharma stock wins in a head-to-head matchup between Pfizer and Lilly?
LLY,LLY:US,BBG000BNBDC2,Beauty of Weakness; Uncertainty Remains: Rev Shark's Best Blog,2017-07-01 01:00:00 +0000,http://finance.yahoo.com/r/f5670848-fd44-3921-8f28-95a972156d43/on-not-talking-about-the-market-darth-vader-meet-amazon-jim-cramer-s-best-blog.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Guest James 'Rev Shark' DePorre discusses the beauty of weakness and also mentions that uncertainty remains.
LLY,LLY:US,BBG000BNBDC2,"Pricing, Competition Remain Headwinds for Pharma in 2017",2017-06-29 23:03:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2bAOJobSSZc/pricing-competition-remain-headwinds-for-pharma-in-2017-cm810281,Although fears regarding the drug pricing issue have waned it will nevertheless remain a headwind until the Trump administration comes out with a policy for controlling drug prices Drug pricing is an issue that weighed on pharma and biotech stocks for more than a year The sector
LLY,LLY:US,BBG000BNBDC2,YieldBoost LLY From 2.5% To 5.2% Using Options,2017-06-29 18:05:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/44XOeLworSY/yieldboost-lly-from-25-to-52-using-options-cm810124,Shareholders of Lilly Eli amp Co Symbol LLY looking to boost their income beyond the stock s 2 5 annualized dividend yield can sell the June 2018 covered call at the 92 50 strike and collect the premium based on the 2 10 bid which annualizes to an additional 2 6 rate of return
LLY,LLY:US,BBG000BNBDC2,Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion,2017-06-29 16:08:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eyIsO9lupAs/novartis-gets-ec-nod-for-lung-cancer-drugs-label-expansion-cm809991,Novartis AG NVS announced that the European Commission has approved a label expansion of oncology drug Zykadia The drug is now approved for the first line treatment of patients with advanced non small cell lung cancer NSCLC whose tumors are anaplastic lymphoma kinase ALK positive
LLY,LLY:US,BBG000BNBDC2,The Crazy Math Behind Drug Prices,2017-06-29 16:00:07 +0000,http://finance.yahoo.com/r/ef23b659-fcee-395b-82a7-348d9f0eb963/the-crazy-math-behind-drug-prices?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Intermediaries that negotiate to lower prices may cause them to increase, too."
LLY,LLY:US,BBG000BNBDC2,Better Days Ahead for the Pharma Sector?,2017-06-28 22:03:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3MnO6tocceA/better-days-ahead-for-the-pharma-sector-cm809665,We are halfway through 2017 and the pharma and biotech sector has bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 12 9 while the NASDAQ Biotechnology Index is up 17 2 This is in sharp contrast to 2016 which was a tough year for pharma and biotech stocks with the
LLY,LLY:US,BBG000BNBDC2,Alder's Shares Dip Despite Positive Migraine Trial Results,2017-06-28 17:03:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ibP6RWPrkMM/alders-shares-dip-despite-positive-migraine-trial-results-cm809487,Alder Biopharmaceuticals Inc s ALDR shares plummeted almost 28 despite the announcement of positive top line results from phase III PROMISE I study evaluating its lead pipeline candidate eptinezumab ALD403 for prevention of frequent episodic migraine Though the study has met both
LLY,LLY:US,BBG000BNBDC2,"Notable ETF Inflow Detected - VHT, GILD, LLY, AGN",2017-06-28 16:05:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rE-tqn3HXLI/notable-etf-inflow-detected-vht-gild-lly-agn-cm809432,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Health Care ETF Symbol VHT where we have detected an approximate 67 1 million dollar inflow that s a 1 0 increase week over week in outstanding
LLY,LLY:US,BBG000BNBDC2,Merck's CETP Inhibitor Reduces CV Risk in Phase III Study,2017-06-28 14:06:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3lAgTwR1uBs/mercks-cetp-inhibitor-reduces-cv-risk-in-phase-iii-study-cm809326,Merck amp Co Inc MRK announced that a large late stage cardiovascular outcomes study REVEAL evaluating anacetrapib a cholesterol lowering medicine met the primary endpoint by reducing cardiovascular CV risk Top line data from the phase III study showed that anacetrapib a
LLY,LLY:US,BBG000BNBDC2,Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications,2017-06-28 13:12:00 +0000,https://finance.yahoo.com/news/blink-health-giving-away-10-131200113.html?.tsrc=rss,"NEW YORK, June 28, 2017 /PRNewswire/ -- Blink Health, America's leading prescription drug savings platform, recently launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of diabetes medications.  People living with diabetes who create an account on Blink Health's website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone."
LLY,LLY:US,BBG000BNBDC2,"Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.",2017-06-27 23:51:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m3OVpc8FL3U/better-buy-eli-lilly-and-co-vs-merck-co-inc-cm809125,It looks like the good times will continue to roll for U S pharmaceutical stocks The recently revealed draft of an executive order aims to lower drug prices by easing industry regulations without giving the government power to negotiate directly with drugmakers As drug pricing
LLY,LLY:US,BBG000BNBDC2,"Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.",2017-06-27 21:49:00 +0000,http://finance.yahoo.com/r/fb97ded9-aaf6-3b97-b566-a2d0c34cc016/better-buy-eli-lilly-and-company-vs-merck.aspx?yptr=yahoo&.tsrc=rss,Find out which of these pharmaceutical stocks is the best pick right now.
LLY,LLY:US,BBG000BNBDC2,Why Alder Biopharma Stock Is Crashing Today,2017-06-27 20:51:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eZ2aSaD6150/why-alder-biopharma-stock-is-crashing-today-cm809037,What happened After reporting mixed results from the first of two phase 3 trials of its migraine drug shares in Alder Biopharmaceuticals NASDAQ ALDR are trading 26 lower today as of 3 16 p m EDT So what Alder Biopharmaceuticals is developing 160 eptinezumab to
LLY,LLY:US,BBG000BNBDC2,This Biotech Crashed 28% Despite Positive Migraine Drug Tests,2017-06-27 20:08:49 +0000,http://finance.yahoo.com/r/b239eb6d-e316-3223-99f0-30a46fc0ef96/this-biotech-crashed-20-despite-positive-migraine-drug-tests?src=A00220&yptr=yahoo&.tsrc=rss,"Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva."
LLY,LLY:US,BBG000BNBDC2,[$$] Merck Cholesterol Drug Could Help Unlock Value,2017-06-27 20:03:00 +0000,http://finance.yahoo.com/r/2a6f266a-57eb-37e3-af39-9dd51b843912/merck-cholesterol-drug-could-help-unlock-value-1498593835?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"In the last decade, no fewer than three major pharmaceutical companies have suffered defeat trying to bring a new class of cholesterol-lowering medication to market.s Much to the surprise of investors, Merck & Co. (MRK) could succeed where Pfizer (PFE), Roche (RHHBY) and Eli Lilly & Co. (LLY) have all failed.  Merck has yet to decide if it will seek Food and Drug Administration approval, a sign to some that the company isn’t sure if the study data, though positive, are strong enough to ensure regulatory approval.  Thanks to the growing success of Merck’s immunotherapy cancer drug Keytruda, the shares have gained 19% in the past year to near a 52-week high of $66.80."
LLY,LLY:US,BBG000BNBDC2,Why Alder Biopharma Stock Is Crashing Today,2017-06-27 19:27:41 +0000,http://finance.yahoo.com/r/fe4388be-2947-3021-937a-c463c6aded4f/why-alder-biopharma-stock-is-crashing-today.aspx?yptr=yahoo&.tsrc=rss,Disappointing phase 3 trial results are increasing concerns that its migraine drug might not be a commercial success.
LLY,LLY:US,BBG000BNBDC2,Pfizer Fueling Growth Of Competitors' Pipelines,2017-06-27 12:01:00 +0000,http://finance.yahoo.com/r/e9bab4d9-f3c0-3d80-9cc6-742d2f9992b3/pfizer-fueling-growth-of-competitors-pipelines?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,But it would have been nice to have been able to keep these drugs in-house and bring them to market under the Pfizer banner.
LLY,LLY:US,BBG000BNBDC2,Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour,2017-06-27 12:00:00 +0000,https://finance.yahoo.com/news/lilly-diabetes-brings-extra-splash-120000032.html?.tsrc=rss,"INDIANAPOLIS, June 27, 2017 /PRNewswire/ -- For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, ""you are not alone."" Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps toward self-management and increased self-confidence.  For more than 15 years, Lilly has been at the forefront of support with its Camp Care Package program.  This year, Lilly's diabetes ambassadors, all of whom have type 1 diabetes, will attend camps and share their stories starting July 4 at the Children with Diabetes® Friends for Life® conference."
LLY,LLY:US,BBG000BNBDC2,Tanezumab Receives FDA Fast Track Designation,2017-06-27 11:38:11 +0000,http://finance.yahoo.com/r/81cf0dca-dca0-3413-9a69-2e557d357e85/tanezumab-receives-fda-fast-track-designation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Tanezumab is an investigational drug co-developed by Pfizer (PFE) and Eli Lilly (LLY) for pain management in chronic pain related to cancer, lower back pain, and osteoarthritis."
LLY,LLY:US,BBG000BNBDC2,"ETFs with exposure to Eli Lilly & Co. : June 26, 2017",2017-06-26 20:22:03 +0000,http://finance.yahoo.com/r/88a6a1d6-87ce-3bf2-be2f-1fcd2c1230b0/etfs-with-exposure-to-eli-lilly-co-june-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Eli Lilly & Co. Here are 5 ETFs with the largest exposure to LLY-US. Comparing the performance and risk of Eli Lilly & Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",2017-06-26 14:55:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1pXkDJkLVzE/novartis-cardiovascular-drug-positive-nsclc-drug-approved-cm808013,Shares of Novartis AG NVS were up after the company announced positive top line results from the global phase III study CANTOS The study evaluated the efficacy safety and tolerability of ACZ885 canakinumab in combination with standard of care in patients with a prior heart attack
LLY,LLY:US,BBG000BNBDC2,Quick Tips on Investing in the Pharmaceutical and Medical Device Industry,2017-06-25 20:49:06 +0000,https://finance.yahoo.com/news/quick-tips-investing-pharmaceutical-medical-204906094.html?.tsrc=rss,An introduction to myself as well as a concise resource for new investors looking at better understanding the pharmaceutical and medical device world
LLY,LLY:US,BBG000BNBDC2,Why You Should Add Novo Nordisk Stock to Your Portfolio,2017-06-22 17:20:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HVnjNzlhyaM/why-you-should-add-novo-nordisk-stock-to-your-portfolio-cm806981,Headquartered in Bagsvaerd Denmark Novo Nordisk NVO is healthcare company and a with leadership in the global diabetes market It looks like a great stock to buy now Here are some reasons for the same Favorable Rank and Solid VGM Score Novo Nordisk holds a Zacks Rank 2 Buy and
LLY,LLY:US,BBG000BNBDC2,Merck's Keytruda on a Roll: Can it Retain the Momentum?,2017-06-22 16:24:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H4OPfihB4GU/mercks-keytruda-on-a-roll-can-it-retain-the-momentum-cm806927,As demand for immuno oncology drugs and their combinations rises Merck amp Co Inc s MRK anti PD 1 therapy Keytruda is being touted as a significant top line driver for this Kenilworth NJ based pharma giant Keytruda is presently marketed for the treatment of first line as well
LLY,LLY:US,BBG000BNBDC2,Health-Care Stocks Get a Boost From Senate Bill Rollout,2017-06-22 16:22:07 +0000,http://finance.yahoo.com/r/394e4439-d1e8-317b-a4bc-b1f687ff80f7/health-care-stocks-get-a-boost-from-senate-bill-rollout-1498148525?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion,2017-06-21 17:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KZesjIRd2w8/novo-nordisks-victoza-gets-fda-panel-nod-for-label-expansion-cm806365,Novo Nordisk A S NVO announced that the Endocrinologic and Metabolic Drugs Advisory Committee EMDAC of the FDA voted 17 2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes The positive panel recommendation
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego,2017-06-21 15:00:00 +0000,https://finance.yahoo.com/news/eli-lilly-company-unveils-expanded-150000452.html?.tsrc=rss,"Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.  ""This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market,"" said David A. Ricks, Lilly's chairman, president and chief executive officer."
LLY,LLY:US,BBG000BNBDC2,5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017,2017-06-20 17:20:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6fp94kE4gxM/5-reasons-why-you-should-invest-in-astrazeneca-azn-in-2017-cm805755,London based pharma giant AstraZeneca plc AZN has a strong product portfolio and is one of the key players in the global cardiovascular market AstraZeneca carries a Zacks Rank 2 Buy You can see the complete list of today s Zacks 1 Rank Strong Buy stocks here Here we
LLY,LLY:US,BBG000BNBDC2,"VHT, LLY, ABT, DHR: Large Inflows Detected at ETF",2017-06-20 16:19:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oMZO9l3veSo/vht-lly-abt-dhr-large-inflows-detected-at-etf-cm805652,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Health Care ETF Symbol VHT where we have detected an approximate 65 9 million dollar inflow that s a 1 0 increase week over week in outstanding
LLY,LLY:US,BBG000BNBDC2,Analyzing Eli Lilly’s Collaboration with KeyBioscience AG,2017-06-20 13:06:31 +0000,http://finance.yahoo.com/r/2df4f3e9-c376-3050-aceb-602e61abba20/analyzing-eli-lillys-collaboration-with-keybioscience-ag?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On June 8, 2017, Eli Lilly (LLY) announced a strategic collaboration with KeyBioscience AG to focus on the development of dual amylin calcitonin receptor agonists (or DACRAs)."
LLY,LLY:US,BBG000BNBDC2,Key Updates on Eli Lilly’s Jardiance,2017-06-20 11:36:03 +0000,http://finance.yahoo.com/r/a6af4747-6c18-3513-b08f-9bd9ae422538/key-updates-on-eli-lillys-jardiance?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Jardiance (empagliflozin) is a part of the Boehringer Ingelheim and Eli Lilly’s (LLY) diabetes alliance.
LLY,LLY:US,BBG000BNBDC2,"Daily Dividend Report: LLY, BXP, WSM, RL, AI",2017-06-19 20:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tcounLEzVsQ/daily-dividend-report-lly-bxp-wsm-rl-ai-cm805306,Eli Lilly and Company LLY has declared a dividend for the third quarter of 2017 of 0 52 per share on outstanding common stock The dividend is payable September 8 2017 to shareholders of record at the close of business on August 15 2017 Boston Properties BXP declared a
LLY,LLY:US,BBG000BNBDC2,Lilly Declares Third-Quarter 2017 Dividend,2017-06-19 17:05:00 +0000,https://finance.yahoo.com/news/lilly-declares-third-quarter-2017-170500383.html?.tsrc=rss,"INDIANAPOLIS , June 19, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common stock. ..."
LLY,LLY:US,BBG000BNBDC2,FDA Grants Fast-Track Designation to Tanezumab,2017-06-19 14:37:08 +0000,http://finance.yahoo.com/r/578c27e0-b2e1-3118-b14b-0c7c6d50f808/fda-grants-fast-track-designation-to-tanezumab?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Tanezumab is an investigational drug co-developed by Eli Lilly (LLY) and Pfizer (PFE).
LLY,LLY:US,BBG000BNBDC2,FDA Approves Eli Lilly’s Humalog Junior KwikPen,2017-06-19 13:07:30 +0000,http://finance.yahoo.com/r/41b34d56-1259-3c66-836b-78581e4ddd53/fda-approves-eli-lillys-humalog-junior-kwikpen?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) announced that the US Food and Drug Administration (or FDA) approved the Humalog Junior KwikPen for finer dose adjustments in the treatment of patients with diabetes on June 13, 2017."
LLY,LLY:US,BBG000BNBDC2,Lilly and NRAS Launch New Film for RA Awareness Week to Reveal the True Impact of RA,2017-06-19 12:11:00 +0000,https://finance.yahoo.com/news/lilly-nras-launch-film-ra-121100743.html?.tsrc=rss,"Eli Lilly and Company and the National Rheumatoid Arthritis Society (NRAS), today announced the launch of a new film, called 'Behind the Smile', to encourage people living with rheumatoid arthritis (RA) to have an open conversation with their doctor or nurse about how they are truly feeling and how their disease impacts their day to day life.  To coincide with RA Awareness Week, 'Behind the Smile' aims to increase awareness of the silent struggles, both physical and emotional, that people with RA face on a daily basis as they cope with pain, fatigue and stiff joints and encourage healthcare professionals to listen to what really matters to the individual patient.  The 'Behind the Smile' film is launched to coincide with the results from the new survey by Lilly, RA Matters, which reveals a lack of understanding about the true impact of RA."
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly’s Taltz Performed in Clinical Trials,2017-06-19 11:36:40 +0000,http://finance.yahoo.com/r/ce2c8b74-02b2-3ab6-a550-f793dc705c06/how-eli-lillys-taltz-performed-in-clinical-trials?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On June 15, 2017, Eli Lilly announced data from a study that evaluated the safety and efficacy of Taltz in patients with active psoriatic arthritis."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Investor Conference Call At 10 :00 AM ET,2017-06-19 09:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QDKO91tZnIM/eli-lilly-and-co-investor-conference-call-at-10-00-am-et-20170619-00640,Eli Lilly And Co. Investor Conference Call At 10 :00 AM ET
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Investor Conference Call At 10:00 AM ET,2017-06-19 08:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k_vmYorWZGo/eli-lilly-and-co-investor-conference-call-at-1000-am-et-20170619-00462,Eli Lilly And Co. Investor Conference Call At 10:00 AM ET
LLY,LLY:US,BBG000BNBDC2,Could Legalized Marijuana Be Making Big Pharma Nervous?,2017-06-18 19:19:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hJp4i0ldJpI/could-legalized-marijuana-be-making-big-pharma-nervous-cm804826,An effort in Arizona to legalize recreational marijuana failed last year Insys Therapeutics NASDAQ INSY helped make it happen The drugmaker donated 500 000 to an organization that opposed a marijuana legalization proposition It makes sense that Insys would be
LLY,LLY:US,BBG000BNBDC2,5 Answers to Questions Gilead Sciences' Investors Probably Have,2017-06-18 17:19:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8dAXvPkMCYQ/5-answers-to-questions-gilead-sciences-investors-probably-have-cm804819,If you re a Gilead Sciences NASDAQ GILD shareholder or you re thinking about buying the stock you probably have a lot of questions And if you don t you should have It hasn t been a pretty picture for the biotech for quite a while now Gilead s hepatitis C virus
LLY,LLY:US,BBG000BNBDC2,"Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends",2017-06-16 22:19:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tlvsV006zeY/dow-30-stock-roundup-ge-appoints-flannery-as-ceo-utx-cat-hike-dividends-cm804614,The Dow notched up successive record gains during a week marked by grievous losses for tech stocks Concerns about valuations continued to push tech stocks lower on Monday leading to notable losses for the broader markets However the Dow was able to ride the rebound staged on Tuesday
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused",2017-06-16 14:11:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kzkrRPbC_Dg/pharma-stock-roundup-jj-lilly-present-data-merck-keytruda-study-enrolment-paused-cm804262,This week s highlights include data from companies like Johnson amp Johnson JNJ and Lilly LLY while Merck MRK paused new enrolment in a couple of studies being conducted with Keytruda Recap of the Week s Most Important Stories J amp J Presents Data on Invokana Simponi Aria
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. :LLY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017",2017-06-16 13:34:55 +0000,http://finance.yahoo.com/r/451e52fa-e411-3dfb-96d9-675c137b6f6a/eli-lilly-co-lly-us-earnings-analysis-q1-2017-by-the-numbers-june-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Eli Lilly & Co. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Eli Lilly & Co. – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Amgen Inc. and Novartis ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks,2017-06-16 09:10:00 +0000,https://finance.yahoo.com/news/eular-2017-lillys-taltz-ixekizumab-091000623.html?.tsrc=rss,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
LLY,LLY:US,BBG000BNBDC2,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,2017-06-16 08:15:00 +0000,https://finance.yahoo.com/news/safety-long-term-efficacy-data-081500901.html?.tsrc=rss,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
LLY,LLY:US,BBG000BNBDC2,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,2017-06-16 08:15:00 +0000,https://finance.yahoo.com/news/safety-long-term-efficacy-data-081500887.html?.tsrc=rss,"INDIANAPOLIS, June 16, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents.  Additionally, new data from the long-term extension (LTE) of Phase 3 trials showed that two years of baricitinib treatment significantly lowered the rate of joint damage progression and maintained an overall low disease activity (LDA) throughout the treatment period in these patients."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib",2017-06-16 05:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gNY6vXR_lIg/eli-lilly-incyte-announce-positive-results-from-pooled-analysis-of-baricitinib-20170616-00126,"Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial,2017-06-16 05:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ypYc2kF21bQ/eli-lilly-reports-results-from-extension-period-of-spiritp1-trial-20170616-00125,Eli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis",2017-06-16 05:00:00 +0000,https://finance.yahoo.com/news/eli-lilly-company-ra-matters-050000906.html?.tsrc=rss,"Eli Lilly and Company (LLY) today announced the results of the RA Matters survey.  The results showed regardless of characteristic or country, that the understanding of rheumatoid arthritis (RA), its symptoms and how RA makes people feel, has a large impact on people's lives.  The RA Matters survey uncovered that despite major advances in the treatment of RA, physical symptoms such as fatigue (43%) and pain (39%), continue to be the biggest barriers for people with RA in the workplace.[1] Difficulty using their hands was the biggest challenge to people carrying out work."
LLY,LLY:US,BBG000BNBDC2,"ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits",2017-06-15 22:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0co6saDS3KE/admp-soars-on-fda-nod-it-is-advantage-oxfd-lly-in-good-spirits-20170615-01389,"ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits"
LLY,LLY:US,BBG000BNBDC2,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?,2017-06-15 21:07:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hQ23dJRFkMQ/why-is-immunogen-imgn-stock-up-131-this-year-cm804075,Shares of ImmunoGen Inc IMGN are massively up 130 9 this year so far outperforming the the Zacks classified Medical Drugs industry s registered 3 6 increase during this period Let s analyze the factors that led to the rally Waltham MA based ImmunoGen is a development
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : June 15, 2017",2017-06-15 20:22:50 +0000,http://finance.yahoo.com/r/515238c3-0081-30de-af2d-d204438340c8/eli-lilly-co-value-analysis-nyselly-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Eli Lilly & Co. a score of 59. Our analysis is based on comparing Eli Lilly & Co. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Roche Holding Ltd ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,"ETFs with exposure to Eli Lilly & Co. : June 15, 2017",2017-06-15 18:26:42 +0000,http://finance.yahoo.com/r/7cd65f3f-7dbf-391f-892a-452c347fba60/etfs-with-exposure-to-eli-lilly-co-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Eli Lilly & Co. Here are 5 ETFs with the largest exposure to LLY-US. Comparing the performance and risk of Eli Lilly & Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,Health-care reform should include 'faster' FDA on drug ap...,2017-06-15 16:30:00 +0000,https://finance.yahoo.com/video/health-care-reform-faster-fda-163000593.html?.tsrc=rss,"CNBC's Meg Tirrell talks to David Ricks, CEO of Eli Lilly, about health-care reform live from the Heartland Health Summit."
LLY,LLY:US,BBG000BNBDC2,"Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch",2017-06-15 16:09:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RqHroVafxqQ/johnson-johnsons-type-2-diabetes-drug-is-stellar-in-cardiovascular-trials-but-comes-with-a-catch-cm803883,Healthcare conglomerate Johnson amp Johnson s NYSE JNJ long awaited data from Invokana its type 2 diabetes blockbuster drug has arrived The rise of SGLT 2 inhibitors Invokana is a next generation SGLT 2 inhibitor that has the opportunity to slowly
LLY,LLY:US,BBG000BNBDC2,"Johnson & Johnson&apos;s Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch",2017-06-15 14:47:00 +0000,http://finance.yahoo.com/r/e581064c-53e4-39df-aa53-1b188049b953/johnson-johnsons-type-2-diabetes-drug-is-stellar-i.aspx?yptr=yahoo&.tsrc=rss,"Invokana matches and tops Jardiance in some respects, but this major side effect could be tough to overcome."
LLY,LLY:US,BBG000BNBDC2,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors,2017-06-15 14:35:00 +0000,https://finance.yahoo.com/news/eular-2017-lillys-taltz-ixekizumab-143500988.html?.tsrc=rss,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response ...
LLY,LLY:US,BBG000BNBDC2,How Did Incyte’s Product Portfolio Look in 1Q17?,2017-06-15 13:07:51 +0000,http://finance.yahoo.com/r/ec25bbe5-7330-39da-b1fc-0e0a365a4625/how-did-incytes-product-portfolio-look-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte’s (INCY) product portfolio includes oncology and non-oncology drugs.
LLY,LLY:US,BBG000BNBDC2,Analyzing Incyte’s Revenue Streams in 1Q17,2017-06-15 11:37:06 +0000,http://finance.yahoo.com/r/77097dd8-5021-34c2-8fef-5911b58253d0/analyzing-incytes-revenue-streams-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte (INCY) reported revenues of $384.1 million in its 1Q17 results, which translates to 45.7% revenue growth in 1Q17 as compared to $263.5 million in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Lilly's Taltz Shows Improvements In Disease Signs And Symptoms In PsA,2017-06-15 11:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IiNkByliMpo/lillys-taltz-shows-improvements-in-disease-signs-and-symptoms-in-psa-20170615-00821,Lilly's Taltz Shows Improvements In Disease Signs And Symptoms In PsA
LLY,LLY:US,BBG000BNBDC2,5 Things You Didn't Know About Eli Lilly and Co,2017-06-14 20:08:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7sbjLu_VJiI/5-things-you-didnt-know-about-eli-lilly-and-co-cm803490,Lately things have been a bit topsy turvy at Eli Lilly and Co NYSE LLY Shareholders and casual observers of the pharmaceutical industry probably know that the pharmaceutical giant began the year with a new CEO and the current CFO has announced her retirement after 27 years
LLY,LLY:US,BBG000BNBDC2,5 Things You Didn&apos;t Know About Eli Lilly and Co,2017-06-14 18:51:00 +0000,http://finance.yahoo.com/r/8c298d43-cb8a-3d99-a793-bcc73aa1821b/5-things-you-didnt-know-about-eli-lilly-and-co.aspx?yptr=yahoo&.tsrc=rss,Here are a handful of things you probably haven&apos;t heard about one of the world&apos;s largest pharmaceutical companies.
LLY,LLY:US,BBG000BNBDC2,Pfizer & Lilly Get Fast Track Designation for Pain Candidate,2017-06-14 17:08:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r96pw6frSEc/pfizer-lilly-get-fast-track-designation-for-pain-candidate-cm803406,Pfizer Inc PFE and Eli Lilly and Company LLY announced that the FDA has granted fast track designation to their pipeline candidate tanezumab for the treatment of chronic pain in patients with osteoarthritis OA and chronic low back pain CLBP We note that the FDA s fast track
LLY,LLY:US,BBG000BNBDC2,"Company News for June 14, 2017",2017-06-14 16:09:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VExi_t8Hc20/company-news-for-june-14-2017-cm803302,160 160 160 Shares of Eli Lilly and Company LLY advanced 0 4 after the company declared that the pain drug it has developed with Pfizer Inc PFE has been granted fast track designation by the Food and Drug Administration 160 160 160 The Cheesecake Factory Incorporated s
LLY,LLY:US,BBG000BNBDC2,"[$$] JNJ Diabetes Data Benefit Lilly, Hurt Merck",2017-06-14 15:12:00 +0000,http://finance.yahoo.com/r/261dab72-88d2-39ce-8936-01aa9778650a/jnj-diabetes-data-benefit-lilly-hurt-merck-1497453175?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse We attended the American Diabetes Association Meeting and the presentation of the CANVAS Outcomes data for Johnson & Johnson’s Invokana.  Note that we are currently Restricted on Johnson & Johnson (JNJ), as Credit Suisse is acting as an advisor to Actelion in Johnson & Johnson’s pending acquisition of the company."
LLY,LLY:US,BBG000BNBDC2,Pfizer & Lilly Get Fast Track Designation for Pain Candidate,2017-06-14 14:57:02 +0000,https://finance.yahoo.com/news/pfizer-lilly-fast-track-designation-145702847.html?.tsrc=rss,"Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP)."
LLY,LLY:US,BBG000BNBDC2,"Company News for June 14, 2017",2017-06-14 14:28:02 +0000,https://finance.yahoo.com/news/company-news-june-14-2017-142802499.html?.tsrc=rss,"Companies in the News are: LLY,PFE,CAKE,JW.A,CVCO"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : June 14, 2017",2017-06-14 12:22:18 +0000,http://finance.yahoo.com/r/f479f8af-5543-3779-a273-0f228addf67c/eli-lilly-co-breached-its-50-day-moving-average-in-a-bullish-manner-lly-us-june-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Eli Lilly & Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Present At Goldman Sachs Conference; Webcast At 11:40 AM ET,2017-06-14 10:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YM5MBF1T9VU/eli-lilly-to-present-at-goldman-sachs-conference-webcast-at-1140-am-et-20170614-00744,Eli Lilly To Present At Goldman Sachs Conference; Webcast At 11:40 AM ET
LLY,LLY:US,BBG000BNBDC2,[$$] Blink Health Terminates Pact With Express Scripts for Lilly Insulin Price Discounts,2017-06-14 04:55:54 +0000,http://finance.yahoo.com/r/2505795c-e08f-3c4f-9927-d1a399c5d6bf/blink-health-terminates-pact-with-express-scripts-for-lilly-insulin-price-discounts-1497383561?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange ..."
LLY,LLY:US,BBG000BNBDC2,Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017),2017-06-13 22:01:00 +0000,https://finance.yahoo.com/news/lilly-present-data-olumiant-baricitinib-220100628.html?.tsrc=rss,"Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz INDIANAPOLIS , June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: ..."
LLY,LLY:US,BBG000BNBDC2,Dow&apos;s J&J Hosted A Diabetes Study — And Lilly Will Benefit Most,2017-06-13 20:03:16 +0000,http://finance.yahoo.com/r/e08d0bd2-ac39-37eb-97d9-01e12caaeb5c/dow-stock-jj-hosted-a-diabetes-study-and-lilly-will-benefit-most?src=A00220&yptr=yahoo&.tsrc=rss,"Johnson&apos;s diabetes drug, Invokana, cut down on cardiovascular events — but Eli Lilly stands to benefit most."
LLY,LLY:US,BBG000BNBDC2,[$$] Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts,2017-06-13 19:52:44 +0000,http://finance.yahoo.com/r/2505795c-e08f-3c4f-9927-d1a399c5d6bf/blink-health-terminates-pact-with-express-scripts-for-lilly-insulin-price-discounts-1497383561?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange ..."
LLY,LLY:US,BBG000BNBDC2,Biotech Stocks To Watch And Pharma Industry News,2017-06-13 19:18:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
LLY,LLY:US,BBG000BNBDC2,Jardiance® (empagliflozin) analysis reinforces established safety profile,2017-06-13 18:00:00 +0000,https://finance.yahoo.com/news/jardiance-empagliflozin-analysis-reinforces-established-180000068.html?.tsrc=rss,"RIDGEFIELD, Conn., and INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- An analysis of pooled safety data from 19 studies, including the EMPA-REG OUTCOME® trial, involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower limb amputations or bone fractures compared with placebo, Boehringer Ingelheim and Eli Lilly and Company (LLY) announced today.  ""This is an exciting time in the advancement of treatment options for people living with type 2 diabetes and cardiovascular disease,"" said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs, Primary Care, Boehringer Ingelheim Pharmaceuticals, Inc. ""Boehringer Ingelheim and Lilly are committed to providing available data about the efficacy and safety of our treatment options."
LLY,LLY:US,BBG000BNBDC2,"J&J's Invokana Lowers Heart Issues, Raises Amputation Risk",2017-06-13 16:32:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/56fyKuWJisw/jjs-invokana-lowers-heart-issues-raises-amputation-risk-cm802797,Johnson amp Johnson JNJ announced data from a large CANVAS outcomes program which demonstrated that its type II diabetes drug Invokana canagliflozin was successful in reducing the risks of heart attacks and strokes However the study also showed that the drug increased the risk
LLY,LLY:US,BBG000BNBDC2,"Pfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug",2017-06-13 16:16:00 +0000,http://finance.yahoo.com/r/e35a229f-f444-39f8-9afc-e446418be1a2/pfizer-eli-lilly-granted-fda-accelerated-review-for-non-opiod-pain-relief-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The FDA approval comes amidst America's struggle with an opioid epidemic.
LLY,LLY:US,BBG000BNBDC2,Lilly Plans New Outcomes Study to Expand Jardiance Label,2017-06-13 15:33:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vO9GTNhM4LE/lilly-plans-new-outcomes-study-to-expand-jardiance-label-cm802708,Eli Lilly and Company LLY along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance empagliflozin for treatment of patients with chronic kidney disease Last year Lilly received an FDA approval to
LLY,LLY:US,BBG000BNBDC2,Merck Stalls Enrolment in Two Myeloma Studies of Keytruda,2017-06-13 15:32:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dBb2SZtz8ks/merck-stalls-enrolment-in-two-myeloma-studies-of-keytruda-cm802663,Merck amp Co Inc MRK announced that it is pausing two late stage studies evaluating its anti PD 1 therapy Keytruda as a combination therapy for the treatment of multiple melanoma a form of blood cancer Shares were down more than 1 in after hours trading Merck s shares are up 9 2
LLY,LLY:US,BBG000BNBDC2,"J&J&apos;s Invokana Lowers Heart Issues, Raises Amputation Risk",2017-06-13 13:49:01 +0000,https://finance.yahoo.com/news/j-j-apos-invokana-lowers-134901774.html?.tsrc=rss,"Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes."
LLY,LLY:US,BBG000BNBDC2,Merck: A Speed Bump For Keytruda?,2017-06-13 13:18:00 +0000,http://finance.yahoo.com/r/3a9481fa-28e1-3b22-9b71-281369492229/merck-a-speed-bump-for-keytruda-1497359892?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Shares of Merck (MRK) are falling today after the drug maker announced late Monday that it was hitting the brakes on two late-stage studies involving the use of its immuno-cancer drug Keytruda as a treatment for multiple myeloma.  Merck is investigating increased reports of deaths in the groups using the drug.  Evercore ISI analyst  Umer Raffat has the details.
LLY,LLY:US,BBG000BNBDC2,Lilly Plans New Outcomes Study to Expand Jardiance Label,2017-06-13 12:58:12 +0000,https://finance.yahoo.com/news/lilly-plans-outcomes-study-expand-125812320.html?.tsrc=rss,Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly stock rises 1.5% after pain drug gets fast track designation from FDA,2017-06-13 12:53:50 +0000,http://finance.yahoo.com/r/8f5890bb-88b5-347b-9b4e-9673363d352b/Story.aspx?guid=4160BF6F-1210-479B-8A31-E0F85510A8BF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. shares rose 1.5% in premarket trade Tuesday after the company said its pain drug with Pfizer Inc. has received fast track designation from the Food and Drug Administration, which is intended ..."
LLY,LLY:US,BBG000BNBDC2,Corporate News Blog - Lilly Announces Galcanezumab Results Presented at AHS; Reported Reduced Number of Migraine Headache Days for Patients with Acute Migraine,2017-06-13 12:15:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-lilly-announces-121500318.html?.tsrc=rss,"Research Desk Line-up: Tonix Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Eli Lilly ..."
LLY,LLY:US,BBG000BNBDC2,Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab,2017-06-13 12:00:00 +0000,https://finance.yahoo.com/news/pfizer-lilly-receive-fda-fast-120000341.html?.tsrc=rss,Pfizer Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis and chronic low back pain .
LLY,LLY:US,BBG000BNBDC2,Chi-Med steps closer to Chinese pharma first with drug filing,2017-06-13 08:20:03 +0000,https://finance.yahoo.com/news/chi-med-steps-closer-chinese-082003708.html?.tsrc=rss,"Hutchison China MediTech  , the Shanghai-based drugmaker listed in London, is a  step closer to winning approval for a modern drug developed in a  Chinese lab with the submission of its cancer medicine  fruquintinib to China's drug watchdog.  The company, controlled by Li Ka-shing's CK Hutchison  group, said on Monday the China Food and Drug  Administration would now review the drug as a treatment for  advanced colorectal cancer.  The move triggers a milestone payment of $4.5 million from  U.S. partner Eli Lilly to the Chinese firm, which is  commonly known as Chi-Med."
LLY,LLY:US,BBG000BNBDC2,Pfizer And Lilly Gets FDA Fast Track Designation For Tanezumab,2017-06-13 08:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wTV0dj6_-zo/pfizer-and-lilly-gets-fda-fast-track-designation-for-tanezumab-20170613-00450,Pfizer And Lilly Gets FDA Fast Track Designation For Tanezumab
LLY,LLY:US,BBG000BNBDC2,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,2017-06-12 23:27:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gzatca_SWnI/novartis-presents-positive-data-on-car-t-cell-therapy-drug-cm802378,Novartis AG NVS announced data from an interim analysis from its multi center global phase II study JULTIET NCT02445248 The study examined pipeline candidate CTL019 among adult patients suffering from relapsed or refractory r r diffuse large B cell lymphoma DLBCL The study showed
LLY,LLY:US,BBG000BNBDC2,J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes,2017-06-12 22:17:00 +0000,http://finance.yahoo.com/r/9a30e330-3e97-3916-8dee-91e30a0fdbbf/jj-drug-prevents-heart-attacks-at-cost-of-amputated-toes?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"In a blow to J&J, for every three heart attacks, strokes, or cardiovascular deaths prevented by Invokana, there were two amputations, 71% of them of toes or the lower foot, according to the results of the 10,142-patient study."
LLY,LLY:US,BBG000BNBDC2,U.S. finalizes talks to resume beef exports to China after ban,2017-06-12 21:20:40 +0000,https://finance.yahoo.com/news/u-finalizes-talks-resume-beef-212040761.html?.tsrc=rss,"Final details are in place to  allow U.S. exporters to resume beef shipments to China, U.S.  officials said on Monday, allowing companies to prepare for  their first shipments in 14 years.  After concluding talks with Beijing, the U.S. Department of  Agriculture said U.S. producers must track the birthplace of  cattle born in the United States that are destined for export to  China.  In another rule, U.S. beef shipments to China must come from  cattle less than 30 months of age, according to the USDA."
LLY,LLY:US,BBG000BNBDC2,Elanco Releases First-Ever Corporate Social Responsibility Impact Report,2017-06-12 19:00:00 +0000,https://finance.yahoo.com/news/elanco-releases-first-ever-corporate-190000188.html?.tsrc=rss,"GREENFIELD, Ind., June 12, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), today released its inaugural global Corporate Social Responsibility (CSR) Impact Report demonstrating its commitment to impact food security and the support of the human-animal bond.  The Impact Report is available at Elanco.com on the Giving Back section of the website.  ""Elanco's vision of Food and Companionship Enriching Life isn't just a phrase that lives on a plaque, it lives in the hearts and minds of our employees,"" said Simmons, president, Elanco."
LLY,LLY:US,BBG000BNBDC2,Alkermes Commences Phase III Study for Schizophrenia Drug,2017-06-12 16:26:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5-ncSNkC13k/alkermes-commences-phase-iii-study-for-schizophrenia-drug-cm802086,Alkermes plc ALKS announced that it initiated a phase III study ENLIGHTEN Early on experimental candidate ALKS 3831 The study is a supportive study in the broad clinical development program ENLIGTHEN on ALKS 3831 We note that 160 160 160 ALKS 3831 is a once daily oral
LLY,LLY:US,BBG000BNBDC2,Alkermes Commences Phase III Study for Schizophrenia Drug,2017-06-12 14:47:02 +0000,https://finance.yahoo.com/news/alkermes-commences-phase-iii-study-144702932.html?.tsrc=rss,"Alkermes plc (ALKS) announced that it initiated a phase III study, ENLIGHTEN-Early on experimental candidate, ALKS 3831."
LLY,LLY:US,BBG000BNBDC2,Merck's Diabetes Drug Meets Primary Endpoint in Key Studies,2017-06-12 14:32:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4hzgO3Fer1U/mercks-diabetes-drug-meets-primary-endpoint-in-key-studies-cm801963,Merck amp Co Inc MRK and partner Pfizer Inc PFE announced that its pipeline candidate ertugliflozin met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes The results were presented at the Scientific Sessions of the American
LLY,LLY:US,BBG000BNBDC2,Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease,2017-06-12 12:00:00 +0000,https://finance.yahoo.com/news/jardiance-empagliflozin-tablets-studied-chronic-120000740.html?.tsrc=rss,"RIDGEFIELD, Conn. and INDIANAPOLIS, June 12, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced plans to conduct a new, large clinical outcomes trial investigating Jardiance® (empagliflozin) tablets for the treatment of people with chronic kidney disease.  The trial will enroll people with chronic kidney disease both with and without type 2 diabetes.  ""Our plans for this new trial are yet another example of our ongoing commitment to improving patient health, especially in areas where unmet needs exist,"" said Prof. Hans-Juergen Woerle, global vice president medicine, Boehringer Ingelheim."
LLY,LLY:US,BBG000BNBDC2,"Boehringer, Eli Lilly To Conduct New Trial Investigating Jardiance Tablets",2017-06-12 08:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y0ZovAv2nUs/boehringer-eli-lilly-to-conduct-new-trial-investigating-jardiance-tablets-20170612-00376,"Boehringer, Eli Lilly To Conduct New Trial Investigating Jardiance Tablets"
LLY,LLY:US,BBG000BNBDC2,Chi-Med steps closer to Chinese pharma first with drug filing,2017-06-12 07:28:31 +0000,https://finance.yahoo.com/news/chi-med-steps-closer-chinese-072831147.html?.tsrc=rss,"Hutchison China MediTech  , the Shanghai-based drugmaker listed in London, is a  step closer to winning approval for a modern drug developed in a  Chinese lab with the submission of its cancer medicine  fruquintinib to China's drug watchdog.  The company, controlled by Li Ka-shing's CK Hutchison  group, said on Monday the China Food and Drug  Administration would now review the drug as a treatment for  advanced colorectal cancer.  The move triggers a milestone payment of $4.5 million from  U.S. partner Eli Lilly to the Chinese firm, which is  commonly known as Chi-Med."
LLY,LLY:US,BBG000BNBDC2,"Sector Gamma As Buys Bristol-Myers Squibb Company, Perrigo Co PLC, Abbott Laboratories, Sells ...",2017-06-10 10:26:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3QS2pCW3_AU/sector-gamma-as-buys-bristol-myers-squibb-company-perrigo-co-plc-abbott-laboratories-sells-cm801567,Sector Gamma As New Purchases PRGO LH LXRX Added Positions BMY ABT ANTM GILD SHPG BAX BSX IPXL Reduced Positions UTHR VRTX MASI IART OMI CI MNTA IRWD Sold Out MRK EXEL ALXN New Purchases PRGO LH LXRX
LLY,LLY:US,BBG000BNBDC2,Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags,2017-06-09 17:43:00 +0000,http://finance.yahoo.com/r/d9884dd8-aa72-3975-a4cc-820c24fa4865/pharmaceutical-stocks-gain-on-promising-migraine-drugs-with-hefty-price-tags.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.
LLY,LLY:US,BBG000BNBDC2,PowerShares Dynamic Pharmaceuticals Portfolio Experiences Big Outflow,2017-06-09 16:27:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q-kPk1L9HvY/powershares-dynamic-pharmaceuticals-portfolio-experiences-big-outflow-cm801254,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the PowerShares Dynamic Pharmaceuticals Portfolio Symbol PJP where we have detected an approximate 113 8 million dollar outflow that s a 13 5 decrease week
LLY,LLY:US,BBG000BNBDC2,"New migraine drugs have promise — and a $8,500 price tag",2017-06-09 16:02:31 +0000,http://finance.yahoo.com/r/6e35c1d6-15ea-384a-8124-ffdec256b78b/Story.aspx?guid=3955D604-4C89-11E7-8F25-FFB46009C8A4&siteid=yhoof2&yptr=yahoo&.tsrc=rss,They’re the first drugs developed for migraine in a long time. But migraine patients worry they won’t be able to access them.
LLY,LLY:US,BBG000BNBDC2,"New migraine drugs have promise — and a $8,500 price tag",2017-06-09 16:02:31 +0000,https://finance.yahoo.com/news/migraine-drugs-promise-8-500-160231070.html?.tsrc=rss,They’re the first drugs developed for migraine in a long time. But migraine patients worry they won’t be able to access them.
LLY,LLY:US,BBG000BNBDC2,7 Reasons Why Prescription Drug Prices Are Extremely Expensive,2017-06-09 11:28:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D3tBCPPcZXw/7-reasons-why-prescription-drug-prices-are-extremely-expensive-cm800997,Image source Getty Images Spending on prescription drugs increased by 3 8 in 2016 according 160 to pharmacy benefit manager Express Scripts While that s slower growth than the 5 2 year over year increase experienced in 2015 spending is still headed in the wrong
LLY,LLY:US,BBG000BNBDC2,"IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention",2017-06-09 10:30:00 +0000,https://finance.yahoo.com/news/idf-partnership-lilly-announces-second-103000072.html?.tsrc=rss,"BRUSSELS and INDIANAPOLIS, June 9, 2017 /PRNewswire/ -- More than 400 million people are living with diabetes.  In a further effort to help spread lessons learned from clinical research to benefit people affected by this condition, the International Diabetes Federation (IDF) and Eli Lilly and Company (LLY) have come together for the second phase of the Bringing Research in Diabetes to Global Environments and Systems programme (BRIDGES 2), reaffirming their commitment to helping people with diabetes effectively manage their condition.  BRIDGES 2 will build upon the work undertaken and the lessons learned during the initial phase of the programme which operated from 2007 to 2015."
LLY,LLY:US,BBG000BNBDC2,How This Small Biotech Could Ruffle The Market In Migraine Drugs,2017-06-08 20:20:22 +0000,http://finance.yahoo.com/r/78e4dd50-6dc8-3ff4-b0c0-fd957116a581/how-this-amgen-lilly-teva-rival-could-ruffle-the-migraine-market?src=A00220&yptr=yahoo&.tsrc=rss,"Wall Street is undervaluing Alder which stands to outperform larger rivals Amgen, Lilly and Teva in migraine drugs, an analyst said Thursday."
LLY,LLY:US,BBG000BNBDC2,InPlay from Briefing.com,2017-06-08 19:49:13 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
LLY,LLY:US,BBG000BNBDC2,Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting,2017-06-08 19:25:00 +0000,https://finance.yahoo.com/news/lilly-present-breaking-data-galcanezumab-192500707.html?.tsrc=rss,"INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for migraine, at ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Webcast to Discuss Pain Management Portfolio,2017-06-08 19:00:00 +0000,https://finance.yahoo.com/news/lilly-announces-webcast-discuss-pain-190000496.html?.tsrc=rss,"INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, and data from one Phase 3 study of lasmiditan, an investigational treatment for the acute treatment of migraine.  Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm."
LLY,LLY:US,BBG000BNBDC2,Teva Migraine Candidate Succeeds in Second Phase III Study,2017-06-08 16:31:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qckKAoLJf5o/teva-migraine-candidate-succeeds-in-second-phase-iii-study-cm800670,Teva Pharmaceutical Industries Ltd TEVA announced that its experimental migraine prevention drug fremanezumab met all the primary and secondary endpoints in a second late stage study Pivotal data from the second phase III HALO study in episodic migraine prevention showed that patients
LLY,LLY:US,BBG000BNBDC2,AbbVie (ABBV) Announced Positive Phase III RA Candidate Data,2017-06-08 16:31:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HHwNWDsnVwc/abbvie-abbv-announced-positive-phase-iii-ra-candidate-data-cm800663,AbbVie Inc ABBV announced positive top line results from a phase III study on rheumatoid arthritis candidate upadacitinib ABT 494 Upadacitinib is an investigational oral JAK1 selective inhibitor being studied as a once a day oral therapy AbbVie s shares have rallied 13 2 in the past
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Strategic Collaboration with KeyBioscience AG,2017-06-08 10:30:00 +0000,https://finance.yahoo.com/news/lilly-announces-strategic-collaboration-keybioscience-103000672.html?.tsrc=rss,"The collaboration includes access to the DACRA platform with multiple molecules including KBP-042, KBP-089 and KBP-056.  KeyBioscience has initiated Phase 2 development with KBP-042.  Other assets included in the collaboration, engineered for differences in effect or potency, range from Phase 1 to pre-clinical.  Under terms of the agreement, Lilly will receive worldwide rights to develop and commercialize these molecules."
LLY,LLY:US,BBG000BNBDC2,News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment,2017-06-07 16:23:00 +0000,https://finance.yahoo.com/news/news-alert-blink-health-away-162300201.html?.tsrc=rss,"NEW YORK, June 7, 2017 /PRNewswire/ -- Blink Health, America's leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes.  People living with diabetes who create an account on Blink Health's website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone.  The program will also cover these three medications for existing Blink Health patients who use them."
LLY,LLY:US,BBG000BNBDC2,Novartis' (NVS) Tasigna Receives Label Update Nod in EU,2017-06-07 15:28:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4L41Nd5hfqc/novartis-nvs-tasigna-receives-label-update-nod-in-eu-cm800064,Novartis AG NVS announced that the European Commission EC has approved the inclusion of Treatment free Remission TFR data in the oncology drug Tasigna s Summary of Product Characteristics SmPC We note that Tasigna is approved for the treatment of chronic phase and accelerated
LLY,LLY:US,BBG000BNBDC2,Blink Health Commits To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment,2017-06-07 12:00:00 +0000,https://finance.yahoo.com/news/blink-health-commits-away-10-120000560.html?.tsrc=rss,"NEW YORK, June 7, 2017 /PRNewswire/ -- Blink Health, America's leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes.  People living with diabetes who create an account on Blink Health's website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone."
LLY,LLY:US,BBG000BNBDC2,Seattle Genetics Reports Updated Results on Cancer Drug,2017-06-07 00:16:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KfZyu4YU_h4/seattle-genetics-reports-updated-results-on-cancer-drug-cm799730,Seattle Genetics Inc SGEN and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin ASG 22ME The candidate was assessed as monotherapy treatment for metastatic urothelial cancer mUC Enfortumab vedotin is an investigational antibody drug conjugate ADC
LLY,LLY:US,BBG000BNBDC2,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-07 00:16:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d8OUTMPlgXQ/novartis-bristol-myers-collaborate-for-opdivo-combination-cm799724,Novartis AG NVS announced that it has entered into clinical research collaboration with Bristol Myers Squibb Company BMY Per the terms of the agreement Bristol Myers will investigate the safety tolerability and efficacy of Novartis s Mekinist in combination with its own Opdivo
LLY,LLY:US,BBG000BNBDC2,Seattle Genetics Reports Updated Results on Cancer Drug,2017-06-06 22:08:10 +0000,https://finance.yahoo.com/news/seattle-genetics-reports-updated-results-220810733.html?.tsrc=rss,"Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME)."
LLY,LLY:US,BBG000BNBDC2,Novartis Presents Data on Tafinlar-Mekinist Combination,2017-06-06 00:00:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sfZTIliA3Ek/novartis-presents-data-on-tafinlar-mekinist-combination-cm799050,Novartis AG NVS announced results from a phase II study BRF113220 on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology ASCO The results from the study showed a durable survival benefit for some patients with BRAF
LLY,LLY:US,BBG000BNBDC2,Tesaro Crashes Despite Beating AstraZeneca With &apos;Stronger&apos; Data,2017-06-05 21:14:00 +0000,http://finance.yahoo.com/r/58a8f9bf-ecf3-3ff4-a2d8-f192d2e8966f/tesaro-crashes-despite-beating-astrazeneca-with-stronger-data?src=A00220&yptr=yahoo&.tsrc=rss,Tesaro stock plunged Monday despite a Sunday presentation during a meeting that showed its Zejula could be stronger than drugs from AstraZeneca in breast cancer.
LLY,LLY:US,BBG000BNBDC2,Pfizer Provides Final Update on Phase II Talazoparib Study,2017-06-05 17:03:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vf13TjdWlh8/pfizer-provides-final-update-on-phase-ii-talazoparib-study-cm798793,Pfizer Inc PFE announced data from its phase II study ABRAZO which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1 2 positive gBRCA mutations showing anti tumor activity The results were presented at the Annual Meeting of the American Society of
LLY,LLY:US,BBG000BNBDC2,Performance of Elanco in 1Q17,2017-06-05 14:36:28 +0000,http://finance.yahoo.com/r/758b3e66-e1de-3767-8760-f56fa157cf10/performance-of-elanco-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Elanco's 1Q17 revenues include revenues from the acquired Novartis Animal Health products. The US Animal Health franchise reported growth of 5% in its 1Q17 revenues to $413.8 million.
LLY,LLY:US,BBG000BNBDC2,Here's the Best Dividend Stock in Big Pharma,2017-06-05 14:03:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YspTbm6EHi0/heres-the-best-dividend-stock-in-big-pharma-cm798559,Not long ago I labeled Bristol Myers Squibb Co NYSE BMY Eli Lilly and Co NYSE LLY Johnson amp Johnson NYSE JNJ and Pfizer Inc NYSE PFE the best dividend stocks in pharmaceuticals 160 I still believe all four have what it takes to boost
LLY,LLY:US,BBG000BNBDC2,Merck's Grip on a Hot Cancer-Drug Market May Tighten,2017-06-05 13:16:07 +0000,http://finance.yahoo.com/r/8133db4a-3311-3ed8-a749-b4fca25712c4/eli-lilly-alimta-patent-case-how-merck-wins-if-it-loses?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Its IO combo with Alimta could get a boost if Lilly loses patent protection.
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Neuroscience Products in 1Q17,2017-06-05 13:06:32 +0000,http://finance.yahoo.com/r/d8fcef96-b81f-3d3f-94a5-7b19a73900d7/performance-of-eli-lillys-neuroscience-products-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Strattera, a drug for the treatment of ADHD, reported 4% growth in its 1Q17 revenues to $196.2 million, compared to $188.1 million for 1Q16."
LLY,LLY:US,BBG000BNBDC2,Here&apos;s the Best Dividend Stock in Big Pharma,2017-06-05 12:47:00 +0000,http://finance.yahoo.com/r/eca3cdc4-958c-36c8-9ba8-9e9a91956ff7/heres-the-best-dividend-stock-in-big-pharma.aspx?yptr=yahoo&.tsrc=rss,Pharmaceutical industry stocks are famous for fast-growing dividends -- and infamous for cutting them when conditions change.
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Cardiovascular Products in 1Q17,2017-06-05 11:36:14 +0000,http://finance.yahoo.com/r/d4ca2bd9-9bf4-3922-a242-f4f2d2a3d336/performance-of-eli-lillys-cardiovascular-products-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Effient reported a 3% decline in its 1Q17 revenues to $127.8 million, compared to $131.5 million in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer,2017-06-03 18:15:00 +0000,https://finance.yahoo.com/news/lilly-builds-upon-body-data-181500983.html?.tsrc=rss,"INDIANAPOLIS, June 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results from the Phase 3 MONARCH 2 study showed that abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 ..."
LLY,LLY:US,BBG000BNBDC2,Zoetis Just Hit an All-Time High: Here's Why the Stock Should Go Higher,2017-06-03 17:30:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C1JmpDrmZUE/zoetis-just-hit-an-all-time-high-heres-why-the-stock-should-go-higher-cm798373,Zoetis NYSE ZTS stock has more than doubled since the animal health company was spun off from Pfizer in 2013 Roughly half of those gains have come in just the last 12 months So far 2017 is turning out to be the best year yet for Zoetis The stock just hit yet another all
LLY,LLY:US,BBG000BNBDC2,Zoetis Just Hit an All-Time High: Here&apos;s Why the Stock Should Go Higher,2017-06-03 16:03:00 +0000,http://finance.yahoo.com/r/aa273ce3-a117-31ae-bf71-da9b9266a55f/zoetis-just-hit-an-all-time-high-heres-why-the-sto.aspx?yptr=yahoo&.tsrc=rss,Can animal-health stock Zoetis keep its red-hot momentum going?
LLY,LLY:US,BBG000BNBDC2,Novartis Reports Positive Data on Breast Cancer Drug Kisqali,2017-06-02 17:32:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7O3SKS8XtGk/novartis-reports-positive-data-on-breast-cancer-drug-kisqali-cm798080,Novartis AG NVS announced positive data from the phase III study MONALEESA 2 on breast cancer drug Kisqali The study reinforced the efficacy and safety of Kisqali plus letrozole in postmenopausal women with hormone receptor positive human epidermal growth factor receptor 2
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Endocrine Products in 1Q17,2017-06-02 14:36:33 +0000,http://finance.yahoo.com/r/ca7eab29-69cf-3c61-940a-707f9617da1a/performance-of-eli-lillys-endocrine-products-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Humalog reported growth of 17% to $708.4 million during 1Q17, compared to $606.3 million for 1Q16."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More",2017-06-02 14:36:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zyOvflCjBeA/pharma-stock-roundup-positive-data-from-lilly-teva-bmys-deals-more-cm797951,This week there were quite a few regulatory and pipeline updates with Lilly LLY reporting positive results on its cancer drug Cyramza while the FDA expanded the label of Merck s MRK HIV drug Isentress Recap of the Week s Most Important Stories Lilly s Cyramza Hits Primary
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s Oncology Products in 1Q17,2017-06-02 13:07:11 +0000,http://finance.yahoo.com/r/fdf7e4b3-790c-3af0-869e-4040fed51655/performance-of-eli-lillys-oncology-products-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co.’s (LLY) Human Pharmaceuticals segment reported an increase of ~8% to ~$4.5 billion in 1Q17, compared to ~$4.1 billion in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Eli Lilly's Late-Stage Bladder Cancer Drug CYRAMZA Meets Primary Endpoint,2017-06-02 12:15:00 +0000,https://finance.yahoo.com/news/blog-coverage-eli-lillys-stage-121500951.html?.tsrc=rss,"Upcoming AWS Coverage on Alimera Sciences Post-Earnings Results LONDON, UK / ACCESSWIRE / June 2, 2017 / Active Wall St. blog coverage looks at the headline from Global Pharma MNC Eli Lilly And Co. (NYSE: ..."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY&apos;s Deals & More",2017-06-02 12:12:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-positive-data-121212412.html?.tsrc=rss,Lilly (LLY) posted positive data on Cyramza while Teva&apos;s migraine drug delivered positive results in a late-stage study.
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly’s New Products Portfolio in 1Q17,2017-06-02 11:37:10 +0000,http://finance.yahoo.com/r/e8bf8d5b-6ff6-340f-bd4e-8493ea7a6590/performance-of-eli-lillys-new-products-portfolio-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Basaglar, an insulin glargine injection to control blood sugar levels, reported growth over 300% to $46.0 million in 1Q17, compared to $10.9 million in 1Q16."
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Financial Chief to Retire After 11 Years in Role,2017-06-02 04:06:33 +0000,http://finance.yahoo.com/r/ae6b307c-79f5-3621-b69d-7fad68f5ec40/eli-lilly-financial-chief-to-retire-after-11-years-in-role-1496318130?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. said Thursday that longtime Chief Financial Officer Derica Rice will retire at the end of this year after more than a decade in the position.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III,2017-06-01 20:31:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PDasyHeEIws/eli-lillys-lly-cancer-drug-cyramza-positive-in-phase-iii-cm797636,Eli Lilly and Company LLY announced positive results from a phase III RANGE study evaluating its oncology drug Cyramza ramucirumab for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma Note that Cyramza
LLY,LLY:US,BBG000BNBDC2,Eli Lilly&apos;s (LLY) Cancer Drug Cyramza Positive in Phase III,2017-06-01 18:56:06 +0000,https://finance.yahoo.com/news/eli-lilly-apos-lly-cancer-185606237.html?.tsrc=rss,Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Financial Chief to Retire After 11 Years in Role,2017-06-01 16:46:15 +0000,http://finance.yahoo.com/r/ae6b307c-79f5-3621-b69d-7fad68f5ec40/eli-lilly-financial-chief-to-retire-after-11-years-in-role-1496318130?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. said Thursday that longtime Chief Financial Officer Derica Rice will retire at the end of this year after more than a decade in the position.
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana",2017-06-01 15:35:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FLloGaZAquI/the-zacks-analyst-blog-highlights-eli-lilly-hsbc-marriott-american-airlines-and-humana-cm797512,For Immediate Release Chicago IL June 01 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Business Segments’ Performance in 1Q17,2017-06-01 14:37:56 +0000,http://finance.yahoo.com/r/4861788a-e466-3a71-9ca6-910c5f044ac2/eli-lillys-business-segments-performance-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Elanco, Eli Lilly's Animal Health business, reported growth of 2% to $769.4 million during 1Q17."
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana",2017-06-01 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-133001034.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Revenues in 1Q17,2017-06-01 13:09:20 +0000,http://finance.yahoo.com/r/82441c16-e9bc-3bce-bb6a-d956ea3c414b/eli-lilly-co-s-revenues-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. (LLY) reported 7% growth in its 1Q17 revenues to ~$5.2 billion, compared to ~$4.9 billion in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®,2017-06-01 12:30:00 +0000,https://finance.yahoo.com/news/boehringer-ingelheim-lilly-diabetes-alliance-123000124.html?.tsrc=rss,"RIDGEFIELD, Conn. and INDIANAPOLIS, June 1, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) will present 33 abstracts highlighting the companies' wide range of diabetes treatment options at the 77th American Diabetes Association's (ADA) Scientific Sessions® in San Diego, June 9-13.  With compounds representing several of the largest diabetes treatment classes, Boehringer Ingelheim and Lilly will feature posters, abstracts and oral presentations for their range of products, including Jardiance® (empagliflozin) tablets, Tradjenta® (linagliptin) tablets and Basaglar® (insulin glargine injection) 100 units/mL."
LLY,LLY:US,BBG000BNBDC2,Top Eli Lilly financial officer to retire in December,2017-06-01 12:05:43 +0000,https://finance.yahoo.com/news/top-eli-lilly-financial-officer-120543914.html?.tsrc=rss,"Drugmaker Eli Lilly will end 2017 like it did 2016, with the departure of a top executive. The diabetes drug maker said Thursday that Chief Financial Officer Derica Rice will retire in December, ending ..."
LLY,LLY:US,BBG000BNBDC2,Has The Final Piece To Eliminate Heart Disease Been Discovered? Probably Not,2017-06-01 12:02:00 +0000,http://finance.yahoo.com/r/93d2b59d-5a21-38f3-9ab6-c95eb2625208/has-the-final-piece-to-eliminate-heart-disease-been-discovered-probably-not?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Do we now have the final nail for the heart disease coffin? Perhaps, but a lot of time and money are going to be needed to prove that."
LLY,LLY:US,BBG000BNBDC2,Changes in Eli Lilly & Co.’s Valuation after Its 1Q17 Earnings,2017-06-01 11:39:08 +0000,http://finance.yahoo.com/r/f872b1f0-255f-3477-8685-cc7851a3444e/changes-eli-lilly-co-s-valuation-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Eli Lilly (LLY) reported 7% growth in revenues to ~$5.2 billion. However, LLY reported a loss of $0.10 per share due to its acquisition of CoLucid Pharmaceuticals."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CFO Derica Rice to retire at year end,2017-06-01 11:21:39 +0000,http://finance.yahoo.com/r/d947b6fa-0982-39cb-a0ef-f29e7e2f7001/Story.aspx?guid=01E0B4A0-5CBA-436B-8696-A6A5B922AB09&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. said premarket Thursday that Chief Financial Officer Derica Rice will retire at the end of the year after working at the company for 27 years. The company said it is considering internal ...
LLY,LLY:US,BBG000BNBDC2,Lilly CFO to retire by the end of this year,2017-06-01 10:59:18 +0000,https://finance.yahoo.com/news/lilly-cfo-retire-end-105918758.html?.tsrc=rss,"Eli Lilly and Co said on Thursday its chief financial officer Derica Rice will retire by the end of 2017. Rice, who has spent 27 years with the company, is also a member of Lilly's executive committee. ..."
LLY,LLY:US,BBG000BNBDC2,Derica Rice to Retire as Lilly Chief Financial Officer,2017-06-01 10:45:00 +0000,https://finance.yahoo.com/news/derica-rice-retire-lilly-chief-104500733.html?.tsrc=rss,"INDIANAPOLIS, June 1, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company.  Rice is also a member of Lilly's executive committee.  ""On behalf of our shareholders, our board, our executive team and the company, I want to thank Derica for his leadership as our CFO over the past eleven years,"" said David A. Ricks, Lilly's chairman, president and chief executive officer."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CFO Derica Rice To Retire By End Of 2017  - Quick Facts,2017-06-01 07:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-yli_gqPFZM/eli-lilly-cfo-derica-rice-to-retire-by-end-of-2017---quick-facts-20170601-00325,Eli Lilly CFO Derica Rice To Retire By End Of 2017  - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Big Pharma Diabetes Drugs Not So Sweet. What's in Store?,2017-05-31 22:33:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OfOVj3frOks/big-pharma-diabetes-drugs-not-so-sweet-whats-in-store-cm797135,It is a common practice for pharma companies to invest R amp D dollars copiously in developing treatments and devices for diabetes and diabetes management The diabetes market is chock a block with companies coming up with innovative treatments promising higher efficacy with lower side
LLY,LLY:US,BBG000BNBDC2,"Teva Pharma Ran A Migraine Trial — And Lilly, Amgen Benefited",2017-05-31 20:25:30 +0000,http://finance.yahoo.com/r/2ac45023-0f45-3ce6-9202-458c3e2a655b/teva-pharma-ran-a-migraine-trial-and-lilly-amgen-benefited?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly and Amgen stocks got a boost Wednesday after rival Teva unveiled strong results of a trial in chronic migraines.
LLY,LLY:US,BBG000BNBDC2,Big Pharma Diabetes Drugs Not So Sweet. What&apos;s in Store?,2017-05-31 20:05:08 +0000,https://finance.yahoo.com/news/big-pharma-diabetes-drugs-not-200508873.html?.tsrc=rss,Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
LLY,LLY:US,BBG000BNBDC2,"Top Stock Reports for Eli Lily, HSBC, Marriott & Others",2017-05-31 19:31:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sN-Y9xr7Qko/top-stock-reports-for-eli-lily-hsbc-marriott-others-cm797068,Wednesday May 31 2017 Today s Research Daily features new research reports on 16 major stocks including Eli Lily LLY HSBC HSBC and Marriott MAR You can see 160 all of 160 today s 160 research reports here gt gt gt Pharmaceutical stocks have
LLY,LLY:US,BBG000BNBDC2,Lilly to Participate in Goldman Sachs Global Healthcare Conference,2017-05-31 18:30:00 +0000,https://finance.yahoo.com/news/lilly-participate-goldman-sachs-global-183000495.html?.tsrc=rss,"INDIANAPOLIS, May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday, June 14, 2017. Sue Mahony, Ph.D., ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Begins to Lift,2017-05-31 17:46:00 +0000,http://finance.yahoo.com/r/f8aec06c-132a-353d-bf79-125b4d5f12de/eli-lilly-begins-to-lift.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Eli Lilly's steep slide from its early April peak may be ending as shares regain their footing near major support.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's late-stage bladder cancer drug met primary endpoint but will wait for mid-2018 results,2017-05-31 11:14:59 +0000,http://finance.yahoo.com/r/25c561a5-388d-32ae-b999-92995ed2925e/Story.aspx?guid=43B8CF28-2BA5-486E-BC76-57BE9727AEA1&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said premarket Wednesday that its urothelial carcinoma drug met the primary endpoint in a phase 3 clinical trial. The drug, Cyramza, showed a statistically significant improvement in progression-free ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's late-stage bladder cancer drug met primary endpoint but will wait is for mid-2018 results,2017-05-31 11:12:18 +0000,https://finance.yahoo.com/news/eli-lillys-stage-bladder-cancer-111459737.html?.tsrc=rss,"Eli Lilly & Co. said premarket Wednesday that its urothelial carcinoma drug met the primary endpoint in a phase 3 clinical trial. The drug, Cyramza, showed a statistically significant improvement in progression-free ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival",2017-05-31 10:45:00 +0000,https://finance.yahoo.com/news/lilly-announces-phase-3-range-104500253.html?.tsrc=rss,"INDIANAPOLIS, May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA ® (ramucirumab) met its primary endpoint of progression-free survival ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Says Phase 3 RANGE Urothelial Cancer Trial Of CYRAMZA Met Primary Endpoint,2017-05-31 06:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BEwncCY6fjU/lilly-says-phase-3-range-urothelial-cancer-trial-of-cyramza-met-primary-endpoint-20170531-00264,Lilly Says Phase 3 RANGE Urothelial Cancer Trial Of CYRAMZA Met Primary Endpoint
LLY,LLY:US,BBG000BNBDC2,"ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD",2017-05-31 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1kC8AtzGbnA/albo-spikes-glyc-abuzz-fda-approves-1st-generic-strattera-for-adhd-20170531-00065,"ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD"
LLY,LLY:US,BBG000BNBDC2,Lilly Is Wilting,2017-05-30 17:51:00 +0000,http://finance.yahoo.com/r/789fd3b7-bd53-30c0-b390-f04b6fae9075/lilly-wilting?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Struggling stock is downgraded.
LLY,LLY:US,BBG000BNBDC2,Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals,2017-05-30 15:38:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nUu9Fz8v0Eo/sanofi-sny-stock-continues-to-gain-on-key-drug-approvals-cm796214,After declining in 2016 share price of French pharma giant Sanofi SNY has picked up in 2017 This Zacks Rank 2 Buy stock has risen 21 1 this year so far outperforming the return of the Zacks classified Large Cap Pharma industry of 8 8 Let us analyze the reasons for the share
LLY,LLY:US,BBG000BNBDC2,Top Presentations to Look for at ASCO,2017-05-27 12:40:04 +0000,https://finance.yahoo.com/news/top-presentations-look-asco-124004427.html?.tsrc=rss,"The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be presented ..."
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson's Analyst Day Was Overshadowed by This Worrisome Data,2017-05-26 21:32:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lG_jhKdTgEI/johnson-johnsons-analyst-day-was-overshadowed-by-this-worrisome-data-cm795576,Healthcare conglomerate Johnson amp Johnson NYSE JNJ is a common holding in long term investors portfolios for one reason its consistency Johnson amp Johnson s consistency derives from its business structure Although J amp J reports as a single entity it consists of
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data",2017-05-26 13:34:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QKdPN0FpI-w/pharma-stock-roundup-label-expansion-for-merck-drug-aerie-up-on-eye-data-cm795202,This week there were quite a few regulatory updates with Merck MRK getting FDA approval for yet another indication for Keytruda while Bristol Myers BMY got priority review for a regulatory application for Opdivo Recap of the Week s Most Important Stories Aerie Soars on Positive
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data",2017-05-26 12:08:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-label-expansion-120812582.html?.tsrc=rss,Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
LLY,LLY:US,BBG000BNBDC2,Nplate and Vectibix Could Contribute to Amgen’s Revenue Growth in 2017,2017-05-26 11:36:00 +0000,http://finance.yahoo.com/r/e54bf33a-9942-387f-acf5-5e2620967142/nplate-and-vectibix-could-contribute-to-amgens-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%."
LLY,LLY:US,BBG000BNBDC2,Radius Health Osteoporosis Drug Positive in Phase III Study,2017-05-25 15:36:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TY65-J7YeEM/radius-health-osteoporosis-drug-positive-in-phase-iii-study-cm794568,Radius Health Inc RDUS announced positive data from the ACTIVExtend study on Tymlos The 24 month ACTIVExtend study on Tymlos enrolled patients who had completed 18 months of treatment with Tymlos abaloparatide injections or placebo in the phase III trial ACTIVE These patients were
LLY,LLY:US,BBG000BNBDC2,Radius Health Osteoporosis Drug Positive in Phase III Study,2017-05-25 13:24:01 +0000,https://finance.yahoo.com/news/radius-health-osteoporosis-drug-positive-132401677.html?.tsrc=rss,"Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months."
LLY,LLY:US,BBG000BNBDC2,Merck’s Immunology and Cardiovascular Franchise in 1Q17,2017-05-25 11:35:53 +0000,http://finance.yahoo.com/r/a2f3e365-8b4f-3686-9f98-c0c22c6765dd/mercks-immunology-and-cardiovascular-franchise-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Remicade, a top-selling drugs for the treatment of inflammatory disorders, is losing market share after the loss of exclusivity in European markets in February 2015."
LLY,LLY:US,BBG000BNBDC2,Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers,2017-05-24 16:35:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RB6NfVhUAp4/mercks-mrk-keytruda-gets-fda-nod-for-solid-tumor-cancers-cm793978,Merck amp Co Inc MRK announced that its anti PD 1 therapy Keytruda has received accelerated approval for the treatment of microsatellite instability high MSI H or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no
LLY,LLY:US,BBG000BNBDC2,AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk,2017-05-24 16:34:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DUU5Lhkovkg/astrazenecas-bydureon-fails-to-reduce-cardiovascular-risk-cm793961,AstraZeneca plc AZN announced top line results from the EXSCEL study evaluating the cardiovascular CV safety profile of its type II diabetes drug Bydureon Though the study met the primary safety objective in the study Bydureon a human glucagon like peptide 1 GLP 1 analogue failed
LLY,LLY:US,BBG000BNBDC2,11.1% of VTV Holdings Seeing Recent Insider Buys,2017-05-24 14:31:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0UgH7uWRCxI/111-of-vtv-holdings-seeing-recent-insider-buys-cm793830,A look at the weighted underlying holdings of the Vanguard Value ETF VTV shows an impressive 11 1 of holdings on a weighted basis have experienced insider buying within the past six months Lilly Eli amp Co Symbol LLY which makes up 0 71 of the Vanguard Value ETF VTV
LLY,LLY:US,BBG000BNBDC2,AstraZeneca&apos;s Bydureon Fails to Reduce Cardiovascular Risk,2017-05-24 14:28:02 +0000,https://finance.yahoo.com/news/astrazeneca-apos-bydureon-fails-reduce-142802381.html?.tsrc=rss,AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
LLY,LLY:US,BBG000BNBDC2,"Elanco Animal Health Works to Bring Products to Small Holder Farmers, Increasing Food Security in East Africa",2017-05-24 11:00:00 +0000,https://finance.yahoo.com/news/elanco-animal-health-works-bring-110000177.html?.tsrc=rss,"GREENFIELD, Ind., May 24, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), today announced that it received a grant from the Bill & Melinda Gates Foundation to provide sustainable development solutions to address food insecurity in East African countries.  The commitment will work to improve animal health and productivity in dairy herds and poultry flocks for smallholder farms in Kenya, Uganda and Tanzania.  Elanco received the $2.86 million grant from the Bill & Melinda Gates Foundation to enable the registration and distribution of high-quality veterinary products, in conjunction with training initiatives for smallholder farmers to assist with improved animal health practices as well as disease prevention and treatment."
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial,2017-05-23 20:21:21 +0000,http://finance.yahoo.com/r/2132ab3c-3e7f-3b37-9adc-cc38f96544bc/novo-nordisk-diabetes-lead-unscathed-following-astrazeneca-trial?src=A00220&yptr=yahoo&.tsrc=rss,Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn&apos;t reduce the risk of cardiovascular events in a trial.
LLY,LLY:US,BBG000BNBDC2,Stocks clawing back more lost ground with 4th straight gain,2017-05-23 19:02:03 +0000,http://finance.yahoo.com/r/f3b4390c-2cb6-3d66-8ca6-4cc67509e36d/us-stocks-inch-higher-health-care-companies-gain-142339678--finance.html?.tsrc=rss,"NEW YORK (AP) — US stocks are clawing back more of the ground they lost last week and approaching record high levels Tuesday. Banks were rising in tandem with interest rates, which will allow them to charge higher rates on loans. Gains for health care and beverage companies are also contributing. Consumer-focused companies like auto parts retailers and homebuilders are down, and auto parts companies are falling after weak results from AutoZone."
LLY,LLY:US,BBG000BNBDC2,iShares Core High Dividend ETF Experiences Big Outflow,2017-05-23 16:15:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ry8SWE7Kbts/ishares-core-high-dividend-etf-experiences-big-outflow-cm793338,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core High Dividend ETF Symbol HDV where we have detected an approximate 37 4 million dollar outflow that s a 0 6 decrease week over week
LLY,LLY:US,BBG000BNBDC2,These Big Drug Stocks May Cure the Trump Blues,2017-05-23 10:00:00 +0000,http://finance.yahoo.com/r/ad6e33fd-3aef-3631-9290-e28ffb47ad85/these-big-drug-stocks-may-cure-trump-blues-mrk-lly?partner=YahooSA&yptr=yahoo&.tsrc=rss,Certain pharma stocks have significant upside potential.
LLY,LLY:US,BBG000BNBDC2,Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion,2017-05-23 00:11:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ymxyvSK-Pe0/novartis-nvs-lung-cancer-drug-gets-positive-chmp-opinion-cm792969,Novartis NVS recently announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has recommended the approval of a label expansion of Zykadia ceritinib to include the first line treatment of patients with advanced non small cell lung
LLY,LLY:US,BBG000BNBDC2,Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog,2017-05-22 23:12:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/juq46GhItkA/sanofi-wins-favorable-chmp-opinion-for-biosimilar-humalog-cm792963,Sanofi SNY recently announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has given a positive opinion recommending marketing approval to a biosimilar version of Eli Lilly amp Company s LLY Humalog insulin lispro The biosimilar
LLY,LLY:US,BBG000BNBDC2,Here's Why Radius Health Gained as Much as 20.2% Today,2017-05-22 20:12:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TyqpQcFE11E/heres-why-radius-health-gained-as-much-as-202-today-cm792857,What happened Shares of Radius Health NASDAQ RDUS rose over 20 Monday morning after Amgen NASDAQ AMGN announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate Evenity While the drug candidate met its primary endpoint in
LLY,LLY:US,BBG000BNBDC2,Here&apos;s Why Radius Health Gained as Much as 20.2% Today,2017-05-22 17:23:00 +0000,http://finance.yahoo.com/r/bc46c678-c106-3920-a2e9-1253e39c7fc2/heres-why-radius-health-gained-as-much-as-202-toda.aspx?yptr=yahoo&.tsrc=rss,A leading competitor&apos;s osteoporosis drug encountered serious side effects in a late stage trial.
LLY,LLY:US,BBG000BNBDC2,3 Top Animal-Health Companies to Buy in 2017,2017-05-21 20:11:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fll8X4N5bOU/3-top-animal-health-companies-to-buy-in-2017-cm792363,Animal health is probably a bigger business than you think The global market for animal health was around 34 5 billion in 2015 By 2025 it s expected to grow to more than 58 billion With this rapidly growing market there are plenty of opportunities for investors Zoetis
LLY,LLY:US,BBG000BNBDC2,3 Top Animal-Health Companies to Buy in 2017,2017-05-21 19:02:00 +0000,http://finance.yahoo.com/r/50b3ec7a-4db7-3c8e-88a8-d84192f2484a/3-top-animal-health-companies-to-buy-in-2017.aspx?yptr=yahoo&.tsrc=rss,"Looking for top animal-health companies to buy? Check out Zoetis, Merck, and Lilly."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly is Oversold,2017-05-19 22:11:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VI-31yg3Fo4/eli-lilly-is-oversold-cm792165,The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics strong fundamentals and a valuation that looks inexpensive Lilly
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO on Tax Reform and GOP's Health-Care Bill,2017-05-19 19:14:49 +0000,https://finance.yahoo.com/video/eli-lilly-ceo-tax-reform-191449077.html?.tsrc=rss,"May.19 -- David Ricks, Eli Lilly & Co.'s president and chief executive officer, discusses U.S. tax reform and the GOP's health-care bill with Bloomberg's Scarlet Fu and Julia Chatterley on &quot;Bloomberg Markets.&quot;"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO on Tax Reform and GOP's Health-Care Bill,2017-05-19 19:14:39 +0000,http://finance.yahoo.com/r/dff9c589-4c39-3283-968a-444838ddd986/eli-lilly-ceo-on-tax-reform-and-gop-s-health-bill-video?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"David Ricks, Eli Lilly & Co.'s president and chief executive officer, discusses U.S. tax reform and the GOP's health-care bill with Bloomberg's Scarlet Fu and Julia Chatterley on ""Bloomberg Markets."" ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO Says 'Time Is Now' for Corporate Tax Reform,2017-05-19 19:02:21 +0000,https://finance.yahoo.com/video/eli-lilly-ceo-says-time-190221767.html?.tsrc=rss,"May.19 -- David Ricks, Eli Lilly & Co.'s president and chief executive officer, comments on U.S. tax reform during an interview with Bloomberg's Scarlet Fu and Julia Chatterley on &quot;Bloomberg Markets.&quot;"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO Says 'Time Is Now' for Corporate Tax Reform,2017-05-19 19:02:14 +0000,http://finance.yahoo.com/r/ed5003bc-36d2-3b2d-9d94-c449a565c6f2/eli-lilly-ceo-says-time-is-now-for-tax-reform-video?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"David Ricks, Eli Lilly & Co.'s president and chief executive officer, comments on U.S. tax reform during an interview with Bloomberg's Scarlet Fu and Julia Chatterley on ""Bloomberg Markets."" ..."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More",2017-05-19 13:15:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7Syp6ebPPDY/pharma-stock-roundup-jjs-pharma-pipeline-update-shires-hae-data-more-cm791797,This week industry bellwether J amp J JNJ provided an update on its pharmaceutical products pipeline at a meeting and said it expects to launch or file for approval for more than 10 new blockbuster products by 2021 Meanwhile Shire s SHPG shares were up 4 3 on pipeline data Recap of
LLY,LLY:US,BBG000BNBDC2,United Therapeutics reworks deal ahead of a key patent's expiration,2017-05-19 10:50:12 +0000,http://finance.yahoo.com/r/a4513009-3060-3dc0-86f2-0551c23ec0d6/united-therapeutics-reworks-deal-ahead-of-a-key.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Silver Spring drugmaker United Therapeutics Corp. extended an exclusive license with drug giant Eli Lilly & Co. to cover its pulmonary hypertension drug Adcirca, which will lose part of its patent protection later this year.  The active ingredient in Adcirca is tadalafil, also the active pharmaceutical ingredient in Cialis, which is marketed by Eli Lilly (LLY) to treat erectile dysfunction.  United Therapeutics (UTHR), in 2008, acquired the commercial rights to Adcirca from Eli Lilly for the treatment of pulmonary hypertension — but one of three patents held by the larger company that protects Adcirca is set to expire in November."
LLY,LLY:US,BBG000BNBDC2,Endocyte (ECYT) Focused on Two Lead Pipeline Candidates,2017-05-18 23:12:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YDHwneBq65Y/endocyte-ecyt-focused-on-two-lead-pipeline-candidates-cm791611,We issued an updated report on Endocyte Inc ECYT on May 17 Endocyte s share price has increased 10 2 year to date while the Zacks classified Medical Drugs industry gained 4 9 Currently the company is focused on the development of two candidates EC1456 and EC1169 both of
LLY,LLY:US,BBG000BNBDC2,Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments,2017-05-18 19:44:45 +0000,http://finance.yahoo.com/r/fe46b8b5-dce5-35cf-9497-7339351dd0e6/conference-spotlights-lilly-pfizer-merck-bristol-donnybrooks-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,"Preliminary data highlights breast, ovarian, lung and skin cancer data to presented during the American Society of Clinical Oncology meeting next month."
LLY,LLY:US,BBG000BNBDC2,Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017,2017-05-17 21:00:00 +0000,https://finance.yahoo.com/news/lilly-present-results-pivotal-breast-210000212.html?.tsrc=rss,"INDIANAPOLIS, May 17, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new research demonstrating advances in the Company's oncology pipeline and product portfolio will be presented ..."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Stock Faces Uncertainty, Bernstein Says",2017-05-17 17:09:00 +0000,http://finance.yahoo.com/r/e1e7c159-94ca-39c0-b33a-d709ba3d908e/eli-lilly-stock-faces-uncertainty-bernstein-says.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Although Berstein analyst Tim Anderson has an 'Outperfrom' rating and $88 price target on Eli Lilly, he warned clients in a note today that investors may be overlooking risks."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Worries Ahead In Patent Fight,2017-05-17 16:39:00 +0000,http://finance.yahoo.com/r/ad3fe1db-7d9b-3d32-97cd-77f760dd6edc/eli-lilly-but-investors-may-under-appreciate-the-downside-risk-the-company-faces-from-the-ipr-patent-challenge-on-the-cancer-drug-alimta-for-which-a-decision-is-expected-between-now-and-june-3-worries-ahead-in-patent-fight-1495039189?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bernstein Research warns that Eli Lilly (LLY) could be in for a bumpy ride.  Tim Anderson and his team remain bullish on the stock, with an Outperform rating and a $88 price target, which implies a 12% upside from the $78.68 a share it fetches today.  In a worst-case scenario, Alimta could face generics in 2017, even though it won an earlier appeals court ruling on a more ""traditional"" patent challenge."
LLY,LLY:US,BBG000BNBDC2,5 Reasons Why Merck (MRK) is a Good Stock to Buy Now,2017-05-17 16:17:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bcsD2aobtg8/5-reasons-why-merck-mrk-is-a-good-stock-to-buy-now-cm790637,Kenilworth NJ based Merck amp Co Inc MRK is a research driven pharmaceutical company which is a global leader in the discovery and development of vaccines and pharmaceutical drugs The company currently makes noteworthy treatments or vaccines for HPV type 2 diabetes cancer and
LLY,LLY:US,BBG000BNBDC2,The Implied Analyst 12-Month Target For PPH,2017-05-17 14:13:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cYEKScf1HTc/the-implied-analyst-12-month-target-for-pph-cm790455,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
LLY,LLY:US,BBG000BNBDC2,"Vanguard Health Care Fund Buys Abbott Laboratories, Tesaro Inc, Teva Pharmaceutical Industries, ...",2017-05-17 13:14:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bX4cvX8yJQg/vanguard-health-care-fund-buys-abbott-laboratories-tesaro-inc-teva-pharmaceutical-industries-cm790414,Vanguard Health Care Fund New Purchases TSRO CNC PTHN HUM Added Positions ABT REGN TEVA BMY IONS CTEC GEN EVHC APN ACHC Reduced Positions INCY AGN AMGN AET MRK Q UNH HCA MDT BSX Sold Out STJ INOV BIVV New Purchases
LLY,LLY:US,BBG000BNBDC2,"Notable Tuesday Option Activity: LLY, HON, XONE",2017-05-16 21:16:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yYa_eskVkq8/notable-tuesday-option-activity-lly-hon-xone-cm790199,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Lilly Eli amp Co Symbol LLY where a total volume of 24 278 contracts has been traded thus far today a contract volume which is representative of approximately 2 4
LLY,LLY:US,BBG000BNBDC2,Lilly Could Grab Diabetes Share From Dow&apos;s J&J On Amputation Woes,2017-05-16 20:40:54 +0000,http://finance.yahoo.com/r/1808ebf3-6dc7-36d6-81ce-83fb7e99240b/eli-lilly-could-snake-jjs-diabetes-share-on-amputation-warning?src=A00220&yptr=yahoo&.tsrc=rss,Lilly&apos;s Jardiance will likely benefit most after regulators required J&J to warn patients of amputations associated with diabetes drug Invokana.
LLY,LLY:US,BBG000BNBDC2,"Dow&apos;s Pfizer, Eli Lilly Topple To 3-Month Lows On Downgrades",2017-05-16 20:13:19 +0000,http://finance.yahoo.com/r/732a5799-33ef-3cad-bc6d-702c4cb2f0c6/dows-pfizer-eli-lilly-topple-to-3-month-lows-on-downgrades?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly and Pfizer stocks toppled to three-month lows Tuesday after sustaining a pair of downgrades.
LLY,LLY:US,BBG000BNBDC2,Pfizer: Is It Time To Sell?,2017-05-16 17:07:00 +0000,http://finance.yahoo.com/r/49cb4243-7bd7-3941-b7d4-3cb907037066/pfizer-is-it-time-to-sell-1494954450?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Eli Lilly (LLY) isn’t the only Big Pharma name getting pressured by a downgrade. Shares of Pfizer (PFE) fell to a three-month low today after Citigroup turned bearish on the stock. Analyst Andrew Baum ...
LLY,LLY:US,BBG000BNBDC2,"Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka",2017-05-16 16:20:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZTg-U2W4p0o/teva-teva-launches-glumetza-generic-inks-deal-with-otsuka-cm789994,Teva Pharmaceutical Industries Ltd TEVA announced the launch of a generic version of Valeant Pharmaceuticals International Inc s VRX diabetes drug Glumetza in the U S The drug will be available in 500 mg and 1000 mg tablets Teva s shares have underperformed the Zacks
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Has This Bloom Begun To Wilt?,2017-05-16 16:17:00 +0000,http://finance.yahoo.com/r/55cd360a-9ebc-3b18-869a-ffe0b69e3995/eli-lilly-has-this-bloom-begun-to-wilt-1494951434?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Shares of U.S. drug maker Eli Lilly & Co. (LLY) fell to a three-month low after Goldman Sachs pulled the stock off its closely-followed Conviction Buy List. Don’t panic. It isn’t as if Goldman analyst ...
LLY,LLY:US,BBG000BNBDC2,Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom,2017-05-16 11:30:00 +0000,https://finance.yahoo.com/news/actress-angela-bassett-joins-sweetheart-113000230.html?.tsrc=rss,"RIDGEFIELD, Conn. and INDIANAPOLIS, May 16, 2017 /PRNewswire/ -- Award-winning actress Angela Bassett, along with 11 leading patient and professional organizations, is joining For Your SweetHeart™: Where diabetes and heart disease meet — a nationwide movement to raise awareness of the critical link between type 2 diabetes and heart disease, the number one killer of people with type 2 diabetes.  Bassett, known for her portrayal of legendary singer Tina Turner in What's Love Got to Do With It and role in American Horror Story, is spreading this important message in remembrance of her mom, who had type 2 diabetes and died of heart disease."
LLY,LLY:US,BBG000BNBDC2,Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint,2017-05-16 01:14:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/STYoVlgLLJA/lillys-migraine-drug-phase-iii-trials-meet-primary-endpoint-cm789605,Eli Lilly and Company LLY recently announced that its migraine candidate galcanezumab met primary endpoint in phase III studies The data from the evaluation demonstrated that the galcanezumab led to statistically significant reduction in the number of migraine headaches days per month
LLY,LLY:US,BBG000BNBDC2,Lilly&apos;s Migraine Drug Phase III Trials Meet Primary Endpoint,2017-05-15 23:06:11 +0000,https://finance.yahoo.com/news/lilly-apos-migraine-drug-phase-230611088.html?.tsrc=rss,"Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies"
LLY,LLY:US,BBG000BNBDC2,The prices for life-saving diabetes medications have increased again,2017-05-15 19:23:31 +0000,https://finance.yahoo.com/news/prices-life-saving-diabetes-medications-192331334.html?.tsrc=rss,Insulin prices have been rising — increases that mean some people are spending as much on...
LLY,LLY:US,BBG000BNBDC2,"HDV, BA, TXN, LLY: Large Outflows Detected at ETF",2017-05-15 16:15:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eVGqbmibSak/hdv-ba-txn-lly-large-outflows-detected-at-etf-cm789261,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core High Dividend ETF Symbol HDV where we have detected an approximate 187 0 million dollar outflow that s a 2 8 decrease week over week
LLY,LLY:US,BBG000BNBDC2,Retail Spoils New Highs,2017-05-15 14:17:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n2ry6cWxQYc/retail-spoils-new-highs-cm789029,Stocks looked all set to bust out to new highs at the closing bell on Wednesday the S amp P was only 0 37 of a point away but weak results from some big department stores ruined it By the end of Friday the S amp P had slipped 0 4 for the week while the Dow was off 0 5 This was
LLY,LLY:US,BBG000BNBDC2,Can Teva Hold Its Own In Bringing Migraine Drugs To Market?,2017-05-12 20:20:16 +0000,http://finance.yahoo.com/r/0c80360d-ceac-374a-ad04-a77e44d33a28/can-teva-hold-its-own-in-migraine-vs-lilly-amgen-alder?src=A00220&yptr=yahoo&.tsrc=rss,"Teva will square off with Eli Lilly, Amgen, Novartis and Alder next month when it unveils the results of a Phase 3 study in migraines."
LLY,LLY:US,BBG000BNBDC2,Health Care Sector Update for 05/12/2017: LLY,2017-05-12 14:01:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S4nedE6kBLI/health-care-sector-update-for-05122017-lly-cm788385,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE flatPFE flat ABT 0 2 ABT 0 2 MRK flatMRK flat AMGN 0 4 AMGN 0 4 Health care shares were mainly unchanged in pre market trade on Friday Health care shares were mainly unchanged in pre market trade on Friday
LLY,LLY:US,BBG000BNBDC2,"Stocks to Watch: Apple, Corning, J.C. Penney, Eli Lilly",2017-05-12 13:29:58 +0000,http://finance.yahoo.com/r/cff77043-d9d5-3b23-aa5e-db1d4b24e5a2/stocks-to-watch-apple-corning-j-c-penney-eli-lilly?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Among the companies with shares expected to trade actively in Friday's session are Apple Inc., Corning Inc., J.C. Penney Co. and Eli Lilly & Co."
LLY,LLY:US,BBG000BNBDC2,[$$] Lilly's New Migraine Drug Shows Positive Results,2017-05-12 13:26:59 +0000,http://finance.yahoo.com/r/de5f260e-6893-3710-a549-fafa3056c207/lillys-new-migraine-drug-shows-positive-results-1494593034?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said it will seek regulatory approval of a migraine drug this year after seeing positive results from late-stage studies, raising hopes for a new class of treatments for the debilitating ..."
LLY,LLY:US,BBG000BNBDC2,Lilly migraine treatment meets main goal in late-stage studies,2017-05-12 13:14:03 +0000,http://finance.yahoo.com/news/lilly-migraine-treatment-meets-main-111853345.html?.tsrc=rss,"Eli Lilly and Co said on Friday  patients with episodic and chronic migraine reported fewer  debilitating headaches after using the drugmaker's experimental  drug compared to those on placebo.  About 40 million Americans suffer from migraines, and the  disease costs the United States about $36 billion annually in  healthcare and lost productivity, according to the Migraine  Research Foundation.  Lilly's galcanezumab is among three other drugs racing to  capture the 13 million patient population afflicted with a  severe form of the condition."
LLY,LLY:US,BBG000BNBDC2,UPDATE: Eli Lilly reports positive results in trial of migraine treatment,2017-05-12 11:35:55 +0000,http://finance.yahoo.com/r/50bfe2d7-0924-3ecb-bb32-10bb8a2e1ce3/Story.aspx?guid=305196CC-C953-4B57-B278-4E4CDCAB8DA1&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Eli Lilly and Co. jumped 1.6% in premarket trade Friday, after the company said a late-stage study of a migraine treatment met its primary goals. The trial of galcanezumab, an investigational ..."
LLY,LLY:US,BBG000BNBDC2,InPlay from Briefing.com,2017-05-12 10:57:15 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,2017-05-12 10:45:00 +0000,http://finance.yahoo.com/news/lilly-announces-positive-results-three-104500010.html?.tsrc=rss,"INDIANAPOLIS, May 12, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) demonstrating statistically significant reductions in the number of monthly migraine headache days compared to placebo at both studied doses.  ""The impact of migraine is underestimated, with people who experience migraine attacks often missing work, family activities or social engagements.  Based on these results, Lilly will submit a Biologics License Application to the U.S. Food and Drug Administration (FDA) for galcanezumab in the second half of 2017, followed by submissions to other regulatory agencies around the world."
LLY,LLY:US,BBG000BNBDC2,Migraine Drug From Eli Lilly Is Successful in Late-Stage Trials,2017-05-12 10:45:00 +0000,http://finance.yahoo.com/r/318678f3-3d36-3934-95f1-612580adccbd/migraine-drug-from-eli-lilly-is-successful-in-late-stage-trials?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"An experimental drug from Eli Lilly & Co. significantly reduced patients’ number of migraines in a series of final-stage trials, bringing the medicine closer to approval in a competitive field."
LLY,LLY:US,BBG000BNBDC2,Lilly: Galcanezumab For Migraine Met Primary Endpoint In Three Phase 3 Trials,2017-05-12 06:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dO7HvnOZato/lilly-galcanezumab-for-migraine-met-primary-endpoint-in-three-phase-3-trials-20170512-00225,Lilly: Galcanezumab For Migraine Met Primary Endpoint In Three Phase 3 Trials
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. : LLY-US: Dividend Analysis : May 15th, 2017 (record date) : By the numbers : May 11, 2017",2017-05-11 17:18:34 +0000,http://finance.yahoo.com/r/029724e8-bc9b-3d0e-8829-f6915ac8719a/eli-lilly-co-lly-us-dividend-analysis-may-15th-2017-record-date-by-the-numbers-may-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing Eli Lilly & Co. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Roche Holding Ltd Genusssch., Amgen Inc. and Novartis AG Sponsored ADR (JNJ-US, MRK-US, PFE-US, BMY-US, ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,Merck: Seal of Approval?,2017-05-11 15:20:00 +0000,http://finance.yahoo.com/r/e7176f89-530d-3b1b-9f6f-c689618e1877/merck-seal-of-approval-1494516052?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Merck (MRK) are gaining today after the FDA expanded the use of Keytruda to patients with advanced lung cancer when combined with chemotherapy, even when a high level of a key protein is missing. ..."
LLY,LLY:US,BBG000BNBDC2,Lilly to Participate in Bernstein Strategic Decisions Conference,2017-05-10 17:00:00 +0000,http://finance.yahoo.com/news/lilly-participate-bernstein-strategic-decisions-170000465.html?.tsrc=rss,"INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the Bernstein Strategic Decisions Conference on Wednesday, May 31, 2017. David A. Ricks, Lilly's president and chief ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly raised prices on 9 drugs last week,2017-05-10 16:36:41 +0000,https://finance.yahoo.com/news/eli-lilly-raised-prices-9-163641778.html?.tsrc=rss,"The increases fit a pattern at Lilly and many other drugmakers of single-digit percentage hikes once or twice a year, despite political pressure."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly raised prices on 9 drugs last week,2017-05-10 16:36:41 +0000,http://finance.yahoo.com/r/e7902ae2-e766-3634-9a18-85161e219618/104460589?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104460589&yptr=yahoo&.tsrc=rss,"The increases fit a pattern at Lilly and many other drugmakers of single-digit percentage hikes once or twice a year, despite political pressure."
LLY,LLY:US,BBG000BNBDC2,Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications,2017-05-10 12:00:00 +0000,http://finance.yahoo.com/news/leigh-ann-pusey-joins-lilly-120000764.html?.tsrc=rss,"INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017.  Pusey currently serves as president and CEO of the American Insurance Association (AIA), an insurance industry trade association representing more than 300 insurers that provide property and casualty insurance in the United States."
LLY,LLY:US,BBG000BNBDC2,"Aratana is tracking to hit canine drug milestone, fetches funds to build inventory",2017-05-09 18:40:13 +0000,http://finance.yahoo.com/r/aa2c4e4c-bccb-3c3c-8de6-868378f0f4de/aratana-therapeutics-eli-lilly-elanco-galliprant.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Aratana Therapeutics is on track to hit a big sales milestone for its planned blockbuster drug and is making moves to stockpile more of it.  The Leawood-based animal health company is seeing strong demand for its canine osteoarthritis drug, Galliprant, licensed through Eli Lilly and Co.’s (LLY) animal health subsidiary.  “We’re very pleased with where Galliprant is."
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One",2017-05-09 16:06:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1MKJifQ6pYc/the-zacks-analyst-blog-highlights-united-technologies-lilly-american-express-aetna-las-vegas-sands-and-capital-one-cm786558,For Immediate Release Chicago IL May 09 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One",2017-05-09 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-united-133001755.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One"
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Today: UTX, LLY & AXP",2017-05-09 00:01:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zNuz-Pbz7Fw/top-research-reports-for-today-utx-lly-axp-cm786243,Monday May 8 2017 Today s Research Daily features new research reports on 16 major stocks including United Technologies UTX Lilly LLY and American Express AXP United Technologies shares have gained 10 2 over the last three months higher than the 4 5 increase for the
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks Poised to Beat this Earnings Season,2017-05-09 00:00:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/81zTX7EO4TY/4-drug-stocks-poised-to-beat-this-earnings-season-cm786223,This earnings season started on a promising note for the pharma biotech sector after a challenging 2016 The sector has been going through a rough patch due to media and political focus on steep drug pricing issues Interestingly the NASDAQ Biotechnology Index NBI and the NYSE
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Today: UTX, LLY & AXP",2017-05-08 20:59:08 +0000,http://finance.yahoo.com/news/top-research-reports-today-utx-205908946.html?.tsrc=rss,"Top Research Reports for Today: UTX, LLY & AXP"
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit",2017-05-08 14:48:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8K6xYdrQySI/pharma-stock-roundup-merck-pfizer-report-q1-earnings-jj-talc-powder-lawsuit-cm785710,Last week big names like Merck MRK and Pfizer PFE reported earnings results Johnson amp Johnson JNJ was also in the news related to a jury verdict for its talc powder lawsuit 160 Recap of the Week s Most Important Stories A Look at Earnings Results Two major
LLY,LLY:US,BBG000BNBDC2,J&J: What's In Store At Next Week's Analyst Meeting,2017-05-08 13:34:00 +0000,http://finance.yahoo.com/r/226b7c4c-3ef1-320c-8f8d-069fd79070e0/j-j-whats-in-store-at-next-weeks-analyst-meeting-1494250482?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The biggest source of revenue for Johnson & Johnson (JNJ) is its famed pharmaceutical business.  It alone generated 46% of the company’s 2016 revenue, and has been a key driver of top line growth over the past few years.  Wells Fargo analyst Larry Biegelsen notes that the unit’s revenue growth is set to slow into the low single digits in the face of several headwinds -- or at least that’s what J&J’s 2017 guidance has implied."
LLY,LLY:US,BBG000BNBDC2,Express Scripts and Eli Lilly CEOs on lowering drug costs with Inside Rx,2017-05-08 12:47:23 +0000,https://www.yahoo.com/news/express-scripts-eli-lilly-ceos-124723861.html?.tsrc=rss,"Americans spent an estimated $450 billion on prescription drugs in 2016, and drug costs are rising. The nation's largest pharmacy benefit manager (PBM), Express Scripts, and eight major drug companies are unveiling a plan designed to lower out-of-pocket costs for brand-name drugs, for those without insurance and with higher deductibles. First on &quot;CBS This Morning,&quot; Express Scripts president and CEO Tim Wentworth along with Eli Lilly and Company president and CEO Dave Ricks discuss the Inside Rx program."
LLY,LLY:US,BBG000BNBDC2,"HDV, TXN, LLY, EMR: ETF Outflow Alert",2017-05-05 17:27:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qeuKhZI4rpg/hdv-txn-lly-emr-etf-outflow-alert-cm785107,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core High Dividend ETF Symbol HDV where we have detected an approximate 29 0 million dollar outflow that s a 0 4 decrease week over week
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Company -- Moody's assigns A2 to Eli Lilly's notes; stable outlook,2017-05-04 17:08:08 +0000,http://finance.yahoo.com/r/51fefaf1-e273-3464-af80-0783b82e7bc6/viewresearchdoc.aspx?docid=PR_365976&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20170504_PR_365976&yptr=yahoo&.tsrc=rss,"Rating Action: Moody's assigns A2 to Eli Lilly's notes; stable outlook. Global Credit Research- 04 May 2017. New York, May 04, 2017-- Moody's Investors Service assigned an A2 rating to the new senior unsecured ..."
LLY,LLY:US,BBG000BNBDC2,10 Companies That Have Paid Dividends for More Than 120 Years,2017-05-04 11:12:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yWS6B2Q_-gY/10-companies-that-have-paid-dividends-for-more-than-120-years-cm783923,Image source Getty Images Investors rely on dividend stocks for the income they need and that makes it critically important to choose companies that have a track record of paying dividends through good times and bad Out of the thousands of stocks on the market only
LLY,LLY:US,BBG000BNBDC2,10 Companies That Have Paid Dividends for More Than 120 Years,2017-05-04 10:00:00 +0000,http://finance.yahoo.com/r/59afbff6-cd60-3e86-b68b-ae2dbbef2f3e/10-companies-that-have-paid-dividends-for-more-tha.aspx?yptr=yahoo&.tsrc=rss,Pick dividend stocks you can rely on.
LLY,LLY:US,BBG000BNBDC2,Lilly to Participate in UBS Global Healthcare Conference,2017-05-03 17:00:00 +0000,http://finance.yahoo.com/news/lilly-participate-ubs-global-healthcare-170000014.html?.tsrc=rss,"INDIANAPOLIS, May 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017. Derica Rice, Lilly's executive vice president for ..."
LLY,LLY:US,BBG000BNBDC2,Is Eli Lilly & Co.’s Valuation Higher Than Its Peers?,2017-05-03 11:35:53 +0000,http://finance.yahoo.com/r/b36d035a-b4ee-3cfe-8aab-35664fa6cc4c/is-eli-lilly-co-s-valuation-higher-than-its-peers?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Over the last year, Eli Lilly’s (LLY) forward PE has traded in the range of 18.9x–25.5x."
LLY,LLY:US,BBG000BNBDC2,"Trust Investment Advisors Buys New Residential Investment Corp, Carnival Corp, Lear Corp, Sells ...",2017-05-03 08:25:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jo7yuXve2P0/trust-investment-advisors-buys-new-residential-investment-corp-carnival-corp-lear-corp-sells-cm783179,Trust Investment Advisors New Purchases NRZ CCL LEA ADNT UA Added Positions NKE IRM F QCOM UHS GSK SIG AFSI CTL AMLP Reduced Positions BA MSFT LUV AOS PKG VLO NSC AAPL FDX DFS Sold Out CSX CMI ARNC BG AA New
LLY,LLY:US,BBG000BNBDC2,"Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved",2017-05-02 21:27:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dvKLkBONJj4/radius-health-rdus-posts-wider-q1-loss-tymlos-approved-cm783021,Radius Health Inc RDUS posted a loss of 1 32 per share in the first quarter of 2017 compared with a loss of 94 cents per share in the year ago quarter and wider than the Zacks Consensus Estimate loss of 1 25 The year over year increase in net loss was attributable to an increase in
LLY,LLY:US,BBG000BNBDC2,"Dow&apos;s Pfizer Tops Earnings Views, But Sales Come Up Short",2017-05-02 20:27:58 +0000,http://finance.yahoo.com/r/2eae07a9-fbd1-353c-9555-e00a3f5daddb/pfizer-earnings-top-but-sales-come-up-short?src=A00220&yptr=yahoo&.tsrc=rss,Pfizer on Tuesday reported mixed first-quarter results on declining sales in its what it calls its Essential Health unit.
LLY,LLY:US,BBG000BNBDC2,Here&apos;s Why Ignyta Shares Dropped as Much as 21.9% Today,2017-05-02 19:43:00 +0000,http://finance.yahoo.com/r/9bc84c0b-7963-37a3-a26f-bfc0ca627c76/heres-why-ignyta-shares-dropped-as-much-as-219-tod.aspx?yptr=yahoo&.tsrc=rss,"The company released first-quarter 2017 earnings, but the drop seems a bit overdone."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Webcast to Discuss Oncology Pipeline,2017-05-02 19:30:00 +0000,http://finance.yahoo.com/news/lilly-announces-webcast-discuss-oncology-193000300.html?.tsrc=rss,"INDIANAPOLIS, May 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Saturday, June 3, 2017, to discuss the company's oncology pipeline, including data from the MONARCH ..."
LLY,LLY:US,BBG000BNBDC2,"Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View",2017-05-02 18:27:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/On3esB0Ln1w/merck-mrk-beats-on-q1-earnings-sales-ups-annual-view-cm782874,Merck amp Co Inc MRK reported first quarter 2017 earnings of 88 cents per share which beat the Zacks Consensus Estimate of 83 cents However earnings declined 1 1 from the year ago period Merck s shares rallied 6 1 so far this year while the Zacks classified Large Cap
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Developments in 1Q17,2017-05-02 14:36:35 +0000,http://finance.yahoo.com/r/00466f46-9b3b-38eb-8b22-09f1fda2998f/eli-lilly-co-s-developments-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Eli Lilly and Boehringer Ingelheim launched Synjardy XR tablets in the US for patients with type 2 diabetes."
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly & Co.’s Elanco in 1Q17,2017-05-02 13:06:39 +0000,http://finance.yahoo.com/r/f92838f2-5e92-3b13-9d33-b5867b9a5b11/performance-of-eli-lilly-co-s-elanco-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Earnings: Cialis and Other Cardiovascular Products,2017-05-02 11:37:34 +0000,http://finance.yahoo.com/r/7b7821b6-a5e1-3e59-bb93-9f138a77d8c7/eli-lillys-1q17-earnings-cialis-and-other-cardiovascular-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Cialis sales decreased over 7% to $533.6 million during 1Q17, compared to $576.7 million for 1Q16."
LLY,LLY:US,BBG000BNBDC2,"Daily Dividend Report: LLY, ETE, GGP, HOG, SMG",2017-05-01 21:26:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I9pp2magClk/daily-dividend-report-lly-ete-ggp-hog-smg-cm782289,Eli Lilly and Company LLY has declared a dividend for the second quarter of 2017 of 0 52 per share on outstanding common stock The dividend is payable June 9 2017 to shareholders of record at the close of business on May 15 2017 Energy Transfer Equity ETE announced
LLY,LLY:US,BBG000BNBDC2,Lilly Declares Second-Quarter 2017 Dividend,2017-05-01 18:45:00 +0000,http://finance.yahoo.com/news/lilly-declares-second-quarter-2017-184500764.html?.tsrc=rss,"INDIANAPOLIS, May 1, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding common stock. ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly says it has received civil investigative demands about insulin pricing from two state attorney generals,2017-05-01 16:15:33 +0000,http://finance.yahoo.com/r/43d0426a-38c3-357f-b54d-90145e9cd5b6/Story.aspx?guid=3DD47346-B70E-4181-A12E-B3F6AEFFD866&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. has received civil investigative demands related to its insulin prices from the attorney generals in Washington State and New Mexico, according to a 10-Q financial filing. The Washington ..."
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD",2017-05-01 15:31:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/53GFHnUIF8Q/drug-stocks-q1-earnings-slated-for-may-2-mrk-pfe-gild-cm781951,The Q1 earnings season is in full swing with financial results from 288 S amp P 500 members or 63 8 of the index already out as of Apr 28 2017 according to the latest Earnings Preview report Total earnings for these index members jumped 13 7 from the year ago quarter driven by 8
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Earnings: Strattera and Other Neuroscience Products,2017-05-01 14:38:18 +0000,http://finance.yahoo.com/r/e69c65fa-c1ee-3926-833d-99eb9b730d91/eli-lillys-1q17-earnings-strattera-and-other-neuroscience-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Strattera, a drug for attention-deficit hyperactivity disorder, reported a 4% increase in revenues to $196.2 million in 1Q17, compared to $188.1 million in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Neurotrope Alzheimer's drug data fails to impress; shares crater,2017-05-01 14:33:39 +0000,http://finance.yahoo.com/news/neurotrope-alzheimers-drug-data-fails-111008321.html?.tsrc=rss,"Neurotrope Inc's shares more than  halved after data from a small trial on the company's  Alzheimer's drug failed to impress investors, the latest in a  series of setbacks in the quest for an effective treatment for  the memory-robbing disease.  A total of 113 patients completed the study and Neurotrope  said the higher 40 microgram (mcg) dose showed ""very modest  efficacy"".  Statistical significance in late-stage trials is typically  defined by a p-value of 0.05 or less, but this was more an  exploratory mid-stage study and the data is encouraging, Chief  Scientific Officer Daniel Alkon said on a call with analysts."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Earnings: Alimta and Other Oncology Products,2017-05-01 13:08:45 +0000,http://finance.yahoo.com/r/48c80716-954a-3208-9864-a14bd48f458b/eli-lillys-1q17-earnings-alimta-and-other-oncology-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co.’s (LLY) Human Pharmaceuticals segment includes the oncology franchise, which includes drugs like Alimta, Erbitux, Cyramza, and new entrant Portrazza."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Earnings: Humalog and Other Endocrine Products,2017-05-01 11:39:46 +0000,http://finance.yahoo.com/r/af6c3eb1-a029-3b42-86df-fd1b5829ff37/eli-lillys-1q17-earnings-humalog-and-other-endocrine-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly's sales of Forteo increased ~9% to $347.5 million in 1Q17, compared to $318.6 million in 1Q16."
LLY,LLY:US,BBG000BNBDC2,Edited Transcript of LLY earnings conference call or presentation 25-Apr-17 1:00pm GMT,2017-04-29 11:23:27 +0000,http://finance.yahoo.com/news/edited-transcript-lly-earnings-conference-123539137.html?.tsrc=rss,Q1 2017 Eli Lilly and Co Earnings Call
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Earnings: Performance of New Products,2017-04-28 21:05:48 +0000,http://finance.yahoo.com/r/7a9aba7b-81f4-36e3-8de0-8037ca8cbfe3/eli-lillys-1q17-earnings-performance-of-new-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co.'s (LLY) new products include Cyramza, Basaglar, Jardiance, and Lartruvo."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Business Segments and Their Performance in 1Q17,2017-04-28 19:35:48 +0000,http://finance.yahoo.com/r/831b30dc-0410-339d-97e0-f6eb2b45a421/eli-lillys-business-segments-and-their-performance-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The growth for Eli Lilly's Human Pharmaceuticals segment, which contributes ~85.3% to its total revenues, was driven by increased sales of products such as Trulicity, Humalog, and Cyramza."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Earnings: Losses despite Revenue Growth,2017-04-28 17:48:33 +0000,http://finance.yahoo.com/r/2c035dcb-69c8-3792-aff1-bacd27dc3a43/eli-lillys-1q17-earnings-losses-despite-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. (LLY) released its 1Q17 earnings on April 25, 2017, reporting 7% growth in its top line for 1Q17 compared to 1Q16. LLY stock has risen ~4.2% in the last 12 months."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More",2017-04-28 14:31:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hbwmZ5eBk3Y/pharma-stock-roundup-lilly-bristol-myers-novartis-q1-earnings-more-cm780993,Earnings season for the pharma sector started in full flow this week with companies like Lilly LLY Novartis NVS Bristol Myers BMY Roche AstraZeneca Glaxo GSK and Sanofi SNY reporting results So far it looks like a mixed quarter for the sector Recap of the Week s Most
LLY,LLY:US,BBG000BNBDC2,These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016,2017-04-28 13:29:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JG2eDRSt064/these-7-drugmakers-relied-on-price-hikes-for-100-of-their-earnings-growth-in-2016-cm780928,If I told you that drug companies lean on their exceptional pricing power to grow their top and bottom lines it probably wouldn t come as a shock in the least If you ve picked up a prescription from the pharmacy at any point over the past couple of years you re probably well aware of
LLY,LLY:US,BBG000BNBDC2,These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016,2017-04-28 12:02:00 +0000,http://finance.yahoo.com/r/fd720da2-c405-315d-af88-671123b30b69/these-7-drugmakers-relied-on-price-hikes-for-100-o.aspx?yptr=yahoo&.tsrc=rss,"If President Trump cracks down on drug price inflation, these pharma and biotech offenders could be in big trouble."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Stock Downgraded at Argus,2017-04-27 19:40:00 +0000,http://finance.yahoo.com/r/e533b57e-7c55-311a-bab4-c751ddbaa362/eli-lilly-stock-downgraded-at-argus.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Eli Lilly stock is trading near its 52-week high and is 'well above peer-average multiples,' Argus said."
LLY,LLY:US,BBG000BNBDC2,iShares Russell 1000 Growth ETF Experiences Big Outflow,2017-04-27 17:25:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iXdz8l561dE/ishares-russell-1000-growth-etf-experiences-big-outflow-cm780411,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 63 7 million dollar outflow that s a 0 2 decrease week over week
LLY,LLY:US,BBG000BNBDC2,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold",2017-04-27 14:06:48 +0000,http://finance.yahoo.com/news/analyst-sees-eli-lilly-fairly-140648725.html?.tsrc=rss,"Argus analyst Katelyn Bayone believes shares of Eli Lilly and Co (NYSE: LLY ) are fairly valued at around $81, which prompted her to downgrade the stock from Buy to Hold. According to Bayone, shares are ..."
LLY,LLY:US,BBG000BNBDC2,"Company News for April 26, 2017",2017-04-26 17:07:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RuhEvBURKx8/company-news-for-april-26-2017-cm779673,160 160 160 Shares of Rite Aid Corporation RAD gained 6 4 after the company reported fourth quarter 2016 revenue of 8 5 billion increasing 2 7 year over year 160 160 160 Corning Incorporated s GLW shares advanced 3 7 after the company posted first quarter 2017
LLY,LLY:US,BBG000BNBDC2,"Company News for April 26, 2017",2017-04-26 14:33:02 +0000,http://finance.yahoo.com/news/company-news-april-26-2017-143302842.html?.tsrc=rss,"Companies in the News are: RAD,GLW,LLY,NFLX"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Stock Dips Though Q1 Profits Top, Guidance Reaffirmed",2017-04-25 20:48:04 +0000,http://finance.yahoo.com/r/51cac877-9ce5-39da-acb3-a5d416ad6492/what-to-expect-can-lillys-q2-report-boost-the-stock-after-drug-flop?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly stock dipped early Tuesday though the drugmaker topped Wall Street&apos;s first-quarter sales and profits expectations.
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down",2017-04-25 17:09:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YP7nF9VrEV8/lilly-lly-tops-q1-earnings-misses-sales-shares-down-cm778822,Eli Lilly and Company LLY reported first quarter 2017 adjusted earnings per share of 98 cents which beat the Zacks Consensus Estimate of 96 cents by 2 1 Earnings rose 18 from the year ago quarter backed by volume driven pharma sales growth and higher profits Including a
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Stock Falls on Continued Arthritis Drug Approval Delay,2017-04-25 17:09:00 +0000,http://finance.yahoo.com/r/7a28f8e3-e39d-3587-99ba-7afe10afda6b/eli-lilly-stock-falls-on-continued-arthritis-drug-approval-delay.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Eli Lilly's EPS for the 2017 first quarter was slightly better than analysts expected.
LLY,LLY:US,BBG000BNBDC2,2 Reasons Eli Lilly is Getting Crushed,2017-04-25 17:07:00 +0000,http://finance.yahoo.com/r/365d63a4-b42f-3c5c-b7b4-14eb950bd4a0/2-reasons-eli-lilly-is-getting-crushed?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) reported better-than-expected earnings today, yet shares are getting beaten down today. Shares of Eli Lilly have 2.96% to $80.95 at 12:50 a.m. today. I wish I could say that's as bad as ..."
LLY,LLY:US,BBG000BNBDC2,Chill Pill: Eli Lilly Cuts Guidance with Earnings,2017-04-25 17:00:00 +0000,http://finance.yahoo.com/r/ce30bef7-115c-3462-9d78-b9c57915a070/chill-pill-eli-lilly-cuts-guidance-earnings?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Lilly trimmed its full-year GAAP EPS guidance, dragging shares lower today."
LLY,LLY:US,BBG000BNBDC2,Lilly gives no time frame on arthritis drug delay; shares fall,2017-04-25 16:34:46 +0000,http://finance.yahoo.com/news/drugmaker-eli-lillys-revenue-rises-105103465.html?.tsrc=rss,"Lilly shares, which have outperformed its rivals this year, fell 3 percent to $80.83 even though the U.S. drugmaker reported a slightly higher-than-expected quarterly profit.  ""Maybe people are trying to understand where the near-term upside is going to come from,"" said Credit Suisse analyst Vamil Divan, adding that investors may be taking profit while waiting for clarity on baricitinib.  Lilly reiterated that it was disappointed and disagreed with the FDA assessment on baricitinib, particularly since the medicine won European approval."
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down",2017-04-25 15:05:03 +0000,http://finance.yahoo.com/news/lilly-lly-tops-q1-earnings-150503720.html?.tsrc=rss,"Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%."
LLY,LLY:US,BBG000BNBDC2,Key Factors to Look Out for in Celgene's (CELG) Q1 Results,2017-04-25 14:08:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UsVLGeMUSN0/key-factors-to-look-out-for-in-celgenes-celg-q1-results-cm778639,Earnings season for the pharma and biotech sector will start in full flow this week with several major companies scheduled to report results Celgene Corporation CELG is one of the companies that will be reporting results later this week A look at the company s earnings track record
LLY,LLY:US,BBG000BNBDC2,Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?,2017-04-25 14:05:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_luUbEaDs2o/will-low-pricing-for-siliq-be-enough-to-help-valeant-turn-things-around-cm778473,Valeant Pharmaceuticals NYSE VRX has been more bullish about the prospects for brodalumab now branded as Siliq than anyone Amgen bailed out on the 160 psoriasis drug after late stage study results raised concerns about Siliq causing patients to have suicidal
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly,2017-04-25 13:05:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zJfAkBNmhp8/eli-lilly-lly-tops-earnings-in-q1-sales-miss-slightly-cm778483,Indianapolis IN based Eli Lilly and Company LLY is a global healthcare company with core products in a number of primary care pharmaceutical markets Lilly generates revenues from its pharmaceutical product and animal health segments The company s portfolio includes Zyprexa schizophrenia
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly swings to loss though sales rise, cuts outlook",2017-04-25 12:52:02 +0000,http://finance.yahoo.com/r/7ba83e32-0300-31d1-aeb7-cf55395bbac8/Story.aspx?guid=071A5648-C19B-4053-9CA4-F488750C36F4&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. on Tuesday said it swung to a quarterly net loss, but adjusted earnings and revenue exceeded expectations. The drug maker swung to a first-quarter loss of $110.8 million, or 10 cents a ..."
LLY,LLY:US,BBG000BNBDC2,Morning Movers: More Stocks Than I Know What To Do With!,2017-04-25 12:50:00 +0000,http://finance.yahoo.com/r/c10d992a-cced-3416-bf27-d06444a8f530/morning-movers-more-stocks-than-i-know-what-to-do-with-with?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Stocks look set to continue their rally following yesterday's big gains. S&P 500 futures have risen 0.3%, while Dow Jones Industrial Average futures have gained 0.7%. Nasdaq Composite futures have advanced ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO Says Diabetes Is ‘Core Engine’ to Strategy,2017-04-25 12:46:05 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-says-diabetes-124605840.html?.tsrc=rss,"Apr.25 -- Dave Ricks, chief executive officer at Eli Lilly, discusses the company’s earnings and outlook for various treatments. He speaks with Bloomberg's David Westin on &quot;Bloomberg Daybreak: Americas.&quot;"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO Says Diabetes Is ‘Core Engine’ to Strategy,2017-04-25 12:43:58 +0000,http://finance.yahoo.com/r/b52d0a6e-9830-3984-b749-3ab538cd227a/eli-lilly-ceo-diabetes-is-core-engine-to-strategy-video?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Dave Ricks, chief executive officer at Eli Lilly, discusses the company’s earnings and outlook for various treatments. He speaks with Bloomberg's David Westin on ""Bloomberg Daybreak: Americas."" ..."
LLY,LLY:US,BBG000BNBDC2,Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?,2017-04-25 12:22:00 +0000,http://finance.yahoo.com/r/76d5aafd-2c86-3a08-a9b8-17abb615f26a/will-low-pricing-for-siliq-be-enough-to-help-valea.aspx?yptr=yahoo&.tsrc=rss,Valeant is undercutting Novartis and Lilly with its pricing of psoriasis drug Siliq. How much will the strategy help?
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Eli Lilly's Breast Cancer Drug Achieved its Primary Endpoint in Late Stage Trial,2017-04-25 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-eli-lillys-breast-121500758.html?.tsrc=rss,"Upcoming AWS Coverage on Shire Post-Earnings Results LONDON, UK / ACCESSWIRE / April 25, 2017 / Active Wall St. blog coverage looks at the headline from Eli Lilly and Co. (NYSE: LLY ) as the Company announced ..."
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Working to Cut Costs,2017-04-25 11:59:01 +0000,http://finance.yahoo.com/r/10a63591-ba56-3a26-918c-66f8e1933e5b/eli-lilly-working-to-cut-costs-1493121538?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. on Tuesday reported higher revenue but swung to a loss and cut its profit forecast due to charges related to cost-cutting efforts.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly,2017-04-25 11:54:11 +0000,http://finance.yahoo.com/news/eli-lilly-lly-tops-earnings-115411615.html?.tsrc=rss,Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
LLY,LLY:US,BBG000BNBDC2,Deal charge pushes drugmaker Eli Lilly to 1Q loss,2017-04-25 11:51:39 +0000,http://finance.yahoo.com/news/lilly-reports-1q-loss-103244740.html?.tsrc=rss,"Eli Lilly and Co. booked a $110.8 million loss in the first quarter, as the drugmaker absorbed a charge tied to its purchase of CoLucid Pharmaceuticals, but the insulin maker's bottom line beat expectations ..."
LLY,LLY:US,BBG000BNBDC2,LLY CEO: New products drove 'solid' growth,2017-04-25 11:15:00 +0000,http://finance.yahoo.com/video/lly-ceo-products-drove-solid-111500064.html?.tsrc=rss,"David Ricks, Eli Lilly CEO, talks about the company's quarterly earnings, the Affordable Care Act, innovation in drug therapy and meeting with the FDA to talk about getting their new arthritis drug approved."
LLY,LLY:US,BBG000BNBDC2,"Earnings Reaction History: Eli Lilly & Co., 27.3% Follow-Through Indicator, 1.2% Sensitive",2017-04-25 11:03:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/krEacGEW_H4/earnings-reaction-history-eli-lilly-co-273-follow-through-indicator-12-sensitive-cm778383,Expected Earnings Release 04 25 2017 PremarketExpected Earnings Release 04 25 2017 Premarket Avg Extended Hours Dollar Volume 1 014 762Avg Extended Hours Dollar Volume 1 014 762 Eli Lilly amp Co LLY is due to issue its quarterly earnings report in the upcoming extended
LLY,LLY:US,BBG000BNBDC2,Lilly Diabetes Drug Jardiance Falls Short,2017-04-25 10:53:06 +0000,http://finance.yahoo.com/r/ef06fa3a-9aca-33cb-b6bc-f89fe77ebf11/lilly-s-diabetes-drug-jardiance-falls-short-as-challenges-loom?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co.’s promising diabetes drug Jardiance fell short last quarter, a sign of the major challenges ahead for its new chief executive officer after recent setbacks on other potential new treatments...."
LLY,LLY:US,BBG000BNBDC2,Lilly Reports First-Quarter 2017 Results,2017-04-25 10:25:00 +0000,http://finance.yahoo.com/news/lilly-reports-first-quarter-2017-102500254.html?.tsrc=rss,"INDIANAPOLIS, April 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017.   $ in millions, except per share data First Quarter % 2017 ..."
LLY,LLY:US,BBG000BNBDC2,America&apos;s 12 Most Charitable Companies,2017-04-25 10:05:00 +0000,http://finance.yahoo.com/r/61aa756c-4b02-3bf5-b3cb-ac17adbd591e/americas-12-most-charitable-companies.aspx?yptr=yahoo&.tsrc=rss,"These healthcare, bank, and tech companies are leading the way in investing in global change."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Q1 17 Earnings Conference Call At 9:00 AM ET,2017-04-25 08:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4cFbkRKkVpM/eli-lilly-q1-17-earnings-conference-call-at-900-am-et-20170425-00554,Eli Lilly Q1 17 Earnings Conference Call At 9:00 AM ET
LLY,LLY:US,BBG000BNBDC2,Wall Street Set To Open Strong,2017-04-25 07:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TDJxxkkvMMo/wall-street-set-to-open-strong-20170425-00467,Wall Street Set To Open Strong
LLY,LLY:US,BBG000BNBDC2,Lilly Q1 Results Top Estimates; Cuts 2017 EPS View,2017-04-25 06:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zNQZ9HzHZiw/lilly-q1-results-top-estimates-cuts-2017-eps-view-20170425-00363,Lilly Q1 Results Top Estimates; Cuts 2017 EPS View
LLY,LLY:US,BBG000BNBDC2,European Stocks Called Higher as Global 'French Election' Rally Extends Gains,2017-04-25 06:37:00 +0000,http://finance.yahoo.com/r/effd6d49-b868-3d3f-b181-fbb6857a6a9a/european-stocks-called-higher-as-global-french-election-rally-extends-gains.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,European stocks are expected to extend gains Tuesday as global markets continue to rally in the wake of Emmanuel Macron's victory in Sunday's presidential elections in France.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Announces 18% Increase In Q1 Profit,2017-04-25 06:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fRLsqbOiabw/eli-lilly-and-co-announces-18-increase-in-q1-profit-20170425-00317,Eli Lilly And Co. Announces 18% Increase In Q1 Profit
LLY,LLY:US,BBG000BNBDC2,3 IPOs to Watch For This Week,2017-04-24 23:03:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9010rDSONUI/3-ipos-to-watch-for-this-week-cm778302,The last week of April is scheduled to see eight different companies go public and Zacks has you covered with three unique IPO offerings to watch out for The wide ranging list of companies set to go public this week will help contribute to an already booming 2017 for the IPO world Since
LLY,LLY:US,BBG000BNBDC2,"How Lilly&apos;s New Drug Could Spark A Deeper Rivalry With Pfizer, Novartis",2017-04-24 20:14:13 +0000,http://finance.yahoo.com/r/d01069bd-417e-34dd-949c-a3b4a467022d/how-lillys-new-drug-could-spark-a-deeper-rivalry-with-pfizer-novartis?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly stock popped Monday after the drugmaker said its breast cancer drug &quot;has the potential to be best in class.&quot;
LLY,LLY:US,BBG000BNBDC2,"Pre-Market Earnings Report for April 25, 2017 :  KO, MMM, MCD, LLY, LMT, DD, BIIB, CAT, SPGI, VLO, GLW, BHI",2017-04-24 20:12:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jSF4oKh--Bs/pre-market-earnings-report-for-april-25-2017-ko-mmm-mcd-lly-lmt-dd-biib-cat-spgi-vlo-glw-bhi-cm778233,The following companies are expected to report earnings prior to market open on 04 25 2017 Visit our Earnings Calendar for a full list of expected earnings releases Coca Cola Company KO is reporting for the quarter ending March 31 2017 The
LLY,LLY:US,BBG000BNBDC2,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",2017-04-24 17:45:20 +0000,http://finance.yahoo.com/news/earnings-caterpillar-lockheed-martin-eli-174520594.html?.tsrc=rss,"Overall, first-quarter earnings have been pretty positive and many CEOs struck an optimistic tone discussing outlooks for the remainder of 2017. Two industrial bellwethers, General Electric Company (NYSE: ..."
LLY,LLY:US,BBG000BNBDC2,"Earnings: Caterpillar, Lockheed Martin And Eli Lilly Report Tomorrow",2017-04-24 17:11:00 +0000,http://finance.yahoo.com/r/562a198d-11ef-36b4-9493-d76fd08e3b72/earnings-caterpillar-lockheed-martin-and-eli-lilly-report-tomorrow?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Earnings season continues this week. Find out what might be expected when Caterpillar, Eli Lilly, and Lockheed Martin report Q1 earnings tomorrow."
LLY,LLY:US,BBG000BNBDC2,What's in Store for Vertex (VRTX) this Earnings Season?,2017-04-24 17:07:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/krnlnHozsVA/whats-in-store-for-vertex-vrtx-this-earnings-season-cm777990,Vertex Pharmaceuticals Inc VRTX is scheduled to report first quarter 2017 results on Apr 27 after the market closes Year to date Vertex s shares rose 58 4 while the Zacks classified Medical Biomed Genetics industry recorded an increase of 1 8 Vertex s track record
LLY,LLY:US,BBG000BNBDC2,Lilly reports positive interim data on breast cancer combo drug,2017-04-24 16:01:23 +0000,http://finance.yahoo.com/news/lilly-reports-positive-interim-data-160123276.html?.tsrc=rss,"Eli Lilly and Co said the  combination of its experimental breast cancer drug and a  commonly used treatment met the main goal of a late-stage study  in an interim analysis, setting the stage for a regulatory  submission later this year.  Shares of Indianapolis-based Lilly, which is scheduled to  report its first-quarter results on Tuesday, were up 1.3 percent  at $82.95 on Monday.  Lilly's drug, abemaciclib, is likely to compete with market  leader Pfizer Inc's Ibrance, which brought in $2.1  billion in 2016 sales, and Novartis AG's newly approved  Kisqali."
LLY,LLY:US,BBG000BNBDC2,3 Key Factors to Look Out for in Biogen's Q1 Results,2017-04-24 15:07:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3dEaTYIH2ds/3-key-factors-to-look-out-for-in-biogens-q1-results-cm777766,This week earnings season for the pharma and biotech sector will start in earnest with several major companies scheduled to report results Biotech major Biogen Inc BIIB is one of the companies that will be reporting results tomorrow A look at Biogen s earnings track record shows
LLY,LLY:US,BBG000BNBDC2,Analyst Ratings and Recommendations for Eli Lilly,2017-04-24 14:36:19 +0000,http://finance.yahoo.com/r/a322c4a1-9d7c-330a-8e56-dc8bb6ffc7dd/analyst-ratings-and-recommendations-for-eli-lilly?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of April 19, 2017, there are 22 analysts tracking Eli Lilly. Sixteen of them have recommended a “buy” for the stock."
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly (LLY) Might Surprise This Earnings Season,2017-04-24 14:06:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Iiw7ATq1ZM/why-eli-lilly-lly-might-surprise-this-earnings-season-cm777818,Investors are always looking for stocks that are poised to beat at earnings season and Eli Lilly and Company LLY may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Eli Lilly is seeing favorable
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 1Q17 Estimates for Elanco,2017-04-24 13:06:25 +0000,http://finance.yahoo.com/r/a8578a96-edfa-3c68-b847-0add9bfad6f0/eli-lillys-1q17-estimates-for-elanco?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly’s (LLY) animal health segment, Elanco, deals with products for companion animals as well as food and other products."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Up 8.1% Since Earnings Report: Can It Continue?,2017-04-24 13:06:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vyhd8w9lw50/eli-lilly-lly-up-81-since-earnings-report-can-it-continue-cm777685,A month has gone by since the last earnings report for Eli Lilly and Company LLY Shares have added about 8 1 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before we dive
LLY,LLY:US,BBG000BNBDC2,TransUnion (TRU) Q1 Earnings: What's in Store this Time?,2017-04-24 13:05:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uu-tH04EJ1A/transunion-tru-q1-earnings-whats-in-store-this-time-cm777676,Premium business service company TransUnion TRU is scheduled to release first quarter 2017 results before the market opens on Apr 25 In the last reported quarter adjusted earnings beat the Zacks Consensus Estimate by 10 cents The company recorded an average positive earnings surprise of 13
LLY,LLY:US,BBG000BNBDC2,S&P Global (SPGI) to Post Q1 Earnings: A Beat in the Cards?,2017-04-24 13:05:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/693WqgRWC98/sp-global-spgi-to-post-q1-earnings-a-beat-in-the-cards-cm777672,S amp P Global Inc SPGI is slated to report first quarter 2017 results on Apr 25 before the markets open In the previous quarter the company delivered a positive earnings surprise of 6 7 Notably the company surpassed the Zacks Consensus Estimate in the last four quarters with an
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly (LLY) Might Surprise This Earnings Season,2017-04-24 12:33:12 +0000,http://finance.yahoo.com/news/why-eli-lilly-lly-might-123312148.html?.tsrc=rss,"Eli Lilly (LLY) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season."
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS",2017-04-24 12:04:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AixDPKrsJNM/drug-stocks-q1-earnings-releases-on-apr-25-lly-biib-nvs-cm777652,As the Q1 earnings season gets in full swing this week we believe this quarter is on track to see the highest growth in almost three years As of Apr 21 2017 95 S amp P 500 members accounting for 24 9 of the index s total market capitalization reported results according to the
LLY,LLY:US,BBG000BNBDC2,Read This Before You Buy Biotech Stocks,2017-04-24 11:45:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E0LEFm-9vUA/read-this-before-you-buy-biotech-stocks-cm777613,Investing in biotech tech stocks is a little like venturing into the Wild West of years ago It can be chaotic risky and unpredictable Biotech investing doesn t have to be too scary though Here are seven things you need to know before buying biotech stocks that should help you
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Cialis and Other Cardiovascular Products in 1Q17,2017-04-24 11:36:29 +0000,http://finance.yahoo.com/r/4a815ad9-dcec-3b83-9455-0ff522504122/eli-lillys-cialis-and-other-cardiovascular-products-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly’s (LLY) cardiovascular franchise contributes ~15.0% to the company's total revenues. Key drugs in this segment include Cialis and Effient.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly says breast cancer combination treatment improved survival rates in late-stage trial,2017-04-24 11:08:41 +0000,http://finance.yahoo.com/r/85b78f5f-6abb-34a0-99a2-51bf37cfc7dd/Story.aspx?guid=753F7BF4-8A84-4C7E-8EEF-7EBE5EED22C9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. said early Monday that its combination treatment improved survival rates for patients with advanced breast cancer, which was also the primary endpoint in a late-stage clinical trial. The ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Up 8.1% Since Earnings Report: Can It Continue?,2017-04-24 11:00:11 +0000,http://finance.yahoo.com/news/eli-lilly-lly-8-1-110011116.html?.tsrc=rss,Eli Lilly (LLY) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis,2017-04-24 10:45:00 +0000,http://finance.yahoo.com/news/lilly-announces-phase-3-monarch-104500467.html?.tsrc=rss,"INDIANAPOLIS, April 24, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS).  The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, in combination with an aromatase inhibitor (letrozole or anastrozole) compared to treatment with an aromatase inhibitor alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.  ""Today marks another important milestone in our clinical development program for abemaciclib, a drug we believe has the potential to be best in class,"" said Levi Garraway, M.D., Ph.D., senior vice president, global development and medical affairs, Lilly Oncology."
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS",2017-04-24 09:52:09 +0000,http://finance.yahoo.com/news/drug-stocks-q1-earnings-releases-095209011.html?.tsrc=rss,"As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years."
LLY,LLY:US,BBG000BNBDC2,Lilly :Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Shows Superior PFS,2017-04-24 06:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ov4_H_vj-lM/lilly-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-shows-superior-pfs-20170424-00269,Lilly :Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Shows Superior PFS
LLY,LLY:US,BBG000BNBDC2,What to own ahead of earnings' busiest week,2017-04-21 22:35:00 +0000,http://finance.yahoo.com/video/own-ahead-earnings-busiest-week-223500166.html?.tsrc=rss,Jim Cramer sifts through the noise of earnings season to find the stocks worth buying - and avoiding.
LLY,LLY:US,BBG000BNBDC2,Cramer's game plan: Here's what to own ahead of the busiest week of earnings,2017-04-21 22:13:47 +0000,http://finance.yahoo.com/r/9e53ce2f-e060-3b89-96bb-ef5a61f79bf7/104418816?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104418816&yptr=yahoo&.tsrc=rss,Jim Cramer sifts through the noise of earnings season to find the stocks worth buying - and avoiding.
LLY,LLY:US,BBG000BNBDC2,Cramer&apos;s game plan: Here&apos;s what to own ahead of the busiest week of earnings,2017-04-21 22:13:47 +0000,http://finance.yahoo.com/news/cramer-apos-game-plan-apos-221347617.html?.tsrc=rss,Jim Cramer sifts through the noise of earnings season to find the stocks worth buying - and avoiding.
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly’s Estimate for Strattera, Other Neuroscience Products",2017-04-21 14:36:30 +0000,http://finance.yahoo.com/r/738588c0-ecb1-3791-95ba-851eb0217cab/eli-lillys-estimate-for-strattera-other-neuroscience-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Neuroscience is one of Eli Lilly’s (LLY) franchises in its human pharmaceutical segment. Key drugs in this segment include Zyprexa, Cymbalta, and Strattera."
LLY,LLY:US,BBG000BNBDC2,How Will Eli Lilly’s Alimta and Other Oncology Products Perform?,2017-04-21 13:06:31 +0000,http://finance.yahoo.com/r/e2b45371-2125-3a57-8897-85c56be3a95d/how-will-eli-lillys-alimta-and-other-oncology-products-perform?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Oncology contributes around 18.0% to Eli Lilly's (LLY) total revenues. Key drugs in this segment include Alimta, Erbitux, and Cyramza."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL",2017-04-21 13:05:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lhqx_1cDwZE/pharma-stock-roundup-jj-slips-on-mixed-q1-lilly-hit-by-fda-crl-cm776874,Johnson amp Johnson JNJ kicked off the first quarter earnings season for the pharma sector this week Meanwhile Lilly LLY was also in the news with the company receiving a complete response letter CRL for its experimental rheumatoid arthritis RA treatment baricitinib Recap of
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products",2017-04-21 11:36:48 +0000,http://finance.yahoo.com/r/f16bd763-ff4e-3df4-9c64-003f1631470f/eli-lillys-1q17-estimates-for-humalog-other-endocrine-products?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly's total revenues.
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL",2017-04-21 11:12:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-111211147.html?.tsrc=rss,Key highlights from the pharma sector include J&J&apos;s (JNJ) first quarter results and a CRL for Lilly&apos;s RA drug.
LLY,LLY:US,BBG000BNBDC2,"CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up",2017-04-21 00:02:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dOR6ddTKKho/cytrx-gets-clarity-from-fda-for-aldoxorubicin-nda-shares-up-cm776780,CytRx Corporation CYTR announced that the it has reached an agreement with the regarding the path to filing for its new drug application NDA for its lead candidate aldoxorubicin 160 being developed for the treatment of soft tissue sarcomas STS Shares of the company were up more than
LLY,LLY:US,BBG000BNBDC2,This $26 Billion Company Is the Market's Most Overpriced Biotech Stock,2017-04-20 19:04:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mtjxa2yq-5c/this-26-billion-company-is-the-markets-most-overpriced-biotech-stock-cm776599,Despite learning on Monday that the FDA rejected baricitinib 160 shares of biotech behemoth Incyte NASDAQ INCY have been on a roll Over the past year Incyte s stock is up 64 over five years it s up 450 and since March of 2009 160 its shares are up nearly 5 300 Not
LLY,LLY:US,BBG000BNBDC2,Will New Products Help Eli Lilly in 1Q17?,2017-04-20 18:35:43 +0000,http://finance.yahoo.com/r/574299a5-4896-3715-8335-22d0fb536199/will-new-products-help-eli-lilly-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) has launched various products, including Portrazza, Cyramza, Basaglar, Jardiance, and Trulicity."
LLY,LLY:US,BBG000BNBDC2,This $26 Billion Company Is the Market&apos;s Most Overpriced Biotech Stock,2017-04-20 17:06:00 +0000,http://finance.yahoo.com/r/656ced5d-7ff2-3ba4-81a4-3e66343f6fd6/this-26-billion-company-is-the-markets-most-overpr.aspx?yptr=yahoo&.tsrc=rss,Nearly 90% of this biotech&apos;s sales could be at risk within the next two years.
LLY,LLY:US,BBG000BNBDC2,Growth Expected for Eli Lilly’s 1Q17 Revenue,2017-04-20 17:05:43 +0000,http://finance.yahoo.com/r/f1276138-b715-340f-b77b-25d0e20321a1/growth-expected-for-eli-lillys-1q17-revenue?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Analysts estimate a 7.1% rise in Eli Lilly’s (LLY) 1Q17 revenues due to new and existing products and the inclusion of animal health.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?,2017-04-20 16:04:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WDzeZt_4p28/eli-lilly-lly-to-report-q1-earnings-whats-in-the-cards-cm776409,Eli Lilly and Company LLY will report first quarter 2017 results on Apr 25 before the market opens Last quarter the company delivered a negative earnings surprise of 4 04 So far this year Lilly s share price has risen 10 7 compared with an increase of 5 6 for the Zacks
LLY,LLY:US,BBG000BNBDC2,Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting,2017-04-20 15:35:00 +0000,http://finance.yahoo.com/news/lilly-present-data-galcanezumab-prevention-153500600.html?.tsrc=rss,"INDIANAPOLIS, April 20, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston.  Lilly will present four abstracts at AAN, including safety and patient outcomes data for galcanezumab in patients with migraine and factors associated with a reduction in monthly migraine headache days among patients with episodic migraine.  Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of episodic and chronic migraine and cluster headache."
LLY,LLY:US,BBG000BNBDC2,Analyst Estimates for Eli Lilly’s 1Q17 Earnings,2017-04-20 15:31:53 +0000,http://finance.yahoo.com/r/eaee69e1-d80c-3124-9617-5c968cfde650/analyst-estimates-for-eli-lillys-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) is set to release its 1Q17 earnings on April 25, 2017. Its 4Q16 revenues of ~$5.8 billion surpassed estimates of ~$5.6 billion."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) to Report Q1 Earnings: What&apos;s in the Cards?,2017-04-20 14:21:02 +0000,http://finance.yahoo.com/news/eli-lilly-lly-report-q1-142102950.html?.tsrc=rss,"Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens."
LLY,LLY:US,BBG000BNBDC2,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eli Lilly and Company (LLY)",2017-04-20 14:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-140000483.html?.tsrc=rss,"NEW YORK, April 20, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eli Lilly and Company (""Eli Lilly"" ..."
LLY,LLY:US,BBG000BNBDC2,"Cramer Remix: Thanks to Apple & Samsung, this group just ...",2017-04-19 23:13:00 +0000,http://finance.yahoo.com/video/cramer-remix-thanks-apple-samsung-231300918.html?.tsrc=rss,Jim Cramer uncovers one group that could get a lot juicier in the tech space.
LLY,LLY:US,BBG000BNBDC2,"Cramer Remix: Thanks to Apple and Samsung, this group just got its mojo back",2017-04-19 22:59:56 +0000,http://finance.yahoo.com/r/9eb70f5d-fd83-3b79-b0bc-52b6698adf20/104412808?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104412808&yptr=yahoo&.tsrc=rss,Jim Cramer uncovers one group that could get a lot juicier in the tech space.
LLY,LLY:US,BBG000BNBDC2,"Cramer Remix: Thanks to Apple and Samsung, this group just got its mojo back",2017-04-19 22:59:56 +0000,http://finance.yahoo.com/news/cramer-remix-thanks-apple-samsung-225956438.html?.tsrc=rss,Jim Cramer uncovers one group that could get a lot juicier in the tech space.
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : April 19, 2017",2017-04-19 19:06:46 +0000,http://finance.yahoo.com/r/b1454340-6ead-385a-802d-e07c64193b3c/eli-lilly-co-value-analysis-nyselly-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Eli Lilly & Co. a score of 69. Our analysis is based on comparing Eli Lilly & Co. with the following peers – Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, AbbVie, Inc., Roche Holding Ltd ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY,2017-04-19 15:41:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-154100774.html?.tsrc=rss,"NEW YORK, April 19, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company (""Eli Lilly"" or the ""Company"") (NYSE: LLY).  Such investors ..."
LLY,LLY:US,BBG000BNBDC2,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 11:57:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-fda-crl-115711490.html?.tsrc=rss,Incyte&apos;s (INCY) shares were hit by the FDA&apos;s complete response letter (CRL) for the company&apos;s rheumatoid arthritis drug.
LLY,LLY:US,BBG000BNBDC2,Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds?,2017-04-18 20:36:39 +0000,http://finance.yahoo.com/r/7ba7f433-5ab4-3ca3-836f-d13d5b62232a/could-lilly-outperform-these-bigger-rivals-on-strong-diabetes-meds?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly is set to outperform bigger drugmakers Novartis and Sanofi in terms of first-quarter diabetes sales.
LLY,LLY:US,BBG000BNBDC2,"FDA Rejects Eli Lilly, Incyte's Commercialization Application",2017-04-18 20:33:48 +0000,http://finance.yahoo.com/news/fda-rejects-eli-lilly-incytes-203348034.html?.tsrc=rss,Shares tumbled after agency did not approve the companies' rheumatoid arthritis treatment
LLY,LLY:US,BBG000BNBDC2,The 4 Best Dividend Stocks in Pharmaceuticals,2017-04-18 17:06:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/epOvHju2R5A/the-4-best-dividend-stocks-in-pharmaceuticals-cm775334,If you re looking for steadily growing income the pharmaceutical industry boasts plenty of dividend paying stocks Not all of them are created equal though and plenty of investors in this space have seen their payouts frozen or slashed in recent years as their leading products
LLY,LLY:US,BBG000BNBDC2,"Company News for April 18, 2017",2017-04-18 17:04:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u_ThZQj1IPI/company-news-for-april-18-2017-cm775323,160 160 160 Shares of Moneygram International Inc MGI rose 7 8 after Ant Financial hiked its bid for MoneyGram valuing the company at 1 2 billion 160 160 160 Eli Lilly and Company s LLY shares declined 4 1 after the company s drug to treat rheumatoid arthritis was
LLY,LLY:US,BBG000BNBDC2,"XLV, AMGN, MDT, LLY: Large Inflows Detected at ETF",2017-04-18 15:05:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KhK67evISnA/xlv-amgn-mdt-lly-large-inflows-detected-at-etf-cm775247,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 59 4 million dollar inflow that s a 0 4 increase week over week
LLY,LLY:US,BBG000BNBDC2,The 4 Best Dividend Stocks in Pharmaceuticals,2017-04-18 15:04:00 +0000,http://finance.yahoo.com/r/c46662c2-0dbb-3e46-b8d2-7d7376f59b9f/the-4-best-dividend-stocks-in-pharmaceuticals.aspx?yptr=yahoo&.tsrc=rss,Find out how these pharma stocks could boost your dividend growth portfolio’s performance.
LLY,LLY:US,BBG000BNBDC2,Insiders Bullish on Certain Holdings of DVY,2017-04-18 14:56:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mp5zdi32NIE/insiders-bullish-on-certain-holdings-of-dvy-cm775117,A look at the weighted underlying holdings of the iShares Select Dividend ETF DVY shows an impressive 14 2 of holdings on a weighted basis have experienced insider buying within the past six months CenturyLink Inc Symbol CTL which makes up 1 24 of the iShares Select Dividend
LLY,LLY:US,BBG000BNBDC2,"Company News for April 18, 2017",2017-04-18 14:52:02 +0000,http://finance.yahoo.com/news/company-news-april-18-2017-145202558.html?.tsrc=rss,"Companies in the News are: MGI,LLY,ASH,ALR,ABT"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : April 18, 2017",2017-04-18 12:54:23 +0000,http://finance.yahoo.com/r/53f8a35f-2af3-398d-8d64-958af6be82d2/eli-lilly-co-breached-its-50-day-moving-average-in-a-bearish-manner-lly-us-april-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Eli Lilly & Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day ... Read more
<b>(Read more...)</b>"
LLY,LLY:US,BBG000BNBDC2,What Happened in the Stock Market Today,2017-04-18 04:53:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vvng_26YgJs/what-happened-in-the-stock-market-today-cm774964,Stocks gained today largely led by financials with both the Dow Jones Industrial Average DJINDICES DJI 160 and the S amp P 500 SNPINDEX GSPC 160 indexes finishing up nearly a full percentage point Today s stock
LLY,LLY:US,BBG000BNBDC2,Asian stock markets mixed as North Korea tensions lessen,2017-04-18 03:52:10 +0000,http://finance.yahoo.com/news/us-stocks-start-higher-led-142024488.html?.tsrc=rss,Asian stocks were mixed Tuesday as tensions over the situation on the Korean Peninsula softened somewhat following U.S. Vice President Mike Pence's departure from South Korea for Japan. A strong post-Easter ...
LLY,LLY:US,BBG000BNBDC2,What Happened in the Stock Market Today,2017-04-18 03:23:00 +0000,http://finance.yahoo.com/r/3b4026a6-6549-38fd-8a91-811c4b11efa1/what-happened-in-the-stock-market-today.aspx?yptr=yahoo&.tsrc=rss,"Drugmakers get denied, Chipotle continues gains, and earnings season gets under way. Investors have remained optimistic ahead of what could be a tumultuous week."
LLY,LLY:US,BBG000BNBDC2,Cramer: Have Faith in International Strength,2017-04-17 23:01:00 +0000,http://finance.yahoo.com/r/66f442e7-adf5-3652-bbcd-bac0eb6c1a82/cramer-have-faith-international-strength?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Because there are other things that will take the wind out of your sails.
LLY,LLY:US,BBG000BNBDC2,"Why Snyder's-Lance, Incyte, and Tenet Healthcare Slumped Today",2017-04-17 22:55:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jw5u0CBLGYM/why-snyders-lance-incyte-and-tenet-healthcare-slumped-today-cm774904,The stock market did very well on Monday and the Dow and other major indexes climbed almost 1 on the day Investors seemed ready to embrace the new earnings season which many believe could be a lot stronger than previously anticipated and could spur another leg up in the bull
LLY,LLY:US,BBG000BNBDC2,70 Trades to Make Before Earnings Season,2017-04-17 22:54:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t94Z7UsCZYc/70-trades-to-make-before-earnings-season-cm774929,InvestorPlace Stock Market News Stock Advice amp Trading Tips During these busy times it pays to stay on top of the latest profit opportunities and today s blog post should be a great place to start After taking a close look at the latest data on institutional
LLY,LLY:US,BBG000BNBDC2,Billion dollar drug bust,2017-04-17 21:43:00 +0000,http://finance.yahoo.com/video/billion-dollar-drug-bust-214300736.html?.tsrc=rss,CNBC's Meg Tirrell takes a look at the next potential blockbuster drugs. With the &quot;Fast Money&quot; traders.
LLY,LLY:US,BBG000BNBDC2,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY...",2017-04-17 21:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMfSMx6z5us/gainers--losers-of-apr17-cbli-infi-pbyi-omed-incy-20170417-00923,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY..."
LLY,LLY:US,BBG000BNBDC2,The Biggest Loser: Eli Lilly Drops 4.1%,2017-04-17 21:22:00 +0000,http://finance.yahoo.com/r/9e5e6f7f-baf8-3310-a465-ca9953b20d6b/the-biggest-loser-eli-lilly-drops-4-1?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly and partner Incyte Corp. (  INCY  ) both fell today, on news that approval for its rheumatoid arthritis treatment baricitinib will be delayed at best, according to the complete response letter issued by the FDA.  Things looked different earlier this month when Incyte was the best performer in the S&P 500."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly shares are cratering after the FDA rejected a $1 billion arthritis drug on safety concerns,2017-04-17 20:59:45 +0000,http://finance.yahoo.com/news/eli-lilly-shares-cratering-fda-134413243.html?.tsrc=rss,"Lilly says the FDA needed additional data to ""characterize safety concerns across treatment arms"" and to determine ""the most appropriate doses."""
LLY,LLY:US,BBG000BNBDC2,"Why Amazon.com, Inc. (AMZN) Stock Will Keep Going Higher",2017-04-17 20:55:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tjjW26vKraU/why-amazoncom-inc-amzn-stock-will-keep-going-higher-cm774888,InvestorPlace Stock Market News Stock Advice amp Trading Tips When you have a 160 stock 160 like 160 Amazon com Inc NASDAQ AMZN that continues to inch higher every day and consistently outperform markets it is important to contextualize the performance of AMZN stock in
LLY,LLY:US,BBG000BNBDC2,Close Update: Stocks Rally as Bargain-Hunting Overshadows Geopolitical Tensions,2017-04-17 20:54:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D_pE1z90bo0/close-update-stocks-rally-as-bargain-hunting-overshadows-geopolitical-tensions-cm774867,Buoyed by bargain hunting and expectations for upbeat Q1 earnings from Wall Street heavyhitters this week starting with Bank of America BAC and Johnson amp Johnson JNJ Tuesday the benchmark averages closed substantially higher on Monday with the Nasdaq Composite in the green for
LLY,LLY:US,BBG000BNBDC2,"Why Snyder&apos;s-Lance, Incyte, and Tenet Healthcare Slumped Today",2017-04-17 20:47:12 +0000,http://finance.yahoo.com/r/69952bcb-e6f4-32cd-9972-8ce2813642c4/why-snyders-lance-incyte-and-tenet-healthcare-slum.aspx?yptr=yahoo&.tsrc=rss,"Despite a climbing market, these stocks fell. Find out why."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, Incyte Stocks Break Key Levels After FDA Drug Setback",2017-04-17 20:30:46 +0000,http://finance.yahoo.com/r/e6515a94-6dbf-3249-91f7-d9aaab9f7ee2/eli-lilly-incyte-dive-after-fda-doesnt-ok-rheumatoid-arthritis-drug?src=A00220A&yptr=yahoo&.tsrc=rss,Eli Lilly and Incyte shares plunged Monday morning after the FDA failed to approve their rheumatoid arthritis drug.
LLY,LLY:US,BBG000BNBDC2,"Led by banks, stocks jump after strong report from China",2017-04-17 20:28:32 +0000,http://finance.yahoo.com/r/d0728dbb-6556-3f2e-84fc-dcf0a09d8f99/us-stocks-start-higher-led-142024488.html?.tsrc=rss,NEW YORK (AP) — U.S. stocks bounced back from recent losses Monday after the Chinese government said that country's economy grew at a slightly faster pace in the first quarter. Banks jumped as interest rates recovered.
LLY,LLY:US,BBG000BNBDC2,"Apple, Facebook Get Price-Target Hikes; McDonald&apos;s A Buy",2017-04-17 20:23:35 +0000,http://finance.yahoo.com/r/c9151e15-f91a-3288-bc2e-461a2e3ce8ae/apple-facebook-get-price-target-hikes-mcdonalds-a-buy?src=A00220A&yptr=yahoo&.tsrc=rss,"Analyst actions on Monday included price-target hikes for Apple and Facebook, an upgrade for McDonald&apos;s and a downgrade for Eli Lilly."
LLY,LLY:US,BBG000BNBDC2,Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug?,2017-04-17 20:13:20 +0000,http://finance.yahoo.com/r/6d0ff6dd-72cc-3676-a973-21a9370d3686/can-lilly-survive-rheumatoid-arthritis-flop-on-breast-cancer-diabetes?src=A00220A&yptr=yahoo&.tsrc=rss,AbbVie will get some breathing room in rheumatoid arthritis after Eli Lilly and Incyte&apos;s drug caught an FDA delay.
LLY,LLY:US,BBG000BNBDC2,3 Reasons Ford Motor Company (F) Stock Is Still a Lemon,2017-04-17 19:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JAMuSJHM_Sg/3-reasons-ford-motor-company-f-stock-is-still-a-lemon-cm774858,InvestorPlace Stock Market News Stock Advice amp Trading Tips The shares of Ford Motor Company NYSE F have gotten off to a inauspicious start this year down about 7 Unfortunately this kind of performance has been the norm for some time 160 Since the summer of 2014 F
LLY,LLY:US,BBG000BNBDC2,Go Long International Business Machines Corp. (IBM) Stock With Confidence,2017-04-17 19:56:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uv3-cLXfTBA/go-long-international-business-machines-corp-ibm-stock-with-confidence-cm774855,InvestorPlace Stock Market News Stock Advice amp Trading Tips Back on March 21 I shared a bearish trade on International Business Machines Corp NYSE IBM that delivered more than 1 20 per share in profits With profits in hand and IBM earnings on tap this week I want to
LLY,LLY:US,BBG000BNBDC2,"3 Big Stock Charts for Monday: Eli Lilly and Co (LLY), J B Hunt Transport Services Inc (JBHT) and McDonald’s Corporation (MCD)",2017-04-17 18:56:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/irdUsj0V37E/3-big-stock-charts-for-monday-eli-lilly-and-co-lly-j-b-hunt-transport-services-inc-jbht-and-mcdonalds-corporation-mcd-cm774829,InvestorPlace Stock Market News Stock Advice amp Trading Tips Stocks are starting on a relatively strong foot this morning in response to the strong economic data from China The Dow Jones Industrial Average 160 is up 88 points as of this writing while the S amp P
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co (LLY) Stock Holders Choke on FDA Letter for Barictinib,2017-04-17 18:56:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sMKPbkwdJ9s/eli-lilly-and-co-lly-stock-holders-choke-on-fda-letter-for-barictinib-cm774828,InvestorPlace Stock Market News Stock Advice amp Trading Tips Eli Lilly and Co 160 NYSE LLY was the disaster of the day Monday falling about 4 on early trade after what was called a rejection of its anti arthritis drug barictinib 160 The morning s fall in LLY stock
LLY,LLY:US,BBG000BNBDC2,Why Incyte Corporation Stock Is Plunging Today,2017-04-17 18:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zui4mUT0bRY/why-incyte-corporation-stock-is-plunging-today-cm774788,What happened Shares of Incyte Corporation NASDAQ INCY fell by as much as 11 9 on Monday as a result of the FDA rejecting its once daily 160 rheumatoid arthritis pill baricitinib for safety and dosing reasons Although Eli Lilly NYSE LLY 160 stood the most to
LLY,LLY:US,BBG000BNBDC2,Lilly Uses ‘Horny Goat Weed’ to Fend Off Cialis Royalty Demands,2017-04-17 18:55:29 +0000,http://finance.yahoo.com/r/124e2a63-393f-34b3-a675-958f2621719c/lilly-uses-horny-goat-weed-to-fend-off-cialis-royalty-demands?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. told a federal jury that a German company is trying to take credit for centuries-old Chinese medicine in seeking royalties on the use of its erectile-dysfunction drug Cialis to treat an ...
LLY,LLY:US,BBG000BNBDC2,5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates,2017-04-17 18:53:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j9W4NfDGcZU/5-major-drug-stocks-likely-to-beat-q1-earnings-estimates-cm774773,Pharma and biotech stocks had a difficult 2016 fraught with headwinds mainly related to drug pricing issues Though the drug pricing issues still persist the industry has nonetheless picked up backed by strong results FDA approvals success of new products and significant contributions
LLY,LLY:US,BBG000BNBDC2,Lilly's New-Drug Promise Is Fading,2017-04-17 18:06:12 +0000,http://finance.yahoo.com/r/55141f93-0694-3984-ae63-2f97dd4bbcd7/eli-lilly-baricitinib-delay-makes-stock-valuation-even-shakier?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Each new pipeline setback makes its sky-high valuation shakier.
LLY,LLY:US,BBG000BNBDC2,"Lots of calls on the Street: McDonald's, Apple and more",2017-04-17 18:00:00 +0000,http://finance.yahoo.com/video/lots-calls-street-mcdonalds-apple-180000773.html?.tsrc=rss,The &quot;Halftime Report&quot; traders discuss Monday's biggest calls on the Street.
LLY,LLY:US,BBG000BNBDC2,"Incyte, Eli Lilly Tumble As FDA Delays Arthritis Drug Approval",2017-04-17 17:55:00 +0000,http://finance.yahoo.com/r/55af2705-1e5c-389a-b28a-d57b39f77cd5/incyte-eli-lilly-tumble-as-fda-delays-arthritis-drug-approval?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte Corp. (  INCY  ) and Eli Lilly (  LLY  ) are both falling Monday, on news that the FDA issued a complete response letter concerning its rheumatoid arthritis treatment baricitinib, delaying approval.  The FDA didn't kill the drug, but it didn’t approve it either, saying that more clinical trials would be needed to determine the correct dosage.  Of course, more trials will increase the time and money that the companies will have to spend on baricitinib before its approval.  Incyte and Lilly both said they are committed to working with the agency to get approval."
LLY,LLY:US,BBG000BNBDC2,Midday Update: Market Averages Trade Higher as Bargain-Hunting Overshadows Geopolitical Risks,2017-04-17 17:34:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wLvupU35nTo/midday-update-market-averages-trade-higher-as-bargain-hunting-overshadows-geopolitical-risks-cm774766,The S amp P 500 was higher for the first time in four days as Wall Street shifts its focus to Q1 earnings reports and away from recent geopolitical tensions and downbeat U S economic data Although flows into most safe havens continues bargain hunting in beaten down sectors like financials
LLY,LLY:US,BBG000BNBDC2,5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates,2017-04-17 17:03:05 +0000,http://finance.yahoo.com/news/5-major-drug-stocks-likely-170305134.html?.tsrc=rss,2017 is expected to be a strong year for drug stocks.
LLY,LLY:US,BBG000BNBDC2,Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly,2017-04-17 16:55:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BlP7p0mhnE0/health-etfs-wobble-as-fda-spurns-arthritis-drug-in-blow-to-eli-lilly-cm774697,Exchange traded funds tracking major stock indexes rose on Monday despite a stunning 160 setback to the health sector 160 as the FDA rejected 160 an Eli Lilly LLY drug to treat rheumatoid arthritis SPDR S amp P 500 SPY added 0 3 shortly after the opening bell
LLY,LLY:US,BBG000BNBDC2,Why Incyte Corporation Stock Is Plunging Today,2017-04-17 16:47:00 +0000,http://finance.yahoo.com/r/40dc06f3-2b78-358a-8787-7a551c52af80/why-incyte-corporation-stock-is-plunging-today.aspx?yptr=yahoo&.tsrc=rss,Shares of Incyte and Eli Lilly are reeling following the FDA&apos;s rejection of their once-daily rheumatoid arthritis pill.
LLY,LLY:US,BBG000BNBDC2,FDA rejects Eli Lilly's arthritis drug,2017-04-17 16:11:04 +0000,https://www.yahoo.com/news/fda-rejects-eli-lillys-arthritis-161104646.html?.tsrc=rss,Shares of Eli Lilly and partner Incyte drop after the U.S. Food and Drug Administration declines to approve a new drug for rheumatoid arthritis. Roselle Chen reports.
LLY,LLY:US,BBG000BNBDC2,"Today&apos;s charts: Netflix, United Airlines earnings on tap; Eli Lilly shares drop; Wells Fargo&apos;s bullish call on McDonald&apos;s",2017-04-17 16:02:46 +0000,http://finance.yahoo.com/news/todays-charts-netflix-united-airlines-earnings-tap-eli-lilly-shares-drop-wells-fargos-bullish-call-mcdonalds-160246437.html?.tsrc=rss,"Yahoo Finance is tracking Netflix, United Airlines, Eli Lilly and McDonald’s in intraday trading on Monday. Netflix and United Airlines are set to report earnings after the bell Monday."
LLY,LLY:US,BBG000BNBDC2,Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma,2017-04-17 15:57:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bG7ds7owJSQ/zoetis-zts-inks-agreement-to-acquire-nexvet-biopharma-cm774639,Zoetis Inc ZTS announced an agreement to buy Nexvet Biopharma plc NVET for an aggregate equity valuation of approximately 85 million Nexvet is a biologic therapeutics company developing monoclonal antibody mAb therapies for companion animals Per the agreement Zoetis will pay 6 72
LLY,LLY:US,BBG000BNBDC2,"S&P 500 Movers: INCY, ARNC",2017-04-17 15:57:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BFfG1zqwL8A/sp-500-movers-incy-arnc-cm774649,In early trading on Monday shares of Arconic ARNC topped the list of the day s best performing components of the S amp P 500 index trading up 7 8 Year to date Arconic registers a 50 6 gain And the worst performing S amp P 500 component thus far on the day is Incyte
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.,2017-04-17 15:57:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BGZ6MlHNNDs/eli-lillys-rheumatoid-arthritis-drug-gets-crl-in-the-us-cm774628,Eli Lilly and Company LLY and its partner Incyte Corporation INCY recently announced that they have received a Complete Response Letter CRL from the FDA regarding the new drug application NDA for baricitinib Lilly was seeking approval of baricitinib for the treatment of moderate to
LLY,LLY:US,BBG000BNBDC2,Cancer biotech Zymeworks sets terms for $65 million IPO,2017-04-17 15:55:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nn7Ylrux4Zs/cancer-biotech-zymeworks-sets-terms-for-65-million-ipo-cm774634,Zymeworks an early stage biotech developing antibodies that target HER2 tumors announced terms for its IPO on Monday The Vancouver Canada based company plans to raise 65 million by offering 4 5 million shares at a price range of 13 to 16 Insiders intend to purchase 42 million worth
LLY,LLY:US,BBG000BNBDC2,[$$] FDA arthritis drug rejection hits Eli Lilly shares,2017-04-17 15:20:52 +0000,"http://finance.yahoo.com/r/7dd0deea-00b5-3a9c-bd20-6744a5d38bdf/abc4818c-237a-11e7-a34a-538b4cb30025,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Investors wiped a combined $6bn from the market value of Eli Lilly and its biotech partner Incyte on Monday after the US medicines regulator rejected their new arthritis medicine. In a letter to the companies, ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Company -- Moody's: Lilly's baricitinib delay in US credit negative,2017-04-17 15:09:07 +0000,http://finance.yahoo.com/r/453cdb78-4c3e-3a08-86c3-23a5e2a0286a/viewresearchdoc.aspx?docid=PR_365226&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX0NWX1JhdGluZ19OZXdzX0FsbF9Fbmc=~20170417_PR_365226&yptr=yahoo&.tsrc=rss,"Announcement: Moody's: Lilly's baricitinib delay in US credit negative. Global Credit Research- 17 Apr 2017. New York, April 17, 2017-- Moody's Investors Service commented that the announcement that the ..."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly falls, United changes policy, Amazon&apos;s possible interest in BJ Wholesale and M&T Bank beats",2017-04-17 14:54:00 +0000,http://finance.yahoo.com/news/eli-lilly-falls-united-changes-policy-amazons-possible-interest-bj-wholesale-mt-bank-beats-145400617.html?.tsrc=rss,"Stocks to watch: Eli Lilly falls, United changes policy, Amazon&apos;s possible interest in BJ Wholesale, M&T Bank beats"
LLY,LLY:US,BBG000BNBDC2,Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly,2017-04-17 14:52:59 +0000,http://finance.yahoo.com/r/01e6b672-8992-3020-b187-eaf701a0f6c3/health-etfs-wobble-as-fda-spurns-arthritis-drug-in-blow-to-eli-lilly?src=A00220&yptr=yahoo&.tsrc=rss,The arthritis treatment was expected to generate more than $1 billion in sales by 2020.
LLY,LLY:US,BBG000BNBDC2,Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly,2017-04-17 14:52:59 +0000,http://finance.yahoo.com/r/01e6b672-8992-3020-b187-eaf701a0f6c3/health-etfs-wobble-as-fda-spurns-arthritis-drug-in-blow-to-eli-lilly?src=A00220A&yptr=yahoo&.tsrc=rss,The arthritis treatment was expected to generate more than $1 billion in sales by 2020.
LLY,LLY:US,BBG000BNBDC2,"Gilead, Pfizer, AbbVie Win From Lilly's Loss",2017-04-17 14:51:00 +0000,http://finance.yahoo.com/r/1ef8ca2d-7983-3fbe-a999-6671c00b9621/gilead-pfizer-abbvie-win-from-lilly-s-loss.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
LLY,LLY:US,BBG000BNBDC2,FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte,2017-04-17 14:20:54 +0000,http://finance.yahoo.com/news/fda-delivers-big-rheumatoid-athritis-142054127.html?.tsrc=rss,"When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment."
LLY,LLY:US,BBG000BNBDC2,Incyte Continues To Post Steep Loss After Initial Sell-Off,2017-04-17 13:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CuKxaNDtKvY/incyte-continues-to-post-steep-loss-after-initial-selloff-20170417-00613,Incyte Continues To Post Steep Loss After Initial Sell-Off
LLY,LLY:US,BBG000BNBDC2,Profit from These 5 Sturdy Stocks as Fear Grips Markets,2017-04-17 13:58:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nbDvnYWesiE/profit-from-these-5-sturdy-stocks-as-fear-grips-markets-cm774490,The use of the Mother of All Bombs on Afghanistan to wipe out Islamic terrorists has been quite a geopolitical concern for traders This is understandable especially at a time when ties between the U S and Russia are strained thanks to the indiscriminate gassing of children in Syria
LLY,LLY:US,BBG000BNBDC2,What's in the Cards for IDEX (IEX) this Earnings Season?,2017-04-17 13:57:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A3KKI14nfKA/whats-in-the-cards-for-idex-iex-this-earnings-season-cm774477,Industrial goods manufacturer IDEX Corporation IEX is scheduled to report first quarter 2017 results after the closing bell on Apr 19 In the last reported quarter adjusted earnings beat the Zacks Consensus Estimate by 3 cents IDEX s earnings track record has been quite healthy having
LLY,LLY:US,BBG000BNBDC2,Stock Futures Turn Positive; Empire State Manufacturing Index Dives in April,2017-04-17 13:55:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oMxN4sKYy6U/stock-futures-turn-positive-empire-state-manufacturing-index-dives-in-april-cm774519,Futures flipped to the plus column ahead of Monday s open as Wall Street struggles for direction amid lingering geopolitical tensions against the backdrop of Q1 earnings Early pressure on futures associated with continued saber rattling in North Korean and bearish U S economic data Friday
LLY,LLY:US,BBG000BNBDC2,Eli Lilly&apos;s Rheumatoid Arthritis Drug Gets CRL in the U.S.,2017-04-17 13:47:01 +0000,http://finance.yahoo.com/news/eli-lilly-apos-rheumatoid-arthritis-134701278.html?.tsrc=rss,Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
LLY,LLY:US,BBG000BNBDC2,"Stocks Open Higher: McDonald&apos;s, Apple Rise On The Dow",2017-04-17 13:46:05 +0000,http://finance.yahoo.com/r/d1dfa7e4-98f1-345d-9b0c-194c111d0f54/stock-futures-positive-alibaba-abbott-labs-lilly-stir-early-trade?src=A00220A&yptr=yahoo&.tsrc=rss,"Stocks opened higher Monday, despite a weak reading on New York manufacturing activity in April."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly shares are cratering after the FDA rejected a $1 billion arthritis drug on safety concerns,2017-04-17 13:44:13 +0000,http://finance.yahoo.com/r/5ff88747-6a87-3e40-b909-f7ea99cd6adc/104407007?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104407007&yptr=yahoo&.tsrc=rss,"Lilly says the FDA needed additional data to ""characterize safety concerns across treatment arms"" and to determine ""the most appropriate doses."""
LLY,LLY:US,BBG000BNBDC2,Lilly and Incyte&apos;s Loss Is AbbVie and Regeneron&apos;s Gain,2017-04-17 13:40:00 +0000,http://finance.yahoo.com/r/0b3708c7-2ac3-3fd3-9623-bcc484b45d72/lilly-and-incytes-loss-is-abbvie-and-regenerons-ga.aspx?yptr=yahoo&.tsrc=rss,The FDA has rejected Eli Lilly and Incyte&apos;s application for approval of a potential blockbuster rheumatoid arthritis drug.
LLY,LLY:US,BBG000BNBDC2,"Biotech Movers: OncoMed, Incyte, Omeros",2017-04-17 13:28:00 +0000,http://finance.yahoo.com/r/c5adf711-4efa-3b91-a0f2-c2d941f017c6/biotech-movers-oncomed-incyte-omeros.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Stock Falls Premarket After FDA Rejects Arthritis Drug Due to Safety Concerns,2017-04-17 13:14:00 +0000,http://finance.yahoo.com/r/c4d3f90c-8ae0-3752-8782-decb5a993823/eli-lilly-stock-falls-premarket-after-fda-rejects-arthritis-drug-due-to-safety-concerns.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The drug was expected to bring in more than $1 billion in sales by 2020.
LLY,LLY:US,BBG000BNBDC2,US STOCKS-Wall Street looks set to open slightly higher,2017-04-17 12:59:47 +0000,http://finance.yahoo.com/news/us-stocks-wall-street-looks-125947604.html?.tsrc=rss,"Wall Street was on track to open  slightly higher on Monday as oil prices trimmed losses, but  gains may be limited by geopolitical tensions and soft U.S.  data.  Wall Street was closed for the Good Friday holiday."
LLY,LLY:US,BBG000BNBDC2,"FDA Complete Response Smacks LLY & INCY, What Now?",2017-04-17 12:57:00 +0000,http://finance.yahoo.com/r/a778fc67-cb2f-36ca-a54f-069c4864cf98/fda-complete-response-smacks-lly-incy-what-now?partner=YahooSA&yptr=yahoo&.tsrc=rss,The FDA's complete response letter has beaten the stuffing out of Incyte and Eli Lilly this morning. We examine the implications for the firm.
LLY,LLY:US,BBG000BNBDC2,"Pre-Market Most Active for Apr 17, 2017 :  ALR, SWC, MGI, BAC, XIV, LLY, XXIA, INCY, QQQ, TLT, F, KEP",2017-04-17 12:54:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMQoFVs57Ug/pre-market-most-active-for-apr-17-2017-alr-swc-mgi-bac-xiv-lly-xxia-incy-qqq-tlt-f-kep-cm774467,The NASDAQ 100 Pre Market Indicator is up 5 57 to 5 359 16 The total Pre Market volume is currently 2 311 062 shares traded The following are the most active stocks for the pre market session Alere Inc ALR is 7 13 at 49 44 with 3 141 855 shares traded As reported
LLY,LLY:US,BBG000BNBDC2,Profit from These 5 Sturdy Stocks as Fear Grips Markets,2017-04-17 11:51:11 +0000,http://finance.yahoo.com/news/profit-5-sturdy-stocks-fear-115111142.html?.tsrc=rss,Wall Street&apos;s fear gauge is breaking out higher as geopolitical risks heat up after the U.S. opted for &apos;Mother of All Bombs&apos;.
LLY,LLY:US,BBG000BNBDC2,FDA rejects LLY's rheumatoid arthritis drug,2017-04-17 11:45:00 +0000,http://finance.yahoo.com/video/fda-rejects-llys-rheumatoid-arthritis-114500798.html?.tsrc=rss,CNBC's Meg Tirrell takes a look at what the FDA's rejection of the drug means for Eli Lilly and partner Incyte.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Incyte stock drops after FDA fails to approve rheumatoid arthritis drug,2017-04-17 11:38:42 +0000,http://finance.yahoo.com/r/c6e08b7e-9131-3f50-8433-24ff7734195e/Story.aspx?guid=CEA8A0BC-EA23-4B48-BA33-4C9DC1AA62D9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. shares dropped 5.5% and Incyte Corp. shares dropped 12.7% in premarket trade Monday after the companies said that the Food and Drug Administration failed to approve their drug for moderate-to-severe ...
LLY,LLY:US,BBG000BNBDC2,Incyte (INCY) And Eli Lilly (LLY) Are Sinking After FDA Rejection,2017-04-17 09:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xg-7R6uxDEw/incyte-incy-and-eli-lilly-lly-are-sinking-after-fda-rejection-20170417-00429,Incyte (INCY) And Eli Lilly (LLY) Are Sinking After FDA Rejection
LLY,LLY:US,BBG000BNBDC2,Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis,2017-04-17 01:33:00 +0000,http://finance.yahoo.com/r/93e8e82a-0218-3aa6-b019-9d60cdbb8caa/gilead-pfizer-abbvie-stand-to-gain-from-lilly-incyte-rheumatoid-arthritis-pill-setback.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback."
LLY,LLY:US,BBG000BNBDC2,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move",2017-04-17 00:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o5ZlrIoIdS8/fda-says-no-to-incy-zts-snaps-up-nvet-mdxg-on-the-move-20170417-00004,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move"
LLY,LLY:US,BBG000BNBDC2,[$$] Surprise FDA Rejection Will Sting This Biotech,2017-04-15 04:33:37 +0000,http://finance.yahoo.com/r/eb138240-078b-359d-bbe1-5a6ec540a38c/surprise-fda-rejection-will-sting-this-biotech-1492185721?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.
LLY,LLY:US,BBG000BNBDC2,Company Spotlight: Incyte,2017-04-14 21:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Al1JAVq5xSQ/company-spotlight-incyte-20170414-00197,Company Spotlight: Incyte
LLY,LLY:US,BBG000BNBDC2,Lilly's rheumatoid arthritis pill rejected by regulators,2017-04-14 16:34:46 +0000,http://finance.yahoo.com/r/15864ea8-68a3-35fe-b821-a16f4d9665fd/lillys-rheumatoid-arthritis-pill-rejected-152727599.html?.tsrc=rss,"Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November."
LLY,LLY:US,BBG000BNBDC2,[$$] Surprise FDA Rejection Will Sting This Biotech,2017-04-14 16:02:04 +0000,http://finance.yahoo.com/r/eb138240-078b-359d-bbe1-5a6ec540a38c/surprise-fda-rejection-will-sting-this-biotech-1492185721?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.
LLY,LLY:US,BBG000BNBDC2,U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant,2017-04-14 15:00:18 +0000,http://finance.yahoo.com/news/u-fda-declines-approve-eli-150018238.html?.tsrc=rss,"The U.S. Food and Drug  Administration on Friday declined to approve a new drug for  rheumatoid arthritis made by Eli Lilly and Co and  partner Incyte Corp, the companies said on Friday.  The U.S. FDA indicated that additional clinical data was  needed to determine the most appropriate doses of the drug,  Olumiant, known also as baricitinib, and to further characterize  safety concerns across treatment arms.  The FDA's request for additional data possibly means more  than a year's delay for this important product for both  companies, and represents a break for other drugmakers who were  expected to face tough competition from Olumiant."
LLY,LLY:US,BBG000BNBDC2,How Biogen&apos;s Takeover Prospects Soured In Mere Months,2017-04-14 13:51:24 +0000,http://finance.yahoo.com/r/0f608109-e937-3acc-86e6-c22f9ff1e49b/merck-allergan-lilly-miss-on-biogen-but-ma-could-be-around-corner?src=A00220A&yptr=yahoo&.tsrc=rss,"Potential Biogen acquirers are now likely waiting until 2020, when Biogen is expected to unveil late-stage Alzheimer&apos;s data."
LLY,LLY:US,BBG000BNBDC2,U.S. FDA Issues Complete Response Letter for Baricitinib,2017-04-14 13:00:00 +0000,http://finance.yahoo.com/news/u-fda-issues-complete-response-130000039.html?.tsrc=rss,"INDIANAPOLIS, April 14, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA).  The letter indicates that the FDA is unable to approve the application in its current form.  Specifically, the FDA indicated that additional clinical data are needed to determine the most appropriate doses."
LLY,LLY:US,BBG000BNBDC2,U.S. FDA Issues Complete Response Letter for Baricitinib,2017-04-14 13:00:00 +0000,http://finance.yahoo.com/news/u-fda-issues-complete-response-130000860.html?.tsrc=rss,"Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration has issued a complete response letter for the New Drug Application of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis ."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib,2017-04-14 09:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EoxDsTJostg/eli-lilly-and-incyte-say-fda-issues-crl-for-baricitinib-20170414-00091,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib
LLY,LLY:US,BBG000BNBDC2,J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?,2017-04-13 16:57:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S72ixqilwjg/jj-jnj-to-kick-off-pharma-q1-earnings-will-it-beat-cm773890,We expect Johnson amp Johnson JNJ a healthcare bellwether to beat expectations when it reports first quarter 2017 results on Apr 18 before the opening bell Last quarter the company reported a positive earnings surprise of 1 28 J amp J s share price is up 8 8 so far this
LLY,LLY:US,BBG000BNBDC2,What's in the Cards for Omnicom (OMC) this Earnings Season?,2017-04-13 13:58:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QwMOwdRzBPg/whats-in-the-cards-for-omnicom-omc-this-earnings-season-cm773757,Global marketing and corporate communications firm Omnicom Group Inc OMC is scheduled to report first quarter 2017 results before the opening bell on Apr 18 In the last reported quarter earnings beat the Zacks Consensus Estimate by 2 cents Omnicom s earnings track record has been
LLY,LLY:US,BBG000BNBDC2,Company Spotlight: Incyte,2017-04-13 10:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/thqKkyD3yu8/company-spotlight-incyte-20170413-00737,Company Spotlight: Incyte
LLY,LLY:US,BBG000BNBDC2,How US Drugmakers Profit From China's Biotech Boom,2017-04-13 10:00:00 +0000,http://finance.yahoo.com/r/f80c0cc9-8c91-3b5a-9cdd-a99dbbec21f6/how-drugmakers-profit-china-biotech-boom-mrk-lly-tsro?partner=YahooSA&yptr=yahoo&.tsrc=rss,Major drug companies are partnering with Chinese biotech start-ups to create new drugs
LLY,LLY:US,BBG000BNBDC2,Healthcare Sector Earnings: Making A Comeback In Q1 2017?,2017-04-12 15:46:38 +0000,http://finance.yahoo.com/news/healthcare-sector-earnings-making-comeback-154638460.html?.tsrc=rss,"In 2016, healthcare was the only sector in the S&P 500 (SPX) that ended the year in the red, declining 2.7% versus a positive 12% return for the SPX. However, things appear to be looking up in 2017 with ..."
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for April 11: AAPL, WFC, T",2017-04-11 20:55:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b2xYpILltpY/top-research-reports-for-april-11-aapl-wfc-t-cm772971,Tuesday April 11 2017 Today s Research Daily features new research reports on 16 major stocks including Apple AAPL Wells Fargo WFC and AT amp T T Buy rated Apple shares have gained 22 over the last six months and have outperformed the broader market with the S amp P 500
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for April 11: AAPL, WFC, T",2017-04-11 17:51:05 +0000,http://finance.yahoo.com/news/top-research-reports-april-11-175105519.html?.tsrc=rss,"Top Research Reports for April 11: AAPL, WFC, T"
LLY,LLY:US,BBG000BNBDC2,ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study,2017-04-11 16:55:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UaUnL-kOs-g/anths-anth-blisibimod-completes-dosing-in-phase-iii-study-cm772771,Anthera Pharmaceuticals Inc ANTH recently announced the completion of dosing in a phase II study BRIGHT SC The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy IgAN Please note that blisibimod was acquired from Amgen Inc AMGN in Dec
LLY,LLY:US,BBG000BNBDC2,Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma,2017-04-11 15:09:00 +0000,http://finance.yahoo.com/r/05cd19a8-1f00-3e6a-9769-9d3af3464928/jim-cramer-eli-lilly-is-the-new-darling-of-big-pharma.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said."
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement,2017-04-11 15:00:00 +0000,http://finance.yahoo.com/news/lilly-confirms-date-conference-call-150000980.html?.tsrc=rss,"INDIANAPOLIS, April 11, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial results for the first quarter of 2017 on Tuesday, April 25, 2017.  Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 9 a.m. Eastern time."
LLY,LLY:US,BBG000BNBDC2,Analysts Keep Stacking Up Higher Targets and Expectations for Eli Lilly,2017-04-11 14:45:44 +0000,http://finance.yahoo.com/news/analysts-keep-stacking-higher-targets-144544236.html?.tsrc=rss,"Several analysts and market pundits have been positive toward Eli Lilly lately, including now a price target raise at JPMorgan."
LLY,LLY:US,BBG000BNBDC2,Cramer's Stop Trading:  Eli Lilly,2017-04-11 13:52:00 +0000,http://finance.yahoo.com/video/cramers-stop-trading-eli-lilly-135200157.html?.tsrc=rss,CNBC's Jim Cramer explains why buyers go to Eli Lilly first on any dip.
LLY,LLY:US,BBG000BNBDC2,PRESS DIGEST - Wall Street Journal - April 11,2017-04-11 05:32:03 +0000,http://finance.yahoo.com/news/press-digest-wall-street-journal-053203290.html?.tsrc=rss,The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - The Trump administration held out the prospect Monday of wider ...
LLY,LLY:US,BBG000BNBDC2,[$$] China Emerges as Powerhouse for Biotech Drugs,2017-04-11 04:09:36 +0000,http://finance.yahoo.com/r/41adf4f1-460e-3aa4-a89b-d3e624b354b8/china-emerges-as-powerhouse-for-biotech-drugs-1491816607?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"China, long the world’s supplier of cheap pharmaceutical ingredients and copycat pills, is emerging as a major producer of important new medicines: biotech drugs. And big drug companies around the globe ..."
LLY,LLY:US,BBG000BNBDC2,[$$] Neurological Drug Firm Biohaven Pharmaceutical Plans IPO,2017-04-10 22:35:04 +0000,http://finance.yahoo.com/r/074765d3-128c-371d-b6f3-ade30eb8fdb6/neurological-drug-firm-biohaven-pharmaceutical-plans-ipo-1491863699?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"After raising more than $100 million privately, Biohaven Pharmaceutical Holding Co. has filed for a $100 million initial public offering in a bid to deliver another win for venture investors in the market ..."
LLY,LLY:US,BBG000BNBDC2,Merck's Bid to Add Cardiovascular Data on Januvia Label Fails,2017-04-10 16:55:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PAtKqm2pC-k/mercks-bid-to-add-cardiovascular-data-on-januvia-label-fails-cm772224,Merck amp Co Inc MRK announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug Januvia sitagliptin and other medicines containing Januvia The FDA issued a complete response letter to Merck s supplemental new drug
LLY,LLY:US,BBG000BNBDC2,Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549,2017-04-10 15:58:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C7gad6SeO50/infinity-pharmaceuticals-focuses-on-lead-candidate-ipi-549-cm772184,We issued an updated report on Infinity Pharmaceuticals Inc INFI on Apr 7 Infinity s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date The stock rose 79 3 compared with the industry s gain of 0 2 The company is
LLY,LLY:US,BBG000BNBDC2,"XLV, LLY, ABT, AET: ETF Inflow Alert",2017-04-10 15:55:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BbvJ49RRoik/xlv-lly-abt-aet-etf-inflow-alert-cm772112,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 89 3 million dollar inflow that s a 0 6 increase week over week
LLY,LLY:US,BBG000BNBDC2,5 Pharmaceutical Stocks With the Most Reliable Dividends,2017-04-09 12:54:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cJevdJIwjnM/5-pharmaceutical-stocks-with-the-most-reliable-dividends-cm771822,What s the one thing that dividend seeking investors value the most Several answers could arguably be correct but I suspect that the best answer of all is reliability If you re looking for dividend stocks you want their dividends to be reliable Several pharmaceutical
LLY,LLY:US,BBG000BNBDC2,5 Pharmaceutical Stocks With the Most Reliable Dividends,2017-04-09 11:22:00 +0000,http://finance.yahoo.com/r/48df9374-1b78-3312-ad08-6d30133f34d5/5-pharmaceutical-stocks-with-the-most-reliable-div.aspx?yptr=yahoo&.tsrc=rss,"Johnson & Johnson, Abbott Labs, AbbVie, Novo Nordisk, and Novartis rank as the top drug stocks with the best dividend track records."
LLY,LLY:US,BBG000BNBDC2,Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC,2017-04-07 22:53:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XNabRWKDviI/novartis-nvs-in-licenses-ophthalmic-drug-from-lubris-llc-cm771639,Novartis AG NVS recently announced that it has exercised an option to in license ECF843 for ophthalmic indications worldwide outside Europe from Lubris LLC A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks classified
LLY,LLY:US,BBG000BNBDC2,Barclays Sees Positive Catalysts Ahead for Eli Lilly,2017-04-07 18:54:00 +0000,http://finance.yahoo.com/r/004a3471-2d81-30d1-aa29-72a12efd2aeb/barclays-sees-positive-catalysts-ahead-for-eli-lilly.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Barclays has an 'overweight' rating on Eli Lilly stock.
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: More Catalysts Ahead,2017-04-07 18:24:00 +0000,http://finance.yahoo.com/r/a0af9cf7-9330-3d3c-9a4b-1f636f2e0c30/eli-lilly-more-catalysts-ahead?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. (LLY) is fractionally lower Friday, but Barclays sees the shares, up 16% so far this year, gaining more. Analyst Geoff Meacham and Paul Choi reiterated an Overweight rating on the stock ..."
LLY,LLY:US,BBG000BNBDC2,Analyzing the Performance of Eli Lilly Stock in 1Q17,2017-04-07 15:57:51 +0000,http://finance.yahoo.com/r/cb9c9d0b-5f63-3774-bbe6-cf03b278e61f/analyzing-the-performance-of-eli-lilly-stock-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Eli Lilly and Company (LLY) is a US pharmaceutical company dealing with both human pharmaceuticals and animal health.
LLY,LLY:US,BBG000BNBDC2,Merck's Diabetes Franchise And The Perils In Proving A Drug's Medical Value,2017-04-07 15:19:00 +0000,http://finance.yahoo.com/r/b03da25a-1883-3bb4-94ed-28bb915f0fdf/mercks-diabetes-franchise-and-the-perils-in-proving-a-drugs-medical-value?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"To get good pricing for a new medicine, you have to prove its value. In these two examples, Lilly came out on top."
LLY,LLY:US,BBG000BNBDC2,"Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences",2017-04-07 14:00:00 +0000,http://finance.yahoo.com/news/life-type-1-diabetes-made-140000096.html?.tsrc=rss,"INDIANAPOLIS, ARLINGTON, Va. and ROLLING MEADOWS, Ill., April 7, 2017 /PRNewswire/ -- Living with type 1 diabetes comes with many unique challenges in all stages of life.  To help support people with diabetes and those who love them, Lilly Diabetes today announced it will donate $94,000 to the American Diabetes Association (Association) Campership program and $100,000 to the Diabetes Scholars Foundation (Foundation).  Both donations are part of Lilly's longstanding commitment to give people with diabetes access to education, community and inspiration."
LLY,LLY:US,BBG000BNBDC2,FDA rejects Merck's bid to add heart data on diabetes drug labels,2017-04-07 13:28:39 +0000,http://finance.yahoo.com/news/fda-rejects-mercks-application-add-121455255.html?.tsrc=rss,"Merck & Co Inc said the U.S.  Food and Drug Administration (FDA) declined an application to  include information on the labels of its diabetes drugs -  Januvia and Janumet - that the treatments do not raise the risk  of major heart problems.  Merck is reviewing the regulator's response to its  application, the company said on Friday.  Some 29 million Americans have diabetes, but even when  glucose levels are under control, the disease greatly increases  the risk of heart disease and stroke, according to the American  Heart Association."
LLY,LLY:US,BBG000BNBDC2,The Mutual Fund That Is a Top 10 Guru,2017-04-05 18:09:41 +0000,http://finance.yahoo.com/news/mutual-fund-top-10-guru-180941099.html?.tsrc=rss,"With an average annual return of 10.2% over the past 10 years, Vanguard ranks 6th on the GuruFocus Score Board"
LLY,LLY:US,BBG000BNBDC2,AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA,2017-04-05 16:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x6HKZE064os/abbviejjs-imbruvica-label-expansion-filing-accepted-by-fda-cm770240,AbbVie Inc ABBV and partner Janssen Johnson amp Johnson s JNJ pharmaceuticals subsidiary announced that a supplemental new drug application sNDA for their cancer drug Imbruvica has been accepted for review by the FDA AbbVie is looking to get Imbruvica approved for the treatment
LLY,LLY:US,BBG000BNBDC2,5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now,2017-04-05 15:27:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sZRcWR8_Pe8/5-reasons-to-invest-in-eli-lilly-lly-stock-right-now-cm770127,Indianapolis IN based Eli Lilly and Company LLY is a global healthcare company which enjoys presence across a wide range of therapeutic areas including neuroscience oncology endocrinology immunology and cardiovascular which are all high growth areas and represent significant
LLY,LLY:US,BBG000BNBDC2,AbbVie/J&J&apos;s Imbruvica Label Expansion Filing Accepted by FDA,2017-04-05 15:17:03 +0000,http://finance.yahoo.com/news/abbvie-j-j-apos-imbruvica-151703650.html?.tsrc=rss,"AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson&apos;s (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA."
LLY,LLY:US,BBG000BNBDC2,5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now,2017-04-05 13:16:01 +0000,http://finance.yahoo.com/news/5-reasons-invest-eli-lilly-131601284.html?.tsrc=rss,Lily carries a Zacks Rank #2 (Buy).
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for April 4: XOM, CL, HON",2017-04-04 22:24:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BmJdYCwRKWY/top-research-reports-for-april-4-xom-cl-hon-cm769908,Tuesday April 4 2017 Today s Research Daily features new research reports on 16 major stocks including ExxonMobil XOM Colgate Palmolive CL and Honeywell HON ExxonMobil shares tracked the S amp P 500 index through year end 2016 but have lagged the broader index as well as the
LLY,LLY:US,BBG000BNBDC2,"Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC",2017-04-04 21:24:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O4lDwTmfOeY/novartis-tafinlar-mekinist-get-eu-approval-for-nsclc-cm769828,Novartis AG NVS recently announced that the European Commission has approved Tafinlar dabrafenib in combination with Mekinist trametinib for the treatment of patients with BRAF V600 positive advanced or metastatic non small cell lung cancer NSCLC A look at Novartis share
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for April 4: XOM, CL, HON",2017-04-04 19:31:07 +0000,http://finance.yahoo.com/news/top-research-reports-april-4-193107931.html?.tsrc=rss,"Top Research Reports for April 4: XOM, CL, HON"
LLY,LLY:US,BBG000BNBDC2,Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students,2017-04-04 17:00:00 +0000,http://finance.yahoo.com/news/lilly-ohio-university-heritage-college-170000413.html?.tsrc=rss,"INDIANAPOLIS, April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (LLY) innovative rotation program for aspiring physicians.  Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, from drug discovery and development to bioethics and patient safety.  The Heritage College is one of four medical schools to partner with Lilly on its Medical Student Rotation Program, joining Indiana University School of Medicine, Tulane University School of Medicine, and Washington University School of Medicine."
LLY,LLY:US,BBG000BNBDC2,Democrats found a way to speak Trump&apos;s language in pharma debate,2017-04-04 15:45:40 +0000,http://finance.yahoo.com/news/democrats-found-a-way-to-speak-trumps-language-in-pharma-debate-154540390.html?.tsrc=rss,"The members of congress introduced a bill related to the talk last week.  A quartet of Democratic members of Congress introduced a bill last week in harmony with President Donald Trump’s campaign promises of lowering prescription drug costs.  Entitled the Improving Access to Affordable Prescription Drugs Act, the 128-page bill aims to overhaul what many view as a broken system that has seen bipartisan outrage over skyrocketing prices."
LLY,LLY:US,BBG000BNBDC2,"United Therapeutics Tanks, Remodulin Pump Launch Delayed",2017-04-04 13:39:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bEXBWxoB3r4/united-therapeutics-tanks-remodulin-pump-launch-delayed-cm769423,United Therapeutics Corporation UTHR shares plunged around 9 on Monday after the company announced that regulatory issues will delay the planned U S launch of RemoSynch an implantable pump for delivering Remodulin The company now expects to launch RemoSynch sometime in 2018 against the
LLY,LLY:US,BBG000BNBDC2,What Wall Street Analysts Are Saying about Eli Lilly,2017-04-04 11:36:02 +0000,http://finance.yahoo.com/r/8c3985bf-1482-37c4-8cbe-66724a6bf334/what-wall-street-analysts-are-saying-about-eli-lilly?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) reported EPS (earnings per share) of $2.58 on revenue of $21.2 billion in 2016, compared to EPS of $2.26 on revenue of $20.0 million in 2015."
LLY,LLY:US,BBG000BNBDC2,Recent Developments at Eli Lilly,2017-04-03 14:37:59 +0000,http://marketrealist.com/2017/03/recent-developments-at-eli-lilly/?utm_source=yahoo&utm_medium=feed,Recent Developments at Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Recent Developments at Eli Lilly,2017-04-03 14:37:59 +0000,http://finance.yahoo.com/r/7866355e-0cbb-308b-89a4-bf63fda1c12a/recent-developments-at-eli-lilly?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As discussed earlier, both Eli Lilly's (LLY) Human Pharmaceuticals and Animal Health segments' performances were positive in 2016."
LLY,LLY:US,BBG000BNBDC2,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 13:38:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/72iKZWmPenc/4-fda-decisions-to-watch-out-for-in-apr-2017-cm768879,The FDA which approved 22 treatments last year has given its approval to 12 drugs so far in 2017 including 7 in March Key approvals this year include Roche s RHHBY multiple sclerosis treatment Ocrevus Regeneron REGN and Sanofi s eczema treatment Dupixent Tesaro s TSRO PARP
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly’s Elanco Performed in 2016,2017-04-03 13:06:16 +0000,http://marketrealist.com/2017/03/how-eli-lillys-elanco-performed-in-2016/?utm_source=yahoo&utm_medium=feed,How Eli Lilly’s Elanco Performed in 2016
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly’s Elanco Performed in 2016,2017-04-03 13:06:16 +0000,http://finance.yahoo.com/r/6adfd86a-074c-31bb-9b07-73096eeb5c4e/how-eli-lillys-elanco-performed-in-2016?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Eli Lilly's (LLY) Animal Health segment's company, Elanco, reported a fall of 1% in its revenue to $3.16 billion in 2016, compared to $3.18 billion in 2015."
LLY,LLY:US,BBG000BNBDC2,Pfizer's Ibrance Gets FDA Approval for Breast Cancer,2017-04-03 12:49:00 +0000,http://finance.yahoo.com/r/42e902c1-9cd6-38d7-8194-cb1f38a1b285/pfizers-ibrance-gets-fda-approval-breast-cancer-pfe?partner=YahooSA&yptr=yahoo&.tsrc=rss,Ibrance got FDA approval and an expanded Indication to treat metastatic breast cancer.
LLY,LLY:US,BBG000BNBDC2,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 11:41:11 +0000,http://finance.yahoo.com/news/4-fda-decisions-watch-apr-114111333.html?.tsrc=rss,"Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month."
LLY,LLY:US,BBG000BNBDC2,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 11:41:11 +0000,http://finance.yahoo.com/news/4-fda-decisions-watch-apr-114111333.html,4 FDA Decisions to Watch Out for in Apr 2017
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly’s New Products Performed in 2016,2017-04-03 11:36:16 +0000,http://marketrealist.com/2017/03/how-eli-lillys-new-products-performed-in-2016/?utm_source=yahoo&utm_medium=feed,How Eli Lilly’s New Products Performed in 2016
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks With Big News Coming in April,2017-04-02 17:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2_bq9BTaeoA/4-drug-stocks-with-big-news-coming-in-april-cm768806,Fill in the blank April brings Some might say that April brings April showers Others eyeing the calendar with dread might say that April brings tax day But for four drugmakers April brings big news that could be catalysts for their stocks Here s what s coming up this month
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,https://www.fool.com/investing/2017/04/02/4-drug-stocks-with-big-news-coming-in-april.aspx,4 Drug Stocks With Big News Coming in April
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,http://finance.yahoo.com/r/706729f1-72a5-3e3c-a956-8d7dbde1451c/4-drug-stocks-with-big-news-coming-in-april.aspx?yptr=yahoo&.tsrc=rss,"Major FDA decisions are on the way this month for Neurocrine, Incyte, Lilly, and BioMarin."
LLY,LLY:US,BBG000BNBDC2,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?,2017-03-31 16:21:20 +0000,http://www.investors.com/news/technology/will-trumps-fda-chill-innovation-or-speed-up-to-kill-astronomical-prices/?src=A00220A,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
LLY,LLY:US,BBG000BNBDC2,Exploring Eli Lilly’s Oncology Franchise in 2016,2017-03-31 14:36:14 +0000,http://marketrealist.com/2017/03/exploring-eli-lillys-oncology-franchise-in-2016/?utm_source=yahoo&utm_medium=feed,Exploring Eli Lilly’s Oncology Franchise in 2016
LLY,LLY:US,BBG000BNBDC2,BUZZ-AC Immune Ltd: Drops on block sale,2017-03-31 13:21:48 +0000,http://uk.finance.yahoo.com/news/buzz-ac-immune-ltd-drops-132148843.html,"[Reuters - UK Focus] - ** Shares of Swiss biotech AC Immune down 6.7 pct to $10.79 in light premarket trading on block sale ** Sources say Jefferies re-offered 1.9 mln shares at $11, roughly 5-pct discount to stock's $11.57 ..."
LLY,LLY:US,BBG000BNBDC2,Analyzing LLY’s Cardiovascular Franchise’s 2016 Performance,2017-03-31 11:36:25 +0000,http://marketrealist.com/2017/03/analyzing-llys-cardiovascular-franchises-2016-performance/?utm_source=yahoo&utm_medium=feed,Analyzing LLY’s Cardiovascular Franchise’s 2016 Performance
LLY,LLY:US,BBG000BNBDC2,Why Equal Weighted Mutual Funds Scoring Over Index Funds,2017-03-30 17:59:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jhMjnJeuuA4/why-equal-weighted-mutual-funds-scoring-over-index-funds-cm767869,Index funds that invest in different small mid and large cap companies in the same proportion are specifically known as equal weight index funds Investing in equal weight funds helps in reducing single stock risk and simultaneously generates attractive returns Investors interested in
LLY,LLY:US,BBG000BNBDC2,"Here's Why Halozyme Therapeutics, Inc Is Falling",2017-03-30 17:01:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vd4vvd58B2U/heres-why-halozyme-therapeutics-inc-is-falling-cm767852,What happened After reporting that enrollment in one of its early stage clinical trials has been temporarily suspended shares of Halozyme Therapeutics NASDAQ HALO a small cap biotech focused on creating products that help other drugs work better fell by as much as
LLY,LLY:US,BBG000BNBDC2,Interesting LLY Put And Call Options For May 12th,2017-03-30 16:00:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GLxZ1MmowDI/interesting-lly-put-and-call-options-for-may-12th-cm767732,Investors in Lilly Eli amp Co Symbol LLY saw new options begin trading today for the May 12th expiration At Stock Options Channel our YieldBoost formula has looked up and down the LLY options chain for the new May 12th contracts and identified one put and one call contract of
LLY,LLY:US,BBG000BNBDC2,Exploring the Performance of LLY’s Endocrine Franchise in 2016,2017-03-30 14:37:33 +0000,http://marketrealist.com/2017/03/exploring-the-performance-of-llys-endocrine-franchise-in-2016/?utm_source=yahoo&utm_medium=feed,Exploring the Performance of LLY’s Endocrine Franchise in 2016
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly’s Business Segments Performed in 2016,2017-03-30 13:08:07 +0000,http://marketrealist.com/2017/03/how-eli-lillys-business-segments-performed-in-2016/?utm_source=yahoo&utm_medium=feed,How Eli Lilly’s Business Segments Performed in 2016
LLY,LLY:US,BBG000BNBDC2,A Look Back at Eli Lilly’s 2016 Revenue Trends,2017-03-30 11:37:54 +0000,http://marketrealist.com/2017/03/a-look-back-at-eli-lillys-2016-revenue-trends/?utm_source=yahoo&utm_medium=feed,A Look Back at Eli Lilly’s 2016 Revenue Trends
LLY,LLY:US,BBG000BNBDC2,Hanmi/Beijing Hanmi and Innovent Enter into a Global Strategic Partnership to Co-develop a Novel Immuno-oncology Bispecific Antibody,2017-03-30 05:52:00 +0000,http://au.finance.yahoo.com/news/hanmi-beijing-hanmi-innovent-enter-055200174.html,"[Business Wire] - SEOUL, South Korea & BEIJING--(BUSINESSWIRE)-- Hanmi Pharmaceutical Co. Ltd (Hanmi) (KRX:128940), a Korea-based pharmaceutical company, and Innovent Biologics (Suzhou) Co. Ltd (Innovent), a China based ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Valuation Compared to Its Peers’,2017-03-29 20:50:35 +0000,http://marketrealist.com/2017/03/eli-lillys-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s Valuation Compared to Its Peers’
LLY,LLY:US,BBG000BNBDC2,"Noteworthy ETF Outflows: IYH, MDT, LLY, ABT",2017-03-29 16:00:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WwwItc4mvC8/noteworthy-etf-outflows-iyh-mdt-lly-abt-cm767240,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 39 0 million dollar outflow that s a 2 1 decrease week over week from 12 050
LLY,LLY:US,BBG000BNBDC2,Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe,2017-03-29 14:36:40 +0000,http://marketrealist.com/2017/03/cosentyx-continues-witness-solid-demand-psoriasis-therapy-european-markets/?utm_source=yahoo&utm_medium=feed,Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
LLY,LLY:US,BBG000BNBDC2,Will Novartis See Rise in Net Profit Margins in 2017?,2017-03-28 22:05:43 +0000,http://marketrealist.com/2017/03/novartis-expected-witness-rise-net-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Will Novartis See Rise in Net Profit Margins in 2017?
LLY,LLY:US,BBG000BNBDC2,110 Actions to Take on Today’s Market Dip,2017-03-28 18:59:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ijq67-6KFqM/110-actions-to-take-on-todays-market-dip-cm766860,InvestorPlace Stock Market News Stock Advice amp Trading Tips During these busy times it pays to stay on top of the latest profit opportunities and today s blog post should be a great place to start After taking a close look at the latest data on institutional
LLY,LLY:US,BBG000BNBDC2,What Analysts Recommend for Novartis in 2017,2017-03-28 18:45:44 +0000,http://marketrealist.com/2017/03/analysts-recommendations-novartis-2017/?utm_source=yahoo&utm_medium=feed,What Analysts Recommend for Novartis in 2017
LLY,LLY:US,BBG000BNBDC2,Call buyers make big bet on Eli Lilly,2017-03-28 17:29:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JOpF_uWnw7I/call-buyers-make-big-bet-on-eli-lilly-cm766793,Call buyers are making a bet on Eli Lilly LLY Tuesday More than 10 000 contracts of hte MAy 87 50 call have changed hands today against previous open interest of 354 contracts That volume includes a single lot of 8 989 contracts that moved shortly before noon That lot moved just short
LLY,LLY:US,BBG000BNBDC2,[$$] The Roundup,2017-03-28 13:24:31 +0000,https://www.wsj.com/articles/the-roundup-1490707460?mod=yahoo_hs,[$$] The Roundup
LLY,LLY:US,BBG000BNBDC2,"How 2016 Treated Alcon, Novartis’s Eyecare Business",2017-03-28 11:36:36 +0000,http://marketrealist.com/2017/03/how-2016-treated-alcon-novartiss-eyecare-business/?utm_source=yahoo&utm_medium=feed,"How 2016 Treated Alcon, Novartis’s Eyecare Business"
LLY,LLY:US,BBG000BNBDC2,Merck’s Keytruda Saw Impressive Growth in 2016,2017-03-27 13:08:34 +0000,http://marketrealist.com/2017/03/mercks-keytruda-saw-impressive-growth-in-2016/?utm_source=yahoo&utm_medium=feed,Merck’s Keytruda Saw Impressive Growth in 2016
LLY,LLY:US,BBG000BNBDC2,8:01 am Eli Lilly announces plans to invest $850 mln in its U.S. operations in 2017,2017-03-26 12:01:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#lly,8:01 am Eli Lilly announces plans to invest $850 mln in its U.S. operations in 2017
LLY,LLY:US,BBG000BNBDC2,Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin,2017-03-25 10:00:00 +0000,http://finance.yahoo.com/news/keller-rohrback-l-l-p-100000671.html,"[Business Wire] - Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.L.P. filed suit against the nation’s three largest pharmacy benefit managers , Express Scripts , OptumRx , and CVS Caremark , and the three major insulin manufacturers, Sanofi-Aventis , Novo Nordisk , and Eli Lilly , who produce the well-known and widely-prescribed analog insulins: Lantus, ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to Invest $850M in U.S. Capital Projects This Year,2017-03-24 19:12:00 +0000,https://www.thestreet.com/story/14059062/1/eli-lilly-to-invest-850m-in-u-s-capital-projects-this-year.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly to Invest $850M in U.S. Capital Projects This Year
LLY,LLY:US,BBG000BNBDC2,Novartis’s Valuation Compared to Its Peers’,2017-03-24 19:07:07 +0000,http://marketrealist.com/2017/03/novartiss-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Novartis’s Valuation Compared to Its Peers’
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Invest $850M in US Capital Projects,2017-03-24 16:24:00 +0000,http://www.investopedia.com/news/eli-lilly-invest-850m-us-capital-projects-lly/?partner=YahooSA,Eli Lilly To Invest $850M in US Capital Projects
LLY,LLY:US,BBG000BNBDC2,LPC: Top US firms raise loans on tax reform hopes,2017-03-24 15:25:57 +0000,http://finance.yahoo.com/news/lpc-top-us-firms-raise-152557970.html,"[Reuters] - Top US companies are raising 364-day syndicated loans to keep financial flexibility while they wait for details of a proposed tax windfall as the Trump administration gets ready to approve the first corporate tax holiday in more than a decade, senior bankers said. Healthcare company Eli Lilly and drugmaker Bristol-Myers Squibb have already raised these short-term facilities since the US election, two bankers said. Eli Lilly took up to US$4bn and Bristol-Myers up to US$2bn, a senior banker said."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved",2017-03-24 14:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-mL-5KBKeU/pharma-stock-roundup-is-sanofi-buying-flexion-pfizer-merck-kgaa-drug-approved-cm765118,Shortly after the release of the Budget Blueprint for 2018 which could require companies to shell out higher fees for regulatory reviews as well as a reduction of 5 8 billion in the National Institutes of Health s NIH spending the President continued to focus on drug prices at a meeting
LLY,LLY:US,BBG000BNBDC2,Health Care Sector Update for 03/24/2017: LLY,2017-03-24 13:58:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eUKDDCrSlBc/health-care-sector-update-for-03242017-lly-cm765146,Top Health care stocks Top Health care stocks JNJ 1 7 JNJ 1 7 PFE flatPFE flat ABT flatABT flat MRK 1 4 MRK 1 4 AMGN flatAMGN flat Health care shares were mainly unchanged in pre market trade Friday Health care shares were mainly unchanged in pre market trade Friday In health
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO Ricks Says AHCA Won't Hurt Drug Prices,2017-03-24 13:34:47 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-ricks-says-133447000.html,Eli Lilly CEO Ricks Says AHCA Won't Hurt Drug Prices
LLY,LLY:US,BBG000BNBDC2,Drugmaker Lilly to invest $850 mln in U.S. operations in 2017,2017-03-24 12:13:30 +0000,http://finance.yahoo.com/news/drugmaker-lilly-invest-850-mln-121330866.html,"[Reuters] - Eli Lilly and Co said on Friday it would invest $850 million in its U.S. operations this year. More investments can be expected, particularly if the U.S. introduces more favorable tax laws, Lilly Chief ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017,2017-03-24 12:00:00 +0000,http://finance.yahoo.com/news/lilly-announces-850-million-investment-120000611.html,"[PR Newswire] - INDIANAPOLIS, March 24, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced plans to invest $850 million in its U.S. operations in 2017. David A. Ricks, Lilly's president and chief executive officer, said that Lilly's potential for growth and its long-standing commitment to the U.S. market led to its decision to invest in its U.S. operations and expand its manufacturing footprint in Indianapolis."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Plans $850 Mln Investments In U.S. Operations In FY17 - Quick Facts,2017-03-24 08:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uJbaxY9aHPs/eli-lilly-plans-850-mln-investments-in-us-operations-in-fy17--quick-facts-20170324-00285,Eli Lilly Plans $850 Mln Investments In U.S. Operations In FY17 - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Biotech Stocks Facing FDA Decision In April,2017-03-24 06:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/70ZD2H6sCX8/biotech-stocks-facing-fda-decision-in-april-20170324-00160,Biotech Stocks Facing FDA Decision In April
LLY,LLY:US,BBG000BNBDC2,Cramer's best and worst case scenarios for the health-car...,2017-03-23 22:41:00 +0000,http://finance.yahoo.com/video/cramers-best-worst-case-scenarios-224100617.html,Cramer's best and worst case scenarios for the health-car...
LLY,LLY:US,BBG000BNBDC2,Health care vote: Best and worst case scenarios,2017-03-23 21:42:00 +0000,http://finance.yahoo.com/video/health-care-vote-best-worst-214200848.html,Health care vote: Best and worst case scenarios
LLY,LLY:US,BBG000BNBDC2,AstraZeneca Stock Rising in '17: What's Working in its Favor?,2017-03-23 17:00:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4C9ACmbhKXE/astrazeneca-stock-rising-in-17-whats-working-in-its-favor-cm764754,Shares of London based pharma giant AstraZeneca plc AZN have risen 13 4 this year so far while the Zacks classified Large Cap Pharma industry increased 6 4 This comes after a decline of almost 20 in 2016 AstraZeneca has a strong product portfolio and is one of the key players
LLY,LLY:US,BBG000BNBDC2,Merck Closes Acquisition of Controlling Stake in Vallee S.A,2017-03-23 16:01:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pnoQCYCfquk/merck-closes-acquisition-of-controlling-stake-in-vallee-sa-cm764663,Merck amp Co Inc MRK has completed the previously announced acquisition of a controlling stake in Vallee S A a leading privately held producer of animal health products in Brazil Merck had announced the agreement to acquire Vallee in Jul 2016 Vallee also has its presence in other
LLY,LLY:US,BBG000BNBDC2,Lilly and the William Sansum Diabetes Center announce a five-year research collaboration,2017-03-23 16:00:00 +0000,http://finance.yahoo.com/news/lilly-william-sansum-diabetes-center-160000088.html,"[PR Newswire] - SANTA BARBARA, Calif. and INDIANAPOLIS, March 23, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, education and care."
LLY,LLY:US,BBG000BNBDC2,Merck Closes Acquisition of Controlling Stake in Vallee S.A,2017-03-23 14:00:02 +0000,http://finance.yahoo.com/news/merck-closes-acquisition-controlling-stake-140002289.html,Merck Closes Acquisition of Controlling Stake in Vallee S.A
LLY,LLY:US,BBG000BNBDC2,Novartis' Acute Heart Failure Drug Fails in Late-Stage Study,2017-03-23 00:58:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B4vfKGlyqYU/novartis-acute-heart-failure-drug-fails-in-late-stage-study-cm764455,Novartis AG NVS recently suffered a setback on the announcement of disappointing data from a phase III study RELAX AHF 2 on pipeline candidate serelaxin RLX030 A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks
LLY,LLY:US,BBG000BNBDC2,"Novartis’ Heart Drug Fails Late Stage Trials (NVS, AZN)",2017-03-22 12:52:00 +0000,http://www.investopedia.com/news/novartis-heart-drug-fails-late-stage-trials-nvs-azn/?partner=YahooSA,"Novartis’ Heart Drug Fails Late Stage Trials (NVS, AZN)"
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Eli Lilly Announced Positive Results from Breast Cancer Drug Combination Study,2017-03-22 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-eli-lilly-announced-121500953.html,"[Accesswire] - Upcoming AWS Coverage on AbbVie LONDON, UK / ACCESSWIRE / March 22, 2017 / Active Wall St. blog coverage looks at the headline from US drugmaker Eli Lilly and Co. (NYSE: LLY ) as the Company announced ..."
LLY,LLY:US,BBG000BNBDC2,Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017,2017-03-21 22:05:43 +0000,http://marketrealist.com/2017/03/japan-may-prove-strong-growth-driver-astrazeneca-2017/?utm_source=yahoo&utm_medium=feed,Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017
LLY,LLY:US,BBG000BNBDC2,Why AstraZeneca’s Brilinta Could Become a Blockbuster Drug in 2017,2017-03-21 20:35:48 +0000,http://marketrealist.com/2017/03/astrazenecas-brilinta-expected-become-blockbuster-therapy-2017/?utm_source=yahoo&utm_medium=feed,Why AstraZeneca’s Brilinta Could Become a Blockbuster Drug in 2017
LLY,LLY:US,BBG000BNBDC2,Lilly's Breast Cancer Combo Drug Phase III Results Positive,2017-03-21 14:09:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QSMsf3fTJMs/lillys-breast-cancer-combo-drug-phase-iii-results-positive-cm763321,Eli Lilly and Company LLY recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer met the primary endpoint of progression free survival PFS The double blind MONARCH 2 phase III study evaluated abemaciclib a CDK 4
LLY,LLY:US,BBG000BNBDC2,Lilly's Breast Cancer Combo Drug Phase III Results Positive,2017-03-21 12:16:12 +0000,http://finance.yahoo.com/news/lillys-breast-cancer-combo-drug-121612707.html,Lilly's Breast Cancer Combo Drug Phase III Results Positive
LLY,LLY:US,BBG000BNBDC2,[$$] Sunlight Is the Best Medicine for Pharma,2017-03-21 04:15:37 +0000,https://www.wsj.com/articles/sunlight-is-the-best-medicine-for-pharma-1490026515?ru=yahoo?mod=yahoo_itp,[$$] Sunlight Is the Best Medicine for Pharma
LLY,LLY:US,BBG000BNBDC2,Novartis (NVS) Announces Positive Data on Heart Failure Drug,2017-03-21 00:06:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rqAZrgxK2DA/novartis-nvs-announces-positive-data-on-heart-failure-drug-cm763197,Novartis AG NVS recently announced results of a new post hoc analysis from the PARADIGM HF study on Entresto in a subgroup of patients with reduced ejection fraction heart failure HFrEF and diabetes A look at Novartis share price movement over the past one year shows that the stock
LLY,LLY:US,BBG000BNBDC2,Novartis (NVS) Announces Positive Data on Heart Failure Drug,2017-03-20 22:22:10 +0000,http://finance.yahoo.com/news/novartis-nvs-announces-positive-data-222210122.html,Novartis (NVS) Announces Positive Data on Heart Failure Drug
LLY,LLY:US,BBG000BNBDC2,Why Amgen's Success Was a Big Disappointment,2017-03-20 19:07:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vmAPDGrBzhM/why-amgens-success-was-a-big-disappointment-cm763094,Amgen Inc NASDAQ AMGN recently released conclusive proof that its pricey new cholesterol lowering drug saves lives As hoped results of a long awaited outcome study showed that people taking Repatha were far less likely to suffer heart attacks and strokes Instead of lifting
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Wants You to Know Its Price Hikes Don't Work,2017-03-20 17:36:30 +0000,https://www.bloomberg.com/gadfly/articles/2017-03-20/eli-lilly-our-drug-price-hikes-don-t-work?cmpid=yhoo.headline,Eli Lilly Wants You to Know Its Price Hikes Don't Work
LLY,LLY:US,BBG000BNBDC2,Why Amgen's Success Was a Big Disappointment,2017-03-20 17:18:00 +0000,https://www.fool.com/investing/2017/03/20/why-amgens-success-was-a-big-disappointment.aspx,Why Amgen's Success Was a Big Disappointment
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Breast Cancer Combo Does Well In Trial,2017-03-20 17:16:00 +0000,http://www.investopedia.com/news/eli-lilly-breast-cancer-combo-succeeds-llypfe/?partner=YahooSA,Eli Lilly Breast Cancer Combo Does Well In Trial
LLY,LLY:US,BBG000BNBDC2,[$$] Sunlight Is the Best Medicine for Pharma,2017-03-20 16:15:19 +0000,https://www.wsj.com/articles/sunlight-is-the-best-medicine-for-pharma-1490026515?mod=yahoo_hs,[$$] Sunlight Is the Best Medicine for Pharma
LLY,LLY:US,BBG000BNBDC2,Lilly's breast cancer drug combination succeeds key study,2017-03-20 14:07:00 +0000,http://finance.yahoo.com/news/lillys-breast-cancer-drug-combination-112117597.html,"[Reuters] - Eli Lilly and Co's combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in patients who relapsed or did not benefit enough when treated with the anti-estrogen therapy. In August, an independent data monitoring committee recommended the late-stage study continue without modification, even though interim evaluation suggested the combination treatment was not delaying cancer progression. Lilly's drug, abemaciclib, is part of the same new class of breast cancer treatments as Pfizer Inc's Ibrance, and Novartis AG's newly approved Kisqali."
LLY,LLY:US,BBG000BNBDC2,Lilly's breast cancer drug combination succeeds in key study,2017-03-20 10:58:01 +0000,http://finance.yahoo.com/news/lillys-breast-cancer-drug-combination-105801188.html,Lilly's breast cancer drug combination succeeds in key study
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival,2017-03-20 10:45:00 +0000,http://finance.yahoo.com/news/lilly-announces-phase-3-monarch-104500032.html,"[PR Newswire] - INDIANAPOLIS, March 20, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer who have relapsed or progressed after endocrine therapy. The results demonstrated the addition of abemaciclib to fulvestrant resulted in a statistically significant improvement in PFS, when compared to the control arm of placebo plus fulvestrant."
LLY,LLY:US,BBG000BNBDC2,Wall Street Set For Weak Start,2017-03-20 08:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LTp3OrZxEMQ/wall-street-set-for-weak-start-20170320-00433,Wall Street Set For Weak Start
LLY,LLY:US,BBG000BNBDC2,Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint,2017-03-20 07:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DvorQWqbSIA/lilly-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint-20170320-00242,Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint
LLY,LLY:US,BBG000BNBDC2,European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade,2017-03-20 07:00:00 +0000,https://www.thestreet.com/story/14050477/1/european-stocks-set-for-mixed-open-dollar-slumps-in-quiet-asia-trade.html?puc=yahoo&cm_ven=YAHOO,European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
LLY,LLY:US,BBG000BNBDC2,Newer type 2 diabetes drugs show heart protective quality in study,2017-03-19 18:39:34 +0000,http://uk.finance.yahoo.com/news/newer-type-2-diabetes-drugs-181553661.html,Newer type 2 diabetes drugs show heart protective quality in study
LLY,LLY:US,BBG000BNBDC2,"Andreas Halvorsen Sells Amazon, MasterCard in 4th Quarter",2017-03-18 16:05:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-OS8IlOArsM/andreas-halvorsen-sells-amazon-mastercard-in-4th-quarter-cm762579,Andreas Halvorsen Trades Portfolio is a founding partner of Viking Global Investors LP and serves as its CIO During the fourth quarter he sold shares in the following stocks Andreas Halvorsen Trades Portfolio is a founding partner of Viking Global Investors LP and serves as
LLY,LLY:US,BBG000BNBDC2,Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report,2017-03-17 20:03:00 +0000,https://www.thestreet.com/story/14049570/1/fired-u-s-attorney-preet-bharara-was-investigating-hhs-chief-tom-price-report.html?puc=yahoo&cm_ven=YAHOO,Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
LLY,LLY:US,BBG000BNBDC2,What are Sanofi's (SNY) Strengths and Challenges in 2017?,2017-03-17 14:08:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AMXptNucYM4/what-are-sanofis-sny-strengths-and-challenges-in-2017-cm762167,We issued an updated research report on Sanofi SNY on Mar 16 2017 Paris France based pharma giant Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas including cardiovascular diseases diabetes oncology and CNS disorders among others Sanofi
LLY,LLY:US,BBG000BNBDC2,First dedicated outcome trials of empagliflozin in chronic heart failure initiated,2017-03-17 12:00:00 +0000,http://finance.yahoo.com/news/first-dedicated-outcome-trials-empagliflozin-120000749.html,"[PR Newswire] - RIDGEFIELD, Conn. and INDIANAPOLIS, March 17, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced that the EMPEROR HF clinical trial program was initiated. EMPEROR HF comprises two phase III outcome studies that will investigate empagliflozin for the treatment of adults with chronic heart failure. The trials will involve not only adults with type 2 diabetes who have heart failure, but also heart failure patients who do not have diabetes."
LLY,LLY:US,BBG000BNBDC2,"IWV, PCLN, CVS, LLY: Large Outflows Detected at ETF",2017-03-16 16:06:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xn3qNkJgy7Q/iwv-pcln-cvs-lly-large-outflows-detected-at-etf-cm761650,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 3000 ETF Symbol IWV where we have detected an approximate 42 5 million dollar outflow that s a 0 6 decrease week over week from 52 650 000
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. :LLY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017",2017-03-16 15:33:39 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-lly-us-earnings-analysis-q4-2016-by-the-numbers-march-16-2017/,"Eli Lilly & Co. :LLY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017"
LLY,LLY:US,BBG000BNBDC2,When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17),2017-03-16 10:11:00 +0000,https://www.thestreet.com/story/14046075/1/when-very-predictable-is-highly-profitable-cramer-s-mad-money-recap-wednesday-3-15-17.html?puc=yahoo&cm_ven=YAHOO,When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)
LLY,LLY:US,BBG000BNBDC2,Here's Why Aratana Therapeutics Inc. Is Getting Clobbered,2017-03-14 20:07:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IZxiXNSNAVs/heres-why-aratana-therapeutics-inc-is-getting-clobbered-cm760725,What happened After reporting fourth quarter earnings that came up short of expectations shares of Aratana Therapeutics NASDAQ PETX 160 a biotech company focused on pet health 160 fell by 21 as of 1 40 p m Tuesday So what Here s a review of the headline numbers
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. Pfizer,2017-03-13 22:06:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HwQ06e82rD4/better-buy-eli-lilly-and-company-vs-pfizer-cm760238,Two big pharma stocks posted nearly identical gains over the last 12 months Eli Lilly s NYSE LLY share price is up slightly under 15 during the period The same is true for Pfizer NYSE PFE stock But which of these two drug stocks is the better choice for long
LLY,LLY:US,BBG000BNBDC2,"Lilly, Merck, Allergan Top Analyst's View For 2017 Pharma",2017-03-13 20:25:43 +0000,http://www.investors.com/news/technology/lilly-merck-allergan-top-analysts-view-for-2017-pharma/?src=A00220A,"Lilly, Merck, Allergan Top Analyst's View For 2017 Pharma"
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. Pfizer,2017-03-13 20:23:00 +0000,http://www.fool.com/investing/2017/03/13/better-buy-eli-lilly-and-company-vs-pfizer.aspx,Better Buy: Eli Lilly and Company vs. Pfizer
LLY,LLY:US,BBG000BNBDC2,Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears,2017-03-13 16:51:00 +0000,https://www.thestreet.com/story/14040641/1/neurotrope-shares-soar-as-alzheimer-s-drug-trial-lottery-ticket-call-nears.html?puc=yahoo&cm_ven=YAHOO,Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays,2017-03-13 16:10:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R2O5ZZ-NzDM/novo-nordisks-diabetes-unit-strong-generic-pressure-stays-cm760020,We issued an updated research report on Novo Nordisk NVO on Mar 9 2017 Novo Nordisk s earnings and sales were below the Zacks Consensus Estimate in the fourth quarter of 2016 results announced on Feb 2 Novo Nordisk has a strong presence in the Diabetes care market with a global
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson’s Business Segment Performance,2017-03-13 14:37:11 +0000,http://marketrealist.com/2017/03/johnson-johnsons-business-segment-performance/?utm_source=yahoo&utm_medium=feed,Johnson & Johnson’s Business Segment Performance
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson’s Valuation Compared to Its Peers,2017-03-13 11:37:58 +0000,http://marketrealist.com/2017/03/johnson-johnsons-valuation-compared-to-peers/?utm_source=yahoo&utm_medium=feed,Johnson & Johnson’s Valuation Compared to Its Peers
LLY,LLY:US,BBG000BNBDC2,Waltham-based Radius Health faces 3-month delay on drug approval,2017-03-10 19:45:06 +0000,http://www.bizjournals.com/boston/news/2017/03/10/waltham-based-radius-health-faces-3-month-delay-on.html?ana=yahoo,Waltham-based Radius Health faces 3-month delay on drug approval
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. :LLY-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017",2017-03-10 18:42:36 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-lly-us-earnings-analysis-2016-by-the-numbers-march-10-2017/,"Eli Lilly & Co. :LLY-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017"
LLY,LLY:US,BBG000BNBDC2,How Incyte Stock Became a Bull Market Star for Biotech Investors,2017-03-10 15:16:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_NqMq8anG70/how-incyte-stock-became-a-bull-market-star-for-biotech-investors-cm759211,Despite many twists and turns the U S stock market has had a stupendous run since it reached a bottom in Mar 2009 The bull run has continued for eight years with the S amp P 500 gaining 198 1 during this period While several stocks performed well during this period Incyte
LLY,LLY:US,BBG000BNBDC2,How Incyte Stock Became a Bull Market Star for Biotech Investors,2017-03-10 12:51:12 +0000,http://finance.yahoo.com/news/incyte-stock-became-bull-market-125112909.html,How Incyte Stock Became a Bull Market Star for Biotech Investors
LLY,LLY:US,BBG000BNBDC2,Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know,2017-03-09 18:15:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/huU1zW3f1yo/incyte-corporation-at-the-cowen-healthcare-conference-4-things-youll-want-to-know-cm758651,Few biotechs have enjoyed as fun a ride as Incyte Corporation NASDAQ INCY in recent years The stock has soared more than 700 since early 2012 thanks primarily to tremendous success for cancer drug Jakafi Incyte s chief medical officer Steven Stein and chief financial
LLY,LLY:US,BBG000BNBDC2,Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know,2017-03-09 16:41:00 +0000,http://www.fool.com/investing/2017/03/09/incyte-corporation-at-the-cowen-healthcare-confere.aspx,Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know
LLY,LLY:US,BBG000BNBDC2,This Pharma Firm Is Beating The Pack In Getting Drugs To Market,2017-03-08 21:22:43 +0000,http://www.investors.com/news/technology/this-small-drugmaker-is-routing-pfizer-merck-bristol-in-rd-bang/?src=A00220A,This Pharma Firm Is Beating The Pack In Getting Drugs To Market
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara,2017-03-08 17:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AFZYjxjILLk/eli-lillys-taltz-shows-better-efficacy-than-jjs-stelara-cm757980,Eli Lilly and Company LLY announced superior efficacy in a head to head study evaluating its marketed drug Taltz ixekizumab versus with Johnson amp Johnson s Stelara ustekinumab in patients with moderate to severe plaque The results from the IXORA S study were presented at the
LLY,LLY:US,BBG000BNBDC2,Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs,2017-03-08 17:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eMS5F9JVygY/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs-cm757946,The pharma and biotech industry has been hit badly by concerns over high drug prices in the past few years The initial panic was triggered in September 2015 when the Democratic presidential candidate Hillary Clinton tweeted about price gouging and laid out a proposal for combating
LLY,LLY:US,BBG000BNBDC2,"Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA",2017-03-08 17:14:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uvjdRQbUz3s/merckpfizers-diabetes-drug-accepted-for-review-by-fda-ema-cm757910,Merck amp Co Inc MRK and partner Pfizer Inc PFE announced that the FDA has accepted its new drug applications NDA for its diabetes candidate ertugliflozin as a monotherapy as well as two fixed dose combination tablets The companies had filed three NDAs with the FDA one as
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara,2017-03-08 14:44:02 +0000,http://finance.yahoo.com/news/eli-lillys-taltz-shows-better-144402186.html,Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co (LLY) Taltz Has A Higher Response Rate Than Stelara For Psoriasis,2017-03-08 10:37:21 +0000,http://www.insidermonkey.com/blog/eli-lilly-and-co-lly-taltz-has-a-higher-response-rate-than-stelara-for-psoriasis-564351/,Eli Lilly And Co (LLY) Taltz Has A Higher Response Rate Than Stelara For Psoriasis
LLY,LLY:US,BBG000BNBDC2,Cramer: When a Trump Tweet Is a Buy Signal,2017-03-08 00:01:00 +0000,http://realmoney.thestreet.com/articles/03/07/2017/cramer-when-trump-tweet-buy-signal?puc=yahoo&cm_ven=YAHOO,Cramer: When a Trump Tweet Is a Buy Signal
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Here's One Drug Company Ready to Rally,2017-03-07 20:00:00 +0000,http://realmoney.thestreet.com/articles/03/07/2017/eli-lilly-heres-one-drug-company-ready-rally?puc=yahoo&cm_ven=YAHOO,Eli Lilly: Here's One Drug Company Ready to Rally
LLY,LLY:US,BBG000BNBDC2,"Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan",2017-03-07 17:38:00 +0000,http://finance.yahoo.com/news/pharma-biotech-stocks-fall-trump-173800221.html,"Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan"
LLY,LLY:US,BBG000BNBDC2,Trump's Latest Drug Pricing Tweet Hits Biotech Stocks,2017-03-07 14:48:55 +0000,http://blogs.wsj.com/moneybeat/2017/03/07/trumps-latest-drug-pricing-tweet-hits-biotech-stocks/?mod=yahoo_hs,Trump's Latest Drug Pricing Tweet Hits Biotech Stocks
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Present At Cowen Health Care Conference; Webcast At 8:40 AM ET,2017-03-07 07:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ubsDHSrqT5g/eli-lilly-to-present-at-cowen-health-care-conference-webcast-at-840-am-et-20170307-00424,Eli Lilly To Present At Cowen Health Care Conference; Webcast At 8:40 AM ET
LLY,LLY:US,BBG000BNBDC2,[$$] Graduates reveal the strengths and weaknesses of online MBAs,2017-03-05 22:43:16 +0000,"http://www.ft.com/cms/s/2f11bcbc-ff9f-11e6-96f8-3700c5664d30,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Online MBA, Indiana University: Kelley, US. Global project manager at Eli Lilly, the pharmaceutical group. Learning to work virtually is essential today. By going to school online, I became very comfortable ..."
LLY,LLY:US,BBG000BNBDC2,Lilly: Taltz Shows Superior Efficacy Compared To Stelara In Plaque Psoriasis,2017-03-04 23:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/znbnuFuuro4/lilly-taltz-shows-superior-efficacy-compared-to-stelara-in-plaque-psoriasis-20170304-00013,Lilly: Taltz Shows Superior Efficacy Compared To Stelara In Plaque Psoriasis
LLY,LLY:US,BBG000BNBDC2,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis,2017-03-04 14:20:00 +0000,http://finance.yahoo.com/news/head-head-data-shows-significantly-142000162.html,[CNW Group] - New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis
LLY,LLY:US,BBG000BNBDC2,How Mylan’s Europe Segment Performed,2017-03-03 20:35:43 +0000,http://marketrealist.com/2017/03/how-mylans-europe-segment-performed/?utm_source=yahoo&utm_medium=feed,How Mylan’s Europe Segment Performed
LLY,LLY:US,BBG000BNBDC2,Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®',2017-03-03 19:45:00 +0000,http://finance.yahoo.com/news/lilly-diabetes-becomes-official-diabetes-194500362.html,"[PR Newswire] - DAYTONA BEACH, Fla., March 3, 2017 /PRNewswire/ -- NASCAR ® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Announces Management Changes,2017-03-02 12:38:00 +0000,https://www.thestreet.com/story/14023379/1/eli-lilly-announces-management-changes.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly Announces Management Changes
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Changes in Senior Management,2017-03-02 11:45:00 +0000,http://finance.yahoo.com/news/lilly-announces-changes-senior-management-114500216.html,"[PR Newswire] - Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Development."
LLY,LLY:US,BBG000BNBDC2,Drug Companies Block Shareholder Votes on Price Transparency Proposals,2017-03-02 05:37:30 +0000,https://www.wsj.com/articles/drug-companies-block-shareholder-votes-on-price-transparency-proposals-1488406027?ru=yahoo?mod=yahoo_itp,Drug Companies Block Shareholder Votes on Price Transparency Proposals
LLY,LLY:US,BBG000BNBDC2,Could pharma sector roar even higher? Cramer checks the c...,2017-03-01 23:47:00 +0000,http://finance.yahoo.com/video/could-pharma-sector-roar-even-234700293.html,Could pharma sector roar even higher? Cramer checks the c...
LLY,LLY:US,BBG000BNBDC2,Cramer’s charts uncover 4 pharma stocks ready to explode ...,2017-03-01 23:42:00 +0000,http://finance.yahoo.com/video/cramer-charts-uncover-4-pharma-234200165.html,Cramer’s charts uncover 4 pharma stocks ready to explode ...
LLY,LLY:US,BBG000BNBDC2,Cramer’s charts uncover 4 pharma stocks ready to explode higher,2017-03-01 23:36:07 +0000,http://www.cnbc.com/id/104313689?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104313689,Cramer’s charts uncover 4 pharma stocks ready to explode higher
LLY,LLY:US,BBG000BNBDC2,[$$] Drug Companies Block Shareholders' Voting on Price Transparency,2017-03-01 22:07:10 +0000,https://www.wsj.com/articles/drug-companies-block-shareholder-votes-on-price-transparency-proposals-1488406027?mod=yahoo_hs,[$$] Drug Companies Block Shareholders' Voting on Price Transparency
LLY,LLY:US,BBG000BNBDC2,Big Pharma Is Losing a Fortune Trying to Cure Alzheimer's,2017-03-01 21:00:00 +0000,https://www.bloomberg.com/news/articles/2017-03-01/elusive-alzheimer-s-therapy-leads-drugmakers-to-abandon-caution?cmpid=yhoo.headline,Big Pharma Is Losing a Fortune Trying to Cure Alzheimer's
LLY,LLY:US,BBG000BNBDC2,A Look at Incyte’s Product Portfolio,2017-03-01 14:06:38 +0000,http://marketrealist.com/2017/02/a-look-at-incytes-product-portfolio/?utm_source=yahoo&utm_medium=feed,A Look at Incyte’s Product Portfolio
LLY,LLY:US,BBG000BNBDC2,Lilly Completes Acquisition of CoLucid Pharmaceuticals,2017-03-01 13:45:00 +0000,http://finance.yahoo.com/news/lilly-completes-acquisition-colucid-pharmaceuticals-134500954.html,"[PR Newswire] - INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As of the expiration of the tender offer, 17,410,607 shares of CoLucid common stock were validly tendered, representing approximately 90.3 percent of the shares outstanding, and have been accepted for payment under the terms of the tender offer."
LLY,LLY:US,BBG000BNBDC2,Perrigo Gets FDA Approval For Generic Version Of Axiron Topical Solution,2017-03-01 09:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JAFX0Jybi8s/perrigo-gets-fda-approval-for-generic-version-of-axiron-topical-solution-20170301-00907,Perrigo Gets FDA Approval For Generic Version Of Axiron Topical Solution
LLY,LLY:US,BBG000BNBDC2,Cramer: This Drug Rally Is No Longer 'Trumped Up',2017-03-01 00:01:00 +0000,http://realmoney.thestreet.com/articles/02/28/2017/cramer-drug-rally-no-longer-trumped?puc=yahoo&cm_ven=YAHOO,Cramer: This Drug Rally Is No Longer 'Trumped Up'
LLY,LLY:US,BBG000BNBDC2,Understanding Incyte’s Revenue Stream for 2016,2017-02-28 19:35:43 +0000,http://marketrealist.com/2017/02/understanding-incytes-revenue-stream-for-2016/?utm_source=yahoo&utm_medium=feed,Understanding Incyte’s Revenue Stream for 2016
LLY,LLY:US,BBG000BNBDC2,"Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly",2017-02-28 16:52:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x3veEitpvqg/zacks-industry-outlook-highlights-johnson-johnson-pfizer-glaxo-amgens-and-lilly-cm754237,For Immediate Release Chicago IL February 28 2017 Today Zacks Equity Research discusses the Industry Pharma Part 1 including Johnson amp Johnson NYSE JNJ Free Report Pfizer NYSE PFE Free Report Glaxo NYSE GSK Free Report Amgen s NASDAQ
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Valuation after Its 4Q16 Earnings Report,2017-02-28 15:35:48 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-valuation-after-its-4q16-earnings-report/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Valuation after Its 4Q16 Earnings Report
LLY,LLY:US,BBG000BNBDC2,"Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly",2017-02-28 14:30:02 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-johnson-143002844.html,"Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Recent Developments,2017-02-28 14:06:03 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-recent-developments/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Recent Developments
LLY,LLY:US,BBG000BNBDC2,Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting,2017-02-28 14:00:00 +0000,http://finance.yahoo.com/news/lilly-present-data-taltz-ixekizumab-140000501.html,[CNW Group] - Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting
LLY,LLY:US,BBG000BNBDC2,Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting,2017-02-28 14:00:00 +0000,http://finance.yahoo.com/news/lilly-present-data-taltz-ixekizumab-140000949.html,"[PR Newswire] - INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz ® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and ..."
LLY,LLY:US,BBG000BNBDC2,"Elanco, Eli Lilly & Co.’s Animal Health Segment",2017-02-28 12:36:10 +0000,http://marketrealist.com/2017/02/elanco-eli-lilly-co-s-animal-health-segment/?utm_source=yahoo&utm_medium=feed,"Elanco, Eli Lilly & Co.’s Animal Health Segment"
LLY,LLY:US,BBG000BNBDC2,PAREXEL Names Simon Harford SVP & CFO - Quick Facts,2017-02-28 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/omnT7RI7bkA/parexel-names-simon-harford-svp--cfo--quick-facts-20170228-00562,PAREXEL Names Simon Harford SVP & CFO - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Pharma Industry Outlook - February/March 2017,2017-02-28 06:50:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JnCkTN4-Fz8/pharma-industry-outlook-februarymarch-2017-cm753953,There is no doubt that 2016 was a tough year for pharma and biotech stocks with the sector facing a lot of criticism for rising drug prices Although shares did rally post election in November on hopes that drug pricing would not be a key focus area under a Trump presidency the rally turned
LLY,LLY:US,BBG000BNBDC2,[$$] Medical Megadeals Dominate Deal Flow,2017-02-28 01:38:16 +0000,https://www.wsj.com/articles/medical-megadeals-dominate-deal-flow-1488205287?mod=yahoo_hs,[$$] Medical Megadeals Dominate Deal Flow
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s New Products Portfolio,2017-02-27 15:36:48 +0000,http://marketrealist.com/2017/02/eli-lilly-and-co-s-new-products-portfolio/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s New Products Portfolio
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Oncology Franchise,2017-02-27 14:06:54 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-oncology-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Oncology Franchise
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Neuroscience Franchise,2017-02-27 12:36:57 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-neuroscience-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Neuroscience Franchise
LLY,LLY:US,BBG000BNBDC2,Merck & Co.’s Valuation after Its 4Q16 Earnings,2017-02-27 12:35:53 +0000,http://marketrealist.com/2017/02/mercks-valuation-after-its-4q16-earnings/?utm_source=yahoo&utm_medium=feed,Merck & Co.’s Valuation after Its 4Q16 Earnings
LLY,LLY:US,BBG000BNBDC2,LILLY ELI & CO Financials,2017-02-25 18:04:12 +0000,http://finance.yahoo.com/q/is?s=lly,LILLY ELI & CO Financials
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc,2017-02-25 15:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvoMBOYO904/better-buy-eli-lilly-and-co-vs-glaxosmithkline-plc-cm753201,A couple recent events helped shares of Eli Lilly and Co NYSE LLY bounce back from a big clinical trial failure that sent the stock tumbling late last year Despite some ups and downs over the past year the big pharma stock notched an 12 gain Lilly s peer across the
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc,2017-02-25 14:34:40 +0000,http://www.fool.com/investing/2017/02/25/better-buy-eli-lilly-and-co-vs-glaxosmithkline-plc.aspx,Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Cardiovascular Franchise,2017-02-24 15:38:08 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-cardiovascular-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Cardiovascular Franchise
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 14:54:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IzbzaW6L2ls/pharma-stock-roundup-is-bmy-the-next-acquisition-target-priority-review-for-pfe-novartis-drugs-cm752604,This week focus remained on Bristol Myers BMY with the company making additions to its Board and billionaire activist investor Carl Icahn reportedly acquiring a stake in the company Recap of the Week s Most Important Stories Is Bristol Myers the Next Takeover Target According
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Endocrine Franchise,2017-02-24 14:07:51 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-endocrine-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Endocrine Franchise
LLY,LLY:US,BBG000BNBDC2,Performance of Eli Lilly & Co.’s Business Segments in 4Q16,2017-02-24 12:39:01 +0000,http://marketrealist.com/2017/02/performance-of-eli-lilly-co-s-business-segments-in-4q16/?utm_source=yahoo&utm_medium=feed,Performance of Eli Lilly & Co.’s Business Segments in 4Q16
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 12:27:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-bmy-next-122712720.html,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co.’s Revenues in 4Q16,2017-02-23 22:15:55 +0000,http://marketrealist.com/2017/02/eli-lilly-co-s-revenues-in-4q16/?utm_source=yahoo&utm_medium=feed,Eli Lilly & Co.’s Revenues in 4Q16
LLY,LLY:US,BBG000BNBDC2,"In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs",2017-02-23 18:45:25 +0000,http://www.bizjournals.com/boston/news/2017/02/22/in-groundbreaking-deal-harvard-pilgrim-negotiates.html?ana=yahoo,"In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs"
LLY,LLY:US,BBG000BNBDC2,Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks,2017-02-23 15:07:35 +0000,http://www.insidermonkey.com/blog/why-president-trump-wants-to-transform-the-fda-and-what-it-could-mean-for-biotech-stocks-561604/,Why President Trump Wants To Transform The FDA – And What It Could Mean For Biotech Stocks
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO supports Trump's 'blueprint' for growth,2017-02-22 21:47:17 +0000,http://www.cnbc.com/id/104298158?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104298158,Eli Lilly CEO supports Trump's 'blueprint' for growth
LLY,LLY:US,BBG000BNBDC2,[$$] Alzheimer’s: Pharma’s Great White Whale Is Still Worth Hunting,2017-02-22 05:46:03 +0000,https://www.wsj.com/articles/alzheimers-pharmas-great-white-whale-is-still-worth-hunting-1487599380?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - The drug industry has had multiple expensive failures trying to treat Alzheimer’s disease, yet the big potential payoff keeps it searching."
LLY,LLY:US,BBG000BNBDC2,[$$] Lilly Asia Seeks Up to $450 Million for Fourth Fund,2017-02-21 21:55:41 +0000,https://www.wsj.com/articles/lilly-asia-seeks-up-to-450-million-for-fourth-fund-1487714139?mod=yahoo_hs,[$$] Lilly Asia Seeks Up to $450 Million for Fourth Fund
LLY,LLY:US,BBG000BNBDC2,"LILLY ELI & CO Files SEC form 10-K, Annual Report",2017-02-21 20:35:40 +0000,http://biz.yahoo.com/e/170221/lly10-k.html,"LILLY ELI & CO Files SEC form 10-K, Annual Report"
LLY,LLY:US,BBG000BNBDC2,"XLV, PFE, MRK, LLY: ETF Outflow Alert",2017-02-21 17:07:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ZFL5y8x_II/xlv-pfe-mrk-lly-etf-outflow-alert-cm750661,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 18 4 million dollar outflow that s a 0 1 decrease week over week
LLY,LLY:US,BBG000BNBDC2,These Prescription Products Matter to Sanofi’s Growth,2017-02-20 15:37:58 +0000,http://marketrealist.com/2017/02/these-prescription-products-matter-to-sanofis-growth/?utm_source=yahoo&utm_medium=feed,These Prescription Products Matter to Sanofi’s Growth
LLY,LLY:US,BBG000BNBDC2,Sanofi’s Unique Foothold in Diabetes and Cardiovascular,2017-02-20 14:06:55 +0000,http://marketrealist.com/2017/02/sanofis-unique-foothold-in-diabetes-and-cardiovascular/?utm_source=yahoo&utm_medium=feed,Sanofi’s Unique Foothold in Diabetes and Cardiovascular
LLY,LLY:US,BBG000BNBDC2,[$$] Alzheimer's: Pharma's Great White Whale Is Still Worth Hunting,2017-02-20 14:03:04 +0000,https://www.wsj.com/articles/alzheimers-pharmas-great-white-whale-is-still-worth-hunting-1487599380?mod=yahoo_hs,[$$] Alzheimer's: Pharma's Great White Whale Is Still Worth Hunting
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. Johnson & Johnson,2017-02-18 20:23:43 +0000,http://www.fool.com/investing/2017/02/18/better-buy-eli-lilly-and-company-vs-johnson-johnso.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Eli Lilly and Company vs. Johnson & Johnson
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. Johnson & Johnson,2017-02-18 13:52:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WaY3lf6G_mY/better-buy-eli-lilly-and-company-vs-johnson-johnson-cm749993,Eli Lilly and Company NYSE LLY ranks as one of the largest drugmakers on the planet But Lilly looks relatively small when compared to Johnson amp Johnson NYSE JNJ Based on market cap J amp J is over 3 5 times bigger than Lilly Both of these companies stocks have
LLY,LLY:US,BBG000BNBDC2,Merrimack (MACK): What Awaits the Stock in Q4 Earnings?,2017-02-17 21:51:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p6mayfa5Oa8/merrimack-mack-what-awaits-the-stock-in-q4-earnings-cm749823,Merrimack Pharmaceuticals Inc MACK is scheduled to report fourth quarter 2016 results in the next week Last quarter Merrimack delivered a positive earnings surprise of 23 33 Merrimack s share price decreased 21 9 year to date compared with the Zacks classified Medical Biomedical
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ",2017-02-17 13:57:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YaFi7BW-HOE/pharma-stock-roundup-mercks-alzheimers-study-halted-allergan-to-buy-zeltiq-cm749492,Although companies like Teva Read more Teva Tops on Q4 Earnings Maintains 2017 Guidance and Shire reported fourth quarter results this week focus remained primarily on Merck s MRK announcement regarding its Alzheimer s disease candidate Recap of the Week s Most Important
LLY,LLY:US,BBG000BNBDC2,Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback,2017-02-16 16:58:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1wX91UpN3NM/alzheimers-market-suffers-yet-another-blow-with-merck-drug-setback-cm749011,Merck amp Co Inc MRK suffered a pipeline setback with its investigational Alzheimer s disease treatment verubecestat being halted in a phase II III study The EPOCH study was stopped after an interim analysis by an external Data Monitoring Committee eDMC indicated that the study
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Berkshire Hathaway, Eli Lilly, T-Mobile, Oracle and Marathon Petroleum",2017-02-16 16:57:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uj99ZK4WBBU/the-zacks-analyst-blog-highlights-berkshire-hathaway-eli-lilly-t-mobile-oracle-and-marathon-petroleum-cm748998,For Immediate Release Chicago IL February 16 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,What's Driving Lilly's (LLY) Shares after 2016 Decline?,2017-02-16 16:57:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EmzsWHW3tFw/whats-driving-lillys-lly-shares-after-2016-decline-cm748996,After a rather difficult 2016 share price of pharma giant Eli Lilly amp Company LLY has picked up in 2017 What Hurt Shares in 2016 In 2016 Lilly s shares were hurt due to soft earnings and some negative pipeline updates including the failure of its high profile
LLY,LLY:US,BBG000BNBDC2,What's Driving Lilly's (LLY) Shares after 2016 Decline?,2017-02-16 14:31:02 +0000,http://finance.yahoo.com/news/whats-driving-lillys-lly-shares-143102361.html,What's Driving Lilly's (LLY) Shares after 2016 Decline?
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Berkshire Hathaway, Eli Lilly, T-Mobile, Oracle and Marathon Petroleum",2017-02-16 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-berkshire-143002304.html,"The Zacks Analyst Blog Highlights: Berkshire Hathaway, Eli Lilly, T-Mobile, Oracle and Marathon Petroleum"
LLY,LLY:US,BBG000BNBDC2,"Franklin Resources Inc Buys Time Warner, Cognizant Technology Solutions, Monsanto Co, Sells ...",2017-02-16 13:53:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TNktBEmaBp0/franklin-resources-inc-buys-time-warner-cognizant-technology-solutions-monsanto-co-sells-cm748762,Franklin Resources Inc New Purchases LIVN GT GXPPRB XLF FTI ATH FTS IRTC HMN YUMC Added Positions TWX CTSH MON TEVA BUD NEE LLY SLW MDT COP Reduced Positions CBS ALL MS TGT FOX NXPI JPM IEMG MSFT BHI Sold Out LNKD XRX
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co To Present At Leerink Partners Conference; Webcast At 1:30 PM,2017-02-16 12:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KisU_jrn3tk/eli-lilly-and-co-to-present-at-leerink-partners-conference-webcast-at-130-pm-20170216-01200,Eli Lilly And Co To Present At Leerink Partners Conference; Webcast At 1:30 PM
LLY,LLY:US,BBG000BNBDC2,"Saturna Capital CORP Buys NXP Semiconductors NV, Under Armour, Edwards Lifesciences, Sells ...",2017-02-16 06:53:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pddzeMSyEjM/saturna-capital-corp-buys-nxp-semiconductors-nv-under-armour-edwards-lifesciences-sells-cm748716,Saturna Capital CORP New Purchases NXPI UAA HPQ Added Positions BMY NKE UL EW FB SHPG CHL ECA VFC Reduced Positions ADBE NVS INTU AAPL EL AMGN CHD TJX AKAM ITW Sold Out ESRX INFY UA BIIB CVE SNH SRE ABEV New
LLY,LLY:US,BBG000BNBDC2,DexCom Is a Great Healthcare Stock to Buy Now,2017-02-16 02:14:00 +0000,https://www.thestreet.com/story/14004035/1/dexcom-is-a-great-healthcare-stock-to-buy-now.html?puc=yahoo&cm_ven=YAHOO,DexCom Is a Great Healthcare Stock to Buy Now
LLY,LLY:US,BBG000BNBDC2,Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?,2017-02-16 00:34:18 +0000,http://www.fool.com/investing/2017/02/15/another-potential-alzheimers-disease-treatment-bit.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?
LLY,LLY:US,BBG000BNBDC2,Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?,2017-02-15 23:54:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AP8zTqmzHqk/another-potential-alzheimers-disease-treatment-bites-the-dust-whats-next-cm748650,And another one bites the dust Merck NYSE MRK announced on Tuesday that it was halting a phase 2 3 clinical study of 160 verubecestat in treating Alzheimer s disease This news marked the second major clinical failure in recent months by a big drugmaker for a disease that
LLY,LLY:US,BBG000BNBDC2,Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo,2017-02-15 22:56:00 +0000,http://finance.yahoo.com/news/additional-results-pivotal-ra-beam-225600408.html,"[PR Newswire] - INDIANAPOLIS, Feb. 15, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of ..."
LLY,LLY:US,BBG000BNBDC2,"Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next?",2017-02-15 21:18:06 +0000,http://www.investors.com/news/technology/mercks-alzheimers-drug-fails-are-biogen-roche-astrazeneca-next/,"Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next?"
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Eli Lilly, T-Mobile US & Berkshire Hathaway",2017-02-15 20:54:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IPtvTVq1F4Y/top-research-reports-for-eli-lilly-t-mobile-us-berkshire-hathaway-cm748566,Wednesday February 15 2017 Today s Research Daily features new research reports on 16 major stocks including Berkshire Hathaway BRK B Eli Lilly LLY and T Mobile TMUS Berkshire Hathaway shares have modestly lagged the Zacks Finance over the past 12 months 29 8 vs 35 4 but
LLY,LLY:US,BBG000BNBDC2,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook",2017-02-15 20:54:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r1et009E-30/incytes-incy-beats-on-q4-earnings-provides-2017-outlook-cm748510,Incyte Corporation INCY reported fourth quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents Incyte had reported earnings of 29 cents per share in the year ago quarter Quarterly revenues came in at 326 5 million up 33 9 year over year and beat the Zacks
LLY,LLY:US,BBG000BNBDC2,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook",2017-02-15 19:00:07 +0000,http://finance.yahoo.com/news/incytes-incy-beats-q4-earnings-190007821.html,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook"
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Eli Lilly, T-Mobile US & Berkshire Hathaway",2017-02-15 18:43:06 +0000,http://finance.yahoo.com/news/top-research-reports-eli-lilly-184306445.html,"Top Research Reports for Eli Lilly, T-Mobile US & Berkshire Hathaway"
LLY,LLY:US,BBG000BNBDC2,Warren Buffett's billion dollar bet on Apple stock,2017-02-15 16:49:14 +0000,http://finance.yahoo.com/news/warren-buffetts-billion-dollar-bet-on-apple-stock-164914727.html,Warren Buffett's billion dollar bet on Apple stock
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Is Great Stock to Buy Now,2017-02-15 15:42:00 +0000,https://www.thestreet.com/story/14002149/1/eli-lilly-is-great-stock-to-buy-now.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly Is Great Stock to Buy Now
LLY,LLY:US,BBG000BNBDC2,Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip,2017-02-15 14:58:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6x98WYO8uqo/merck-mrk-halts-late-stage-alzheimer-study-shares-slip-cm748187,Merck amp Co Inc MRK announced that it is discontinuing a late stage study evaluating its pipeline candidate verubecestat for the treatment of mild to moderate Alzheimer s disease due to lack of efficacy Shares of Merck declined almost 2 in after hours trading on Tuesday This year
LLY,LLY:US,BBG000BNBDC2,"Sarah Ketterer Buys Bank of Americaoration, Eli Lilly and Co, Advance Auto Parts, Sells ...",2017-02-15 14:53:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J6SI4d-pcqs/sarah-ketterer-buys-bank-of-americaoration-eli-lilly-and-co-advance-auto-parts-sells-cm748216,Sarah Ketterer New Purchases BAC AZN EEM IEMG TAL GIL IMO Added Positions LLY AAP BIDU QCOM ORCL PDCE PVH NTES ABB VEDL Reduced Positions ALL HAL INDA CSX AMX PBR A MSFT SM BCS C Sold Out PRU BIIB VSS New Purchases
LLY,LLY:US,BBG000BNBDC2,Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip,2017-02-15 13:06:01 +0000,http://finance.yahoo.com/news/merck-mrk-halts-stage-alzheimer-130601147.html,Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
LLY,LLY:US,BBG000BNBDC2,Another Alzheimer's Drug Study Fails. This Time It's Merck's,2017-02-15 12:00:00 +0000,http://www.forbes.com/sites/matthewherper/2017/02/15/another-alzheimers-drug-study-fails-is-there-hope/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Another Alzheimer's Drug Study Fails. This Time It's Merck's
LLY,LLY:US,BBG000BNBDC2,Merck stopping late stage study as another Alzheimer's drug fails,2017-02-14 23:46:50 +0000,http://finance.yahoo.com/news/merck-stopping-stage-study-another-234650719.html,"[Reuters] - Merck & Co Inc said on Tuesday it will halt a late-stage trial of an Alzheimer's drug after it was determined that it had no chance of working, marking the latest in a long line of crushing disappointments in efforts to find an effective treatment for the mind-wasting disease. The company was testing its drug, verubecestat, in patients with mild to moderate Alzheimer's disease. The news sent Merck shares down nearly 2 percent in after hours trading."
LLY,LLY:US,BBG000BNBDC2,Merck Stops Clinical Trial of Alzheimer's Drug,2017-02-14 23:37:01 +0000,https://www.wsj.com/articles/merck-stops-clinical-trial-of-alzheimers-drug-1487115418?mod=yahoo_hs,Merck Stops Clinical Trial of Alzheimer's Drug
LLY,LLY:US,BBG000BNBDC2,Merck to halt study of mild to moderate Alzheimer's drug,2017-02-14 23:04:57 +0000,http://finance.yahoo.com/news/merck-halt-study-mild-moderate-230457119.html,"[Reuters] - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness. Merck said the external data monitoring committee, which assessed overall benefit or risk of verubecestat, determined that there was ""virtually no chance of finding a positive clinical effect"". Patients with mild to moderate Alzheimer's disease exhibit detectable and worsening impairment of cognitive and functional abilities."
LLY,LLY:US,BBG000BNBDC2,Lilly's Olumiant Gets Marketing Authorization in Europe,2017-02-14 16:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7u1obRM1WQA/lillys-olumiant-gets-marketing-authorization-in-europe-cm747595,Eli Lilly and Company LLY along with its partner Incyte Corporation INCY announced that the European Commission has granted marketing authorization to once daily baricitinib in Europe for the treatment of adults with moderate to severe active rheumatoid arthritis RA 160 The drug will
LLY,LLY:US,BBG000BNBDC2,"PRIMECAP Management Buys AstraZeneca PLC, Alkermes PLC, Whirlpool, Sells Union Pacific, ...",2017-02-14 16:17:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G7izrmIteCs/primecap-management-buys-astrazeneca-plc-alkermes-plc-whirlpool-sells-union-pacific-cm747673,PRIMECAP Management New Purchases LGF B LGF A GD CBS SIG MXL TPX DHX A SKX SPLK Added Positions AZN ALKS WHR LLY BMRN NVS KLAC IMAX AAL DAL Reduced Positions AMGN SCHW NVDA MSFT MDT UNP TXN MMC POT XOM Sold Out CPHD
LLY,LLY:US,BBG000BNBDC2,Lilly's Olumiant Gets Marketing Authorization in Europe,2017-02-14 14:32:02 +0000,http://finance.yahoo.com/news/lillys-olumiant-gets-marketing-authorization-143202479.html,Lilly's Olumiant Gets Marketing Authorization in Europe
LLY,LLY:US,BBG000BNBDC2,European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis,2017-02-13 21:21:00 +0000,http://finance.yahoo.com/news/european-commission-approves-once-daily-212100120.html,[CNW Group] - European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More",2017-02-13 16:22:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pLLVWmpV-n4/drug-stocks-earnings-slated-for-feb-14-incy-prta-more-cm747016,The year 2017 seems to have started on a positive note for investors in the U S Approximately 71 6 of the companies or 358 members in the S amp P 500 Index have reported results so far Per the Earnings Trends an impressive 69 of the companies reported in the index have beaten
LLY,LLY:US,BBG000BNBDC2,Better Buy: AbbVie Inc. vs. Eli Lilly,2017-02-11 14:05:06 +0000,http://www.fool.com/investing/2017/02/10/better-buy-abbvie-inc-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: AbbVie Inc. vs. Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Is Biogen a Risky Stock?,2017-02-10 21:14:18 +0000,http://www.fool.com/investing/2017/02/10/is-biogen-a-risky-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Biogen a Risky Stock?
LLY,LLY:US,BBG000BNBDC2,Is Biogen a Risky Stock?,2017-02-10 16:20:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DnPiXoHJ-BU/is-biogen-a-risky-stock-cm746269,Following the spinoff of two of its fastest growing drugs Biogen Inc NASDAQ BIIB is more focused on neurological disease than it s been in years However the company could face a stiff new challenger in multiple sclerosis soon and the best drug in its research pipeline is
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 13, 2017",2017-02-10 14:23:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tukwV8mTvAQ/eli-lilly-and-company-lly-ex-dividend-date-scheduled-for-february-13-2017-cm746165,Eli Lilly and Company LLY will begin trading ex dividend on February 13 2017 A cash dividend payment of 0 52 per share is scheduled to be paid on March 10 2017 Shareholders who purchased LLY prior to the ex dividend date are eligible for the cash dividend payment This represents an 1
LLY,LLY:US,BBG000BNBDC2,Better Buy: AbbVie Inc. vs. Eli Lilly,2017-02-10 14:20:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G9m87kdE4qw/better-buy-abbvie-inc-vs-eli-lilly-cm746063,At the beginning of 2016 AbbVie NYSE ABBV and Eli Lilly NYSE LLY were nearly exactly the same size in terms of market cap However AbbVie s stock outperformed Lilly throughout most of the year making AbbVie the bigger company now Size doesn t matter much though when
LLY,LLY:US,BBG000BNBDC2,Post Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates,2017-02-10 13:15:00 +0000,http://finance.yahoo.com/news/post-earnings-coverage-eli-lillys-131500192.html,"[Accesswire] - Upcoming AWS Coverage on Aerie Pharmaceuticals NEW YORK, NY / ACCESSWIRE / February 10, 2017 / Active Wall St. announces its post-earnings coverage on Eli Lilly and Co. (NYSE: LLY ). The Company reported ..."
LLY,LLY:US,BBG000BNBDC2,Lilly To Present At Leerink Partners Global Healthcare Conference,2017-02-09 18:00:00 +0000,http://finance.yahoo.com/news/lilly-present-leerink-partners-global-180000088.html,"[PR Newswire] - INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, senior vice ..."
LLY,LLY:US,BBG000BNBDC2,Trulicity Label From Eli Lilly And Co (LLY) Will Be Used In Combination With Basal Insulin,2017-02-09 16:16:41 +0000,http://www.insidermonkey.com/blog/trulicity-label-from-eli-lilly-and-co-lly-will-be-used-in-combination-with-basal-insulin-537394/,Trulicity Label From Eli Lilly And Co (LLY) Will Be Used In Combination With Basal Insulin
LLY,LLY:US,BBG000BNBDC2,"Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors",2017-02-09 11:45:00 +0000,http://finance.yahoo.com/news/carolyn-r-bertozzi-ph-d-114500201.html,"[PR Newswire] - INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board. Professor Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute."
LLY,LLY:US,BBG000BNBDC2,Lilly to Present at Cowen Health Care Conference,2017-02-08 21:00:00 +0000,http://finance.yahoo.com/news/lilly-present-cowen-health-care-210000939.html,"[PR Newswire] - INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37 th Annual Health Care Conference on Tuesday, March 7, 2017. David A. Ricks, Lilly's ..."
LLY,LLY:US,BBG000BNBDC2,Biotech Tesaro Climbs on Takeout Reports,2017-02-08 17:49:00 +0000,https://www.thestreet.com/story/13994924/1/biotech-tesaro-climbs-on-takeout-reports.html?puc=yahoo&cm_ven=YAHOO,Biotech Tesaro Climbs on Takeout Reports
LLY,LLY:US,BBG000BNBDC2,GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1,2017-02-08 15:21:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pEEwWq4SJBw/gw-pharma-gwph-posts-narrower-than-expected-loss-in-q1-cm744858,GW Pharmaceuticals plc GWPH reported first quarter fiscal 2017 loss of 77 cents per share much narrower than both the Zacks Consensus Estimate of a loss of 1 35 and the year ago figure of 82 cents The company s shares gained 4 6 following the release of first quarter fiscal
LLY,LLY:US,BBG000BNBDC2,Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.,2017-02-08 15:21:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NOkk6--Ko-A/amgens-secondary-hyperparathyroidism-drug-approved-in-us-cm744857,Amgen Inc AMGN announced that the FDA has approved Parsabiv etelcalcetide for the treatment of secondary hyperparathyroidism HPT in adult patients with chronic kidney disease CKD on hemodialysis Parsabiv is the first therapy in 12 years to be approved for this condition The drug has
LLY,LLY:US,BBG000BNBDC2,GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1,2017-02-08 14:01:02 +0000,http://finance.yahoo.com/news/gw-pharma-gwph-posts-narrower-140102653.html,GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1
LLY,LLY:US,BBG000BNBDC2,Lilly's Trulicity® (dulaglutide) Label Updated to Include Use in Combination with Basal Insulin for Adults with Type 2 Diabetes,2017-02-08 11:45:00 +0000,http://finance.yahoo.com/news/lillys-trulicity-dulaglutide-label-updated-114500440.html,"[PR Newswire] - INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- The label for Eli Lilly and Company's (LLY) once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes. Trulicity is available in a prefilled pen in 0.75 and 1.5 mg doses. ""Despite best efforts to manage their A1C, many adults with type 2 diabetes may need to add to or change their treatment plan to help them reach their blood sugar goals,"" said Sherry Martin, M.D., vice president, Global Medical Affairs, Lilly Diabetes."
LLY,LLY:US,BBG000BNBDC2,Lilly's Trulicity Label Updated On Basal Insulin,2017-02-08 06:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c_GSEyfxzrI/lillys-trulicity-label-updated-on-basal-insulin-20170208-00377,Lilly's Trulicity Label Updated On Basal Insulin
LLY,LLY:US,BBG000BNBDC2,"Should I Buy Valeant Pharmaceuticals Intl Inc (VRX) Stock? 3 Pros, 3 Cons",2017-02-07 22:17:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P31fDpXeEGk/should-i-buy-valeant-pharmaceuticals-intl-inc-vrx-stock-3-pros-3-cons-cm744551,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips When writing a pros cons article 160 on Valeant Pharmaceuticals Intl Inc NYSE VRX I admittedly 160 did not have much trouble coming up with the cons Let s face it the company has been an
LLY,LLY:US,BBG000BNBDC2,New Research Reveals Powerful Health Benefits of Dog Companionship,2017-02-07 16:38:00 +0000,http://finance.yahoo.com/news/research-reveals-powerful-health-benefits-163800584.html,"[PR Newswire] - GREENFIELD, Ind., Feb. 7, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), in collaboration with Purdue University's College of Veterinary Medicine, today released preliminary research findings that support the power of the human-animal bond. The preliminary study results, which were shared during a presentation at the North American Veterinary Conference (NAVC) in Orlando, Fla., show that in addition to the physical benefits service dogs provide their owners, they also contribute to emotional and psychosocial well-being. This new research on the human-animal bond is part of a four-year primary research study on the emotional and health benefits of service dogs to their recipients."
LLY,LLY:US,BBG000BNBDC2,ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib,2017-02-07 14:19:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zqNI3ifI6zE/ariad-files-for-eu-approval-of-lung-cancer-drug-brigatinib-cm744117,ARIAD Pharmaceuticals Inc ARIA announced the submission of a Marketing Authorisation Application MAA for its experimental ALK inhibitor brigatinib with the European Medicines Agency EMA ARIAD is looking to get brigatinib approved for the treatment of adult patients with
LLY,LLY:US,BBG000BNBDC2,ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib,2017-02-07 13:16:01 +0000,http://finance.yahoo.com/news/ariad-files-eu-approval-lung-131601692.html,ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
LLY,LLY:US,BBG000BNBDC2,Auris (EARS) Expands Pipeline with Intranasal Betahistine,2017-02-07 00:17:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_wl95Rf4Ico/auris-ears-expands-pipeline-with-intranasal-betahistine-cm743919,Shares of Auris Medical Holding AG EARS was up 2 6 after the company announced that it has added AM 125 a third clinical stage program to its pipeline which allowed it to 160 expand into the field of vestibular disorders A look at Auris share price movement over the past one year
LLY,LLY:US,BBG000BNBDC2,Auris (EARS) Expands Pipeline with Intranasal Betahistine,2017-02-06 21:45:09 +0000,http://finance.yahoo.com/news/auris-ears-expands-pipeline-intranasal-214509172.html,Auris (EARS) Expands Pipeline with Intranasal Betahistine
LLY,LLY:US,BBG000BNBDC2,Q4 Earnings Faring Well for Pharma ETFs,2017-02-06 17:19:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2oG8p1Qtx2o/q4-earnings-faring-well-for-pharma-etfs-cm743689,The Q4 earnings season is faring better than the last few years with not only earnings growth on track to reach the highest level in two years but also total earnings set to create a new quarterly record Most sectors are coming up with good results with healthcare being no exception The
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More",2017-02-06 16:22:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ilur_ld5S1U/drug-stocks-reporting-earnings-on-feb-7-gild-mnk-more-cm743617,2017 seems to have started on an encouraging note for investors when compared to the year ago periods Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season As per our Earnings Preview report approximately
LLY,LLY:US,BBG000BNBDC2,Q4 Earnings Faring Well for Pharma ETFs,2017-02-06 14:55:02 +0000,http://finance.yahoo.com/news/q4-earnings-faring-well-pharma-145502433.html,Q4 Earnings Faring Well for Pharma ETFs
LLY,LLY:US,BBG000BNBDC2,Trump's Plan to Lower Drug Costs Is a Fairy Tale,2017-02-05 13:18:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d7f5Y4cTqzI/trumps-plan-to-lower-drug-costs-is-a-fairy-tale-cm743331,Image source U S Department of Defense Current Photos Flickr The first days of the Trump presidency could appropriately be described as a whirlwind During Trump s first 10 1 2 days in office he issued more aggregate executive orders and proclamations 20 than any modern
LLY,LLY:US,BBG000BNBDC2,[$$] Analysts Upbeat on Earnings,2017-02-04 05:01:00 +0000,http://www.barrons.com/articles/analysts-upbeat-on-earnings-1486185997?mod=yahoobarrons&ru=yahoo,[$$] Analysts Upbeat on Earnings
LLY,LLY:US,BBG000BNBDC2,Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC,2017-02-04 00:56:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gsVauqDhe54/bristol-myers-injectable-opdivo-gets-fda-approval-for-muc-cm743202,Bristol Myers Squibb Company BMY announced that the FDA has approved an injectable form of immuno oncology drug Opdivo The drug will have an intravenous use in metastatic urothelial carcinoma mUC with a recommended dose of 240 mg Opdivo will be administered as an intravenous infusion over
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint",2017-02-03 16:35:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d9tRINIivno/the-zacks-analyst-blog-highlights-eli-lilly-aetna-automatic-data-processing-dollar-general-and-sprint-cm742881,For Immediate Release Chicago IL February 03 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales,2017-02-03 14:34:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4hoKKNmaE7s/astrazeneca-azn-beats-on-q4-earnings-but-misses-on-sales-cm742825,AstraZeneca PLC AZN reported fourth quarter 2016 core earnings of 1 21 per American Depositary Share which comfortably beat the Zacks Consensus Estimate of 51 cents Core earnings also rose 9 year over year at constant currency rates CER AstraZeneca s shares were up 0 9 so
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint",2017-02-03 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-eli-143002789.html,"The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint"
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling",2017-02-03 13:33:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3s3hs5m8cow/pharma-stock-roundup-pfizer-merck-lly-report-results-teva-hit-by-copaxone-ruling-cm742674,Major pharma companies like Pfizer PFE Merck MRK and Lilly LLY reported fourth quarter results this week Meanwhile Teva TEVA was hit by an unfavorable ruling in the Copaxone patent infringement lawsuit Recap of the Week s Most Important Stories A Look at Earnings
LLY,LLY:US,BBG000BNBDC2,AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales,2017-02-03 13:09:01 +0000,http://finance.yahoo.com/news/astrazeneca-azn-beats-q4-earnings-130901030.html,AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling",2017-02-03 11:54:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-pfizer-merck-115411134.html,"Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling"
LLY,LLY:US,BBG000BNBDC2,Good News and Bad News for MannKind Corporation,2017-02-02 22:33:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P0DWpBQtrTg/good-news-and-bad-news-for-mannkind-corporation-cm742529,There s been a lot of bad news over the past couple of years for MannKind Corporation NASDAQ MNKD On Wednesday the drugmaker s executives talked about what many would consider to be more bad news But there was good news for MannKind as well Here s what you need to know from
LLY,LLY:US,BBG000BNBDC2,"Biogen Trails Merck, Lilly In Alzheimer's; Hemophilia Spinoff Begins Trading",2017-02-02 21:51:25 +0000,http://www.investors.com/news/technology/biogen-trails-merck-lilly-in-alzheimers-hemophilia-spin-off-begins-trading/,"Biogen Trails Merck, Lilly In Alzheimer's; Hemophilia Spinoff Begins Trading"
LLY,LLY:US,BBG000BNBDC2,"Q4 Scorecard and Analyst Reports for Eli Lilly, ADP & Aetna",2017-02-02 21:32:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SxTYe5DGb7Q/q4-scorecard-and-analyst-reports-for-eli-lilly-adp-aetna-cm742543,Thursday February 2 2017 The Zacks Research Daily features the best output of our research team every day In today s write up we are featuring analyst reports on 16 major stocks including reports on Eli Lilly LLY Aetna AET and Automatic Data Processing ADP These stock research
LLY,LLY:US,BBG000BNBDC2,"Q4 Scorecard and Analyst Reports for Eli Lilly, ADP & Aetna",2017-02-02 18:59:06 +0000,http://finance.yahoo.com/news/q4-scorecard-analyst-reports-eli-185906929.html,"Q4 Scorecard and Analyst Reports for Eli Lilly, ADP & Aetna"
LLY,LLY:US,BBG000BNBDC2,Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down,2017-02-02 16:36:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1fKnkk-5Qok/merck-mrk-tops-q4-earnings-pharmaceutical-sales-down-cm742200,Merck amp Co Inc MRK reported fourth quarter 2016 earnings of 89 cents per share which beat the Zacks Consensus Estimate of 88 cents by a penny However earnings declined 4 3 from the year ago period FindTheCompany Graphiq Merck s shares were up 5 5 so far
LLY,LLY:US,BBG000BNBDC2,Insiders Bullish on Certain Holdings of FTXH,2017-02-02 16:34:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/epmsjUkv8oQ/insiders-bullish-on-certain-holdings-of-ftxh-cm742204,A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF FTXH shows an impressive 16 1 of holdings on a weighted basis have experienced insider buying within the past six months Lilly Eli amp Co Symbol LLY which makes up 4 73 of the First
LLY,LLY:US,BBG000BNBDC2,Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents,2017-02-02 14:00:00 +0000,http://finance.yahoo.com/news/japan-ip-high-court-rules-140000541.html,"[PR Newswire] - INDIANAPOLIS, Feb. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by Sawai regarding Lilly's vitamin regimen patents for Alimta. In the fourth quarter of 2015, the Japan Patent Office issued written decisions upholding the validity of the Alimta vitamin regimen patents."
LLY,LLY:US,BBG000BNBDC2,Trump exerts more pressure on pharma CEOs,2017-02-01 23:01:14 +0000,http://au.finance.yahoo.com/news/trump-exerts-more-pressure-pharma-230114422.html,"[AAP] - US President Donald Trump has called on pharmaceutical executives to manufacture more of their drugs in the United States and cut prices, while vowing to speed approval of new medicines and ease regulation. Trump told them the government was paying ""astronomical"" prices for medicines in its health programs for older, disabled and poor people and said he would soon appoint a new U.S. Food and Drug Administration leader. ""We're going to streamline the FDA,"" Trump said in a statement, referring to the regulatory agency responsible for vetting that new drugs are safe and effective."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Fiscal 2016 Earnings,2017-02-01 23:00:02 +0000,http://finance.yahoo.com/news/eli-lillys-fiscal-2016-earnings-230002306.html,Eli Lilly's Fiscal 2016 Earnings
LLY,LLY:US,BBG000BNBDC2,Lilly Hijacks J&J Diabetes Share In Q4; Trump-Rattled Sector Dips,2017-02-01 21:09:05 +0000,http://www.investors.com/news/technology/lilly-hijacks-jj-diabetes-share-in-q4-trump-rattled-sector-dips/,Lilly Hijacks J&J Diabetes Share In Q4; Trump-Rattled Sector Dips
LLY,LLY:US,BBG000BNBDC2,Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16,2017-02-01 20:05:43 +0000,http://marketrealist.com/2017/02/weighing-the-foreign-exchange-impact-on-novartiss-revenues-in-4q16/?utm_source=yahoo&utm_medium=feed,Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16
LLY,LLY:US,BBG000BNBDC2,The Contrarian: A Closer Look at LLY Earnings,2017-02-01 17:54:00 +0000,http://www.investopedia.com/articles/investing/020117/contrarian-closer-look-lly-earnings.asp?partner=YahooSA,The Contrarian: A Closer Look at LLY Earnings
LLY,LLY:US,BBG000BNBDC2,"Lilly CEO Encouraged by Trump Meeting, Concerned About Obamacare",2017-02-01 17:05:47 +0000,http://finance.yahoo.com/news/lilly-ceo-encouraged-trump-meeting-170547520.html,"Lilly CEO Encouraged by Trump Meeting, Concerned About Obamacare"
LLY,LLY:US,BBG000BNBDC2,Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN,2017-02-01 15:34:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qERKto41_a4/drug-stocks-to-report-q4-earnings-on-feb-2-mrk-amgn-cm741446,With the Q4 earnings season well underway approximately 170 S amp P 500 members representing 33 9 of the index s total market capitalization have reported quarterly results as of Jan 27 An impressive 64 1 of these companies managed to post an earnings beat while 54 7
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO to Trump: We're not jacking up our drug costs for profit,2017-02-01 15:10:49 +0000,http://www.cnbc.com/id/104254079?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104254079,Eli Lilly CEO to Trump: We're not jacking up our drug costs for profit
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: Want to Work With U.S. on Drug Prices,2017-02-01 14:55:51 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-want-u-145551314.html,Eli Lilly CEO: Want to Work With U.S. on Drug Prices
LLY,LLY:US,BBG000BNBDC2,Health Care Sector Strengthened after Executives Met with Trump,2017-02-01 14:40:14 +0000,http://marketrealist.com/2017/02/health-care-regained-strength-executives-meeting-donald-trump/?utm_source=yahoo&utm_medium=feed,Health Care Sector Strengthened after Executives Met with Trump
LLY,LLY:US,BBG000BNBDC2,Drug Stocks Rally on Trump Meet with Pharma Bigwigs,2017-02-01 13:33:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QhqKQpny0z4/drug-stocks-rally-on-trump-meet-with-pharma-bigwigs-cm741361,Pharma and biotech shares rallied yesterday following a meeting between President Donald Trump and industry leaders including CEOs of companies like Merck amp Co Inc MRK Johnson amp Johnson JNJ Novartis AG NVS Celgene Corporation CELG Eli Lilly and Company LLY and Amgen
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: Looking for 'market based solutions' on dr...,2017-02-01 12:17:00 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-looking-market-121700444.html,Eli Lilly CEO: Looking for 'market based solutions' on dr...
LLY,LLY:US,BBG000BNBDC2,"High-Quality Dividend-Payers: What's Cheap, What's Not?",2017-02-01 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=790638&SR=Yahoo,"High-Quality Dividend-Payers: What's Cheap, What's Not?"
LLY,LLY:US,BBG000BNBDC2,Edited Transcript of LLY earnings conference call or presentation 31-Jan-17 4:30pm GMT,2017-02-01 01:21:50 +0000,http://finance.yahoo.com/news/edited-transcript-lly-earnings-conference-012150955.html,Edited Transcript of LLY earnings conference call or presentation 31-Jan-17 4:30pm GMT
LLY,LLY:US,BBG000BNBDC2,Cramer Remix: What is really freaking investors out about...,2017-02-01 00:11:00 +0000,http://finance.yahoo.com/video/cramer-remix-really-freaking-investors-001100985.html,Cramer Remix: What is really freaking investors out about...
LLY,LLY:US,BBG000BNBDC2,Cramer warns pharma still not safe to own despite Trump’s...,2017-01-31 23:44:00 +0000,http://finance.yahoo.com/video/cramer-warns-pharma-still-not-234400420.html,Cramer warns pharma still not safe to own despite Trump’s...
LLY,LLY:US,BBG000BNBDC2,LLY Crosses Above Key Moving Average Level,2017-01-31 22:32:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qA-ZuvVBcCw/lly-crosses-above-key-moving-average-level-cm741171,In trading on Tuesday shares of Lilly Eli amp Co Symbol LLY crossed above their 200 day moving average of 76 66 changing hands as high as 77 28 per share Lilly Eli amp Co shares are currently trading up about 3 on the day The chart below shows the one year performance of
LLY,LLY:US,BBG000BNBDC2,Making pharma great again?,2017-01-31 22:28:00 +0000,http://finance.yahoo.com/video/making-pharma-great-again-222800743.html,Making pharma great again?
LLY,LLY:US,BBG000BNBDC2,"Close Update: Dow Plagued by Immigration Ban and Earnings, But Ends Higher for Third Straight Month",2017-01-31 22:11:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FW2IugBXANI/close-update-dow-plagued-by-immigration-ban-and-earnings-but-ends-higher-for-third-straight-month-cm741174,The Dow Jones Industrial Average closed lower for a third straight day plagued by the fallout from President Donald Trump s immigration ban and disappointing Q4 earnings from some of Wall Street s heavyweights The S amp P 500 erased nearly all of today s losses to close nearly flat on the
LLY,LLY:US,BBG000BNBDC2,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD",2017-01-31 21:38:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-213800207.html,"[PR Newswire] - NEW YORK, Jan. 31, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) stock prior ..."
LLY,LLY:US,BBG000BNBDC2,Fmr. Onyx CEO: Responsibility to find and research cures ...,2017-01-31 21:17:00 +0000,http://finance.yahoo.com/video/fmr-onyx-ceo-responsibility-research-211700370.html,Fmr. Onyx CEO: Responsibility to find and research cures ...
LLY,LLY:US,BBG000BNBDC2,"Lilly Posts Mixed Q4, But Stock Gets A Trump Bump",2017-01-31 21:12:39 +0000,http://www.investors.com/news/technology/lilly-posts-200-million-q4-beat-on-diabetes-ed-meds-but-eps-lags/,"Lilly Posts Mixed Q4, But Stock Gets A Trump Bump"
LLY,LLY:US,BBG000BNBDC2,Biotech Stocks Gain on Latest Trump Drug Price Statements,2017-01-31 20:30:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zgx7TDxcRYs/biotech-stocks-gain-on-latest-trump-drug-price-statements-cm741065,It has been a rocky start for the Trump administration whose controversial decisions on immigration and refugees have already led to worldwide protests and clashes with leadership from both parties Nevertheless President Trump continues to double down on his campaign promises and his
LLY,LLY:US,BBG000BNBDC2,"Trump pushes drugmakers for lower prices, more U.S. production",2017-01-31 20:27:32 +0000,http://sg.finance.yahoo.com/news/trump-meet-novartis-ceo-other-121249594.html,"Trump pushes drugmakers for lower prices, more U.S. production"
LLY,LLY:US,BBG000BNBDC2,[$$] Trump Tells Pharmaceutical CEOs He Wants Prices Down,2017-01-31 20:21:45 +0000,http://www.wsj.com/articles/trump-tells-pharmaceutical-ceos-he-wants-prices-down-1485875553?mod=yahoo_hs,[$$] Trump Tells Pharmaceutical CEOs He Wants Prices Down
LLY,LLY:US,BBG000BNBDC2,Lilly Shares Pop Following Top-Line Beat,2017-01-31 18:52:00 +0000,http://www.investopedia.com/news/eli-lilly-co-revenue-beat-lly/?partner=YahooSA,Lilly Shares Pop Following Top-Line Beat
LLY,LLY:US,BBG000BNBDC2,Surviving a Trump Meeting Doesn’t Mean All Clear for Drug Industry,2017-01-31 18:36:00 +0000,http://finance.yahoo.com/news/surviving-trump-meeting-doesn-t-183600248.html,Surviving a Trump Meeting Doesn’t Mean All Clear for Drug Industry
LLY,LLY:US,BBG000BNBDC2,"Early movers: UAA, XOM, UPS, MA, LLY, HOG, PFE & more",2017-01-31 18:24:55 +0000,http://www.cnbc.com/id/104251508?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104251508,"Early movers: UAA, XOM, UPS, MA, LLY, HOG, PFE & more"
LLY,LLY:US,BBG000BNBDC2,Klain: Pharma will be net winner in exchange with Trump a...,2017-01-31 18:06:00 +0000,http://finance.yahoo.com/video/klain-pharma-net-winner-exchange-180600309.html,Klain: Pharma will be net winner in exchange with Trump a...
LLY,LLY:US,BBG000BNBDC2,Trump will have a hard time pushing drug prices down,2017-01-31 18:00:25 +0000,http://finance.yahoo.com/news/trump-will-have-a-hard-time-pushing-drug-prices-down-180025317.html,Trump will have a hard time pushing drug prices down
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues",2017-01-31 17:32:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-Coc4GmgN8U/eli-lilly-lly-misses-on-q4-earnings-beats-on-revenues-cm740899,Eli Lilly and Company s LLY fourth quarter results were mixed with the company beating on revenues but missing earnings expectations In the past one year Lilly s share price was down 4 8 comparing unfavorably with the 2 5 decrease witnessed by the Zacks classified Large Cap
LLY,LLY:US,BBG000BNBDC2,Incyte and Calithera Enter into Deal for Oncology Candidate,2017-01-31 16:34:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TY1o_SUpnAw/incyte-and-calithera-enter-into-deal-for-oncology-candidate-cm740811,Incyte Corporation INCY and Calithera Biosciences Inc CALA entered into a global collaboration and license agreement for research development and commercialization of the latter s arginase inhibitor candidate CB 1158 in the fields of hematology
LLY,LLY:US,BBG000BNBDC2,Healthcare Names Rally as Pharma Meets with Trump,2017-01-31 16:29:00 +0000,http://www.investopedia.com/news/trump-meets-pharma-ceos-stocks-pop-pfe-lly/?partner=YahooSA,Healthcare Names Rally as Pharma Meets with Trump
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues",2017-01-31 15:46:03 +0000,http://finance.yahoo.com/news/eli-lilly-lly-misses-q4-154603783.html,"Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump",2017-01-31 15:41:00 +0000,http://www.thestreet.com/video/13972845/eli-lilly-confirms-guidance-for-2017-ceo-meets-with-trump.html?puc=yahoov&cm_ven=YAHOOV,"Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump"
LLY,LLY:US,BBG000BNBDC2,Incyte and Calithera Enter into Deal for Oncology Candidate,2017-01-31 14:55:02 +0000,http://finance.yahoo.com/news/incyte-calithera-enter-deal-oncology-145502787.html,Incyte and Calithera Enter into Deal for Oncology Candidate
LLY,LLY:US,BBG000BNBDC2,"Stock Futures Defensive as Immigration Ban, Earnings Weigh on Wall Street",2017-01-31 14:51:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/147wGG0CdyA/stock-futures-defensive-as-immigration-ban-earnings-weigh-on-wall-street-cm740740,Stocks were set to add to Monday s sizable losses as President Trump s immigration ban continued to weigh on Wall Street and Q4 earnings failed to meet investor s expectations Stocks were set to add to Monday s sizable losses as President Trump s immigration ban continued to weigh on Wall
LLY,LLY:US,BBG000BNBDC2,How Eli Lilly Earnings Won Big on New Drug Sales,2017-01-31 14:50:59 +0000,http://finance.yahoo.com/news/eli-lilly-earnings-won-big-145059224.html,How Eli Lilly Earnings Won Big on New Drug Sales
LLY,LLY:US,BBG000BNBDC2,Trump says drug prices are 'astronomical',2017-01-31 14:48:07 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=A18FAF41-1B41-4FB3-A3D2-8DA9D94CCCC3&siteid=yhoof2,Trump says drug prices are 'astronomical'
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Q4 Earnings Miss, Revenues Beat",2017-01-31 14:35:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2ozsPWdU4Po/lilly-lly-q4-earnings-miss-revenues-beat-cm740795,Indianapolis IN based Eli Lilly and Company LLY is a global healthcare company with core products in a number of primary care pharmaceutical markets Lilly generates revenues from its pharmaceutical product and animal health segments The company s portfolio includes Zyprexa
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Profit and Revenue Rise on New Drugs,2017-01-31 14:24:15 +0000,http://www.wsj.com/articles/eli-lilly-profit-and-revenue-rise-on-new-drugs-1485865338?mod=yahoo_hs,[$$] Eli Lilly Profit and Revenue Rise on New Drugs
LLY,LLY:US,BBG000BNBDC2,Lilly revenue beats as diabetes drug sales rise,2017-01-31 14:01:45 +0000,http://finance.yahoo.com/news/lilly-revenue-beats-diabetes-drug-115601627.html,Lilly revenue beats as diabetes drug sales rise
LLY,LLY:US,BBG000BNBDC2,Trump Calls For Increased Competition To Reduce Drug Prices,2017-01-31 13:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yqw5STKRvP0/trump-calls-for-increased-competition-to-reduce-drug-prices-20170131-01172,Trump Calls For Increased Competition To Reduce Drug Prices
LLY,LLY:US,BBG000BNBDC2,Lilly 4Q profit surges on diabetes drug sales,2017-01-31 13:23:32 +0000,http://sg.finance.yahoo.com/news/lilly-misses-4q-profit-forecasts-113642461.html,Lilly 4Q profit surges on diabetes drug sales
LLY,LLY:US,BBG000BNBDC2,How Risky Is Acadia Pharmaceuticals Stock?,2017-01-31 13:12:51 +0000,http://www.fool.com/investing/2017/01/30/how-risky-is-acadia-pharmaceuticals-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How Risky Is Acadia Pharmaceuticals Stock?
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Q4 Earnings Miss, Revenues Beat",2017-01-31 13:08:01 +0000,http://finance.yahoo.com/news/lilly-lly-q4-earnings-miss-130801554.html,"Lilly (LLY) Q4 Earnings Miss, Revenues Beat"
LLY,LLY:US,BBG000BNBDC2,Lilly Earnings Guidance for 2017 Remains Unchanged,2017-01-31 12:28:00 +0000,https://www.thestreet.com/story/13972271/1/lilly-earnings-guidance-for-2017-remains-unchanged.html?puc=yahoo&cm_ven=YAHOO,Lilly Earnings Guidance for 2017 Remains Unchanged
LLY,LLY:US,BBG000BNBDC2,The Swiss Stock Market Pared Its Early Gains And Finished With A Loss,2017-01-31 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzS20DwJOd0/the-swiss-stock-market-pared-its-early-gains-and-finished-with-a-loss-20170131-01090,The Swiss Stock Market Pared Its Early Gains And Finished With A Loss
LLY,LLY:US,BBG000BNBDC2,Market Recon: Political Risk Shows Signs of Becoming Ongoing Condition,2017-01-31 12:14:00 +0000,https://www.thestreet.com/story/13972252/1/market-recon-political-risk-shows-signs-of-becoming-ongoing-condition.html?puc=yahoo&cm_ven=YAHOO,Market Recon: Political Risk Shows Signs of Becoming Ongoing Condition
LLY,LLY:US,BBG000BNBDC2,Q4 2016 Eli Lilly and Co Earnings Release - Before Market Open,2017-01-31 12:07:06 +0000,http://biz.yahoo.com/research/earncal/20170131.html?t=lly,Q4 2016 Eli Lilly and Co Earnings Release - Before Market Open
LLY,LLY:US,BBG000BNBDC2,Lilly’s Strong Humalog Sales Fuel Rise in Fourth-Quarter Revenue,2017-01-31 11:36:18 +0000,http://www.bloomberg.com/news/articles/2017-01-31/lilly-misses-analysts-estimates-as-sales-of-older-products-fall?cmpid=yhoo.headline,Lilly’s Strong Humalog Sales Fuel Rise in Fourth-Quarter Revenue
LLY,LLY:US,BBG000BNBDC2,Lilly revenue rises 7.2 pct on higher demand for new drugs,2017-01-31 11:33:40 +0000,http://finance.yahoo.com/news/lilly-revenue-rises-7-2-113340699.html,Lilly revenue rises 7.2 pct on higher demand for new drugs
LLY,LLY:US,BBG000BNBDC2,Lilly Reports Fourth-Quarter and Full-Year 2016 Results,2017-01-31 11:25:00 +0000,http://finance.yahoo.com/news/lilly-reports-fourth-quarter-full-112500078.html,"[PR Newswire] - INDIANAPOLIS, Jan. 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2016. $ in millions, except per share data Fourth ..."
LLY,LLY:US,BBG000BNBDC2,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M",2017-01-31 10:05:38 +0000,http://finance.yahoo.com/news/jaguar-animal-health-elanco-announce-100538246.html,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M"
LLY,LLY:US,BBG000BNBDC2,"Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of Canalevia",2017-01-31 10:00:00 +0000,http://finance.yahoo.com/news/jaguar-animal-health-elanco-enter-100000136.html,"[Business Wire] - Jaguar Animal Health, Inc. and Elanco US Inc., a subsidiary of Eli Lilly and Company , today announced an agreement to license, develop, and commercialize Canalevia™, a Jaguar drug product candidate under investigation for treatment of acute and chemotherapy-induced diarrhea in dogs."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Q4 16 Earnings Conference Call At 9:00 AM ET,2017-01-31 08:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2dWuu3N_UPg/eli-lilly-q4-16-earnings-conference-call-at-900-am-et-20170131-00558,Eli Lilly Q4 16 Earnings Conference Call At 9:00 AM ET
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Q4 Profit Misses, But Revenues Beat",2017-01-31 06:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fZ2hOrHXFBA/eli-lilly-q4-profit-misses-but-revenues-beat-20170131-00318,"Eli Lilly Q4 Profit Misses, But Revenues Beat"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Q4 16 Earnings Conference Call At 9:00 AM ET,2017-01-31 06:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Oy9x9QPbSFU/eli-lilly-and-co-q4-16-earnings-conference-call-at-900-am-et-20170131-00285,Eli Lilly And Co. Q4 16 Earnings Conference Call At 9:00 AM ET
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Announces 22% Gain In Q4 Profit,2017-01-31 06:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jTlK-YQsgEM/eli-lilly-and-co-announces-22-gain-in-q4-profit-20170131-00281,Eli Lilly And Co. Announces 22% Gain In Q4 Profit
LLY,LLY:US,BBG000BNBDC2,Jaguar Animal Health Signs With Elanco Global To Co-Promote Canalevia,2017-01-31 05:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7gyyvJPFPv8/jaguar-animal-health-signs-with-elanco-global-to-copromote-canalevia-20170131-00188,Jaguar Animal Health Signs With Elanco Global To Co-Promote Canalevia
LLY,LLY:US,BBG000BNBDC2,"Sanofi, Novo Nordisk, Lilly being sued",2017-01-31 03:06:05 +0000,http://au.finance.yahoo.com/news/sanofi-novo-nordisk-lilly-being-030605247.html,"[AAP] - Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly & Co, have been named in a class action lawsuit about price fixing filed by a group of patients. The suit, filed on Monday in a federal court in Massachusetts, said the companies have simultaneously hiked the price of insulin by over 150 per cent during the past five years. The 12 named plaintiffs, residents of Georgia, Florida, California and Massachusetts who have diabetes, claim Sanofi, Novo Nordisk and Lilly raised their public benchmark price for insulin products while maintaining a lower ""true"" price they charged large pharmacy benefit managers like Express Scripts, CVS Health and OptumRX."
LLY,LLY:US,BBG000BNBDC2,LLY Named in Latest Drug Pricing Controversy,2017-01-30 22:15:00 +0000,http://www.investopedia.com/news/eli-lilly-co-part-lawsuit-over-insulin-lly/?partner=YahooSA,LLY Named in Latest Drug Pricing Controversy
LLY,LLY:US,BBG000BNBDC2,"Pre-Market Earnings Report for January 31, 2017 :  XOM, PFE, MA, LLY, UPS, TMO, SPG, DHR, AET, S, VLO, HCA",2017-01-30 21:11:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qmAOdReUxPs/pre-market-earnings-report-for-january-31-2017-xom-pfe-ma-lly-ups-tmo-spg-dhr-aet-s-vlo-hca-cm740464,The following companies are expected to report earnings prior to market open on 01 31 2017 Visit our Earnings Calendar for a full list of expected earnings releases Exxon Mobil Corporation XOM is reporting for the quarter ending December 31 2016 The
LLY,LLY:US,BBG000BNBDC2,"Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit",2017-01-30 20:18:30 +0000,http://finance.yahoo.com/news/sanofi-novo-nordisk-lilly-named-201830580.html,"[Reuters] - Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly & Co, were named in a class action lawsuit about price fixing filed by a group of patients. The suit, filed in ..."
LLY,LLY:US,BBG000BNBDC2,"XPH, JAZZ, LLY, HZNP: Large Outflows Detected at ETF",2017-01-30 17:31:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wup6DXNV_VQ/xph-jazz-lly-hznp-large-outflows-detected-at-etf-cm740205,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Pharmaceuticals ETF Symbol XPH where we have detected an approximate 32 1 million dollar outflow that s a 7 1 decrease week over week
LLY,LLY:US,BBG000BNBDC2,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour",2017-01-30 17:26:00 +0000,http://finance.yahoo.com/news/mixed-bag-earnings-ahead-eli-172600301.html,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour"
LLY,LLY:US,BBG000BNBDC2,Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement,2017-01-30 17:00:00 +0000,http://finance.yahoo.com/news/lilly-revises-time-conference-call-170000528.html,"[PR Newswire] - INDIANAPOLIS, Jan. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to discuss the company's fourth-quarter and full-year 2016 financial results. A live webcast of the conference call will be available through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm. The company's press release announcing its fourth-quarter and full-year 2016 financial results will be issued as originally planned at approximately 6:30 a.m. Eastern Time."
LLY,LLY:US,BBG000BNBDC2,Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline,2017-01-30 15:36:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cNnexRSJ6zQ/key-takeaways-from-abbvies-q4-call-humira-and-the-pipeline-cm740105,AbbVie Inc s ABBV shares were down 2 1 following the release of fourth quarter and full year 2016 results on Friday Although earnings were in line with expectations revenues fell short mainly due to Imbruvica and Viekira sales Read more AbbVie Q4 Earnings Meet Estimates Revenues
LLY,LLY:US,BBG000BNBDC2,Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?,2017-01-30 15:36:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0bQD2_ATjdo/is-a-surprise-coming-for-eli-lilly-lly-this-earnings-season-cm740090,Investors are always looking for stocks that are poised to beat at earnings season and Eli Lilly and Company LLY may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Eli Lilly is seeing favorable
LLY,LLY:US,BBG000BNBDC2,How Risky Is Acadia Pharmaceuticals Stock?,2017-01-30 14:34:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3xlNO9Y9ysg/how-risky-is-acadia-pharmaceuticals-stock-cm740003,Acadia Pharmaceuticals NASDAQ ACAD is probably in better shape now than it s ever been The biotech won approval last year for its lead product Nuplazid in treating Parkinson s disease psychosis Acadia s stock is up more than 30 over the past 12 months Additional studies
LLY,LLY:US,BBG000BNBDC2,Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE,2017-01-30 13:33:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8OwP6JmTR8U/drug-stocks-reporting-q4-earnings-on-jan-31-lly-and-pfe-cm739957,As the Q4 earnings season picks up pace we believe this quarter is witnessing the highest growth momentum in the last eight quarters As of Jan 27 2017 170 S amp P 500 members accounting for 33 9 of the index s total market capitalization have reported results according to the
LLY,LLY:US,BBG000BNBDC2,Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?,2017-01-30 13:32:01 +0000,http://finance.yahoo.com/news/surprise-coming-eli-lilly-lly-133201884.html,Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?
LLY,LLY:US,BBG000BNBDC2,Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline,2017-01-30 13:21:01 +0000,http://finance.yahoo.com/news/key-takeaways-abbvies-q4-call-132101008.html,Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline
LLY,LLY:US,BBG000BNBDC2,Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE,2017-01-30 11:06:11 +0000,http://finance.yahoo.com/news/drug-stocks-reporting-q4-earnings-110611159.html,Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE
LLY,LLY:US,BBG000BNBDC2,"Week Ahead: Apple Earnings Headline Busy Week of Fed Meetings, Jobs Numbers",2017-01-29 15:00:00 +0000,https://www.thestreet.com/story/13969724/1/week-ahead-apple-earnings-headline-busy-week-of-fed-meetings-jobs-numbers.html?puc=yahoo&cm_ven=YAHOO,"Week Ahead: Apple Earnings Headline Busy Week of Fed Meetings, Jobs Numbers"
LLY,LLY:US,BBG000BNBDC2,You Better Not Behave Like an Over-Caffeinated Day Trader Right Now,2017-01-28 16:05:00 +0000,https://www.thestreet.com/story/13970325/1/investor-euphoria-lasting-momentum-or-sugar-high.html?puc=yahoo&cm_ven=YAHOO,You Better Not Behave Like an Over-Caffeinated Day Trader Right Now
LLY,LLY:US,BBG000BNBDC2,"Earnings Growth Returns, Will it Continue?",2017-01-28 06:30:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VQrXaufF75o/earnings-growth-returns-will-it-continue-cm739733,Corporate earnings have started growing again with growth in the ongoing Q4 earnings season on track to reach its highest level in 8 quarters Growth is still modest the Q4 earnings growth is currently on track to reach 5 2 and the final growth tally for the quarter will at best be a couple
LLY,LLY:US,BBG000BNBDC2,Biogen Inc Makes Up for Lackluster Revenue Growth,2017-01-27 20:31:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8o8GYbMJ2-s/biogen-inc-makes-up-for-lackluster-revenue-growth-cm739551,Biogen s NASDAQ BIIB fourth quarter revenue 160 left something to be desired but the biotech made up for the lackluster growth with a curtailing of expenses resulting in a solid 12 increase in adjusted earnings per share Image source Getty Images
LLY,LLY:US,BBG000BNBDC2,Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?,2017-01-27 16:36:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EWjzfYpdrD8/will-amgen-amgn-keep-the-earnings-streak-alive-in-q4-cm739399,We expect biotech major Amgen Inc AMGN to beat expectations when it reports fourth quarter 2016 and full year results on Feb 2 after the market closes Amgen had delivered a positive earnings surprise of 8 24 in the last quarter Amgen s shares were up 4 6 so far this year This
LLY,LLY:US,BBG000BNBDC2,Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?,2017-01-27 16:35:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q7tnTQxQd3U/merck-mrk-stock-to-gain-on-likely-earnings-beat-in-q4-cm739358,We expect pharma heavyweight Merck amp Co Inc MRK to beat expectations when it reports fourth quarter 2016 and full year earnings results on Feb 2 before the market opens Last quarter the company delivered a positive earnings surprise of 9 18 Merck s shares rose 3 9 so far this
LLY,LLY:US,BBG000BNBDC2,What Recent Developments Could Drive Eli Lilly’s Growth?,2017-01-27 15:36:00 +0000,http://marketrealist.com/2017/01/what-recent-developments-could-drive-eli-lillys-growth/?utm_source=yahoo&utm_medium=feed,What Recent Developments Could Drive Eli Lilly’s Growth?
LLY,LLY:US,BBG000BNBDC2,What to Expect from Eli Lilly’s Elanco in 4Q16,2017-01-27 14:05:57 +0000,http://marketrealist.com/2017/01/what-to-expect-from-eli-lillys-elanco-in-4q16/?utm_source=yahoo&utm_medium=feed,What to Expect from Eli Lilly’s Elanco in 4Q16
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint",2017-01-27 13:33:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kLuU7W2doGg/pharma-stock-roundup-jj-to-buy-actelion-bristol-myers-4q-results-disappoint-cm739155,Healthcare giant Johnson amp Johnson JNJ and Swiss company Actelion finally announced an agreement under which J amp J will acquire Actelion for about 30 billion Meanwhile companies like J amp J Read more J amp J Q4 Earnings Top Seeks Options for Diabetes Unit Novartis Read
LLY,LLY:US,BBG000BNBDC2,What Are Eli Lilly’s 4Q16 Expectations for New Products?,2017-01-27 12:36:01 +0000,http://marketrealist.com/2017/01/what-are-eli-lillys-4q16-expectations-for-new-products/?utm_source=yahoo&utm_medium=feed,What Are Eli Lilly’s 4Q16 Expectations for New Products?
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint",2017-01-27 11:04:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-110411214.html,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Ends Collaboration Agreement On Adocia's Lispro Insulin - Quick Facts,2017-01-27 01:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xd50npHkOBs/eli-lilly-ends-collaboration-agreement-on-adocias-lispro-insulin--quick-facts-20170127-00035,Eli Lilly Ends Collaboration Agreement On Adocia's Lispro Insulin - Quick Facts
LLY,LLY:US,BBG000BNBDC2,"Big companies' share prices went up, but not in this one industry",2017-01-26 17:45:05 +0000,http://www.bizjournals.com/bizjournals/news/2017/01/26/big-companies-share-prices-go-up-but-not-in-this.html?ana=yahoo,"Big companies' share prices went up, but not in this one industry"
LLY,LLY:US,BBG000BNBDC2,What to Expect from Eli Lilly’s Oncology Franchise in 4Q16,2017-01-26 15:36:17 +0000,http://marketrealist.com/2017/01/what-to-expect-from-eli-lillys-oncology-franchise-in-4q16/?utm_source=yahoo&utm_medium=feed,What to Expect from Eli Lilly’s Oncology Franchise in 4Q16
LLY,LLY:US,BBG000BNBDC2,What to Expect from Eli Lilly’s Cardiovascular Franchise in 4Q16,2017-01-26 14:06:33 +0000,http://marketrealist.com/2017/01/what-to-expect-from-eli-lillys-cardiovascular-franchise-in-4q16/?utm_source=yahoo&utm_medium=feed,What to Expect from Eli Lilly’s Cardiovascular Franchise in 4Q16
LLY,LLY:US,BBG000BNBDC2,How Will Eli Lilly’s Neuroscience Franchise Fare in 4Q16?,2017-01-26 12:37:11 +0000,http://marketrealist.com/2017/01/how-will-eli-lilys-neuroscience-franchise-fare-in-4q16/?utm_source=yahoo&utm_medium=feed,How Will Eli Lilly’s Neuroscience Franchise Fare in 4Q16?
LLY,LLY:US,BBG000BNBDC2,Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug,2017-01-25 21:30:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Exl7mazC7A8/lillys-elanco-unit-aratana-launch-veterinary-pain-drug-cm738292,Eli Lilly and Company s LLY animal health subsidiary Elanco and partner Aratana Therapeutics Inc PETX together announced the availability of a new drug Galliprant grapiprant tablets to the veterinarians for the management of pain and inflammation associated with canine
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson's 2017 Guidance Disappoints -- Could This Be the Issue?,2017-01-25 20:32:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TOLUriVe5Ac/johnson-johnsons-2017-guidance-disappoints-could-this-be-the-issue-cm738256,Image source Getty Images Before the opening bell on Tuesday morning healthcare conglomerate Johnson amp Johnson NYSE JNJ kicked off earnings season for the sector by reporting its fourth quarter and full year results for fiscal 2016 Often known for being a source
LLY,LLY:US,BBG000BNBDC2,Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug,2017-01-25 19:52:07 +0000,http://finance.yahoo.com/news/lillys-elanco-unit-aratana-launch-195207226.html,Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
LLY,LLY:US,BBG000BNBDC2,How Will Eli Lilly’s Endocrine Franchise Fare in 4Q16?,2017-01-25 18:35:43 +0000,http://marketrealist.com/2017/01/how-will-eli-lillys-endocrine-franchise-fare-in-4q16/?utm_source=yahoo&utm_medium=feed,How Will Eli Lilly’s Endocrine Franchise Fare in 4Q16?
LLY,LLY:US,BBG000BNBDC2,Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?,2017-01-25 17:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YtmLGFJ0mU8/will-eli-lillys-lly-earnings-surpass-estimates-in-q4-cm738127,We expect Eli Lilly and Company LLY to beat expectations when it reports fourth quarter and full year 2016 earnings results on Jan 31 before market opens So far this year Lilly s share price has improved 1 7 as against a decrease of 1 6 for the Zacks classified Large Cap Pharma
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly Expects to See Revenue Growth in 4Q16,2017-01-25 17:05:53 +0000,http://marketrealist.com/2017/01/why-eli-lilly-expects-to-see-revenue-growth-in-4q16/?utm_source=yahoo&utm_medium=feed,Why Eli Lilly Expects to See Revenue Growth in 4Q16
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical",2017-01-25 16:36:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fJbLOcw-oFU/the-zacks-analyst-blog-highlights-american-express-time-warner-eli-lilly-hewlett-packard-and-dow-chemical-cm738021,For Immediate Release Chicago IL January 25 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,What Can Investors Expect from Eli Lilly’s 4Q16 Earnings?,2017-01-25 15:20:42 +0000,http://marketrealist.com/2017/01/what-can-investors-expect-from-eli-lillys-4q16-earnings/?utm_source=yahoo&utm_medium=feed,What Can Investors Expect from Eli Lilly’s 4Q16 Earnings?
LLY,LLY:US,BBG000BNBDC2,Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?,2017-01-25 15:20:03 +0000,http://finance.yahoo.com/news/eli-lillys-lly-earnings-surpass-152003599.html,Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical",2017-01-25 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-american-143002042.html,"The Zacks Analyst Blog Highlights: American Express, Time Warner, Eli Lilly, Hewlett Packard and Dow Chemical"
LLY,LLY:US,BBG000BNBDC2,"Novartis launches $5 billion share buyback, mulls Alcon spin-off",2017-01-25 11:32:53 +0000,http://sg.finance.yahoo.com/news/novartis-weighs-alcon-spinoff-launches-062857758.html,"Novartis launches $5 billion share buyback, mulls Alcon spin-off"
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for January 24, 2017",2017-01-24 23:32:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KXdjGFZs8hw/top-research-reports-for-january-24-2017-cm737722,Tuesday January 24 2017 Today s Research Daily features new research reports on 16 major stocks including American Express AXP Time Warner TWX and Eli Lilly LLY Buy rated American Express fourth quarter 2016 adjusted earnings per share EPS missed the Zacks Consensus Estimate
LLY,LLY:US,BBG000BNBDC2,Can AbbVie (ABBV) Spring a Surprise This Earnings Season?,2017-01-24 23:32:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kk9B-RTCfo0/can-abbvie-abbv-spring-a-surprise-this-earnings-season-cm737701,AbbVie Inc ABBV is slated to release fourth quarter and full year 2016 earnings results before the opening bell on Jan 27 AbbVie s shares improved 4 0 in the past one year while the Zacks classified Biomed Genetics industry recorded a decline of 1 6 Last quarter the
LLY,LLY:US,BBG000BNBDC2,Roche Gouges Bristol-Myers' Q4 Lung Cancer Share Amid Merck Rivalry,2017-01-24 22:07:47 +0000,http://www.investors.com/news/technology/roche-gouges-bristol-myers-q4-lung-cancer-share-amid-merck-rivalry/,Roche Gouges Bristol-Myers' Q4 Lung Cancer Share Amid Merck Rivalry
LLY,LLY:US,BBG000BNBDC2,Galliprant® (grapiprant tablets) Now Available for Canine Osteoarthritis,2017-01-24 21:35:00 +0000,http://finance.yahoo.com/news/galliprant-grapiprant-tablets-now-available-213500538.html,"[PR Newswire] - GREENFIELD, Ind. and LEAWOOD, Kan., Jan. 24, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), and Aratana Therapeutics, Inc. (PETX) have announced veterinarians have a new targeted tool for the management of pain and inflammation associated with canine osteoarthritis (OA). Galliprant® (grapiprant tablets), a first-in-class piprant, is now available to veterinarians for once-daily use in dogs with OA. ""Osteoarthritis is one of the most common causes of chronic pain in dogs—and there is no cure1,"" stated Dr. Tony Rumschlag, Director of Regional Consulting Veterinarians for Elanco Animal Health."
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for January 24, 2017",2017-01-24 20:31:08 +0000,http://finance.yahoo.com/news/top-research-reports-january-24-203108159.html,"Top Research Reports for January 24, 2017"
LLY,LLY:US,BBG000BNBDC2,Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?,2017-01-24 17:30:57 +0000,http://www.insidermonkey.com/blog/can-acorda-therapeutics-inc-acor-give-eli-lilly-and-co-lly-a-run-for-its-money-in-migraine-drug-market-523233/,Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?
LLY,LLY:US,BBG000BNBDC2,"Dems challenge Trump health nominee on stocks, health policy",2017-01-24 16:57:29 +0000,http://finance.yahoo.com/news/trumps-pick-health-secretary-faces-senate-hearing-082612827--finance.html,"Dems challenge Trump health nominee on stocks, health policy"
LLY,LLY:US,BBG000BNBDC2,Incyte Has Insight Into Market With Potential Blockbuster Drugs,2017-01-23 22:31:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aNJsNL6Dqnc/incyte-has-insight-into-market-with-potential-blockbuster-drugs-cm736068,The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year but midcap Incyte INCY is one of the few companies with potential blockbusters in its pipeline Incyte closed out 2016 and started 2017 with some major developments The
LLY,LLY:US,BBG000BNBDC2,Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset,2017-01-23 22:03:36 +0000,http://www.investors.com/news/technology/acorda-could-rival-lillys-novel-migraine-drug-with-faster-onset/,Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
LLY,LLY:US,BBG000BNBDC2,"LLY Reports On Jan. 31st, What Should You Look For",2017-01-23 18:17:00 +0000,http://www.investopedia.com/news/what-expect-ely-lilly-co-q4-lly/?partner=YahooSA,"LLY Reports On Jan. 31st, What Should You Look For"
LLY,LLY:US,BBG000BNBDC2,"Noteworthy ETF Inflows: VTV, USB, LLY, LMT",2017-01-23 17:32:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IuIu_6kfeFw/noteworthy-etf-inflows-vtv-usb-lly-lmt-cm736787,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Value ETF Symbol VTV where we have detected an approximate 268 3 million dollar inflow that s a 1 0 increase week over week in outstanding units
LLY,LLY:US,BBG000BNBDC2,10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report,2017-01-23 16:05:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4S5b7CjHka8/10-questions-that-need-to-be-asked-ahead-of-johnson-johnsons-q4-report-cm736527,Image source Getty Images Though it technically never ends earnings season is about to kick into high gear For about a six week stretch a vast majority of S amp P 500 companies are set to report their performance from the previous quarter Conglomerate Johnson amp
LLY,LLY:US,BBG000BNBDC2,10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report,2017-01-23 13:31:08 +0000,http://www.fool.com/investing/2017/01/23/10-questions-that-need-to-be-asked-ahead-of-johnso.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report
LLY,LLY:US,BBG000BNBDC2,Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting,2017-01-23 12:55:00 +0000,http://finance.yahoo.com/news/inovalon-announces-agreement-boehringer-ingelheim-125500025.html,"[GlobeNewswire] - BOWIE, Md., Jan. 23, 2017-- Inovalon, a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based models across the healthcare ..."
LLY,LLY:US,BBG000BNBDC2,Inovalon Announces Deal With Boehringer Ingelheim,2017-01-23 08:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIQk3s91wd0/inovalon-announces-deal-with-boehringer-ingelheim-20170123-00481,Inovalon Announces Deal With Boehringer Ingelheim
LLY,LLY:US,BBG000BNBDC2,What's in Store for Abbott Labs (ABT) This Earnings Season?,2017-01-21 00:36:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mSSltGEFQ2Q/whats-in-store-for-abbott-labs-abt-this-earnings-season-cm736279,Abbott Laboratories ABT is scheduled to report fourth quarter and full year 2016 results before the opening bell on Jan 25 Shares of Abbott Labs have outperformed the Zacks classified Large Cap Pharmaceuticals industry in the last 12 months In fact the stock improved 1 1 during
LLY,LLY:US,BBG000BNBDC2,Incyte Poised To Outperform Biotech Industry On Strong Pipeline,2017-01-20 22:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y-pPosM2-7s/incyte-poised-to-outperform-biotech-industry-on-strong-pipeline-cm736068,The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year but midcap Incyte INCY is one of the few companies with potential blockbusters in its pipeline Incyte closed out 2016 and started 2017 with some major developments The
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks Poised to Surprise this Earnings Season,2017-01-20 21:37:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vsXrsR8Pacs/4-drug-stocks-poised-to-surprise-this-earnings-season-cm736210,In the biotech sector investor focus will now shift from the annual J P Morgan Healthcare Conference to the Q4 earnings season The sector has faced challenging conditions for more than a year due to media and political focus on steep drug pricing issues Meanwhile merger
LLY,LLY:US,BBG000BNBDC2,Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?,2017-01-20 21:37:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/su_u7lvh8KE/novartis-nvs-q4-earnings-stock-likely-to-disappoint-cm736208,Swiss pharmaceutical company Novartis AG NVS is scheduled to report fourth quarter and full year 2016 results on Jan 25 A look at Novartis share price movement in the last 12 months shows that the stock has underperformed the Zacks classified Large Cap
LLY,LLY:US,BBG000BNBDC2,Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?,2017-01-20 19:52:07 +0000,http://finance.yahoo.com/news/novartis-nvs-q4-earnings-stock-195207259.html,Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
LLY,LLY:US,BBG000BNBDC2,4 Drug Stocks Poised to Surprise this Earnings Season,2017-01-20 19:41:07 +0000,http://finance.yahoo.com/news/4-drug-stocks-poised-surprise-194107646.html,4 Drug Stocks Poised to Surprise this Earnings Season
LLY,LLY:US,BBG000BNBDC2,"Top 5 pharma companies by profitability : January 20, 2017",2017-01-20 15:49:43 +0000,http://www.capitalcube.com/blog/index.php/top-5-pharma-companies-by-profitability-january-20-2017/,"Top 5 pharma companies by profitability : January 20, 2017"
LLY,LLY:US,BBG000BNBDC2,Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?,2017-01-20 15:42:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JzyJ_JWgrrs/celgene-celg-q4-earnings-will-the-stock-pull-a-surprise-cm735907,Celgene Corporation CELG is scheduled to report fourth quarter 2016 results on Jan 26 before the opening bell Last quarter the company reported a positive earnings surprise of 6 11 Notably shares of Celgene have outperformed the Zacks classified Medical Biomedical and Genetics industry
LLY,LLY:US,BBG000BNBDC2,Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?,2017-01-20 13:45:01 +0000,http://finance.yahoo.com/news/celgene-celg-q4-earnings-stock-134501406.html,Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
LLY,LLY:US,BBG000BNBDC2,Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday,2017-01-19 21:38:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LcvpqJXmweA/heres-why-colucid-pharmaceuticals-inc-popped-yesterday-cm735652,Image source Getty Images What happened Investors in CoLucid Pharmaceuticals NASDAQ CLCD 160 should be smiling from ear to ear today Shares of the clinical stage biopharmaceutical company shot up 33 yesterday in response to receiving a buyout offer from
LLY,LLY:US,BBG000BNBDC2,Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday,2017-01-19 19:42:10 +0000,http://www.fool.com/investing/2017/01/19/heres-why-colucid-pharmaceuticals-inc-popped-yeste.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday
LLY,LLY:US,BBG000BNBDC2,Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal,2017-01-19 18:40:36 +0000,http://www.insidermonkey.com/blog/heres-what-you-need-to-know-about-the-eli-lilly-and-co-lly-and-colucid-pharmaceuticals-inc-clcd-deal-520673/,Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal
LLY,LLY:US,BBG000BNBDC2,Why is Pharma Struggling to Grow EPS?,2017-01-19 18:15:00 +0000,http://www.investopedia.com/news/transition-continues-glaxosmithkline-gsk-lly/?partner=YahooSA,Why is Pharma Struggling to Grow EPS?
LLY,LLY:US,BBG000BNBDC2,Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?,2017-01-19 15:42:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FBxpCbvYNfY/vertex-pharma-vrtx-q4-earnings-stock-likely-to-beat-cm735337,We expect biotech company Vertex Pharmaceuticals Inc VRTX to beat expectations when it reports fourth quarter 2016 and full year earnings results on Jan 25 after the market closes Vertex s share price lost 14 9 in the past one year comparing unfavorably with the 12 9 decline
LLY,LLY:US,BBG000BNBDC2,Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?,2017-01-19 15:41:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aC3UeT0E4C8/bristol-myers-bmy-q4-earnings-will-the-stock-disappoint-cm735331,Bristol Myers Squibb Company BMY is scheduled to report fourth quarter 2016 results on Jan 26 before the opening bell Last quarter the company posted a positive earnings surprise of 18 46 Bristol Myers has underperformed the Zacks classified Large Cap Pharmaceuticals industry in the
LLY,LLY:US,BBG000BNBDC2,Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?,2017-01-19 15:41:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-IICdyRleIM/biogen-biib-q4-earnings-whats-in-store-for-the-stock-cm735329,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will be reporting fourth quarter 2016 and full year earnings on Jan 26 before the market opens Last quarter the company delivered a positive earnings surprise of 4 01 Biogen s shares rose 5 3 in the past one
LLY,LLY:US,BBG000BNBDC2,Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout,2017-01-19 15:41:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HuTTxIy3wBA/lilly-to-boost-migraine-pipeline-with-960m-colucid-buyout-cm735316,Eli Lilly and Company LLY announced that it plans to buy Cambridge MA based biotech firm CoLucid Pharmaceuticals Inc CLCD for approximately 960 million in cash The deal will enhance Lilly s pain management portfolio for migraine The announcement sent CoLucid s soaring over 32
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative,2017-01-19 14:41:03 +0000,http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_360820&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20170119_PR_360820,Eli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative
LLY,LLY:US,BBG000BNBDC2,Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout,2017-01-19 13:42:01 +0000,http://finance.yahoo.com/news/lilly-boost-migraine-pipeline-960m-134201646.html,Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Eli Lilly Announced Acquisition of CoLucid; Adds Lasmiditan to the Pain Management Portfolio,2017-01-19 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-eli-lilly-announced-131500475.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / January 19, 2017 / Active Wall St. blog coverage looks at the headline from Eli Lilly and Co. (NYSE: LLY ) and CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ) as both companies ..."
LLY,LLY:US,BBG000BNBDC2,"DERM Delights With A Hat-trick, Shot In The Arm For APRI, FDA Nod For TEVA",2017-01-19 03:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MGyqv56qtxs/derm-delights-with-a-hattrick-shot-in-the-arm-for-apri-fda-nod-for-teva-20170119-00163,"DERM Delights With A Hat-trick, Shot In The Arm For APRI, FDA Nod For TEVA"
LLY,LLY:US,BBG000BNBDC2,[$$] Overheard,2017-01-19 03:17:36 +0000,http://online.wsj.com/article/SB20782002109759823356104582567271620384982.html?ru=yahoo?mod=yahoo_itp,[$$] Overheard
LLY,LLY:US,BBG000BNBDC2,"Why Fastenal, Mead Johnson Nutrition, and CoLucid Pharmaceuticals Jumped Today",2017-01-19 00:36:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9aivLgRTmzw/why-fastenal-mead-johnson-nutrition-and-colucid-pharmaceuticals-jumped-today-cm735148,The stock market was mixed on Wednesday as the Dow Jones Industrials fell 22 points even as the S amp P 500 and Nasdaq Composite rose slightly on the day Investors continue to expect an improving economy that will likely spur the Federal Reserve to raise interest rates and that led
LLY,LLY:US,BBG000BNBDC2,5 Expensive Drugs That Could End Up in Trump's Crosshairs,2017-01-18 23:37:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oblDGAE3opo/5-expensive-drugs-that-could-end-up-in-trumps-crosshairs-cm735129,Donald Trump s taking aim at drug companies that have increasingly found themselves in the hot seat because of sky high drug price increases in the past Last week Trump likened the industry s history of price hikes as akin to getting away with murder and he hinted that
LLY,LLY:US,BBG000BNBDC2,"Why Fastenal, Mead Johnson Nutrition, and CoLucid Pharmaceuticals Jumped Today",2017-01-18 23:06:05 +0000,http://www.fool.com/investing/2017/01/18/why-fastenal-mead-johnson-nutrition-and-colucid-ph.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Fastenal, Mead Johnson Nutrition, and CoLucid Pharmaceuticals Jumped Today"
LLY,LLY:US,BBG000BNBDC2,"Gainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC...",2017-01-18 22:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7u2MGVyxp3Y/gainers--losers-of-the-day-apri-life-jazz-etrm-bioc-20170118-01547,"Gainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC..."
LLY,LLY:US,BBG000BNBDC2,5 Expensive Drugs That Could End Up in Trump's Crosshairs,2017-01-18 21:41:08 +0000,http://www.fool.com/investing/2017/01/18/5-expensive-drugs-that-could-end-up-in-trumps-cros.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Expensive Drugs That Could End Up in Trump's Crosshairs
LLY,LLY:US,BBG000BNBDC2,Lilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition,2017-01-18 21:19:24 +0000,http://www.investors.com/news/technology/lilly-regains-key-migraine-drug-with-960-million-colucid-acquisition/,Lilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition
LLY,LLY:US,BBG000BNBDC2,"Health Care Sector Update for 01/18/2017: CLCD,LLY,APRI,IRMD",2017-01-18 18:56:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jDq7oJO9LjE/health-care-sector-update-for-01182017-clcdllyapriirmd-cm734983,Top Health Care StocksTop Health Care Stocks JNJ 0 11 JNJ 0 11 PFE 0 11 PFE 0 11 MRK 0 92 MRK 0 92 ABT 0 25 ABT 0 25 AMGN 0 36 AMGN 0 36 Health care stocks were mostly lower on Wednesday with the NYSE Health Care Index recording a 0 4 retreat while shares of health care
LLY,LLY:US,BBG000BNBDC2,"Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks",2017-01-18 18:47:00 +0000,https://www.thestreet.com/story/13957882/1/how-to-trade-goldman-sachs-ford-and-today-s-other-active-stocks.html?puc=yahoo&cm_ven=YAHOO,"Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks"
LLY,LLY:US,BBG000BNBDC2,Here's Why CoLucid Pharma (CLCD) is Skyrocketing 32% Today,2017-01-18 18:27:06 +0000,http://finance.yahoo.com/news/heres-why-colucid-pharma-clcd-182706048.html,Here's Why CoLucid Pharma (CLCD) is Skyrocketing 32% Today
LLY,LLY:US,BBG000BNBDC2,Midday Update: Retailers Keep Pressure on Dow,2017-01-18 18:17:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RcUOVB5FFEo/midday-update-retailers-keep-pressure-on-dow-cm734952,The Dow was struggling to stay positive as strength in the banking sector was offset by losses for retailers after Target TGT issued a profit warning due to weak holiday sales The financial sector was one of the S amp P 500 s top performing sectors following upbeat Q4 results from
LLY,LLY:US,BBG000BNBDC2,"Trump health pick Price defends investments, Obamacare replacement",2017-01-18 17:12:26 +0000,http://finance.yahoo.com/news/trump-health-pick-price-defends-171226629.html,"[Reuters] - President-elect Donald Trump's nominee for health secretary defended his personal stock investments and proposals to dismantle Obamacare on Wednesday in response to questioning by a U.S. Senate panel. Representative Tom Price, a Georgia orthopedic surgeon who has been in politics for more than 20 years, was chosen by fellow Republican Trump, who will become president on Friday, to head an agency that manages scores of healthcare programs. Price laid out a timeline for making changes to President Barack Obama's national healthcare law, often called Obamacare, agreeing with some Republicans that the plan to replace the law will be unveiled in the next few months but implemented over several years."
LLY,LLY:US,BBG000BNBDC2,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views,2017-01-18 16:57:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S1EI-_dEIKk/mid-morning-market-update-markets-mixed-goldman-sachs-profit-beats-views-cm734907,Following the market opening Wednesday the Dow traded down 0 11 percent to 19 804 87 while the NASDAQ gained 0 23 percent to 5 551 59 The S amp P also rose gaining 0 06 percent to 2 269 31 Leading and Lagging Sectors Non cyclical consumer goods amp services shares gained
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Acquires CoLucid for $46.50 Per Share,2017-01-18 16:47:00 +0000,http://www.investopedia.com/news/eli-lilly-buys-colucid-lly-clcd/?partner=YahooSA,Eli Lilly Acquires CoLucid for $46.50 Per Share
LLY,LLY:US,BBG000BNBDC2,Stocks Struggle for Direction as Economic Improvements May Push Fed Moves,2017-01-18 16:07:00 +0000,https://www.thestreet.com/story/13957561/1/stocks-mixed-as-u-s-consumer-prices-industrial-output-rise.html?puc=yahoo&cm_ven=YAHOO,Stocks Struggle for Direction as Economic Improvements May Push Fed Moves
LLY,LLY:US,BBG000BNBDC2,Wednesday’s Top Biopharma Winners,2017-01-18 16:05:11 +0000,http://finance.yahoo.com/news/wednesday-top-biopharma-winners-160511481.html,Wednesday’s Top Biopharma Winners
LLY,LLY:US,BBG000BNBDC2,What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?,2017-01-18 15:41:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HbQ5ENfrYgM/whats-ahead-for-johnson-johnson-jnj-in-q4-earnings-cm734731,Johnson amp Johnson JNJ the bellwether of healthcare companies is scheduled to report fourth quarter 2016 and full year results on Jan 24 before the opening bell Last quarter the company reported a positive earnings surprise of 1 82 J amp J s share price was up 17 9 in the past
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Pricey Headache,2017-01-18 15:17:33 +0000,http://blogs.wsj.com/moneybeat/2017/01/18/eli-lillys-pricey-headache/?mod=yahoo_hs,Eli Lilly's Pricey Headache
LLY,LLY:US,BBG000BNBDC2,"Wall Street Inches Higher Ahead of Yellen Speech; Goldman Sachs, Citigroup Top Profit Estimates",2017-01-18 14:38:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jtlUr0TWC-E/wall-street-inches-higher-ahead-of-yellen-speech-goldman-sachs-citigroup-top-profit-estimates-cm734671,U S stocks were pointing to a higher open on Wednesday as traders evaluated earnings reports from Goldman Sachs and Citigroup that topped Street estimates on profit and looked ahead to a speech from Fed Chair Janet Yellen U S stocks were pointing to a higher open on Wednesday as traders
LLY,LLY:US,BBG000BNBDC2,"Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost",2017-01-18 14:21:00 +0000,https://www.thestreet.com/story/13956398/1/stock-futures-seek-direction-after-trump-rally-fades.html?puc=yahoo&cm_ven=YAHOO,"Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost"
LLY,LLY:US,BBG000BNBDC2,"Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers",2017-01-18 14:13:00 +0000,https://www.thestreet.com/story/13957359/1/jazz-pharma-colucid-spike-pre-market-plus-other-biotech-movers.html?puc=yahoo&cm_ven=YAHOO,"Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline",2017-01-18 12:53:00 +0000,https://www.thestreet.com/story/13957207/1/eli-lilly-acquires-colucid-pharma-adds-migraine-drug-to-pipeline.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline"
LLY,LLY:US,BBG000BNBDC2,What Eli Lilly Gets With CoLucid Acquisition,2017-01-18 12:40:36 +0000,http://finance.yahoo.com/news/eli-lilly-gets-colucid-acquisition-124036373.html,What Eli Lilly Gets With CoLucid Acquisition
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly to Buy Migraine Drug Developer,2017-01-18 12:24:57 +0000,http://www.wsj.com/articles/eli-lilly-to-buy-migraine-drug-developer-colucid-pharmaceuticals-1484742294?mod=yahoo_hs,[$$] Eli Lilly to Buy Migraine Drug Developer
LLY,LLY:US,BBG000BNBDC2,Lilly to buy CoLucid for $960 mln to beef up migraine portfolio,2017-01-18 11:58:43 +0000,http://finance.yahoo.com/news/lilly-buy-colucid-960-mln-115843483.html,Lilly to buy CoLucid for $960 mln to beef up migraine portfolio
LLY,LLY:US,BBG000BNBDC2,CoLucid's stock soars after $960 million buyout deal with Eli Lilly,2017-01-18 11:56:29 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=1E50125F-FF61-4519-8A3C-8FEB76B170A1&siteid=yhoof2,CoLucid's stock soars after $960 million buyout deal with Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid,2017-01-18 11:45:00 +0000,http://finance.yahoo.com/news/lilly-colucid-pharmaceuticals-announce-agreement-114500706.html,"[GlobeNewswire] - $960 million deal will enhance Lilly’ s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline. INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017-- Eli ..."
LLY,LLY:US,BBG000BNBDC2,CoLucid Pharmaceuticals Inc. (CLCD) Has Jumped To A New High After Merger,2017-01-18 09:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hgcsnHaRR1g/colucid-pharmaceuticals-inc-clcd-has-jumped-to-a-new-high-after-merger-20170118-00733,CoLucid Pharmaceuticals Inc. (CLCD) Has Jumped To A New High After Merger
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Buy CoLucid Pharma In $960 Mln Deal - Quick Facts,2017-01-18 06:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jyuchN6vDbA/eli-lilly-to-buy-colucid-pharma-in-960-mln-deal--quick-facts-20170118-00248,Eli Lilly To Buy CoLucid Pharma In $960 Mln Deal - Quick Facts
LLY,LLY:US,BBG000BNBDC2,FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink,2017-01-17 19:21:30 +0000,http://www.investors.com/news/technology/fda-track-record-bodes-well-for-merck-keytruda-plus-lilly-chemo-leerink/,FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Wells Fargo, Accenture, Eli Lilly, American Airlines and Domino's Pizza",2017-01-17 16:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JAcRpOgZ948/the-zacks-analyst-blog-highlights-wells-fargo-accenture-eli-lilly-american-airlines-and-dominos-pizza-cm734232,For Immediate Release Chicago IL January 17 2017 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Wells Fargo, Accenture, Eli Lilly, American Airlines and Domino's Pizza",2017-01-17 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-wells-143002337.html,"The Zacks Analyst Blog Highlights: Wells Fargo, Accenture, Eli Lilly, American Airlines and Domino's Pizza"
LLY,LLY:US,BBG000BNBDC2,Is LLY's Arthritis Drug Delay a Minor Setback?,2017-01-17 14:27:00 +0000,http://www.investopedia.com/news/lilly-arthritis-drug-delayed-fda-lly-incy/?partner=YahooSA,Is LLY's Arthritis Drug Delay a Minor Setback?
LLY,LLY:US,BBG000BNBDC2,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",2017-01-17 14:14:23 +0000,http://finance.yahoo.com/news/barictinib-fda-delay-only-short-141423422.html,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse"
LLY,LLY:US,BBG000BNBDC2,FDA Delays Decision On Lilly's Rheumatoid Arthritis Drug Candidate,2017-01-17 04:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gBqQD44MMTU/fda-delays-decision-on-lillys-rheumatoid-arthritis-drug-candidate-20170117-00139,FDA Delays Decision On Lilly's Rheumatoid Arthritis Drug Candidate
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for 16th January, 2017",2017-01-16 23:36:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vKABdgtANE0/top-research-reports-for-16th-january-2017-cm734002,Monday January 16 2017 Today s Research Daily features new research reports on 16 major stocks including Wells Fargo WFC Accenture ACN and Eli Lilly LLY We also issued an early take on the Q4 earnings season which ramps up materially in the coming days The earnings report is
LLY,LLY:US,BBG000BNBDC2,FDA Delays Decision On Lilly''s Rheumatoid Arthritis Drug Candidate,2017-01-16 22:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uJeemo0hDNI/fda-delays-decision-on-lillys-rheumatoid-arthritis-drug-candidate-20170116-00741,FDA Delays Decision On Lilly''s Rheumatoid Arthritis Drug Candidate
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for 16th January, 2017",2017-01-16 21:23:09 +0000,http://finance.yahoo.com/news/top-research-reports-16th-january-212309058.html,"Top Research Reports for 16th January, 2017"
LLY,LLY:US,BBG000BNBDC2,How Is Novartis’s Revenue Trending?,2017-01-16 15:37:03 +0000,http://marketrealist.com/2017/01/what-are-novartiss-revenue-trends/?utm_source=yahoo&utm_medium=feed,How Is Novartis’s Revenue Trending?
LLY,LLY:US,BBG000BNBDC2,Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended,2017-01-16 14:39:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J0q2VXUFt7o/lilly-incyte-rheumatoid-arthritis-drug-pdufa-date-extended-cm733817,Eli Lilly and Company LLY and partner Incyte Corporation INCY announced that the FDA has extended the time to review the company s New Drug Application NDA seeking approval of its pipeline candidate baricitinib for the treatment of rheumatoid arthritis RA Previously the FDA was
LLY,LLY:US,BBG000BNBDC2,Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended,2017-01-16 12:39:12 +0000,http://finance.yahoo.com/news/lilly-incyte-rheumatoid-arthritis-drug-123912305.html,Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
LLY,LLY:US,BBG000BNBDC2,"No new antidepressants in sight despite growing need, experts warn",2017-01-16 09:36:04 +0000,http://finance.yahoo.com/news/no-antidepressants-sight-despite-growing-093604583.html,"No new antidepressants in sight despite growing need, experts warn"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly is the best stock in pharma: Trader,2017-01-13 22:11:00 +0000,http://finance.yahoo.com/video/eli-lilly-best-stock-pharma-221100764.html,Eli Lilly is the best stock in pharma: Trader
LLY,LLY:US,BBG000BNBDC2,"U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment",2017-01-13 21:51:00 +0000,http://finance.yahoo.com/news/u-fda-extends-review-period-215100650.html,"[PR Newswire] - INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review ..."
LLY,LLY:US,BBG000BNBDC2,Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference,2017-01-13 21:16:00 +0000,http://www.investors.com/news/technology/trumps-disastrous-pharma-view-doesnt-rattle-healthcare-conference/,Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference
LLY,LLY:US,BBG000BNBDC2,"Company News for January 13, 2017",2017-01-13 17:38:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RMjuyzInIcg/company-news-for-january-13-2017-cm733342,160 160 160 Shares of Delta Air Lines Inc DAL declined 1 1 after the company witnessed a 2 7 decline in consolidated passenger revenue per available seat mile in the fourth quarter 160 160 160 Shares of Applied Optoelectronics Inc AAOI surged 31 4 after
LLY,LLY:US,BBG000BNBDC2,"Company News for January 13, 2017",2017-01-13 15:10:03 +0000,http://finance.yahoo.com/news/company-news-january-13-2017-151003546.html,"Company News for January 13, 2017"
LLY,LLY:US,BBG000BNBDC2,Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit,2017-01-13 14:40:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VzUn73dxtJE/lilly-wins-appeal-against-teva-in-alimta-patent-lawsuit-cm733160,Eli Lilly and Company LLY announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited TEVA related to the infringement of a vitamin regimen patent for its cancer drug Alimta by the U S Court of Appeals for the Federal
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News",2017-01-13 13:39:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cwbyLAch2ws/pharma-stock-roundup-trump-targets-pharma-again-merck-up-on-keytruda-news-cm733130,The sector was once again slammed by president elect Donald Trump s comments this week regarding drug pricing and other issues Read more Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again The drug pricing issue in fact overshadowed guidance updates and pipeline news presented at
LLY,LLY:US,BBG000BNBDC2,Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit,2017-01-13 12:09:12 +0000,http://finance.yahoo.com/news/lilly-wins-appeal-against-teva-120912846.html,Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
LLY,LLY:US,BBG000BNBDC2,Teva Loses Alimta Appeal Against Eli Lilly,2017-01-12 23:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pr-k3yyV6iw/teva-loses-alimta-appeal-against-eli-lilly-20170112-01002,Teva Loses Alimta Appeal Against Eli Lilly
LLY,LLY:US,BBG000BNBDC2,​Trump’s HHS nominee has promised to divest from these Mass. companies,2017-01-12 22:10:08 +0000,http://www.bizjournals.com/boston/news/2017/01/12/trump-s-hhs-nominee-has-promised-to-divest-from.html?ana=yahoo,​Trump’s HHS nominee has promised to divest from these Mass. companies
LLY,LLY:US,BBG000BNBDC2,US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty,2017-01-12 21:36:04 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-falls-213604292.html,US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva,2017-01-12 21:18:57 +0000,http://www.investors.com/news/technology/eli-lilly-rebounds-on-chemo-drug-patent-win-vs-generic-teva/,Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva
LLY,LLY:US,BBG000BNBDC2,Patent Victory Secures Lilly Hold on Cancer Drug Until 2022,2017-01-12 20:39:00 +0000,https://www.thestreet.com/story/13952863/1/patent-victory-secures-lilly-hold-on-cancer-drug-until-2022.html?puc=yahoo&cm_ven=YAHOO,Patent Victory Secures Lilly Hold on Cancer Drug Until 2022
LLY,LLY:US,BBG000BNBDC2,"Investors in big pharma, biotech look to ride out Trump storm",2017-01-12 20:22:50 +0000,http://finance.yahoo.com/news/investors-big-pharma-biotech-look-202250238.html,"Investors in big pharma, biotech look to ride out Trump storm"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2016 (record date) : By the numbers : January 12, 2017",2017-01-12 18:05:15 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-lly-us-dividend-analysis-november-15th-2016-record-date-by-the-numbers-january-12-2017/,"Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2016 (record date) : By the numbers : January 12, 2017"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's stock rallies after appeals court upholds favorable patent ruling,2017-01-12 17:26:27 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=7C41CABF-ACF7-4EAF-BDA8-9ED561B3EBEC&siteid=yhoof2,Eli Lilly's stock rallies after appeals court upholds favorable patent ruling
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Up 2% in Weak Tape on Positive Ruling,2017-01-12 17:21:00 +0000,http://www.investopedia.com/news/eli-lilly-pops-positive-court-ruling-lly-teva/?partner=YahooSA,Eli Lilly Up 2% in Weak Tape on Positive Ruling
LLY,LLY:US,BBG000BNBDC2,Trump Attacks Biotech & Pharma: ETFs Bleed,2017-01-12 16:57:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FXC6m2w_ZhQ/trump-attacks-biotech-pharma-etfs-bleed-cm732747,The pharma and biotech industry is a victim of concerns over increased regulatory scrutiny on high drug prices over the past two years The worries cooled down after Trump s victory and gave biotech stocks a shot in the arm But the trend has reversed again following Trump s first press
LLY,LLY:US,BBG000BNBDC2,U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent,2017-01-12 16:05:00 +0000,http://finance.yahoo.com/news/u-court-appeals-rules-lillys-160500583.html,"[PR Newswire] - INDIANAPOLIS, Jan. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). In the case of Eli Lilly and Company v. Teva Parenteral Medicines, Inc., et al., the court affirmed the earlier district court's rulings that the vitamin regimen patent is valid and would be infringed by the generic challengers' proposed products. If the patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022, preventing marketing of generic products for as long as the patent remains in force."
LLY,LLY:US,BBG000BNBDC2,Teva loses appeal against Eli Lilly in Alimta patent case,2017-01-12 15:40:46 +0000,http://finance.yahoo.com/news/teva-loses-appeal-against-eli-154046375.html,"[Reuters] - A U.S. appeals court on Thursday ruled in favor of Eli Lilly & Co in a closely-watched patent case, saying a lower court judge correctly found Teva Pharmaceutical Industries Ltd and other companies liable for inducing the infringement of Lilly's lung cancer drug Alimta. The decision by the U.S. Federal Circuit Court of Appeals came in a case in which Lilly sought to block Teva and other defendants from launching generic versions of Alimta, one of its best-selling drugs, before patent protections fully expire in 2022."
LLY,LLY:US,BBG000BNBDC2,"Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo",2017-01-12 15:02:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3dpfpXodMe8/lilly-merck-expand-tie-up-to-study-lartruvo-keytruda-combo-cm732607,Eli Lilly and Company LLY and Merck amp Co Inc MRK expanded their existing immuno oncology partnership to include a new study that will evaluate Lilly s Lartruvo in combination with Merck s Keytruda in patients with previously treated advanced or metastatic soft tissue sarcoma
LLY,LLY:US,BBG000BNBDC2,Lilly Jumps After Lung Cancer Drug Patent Upheld,2017-01-12 14:36:52 +0000,http://www.bloomberg.com/news/articles/2017-01-12/lilly-wins-appeal-upholding-patent-on-alimta-cancer-drug-ixuhatta?cmpid=yhoo.headline,Lilly Jumps After Lung Cancer Drug Patent Upheld
LLY,LLY:US,BBG000BNBDC2,"Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo",2017-01-12 12:48:12 +0000,http://finance.yahoo.com/news/lilly-merck-expand-tie-study-124812500.html,"Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo"
LLY,LLY:US,BBG000BNBDC2,3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference,2017-01-11 22:58:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DSG816m4T2Y/3-surprises-from-pfizer-at-the-j-p-morgan-healthcare-conference-cm732475,It s always fun to hear what pharmaceutical company executives might say at the J P Morgan NYSE JPM Healthcare Conference This year Pfizer NYSE PFE was represented by three top members of its management team at the conference Here are three things the Pfizer
LLY,LLY:US,BBG000BNBDC2,JPMorgan Makes Big Changes to US Analyst Focus List for January,2017-01-11 14:35:49 +0000,http://finance.yahoo.com/news/jpmorgan-makes-big-changes-us-143549658.html,[24/7 Wall St.] - These are five top new picks that the JPMorgan team likes this month. All make good sense for growth portfolios.
LLY,LLY:US,BBG000BNBDC2,Lilly and Merck Expand Immuno-Oncology Collaboration,2017-01-11 11:45:00 +0000,http://finance.yahoo.com/news/lilly-merck-expand-immuno-oncology-114500991.html,"[PR Newswire] - INDIANAPOLIS, Jan. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly, Merck Expand Immuno-Oncology Collaboration",2017-01-11 06:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qqt5vNIfBMk/lilly-merck-expand-immunooncology-collaboration-20170111-00133,"Lilly, Merck Expand Immuno-Oncology Collaboration"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: System Getting a Good Deal With Obamacare,2017-01-10 16:22:13 +0000,http://finance.yahoo.com/video/eli-lily-ceo-system-getting-162213370.html,Eli Lilly CEO: System Getting a Good Deal With Obamacare
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Present At J.P. Morgan Conference; Webcast At 7:30 PM ET,2017-01-10 15:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BbdrJtGegVQ/eli-lilly-to-present-at-jp-morgan-conference-webcast-at-730-pm-et-20170110-00877,Eli Lilly To Present At J.P. Morgan Conference; Webcast At 7:30 PM ET
LLY,LLY:US,BBG000BNBDC2,Incyte's Prospects Get Even Brighter With Merck Announcement,2017-01-10 13:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1EzlbKd4K00/incytes-prospects-get-even-brighter-with-merck-announcement-cm731412,Incyte NASDAQ INCY didn t have to wait for its presentation at the J P Morgan Healthcare Conference on Monday to make investors happy Merck NYSE MRK and Incyte announced earlier in the day that a combination of 160 epacadostat and Keytruda would advance to pivotal
LLY,LLY:US,BBG000BNBDC2,This Could Very Well Be the Greatest Drug Advancement in a Decade,2017-01-09 19:50:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5e5_lqVKef0/this-could-very-well-be-the-greatest-drug-advancement-in-a-decade-cm731243,There have been a lot of exciting advances in medicine over the past 10 years Drugs that help cancer patients live longer have become available as have therapies that functionally cure hepatitis C However one area of research that hasn t advanced is the development of new weapons in
LLY,LLY:US,BBG000BNBDC2,Piper Bullish On Pfizer and Eli Lilly,2017-01-09 19:19:00 +0000,http://www.investopedia.com/news/piper-likes-pfizer-and-eli-lilly-pfe-jnj/?partner=YahooSA,Piper Bullish On Pfizer and Eli Lilly
LLY,LLY:US,BBG000BNBDC2,This Could Very Well Be the Greatest Drug Advancement in a Decade,2017-01-09 18:01:07 +0000,http://www.fool.com/investing/2017/01/09/this-could-very-well-be-the-greatest-drug-advancem.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,This Could Very Well Be the Greatest Drug Advancement in a Decade
LLY,LLY:US,BBG000BNBDC2,Why Aratana Therapeutics Inc. Rocketed 42.7% Higher in 2016,2017-01-09 17:52:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A7j4wBOZug4/why-aratana-therapeutics-inc-rocketed-427-higher-in-2016-cm731150,Image source Getty Images What happened Investors in Aratana Therapeutics NASDAQ PETX a small cap biotech company focused on developing therapies for pets had a prosperous 2016 The company s shares rose by more than 42 during the year according to data
LLY,LLY:US,BBG000BNBDC2,Why Aratana Therapeutics Inc. Rocketed 42.7% Higher in 2016,2017-01-09 16:11:34 +0000,http://www.fool.com/investing/2017/01/09/why-aratana-therapeutics-rocketed-427-higher-in-20.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Aratana Therapeutics Inc. Rocketed 42.7% Higher in 2016
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: Happy to work with Trump administration to...,2017-01-09 15:23:00 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-happy-trump-152300105.html,Eli Lilly CEO: Happy to work with Trump administration to...
LLY,LLY:US,BBG000BNBDC2,What’s in Incyte’s Product Portfolio?,2017-01-09 12:36:21 +0000,http://marketrealist.com/2017/01/whats-in-incytes-product-portfolio/?utm_source=yahoo&utm_medium=feed,What’s in Incyte’s Product Portfolio?
LLY,LLY:US,BBG000BNBDC2,3 Takeover Candidates in the Drug Space,2017-01-08 19:00:00 +0000,http://realmoney.thestreet.com/articles/01/08/2017/3-takeover-candidates-drug-space?puc=yahoo&cm_ven=YAHOO,3 Takeover Candidates in the Drug Space
LLY,LLY:US,BBG000BNBDC2,[$$] Cavion Takes Aim at Common Tremor Disorder Through $26 Million Series A,2017-01-07 01:53:11 +0000,http://www.wsj.com/articles/cavion-takes-aim-at-common-tremor-disorder-through-26-million-series-a-1483753988?mod=yahoo_hs,[$$] Cavion Takes Aim at Common Tremor Disorder Through $26 Million Series A
LLY,LLY:US,BBG000BNBDC2,"Buy This 8.5% Yielder Now and Hold It Forever (SDY, EVT)",2017-01-06 17:40:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iUaKhAXQBOs/buy-this-85-yielder-now-and-hold-it-forever-sdy-evt-cm730465,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips If you want to diversify get high quality dividend growth and avoid risky speculation the SPDR S amp P Dividend ETF SDY may seem like a no brainer But
LLY,LLY:US,BBG000BNBDC2,"2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016",2017-01-06 16:40:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AqQYh73zTsU/2-big-reasons-merck-co-inc-stock-surged-11-in-2016-cm730396,Image source Getty Images What happened Shares of Merck amp Co Inc NYSE MRK a U S based global drug behemoth climbed 11 higher in 2016 according to data from S amp P Global Market Intelligence slightly outpacing the 9 5 return of the S amp P 500
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement,2017-01-05 22:55:10 +0000,http://www.publicnow.com/view/8D92D1AC0104EA8391D1D9205C35195BA528E4D1,"[at noodls] - INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will also conduct ..."
LLY,LLY:US,BBG000BNBDC2,Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs,2017-01-05 22:25:00 +0000,https://www.thestreet.com/story/13943979/1/eli-lilly-announces-exec-appointments-organizational-changes.html?puc=yahoo&cm_ven=YAHOO,Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement,2017-01-05 21:45:00 +0000,http://finance.yahoo.com/news/lilly-confirms-date-conference-call-214500658.html,"[PR Newswire] - INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Shakes Things Up To Drive Growth,2017-01-05 20:54:00 +0000,http://www.investopedia.com/news/lly-shakes-things-lly/?partner=YahooSA,Eli Lilly Shakes Things Up To Drive Growth
LLY,LLY:US,BBG000BNBDC2,"Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio",2017-01-05 17:36:00 +0000,https://www.thestreet.com/story/13944072/1/senate-dems-d-c-watchdog-call-for-ethics-investigation-into-trump-hhs-pick-tom-price.html?puc=yahoo&cm_ven=YAHOO,"Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio"
LLY,LLY:US,BBG000BNBDC2,Lilly Jardiance Family Diabetes Drugs' Label to be Updated,2017-01-05 14:41:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eZZzpUzi1Vc/lilly-jardiance-family-diabetes-drugs-label-to-be-updated-cm729797,Eli Lilly amp Company LLY recently announced that the FDA has approved the inclusion of cardiovascular CV risk reduction data from the EMPA REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family Synjardy Synjardy XR and Glyxambi The data
LLY,LLY:US,BBG000BNBDC2,Lilly Jardiance Family Diabetes Drugs' Label to be Updated,2017-01-05 13:06:01 +0000,http://finance.yahoo.com/news/lilly-jardiance-family-diabetes-drugs-130601238.html,Lilly Jardiance Family Diabetes Drugs' Label to be Updated
LLY,LLY:US,BBG000BNBDC2,Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities,2017-01-05 12:54:08 +0000,http://www.publicnow.com/view/3F4B6EB29B52108CA45C6F0D0542C07FE71F0C8F,"[at noodls] - INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth ..."
LLY,LLY:US,BBG000BNBDC2,Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities,2017-01-05 11:45:00 +0000,http://finance.yahoo.com/news/lilly-adjust-organization-leadership-structure-114500465.html,"[PR Newswire] - INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need for these changes, David A. Ricks, Lilly's president and CEO, said, ""Lilly begins 2017 with a clear view of its opportunities for growth in the years ahead. Christi Shaw has been hired to lead the company's Bio-Medicines business beginning April 3."
LLY,LLY:US,BBG000BNBDC2,"Lilly Announces Changes In Organization, Leadership Structure - Quick Facts",2017-01-05 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DXHcFicIfxU/lilly-announces-changes-in-organization-leadership-structure--quick-facts-20170105-00263,"Lilly Announces Changes In Organization, Leadership Structure - Quick Facts"
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly's new chief seeks to recover from Alzheimer's drug flop,2017-01-05 05:01:22 +0000,"http://www.ft.com/cms/s/a5070036-d2c6-11e6-b06b-680c49b4b4c0,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - The tenure of David Ricks as Eli Lilly's chief executive was not supposed to start like this. In the months before he took the top job, scientists at the drugmaker had become increasingly confident that ..."
LLY,LLY:US,BBG000BNBDC2,"U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empa",2017-01-04 22:09:00 +0000,http://finance.yahoo.com/news/u-fda-approves-supplemental-drug-220900787.html,"[PR Newswire] - RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 4, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include data from the landmark EMPA-REG OUTCOME® trial. The data show that empagliflozin reduced the risk for cardiovascular death compared with placebo when added to standard of care type 2 diabetes and cardiovascular medicines in adults with type 2 diabetes and established cardiovascular disease. The data have been added to the ""Clinical Studies"" sections of the Prescribing Information for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linagliptin) tablets, all of which are marketed by Boehringer Ingelheim and Eli Lilly and Company (LLY)."
LLY,LLY:US,BBG000BNBDC2,"Lilly Nears FDA Nod On Arthritis Drug, But Chemo Med Stuck In Court",2017-01-04 21:15:19 +0000,http://www.investors.com/news/technology/lilly-nears-fda-nod-on-arthritis-drug-but-chemo-med-stuck-in-court/,"Lilly Nears FDA Nod On Arthritis Drug, But Chemo Med Stuck In Court"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit,2017-01-04 16:41:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6md6qq5DIw/eli-lilly-acquires-boehringer-ingelheims-pet-vaccines-unit-cm729291,Eli Lilly and Company s LLY animal health subsidiary Elanco announced that it has closed the previously stated acquisition of German drugmaker Boehringer Ingelheim s Vetmedica U S pet vaccines unit along with a fully integrated manufacturing and R amp D site for 885 million Lilly s
LLY,LLY:US,BBG000BNBDC2,Blink Offers Prescription for Customers' Discount Drugs,2017-01-04 15:25:34 +0000,http://finance.yahoo.com/video/blink-offers-prescription-customers-discount-152534712.html,Blink Offers Prescription for Customers' Discount Drugs
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit,2017-01-04 14:34:02 +0000,http://finance.yahoo.com/news/eli-lilly-acquires-boehringer-ingelheims-143402737.html,Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
LLY,LLY:US,BBG000BNBDC2,My Worst Predictions for Biotech in 2016,2017-01-04 00:37:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LkRSCAzdKpU/my-worst-predictions-for-biotech-in-2016-cm729008,It s never fun to admit you re wrong but anyone who has been involved in the markets for years knows that much like in baseball failure is more common than success Last year my 5 Biotech Predictions for 2016 was filled with failure including a doozy of a prediction that
LLY,LLY:US,BBG000BNBDC2,"Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio",2017-01-03 20:03:06 +0000,http://www.publicnow.com/view/54933CF92C259230E8D0954232E19FB0485B6B76,"[at noodls] - GREENFIELD, Ind., Jan. 3, 2017 /PRNewswire/ -- Today Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, ..."
LLY,LLY:US,BBG000BNBDC2,"Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio",2017-01-03 19:00:00 +0000,http://finance.yahoo.com/news/elanco-animal-health-completes-acquisition-190000148.html,"[PR Newswire] - GREENFIELD, Ind., Jan. 3, 2017 /PRNewswire/ -- Today Elanco US Inc., a subsidiary of Eli Lilly and Company (LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc's (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site and several pipeline assets. The acquisition diversifies Elanco's U.S. companion animal portfolio by adding vaccines for a range of common concerns such as bordetella, Lyme disease, feline leukemia, rabies, and parvovirus. Product will be made available by Elanco immediately, with no interruption in supply to veterinarians who rely on these products to keep pets living longer, healthier lives."
LLY,LLY:US,BBG000BNBDC2,"Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day",2017-01-03 17:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4p6XQrVvMvY/bluerock-residential-growth-reit-cal-maine-foods-incyte-eli-lilly-and-synergy-pharmaceuticals-highlighted-as-zacks-bull-and-bear-of-the-day-cm728713,For Immediate Release Chicago IL January 03 2017 Zacks Equity Research highlights Bluerock Residential Growth REIT AMEX BRG Free Report as the Bull of the Day and Cal Maine Foods Nasdaq CALM Free Report as the Bear of the Day In addition Zacks Equity
LLY,LLY:US,BBG000BNBDC2,A Look at BDX’s Recent Product Launches,2017-01-03 15:36:38 +0000,http://marketrealist.com/2017/01/a-look-at-bdxs-recent-product-launches/?utm_source=yahoo&utm_medium=feed,A Look at BDX’s Recent Product Launches
LLY,LLY:US,BBG000BNBDC2,Lilly to Present at J.P. Morgan Healthcare Conference,2017-01-03 14:45:00 +0000,http://finance.yahoo.com/news/lilly-present-j-p-morgan-144500222.html,"[PR Newswire] - INDIANAPOLIS, Jan. 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the 35 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017. David A. Ricks, Lilly's president ..."
LLY,LLY:US,BBG000BNBDC2,Two Key FDA Decisions to Watch Out for in January 2017,2017-01-02 15:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FFiQ2xLzIXg/two-key-fda-decisions-to-watch-out-for-in-january-2017-cm728367,The drug development process is often lengthy and time consuming and requires the utilization of a lot of funds and resources It may well take a drug anything between 10 12 years to be successfully developed and reach the market In such a scenario key pipeline events including data readouts
LLY,LLY:US,BBG000BNBDC2,A Countdown of 10 Memorable Moments From 2016,2016-12-31 21:02:11 +0000,http://www.publicnow.com/view/D29620E5BB2480F86BCDFAB6FA7763FC1CE3FFEF,"[at noodls] - NASA's spacecraft Juno successfully entered Jupiter's orbit, Tiger numbers rose for the first time in a century, cars are driving themselves; in 2016, we have seen triumphs great and small across all industries, ..."
LLY,LLY:US,BBG000BNBDC2,Johnson & Johnson's 4 Biggest Catalysts in 2017,2016-12-29 17:01:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-SDrEipjw_k/johnson-johnsons-4-biggest-catalysts-in-2017-cm727489,Image source Getty Images Though it was a very difficult year for drugmakers with the SPDR S amp P Pharmaceuticals ETF 160 losing just shy of a quarter of its value the same can t be said of healthcare conglomerate Johnson amp Johnson NYSE JNJ a company that
LLY,LLY:US,BBG000BNBDC2,Biotech Stocks Facing FDA Decision In January,2016-12-29 05:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0PaWkzXTG0o/biotech-stocks-facing-fda-decision-in-january-20161229-00031,Biotech Stocks Facing FDA Decision In January
LLY,LLY:US,BBG000BNBDC2,U.S. FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal,2016-12-29 03:24:17 +0000,http://sg.finance.yahoo.com/news/u-ftc-requires-divestitures-13-010200100.html,U.S. FTC requires divestitures in $13.53 billion Boehringer-Sanofi deal
LLY,LLY:US,BBG000BNBDC2,U.S. FTC Requires Divestitures In $13.53 Bln Boehringer Ingelheim - Sanofi Deal,2016-12-28 23:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OKTeCrAfPrU/us-ftc-requires-divestitures-in-1353-bln-boehringer-ingelheim--sanofi-deal-20161228-00347,U.S. FTC Requires Divestitures In $13.53 Bln Boehringer Ingelheim - Sanofi Deal
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech",2016-12-28 17:02:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LHXNZZdyNGs/the-zacks-analyst-blog-highlights-alexion-pharmaceuticals-celgene-incyte-eli-lilly-regeneron-pharmaceuticals-and-ophthotech-cm726995,For Immediate Release Chicago IL December 28 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,"VTV, USB, LLY, LMT: ETF Inflow Alert",2016-12-28 16:58:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EJIHfOF6gNU/vtv-usb-lly-lmt-etf-inflow-alert-cm726951,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Value ETF Symbol VTV where we have detected an approximate 237 5 million dollar inflow that s a 0 9 increase week over week in outstanding units
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech",2016-12-28 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-alexion-143002668.html,"The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech"
LLY,LLY:US,BBG000BNBDC2,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 19:32:56 +0000,http://finance.yahoo.com/news/expect-availability-biogens-newly-approved-193256344.html,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
LLY,LLY:US,BBG000BNBDC2,"Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead",2016-12-27 16:02:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7vFwp3s2r4/forget-alexion-alxn-buy-these-3-biotech-stocks-instead-cm726406,New Haven CT based Alexion Pharmaceuticals Inc ALXN has had a tough year with shares falling 33 3 year to date YTD The company which is known for its focus on developing treatments for rare disorders has underperformed the Zacks categorized Medical Biomed Genetics industry which
LLY,LLY:US,BBG000BNBDC2,Top Insider Buys of the Week,2016-12-25 15:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3niXhQAqv4E/top-insider-buys-of-the-week-cm726018,The largest insider buys during the week were for Eli Lilly and Co LLY Abbott Laboratories ABT Regency Centers Corp REG and TiVo Corp TIVO Eli Lilly and Co LLY Director Jackson P Tai bought 75 shares Tai bought 75 shares of LLY stock on Dec
LLY,LLY:US,BBG000BNBDC2,Top Insider Buys of the Week,2016-12-24 19:35:54 +0000,http://finance.yahoo.com/news/top-insider-buys-week-193554244.html,Top Insider Buys of the Week
LLY,LLY:US,BBG000BNBDC2,The Most Likely Incyte Acquisition Deal for 2017?,2016-12-24 13:06:56 +0000,http://www.fool.com/investing/2016/12/23/is-this-the-most-likely-incyte-acquisition-deal-fo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Most Likely Incyte Acquisition Deal for 2017?
LLY,LLY:US,BBG000BNBDC2,December Delivers Again for FCPA Enforcement Watchers,2016-12-23 21:54:44 +0000,http://blogs.wsj.com/riskandcompliance/2016/12/23/december-delivers-again-for-fcpa-enforcement-watchers/?mod=yahoo_hs,December Delivers Again for FCPA Enforcement Watchers
LLY,LLY:US,BBG000BNBDC2,"Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider",2016-12-23 19:32:32 +0000,http://www.insidermonkey.com/blog/gilead-sciences-inc-gild-is-a-hail-mary-3-better-stocks-to-consider-513001/,"Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider"
LLY,LLY:US,BBG000BNBDC2,The Most Likely Incyte Acquisition Deal for 2017?,2016-12-23 14:59:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PBqoouCoyEg/the-most-likely-incyte-acquisition-deal-for-2017-cm725574,Lots of folks want Incyte Corporation NASDAQ INCY to be part of a major acquisition Many of them would love to see Gilead Sciences NASDAQ GILD buy Incyte Could another acquisition involving Incyte be more likely though Here are some potential 2017 acquisition
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : December 23, 2016",2016-12-23 14:31:37 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-value-analysis-nyselly-december-23-2016/,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : December 23, 2016"
LLY,LLY:US,BBG000BNBDC2,Continuing the Fight to End Alzheimer’s,2016-12-23 09:38:11 +0000,http://www.publicnow.com/view/C679A2CA96039D5E6AF60929223E911881116649,"[at noodls] - Today's guest post comes from Alonso Montoya, Senior Medical Advisor at Lilly Canada, and Luc Boulay, Clinical Research Senior Scientist with Lilly Canada. Science is experimentation, iteration, and learning. ..."
LLY,LLY:US,BBG000BNBDC2,[$$] Trump's Health Pick Traded Medical Stocks While in House,2016-12-23 00:51:11 +0000,http://www.wsj.com/articles/donald-trumps-pick-for-health-secretary-traded-medical-stocks-while-in-house-1482451061?mod=yahoo_hs,"[at The Wall Street Journal] - Donald Trump’s pick for HHS secretary, Rep. Tom Price, traded more than $300,000 in shares of health-related companies in the past four years while advocating legislation that could affect those companies’ ..."
LLY,LLY:US,BBG000BNBDC2,Donald Trump's Pick for Health Secretary Traded Medical Stocks While in House,2016-12-22 19:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y-SvAjAW02s/donald-trumps-pick-for-health-secretary-traded-medical-stocks-while-in-house-20161222-00836,Donald Trump's Pick for Health Secretary Traded Medical Stocks While in House
LLY,LLY:US,BBG000BNBDC2,Insiders Buy the Holdings of FTXH ETF,2016-12-22 16:00:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UQu5IoElPzU/insiders-buy-the-holdings-of-ftxh-etf-cm725055,A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF FTXH shows an impressive 18 4 of holdings on a weighted basis have experienced insider buying within the past six months Eli Lilly amp Co Symbol LLY which makes up 8 34 of the First
LLY,LLY:US,BBG000BNBDC2,2016's Worst Clinical Failures,2016-12-22 14:36:19 +0000,http://www.fool.com/investing/2016/12/21/2016s-worst-clinical-failures.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2016's Worst Clinical Failures
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : December 22, 2016",2016-12-22 12:28:38 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-breached-its-50-day-moving-average-in-a-bearish-manner-lly-us-december-22-2016/,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : December 22, 2016"
LLY,LLY:US,BBG000BNBDC2,2016's Worst Clinical Failures,2016-12-21 15:59:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Y3zSc1N59g/2016s-worst-clinical-failures-cm724489,It s been a depressing year for drugmakers and clinical trial failures made 2016 particularly upsetting Neurology has always been a difficult field but this one was unusually nerve wracking for Eli LIlly amp Co NYSE LLY and Biogen NASDAQ BIIB In their own
LLY,LLY:US,BBG000BNBDC2,Bristol-Myers Squibb Plans to Strengthen Its Operating Model in 2017,2016-12-21 12:36:38 +0000,http://marketrealist.com/2016/12/bristol-myers-squibb-plans-strengthen-operating-model-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb Plans to Strengthen Its Operating Model in 2017
LLY,LLY:US,BBG000BNBDC2,3 Incredibly Cheap Biotech Stocks,2016-12-20 14:58:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1ISynuyV0RI/3-incredibly-cheap-biotech-stocks-cm723783,If you re looking for cheap biotech stocks to buy going into the new year you re in luck Shares of Celgene NASDAQ CELG Incyte NASDAQ INCY and Ionis Pharmaceuticals NASDAQ IONS are far less expensive than they appear on the surface Image
LLY,LLY:US,BBG000BNBDC2,UPDATE 1-Acadia says Alzheimer's disease psychosis drug clears study,2016-12-20 14:22:22 +0000,http://finance.yahoo.com/news/acadia-says-alzheimers-disease-psychosis-133925210.html,UPDATE 1-Acadia says Alzheimer's disease psychosis drug clears study
LLY,LLY:US,BBG000BNBDC2,"Andersons Increased Its Quarterly Dividend, Stock Rose",2016-12-20 13:56:38 +0000,http://marketrealist.com/2016/12/andersons-inc-raises-quarterly-dividend-stock-shot-yearly-highs/?utm_source=yahoo&utm_medium=feed,"Andersons Increased Its Quarterly Dividend, Stock Rose"
LLY,LLY:US,BBG000BNBDC2,Vanguard Value ETF Experiences Big Inflow,2016-12-19 17:59:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wXXlpD_c9ik/vanguard-value-etf-experiences-big-inflow-cm723387,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Value ETF Symbol VTV where we have detected an approximate 520 9 million dollar inflow that s a 1 9 increase week over week in outstanding units
LLY,LLY:US,BBG000BNBDC2,"BloodCenter, Versiti name ex-Eli Lilly exec to succeed Jackie Frederick as CEO",2016-12-19 16:40:12 +0000,http://www.bizjournals.com/milwaukee/news/2016/12/19/bloodcenter-versiti-name-ex-eli-lilly-exec-to.html?ana=yahoo,"BloodCenter, Versiti name ex-Eli Lilly exec to succeed Jackie Frederick as CEO"
LLY,LLY:US,BBG000BNBDC2,Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis,2016-12-19 16:01:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wXikCLKndTE/incytelilly-olumiant-wins-chmp-nod-for-rheumatoid-arthritis-cm723233,Incyte Corporation INCY and partner Eli Lilly and Company LLY announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has issued a positive opinion for the approval of Olumiant baricitinib for the treatment of adults with moderate to
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case",2016-12-19 13:58:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kl0cHeX8hw8/pharma-stock-roundup-lilly-up-on-guidance-merck-awarded-254b-in-hcv-case-cm723128,Lilly LLY provided better than expected guidance for 2017 leaving investors happy with the numbers Merck MRK also had some good news with a jury awarding the company 2 54 billion in its patent infringement case against Gilead Meanwhile drug pricing remains in the news with 20 states
LLY,LLY:US,BBG000BNBDC2,Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis,2016-12-19 13:36:01 +0000,http://finance.yahoo.com/news/incyte-lilly-olumiant-wins-chmp-133601910.html,Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case",2016-12-19 12:33:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-guidance-123312897.html,"Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case"
LLY,LLY:US,BBG000BNBDC2,Drugs Were a Downer in 2016 and Could Be Again in 2017: Exane BNP,2016-12-19 08:23:00 +0000,https://www.thestreet.com/story/13928943/1/drugs-were-a-downer-in-2016-and-could-be-again-in-2017-exane-bnp.html?puc=yahoo&cm_ven=YAHOO,Drugs Were a Downer in 2016 and Could Be Again in 2017: Exane BNP
LLY,LLY:US,BBG000BNBDC2,3 Biggest Risks for Incyte Corporation,2016-12-17 18:56:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E3ph42Ze8j4/3-biggest-risks-for-incyte-corporation-cm722918,Can anything slow down Incyte NASDAQ INCY The biotech s stock is up 30 in just the last three months A potential rival to the company s Jakafi in treating myelofibrosis underperformed in a late stage clinical study Another possible blockbuster drug for Incyte awaits
LLY,LLY:US,BBG000BNBDC2,3 Biggest Risks for Incyte Corporation,2016-12-17 17:06:17 +0000,http://www.fool.com/investing/2016/12/17/3-biggest-risks-for-incyte-corporation.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biggest Risks for Incyte Corporation
LLY,LLY:US,BBG000BNBDC2,Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) Tablets in Updated American Diabetes Association's 2017 Standards,2016-12-16 20:50:13 +0000,http://www.publicnow.com/view/0E324AE8AD7EDD131CB5F7963D548B7BD640F1F1,"[at noodls] - RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ -- The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider ..."
LLY,LLY:US,BBG000BNBDC2,White House Kills Plan for Drug Price Cap,2016-12-16 20:12:00 +0000,https://www.thestreet.com/story/13929151/1/white-house-kills-plan-for-drug-price-cap.html?puc=yahoo&cm_ven=YAHOO,White House Kills Plan for Drug Price Cap
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: Why Morgan Stanley Sees More Upside,2016-12-16 17:14:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/16/eli-lilly-why-morgan-stanley-sees-more-upside/?mod=yahoobarrons&ru=yahoo,Eli Lilly: Why Morgan Stanley Sees More Upside
LLY,LLY:US,BBG000BNBDC2,Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro,2016-12-16 17:10:07 +0000,http://www.publicnow.com/view/C3D445E46F8BFB4A747775481DCDBF8EA6750426,[at noodls] - PRESS RELEASE in people with type 1 diabetes BioChaperone Lispro U100 demonstrated a statistically significant increase in insulin exposure over the first 30 minutes after a mealtime bolus compared to ...
LLY,LLY:US,BBG000BNBDC2,"Stock Market News for December 16, 2016",2016-12-16 16:56:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ANQU71cZ93U/stock-market-news-for-december-16-2016-cm722506,Benchmarks finished in positive territory on Wednesday as the Trump induced rally continued to have a broad based positive impact on key indexes Also investors reassessed Fed s decision to raise key interest rates at a faster pace next year and welcomed a slew of encouraging economic data
LLY,LLY:US,BBG000BNBDC2,"Company News for December 16, 2016",2016-12-16 16:56:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TqyK4GZzfIw/company-news-for-december-16-2016-cm722505,Mondelez International Inc MDLZ shares increased 4 4 on news that Kraft Heinz Company KHC plans to acquire the company for around 90 billion Shares of Eli Lilly and Company LLY advanced 5 5 after forecasting 2017 adjusted earnings per share in the range of 4 05
LLY,LLY:US,BBG000BNBDC2,"Company News for December 16, 2016",2016-12-16 15:10:03 +0000,http://finance.yahoo.com/news/company-news-december-16-2016-151003005.html,"Company News for December 16, 2016"
LLY,LLY:US,BBG000BNBDC2,"Stock Market News for December 16, 2016",2016-12-16 15:10:03 +0000,http://finance.yahoo.com/news/stock-market-news-december-16-151003160.html,"Stock Market News for December 16, 2016"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co. is Higher For Second Day In a Row,2016-12-16 14:29:00 +0000,http://www.investopedia.com/news/lly-positive-european-ad-comm-review/?partner=YahooSA,Eli Lilly & Co. is Higher For Second Day In a Row
LLY,LLY:US,BBG000BNBDC2,Lilly Stock Surges on Robust 2017 View; Launches Basaglar,2016-12-16 13:59:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OY3fBF-G7c4/lilly-stock-surges-on-robust-2017-view-launches-basaglar-cm722328,Eli Lilly and Company LLY issued a better than expected financial guidance for 2017 alleviating investor concern to a large extent The company also re affirmed the previously issued 2016 projection as well as its long term expectations 2017 Forecast Impresses In 2017 top line growth
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Guidance Beat Expectations for the First Time in 3 Years,2016-12-16 13:52:38 +0000,http://marketrealist.com/2016/12/eli-lillys-guidance-beat-expectation-first-time-three-years/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s Guidance Beat Expectations for the First Time in 3 Years
LLY,LLY:US,BBG000BNBDC2,CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA),2016-12-16 13:48:13 +0000,http://www.publicnow.com/view/99D5D716033542E4F141C9F55661D2E40B256376,"[at noodls] - INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly upgraded by Morgan Stanley,2016-12-16 12:33:33 +0000,http://finance.yahoo.com/q/ud?s=LLY,Eli Lilly upgraded by Morgan Stanley
LLY,LLY:US,BBG000BNBDC2,Lilly Stock Surges on Robust 2017 View; Launches Basaglar,2016-12-16 11:58:11 +0000,http://finance.yahoo.com/news/lilly-stock-surges-robust-2017-115811373.html,Lilly Stock Surges on Robust 2017 View; Launches Basaglar
LLY,LLY:US,BBG000BNBDC2,Getting Real With a Lilly Neurologist,2016-12-16 11:48:08 +0000,http://www.publicnow.com/view/36A2F38F4E10B13E1C0AEC489E7359D12CE27158,"[at noodls] - For Lilly scientist Brandy Matthews, M.D., senior advisor on the Alzheimer's disease team, perseverance is the name of the game when it comes to Alzheimer's research. In the December issue ..."
LLY,LLY:US,BBG000BNBDC2,Why Every Minute Counts in Our Manufacturing,2016-12-16 11:48:08 +0000,http://www.publicnow.com/view/20DA404C51ABAE54FDCB7BA6464EAD560DC619F5,[at noodls] - This is the seventh post in our Lilly Discovery series that describes how Lilly employees discover and develop innovative treatments for patients. We're also highlighting many of the passionate scientists ...
LLY,LLY:US,BBG000BNBDC2,Improving Global Health Through Personal Connection,2016-12-16 11:48:08 +0000,http://www.publicnow.com/view/D477C19B15589EC0813FC48525EC8B5DAF52FC94,"[at noodls] - Today's guest post comes from Pauline Mlynek, Senior Financial Operations/Treasury Analyst at Lilly Canada. Her post originally appeared atLillyPad.CA. ... This is an abstract of the original ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Program to Provide Insulin at Discounted Prices,2016-12-16 11:28:11 +0000,http://www.publicnow.com/view/7801F1E680752CD54D8C763AD9F5BC5F7D9FCCDB,"[at noodls] - INDIANAPOLIS, Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade",2016-12-16 11:28:11 +0000,http://www.publicnow.com/view/E45A486493AA76BB7798D07D5EE7B07E8BDD66AD,"[at noodls] - INDIANAPOLIS, Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company reaffirmed its financial ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Dividend Increase,2016-12-16 11:28:11 +0000,http://www.publicnow.com/view/E43CE6EA865D75596E34AA491F86EDAE2C9CD6F2,"[at noodls] - INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the first quarter ..."
LLY,LLY:US,BBG000BNBDC2,"[$$] Eli Lilly on Sale With 3% Yield, Cheap Valuation",2016-12-16 11:03:00 +0000,http://www.barrons.com/articles/eli-lilly-on-sale-with-3-yield-cheap-valuation-1481886222?mod=yahoobarrons&ru=yahoo,"[$$] Eli Lilly on Sale With 3% Yield, Cheap Valuation"
LLY,LLY:US,BBG000BNBDC2,CHMP Recommends Approval Of Lilly's Baricitinib For Rheumatoid Arthritis,2016-12-16 08:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nV5bJ8ivgJI/chmp-recommends-approval-of-lillys-baricitinib-for-rheumatoid-arthritis-20161216-00220,CHMP Recommends Approval Of Lilly's Baricitinib For Rheumatoid Arthritis
LLY,LLY:US,BBG000BNBDC2,"Asian shares muted, dollar climbs as rate outlook sinks in",2016-12-16 03:10:50 +0000,http://sg.finance.yahoo.com/news/banks-lead-us-stock-indexes-150749040.html,"Asian shares muted, dollar climbs as rate outlook sinks in"
LLY,LLY:US,BBG000BNBDC2,"Why Eli Lilly, Xilinx, and InterDigital Jumped Today",2016-12-16 00:56:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j_0fYJtPKqw/why-eli-lilly-xilinx-and-interdigital-jumped-today-cm722250,The stock market bounced back on Thursday regaining some of its lost ground from the previous day following news of an interest rate hike from the Federal Reserve High rates helped send the U S dollar to levels it hasn t seen in nearly 15 years and that had a positive influence on
LLY,LLY:US,BBG000BNBDC2,"Why Eli Lilly, Xilinx, and InterDigital Jumped Today",2016-12-15 23:25:07 +0000,http://www.fool.com/investing/2016/12/15/why-eli-lilly-xilinx-and-interdigital-jumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Eli Lilly, Xilinx, and InterDigital Jumped Today"
LLY,LLY:US,BBG000BNBDC2,"Lilly Spikes On 2017 Guidance, Clawing Back From Alzheimer's Drug Flop",2016-12-15 21:39:36 +0000,http://www.investors.com/news/technology/lilly-spikes-post-alzheimers-flop-on-street-topping-2017-guidance/,"Lilly Spikes On 2017 Guidance, Clawing Back From Alzheimer's Drug Flop"
LLY,LLY:US,BBG000BNBDC2,"LILLY ELI & CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-12-15 21:29:57 +0000,http://biz.yahoo.com/e/161215/lly8-k.html,"LILLY ELI & CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
LLY,LLY:US,BBG000BNBDC2,Technical Analysis Shows Trio of Healthcare Stocks May Not Be Buys Yet,2016-12-15 20:57:00 +0000,https://www.thestreet.com/story/13927977/1/technical-analysis-shows-trio-of-healthcare-stocks-may-not-be-buys-yet.html?puc=yahoo&cm_ven=YAHOO,Technical Analysis Shows Trio of Healthcare Stocks May Not Be Buys Yet
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co. Surges on Strong FY'17 Guidance,2016-12-15 20:22:00 +0000,http://www.investopedia.com/news/eli-lilly-co-surges-strong-fy17-guidance-lly/?partner=YahooSA,Eli Lilly & Co. Surges on Strong FY'17 Guidance
LLY,LLY:US,BBG000BNBDC2,Stocks Higher as Banks Lead Wall Street Rebound,2016-12-15 19:47:00 +0000,https://www.thestreet.com/story/13927601/1/dow-edges-toward-20-000-in-rebound-from-fed-triggered-selloff.html?puc=yahoo&cm_ven=YAHOO,Stocks Higher as Banks Lead Wall Street Rebound
LLY,LLY:US,BBG000BNBDC2,Inside Eli Lilly's Surging Stock Price,2016-12-15 17:34:00 +0000,http://www.thestreet.com/video/13927696/inside-eli-lilly-s-surging-stock-price.html?puc=yahoov&cm_ven=YAHOOV,Inside Eli Lilly's Surging Stock Price
LLY,LLY:US,BBG000BNBDC2,Lilly eases investors' jitters with strong 2017 forecast,2016-12-15 17:08:29 +0000,http://finance.yahoo.com/news/lilly-forecasts-2017-revenue-profit-123446454.html,Lilly eases investors' jitters with strong 2017 forecast
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Bristol-Myers, Shell, Facebook, Baker Hughes, Eli Lilly and Fifth Third Bancorp",2016-12-15 17:01:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ee1Mg5oPQ1g/the-zacks-analyst-blog-highlights-bristol-myers-shell-facebook-baker-hughes-eli-lilly-and-fifth-third-bancorp-cm722020,For Immediate Release Chicago IL December 15 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Surges After 2017 Guidance Beats Street Forecast,2016-12-15 16:33:00 +0000,http://www.thestreet.com/video/13927523/eli-lilly-surges-after-2017-guidance-beats-street-forecast.html?puc=yahoov&cm_ven=YAHOOV,Eli Lilly Surges After 2017 Guidance Beats Street Forecast
LLY,LLY:US,BBG000BNBDC2,A cheaper version of the lifesaving diabetes medication just launched in the US,2016-12-15 15:58:00 +0000,http://finance.yahoo.com/news/cheaper-version-lifesaving-diabetes-medication-155800843.html,A cheaper version of the lifesaving diabetes medication just launched in the US
LLY,LLY:US,BBG000BNBDC2,"Dow Back on Track for 20,000 as Wall Street Rebounds From Fed Selloff",2016-12-15 15:50:00 +0000,https://www.thestreet.com/story/13927318/1/stocks-edge-higher-as-wall-street-digests-fed-s-outlook-on-rates.html?puc=yahoo&cm_ven=YAHOO,"Dow Back on Track for 20,000 as Wall Street Rebounds From Fed Selloff"
LLY,LLY:US,BBG000BNBDC2,"Yahoo falls after latest hack, Mondelez, Kraft Heinz deal talks?, Eli Lilly soars on bullish outlook",2016-12-15 15:05:59 +0000,http://finance.yahoo.com/news/yahoo-falls-after-latest-hack-mondelez-kraft-heinz-deal-talks-eli-lilly-soars-on-bullish-outlook-150559303.html,"Yahoo falls after latest hack, Mondelez, Kraft Heinz deal talks?, Eli Lilly soars on bullish outlook"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly's sees strength in 2017, shares take off",2016-12-15 14:18:20 +0000,http://sg.finance.yahoo.com/news/eli-lillys-sees-strength-2017-141820393.html,"Eli Lilly's sees strength in 2017, shares take off"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Announces Guidance, U.S. Insulin Release",2016-12-15 13:55:20 +0000,http://finance.yahoo.com/news/eli-lilly-announces-guidance-u-135520448.html,"Eli Lilly Announces Guidance, U.S. Insulin Release"
LLY,LLY:US,BBG000BNBDC2,Stock Futures Trade Lower as Consumer Prices Hit Two-Year High,2016-12-15 13:43:00 +0000,https://www.thestreet.com/story/13926053/1/stock-futures-trade-mixed-as-markets-adjust-to-fed-s-outlook-on-rates.html?puc=yahoo&cm_ven=YAHOO,Stock Futures Trade Lower as Consumer Prices Hit Two-Year High
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's 2017 Guidance Pleases Investors as Shares Soar,2016-12-15 13:39:00 +0000,https://www.thestreet.com/story/13927096/1/eli-lilly-s-2017-guidance-pleases-investors-as-shares-soar.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly's 2017 Guidance Pleases Investors as Shares Soar
LLY,LLY:US,BBG000BNBDC2,"Early movers: MDLZ, ZTS, YHOO, GIS, VRX, PIS, JBLU, UAL & more",2016-12-15 13:11:48 +0000,http://www.cnbc.com/id/104168800?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104168800,"Early movers: MDLZ, ZTS, YHOO, GIS, VRX, PIS, JBLU, UAL & more"
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Gives Bullish Outlook,2016-12-15 13:04:31 +0000,http://www.wsj.com/articles/eli-lilly-gives-bullish-outlook-on-revenue-and-profit-1481807059?mod=yahoo_hs,[$$] Eli Lilly Gives Bullish Outlook
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Guides Higher in 2017 Financial Forecast,2016-12-15 13:03:52 +0000,http://finance.yahoo.com/video/eli-lilly-guides-higher-2017-130352640.html,Eli Lilly Guides Higher in 2017 Financial Forecast
LLY,LLY:US,BBG000BNBDC2,"BASAGLAR® (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.",2016-12-15 12:00:00 +0000,http://finance.yahoo.com/news/basaglar-insulin-glargine-injection-100-120000600.html,"[PR Newswire] - INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. announced today that BASAGLAR® (insulin glargine injection 100 units/mL) is available by prescription in the U.S. BASAGLAR is a follow-on insulin to Lantus®. It is a long-acting insulin with an amino acid sequence identical to Lantus, another U-100 insulin glargine. In December 2015, the U.S. Food and Drug Administration (FDA) approved BASAGLAR as a long-acting insulin used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's stock jumps after profit and sales outlook exceed expectations,2016-12-15 11:58:01 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CB20E6FD-0970-4586-BD33-E63FD011B716&siteid=yhoof2,Eli Lilly's stock jumps after profit and sales outlook exceed expectations
LLY,LLY:US,BBG000BNBDC2,"Lilly forecasts 2017 revenue, profit above estimates",2016-12-15 11:56:27 +0000,http://finance.yahoo.com/news/lilly-forecasts-2017-revenue-profit-115627416.html,"Lilly forecasts 2017 revenue, profit above estimates"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co. 2017 Financial Guidance Conference Call; Webcast At 10:00 AM ET,2016-12-15 09:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mjlQYE0jW14/eli-lilly--co-2017-financial-guidance-conference-call-webcast-at-1000-am-et-20161215-00566,Eli Lilly & Co. 2017 Financial Guidance Conference Call; Webcast At 10:00 AM ET
LLY,LLY:US,BBG000BNBDC2,"Lilly, Boehringer: Basaglar, A Long-Acting Basal Insulin, Now Available In US",2016-12-15 07:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C-AzheUOi4c/lilly-boehringer-basaglar-a-longacting-basal-insulin-now-available-in-us-20161215-00235,"Lilly, Boehringer: Basaglar, A Long-Acting Basal Insulin, Now Available In US"
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Today: BMY, RDS.A, FB",2016-12-15 06:56:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pKT6bIo1-p8/top-research-reports-for-today-bmy-rdsa-fb-cm721689,Wednesday December 14 2016 Today s Research Daily features new research reports on 16 major stocks including Bristol Myers BMY Shell RDS A and Facebook FB Buy rated Bristol Myers shares have underperformed the broader market as well as the large cap pharma group this year though
LLY,LLY:US,BBG000BNBDC2,"Lilly Cuts FY16 EPS View, Backs Adj. EPS Forecast; Sees Growth In FY17",2016-12-15 06:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lMSLluWKdIQ/lilly-cuts-fy16-eps-view-backs-adj-eps-forecast-sees-growth-in-fy17-20161215-00196,"Lilly Cuts FY16 EPS View, Backs Adj. EPS Forecast; Sees Growth In FY17"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly 2017 Financial Guidance Conference Call; Webcast At 10:00 AM ET,2016-12-15 06:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yl29Y4C03xM/eli-lilly-2017-financial-guidance-conference-call-webcast-at-1000-am-et-20161215-00160,Eli Lilly 2017 Financial Guidance Conference Call; Webcast At 10:00 AM ET
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Today: BMY, RDS.A, FB",2016-12-14 22:16:10 +0000,http://finance.yahoo.com/news/top-research-reports-today-bmy-221610646.html,"Top Research Reports for Today: BMY, RDS.A, FB"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly In 2017: Boom Or Bust?,2016-12-14 18:50:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/14/eli-lilly-in-2017-boom-or-bust/?mod=yahoobarrons&ru=yahoo,Eli Lilly In 2017: Boom Or Bust?
LLY,LLY:US,BBG000BNBDC2,"Company News for December 14, 2016",2016-12-14 16:57:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/08qCo_-uk_s/company-news-for-december-14-2016-cm721351,VeriFone Systems Inc s PAY shares increased 8 6 after reporting fiscal fourth quarter adjusted earnings of 0 21 per share beating the Zacks Consensus Estimate of 0 20 Shares of Eli Lilly and Company LLY rose 1 5 after raising its quarterly dividend by 2 to 0 52 per
LLY,LLY:US,BBG000BNBDC2,"Company News for December 14, 2016",2016-12-14 15:10:03 +0000,http://finance.yahoo.com/news/company-news-december-14-2016-151003685.html,"Company News for December 14, 2016"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) to Offer Discount on Insulin from January,2016-12-14 15:01:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/34TDjTSi3XE/eli-lilly-lly-to-offer-discount-on-insulin-from-january-cm721168,Pharma major Eli Lilly and Company LLY in partnership with Express Scripts Holding Company ESRX announced that it will offer insulin products at discounted prices starting Jan 2017 to patients via Blink Health s mobile and web platforms Note that drug pricing is back in the
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) to Offer Discount on Insulin from January,2016-12-14 13:09:01 +0000,http://finance.yahoo.com/news/eli-lilly-lly-offer-discount-130901815.html,Eli Lilly (LLY) to Offer Discount on Insulin from January
LLY,LLY:US,BBG000BNBDC2,"New diabetes guidelines imminent, Jardiance sales may surge",2016-12-14 01:04:48 +0000,http://finance.yahoo.com/news/diabetes-guidelines-imminent-jardiance-sales-010448698.html,"New diabetes guidelines imminent, Jardiance sales may surge"
LLY,LLY:US,BBG000BNBDC2,Better Buy: Anavex Life Sciences Corp. vs. Eli Lilly,2016-12-13 21:57:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pvjUx6ReR5g/better-buy-anavex-life-sciences-corp-vs-eli-lilly-cm720975,No company has succeeded in the battle against Alzheimer s disease Anavex Life Sciences NASDAQ AVXL and Eli Lilly NYSE LLY are two that are still trying though Which of these two stocks is the better pick for investors Here s how they compare Image
LLY,LLY:US,BBG000BNBDC2,Eli Lilly offers discount for insulin,2016-12-13 21:24:00 +0000,http://finance.yahoo.com/video/eli-lilly-offers-discount-insulin-212400084.html,Eli Lilly offers discount for insulin
LLY,LLY:US,BBG000BNBDC2,"Daily Dividend Report: BA, LLY, WDFC, SHO, HEI",2016-12-13 20:56:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/df5_chHawzo/daily-dividend-report-ba-lly-wdfc-sho-hei-cm720942,The Boeing board of directors declared the company s quarterly dividend will increase 30 percent to 1 42 per share The board also replaced the existing share repurchase program with a new 14 billion authorization The new dividend will be payable March 3 2017 to shareholders of record as
LLY,LLY:US,BBG000BNBDC2,Better Buy: Anavex Life Sciences Corp. vs. Eli Lilly,2016-12-13 20:49:10 +0000,http://www.fool.com/investing/2016/12/13/better-buy-anavex-life-sciences-corp-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Anavex Life Sciences Corp. vs. Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Lilly Fills a Gap in Pharma's Pricing Defense,2016-12-13 19:13:19 +0000,http://www.bloomberg.com/gadfly/articles/2016-12-13/eli-lilly-insulin-discount-offer-fills-a-gap-in-pricing-defense?cmpid=yhoo.headline,Lilly Fills a Gap in Pharma's Pricing Defense
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Offers Discount for Insulin,2016-12-13 18:40:47 +0000,http://www.wsj.com/articles/eli-lilly-offers-discount-for-insulin-as-prices-soar-1481635357?mod=yahoo_hs,[$$] Eli Lilly Offers Discount for Insulin
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Teams With Express Scripts to Offer Discounted Insulin,2016-12-13 17:35:00 +0000,http://www.thestreet.com/video/13924150/eli-lilly-teams-with-express-scripts-to-offer-discounted-insulin.html?puc=yahoov&cm_ven=YAHOOV,Eli Lilly Teams With Express Scripts to Offer Discounted Insulin
LLY,LLY:US,BBG000BNBDC2,Some people spend as much on insulin as their mortgage — and drugmakers are taking note,2016-12-13 15:15:21 +0000,http://finance.yahoo.com/news/people-spend-much-insulin-mortgage-151521539.html,Some people spend as much on insulin as their mortgage — and drugmakers are taking note
LLY,LLY:US,BBG000BNBDC2,3 Beat-Up Health Care Stocks to Buy Now,2016-12-13 15:12:00 +0000,https://www.thestreet.com/story/13922212/1/3-beat-up-health-care-stocks-to-buy-now.html?puc=yahoo&cm_ven=YAHOO,3 Beat-Up Health Care Stocks to Buy Now
LLY,LLY:US,BBG000BNBDC2,Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy,2016-12-13 14:59:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S-YSPjEOWeM/lilly-lly-gets-fda-nod-for-once-daily-version-of-synjardy-cm720568,Eli Lilly and Company LLY announced the FDA approval of an extended release formulation of its type II diabetes prescription drug Synjardy The approval provides patients with a type II diabetes treatment in a once daily dosing option Synjardy XR tablet is a combination of Jardiance SGLT
LLY,LLY:US,BBG000BNBDC2,Lilly to offer insulin at discounted prices to certain patients,2016-12-13 14:59:06 +0000,http://finance.yahoo.com/news/lilly-offer-insulin-discounted-prices-135309601.html,Lilly to offer insulin at discounted prices to certain patients
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Express Scripts Announce Program to Lower Insulin Prices to Avoid Mylan-Like Uproar,2016-12-13 14:53:00 +0000,https://www.thestreet.com/story/13923886/1/eli-lilly-and-express-scripts-announce-program-to-lower-insulin-prices-to-avoid-mylan-like-uproar.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly and Express Scripts Announce Program to Lower Insulin Prices to Avoid Mylan-Like Uproar
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Boosts Dividend 2%, Despite Recent Woes",2016-12-13 14:44:25 +0000,http://www.investopedia.com/stock-analysis/121316/eli-lilly-boosts-dividend-2-despite-recent-woes-lly.aspx?partner=YahooSA,"Eli Lilly Boosts Dividend 2%, Despite Recent Woes"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Offers Discount for Insulin as Prices Soar -- Update,2016-12-13 13:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h6davrVJ7sM/eli-lilly-offers-discount-for-insulin-as-prices-soar--update-20161213-00765,Eli Lilly Offers Discount for Insulin as Prices Soar -- Update
LLY,LLY:US,BBG000BNBDC2,Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy,2016-12-13 13:07:01 +0000,http://finance.yahoo.com/news/lilly-lly-gets-fda-nod-130701239.html,Lilly (LLY) Gets FDA Nod for Once-Daily Version of Synjardy
LLY,LLY:US,BBG000BNBDC2,Lilly to offer insulin at discounted prices,2016-12-13 12:29:47 +0000,http://finance.yahoo.com/news/lilly-offer-insulin-discounted-prices-122947026.html,Lilly to offer insulin at discounted prices
LLY,LLY:US,BBG000BNBDC2,Top 10 Holdings of Our Ultimate Stock-Pickers' Index,2016-12-13 12:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=784462&SR=Yahoo,Top 10 Holdings of Our Ultimate Stock-Pickers' Index
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Program to Provide Insulin at Discounted Prices,2016-12-13 11:30:00 +0000,http://finance.yahoo.com/news/lilly-announces-program-insulin-discounted-113000024.html,"[PR Newswire] - INDIANAPOLIS, Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Offers Discount for Insulin,2016-12-13 08:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HFgOzuJJZP8/eli-lilly-offers-discount-for-insulin-20161213-00412,Eli Lilly Offers Discount for Insulin
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Offers Discount for Insulin as Prices Soar,2016-12-13 08:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W165AwQ7Nkg/eli-lilly-offers-discount-for-insulin-as-prices-soar-20161213-00404,Eli Lilly Offers Discount for Insulin as Prices Soar
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Program To Provide Insulin At Discounted Prices Starting Jan. 1,2016-12-13 06:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8tUHY1KQ4EU/lilly-announces-program-to-provide-insulin-at-discounted-prices-starting-jan-1-20161213-00144,Lilly Announces Program To Provide Insulin At Discounted Prices Starting Jan. 1
LLY,LLY:US,BBG000BNBDC2,Lilly : FDA Approves Synjardy XR Tablets For Adults With Type 2 Diabetes,2016-12-12 23:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gGFxq0HXghI/lilly--fda-approves-synjardy-xr-tablets-for-adults-with-type-2-diabetes-20161212-01052,Lilly : FDA Approves Synjardy XR Tablets For Adults With Type 2 Diabetes
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Dividend Increase,2016-12-12 23:00:00 +0000,http://finance.yahoo.com/news/lilly-announces-dividend-increase-230000927.html,"[PR Newswire] - INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the first quarter ..."
LLY,LLY:US,BBG000BNBDC2,U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes,2016-12-12 20:28:00 +0000,http://finance.yahoo.com/news/u-fda-approves-synjardy-xr-202800193.html,"[PR Newswire] - RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken. It is marketed by Boehringer Ingelheim and Eli Lilly and Company (LLY)."
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for December 12th, 2016",2016-12-12 17:44:05 +0000,http://finance.yahoo.com/news/top-research-reports-december-12th-174405956.html,"Top Research Reports for December 12th, 2016"
LLY,LLY:US,BBG000BNBDC2,Lilly/AstraZeneca Expand Alzheimer Disease Collaboration,2016-12-12 16:00:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ot5Bf4-IUi4/lillyastrazeneca-expand-alzheimer-disease-collaboration-cm719999,Eli Lilly and Company LLY and AstraZeneca plc AZN expanded their existing collaboration to develop the second treatment for Alzheimer s disease MEDI1814 Incidentally failure of Lilly s high profile investigational Alzheimer disease candidate solanezumab hurt the company s share price
LLY,LLY:US,BBG000BNBDC2,Biogen Presents Positive Early Data from Alzheimer's Study,2016-12-12 16:00:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OsmoRopeX1A/biogen-presents-positive-early-data-from-alzheimers-study-cm719988,Last week Biogen Inc BIIB presented positive data from a phase I study PRIME on its anti amyloid treatments in development aducanumab at the Clinical Trials on Alzheimer s Disease CTAD meeting in San Diego Biogen s share price has slipped 10 5 in the past one month underperforming
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY): Moving Average Crossover Alert,2016-12-12 14:59:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ufkgcFMzbY4/eli-lilly-lly-moving-average-crossover-alert-cm720078,Eli Lilly and Company LLY could be a stock to avoid from a technical perspective as the firm is seeing unfavorable trends on the moving average crossover front Recently the 50 Day Moving Average for LLY broke out below the 200 Day Simple Moving Average suggesting short term bearishness
LLY,LLY:US,BBG000BNBDC2,Biogen Presents Positive Early Data from Alzheimer's Study,2016-12-12 14:21:02 +0000,http://finance.yahoo.com/news/biogen-presents-positive-early-data-142102177.html,Biogen Presents Positive Early Data from Alzheimer's Study
LLY,LLY:US,BBG000BNBDC2,Lilly/AstraZeneca Expand Alzheimer Disease Collaboration,2016-12-12 14:19:02 +0000,http://finance.yahoo.com/news/lilly-astrazeneca-expand-alzheimer-disease-141902194.html,Lilly/AstraZeneca Expand Alzheimer Disease Collaboration
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY): Moving Average Crossover Alert,2016-12-12 13:31:01 +0000,http://finance.yahoo.com/news/eli-lilly-lly-moving-average-133101962.html,Eli Lilly (LLY): Moving Average Crossover Alert
LLY,LLY:US,BBG000BNBDC2,Wall Street Set For Mixed Start,2016-12-12 06:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JEj0i5tNTA/wall-street-set-for-mixed-start-20161212-00147,Wall Street Set For Mixed Start
LLY,LLY:US,BBG000BNBDC2,Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly,2016-12-11 17:55:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Swv8eWKbPow/big-alzheimer-flop-creates-buying-opportunity-for-eli-lilly-cm719853,Eli Lilly LLY made the news for the wrong reasons on Nov after announcing that its experimental treatment for Alzheimer s drug Solanezumab had failed If it had been successful Eli Lilly would have the distinction of researching the first effective disease modifying drug in the
LLY,LLY:US,BBG000BNBDC2,Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly,2016-12-10 21:32:32 +0000,http://finance.yahoo.com/news/big-alzheimer-flop-creates-buying-213232446.html,Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Will Trump Break With Republicans And Push Major Drug Price Reform?,2016-12-10 14:42:35 +0000,http://www.investors.com/news/technology/will-trump-break-with-republicans-to-champion-against-drug-prices/,Will Trump Break With Republicans And Push Major Drug Price Reform?
LLY,LLY:US,BBG000BNBDC2,Biogen Underplays Promising Alzheimer's Data On Seizure Worries,2016-12-09 22:29:57 +0000,http://www.investors.com/news/technology/biogen-underplays-promising-alzheimers-data-on-seizure-worries/,Biogen Underplays Promising Alzheimer's Data On Seizure Worries
LLY,LLY:US,BBG000BNBDC2,"New diabetes guidelines imminent, Jardiance sales may surge",2016-12-09 20:41:12 +0000,http://finance.yahoo.com/news/diabetes-guidelines-imminent-jardiance-sales-204112404.html,[Reuters] - Two leading U.S. medical societies are poised in the coming weeks to issue new diabetes treatment guidelines reflecting the lifesaving cardiovascular effects of Eli Lilly's Jardiance in a move expected to drive up the drug's sales. The forthcoming guidelines from the American Diabetes Association and the American Association of Clinical Endocrinologists follow last Friday's decision by U.S. regulators to expand the health benefits Lilly can claim for Jardiance to include preventing fatal heart attacks and strokes in type 2 diabetes patients.
LLY,LLY:US,BBG000BNBDC2,Why the latest Alzheimer’s data is (mostly) great news for Biogen,2016-12-09 19:55:06 +0000,http://www.bizjournals.com/boston/news/2016/12/09/why-the-latest-alzheimer-s-data-is-mostly-great.html?ana=yahoo,Why the latest Alzheimer’s data is (mostly) great news for Biogen
LLY,LLY:US,BBG000BNBDC2,Postive results in study of Alzheimer's,2016-12-09 19:37:00 +0000,http://finance.yahoo.com/video/postive-results-study-alzheimers-193700902.html,Postive results in study of Alzheimer's
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. AbbVie,2016-12-09 18:58:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hasuCJ794bg/better-buy-eli-lilly-and-company-vs-abbvie-cm719464,A less than surprising clinical failure recently sent Eli Lilly amp Co NYSE LLY shares tumbling while AbbVie NYSE ABBV stock has traded sideways for most of the year Since spinning off from its parent Abbott AbbVie has made an impressive effort to diversify
LLY,LLY:US,BBG000BNBDC2,How Much Hope Is There For Alzheimer's Drugs?,2016-12-09 18:14:00 +0000,http://www.forbes.com/sites/matthewherper/2016/12/09/how-much-hope-is-there-for-alzheimers-drugs/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,How Much Hope Is There For Alzheimer's Drugs?
LLY,LLY:US,BBG000BNBDC2,Vanguard Value ETF Experiences Big Inflow,2016-12-09 17:57:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RvelO4smba8/vanguard-value-etf-experiences-big-inflow-cm719403,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Value ETF Symbol VTV where we have detected an approximate 234 2 million dollar inflow that s a 0 9 increase week over week in outstanding units
LLY,LLY:US,BBG000BNBDC2,"Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’",2016-12-09 17:55:27 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=FDE25AB0-BE13-11E6-A55C-7986D69D84E4&siteid=yhoof2,"Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’"
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Company vs. AbbVie,2016-12-09 17:19:32 +0000,http://www.fool.com/investing/2016/12/09/better-buy-eli-lilly-and-company-vs-abbvie.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Eli Lilly and Company vs. AbbVie
LLY,LLY:US,BBG000BNBDC2,Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results,2016-12-09 15:39:00 +0000,https://www.thestreet.com/story/13920670/1/attention-shifts-to-biogen-s-alzheimer-s-drug-in-wake-of-lilly-results.html?puc=yahoo&cm_ven=YAHOO,Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results
LLY,LLY:US,BBG000BNBDC2,"AstraZeneca PLC (ADR) (AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly And Co (LLY)",2016-12-09 15:09:10 +0000,http://www.insidermonkey.com/blog/astrazeneca-plc-adr-azn-cuts-jobs-signs-new-collaboration-with-eli-lilly-and-co-lly-503600/,"AstraZeneca PLC (ADR) (AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly And Co (LLY)"
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs",2016-12-09 14:59:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z4k6ihoe7Kw/pharma-stock-roundup-drug-pricing-heat-back-on-sector-endo-mylan-azn-to-cut-jobs-cm719273,Drug pricing is back in focus with President elect Donald Trump making it clear that he does not like price increases In an interview with TIME magazine which has named him 2016 Person of the Year Trump said that his intentions may have been misread by some stock analysts and that his
LLY,LLY:US,BBG000BNBDC2,Better Buy: AbbVie Inc. vs. Eli Lilly,2016-12-09 14:59:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lr4jlZJ-L_8/better-buy-abbvie-inc-vs-eli-lilly-cm719143,Both AbbVie NYSE ABBV and Eli Lilly NYSE LLY have experienced recent clinical setbacks But while AbbVie s phase 2 study of 160 veliparib was disappointing it didn t impact the stock too much Lilly s shares on the other hand plunged on the failure of
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Continues Alzheimer's Push After Flop, Biogen Extends Rise",2016-12-09 14:39:25 +0000,http://www.investors.com/news/technology/biogen-alzheimers-drug-shows-more-promise-lilly-data-tonight/,"Eli Lilly Continues Alzheimer's Push After Flop, Biogen Extends Rise"
LLY,LLY:US,BBG000BNBDC2,"Astra, Lilly stick with Alzheimer's approach despite setback",2016-12-09 13:45:47 +0000,http://in.finance.yahoo.com/news/astra-lilly-stick-alzheimers-approach-134547087.html,"Astra, Lilly stick with Alzheimer's approach despite setback"
LLY,LLY:US,BBG000BNBDC2,Better Buy: AbbVie Inc. vs. Eli Lilly,2016-12-09 13:18:08 +0000,http://www.fool.com/investing/2016/12/09/better-buy-abbvie-inc-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: AbbVie Inc. vs. Eli Lilly
LLY,LLY:US,BBG000BNBDC2,How Does Johnson & Johnson’s Valuation Compare to Its Peers?,2016-12-09 13:06:42 +0000,http://marketrealist.com/2016/12/how-does-johnson-johnsons-valuation-compare-to-its-peers/?utm_source=yahoo&utm_medium=feed,How Does Johnson & Johnson’s Valuation Compare to Its Peers?
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to pay AstraZeneca $30 million as part of a collaboration on an Alzheimer's treatment,2016-12-09 12:12:54 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=96AEE5BB-E5CD-452C-A37A-DA450531849C&siteid=yhoof2,Eli Lilly to pay AstraZeneca $30 million as part of a collaboration on an Alzheimer's treatment
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and AstraZeneca to co-develop Alzheimer's Disease treatment,2016-12-09 12:08:26 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=3A6E6F53-D847-48E6-813F-499B145307D2&siteid=yhoof2,Eli Lilly and AstraZeneca to co-develop Alzheimer's Disease treatment
LLY,LLY:US,BBG000BNBDC2,Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease,2016-12-09 12:00:00 +0000,http://finance.yahoo.com/news/lilly-astrazeneca-develop-second-potentially-120000746.html,"[PR Newswire] - INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase 1 trials as a potential disease-modifying treatment for Alzheimer's disease (AD). ""At Lilly, we recognize the significant burden Alzheimer's disease places on patients, caregivers and our society, and we remain committed to finding ways to change the course of the disease,"" said Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories. ""We are pleased to be expanding our alliance with AstraZeneca to further build our pipeline of potential medicines and diagnostic agents."
LLY,LLY:US,BBG000BNBDC2,Biogen stock gains on leaked Alzheimer's drug data,2016-12-09 10:51:54 +0000,http://www.bizjournals.com/boston/news/2016/12/08/biogen-stock-gains-on-leaked-alzheimers-drug-data.html?ana=yahoo,Biogen stock gains on leaked Alzheimer's drug data
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met,2016-12-09 09:11:27 +0000,http://finance.yahoo.com/news/lilly-announces-detailed-results-solanezumab-091127082.html,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met
LLY,LLY:US,BBG000BNBDC2,Lilly And AstraZeneca In Deal To Co-develop MEDI1814,2016-12-09 07:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N5SWO690gyc/lilly-and-astrazeneca-in-deal-to-codevelop-medi1814-20161209-00136,Lilly And AstraZeneca In Deal To Co-develop MEDI1814
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting,2016-12-09 02:15:00 +0000,http://finance.yahoo.com/news/lilly-announces-detailed-results-solanezumab-021500838.html,"[PR Newswire] - INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting. As previously disclosed, solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a study of solanezumab initiated in people with mild dementia due to Alzheimer's disease (AD), and Lilly will not pursue regulatory submissions for solanezumab for the treatment of mild dementia due to AD."
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting,2016-12-09 02:15:00 +0000,http://finance.yahoo.com/news/lilly-announces-detailed-results-solanezumab-021500594.html,[CNW Group] - Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting
LLY,LLY:US,BBG000BNBDC2,5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices,2016-12-08 22:57:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YofTRa5XzCU/5-drug-stocks-to-avoid-as-trump-vows-to-lower-drug-prices-cm718932,For those who thought that the pharma biotech sector is in for an extraordinary run after Donald Trump s unexpected victory his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue This year has been fraught with headwinds for the pharma biotech sector
LLY,LLY:US,BBG000BNBDC2,Further promising data seen with Biogen Alzheimer's drug -study,2016-12-08 22:20:04 +0000,http://finance.yahoo.com/news/further-promising-data-seen-biogen-222004418.html,Further promising data seen with Biogen Alzheimer's drug -study
LLY,LLY:US,BBG000BNBDC2,Lilly Reports Detailed Results Of Solanezumab Phase 3 EXPEDITION3 Study,2016-12-08 21:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3kbcYlHbX2Q/lilly-reports-detailed-results-of-solanezumab-phase-3-expedition3-study-20161208-01146,Lilly Reports Detailed Results Of Solanezumab Phase 3 EXPEDITION3 Study
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co (LLY) Discusses Job Cuts,2016-12-08 17:35:40 +0000,http://www.insidermonkey.com/blog/eli-lilly-and-co-lly-discusses-job-cuts-502437/,Eli Lilly And Co (LLY) Discusses Job Cuts
LLY,LLY:US,BBG000BNBDC2,Why Biotech is Getting Killed…And Why It WIll Bounce Back,2016-12-08 15:44:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/08/why-biotech-is-getting-killed-and-why-it-will-bounce-back/?mod=yahoobarrons&ru=yahoo,Why Biotech is Getting Killed…And Why It WIll Bounce Back
LLY,LLY:US,BBG000BNBDC2,Can Biogen solve the Alzheimer’s drug riddle? We could find out within days,2016-12-08 15:15:08 +0000,http://www.bizjournals.com/boston/news/2016/12/07/can-biogen-solve-the-alzheimer-s-drug-riddle-we.html?ana=yahoo,Can Biogen solve the Alzheimer’s drug riddle? We could find out within days
LLY,LLY:US,BBG000BNBDC2,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer,2016-12-08 13:30:00 +0000,http://finance.yahoo.com/news/lilly-presents-neomonarch-phase-2-133000701.html,"[PR Newswire] - SAN ANTONIO, Dec. 8, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferation, after two weeks of treatment. Final data from the Phase 2 trial presented during the official press program at the 2016 San Antonio Breast Cancer Symposium (SABCS) evaluated abemaciclib, both alone or in combination with the non-steroidal aromatase-inhibitor anastrozole, in postmenopausal women with previously untreated early stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. ""Lilly is committed to the scientific discovery and development of new therapies that change current standards of cancer care,"" said Sue Mahony, Ph.D., senior vice president and president, Lilly Oncology."
LLY,LLY:US,BBG000BNBDC2,Lilly Presents NeoMONARCH Phase2 Data On Abemaciclib In EarlyStage Breast Cancer,2016-12-08 08:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/myxeHoxzcCM/lilly-presents-neomonarch-phase2-data-on-abemaciclib-in-earlystage-breast-cancer-20161208-00438,Lilly Presents NeoMONARCH Phase2 Data On Abemaciclib In EarlyStage Breast Cancer
LLY,LLY:US,BBG000BNBDC2,Correction to Novo Nordisk Pledges to Limit Price Increases in US for Its Drugs Story on Tuesday,2016-12-08 06:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wu5QwPvw-Oo/correction-to-novo-nordisk-pledges-to-limit-price-increases-in-us-for-its-drugs-story-on-tuesday-20161208-00141,Correction to Novo Nordisk Pledges to Limit Price Increases in US for Its Drugs Story on Tuesday
LLY,LLY:US,BBG000BNBDC2,Better Buy: Johnson & Johnson vs. Eli Lilly,2016-12-07 21:57:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nzqbDwKqqWc/better-buy-johnson-johnson-vs-eli-lilly-cm718278,Just ahead of the Thanksgiving holiday Eli Lilly NYSE LLY announced the third late stage clinical failure for its Alzheimer s disease candidate The stock had given up some ground this year and following the flop it s down about 20 in 2016 Meanwhile it s hardly been a
LLY,LLY:US,BBG000BNBDC2,Better Buy: Johnson & Johnson vs. Eli Lilly,2016-12-07 20:48:54 +0000,http://www.fool.com/investing/2016/12/07/better-buy-johnson-johnson-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Johnson & Johnson vs. Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Sanofi and Johnson & Johnson May Battle for the Right to Overpay for Actelion,2016-12-07 13:56:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h6uJ_TbYeJ8/sanofi-and-johnson-johnson-may-battle-for-the-right-to-overpay-for-actelion-cm717825,Image source Getty Images Who said mergers and acquisitions M amp A were slowing down in the drug industry Certainly not healthcare conglomerate Johnson amp Johnson NYSE JNJ which has made two bids now to acquire Swiss drugmaker Actelion NASDAQOTH ALIOF
LLY,LLY:US,BBG000BNBDC2,Illumina Names Sam Samad CFO - Qick Facts,2016-12-07 06:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RQ1U7nEkm90/illumina-names-sam-samad-cfo--qick-facts-20161207-00160,Illumina Names Sam Samad CFO - Qick Facts
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Amazon, Dow Chemical, Ford, Eli Lilly and Eni",2016-12-06 21:29:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d58yWyM0s9s/the-zacks-analyst-blog-highlights-amazon-dow-chemical-ford-eli-lilly-and-eni-cm717682,For Immediate Release Chicago IL December 06 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,Lilly: Jardiance Label to Add Cardiovascular Indication,2016-12-06 21:25:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6HczQVYMSEk/lilly-jardiance-label-to-add-cardiovascular-indication-cm717564,Eli Lilly amp Company LLY recently announced that the FDA 160 has approved the inclusion of cardiovascular CV risk reduction data from the EMPA REG OUTCOME study on its type II diabetes drug Jardiance s SGLT 2 inhibitor label Jardiance was approved in 2014 for lowering blood sugar
LLY,LLY:US,BBG000BNBDC2,Lilly: Jardiance Label to Add Cardiovascular Indication,2016-12-06 15:36:03 +0000,http://finance.yahoo.com/news/lilly-jardiance-label-add-cardiovascular-153603583.html,Lilly: Jardiance Label to Add Cardiovascular Indication
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs,2016-12-06 15:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wd-tHD63scU/novo-nordisk-pledges-to-limit-price-increases-in-us-for-its-drugs-20161206-00988,Novo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
LLY,LLY:US,BBG000BNBDC2,Anavex Life Sciences Corp. in 3 Charts,2016-12-06 12:34:20 +0000,http://www.fool.com/investing/2016/12/06/anavex-life-sciences-corp-in-3-charts.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Anavex Life Sciences Corp. in 3 Charts
LLY,LLY:US,BBG000BNBDC2,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 20:55:28 +0000,http://finance.yahoo.com/news/pressure-biosciences-ceo-biological-samples-205528437.html,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
LLY,LLY:US,BBG000BNBDC2,"Top Research Reports for Amazon, Ford & Dow Chemical",2016-12-05 17:48:05 +0000,http://finance.yahoo.com/news/top-research-reports-amazon-ford-174805615.html,"Top Research Reports for Amazon, Ford & Dow Chemical"
LLY,LLY:US,BBG000BNBDC2,Why Did the S&P 500 Post Moderate Gains on December 2?,2016-12-05 14:37:54 +0000,http://marketrealist.com/2016/12/sp-500-posted-moderate-gains-due-soft-jobs-data/?utm_source=yahoo&utm_medium=feed,Why Did the S&P 500 Post Moderate Gains on December 2?
LLY,LLY:US,BBG000BNBDC2,4 Merrill Lynch Med Tech and Drug Dividend Stocks to Buy With Huge 2017 Potential,2016-12-05 13:20:33 +0000,http://247wallst.com/healthcare-business/2016/12/05/4-merrill-lynch-med-tech-and-drug-dividend-stocks-to-buy-with-huge-2017-potential/,4 Merrill Lynch Med Tech and Drug Dividend Stocks to Buy With Huge 2017 Potential
LLY,LLY:US,BBG000BNBDC2,U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease,2016-12-05 13:00:00 +0000,http://finance.yahoo.com/news/u-fda-approves-jardiance-empagliflozin-130000303.html,"[PR Newswire] - RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 5, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. JARDIANCE is the first type 2 diabetes treatment approved with this additional indication and the only oral type 2 diabetes medicine shown in a clinical trial to provide a life-saving cardiovascular benefit. JARDIANCE is marketed by Boehringer Ingelheim and Eli Lilly and Company (LLY). ""As the only diabetes treatment approved by the FDA to reduce the risk of cardiovascular death, JARDIANCE represents a tremendous step forward in our efforts to reduce the impact of heart disease among adults with type 2 diabetes and cardiovascular disease,"" said Paul Fonteyne, president and CEO, Boehringer Ingelheim Pharmaceuticals, Inc. ""This approval is another example of our commitment to the discovery and development of treatment options for adults with type 2 diabetes."
LLY,LLY:US,BBG000BNBDC2,FDA Approves Jardiance Tablets To Reduce Cardiovascular Death Risk In Diabetes,2016-12-05 08:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UzyKkdEoVfs/fda-approves-jardiance-tablets-to-reduce-cardiovascular-death-risk-in-diabetes-20161205-00389,FDA Approves Jardiance Tablets To Reduce Cardiovascular Death Risk In Diabetes
LLY,LLY:US,BBG000BNBDC2,[$$] Prevention of Alzheimer's is the way forward,2016-12-04 22:45:16 +0000,"http://www.ft.com/cms/s/67e82516-b716-11e6-ba85-95d1533d9a62,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Sir, For a small fraction of the $3bn spent by Eli Lilly on anti-amyloid drug development (""Symptoms of failure"", The Big Read, December 1), a trial could be done on a preventive intervention ..."
LLY,LLY:US,BBG000BNBDC2,7 of the Most Shocking Biotech Pipeline Blowups of 2016,2016-12-04 18:04:17 +0000,http://www.fool.com/investing/2016/12/04/7-of-the-most-shocking-biotech-pipeline-blowups-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,7 of the Most Shocking Biotech Pipeline Blowups of 2016
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly Shares Lost 8% in November,2016-12-03 13:04:03 +0000,http://www.fool.com/investing/2016/12/03/why-eli-lilly-shares-lost-8-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Eli Lilly Shares Lost 8% in November
LLY,LLY:US,BBG000BNBDC2,Lilly Could Pocket $1.7 Billion In Fresh Diabetes Drug Sales In 2025,2016-12-02 21:35:39 +0000,http://www.investors.com/news/technology/lilly-could-pocket-1-7-billion-in-fresh-diabetes-drug-sales-in-2025/,Lilly Could Pocket $1.7 Billion In Fresh Diabetes Drug Sales In 2025
LLY,LLY:US,BBG000BNBDC2,Eli Lilly spikes after FDA approves label change for diabetes drug to reduce cardiovascular death,2016-12-02 21:23:05 +0000,http://www.cnbc.com/id/104143540?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104143540,Eli Lilly spikes after FDA approves label change for diabetes drug to reduce cardiovascular death
LLY,LLY:US,BBG000BNBDC2,Lilly Spikes on FDA Jardiance Approval (LLY),2016-12-02 20:30:00 +0000,http://www.investopedia.com/news/lilly-shares-spike-jardiance-approval-lly/?partner=YahooSA,Lilly Spikes on FDA Jardiance Approval (LLY)
LLY,LLY:US,BBG000BNBDC2,"FDA lets Lilly cite Jardiance heart data, shares jump",2016-12-02 20:28:11 +0000,http://finance.yahoo.com/news/fda-allows-diabetes-drug-jardiance-194545709.html,"[Reuters] - U.S regulators said on Friday they would allow Eli Lilly and Co to state that its diabetes drug Jardiance reduces risk of death from heart problems, lifting company shares almost 3 percent and potentially giving a strong boost to the drug's future sales. Jardiance, a once-daily pill also known as empagliflozin, was approved by the FDA in 2014 to help lower blood sugar in patients with type 2 diabetes. At the time of approval the FDA asked that a separate trial be conducted to show the drug did not increase the risk of cardiovascular problems."
LLY,LLY:US,BBG000BNBDC2,Lilly's diabetes drug Jardiance cuts risk of cardiovascular death: FDA,2016-12-02 18:32:14 +0000,http://finance.yahoo.com/news/lillys-diabetes-drug-jardiance-cuts-183214231.html,"[Reuters] - The U.S Food and Drug Administration said on Friday it had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc's drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes. Jardiance, also known as empagliflozin, was approved in 2014 to help lower blood sugar in patients with type 2 diabetes. The risk of death from heart disease is 70 percent higher in diabetics compared to those without diabetes, according to the U.S. Centers for Disease Control and Prevention."
LLY,LLY:US,BBG000BNBDC2,FDA: Eli Lilly drug reduces cardiovascular death,2016-12-02 18:15:00 +0000,http://finance.yahoo.com/video/fda-eli-lilly-drug-reduces-181500094.html,FDA: Eli Lilly drug reduces cardiovascular death
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date and Conference Call for 2017 Financial Guidance Announcement,2016-12-02 15:30:00 +0000,http://finance.yahoo.com/news/lilly-confirms-date-conference-call-153000569.html,"[PR Newswire] - INDIANAPOLIS, Dec. 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2017 and provide updated financial guidance for 2016 on Thursday, December 15, 2016. ..."
LLY,LLY:US,BBG000BNBDC2,5 Dividend Retirement Stocks to Buy Now and Hold Forever,2016-12-02 15:05:53 +0000,http://247wallst.com/investing/2016/12/02/5-dividend-retirement-stocks-to-buy-now-and-hold-forever/,5 Dividend Retirement Stocks to Buy Now and Hold Forever
LLY,LLY:US,BBG000BNBDC2,Sensex Down 170 Points On Capital Outflow Worries; Nifty Sheds 58 Points,2016-12-01 23:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3aj23aT9HkE/sensex-down-170-points-on-capital-outflow-worries-nifty-sheds-58-points-20161201-01397,Sensex Down 170 Points On Capital Outflow Worries; Nifty Sheds 58 Points
LLY,LLY:US,BBG000BNBDC2,Sensex Down 170 Points On Capital Outflow Worries; Nifty Sheds 58 Points,2016-12-01 23:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XRuX2G6pZBQ/sensex-down-170-points-on-capital-outflow-worries-nifty-sheds-58-points-20161201-01398,Sensex Down 170 Points On Capital Outflow Worries; Nifty Sheds 58 Points
LLY,LLY:US,BBG000BNBDC2,Oramed Vs. Novo Nordisk In Race For Oral GLP-1,2016-12-01 22:35:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cGK8LuoB9po/oramed-vs-novo-nordisk-in-race-for-oral-glp-1-cm715418,By Sharon di Stefano BySharon di Stefano As diabetes drug frontrunners scramble to create the next best thing GLP 1 a powerful hormone designed to tell the pancreas when to release insulin brings face to face two strong contenders for an oral version Oramed Pharmaceuticals Inc
LLY,LLY:US,BBG000BNBDC2,"VTV, MSFT, INTC, LLY: Large Inflows Detected at ETF",2016-12-01 17:16:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uXbxM0-h5Tc/vtv-msft-intc-lly-large-inflows-detected-at-etf-cm716374,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Value ETF Symbol VTV where we have detected an approximate 178 5 million dollar inflow that s a 0 7 increase week over week in outstanding units
LLY,LLY:US,BBG000BNBDC2,Bringing foreign drugs into the US market is a dangerous ...,2016-12-01 15:55:00 +0000,http://finance.yahoo.com/video/bringing-foreign-drugs-us-market-155500482.html,Bringing foreign drugs into the US market is a dangerous ...
LLY,LLY:US,BBG000BNBDC2,Analyst’s Top Pharmaceutical Buys Offer Big Dividends and Growth Potential,2016-12-01 13:10:29 +0000,http://247wallst.com/healthcare-business/2016/12/01/analysts-top-pharmaceutical-buys-offer-big-dividends-and-growth-potential/,Analyst’s Top Pharmaceutical Buys Offer Big Dividends and Growth Potential
LLY,LLY:US,BBG000BNBDC2,"Celgene, Kite, Spark Look To Sidestep Lilly Alzheimer's Flop",2016-11-30 21:15:50 +0000,http://www.investors.com/news/technology/celgene-kite-spark-look-to-sidestep-lilly-alzheimers-flop-at-ash/,"Celgene, Kite, Spark Look To Sidestep Lilly Alzheimer's Flop"
LLY,LLY:US,BBG000BNBDC2,Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students,2016-11-30 19:34:00 +0000,http://finance.yahoo.com/news/lilly-introduces-scholars-programs-florida-193400610.html,"[PR Newswire] - INDIANAPOLIS, Nov. 30, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) will deepen its partnership with Florida Agricultural and Mechanical University (FAMU) and Howard University with the inaugural Sybil C. Mobley Scholars Program and the inaugural H. Naylor Fitzhugh Scholars Program. The programs, in part, aim to increase the representation of diverse talent in Lilly's marketing organization. For many years, Lilly has partnered with Howard University as a corporate sponsor of Howard University's 21 Century Advantage Program (CAP), a program in which Fortune 500 companies adopt teams of freshmen and sophomore students to enhance their business skills and professional development."
LLY,LLY:US,BBG000BNBDC2,AbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019,2016-11-30 16:05:04 +0000,http://marketrealist.com/2016/11/abbvie-expects-launch-investigational-psoriasis-therapy-risankizumab-2019/?utm_source=yahoo&utm_medium=feed,AbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
LLY,LLY:US,BBG000BNBDC2,J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance,2016-11-30 15:59:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/646g1EeOt2Y/jj-jnj-stands-tall-in-2016-reasons-for-outperformance-cm715680,Johnson amp Johnson JNJ the bellwether among healthcare companies has a strong presence in the pharmaceutical medical devices and consumer care markets across the world This New Jersey based company is well known for its baby care products and brands like Tylenol in addition to drugs
LLY,LLY:US,BBG000BNBDC2,"After Lilly Bombs, Could Alzheimer's Become Healthcare's Trumpshot?",2016-11-30 13:35:00 +0000,http://www.forbes.com/sites/stephenbrozak/2016/11/30/after-lilly-bombs-could-alzheimers-become-healthcares-trumpshot/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"After Lilly Bombs, Could Alzheimer's Become Healthcare's Trumpshot?"
LLY,LLY:US,BBG000BNBDC2,Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield,2016-11-30 13:34:00 +0000,https://www.thestreet.com/story/13908604/1/biotech-stock-mailbag-looking-for-an-investable-idea-in-alzheimer-s-mine-field.html?puc=yahoo&cm_ven=YAHOO,Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
LLY,LLY:US,BBG000BNBDC2,"Drugmakers' Price Duopoly (PFE, LLY)",2016-11-30 11:00:00 +0000,http://www.investopedia.com/news/drugmakers-price-duopoly-pfe-lly/?partner=YahooSA,"Drugmakers' Price Duopoly (PFE, LLY)"
LLY,LLY:US,BBG000BNBDC2,"Pfizer Inc. (PFE), Eli Lilly And Co (LLY) Impotence Drugs Price Increases Leave Patients Disgruntled",2016-11-29 17:50:29 +0000,http://www.insidermonkey.com/blog/pfizer-inc-pfe-eli-lilly-and-co-lly-impotence-drugs-price-increases-leave-patients-disgruntled-494753/,"Pfizer Inc. (PFE), Eli Lilly And Co (LLY) Impotence Drugs Price Increases Leave Patients Disgruntled"
LLY,LLY:US,BBG000BNBDC2,Biogen loses $4 billion in market cap on Eli Lilly Alzheimer's news,2016-11-29 16:50:08 +0000,http://www.bizjournals.com/boston/news/2016/11/23/biogen-loses-4-billion-in-market-cap-on-eli-lilly.html?ana=yahoo,Biogen loses $4 billion in market cap on Eli Lilly Alzheimer's news
LLY,LLY:US,BBG000BNBDC2,The Difference Between Shareholders And Stakeholders,2016-11-29 13:40:18 +0000,http://finance.yahoo.com/news/difference-between-shareholders-stakeholders-134018231.html,The Difference Between Shareholders And Stakeholders
LLY,LLY:US,BBG000BNBDC2,Merrill Lynch Makes Huge Changes by Removing 2 Blue Chips From US 1 List,2016-11-29 13:25:15 +0000,http://247wallst.com/investing/2016/11/29/merrill-lynch-makes-huge-changes-by-removing-2-blue-chips-from-us-1-list/,"[at 24/7 Wall St.] - In a recent research note, the analysts at Merrill Lynch make a big move by removing two blue chips from the firm's well-respected US 1 list of stocks to buy."
LLY,LLY:US,BBG000BNBDC2,Pfizer’s Valuation Compared to Peers,2016-11-29 13:06:50 +0000,http://marketrealist.com/2016/11/pfizers-valuation-compared-to-peers/?utm_source=yahoo&utm_medium=feed,Pfizer’s Valuation Compared to Peers
LLY,LLY:US,BBG000BNBDC2,[$$] Big Pharma healthcare R&D steps out into the open,2016-11-29 12:00:11 +0000,"http://www.ft.com/cms/s/81a910f0-9b91-11e6-8f9b-70e3cabccfae,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Big Pharma healthcare R&D steps out into the open
LLY,LLY:US,BBG000BNBDC2,"[$$] Plaques, tangles and the mystery of Alzheimer's disease",2016-11-29 05:00:23 +0000,"http://www.ft.com/cms/s/2d588dae-b573-11e6-961e-a1acd97f622d,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[$$] Plaques, tangles and the mystery of Alzheimer's disease"
LLY,LLY:US,BBG000BNBDC2,3 Top Drug Stocks for Your Retirement Portfolio,2016-11-28 19:56:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0hozMTH8SI4/3-top-drug-stocks-for-your-retirement-portfolio-cm714673,What makes a stock a good fit for a retirement portfolio Most older investors want steady dividend payments for income but don t want to give up the potential for growth These three pharmaceutical stocks should be able to deliver both Here s why Bristol Myers Squibb NYSE
LLY,LLY:US,BBG000BNBDC2,[$$] Biogen Unfazed by Lilly Disappointment,2016-11-28 19:24:00 +0000,http://www.barrons.com/articles/biogen-unfazed-by-lilly-disappointment-1480361095?mod=yahoobarrons&ru=yahoo,[$$] Biogen Unfazed by Lilly Disappointment
LLY,LLY:US,BBG000BNBDC2,One Battered Stock To Buy As The Market Continues To Surge,2016-11-28 18:49:00 +0000,http://www.forbes.com/sites/genemarcial/2016/11/28/one-battered-stock-to-buy-as-the-market-continues-to-surge/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,One Battered Stock To Buy As The Market Continues To Surge
LLY,LLY:US,BBG000BNBDC2,Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies,2016-11-28 18:24:00 +0000,https://www.thestreet.com/story/13905969/1/lilly-s-setback-raises-stakes-for-other-alzheimer-drug-companies.html?puc=yahoo&cm_ven=YAHOO,Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies
LLY,LLY:US,BBG000BNBDC2,3 Top Drug Stocks for Your Retirement Portfolio,2016-11-28 16:02:32 +0000,http://www.fool.com/investing/2016/11/28/3-top-drug-stocks-for-your-retirement-portfolio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Drug Stocks for Your Retirement Portfolio
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF",2016-11-28 15:32:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jXY0HwZ0e7M/pharma-stock-roundup-lilly-alzheimers-drug-fails-jj-in-acquisition-talks-with-aliof-cm714418,The big news last week was the high profile failure of Lilly s LLY investigational Alzheimer s disease drug solanezumab While the news dented Lilly s shares with the stock touching a 52 week low other companies involved in developing Alzheimer s disease treatments were also not spared
LLY,LLY:US,BBG000BNBDC2,Jim Cramer -- Eli Lilly's Alzheimer Drug Failure Is a Major Disaster,2016-11-28 15:27:00 +0000,https://www.thestreet.com/story/13905968/1/jim-cramer-eli-lilly-s-alzheimer-drug-failure-is-a-major-disaster.html?puc=yahoo&cm_ven=YAHOO,Jim Cramer -- Eli Lilly's Alzheimer Drug Failure Is a Major Disaster
LLY,LLY:US,BBG000BNBDC2,Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails,2016-11-28 14:45:31 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=5651B1BE-B315-11E6-9EED-D4A5BAE29302&siteid=yhoof2,Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails
LLY,LLY:US,BBG000BNBDC2,Investor looks for a rebound in Lilly,2016-11-28 14:02:42 +0000,http://finance.yahoo.com/news/investor-looks-rebound-lilly-140242178.html,Investor looks for a rebound in Lilly
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF",2016-11-28 13:49:01 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-alzheimers-134901886.html,"Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF"
LLY,LLY:US,BBG000BNBDC2,Tandem Drug-Price Increases Take Toll on Some Patients,2016-11-28 05:07:58 +0000,http://www.wsj.com/articles/tandem-drug-price-increases-take-toll-on-some-patients-1480248000?ru=yahoo?mod=yahoo_itp,Tandem Drug-Price Increases Take Toll on Some Patients
LLY,LLY:US,BBG000BNBDC2,Drugmakers Find Competition Doesn’t Keep a Lid on Prices,2016-11-28 05:07:52 +0000,http://www.wsj.com/articles/drugmakers-find-competition-doesnt-keep-a-lid-on-prices-1480248003?ru=yahoo?mod=yahoo_itp,Drugmakers Find Competition Doesn’t Keep a Lid on Prices
LLY,LLY:US,BBG000BNBDC2,Should You Buy Eli Lilly & Co. (LLY)?,2016-11-28 01:45:51 +0000,http://www.insidermonkey.com/blog/should-you-buy-eli-lilly-co-lly-490128/,Should You Buy Eli Lilly & Co. (LLY)?
LLY,LLY:US,BBG000BNBDC2,[$$] Drugmakers Find Competition Doesn't Keep a Lid on Prices,2016-11-27 12:05:39 +0000,http://www.wsj.com/articles/drugmakers-find-competition-doesnt-keep-a-lid-on-prices-1480248003?mod=yahoo_hs,[$$] Drugmakers Find Competition Doesn't Keep a Lid on Prices
LLY,LLY:US,BBG000BNBDC2,[$$] Tandem Drug-Price Increases Take Toll on Some Patients,2016-11-27 12:00:04 +0000,http://www.wsj.com/articles/tandem-drug-price-increases-take-toll-on-some-patients-1480248000?mod=yahoo_hs,[$$] Tandem Drug-Price Increases Take Toll on Some Patients
LLY,LLY:US,BBG000BNBDC2,Drugmakers Find Competition Doesn’t Keep a Lid on Prices,2016-11-27 12:00:00 +0000,http://finance.yahoo.com/news/drugmakers-competition-doesn-t-keep-120000679.html,Drugmakers Find Competition Doesn’t Keep a Lid on Prices
LLY,LLY:US,BBG000BNBDC2,Tandem Drug-Price Increases Take Toll on Some Patients,2016-11-27 07:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bbe6qwGkNYQ/tandem-drugprice-increases-take-toll-on-some-patients-20161127-00006,Tandem Drug-Price Increases Take Toll on Some Patients
LLY,LLY:US,BBG000BNBDC2,Drugmakers Find Competition Doesn't Keep a Lid on Prices,2016-11-27 07:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BnsS0Wg6MWo/drugmakers-find-competition-doesnt-keep-a-lid-on-prices-20161127-00007,Drugmakers Find Competition Doesn't Keep a Lid on Prices
LLY,LLY:US,BBG000BNBDC2,4 Companies That Destroyed Shareholders Last Week,2016-11-26 15:00:36 +0000,http://247wallst.com/investing/2016/11/26/4-companies-that-destroyed-shareholders-last-week-10/,4 Companies That Destroyed Shareholders Last Week
LLY,LLY:US,BBG000BNBDC2,[$$] Lilly’s Bet on Alzheimer’s,2016-11-26 04:10:20 +0000,http://www.wsj.com/articles/lillys-bet-on-alzheimers-1480113474?ru=yahoo?mod=yahoo_itp,[$$] Lilly’s Bet on Alzheimer’s
LLY,LLY:US,BBG000BNBDC2,"[$$] Week in Review, November 26",2016-11-25 22:26:46 +0000,"http://www.ft.com/cms/s/a16fa09c-b30c-11e6-9c37-5787335499a0,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[$$] Week in Review, November 26"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Hits 52-Week Low on Poor Data on Alzheimer's Drug,2016-11-25 21:05:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mc-58FVBTwQ/eli-lilly-hits-52-week-low-on-poor-data-on-alzheimers-drug-cm714109,Indianapolis IN based Eli Lilly and Company s LLY shares tumbled to a new 52 week low of 64 18 on Nov 23 after the company announced disappointing data from a late stage study on its Alzheimer s disease candidate solanezumab The company s shares closed a little higher at 68 00 reflecting
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Hits 52-Week Low on Poor Data on Alzheimer's Drug,2016-11-25 19:10:07 +0000,http://finance.yahoo.com/news/eli-lilly-hits-52-week-191007919.html,Eli Lilly Hits 52-Week Low on Poor Data on Alzheimer's Drug
LLY,LLY:US,BBG000BNBDC2,"Week In Review: Stocks Hit Highs; OPEC Talk Pumps, Dumps Oil; Shoppers Hunt Deals",2016-11-25 18:15:44 +0000,http://www.investors.com/news/week-in-review-stocks-hit-highs-opec-talk-pumps-oil-shoppers-hunt-deals/,"Week In Review: Stocks Hit Highs; OPEC Talk Pumps, Dumps Oil; Shoppers Hunt Deals"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Downgraded On Drug Flop; Whiting, Deere PTs Raised",2016-11-25 18:09:55 +0000,http://www.investors.com/news/eli-lilly-downgraded-on-drug-failure-whiting-deere-pt-raised/,"Eli Lilly Downgraded On Drug Flop; Whiting, Deere PTs Raised"
LLY,LLY:US,BBG000BNBDC2,"Stock Market News for November 25, 2016",2016-11-25 17:05:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iO9Oc0Kf0Bo/stock-market-news-for-november-25-2016-cm713985,Benchmarks finished mixed on Wednesday after strong durable orders and Donald Trump s economic agenda boosted the industrial sector Both the Dow and S amp P 500 reached record high levels for the third straight session following continued expectations that Donald Trump will adopt new policies
LLY,LLY:US,BBG000BNBDC2,52-Week Company Lows,2016-11-25 15:06:48 +0000,http://finance.yahoo.com/news/52-week-company-lows-150648671.html,52-Week Company Lows
LLY,LLY:US,BBG000BNBDC2,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?,2016-11-25 14:40:33 +0000,http://marketrealist.com/2016/11/how-does-bristol-myers-squibbs-valuation-compare-to-peers-2/?utm_source=yahoo&utm_medium=feed,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?
LLY,LLY:US,BBG000BNBDC2,Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?,2016-11-25 14:07:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d3o-q7ihY2I/will-lillys-solanezumab-setback-weigh-on-other-alzheimers-stocks-cm713781,Eli Lilly and Company s LLY shares tumbled 10 5 following the release of highly awaited data on its experimental Alzheimer s disease AD treatment solanezumab from a late stage study The candidate was being investigated to see whether it can slow the progression of memory problems
LLY,LLY:US,BBG000BNBDC2,Key Investor Insights into Eli Lilly’s Recent Developments,2016-11-25 13:04:12 +0000,http://marketrealist.com/2016/11/key-investor-insights-into-eli-lillys-recent-developments/?utm_source=yahoo&utm_medium=feed,Key Investor Insights into Eli Lilly’s Recent Developments
LLY,LLY:US,BBG000BNBDC2,The Right Lesson From Lilly's Alzheimer's Failure,2016-11-25 13:00:30 +0000,http://www.bloomberg.com/gadfly/articles/2016-11-25/eli-lilly-alzheimer-s-failure-the-right-lesson?cmpid=yhoo.headline,The Right Lesson From Lilly's Alzheimer's Failure
LLY,LLY:US,BBG000BNBDC2,What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors,2016-11-25 12:09:33 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CB425EBE-B17C-11E6-909D-6A360671FDAB&siteid=yhoof2,What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors
LLY,LLY:US,BBG000BNBDC2,Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?,2016-11-25 12:00:12 +0000,http://finance.yahoo.com/news/lillys-solanezumab-setback-weigh-other-120012409.html,Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
LLY,LLY:US,BBG000BNBDC2,[$$] The Problem With Lilly Is the Problem With Pharma,2016-11-25 05:17:05 +0000,http://www.wsj.com/articles/the-problem-with-lilly-is-the-problem-with-pharma-1479918700?ru=yahoo?mod=yahoo_itp,[$$] The Problem With Lilly Is the Problem With Pharma
LLY,LLY:US,BBG000BNBDC2,[$$] Failure of Another Alzheimer’s Drug Forces a Reassessment,2016-11-25 05:16:08 +0000,http://www.wsj.com/articles/eli-lillys-setback-highlights-challenges-of-alzheimers-treatment-1479932924?ru=yahoo?mod=yahoo_itp,[$$] Failure of Another Alzheimer’s Drug Forces a Reassessment
LLY,LLY:US,BBG000BNBDC2,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY's Expedition Fails",2016-11-24 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vsjlil17fE0/juno-implodes-as-rocket-is-put-on-hold-again-llys-expedition-fails-20161124-00241,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY's Expedition Fails"
LLY,LLY:US,BBG000BNBDC2,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY''s Expedition Fails",2016-11-24 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sB3G_4szIAQ/juno-implodes-as-rocket-is-put-on-hold-again-llys-expedition-fails-20161124-00237,"JUNO Implodes As ROCKET Is Put On Hold Again, LLY''s Expedition Fails"
LLY,LLY:US,BBG000BNBDC2,Here’s Why These Two Biotechs Just Took A Hit: Eli Lilly And Co (LLY) And Juno Therapeutics Inc (JUNO),2016-11-24 18:12:11 +0000,http://www.insidermonkey.com/blog/heres-why-these-two-biotechs-just-took-a-hit-eli-lilly-and-co-lly-and-juno-therapeutics-inc-juno-491242/,Here’s Why These Two Biotechs Just Took A Hit: Eli Lilly And Co (LLY) And Juno Therapeutics Inc (JUNO)
LLY,LLY:US,BBG000BNBDC2,This Is Eli Lilly’s Animal Health Segment,2016-11-24 16:04:14 +0000,http://marketrealist.com/2016/11/this-is-eli-lillys-animal-health-segment/?utm_source=yahoo&utm_medium=feed,This Is Eli Lilly’s Animal Health Segment
LLY,LLY:US,BBG000BNBDC2,A Deeper Look into Eli Lilly’s New Products Portfolio,2016-11-24 15:04:17 +0000,http://marketrealist.com/2016/11/a-deeper-look-into-eli-lillys-new-products-portfolio/?utm_source=yahoo&utm_medium=feed,A Deeper Look into Eli Lilly’s New Products Portfolio
LLY,LLY:US,BBG000BNBDC2,"Lilly's Alzheimer Drug Fails Phase III Study, Stock Down",2016-11-24 13:06:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SV-ZlB57ots/lillys-alzheimer-drug-fails-phase-iii-study-stock-down-cm713614,Lilly s Eli Lilly and Company LLY announced that its key pipeline candidate solanezumab failed to meet the primary endpoint in a phase III study EXPEDITION3 in patients with mild Alzheimer s dementia The drugmaker s shares declined almost 11 on Wednesday following the disappointing
LLY,LLY:US,BBG000BNBDC2,What You Should Know about Eli Lilly’s Oncology Franchise,2016-11-24 13:04:18 +0000,http://marketrealist.com/2016/11/what-you-should-know-about-eli-lillys-oncology-franchise/?utm_source=yahoo&utm_medium=feed,What You Should Know about Eli Lilly’s Oncology Franchise
LLY,LLY:US,BBG000BNBDC2,Is Lilly's Alzheimer's Fail Good for Biogen? (BIIB),2016-11-24 12:39:00 +0000,http://www.investopedia.com/news/does-lillys-alzheimers-fail-hurt-biogen-biib/?partner=YahooSA,Is Lilly's Alzheimer's Fail Good for Biogen? (BIIB)
LLY,LLY:US,BBG000BNBDC2,"Lilly's Alzheimer Drug Fails Phase III Study, Stock Down",2016-11-24 11:04:11 +0000,http://finance.yahoo.com/news/lillys-alzheimer-drug-fails-phase-110411655.html,"Lilly's Alzheimer Drug Fails Phase III Study, Stock Down"
LLY,LLY:US,BBG000BNBDC2,"Asian stocks mixed in quiet trade, Japan buoyed by lower yen",2016-11-24 03:51:36 +0000,http://sg.finance.yahoo.com/news/us-stocks-recede-record-highs-151148159.html,"Asian stocks mixed in quiet trade, Japan buoyed by lower yen"
LLY,LLY:US,BBG000BNBDC2,"Why Eli Lilly, Kinross Gold, and HP Slumped Today",2016-11-24 01:04:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rGf0n7eJUuQ/why-eli-lilly-kinross-gold-and-hp-slumped-today-cm713574,Wednesday was another strong day for the stock market with major market benchmarks including the Dow S amp P 500 and small cap Russell 2000 setting new all time record highs Holiday cheer and ongoing enthusiasm about the future of the U S economy continued to drive gains for
LLY,LLY:US,BBG000BNBDC2,"Lilly Leads Medical Stocks Lower, But This IBD 50 Stock Broke Out",2016-11-24 00:27:28 +0000,http://finance.yahoo.com/video/lilly-leads-medical-stocks-lower-002728995.html,"Lilly Leads Medical Stocks Lower, But This IBD 50 Stock Broke Out"
LLY,LLY:US,BBG000BNBDC2,"Biogen Inc (BIIB) Stock Tumbles In Sympathy To Eli Lilly And Co (LLY), C’mon Man!",2016-11-24 00:07:48 +0000,http://www.insidermonkey.com/blog/biogen-inc-biib-stock-tumbles-in-sympathy-to-eli-lilly-and-co-lly-cmon-man-490463/,"Biogen Inc (BIIB) Stock Tumbles In Sympathy To Eli Lilly And Co (LLY), C’mon Man!"
LLY,LLY:US,BBG000BNBDC2,Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes,2016-11-24 00:00:00 +0000,https://www.thestreet.com/story/13901545/1/jim-cramer-s-mad-money-recap-what-you-can-learn-from-my-portfolio-mistakes.html?puc=yahoo&cm_ven=YAHOO,Jim Cramer's 'Mad Money' Recap: What You Can Learn From My Portfolio Mistakes
LLY,LLY:US,BBG000BNBDC2,"Why Eli Lilly, Kinross Gold, and HP Slumped Today",2016-11-23 23:31:08 +0000,http://www.fool.com/investing/2016/11/23/why-eli-lilly-kinross-gold-and-hp-slumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Eli Lilly, Kinross Gold, and HP Slumped Today"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Alzheimer's Drug Is a Bust,2016-11-23 23:04:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dkCfU_EgK5c/eli-lillys-alzheimers-drug-is-a-bust-cm713558,In a highly disappointing yet not all too surprising news release earlier today Eli Lilly amp Company NYSE LLY 160 says that its late stage drug solanezumab failed to improve cognition in patients diagnosed with mild to moderate Alzheimer s disease The failure marks the
LLY,LLY:US,BBG000BNBDC2,"Dow, S&P 500 set record high closes ahead of holiday",2016-11-23 22:39:30 +0000,http://in.finance.yahoo.com/news/wall-street-set-flat-open-135834460.html,"Dow, S&P 500 set record high closes ahead of holiday"
LLY,LLY:US,BBG000BNBDC2,Don’t Give Up Hope Yet After Latest Alzheimer’s Drug Setback,2016-11-23 22:33:55 +0000,http://www.bloomberg.com/news/articles/2016-11-23/don-t-give-up-hope-yet-after-latest-alzheimer-s-drug-setback?cmpid=yhoo.headline,Don’t Give Up Hope Yet After Latest Alzheimer’s Drug Setback
LLY,LLY:US,BBG000BNBDC2,"US STOCKS-Dow, S&P 500 set record high closes ahead of holiday",2016-11-23 22:31:55 +0000,http://uk.finance.yahoo.com/news/us-stocks-dow-p-500-223155535.html,"US STOCKS-Dow, S&P 500 set record high closes ahead of holiday"
LLY,LLY:US,BBG000BNBDC2,Drug bust hits healthcare stocks,2016-11-23 22:16:00 +0000,http://finance.yahoo.com/video/drug-bust-hits-healthcare-stocks-221600920.html,Drug bust hits healthcare stocks
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge,2016-11-23 22:06:37 +0000,http://www.wsj.com/articles/eli-lillys-alzheimers-drug-trial-fails-to-achieve-goals-1479902563?mod=yahoo_hs,[$$] Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge
LLY,LLY:US,BBG000BNBDC2,LLY Crosses Above 3% Yield Territory,2016-11-23 22:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/40-dVtljjWU/lly-crosses-above-3-yield-territory-cm713532,Looking at the universe of stocks we cover at Dividend Channel in trading on Wednesday shares of Eli Lilly amp Co Symbol LLY were yielding above the 3 mark based on its quarterly dividend annualized to 2 04 with the stock changing hands as low as 64 18 on the day Dividends
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Alzheimer's Drug Is a Bust,2016-11-23 22:01:09 +0000,http://www.fool.com/investing/general/2016/11/23/eli-lillys-alzheimers-drug-is-a-bust.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Eli Lilly's Alzheimer's Drug Is a Bust
LLY,LLY:US,BBG000BNBDC2,"Dow, S&P 500 notch third straight record close",2016-11-23 21:47:37 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=456DE4D4-B14F-11E6-BE1B-6FF5D091E831&siteid=yhoof2,"[at MarketWatch] - The S&P 500, Dow Jones Industrial Average and the Russell 2000 close at all-time highs Wednesday, while the Nasdaq lags behind ahead of the Thanksgiving Day holiday."
LLY,LLY:US,BBG000BNBDC2,"Health Care Sector Update for 11/23/2016: LLY,MDGS,JUNO",2016-11-23 21:44:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CYACNgh1h68/health-care-sector-update-for-11232016-llymdgsjuno-cm713550,Health care stocks have turned higher Wednesday afternoon with the NYSE Health Care Index climbing about 0 3 while shares of health care companies in the S amp P 500 were up 0 3 as a group Health care stocks have turned higher Wednesday afternoon with the NYSE Health Care Index climbing
LLY,LLY:US,BBG000BNBDC2,[$$] Failure of Another Alzheimer's Drug Forces a Reassessment,2016-11-23 21:27:57 +0000,http://www.wsj.com/articles/eli-lillys-setback-highlights-challenges-of-alzheimers-treatment-1479932924?mod=yahoo_hs,[$$] Failure of Another Alzheimer's Drug Forces a Reassessment
LLY,LLY:US,BBG000BNBDC2,Lilly's drug for Alzheimer's fails big trial; shares drop,2016-11-23 21:25:38 +0000,http://sg.finance.yahoo.com/news/lillys-drug-alzheimers-fails-big-190703746.html,Lilly's drug for Alzheimer's fails big trial; shares drop
LLY,LLY:US,BBG000BNBDC2,Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming,2016-11-23 21:08:00 +0000,https://www.thestreet.com/story/13904292/1/dow-scores-another-record-as-fed-signals-a-rate-hike-could-be-coming.html?puc=yahoo&cm_ven=YAHOO,Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Topples As Alzheimer's Darling Sola Fails; Biogen, Merck Down",2016-11-23 21:07:29 +0000,http://www.investors.com/news/technology/eli-lilly-biogen-merck-topple-after-alzheimers-darling-sola-fails/,"Eli Lilly Topples As Alzheimer's Darling Sola Fails; Biogen, Merck Down"
LLY,LLY:US,BBG000BNBDC2,"Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks",2016-11-23 20:35:01 +0000,http://sg.finance.yahoo.com/news/alzheimers-setback-prompts-rethink-lilly-203501852.html,"Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks"
LLY,LLY:US,BBG000BNBDC2,"US STOCKS-S&P 500 dips with healthcare shares, Dow edges up ahead of holiday",2016-11-23 20:33:20 +0000,http://uk.finance.yahoo.com/news/us-stocks-p-500-dips-203320454.html,"US STOCKS-S&P 500 dips with healthcare shares, Dow edges up ahead of holiday"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co (LLY) Drug Failure Doesn’t Answer the Bigger Question,2016-11-23 20:05:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KUePqSjdx6k/eli-lilly-and-co-lly-drug-failure-doesnt-answer-the-bigger-question-cm713492,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips A tough break for Eli Lilly and Co NYSE LLY shareholders today reports of another failed drug trial have sent LLY shares 12 lower as of this writing The current price near 67 is a two year
LLY,LLY:US,BBG000BNBDC2,Why Biogen Shareholders Lost $3 Billion Today,2016-11-23 20:05:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qd7rXDyH1s0/why-biogen-shareholders-lost-3-billion-today-cm713483,Image source Getty Images What happened Shares of Biogen NASDAQ BIIB were down more than 4 in early afternoon trading on Wednesday in response to Eli Lilly NYSE LLY reporting disappointing news about a late stage clinical trial involving an
LLY,LLY:US,BBG000BNBDC2,Another failure in search for treatment to slow Alzheimer's,2016-11-23 19:56:11 +0000,http://sg.finance.yahoo.com/news/lilly-alzheimers-drug-fails-latest-122535001.html,Another failure in search for treatment to slow Alzheimer's
LLY,LLY:US,BBG000BNBDC2,Why PDL BioPharma Inc. Is Down 14.8% Today,2016-11-23 19:05:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rFdUE9e_CKY/why-pdl-biopharma-inc-is-down-148-today-cm713430,Image source Getty Images What happened Shares in 160 PDL BioPharma NASDAQ PDLI 160 are tumbling 14 8 at 12 30 p m EST Wednesday after management closed on a 150 million convertible notes offering and Eli Lilly amp Co NYSE LLY reported a phase 3
LLY,LLY:US,BBG000BNBDC2,"An Alzheimer's drug fails, but many others still in testing",2016-11-23 18:42:21 +0000,http://sg.finance.yahoo.com/news/alzheimers-drug-fails-many-others-182502980.html,"An Alzheimer's drug fails, but many others still in testing"
LLY,LLY:US,BBG000BNBDC2,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise,2016-11-23 18:38:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bb-z1KLKHCE/mid-day-market-update-eli-lilly-tumbles-after-alzheimers-study-fails-to-meet-goals-euroseas-shares-rise-cm713468,Midway through trading Wednesday the Dow traded up 0 20 percent to 19 061 13 while the NASDAQ declined 0 38 percent to 5 365 65 The S amp P also fell dropping 0 12 percent to 2 200 26 Leading and Lagging Sectors On Wednesday industrial shares gained by 0 39 percent
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly Is Cratering Today,2016-11-23 18:05:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YJRsq60lTCc/why-eli-lilly-is-cratering-today-cm713366,Image source Getty What happened After releasing disappointing results from a late stage clinical trial shares of pharma giant Eli Lilly NYSE LLY fell by more than 12 as of 11 15 a m EST on Wednesday So what The trial in question was called
LLY,LLY:US,BBG000BNBDC2,Instant Analysis: Eli Lilly Drops Pre-holiday Alzheimer's Bomb,2016-11-23 17:06:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NYzPiFu277I/instant-analysis-eli-lilly-drops-pre-holiday-alzheimers-bomb-cm713302,What happened This morning Eli Lilly NYSE LLY dropped a data bomb that s going to spoil the Alzheimer s community s Thanksgiving appetite Long awaited results from a late stage study showed patients with mild Alzheimer s Disease related dementia didn t experience a
LLY,LLY:US,BBG000BNBDC2,"S&P 500 Movers: LLY, DE",2016-11-23 17:05:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cjg2iVM0BgY/sp-500-movers-lly-de-cm713319,In early trading on Wednesday shares of Deere topped the list of the day s best performing components of the S amp P 500 index trading up 9 9 Year to date Deere registers a 32 6 gain And the worst performing S amp P 500 component thus far on the day is Eli Lilly trading down 12
LLY,LLY:US,BBG000BNBDC2,Stocks Hit Fresh High,2016-11-23 17:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u5eCub-x6EQ/stocks-hit-fresh-high-20161123-00701,Stocks Hit Fresh High
LLY,LLY:US,BBG000BNBDC2,"Health Care ETFs Fall As Eli Lilly, Juno Add To Troubled Sector's Woes",2016-11-23 17:03:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bnzeddQZs_s/health-care-etfs-fall-as-eli-lilly-juno-add-to-troubled-sectors-woes-cm713294,Major index tracking 160 ETFs paused at Wednesday s open after notching a string of postelection new highs The stock rally had come as investors cheered President elect Donald Trump s proposals for lower taxes and less regulation of businesses SPDR S amp P 500 SPY
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Scraps Failed Alzheimer's Drug (LLY),2016-11-23 16:50:00 +0000,http://www.investopedia.com/news/eli-lilly-tanks-alzheimers-drug-failure-lly/?partner=YahooSA,Eli Lilly Scraps Failed Alzheimer's Drug (LLY)
LLY,LLY:US,BBG000BNBDC2,What Comes Next for Eli Lilly?,2016-11-23 16:45:44 +0000,http://www.bloomberg.com/news/videos/2016-11-23/what-comes-next-for-eli-lilly?cmpid=yhoo.headline,What Comes Next for Eli Lilly?
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Alzheimer's Drug Fails Key Trial; Lilly, Biogen Dive",2016-11-23 16:39:58 +0000,http://www.investors.com/news/technology/eli-lilly-alzheimers-drug-fails-key-trial-stock-dives/,"Eli Lilly Alzheimer's Drug Fails Key Trial; Lilly, Biogen Dive"
LLY,LLY:US,BBG000BNBDC2,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views,2016-11-23 16:38:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w4Upev5Bjpk/mid-morning-market-update-markets-mostly-lower-deere-tops-q4-views-cm713338,Following the market opening Wednesday the Dow traded up 0 01 percent to 19 025 45 while the NASDAQ declined 0 51 percent to 5 359 03 The S amp P also fell dropping 0 30 percent to 2 196 41 Leading and Lagging Sectors Wednesday morning industrial shares gained by 0 11
LLY,LLY:US,BBG000BNBDC2,Why Eli Lilly Is Cratering Today,2016-11-23 16:37:29 +0000,http://www.fool.com/investing/2016/11/23/why-eli-lilly-is-cratering-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Eli Lilly Is Cratering Today
LLY,LLY:US,BBG000BNBDC2,[$$] The Problem With Lilly is the Problem With Pharma,2016-11-23 16:31:47 +0000,http://www.wsj.com/articles/the-problem-with-lilly-is-the-problem-with-pharma-1479918700?mod=yahoo_hs,[$$] The Problem With Lilly is the Problem With Pharma
LLY,LLY:US,BBG000BNBDC2,Dow Sets Record but Nasdaq Slides as Biotech Tumbles,2016-11-23 16:30:00 +0000,https://www.thestreet.com/story/13904047/1/dow-sets-record-but-nasdaq-slides-as-biotech-tumbles.html?puc=yahoo&cm_ven=YAHOO,Dow Sets Record but Nasdaq Slides as Biotech Tumbles
LLY,LLY:US,BBG000BNBDC2,"Moody's says Eli Lilly failed trial is credit negative, but not enough to lower rating",2016-11-23 16:23:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=3694C0D5-97D6-49E7-B065-4265A594832F&siteid=yhoof2,"Moody's says Eli Lilly failed trial is credit negative, but not enough to lower rating"
LLY,LLY:US,BBG000BNBDC2,"Lilly Has 40% Upside, Despite Alzheimer's Drug Failure, JPM Says",2016-11-23 16:22:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/23/lilly-has-40-upside-despite-alzheimer-drug-failure-jpm-says/?mod=yahoobarrons&ru=yahoo,"Lilly Has 40% Upside, Despite Alzheimer's Drug Failure, JPM Says"
LLY,LLY:US,BBG000BNBDC2,Instant Analysis: Eli Lilly Drops Pre-holiday Alzheimer's Bomb,2016-11-23 16:14:37 +0000,http://www.fool.com/investing/2016/11/23/instant-analysis-eli-lilly-drops-pre-holiday-alzhe.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Instant Analysis: Eli Lilly Drops Pre-holiday Alzheimer's Bomb
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Company -- Moody's: Lilly's solanezumab failure is credit negative,2016-11-23 16:11:04 +0000,http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_358560&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20161123_PR_358560,Eli Lilly and Company -- Moody's: Lilly's solanezumab failure is credit negative
LLY,LLY:US,BBG000BNBDC2,Inside Eli Lilly’s Neuroscience Franchise,2016-11-23 16:04:33 +0000,http://marketrealist.com/2016/11/inside-eli-lillys-neuroscience-franchise/?utm_source=yahoo&utm_medium=feed,Inside Eli Lilly’s Neuroscience Franchise
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Setback Highlights Challenges of Alzheimer's Treatment,2016-11-23 15:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DDC5CM3eq-k/eli-lillys-setback-highlights-challenges-of-alzheimers-treatment-20161123-00628,Eli Lilly's Setback Highlights Challenges of Alzheimer's Treatment
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 4th Update,2016-11-23 15:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kpjVkgMeZjI/eli-lilly-alzheimers-drug-fails-latestage-trial--4th-update-20161123-00623,Eli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 4th Update
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Alzheimer''s Drug Fails Late-Stage Trial -- 4th Update,2016-11-23 15:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tjbnqxlhvm8/eli-lilly-alzheimers-drug-fails-latestage-trial--4th-update-20161123-00622,Eli Lilly Alzheimer''s Drug Fails Late-Stage Trial -- 4th Update
LLY,LLY:US,BBG000BNBDC2,"Allergan Acquires Chase Pharma, Expands CNS Portfolio",2016-11-23 15:07:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ZD5XIl7yPc/allergan-acquires-chase-pharma-expands-cns-portfolio-cm713191,Allergan plc AGN announced that it has acquired Chase Pharmaceuticals Corporation a clinical stage biopharmaceutical company that focuses on the development of treatments for Alzheimer s disease As per the terms of the agreement Allergan provided an upfront payment of 125 million and
LLY,LLY:US,BBG000BNBDC2,"Pre-Market Most Active for Nov 23, 2016 :  LLY, DE, RDY, NVO, BIIB, ERIC, MT, SNY, JUNO, QQQ, XIV, TVIX",2016-11-23 13:53:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kID8OF6hPdw/pre-market-most-active-for-nov-23-2016-lly-de-rdy-nvo-biib-eric-mt-sny-juno-qqq-xiv-tvix-cm713147,The NASDAQ 100 Pre Market Indicator is down 12 65 to 4 861 19 The total Pre Market volume is currently 9 642 054 shares traded The following are the most active stocks for the pre market session Eli Lilly and Company LLY is 10 22 at 65 77 with 3 698 726
LLY,LLY:US,BBG000BNBDC2,The Swiss Stock Market Closed Slightly Higher With Support From Novartis,2016-11-23 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RyphxKdmhI0/the-swiss-stock-market-closed-slightly-higher-with-support-from-novartis-20161123-00520,The Swiss Stock Market Closed Slightly Higher With Support From Novartis
LLY,LLY:US,BBG000BNBDC2,Eli Lilly & Co. (LLY) Has Plunged To A New Low After Phase 3 Study Failed,2016-11-23 09:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nuCMuUndU9o/eli-lilly--co-lly-has-plunged-to-a-new-low-after-phase-3-study-failed-20161123-00398,Eli Lilly & Co. (LLY) Has Plunged To A New Low After Phase 3 Study Failed
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 3rd Update,2016-11-23 09:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0WM_ABat6HA/eli-lilly-alzheimers-drug-fails-latestage-trial--3rd-update-20161123-00397,Eli Lilly Alzheimer's Drug Fails Late-Stage Trial -- 3rd Update
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal -- 2nd Update,2016-11-23 09:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D_c881snuLs/eli-lillys-late-stage-alzheimers-trial-fails-to-achieve-goal--2nd-update-20161123-00385,Eli Lilly's Late Stage Alzheimer's Trial Fails To Achieve Goal -- 2nd Update
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Shares Plunge as Alzheimer's Trial Fails to Achieve Goals -- Update,2016-11-23 07:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O1VVJFW6448/eli-lilly-shares-plunge-as-alzheimers-trial-fails-to-achieve-goals--update-20161123-00218,Eli Lilly Shares Plunge as Alzheimer's Trial Fails to Achieve Goals -- Update
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Alzheimer''s Drug Fails Trial; Shares Plunge,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h3Nid7pkXD0/eli-lilly-alzheimers-drug-fails-trial-shares-plunge-20161123-00393,Eli Lilly Alzheimer''s Drug Fails Trial; Shares Plunge
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yEDUkOEyy10/eli-lilly-alzheimers-drug-fails-trial-shares-plunge-20161123-00715,Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge
LLY,LLY:US,BBG000BNBDC2,Eli Lilly''s Alzheimer''s Drug Trial Fails to Achieve Goals,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F6kJBq60Jfs/eli-lillys-alzheimers-drug-trial-fails-to-achieve-goals-20161123-00183,Eli Lilly''s Alzheimer''s Drug Trial Fails to Achieve Goals
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Alzheimer's Drug Trial Fails to Achieve Goals,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XPxX3-FbEGE/eli-lillys-alzheimers-drug-trial-fails-to-achieve-goals-20161123-00187,Eli Lilly's Alzheimer's Drug Trial Fails to Achieve Goals
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Shares Plunge as Alzheimer''s Trial Fails to Achieve Goals,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NElxzs_RBMk/eli-lilly-shares-plunge-as-alzheimers-trial-fails-to-achieve-goals-20161123-00204,Eli Lilly Shares Plunge as Alzheimer''s Trial Fails to Achieve Goals
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Alzheimer's Drug Fails Trial,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oR0x61LPaHI/eli-lilly-alzheimers-drug-fails-trial-20161123-00309,Eli Lilly Alzheimer's Drug Fails Trial
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Late-Stage Alzheimer's Trial Fails to Achieve Goal,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/84WUktpAKNM/eli-lillys-latestage-alzheimers-trial-fails-to-achieve-goal-20161123-00221,Eli Lilly's Late-Stage Alzheimer's Trial Fails to Achieve Goal
LLY,LLY:US,BBG000BNBDC2,Eli Lilly''s Late-Stage Alzheimer''s Trial Fails to Achieve Goal,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7DK5LyNrts/eli-lillys-latestage-alzheimers-trial-fails-to-achieve-goal-20161123-00222,Eli Lilly''s Late-Stage Alzheimer''s Trial Fails to Achieve Goal
LLY,LLY:US,BBG000BNBDC2,Lilly Sees Charge In Q4 As Solanezumab Trial Fails To Meet Primary Endpoint,2016-11-23 06:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MkHY0VKzsek/lilly-sees-charge-in-q4-as-solanezumab-trial-fails-to-meet-primary-endpoint-20161123-00141,Lilly Sees Charge In Q4 As Solanezumab Trial Fails To Meet Primary Endpoint
LLY,LLY:US,BBG000BNBDC2,[$$] Lilly Alzheimer’s Drug Can Save Dismal Year for Pharma,2016-11-23 04:53:04 +0000,http://www.wsj.com/articles/lilly-alzheimers-drug-can-save-dismal-year-for-pharma-1479834373?ru=yahoo?mod=yahoo_itp,[$$] Lilly Alzheimer’s Drug Can Save Dismal Year for Pharma
LLY,LLY:US,BBG000BNBDC2,[$$] Lilly Alzheimer's Drug Can Save Dismal Year for Pharma,2016-11-22 22:10:16 +0000,http://www.wsj.com/articles/lilly-alzheimers-drug-can-save-dismal-year-for-pharma-1479834373?mod=yahoo_hs,[$$] Lilly Alzheimer's Drug Can Save Dismal Year for Pharma
LLY,LLY:US,BBG000BNBDC2,Eli Lilly may react strongly to Alzheimer's drug trial,2016-11-22 21:52:00 +0000,http://finance.yahoo.com/video/eli-lilly-may-react-strongly-215200363.html,Eli Lilly may react strongly to Alzheimer's drug trial
LLY,LLY:US,BBG000BNBDC2,"Lilly Poised For Big December On Alzheimer's Data, Diabetes Ruling",2016-11-22 21:01:57 +0000,http://www.investors.com/news/technology/lilly-poised-for-holly-december-on-alzheimers-data-diabetes-ruling/,"Lilly Poised For Big December On Alzheimer's Data, Diabetes Ruling"
LLY,LLY:US,BBG000BNBDC2,Understanding Eli Lilly’s Business Segments by 3Q16 Performance,2016-11-22 20:04:05 +0000,http://marketrealist.com/2016/11/understanding-eli-lillys-business-segments-by-3q16-performance/?utm_source=yahoo&utm_medium=feed,Understanding Eli Lilly’s Business Segments by 3Q16 Performance
LLY,LLY:US,BBG000BNBDC2,Inside Eli Lilly’s Revenue Trends,2016-11-22 19:04:09 +0000,http://marketrealist.com/2016/11/inside-eli-lillys-revenue-trends/?utm_source=yahoo&utm_medium=feed,Inside Eli Lilly’s Revenue Trends
LLY,LLY:US,BBG000BNBDC2,Where Does Eli Lilly’s Valuation Stand Next to Peers?,2016-11-22 16:54:12 +0000,http://marketrealist.com/2016/11/where-does-eli-lillys-valuation-stand-next-to-peers/?utm_source=yahoo&utm_medium=feed,Where Does Eli Lilly’s Valuation Stand Next to Peers?
LLY,LLY:US,BBG000BNBDC2,What Do the Analysts Recommend for Bristol-Myers Squibb’s Stock?,2016-11-22 16:04:18 +0000,http://marketrealist.com/2016/11/what-do-the-analysts-recommend-for-bristol-myers-squibbs-stock/?utm_source=yahoo&utm_medium=feed,What Do the Analysts Recommend for Bristol-Myers Squibb’s Stock?
LLY,LLY:US,BBG000BNBDC2,"The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug",2016-11-22 15:04:52 +0000,http://marketrealist.com/2016/11/teva-pharmaceutical-regeneron-continue-develop-ngf-antibody-fasinumab-2016/?utm_source=yahoo&utm_medium=feed,"The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug"
LLY,LLY:US,BBG000BNBDC2,Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes,2016-11-22 14:00:00 +0000,http://finance.yahoo.com/news/survey-reveals-most-people-dont-140000847.html,"[PR Newswire] - RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 22, 2016 /PRNewswire/ -- A new national survey of more than 1,500 adults, including 501 who have type 2 diabetes, finds that three out of four Americans and two out of every three people with type 2 diabetes don't know that heart disease is the number one health-related killer of people with type 2 diabetes. The survey also finds more than half (52 percent) of adults with type 2 diabetes do not understand that they are at an increased risk for heart disease and related life-threatening events, such as heart attack, stroke or even death. To address this critical information gap, Boehringer Ingelheim and Eli Lilly and Company (LLY) are launching For Your SweetHeart™: Where diabetes and heart disease meet."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's new approach for Alzheimer's,2016-11-22 11:33:00 +0000,http://finance.yahoo.com/video/eli-lillys-approach-alzheimers-113300324.html,Eli Lilly's new approach for Alzheimer's
LLY,LLY:US,BBG000BNBDC2,Cramer: Trump Rally is a FANG + FANG Affair,2016-11-22 00:01:00 +0000,http://realmoney.thestreet.com/articles/11/21/2016/cramer-trump-rally-fang-fang-affair?puc=yahoo&cm_ven=YAHOO,Cramer: Trump Rally is a FANG + FANG Affair
LLY,LLY:US,BBG000BNBDC2,$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market,2016-11-21 14:53:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MeNQveCzpFM/13-billion-opportunity-5-companies-that-could-dominate-the-alzheimers-disease-market-cm711826,Alzheimer s disease affects over 5 million Americans It s the sixth highest cause of death in the U S There s such an intense demand for effective treatments that 160 research and consulting firm GlobalData projects the market for Alzheimer s disease drugs could top 13 billion by
LLY,LLY:US,BBG000BNBDC2,$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market,2016-11-21 13:46:45 +0000,http://www.fool.com/investing/2016/11/21/13-billion-opportunity-5-companies-that-could-domi.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market
LLY,LLY:US,BBG000BNBDC2,The 10 Best Pharma Stocks Under President Donald Trump,2016-11-18 21:50:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rr-p2ujnig0/the-10-best-pharma-stocks-under-president-donald-trump-cm710889,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a little over a week yet the news has yet to fully sink in for many folks Donald Trump the mogul the mastermind the most interesting man in the world according to Donald Trump will be
LLY,LLY:US,BBG000BNBDC2,"Athenex inks partnership with major pharma company, Eli Lilly",2016-11-18 17:20:08 +0000,http://www.bizjournals.com/buffalo/news/2016/11/18/athenex-inks-partnership-with-major-pharma-company.html?ana=yahoo,"Athenex inks partnership with major pharma company, Eli Lilly"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know,2016-11-18 12:48:00 +0000,https://www.thestreet.com/story/13899121/1/lilly-s-alzheimer-s-drug-study-results-are-coming-here-s-what-investors-need-to-know.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
LLY,LLY:US,BBG000BNBDC2,10 Pharma Stocks That Are Prescribed Under President Trump,2016-11-17 22:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w2zuywKHp48/10-pharma-stocks-that-are-prescribed-under-president-trump-cm710889,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a little over a week yet the news has yet to fully sink in for many folks Donald Trump the mogul the mastermind the most interesting man in the world according to Donald Trump will be
LLY,LLY:US,BBG000BNBDC2,"Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'",2016-11-17 21:18:05 +0000,http://www.investors.com/news/technology/amgen-on-track-for-2018-migraine-drug-launch-beating-crowded-field/,"Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'"
LLY,LLY:US,BBG000BNBDC2,[$$] High stakes: Eli Lilly's hunt for an Alzheimer's drug,2016-11-17 14:12:06 +0000,"http://www.ft.com/cms/s/80eefb9a-ab84-11e6-9cb3-bb8207902122,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] High stakes: Eli Lilly's hunt for an Alzheimer's drug
LLY,LLY:US,BBG000BNBDC2,"Amgen, Novartis aim for big, crowded migraine market after new drug data",2016-11-17 09:47:15 +0000,http://finance.yahoo.com/news/amgen-novartis-aim-big-crowded-094715360.html,"Amgen, Novartis aim for big, crowded migraine market after new drug data"
LLY,LLY:US,BBG000BNBDC2,"Notable Wednesday Option Activity: NVTA, DE, LLY",2016-11-16 21:50:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JlWT5x1QhVg/notable-wednesday-option-activity-nvta-de-lly-cm710268,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Invitae Corp Symbol NVTA where a total of 608 contracts have traded so far representing approximately 60 800 underlying shares That amounts to about 41 2 of NVTA s average
LLY,LLY:US,BBG000BNBDC2,"Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib",2016-11-16 00:49:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zH31T563-Bk/incyte-eli-lilly-offer-positive-phase-iii-data-on-baricitinib-cm709760,Incyte Corporation INCY and Eli Lilly and Company LLY provided updates from two phase III studies RA BEAM and RA BUILD on baricitinib for the treatment of rheumatoid arthritis RA RA BEAM evaluated baricitinib in comparison to AbbVie Inc s ABBV Humira in patients who had
LLY,LLY:US,BBG000BNBDC2,"Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib",2016-11-15 22:33:10 +0000,http://finance.yahoo.com/news/incyte-eli-lilly-offer-positive-223310457.html,"Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib"
LLY,LLY:US,BBG000BNBDC2,"Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'",2016-11-15 21:28:18 +0000,http://www.investors.com/news/technology/amgen-biogen-eli-lilly-poised-to-rocket-on-the-most-important-event/,"Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'"
LLY,LLY:US,BBG000BNBDC2,4 Top Merrill Lynch Q4 Buy Ideas Look Cheap Now and Pay Dividends,2016-11-15 15:10:17 +0000,http://247wallst.com/investing/2016/11/15/4-top-merrill-lynch-q4-buy-ideas-look-cheap-now-and-pay-dividends/,4 Top Merrill Lynch Q4 Buy Ideas Look Cheap Now and Pay Dividends
LLY,LLY:US,BBG000BNBDC2,Lily's Jardiance Effective in Lowering Cardiovascular Death,2016-11-15 00:27:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x0k1zHhZ9ng/lilys-jardiance-effective-in-lowering-cardiovascular-death-cm709051,Eli Lilly and Company LLY announced that new data presented at the American Heart Association Scientific Sessions 2016 from long term cardiovascular CV outcomes study of its diabetes medicine Jardiance showed that the drug was effective in reducing the risk for cardiovascular death
LLY,LLY:US,BBG000BNBDC2,Lily's Jardiance Effective in Lowering Cardiovascular Death,2016-11-14 22:23:10 +0000,http://finance.yahoo.com/news/lilys-jardiance-effective-lowering-cardiovascular-222310638.html,Lily's Jardiance Effective in Lowering Cardiovascular Death
LLY,LLY:US,BBG000BNBDC2,5 Pharma Stocks in Focus on World Diabetes Day,2016-11-14 16:31:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/axy_v9iMQTc/5-pharma-stocks-in-focus-on-world-diabetes-day-cm708687,Every year World Diabetes Day is celebrated on Nov 14 This year the theme is eyes on diabetes with a focus on promoting the importance of screening to ensure early diagnosis of type II diabetes and reduce the risk of serious complications According to information provided by
LLY,LLY:US,BBG000BNBDC2,Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes,2016-11-14 14:47:19 +0000,http://www.publicnow.com/view/AD286FC2C3522289BE8002E922F3E927A0ADD938,"[at noodls] - - Significant improvement in joint pain, severity of morning joint stiffness and tiredness with baricitinib compared to placebo, were seen as early as day 3 - Post-hoc analysis of two phase 3 studies shows ..."
LLY,LLY:US,BBG000BNBDC2,New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients,2016-11-14 14:47:19 +0000,http://www.publicnow.com/view/183B231AA6F1B222CF4D328D0140D96BD7822021,"[at noodls] - Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDs INDIANAPOLIS, ..."
LLY,LLY:US,BBG000BNBDC2,5 Pharma Stocks in Focus on World Diabetes Day,2016-11-14 14:19:02 +0000,http://finance.yahoo.com/news/5-pharma-stocks-focus-world-141902784.html,5 Pharma Stocks in Focus on World Diabetes Day
LLY,LLY:US,BBG000BNBDC2,New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients,2016-11-14 14:00:00 +0000,http://finance.yahoo.com/news/analyses-phase-3-trials-show-140000727.html,[CNW Group] - New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients
LLY,LLY:US,BBG000BNBDC2,New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients,2016-11-14 14:00:00 +0000,http://finance.yahoo.com/news/analyses-phase-3-trials-show-140000364.html,"[PR Newswire] - Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDs INDIANAPOLIS, ..."
LLY,LLY:US,BBG000BNBDC2,Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes,2016-11-14 14:00:00 +0000,http://finance.yahoo.com/news/baricitinib-demonstrates-early-response-compared-140000725.html,[CNW Group] - Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Dr. Reddy's Labs Launches Generic Osteoporosis Drug Tablets in the US,2016-11-14 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-dr-reddys-labs-131500957.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / November 14, 2016 / Active Wall St. blog coverage looks at the headline from Dr. Reddy's Laboratories Ltd (NYSE: RDY ) as the company announced on November 11, 2016, that it had ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Says New Analyses Of Phase 3 Trials Show Improvements In RA Symptom,2016-11-14 09:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SytgpKSJTOw/lilly-says-new-analyses-of-phase-3-trials-show-improvements-in-ra-symptom-20161114-00695,Lilly Says New Analyses Of Phase 3 Trials Show Improvements In RA Symptom
LLY,LLY:US,BBG000BNBDC2,Richter's generic osteoporosis drug gets EU recommendation,2016-11-14 07:40:48 +0000,http://finance.yahoo.com/news/richters-generic-osteoporosis-drug-gets-074048212.html,Richter's generic osteoporosis drug gets EU recommendation
LLY,LLY:US,BBG000BNBDC2,[$$] Big pharma is failing to do enough for poor countries,2016-11-14 00:34:40 +0000,"http://www.ft.com/cms/s/937eac86-a979-11e6-809d-c9f98a0cf216,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Big pharma is failing to do enough for poor countries
LLY,LLY:US,BBG000BNBDC2,Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline,2016-11-13 20:00:00 +0000,http://finance.yahoo.com/news/jardiance-empagliflozin-consistently-reduced-risk-200000153.html,"[PR Newswire] - RIDGEFIELD, Conn., and INDIANAPOLIS, Nov. 13, 2016 /PRNewswire/ -- New data presented today at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) tablets consistently reduced the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. The findings are part of the landmark EMPA-REG OUTCOME® trial, which is the first trial of a diabetes medication to show a reduction in cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. This study is supported by Boehringer Ingelheim and Eli Lilly and Company (LLY)."
LLY,LLY:US,BBG000BNBDC2,3 Drugmakers That Probably Have Lower Tax Rates Than You Do,2016-11-13 14:28:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zWT8LCWdwHg/3-drugmakers-that-probably-have-lower-tax-rates-than-you-do-cm708324,How much did you pay in taxes last year If you paid any taxes at all there s a good chance that your effective tax rate was higher than the tax rates of three huge drugmakers Amgen NASDAQ AMGN Eli Lilly NYSE LLY and Gilead Sciences NASDAQ GILD And one
LLY,LLY:US,BBG000BNBDC2,3 Drugmakers That Probably Have Lower Tax Rates Than You Do,2016-11-13 12:45:29 +0000,http://www.fool.com/investing/2016/11/13/3-drugmakers-that-probably-have-lower-tax-rates-th.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Drugmakers That Probably Have Lower Tax Rates Than You Do
LLY,LLY:US,BBG000BNBDC2,Inside AstraZeneca’s Revenue Fall in 3Q16,2016-11-11 23:04:10 +0000,http://marketrealist.com/2016/11/inside-astrazenecas-revenue-fall-in-3q16/?utm_source=yahoo&utm_medium=feed,Inside AstraZeneca’s Revenue Fall in 3Q16
LLY,LLY:US,BBG000BNBDC2,3 Highest Growth Stocks in the Market Today,2016-11-11 17:29:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TDCy-MIRJm0/3-highest-growth-stocks-in-the-market-today-cm707917,Most investors are on the hunt for stocks that promise fast sales and earnings growth in the years ahead That makes sense as companies that can do so for extended periods of time stand a good chance of producing market beating returns With that in mind I ran a simple screen on
LLY,LLY:US,BBG000BNBDC2,"Merrimack (MACK) Q3 Loss Lower than Expected, Stock Up",2016-11-11 16:17:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ydWD6mmGFBU/merrimack-mack-q3-loss-lower-than-expected-stock-up-cm707788,Merrimack Pharmaceuticals Inc MACK reported a loss of 23 cents per share in the third quarter of 2016 narrower than the Zacks Consensus Estimate of 30 cents FindTheCompany Graphiq Quarterly revenues came in at 28 1 million down 16 7 sequentially Revenues
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co (LLY) Gets Dedicated Humulin R U-500 Insulin Syringe From Becton Dickinson,2016-11-10 15:12:19 +0000,http://www.insidermonkey.com/blog/eli-lilly-and-co-lly-gets-dedicated-humulin-r-u-500-insulin-syringe-from-becton-dickinson-486745/,Eli Lilly and Co (LLY) Gets Dedicated Humulin R U-500 Insulin Syringe From Becton Dickinson
LLY,LLY:US,BBG000BNBDC2,[$$] Wall Street rallies led by healthcare and banks,2016-11-09 23:08:09 +0000,"http://www.ft.com/cms/s/e670dcd4-a69a-11e6-8898-79a99e2a4de6,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - US stock markets climbed a day after Americans elected Donald Trump as the next president, as a sharp sell-off in Treasuries buoyed financials and investors looked to relaxed regulation as a boon to the ..."
LLY,LLY:US,BBG000BNBDC2,"Stocks Rethink Trump Win, Pare Losses; Pfizer, CAT Lead Dow",2016-11-09 15:28:44 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-rethink-trump-win-pare-losses-pfizer-cat-lead-dow/,"Stocks Rethink Trump Win, Pare Losses; Pfizer, CAT Lead Dow"
LLY,LLY:US,BBG000BNBDC2,"Stocks Open Lower After Stunning Trump Win; Drugs Up, Hospitals Dive",2016-11-09 14:46:41 +0000,http://www.investors.com/market-trend/stock-market-today/stock-futures-down-trim-losses-pfizer-consol-energy-jump-tenet-hca-dive/,"Stocks Open Lower After Stunning Trump Win; Drugs Up, Hospitals Dive"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for November 10, 2016",2016-11-09 14:15:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-BmUrU7ZKBo/eli-lilly-and-company-lly-ex-dividend-date-scheduled-for-november-10-2016-cm706375,Eli Lilly and Company LLY will begin trading ex dividend on November 10 2016 A cash dividend payment of 0 51 per share is scheduled to be paid on December 09 2016 Shareholders who purchased LLY prior to the ex dividend date are eligible for the cash dividend payment This marks the
LLY,LLY:US,BBG000BNBDC2,3 Stocks Set to Thrive in Pharma's New Price-Conscious World,2016-11-09 00:19:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UzXqjV9yn0E/3-stocks-set-to-thrive-in-pharmas-new-price-conscious-world-cm706017,Image source Getty Images With both presidential nominees pushing for 160 drug price reform investors need to start protecting themselves There s no need to dump all your pharma holdings you may want to pull away from those that lean on eye popping price increases on old drugs
LLY,LLY:US,BBG000BNBDC2,3 Stocks Set to Thrive in Pharma's New Price-Conscious World,2016-11-08 21:50:03 +0000,http://www.fool.com/investing/2016/11/08/3-stocks-set-to-thrive-in-pharmas-new-price-consci.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks Set to Thrive in Pharma's New Price-Conscious World
LLY,LLY:US,BBG000BNBDC2,"Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's?",2016-11-08 21:24:30 +0000,http://www.investors.com/news/technology/can-this-small-cap-biotech-take-on-gilead-celgene-biogen-in-alzheimers/,"Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's?"
LLY,LLY:US,BBG000BNBDC2,iShares Global Healthcare ETF Experiences Big Outflow,2016-11-08 19:36:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SzAQiKICFpQ/ishares-global-healthcare-etf-experiences-big-outflow-cm705689,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Global Healthcare ETF Symbol IXJ where we have detected an approximate 136 9 million dollar outflow that s a 9 5 decrease week over week
LLY,LLY:US,BBG000BNBDC2,Merrimack (MACK): What Awaits the Stock in Q3 Earnings?,2016-11-08 18:09:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L0PBoJ2IdHE/merrimack-mack-what-awaits-the-stock-in-q3-earnings-cm705745,Merrimack Pharmaceuticals Inc MACK is scheduled to report third quarter 2016 results on Nov 9 Last quarter Merrimack delivered a negative earnings surprise of 17 65 Let s see how things are shaping up for the company this quarter Factors Influencing the Quarter Apart from
LLY,LLY:US,BBG000BNBDC2,BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin,2016-11-08 11:59:00 +0000,http://finance.yahoo.com/news/bd-launches-first-syringe-designed-115900521.html,"[PR Newswire] - FRANKLIN LAKES, N.J., Nov. 8, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company announced today the launch of the BD™ U-500 Insulin Syringe, ..."
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure",2016-11-07 16:02:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wGjCdid42RA/pharma-stock-roundup-pfizer-allergan-q3-results-fall-short-insulin-drugmakers-under-pricing-pressure-cm704894,This week key earnings updates came from companies like Pfizer PFE and Allergan AGN while pharma stocks remained under drug pricing pressure with lawmakers questioning the prices of insulin drugs Recap of the Week s Most Important Stories Pfizer Allergan Disappoint in
LLY,LLY:US,BBG000BNBDC2,Lilly To Participate In Credit Suisse Healthcare Conference At 6:00 PM ET,2016-11-07 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bBuKUb1-0iM/lilly-to-participate-in-credit-suisse-healthcare-conference-at-600-pm-et-20161107-01083,Lilly To Participate In Credit Suisse Healthcare Conference At 6:00 PM ET
LLY,LLY:US,BBG000BNBDC2,The Path To Global Prosperity,2016-11-06 13:39:44 +0000,http://finance.yahoo.com/tumblr/blog-the-path-to-global-prosperity-133950829.html,The Path To Global Prosperity
LLY,LLY:US,BBG000BNBDC2,"Bernie Sanders Seeks DOJ Drug Probe (LLY, SNY)",2016-11-05 15:01:00 +0000,http://www.investopedia.com/news/bernie-sanders-slams-drug-price-fixing-lly-sny/?partner=YahooSA,"Bernie Sanders Seeks DOJ Drug Probe (LLY, SNY)"
LLY,LLY:US,BBG000BNBDC2,"Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen",2016-11-04 15:12:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h2S-ZpUH7RI/zacks-industry-outlook-highlights-mylan-lilly-pfizer-novartis-and-amgen-cm703967,For Immediate Release Chicago IL November 01 2016 Today Zacks Equity Research discusses the Pharmaceuticals part 1 including Mylan NASDAQ MYL Free Report Lilly NYSE LLY Free Report Pfizer NYSE PFE Free Report Novartis NYSE NVS Free
LLY,LLY:US,BBG000BNBDC2,What Do Analysts Recommend for Novo?,2016-11-04 12:04:11 +0000,http://marketrealist.com/2016/11/what-do-analysts-recommend-for-novo-2/?utm_source=yahoo&utm_medium=feed,What Do Analysts Recommend for Novo?
LLY,LLY:US,BBG000BNBDC2,Pharma Industry Outlook - November 2016,2016-11-04 08:18:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-E90rqxFwkw/pharma-industry-outlook-november-2016-cm703807,It s been a rough year for pharma and biotech stocks with several factors weighing on the sector including media and political focus on the high price of drugs mixed performance results slower than expected new product launches and increasing competition The impact of these issues is
LLY,LLY:US,BBG000BNBDC2,Seattle research institute awarded $15M for tuberculosis drug development,2016-11-03 21:25:12 +0000,http://www.bizjournals.com/seattle/news/2016/11/03/seattle-research-institute-tb-eli-lilly-drug.html?ana=yahoo,Seattle research institute awarded $15M for tuberculosis drug development
LLY,LLY:US,BBG000BNBDC2,Pharma Industry Outlook - November 2016,2016-11-03 21:08:09 +0000,http://finance.yahoo.com/news/pharma-industry-outlook-november-2016-210809481.html,Pharma Industry Outlook - November 2016
LLY,LLY:US,BBG000BNBDC2,"Lilly Presents Clinical Efficacy, Safety and Patient-Reported Outcomes Data of Baricitinib in Patients with Rheumatoid Arthritis at 2016 American College of Rheumatology Annual Meeting",2016-11-03 17:16:00 +0000,http://finance.yahoo.com/news/lilly-presents-clinical-efficacy-safety-171600898.html,"[PR Newswire] - INDIANAPOLIS, Nov. 3, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that new post-hoc analyses of pooled efficacy and safety data from baricitinib phase 3 studies, along with findings ..."
LLY,LLY:US,BBG000BNBDC2,How Tresiba Helps Novo Achieve Its Growth Targets,2016-11-03 14:04:21 +0000,http://marketrealist.com/2016/11/how-tresiba-helps-novo-achieve-its-growth-targets/?utm_source=yahoo&utm_medium=feed,How Tresiba Helps Novo Achieve Its Growth Targets
LLY,LLY:US,BBG000BNBDC2,3 Top Biotech Stocks to Buy in November,2016-11-02 21:08:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wdQ-hSCMES0/3-top-biotech-stocks-to-buy-in-november-cm702818,Image source Getty Images Like Rodney Dangerfield the biotech sector isn t getting a lot of respect these days The iShares Nasdaq Biotech ETF NASDAQ IBB a popular exchange traded fund that owns a wide range of biotech stocks is down 24 year to date which badly trails
LLY,LLY:US,BBG000BNBDC2,3 Top Biotech Stocks to Buy in November,2016-11-02 19:47:14 +0000,http://www.fool.com/investing/2016/11/02/3-top-biotech-stocks-to-buy-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy in November
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co (LLY) Is Awaiting the FDA’s Nod Over a New Indication for Jardiance,2016-11-02 16:38:31 +0000,http://www.insidermonkey.com/blog/eli-lilly-and-co-lly-is-awaiting-the-fdas-nod-over-a-new-indication-for-jardiance-484611/,Eli Lilly And Co (LLY) Is Awaiting the FDA’s Nod Over a New Indication for Jardiance
LLY,LLY:US,BBG000BNBDC2,New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo,2016-11-02 16:20:00 +0000,http://finance.yahoo.com/news/data-pivotal-ra-beacon-study-162000971.html,"[PR Newswire] - INDIANAPOLIS, Nov. 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data from RA-BEACON – a pivotal phase 3 study of baricitinib ..."
LLY,LLY:US,BBG000BNBDC2,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y,2016-11-02 15:10:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/beyAAjTnkUw/incyte-incy-stock-up-as-q3-earnings-revenues-rise-yy-cm702365,Incyte Corporation INCY reported third quarter earnings of 11 cents including the impact of a change in fair value of acquisition related contingent consideration and unrealized gain on long term investment The Zacks Consensus Estimate was of breakeven results Incyte had reported a loss of
LLY,LLY:US,BBG000BNBDC2,Novo’s Dominance in Global Diabetes Market,2016-11-02 14:05:40 +0000,http://marketrealist.com/2016/11/novos-dominance-in-global-diabetes-market/?utm_source=yahoo&utm_medium=feed,Novo’s Dominance in Global Diabetes Market
LLY,LLY:US,BBG000BNBDC2,"If Trump Wins, Look Out: 5 Ultra-Safe Stocks to Hide Out In",2016-11-02 13:55:56 +0000,http://247wallst.com/investing/2016/11/02/if-trump-wins-look-out-5-ultra-safe-stocks-to-hide-out-in/,"If Trump Wins, Look Out: 5 Ultra-Safe Stocks to Hide Out In"
LLY,LLY:US,BBG000BNBDC2,Merck’s 3Q16 Valuation Cheat Sheet,2016-11-02 12:04:14 +0000,http://marketrealist.com/2016/10/mercks-3q16-valuation-cheat-sheet/?utm_source=yahoo&utm_medium=feed,Merck’s 3Q16 Valuation Cheat Sheet
LLY,LLY:US,BBG000BNBDC2,[$$] Big Pharma Sales Need a Booster Shot​,2016-11-02 04:14:15 +0000,http://www.wsj.com/articles/big-pharma-sales-need-a-booster-shot-1478012385?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - Slowing sales, rather than election worries, are pressuring pharmaceutical stocks."
LLY,LLY:US,BBG000BNBDC2,Cramer: I counted seven reasons why stocks were right to ...,2016-11-01 22:00:00 +0000,http://finance.yahoo.com/video/cramer-counted-seven-reasons-why-220000443.html,Cramer: I counted seven reasons why stocks were right to ...
LLY,LLY:US,BBG000BNBDC2,"Whole Sector 'At Risk' for Drug Pricing Outrage After Eli Lilly (LLY), Credit Suisse's Divan Says",2016-11-01 20:53:00 +0000,https://www.thestreet.com/story/13876221/1/whole-sector-at-risk-for-drug-pricing-outrage-after-eli-lilly-lly-credit-suisse-s-divan-says.html?puc=yahoo&cm_ven=YAHOO,"Whole Sector 'At Risk' for Drug Pricing Outrage After Eli Lilly (LLY), Credit Suisse's Divan Says"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly shares fall on Bernie Sanders tweet,2016-11-01 20:38:03 +0000,http://www.cnbc.com/id/104068913?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104068913,Eli Lilly shares fall on Bernie Sanders tweet
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Stock Price Feels the Bern,2016-11-01 19:54:34 +0000,http://blogs.wsj.com/moneybeat/2016/11/01/eli-lillys-stock-prices-feels-the-bern/?mod=yahoo_hs,Eli Lilly's Stock Price Feels the Bern
LLY,LLY:US,BBG000BNBDC2,Bernie Sanders is going after insulin makers over price hikes,2016-11-01 19:20:08 +0000,http://finance.yahoo.com/news/bernie-sanders-going-insulin-makers-192008165.html,Bernie Sanders is going after insulin makers over price hikes
LLY,LLY:US,BBG000BNBDC2,Eli Lilly responds to Bernie Sanders,2016-11-01 18:44:00 +0000,http://finance.yahoo.com/video/eli-lilly-responds-bernie-sanders-184400159.html,Eli Lilly responds to Bernie Sanders
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Is 'One of the Blue Chips in This Sector,' TIAA Global Asset Management's Link Says",2016-11-01 17:47:00 +0000,https://www.thestreet.com/story/13875839/1/eli-lilly-lly-is-one-of-the-blue-chips-in-this-sector-tiaa-global-asset-management-s-link-says.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly (LLY) Is 'One of the Blue Chips in This Sector,' TIAA Global Asset Management's Link Says"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly feels brief pressure after Sanders tweet about Lantus,2016-11-01 17:27:07 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=4994026A-B1AC-47C9-98FB-6647CA9969BE&siteid=yhoof2,Eli Lilly feels brief pressure after Sanders tweet about Lantus
LLY,LLY:US,BBG000BNBDC2,Sanders Takes Aim at Insulin Makers in Latest Price Attack,2016-11-01 17:17:33 +0000,http://www.bloomberg.com/news/articles/2016-11-01/sanders-takes-aim-at-insulin-makers-in-latest-drug-price-attack?cmpid=yhoo.headline,Sanders Takes Aim at Insulin Makers in Latest Price Attack
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Stock Falls, Sanders Criticizes Drug Pricing",2016-11-01 17:06:00 +0000,https://www.thestreet.com/story/13875807/1/eli-lilly-lly-stock-falls-sanders-criticizes-drug-pricing.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly (LLY) Stock Falls, Sanders Criticizes Drug Pricing"
LLY,LLY:US,BBG000BNBDC2,Lilly shares fall after Bernie Sanders tweet,2016-11-01 16:39:00 +0000,http://finance.yahoo.com/video/lilly-shares-fall-bernie-sanders-163900087.html,Lilly shares fall after Bernie Sanders tweet
LLY,LLY:US,BBG000BNBDC2,[$$] Big Pharma Sales Need a Booster Shot​,2016-11-01 14:59:49 +0000,http://www.wsj.com/articles/big-pharma-sales-need-a-booster-shot-1478012385?mod=yahoo_hs,[$$] Big Pharma Sales Need a Booster Shot​
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Has a Dominant Trend: Down,2016-11-01 12:49:00 +0000,http://realmoney.thestreet.com/articles/11/01/2016/eli-lilly-has-dominant-trend-down?puc=yahoo&cm_ven=YAHOO,Eli Lilly Has a Dominant Trend: Down
LLY,LLY:US,BBG000BNBDC2,"Novartis breast cancer drug gets FDA fast track, takes on Pfizer",2016-11-01 08:19:35 +0000,http://finance.yahoo.com/news/novartis-breast-cancer-drug-gets-081935967.html,"[Reuters] - The U.S. Food and Drug Administration gave fast-track review status to Novartis's medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer as the Swiss company seeks to challenge Pfizer's Ibrance drug. Ribociclib, or LEE011, was also accepted by the European Medicines Agency (EMA) for review in use with letrozole in the same patient population, the company said in a statement on Tuesday. The U.S. priority review of LEE011 is based on data presented last month at a cancer conference."
LLY,LLY:US,BBG000BNBDC2,Drugmaker Sanofi hungry for deals after earnings beat,2016-11-01 08:13:42 +0000,http://finance.yahoo.com/news/1-drugmaker-sanofi-hungry-deals-080658064.html,Drugmaker Sanofi hungry for deals after earnings beat
LLY,LLY:US,BBG000BNBDC2,"Pfizer Q3 Sales Challenged By Eli Lilly, Novartis Amid Breakup Bust",2016-10-31 20:19:51 +0000,http://www.investors.com/news/technology/pfizer-q3-sales-challenged-by-eli-lilly-novartis-amid-breakup-bust/,"Pfizer Q3 Sales Challenged By Eli Lilly, Novartis Amid Breakup Bust"
LLY,LLY:US,BBG000BNBDC2,"Amgen, Gilead, Eli Lilly Eat Into AbbVie's Humira Sales: Analyst",2016-10-31 20:01:58 +0000,http://www.investors.com/news/technology/amgen-gilead-eli-lilly-champ-at-abbvies-humira-sales-analyst/,"Amgen, Gilead, Eli Lilly Eat Into AbbVie's Humira Sales: Analyst"
LLY,LLY:US,BBG000BNBDC2,New Edition of Online Tool to Measure Cancer Progress to Launch at World Cancer Congress,2016-10-31 11:00:00 +0000,http://finance.yahoo.com/news/edition-online-tool-measure-cancer-110000375.html,"[PR Newswire] - PARIS, Oct. 31, 2016 /PRNewswire/ -- The 2016 World Cancer Congress (WCC) in Paris – a global gathering of more than 3,500 cancer experts – will be the setting for the introduction of a new, enhanced version of the PACE Continuous Innovation Indicators™ (CII) by PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative. The purpose of the CII – the first evidence-based, customizable online tool to review progress against cancer over time – is to inform public policy discussions and other efforts to accelerate continuous innovation against cancer."
LLY,LLY:US,BBG000BNBDC2,Reflation Alert!,2016-10-30 17:01:15 +0000,http://finance.yahoo.com/tumblr/blog-reflation-alert-170123613.html,Reflation Alert!
LLY,LLY:US,BBG000BNBDC2,"ITOT, MSFT, LLY, UNP: ETF Inflow Alert",2016-10-28 16:31:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jXNIU6S_XtA/itot-msft-lly-unp-etf-inflow-alert-cm700238,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core S amp P Total U S Stock Market ETF Symbol ITOT where we have detected an approximate 58 2 million dollar inflow that s a 1 1 increase week
LLY,LLY:US,BBG000BNBDC2,"LILLY ELI & CO Files SEC form 10-Q, Quarterly Report",2016-10-28 16:04:49 +0000,http://biz.yahoo.com/e/161028/lly10-q.html,"LILLY ELI & CO Files SEC form 10-Q, Quarterly Report"
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Bristol-Myers, Merck Top Estimates, Merck Wins Key FDA Nod",2016-10-28 14:34:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_mEm4L1No38/pharma-stock-roundup-bristol-myers-merck-top-estimates-merck-wins-key-fda-nod-cm700213,Third quarter earnings season is in full flow with several large cap pharma companies like Lilly LLY Merck MRK Bristol Myers BMY Novartis and others reporting results this week While companies like Merck and Bristol Myers surpassed expectations others like Lilly fell short Recap
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Biogen, Merck, Eli Lilly, AbbVie and ImmunoGen",2016-10-28 14:34:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JYmxfv0718g/the-zacks-analyst-blog-highlights-biogen-merck-eli-lilly-abbvie-and-immunogen-cm700193,For Immediate Release Chicago IL October 28 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Biogen, Merck, Eli Lilly, AbbVie and ImmunoGen",2016-10-28 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-biogen-133001048.html,"The Zacks Analyst Blog Highlights: Biogen, Merck, Eli Lilly, AbbVie and ImmunoGen"
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Bristol-Myers, Merck Top Estimates, Merck Wins Key FDA Nod",2016-10-28 13:25:01 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-bristol-myers-132501541.html,"Pharma Stock Roundup: Bristol-Myers, Merck Top Estimates, Merck Wins Key FDA Nod"
LLY,LLY:US,BBG000BNBDC2,Biogen Inc. Working With What It's Got as It Looks to Diversify,2016-10-27 21:44:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QnZy39zbfpo/biogen-inc-working-with-what-its-got-as-it-looks-to-diversify-cm699820,Image source Getty Images Given the dampening U S market for multiple sclerosis drugs Biogen s NASDAQ BIIB bread and butter the biotech s third quarter earnings release on Wednesday was about as good as investors could have hoped for Biogen results The raw
LLY,LLY:US,BBG000BNBDC2,Biotech's election-year political cloud threatens to linger,2016-10-27 20:38:07 +0000,http://finance.yahoo.com/news/biotechs-election-political-cloud-threatens-203807723.html,"[Reuters] - The long, dark tunnel that has been the U.S. presidential election campaign for biotechnology stocks appears to have no bright light beckoning the sector's beleaguered shareholders to a welcoming end. With the race winding down and most national opinion polls predicting victory for Democrat Hillary Clinton over Republican Donald Trump and probable gains for other Democrats in Congress, biotech shares are once again on the back foot, and investors say prospects for a sustained recovery look dim. Clinton, whose pointed criticisms of drug pricing have weighed on the industry for more than a year, has promised tougher oversight, and any big gains for her party on Capitol Hill would only strengthen her hand in that cause."
LLY,LLY:US,BBG000BNBDC2,"ETF’s with exposure to Eli Lilly & Co. : October 27, 2016",2016-10-27 17:26:27 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-eli-lilly-co-october-27-2016/,"ETF’s with exposure to Eli Lilly & Co. : October 27, 2016"
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: United Technologies, Sprint, Eli Lilly, Edwards Lifesciences and Whirlpool",2016-10-27 15:45:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YtyxN6zGl_s/the-zacks-analyst-blog-highlights-united-technologies-sprint-eli-lilly-edwards-lifesciences-and-whirlpool-cm699380,For Immediate Release Chicago IL October 27 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,"Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars",2016-10-27 14:45:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NNj5s05PCvY/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225,Biotech company Biogen Inc BIIB known for its strong position in the multiple sclerosis MS market reported third quarter 2016 results before the market opened yesterday with both earnings and revenues surpassing expectations Read more Biogen Beats on Q3 Earnings Tecfidera Propels
LLY,LLY:US,BBG000BNBDC2,Apple Unveils Macs With Touch-Screen Keyboard,2016-10-27 14:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/exOo2Ja1xEE/apple-unveils-macs-with-touchscreen-keyboard-20161027-01585,Apple Unveils Macs With Touch-Screen Keyboard
LLY,LLY:US,BBG000BNBDC2,"Apple Unveils New Macs, TV App",2016-10-27 14:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E-OZnR-ihno/apple-unveils-new-macs-tv-app-20161027-01200,"Apple Unveils New Macs, TV App"
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: United Technologies, Sprint, Eli Lilly, Edwards Lifesciences and Whirlpool",2016-10-27 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-united-133001209.html,"The Zacks Analyst Blog Highlights: United Technologies, Sprint, Eli Lilly, Edwards Lifesciences and Whirlpool"
LLY,LLY:US,BBG000BNBDC2,Peek Into Drug Stocks' Earnings on Oct 28: ABBV & IMGN,2016-10-27 12:43:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9v6PELMb3YI/peek-into-drug-stocks-earnings-on-oct-28-abbv-imgn-cm699144,The third quarter earnings season is seeing possibly the best growth pace since the first quarter of 2015 As of Oct 26 198 S amp P 500 members as of Oct 26 accounting for 48 9 of the index s total market capitalization have reported results according to the Earnings Trends report
LLY,LLY:US,BBG000BNBDC2,Baby Boomers Retiring and Spending Big: 5 Companies May Benefit Huge,2016-10-27 12:20:29 +0000,http://247wallst.com/investing/2016/10/27/baby-boomers-retiring-and-spending-big-5-companies-may-benefit-huge/,Baby Boomers Retiring and Spending Big: 5 Companies May Benefit Huge
LLY,LLY:US,BBG000BNBDC2,Biotech Stocks Facing FDA Decision In November,2016-10-27 11:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yP8sYx6pvkQ/biotech-stocks-facing-fda-decision-in-november-20161027-01106,Biotech Stocks Facing FDA Decision In November
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Co vs. Pfizer,2016-10-27 11:02:45 +0000,http://www.fool.com/investing/2016/10/26/better-buy-eli-lilly-and-co-vs-pfizer.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Eli Lilly and Co vs. Pfizer
LLY,LLY:US,BBG000BNBDC2,[$$] Overheard: Cheering On a Rival,2016-10-27 04:24:10 +0000,http://www.wsj.com/articles/overheard-cheering-on-a-rival-1477526084?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - Companies don’t usually root for their competitors, but Biogen is pulling for Eli Lilly. The latter’s pending data for its experimental Alzheimer’s disease treatment will be an important read-through for ..."
LLY,LLY:US,BBG000BNBDC2,Better Buy: Eli Lilly and Co vs. Pfizer,2016-10-26 22:51:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3H0Upmrp2Bg/better-buy-eli-lilly-and-co-vs-pfizer-cm699001,Eli Lilly NYSE LLY and Pfizer NYSE PFE are two of the most widely recognized dividend paying Big Pharma stocks in the world However these two elite drugmakers appear to be on drastically different trajectories thanks to their varying strategies in dealing with a spate
LLY,LLY:US,BBG000BNBDC2,Biogen Q3 Tops; Alzheimer's Data Vs. Eli Lilly Positive,2016-10-26 20:10:08 +0000,http://www.investors.com/news/technology/biogen-q3-tops-by-50-million-alzheimers-data-vs-eli-lilly-positive/,Biogen Q3 Tops; Alzheimer's Data Vs. Eli Lilly Positive
LLY,LLY:US,BBG000BNBDC2,"Analyst Reports for Sprint, Eli Lilly, & United Technologies",2016-10-26 19:50:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ltytH362mmE/analyst-reports-for-sprint-eli-lilly-united-technologies-cm698890,Wednesday October 26 2016 Today s Research Daily features new research reports on 16 major stocks including United Technologies UTX Sprint S and Eli Lilly LLY United Technologies shares have performed in line with the broader market in the year to date period though sentiment
LLY,LLY:US,BBG000BNBDC2,"Biogen: Heads Is a Win, Tails Is Complicated",2016-10-26 15:55:54 +0000,http://blogs.wsj.com/moneybeat/2016/10/26/biogen-heads-is-a-win-tails-is-complicated/?mod=yahoo_hs,"Biogen: Heads Is a Win, Tails Is Complicated"
LLY,LLY:US,BBG000BNBDC2,"Analyst Reports for Sprint, Eli Lilly, & United Technologies",2016-10-26 15:43:03 +0000,http://finance.yahoo.com/news/analyst-reports-sprint-eli-lilly-154303713.html,"Analyst Reports for Sprint, Eli Lilly, & United Technologies"
LLY,LLY:US,BBG000BNBDC2,Who Fared Better in Q3 Earnings Season: Merck or Eli Lilly?,2016-10-26 14:53:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eYA0R7cPslQ/who-fared-better-in-q3-earnings-season-merck-or-eli-lilly-cm698586,Yesterday two big names in the U S large cap pharma sector Merck amp Co Inc MRK and Eli Lilly and Company LLY reported third quarter results While Merck surpassed expectations Lilly s results fell short of estimates Here is an in depth look at the third quarter results of
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Diabetes Misery Will Have Company,2016-10-26 13:57:38 +0000,http://www.bloomberg.com/gadfly/articles/2016-10-26/eli-lilly-earnings-diabetes-misery-will-have-company?cmpid=yhoo.headline,Eli Lilly's Diabetes Misery Will Have Company
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. :LLY-US: Earnings Analysis: Q3, 2016 By the Numbers : October 26, 2016",2016-10-26 13:37:45 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-lly-us-earnings-analysis-q3-2016-by-the-numbers-october-26-2016/,"Eli Lilly & Co. :LLY-US: Earnings Analysis: Q3, 2016 By the Numbers : October 26, 2016"
LLY,LLY:US,BBG000BNBDC2,Who Fared Better in Q3 Earnings Season: Merck or Eli Lilly?,2016-10-26 13:13:01 +0000,http://finance.yahoo.com/news/fared-better-q3-earnings-season-131301286.html,Who Fared Better in Q3 Earnings Season: Merck or Eli Lilly?
LLY,LLY:US,BBG000BNBDC2,Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company,2016-10-26 12:43:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HZ2Qgc5SuMw/better-buy-glaxosmithkline-plc-vs-eli-lilly-and-company-cm698365,Image source Getty Images Don t think that Big Pharma stocks march in lockstep GlaxoSmithKline s NYSE GSK stock price is lower than it was five years ago During the same period the share price of Eli Lilly NYSE LLY has more than doubled But which of these
LLY,LLY:US,BBG000BNBDC2,Ways To More Affordable Medicines: Introduction,2016-10-26 12:30:00 +0000,http://www.forbes.com/sites/johnlechleiter/2016/10/26/introduction/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Ways To More Affordable Medicines: Introduction
LLY,LLY:US,BBG000BNBDC2,Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company,2016-10-26 12:27:59 +0000,http://www.fool.com/investing/2016/10/26/better-buy-glaxosmithkline-plc-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company
LLY,LLY:US,BBG000BNBDC2,Edited Transcript of LLY earnings conference call or presentation 25-Oct-16 1:00pm GMT,2016-10-26 04:43:44 +0000,http://finance.yahoo.com/news/edited-transcript-lly-earnings-conference-044344678.html,Edited Transcript of LLY earnings conference call or presentation 25-Oct-16 1:00pm GMT
LLY,LLY:US,BBG000BNBDC2,What this Health Care analyst thinks will happen to the sector if Democrats take both the House and Senate,2016-10-25 21:03:12 +0000,http://finance.yahoo.com/tumblr/blog-what-this-health-care-analyst-thinks-will-happen-210316537.html,What this Health Care analyst thinks will happen to the sector if Democrats take both the House and Senate
LLY,LLY:US,BBG000BNBDC2,Merck Crushes Q3 Expectations Following Lung Cancer Drug Win,2016-10-25 20:35:00 +0000,http://www.investors.com/news/technology/merck-crushes-q3-expectations-following-lung-cancer-drug-win/,Merck Crushes Q3 Expectations Following Lung Cancer Drug Win
LLY,LLY:US,BBG000BNBDC2,Novartis Tumbles On Q3 Sales Miss; Chemo Sales May Boost Incyte,2016-10-25 20:12:53 +0000,http://www.investors.com/news/technology/novartis-tumbles-on-q3-sales-miss-chemo-sales-may-boost-incyte/,Novartis Tumbles On Q3 Sales Miss; Chemo Sales May Boost Incyte
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) CEO Lechleiter Discusses Earnings,2016-10-25 20:12:00 +0000,https://www.thestreet.com/story/13866562/1/eli-lilly-lly-ceo-lechleiter-discusses-earnings.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly (LLY) CEO Lechleiter Discusses Earnings
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Q3 Revenue, EPS Miss; CEO Praises Drug Pipeline",2016-10-25 20:05:22 +0000,http://www.investors.com/news/technology/eli-lilly-plummets-on-q3-sales-eps-miss-announces-ceo-swap/,"Eli Lilly Q3 Revenue, EPS Miss; CEO Praises Drug Pipeline"
LLY,LLY:US,BBG000BNBDC2,Bristol-Myers Squibb’s 3Q16 Estimates: Oncology Segment,2016-10-25 19:04:05 +0000,http://marketrealist.com/2016/10/bristol-myers-squibbs-3q16-estimates-oncology-segment/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s 3Q16 Estimates: Oncology Segment
LLY,LLY:US,BBG000BNBDC2,Drug price pressure,2016-10-25 17:38:00 +0000,http://finance.yahoo.com/video/drug-price-pressure-173800510.html,Drug price pressure
LLY,LLY:US,BBG000BNBDC2,Weak Third Quarter but Eli Lilly Looks Well Positioned,2016-10-25 17:15:00 +0000,http://finance.yahoo.com/news/weak-third-quarter-eli-lilly-171500179.html,Weak Third Quarter but Eli Lilly Looks Well Positioned
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts",2016-10-25 16:28:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fLETdGBg3aA/lilly-lly-misses-on-q3-earnings-sales-animal-health-hurts-cm697939,Eli Lilly and Company s LLY third quarter results were below expectations with both earnings and sales missing the Zacks Consensus Estimate The company revised certain elements of its 2016 outlook Shares declined 1 in pre market trading Earnings Miss Third quarter 2016
LLY,LLY:US,BBG000BNBDC2,"Under Armour Beats Q3 Earnings, Stock Down 14%",2016-10-25 16:27:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d_I2SgHJX04/under-armour-beats-q3-earnings-stock-down-14-cm697909,Tuesday October 25 2016 It s the busiest day we ve yet seen in Q3 earnings season While others mull over the likelihood of an AT amp T T buyout of Time Warner TWX especially two weeks before the U S presidential election in which both major candidates plus Bernie Sanders are
LLY,LLY:US,BBG000BNBDC2,5 Healthcare Stocks to Buy Despite a Clinton Victory,2016-10-25 16:27:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z7WuhrvyqPM/5-healthcare-stocks-to-buy-despite-a-clinton-victory-cm697884,As the race for the presidency enters its last lap Hillary Clinton has emerged as the clear favorite Going by the Real Clear Politics poll average Clinton is leading Donald Trump by more than six points as of now Market watchers and analysts alike are now examining the implications of a
LLY,LLY:US,BBG000BNBDC2,Merck predicts lung cancer dominance for Keytruda immunotherapy,2016-10-25 16:11:30 +0000,http://finance.yahoo.com/news/merck-quarterly-revenue-beats-raises-111623742.html,"[Reuters] - Merck & Co on Tuesday declared its intention to dominate the large and lucrative lung cancer market, bolstered by a significant expansion of approved U.S. uses for its drug that helps the immune system attack tumors. Merck's optimistic comments came after it posted better-than-expected third quarter results, helped by growing sales of the cancer drug Keytruda. Keytruda on Monday became the first of the new immunotherapy drugs approved as an initial lung cancer treatment, when U.S. regulators cleared it for use in patients whose cancer cells express a high level of the PD-L1 protein that the medicine targets."
LLY,LLY:US,BBG000BNBDC2,"Lilly results hurt by disappointing Humalog, animal health sales",2016-10-25 15:24:13 +0000,http://finance.yahoo.com/news/lilly-third-quarter-results-miss-105325887.html,"Lilly results hurt by disappointing Humalog, animal health sales"
LLY,LLY:US,BBG000BNBDC2,How Much Is the Return Opportunity for Novo Nordisk in 3Q16?,2016-10-25 14:52:31 +0000,http://marketrealist.com/2016/10/how-much-is-the-return-opportunity-for-novo-nordisk-in-3q16/?utm_source=yahoo&utm_medium=feed,How Much Is the Return Opportunity for Novo Nordisk in 3Q16?
LLY,LLY:US,BBG000BNBDC2,"Jim Cramer -- Merck, Lilly Pressured by Political Uncertainty",2016-10-25 14:26:00 +0000,https://www.thestreet.com/story/13865836/1/jim-cramer-merck-lilly-pressured-by-political-uncertainty.html?puc=yahoo&cm_ven=YAHOO,"Jim Cramer -- Merck, Lilly Pressured by Political Uncertainty"
LLY,LLY:US,BBG000BNBDC2,"Stock Market News for October 25, 2016",2016-10-25 14:10:02 +0000,http://finance.yahoo.com/news/stock-market-news-october-25-141002614.html,"Stock Market News for October 25, 2016"
LLY,LLY:US,BBG000BNBDC2,"Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts",2016-10-25 13:56:01 +0000,http://finance.yahoo.com/news/lilly-lly-misses-q3-earnings-135601572.html,"Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts"
LLY,LLY:US,BBG000BNBDC2,Lilly (LLY) Misses on Q3 Earnings & Revenues,2016-10-25 13:27:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6ZOHpi5sXBE/lilly-lly-misses-on-q3-earnings-revenues-cm697734,Indianapolis IN based Eli Lilly and Company LLY is a global healthcare company with core products in a number of primary care pharmaceutical markets Lilly generates revenues from its pharmaceutical product and animal health segments The company s portfolio includes Zyprexa
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: We're Pleased With Our 3Q Performance,2016-10-25 12:28:33 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-were-pleased-122833085.html,Eli Lilly CEO: We're Pleased With Our 3Q Performance
LLY,LLY:US,BBG000BNBDC2,Lilly misses 3Q forecasts as sales slip on key drugs,2016-10-25 12:26:04 +0000,http://sg.finance.yahoo.com/news/lilly-misses-street-3q-forecasts-103540433.html,Lilly misses 3Q forecasts as sales slip on key drugs
LLY,LLY:US,BBG000BNBDC2,Lilly (LLY) Misses on Q3 Earnings & Revenues,2016-10-25 12:18:12 +0000,http://finance.yahoo.com/news/lilly-lly-misses-q3-earnings-121812641.html,Lilly (LLY) Misses on Q3 Earnings & Revenues
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Stock Slumps on Q3 Miss,2016-10-25 11:45:00 +0000,https://www.thestreet.com/story/13865184/1/eli-lilly-lly-stock-slumps-on-q3-miss.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly (LLY) Stock Slumps on Q3 Miss
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly's Profit Dented by Higher Costs,2016-10-25 11:30:20 +0000,http://www.wsj.com/articles/eli-lillys-profit-dented-by-higher-costs-1477395013?mod=yahoo_hs,[$$] Eli Lilly's Profit Dented by Higher Costs
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO: Kept our guidance range intact,2016-10-25 11:16:00 +0000,http://finance.yahoo.com/video/eli-lilly-ceo-kept-guidance-111600274.html,Eli Lilly CEO: Kept our guidance range intact
LLY,LLY:US,BBG000BNBDC2,Q3 2016 Eli Lilly and Co Earnings Release - Before Market Open,2016-10-25 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20161025.html?t=lly,Q3 2016 Eli Lilly and Co Earnings Release - Before Market Open
LLY,LLY:US,BBG000BNBDC2,Lilly Reports Third-Quarter 2016 Results,2016-10-25 10:51:03 +0000,http://www.publicnow.com/view/7353EBBBC76D563726E74CA8ABE65106BC9D315D,"[at noodls] - INDIANAPOLIS, Oct. 25, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2016. ... This is an abstract of the original noodl. To continue ..."
LLY,LLY:US,BBG000BNBDC2,Lilly third-quarter revenue rises 4.7 percent,2016-10-25 10:32:44 +0000,http://finance.yahoo.com/news/lilly-third-quarter-revenue-rises-103244067.html,Lilly third-quarter revenue rises 4.7 percent
LLY,LLY:US,BBG000BNBDC2,Lilly Profit Falls Short as Humalog Insulin Sales Disappoint,2016-10-25 10:31:12 +0000,http://www.bloomberg.com/news/articles/2016-10-25/lilly-profit-misses-estimates-on-sluggish-sales-of-humalog?cmpid=yhoo.headline,Lilly Profit Falls Short as Humalog Insulin Sales Disappoint
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Q3 16 Earnings Conference Call At 9:00 AM ET,2016-10-25 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sK_LXi_jnOQ/eli-lilly-and-co-q3-16-earnings-conference-call-at-900-am-et-20161025-00475,Eli Lilly And Co. Q3 16 Earnings Conference Call At 9:00 AM ET
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Profit Dented by Higher Costs,2016-10-25 07:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O5A4kCQD12s/eli-lillys-profit-dented-by-higher-costs-20161025-01179,Eli Lilly's Profit Dented by Higher Costs
LLY,LLY:US,BBG000BNBDC2,"Lilly Q3 Results Miss Estimates; Cuts FY16 EPS View, Backs Adj. EPS Forecast",2016-10-25 07:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qyQUiFtQqjw/lilly-q3-results-miss-estimates-cuts-fy16-eps-view-backs-adj-eps-forecast-20161025-01160,"Lilly Q3 Results Miss Estimates; Cuts FY16 EPS View, Backs Adj. EPS Forecast"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Q3 Profit Declines 2%,2016-10-25 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GYdyKbvvUo0/eli-lilly-and-co-q3-profit-declines-2-20161025-00199,Eli Lilly And Co. Q3 Profit Declines 2%
LLY,LLY:US,BBG000BNBDC2,Reasons behind the Superior YTD Performance of the Vanguard PRIMECAP Fund,2016-10-24 21:04:38 +0000,http://marketrealist.com/2016/10/reasons-behind-superior-ytd-performance-vanguard-primecap-fund/?utm_source=yahoo&utm_medium=feed,Reasons behind the Superior YTD Performance of the Vanguard PRIMECAP Fund
LLY,LLY:US,BBG000BNBDC2,Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC,2016-10-24 20:15:02 +0000,http://www.investors.com/news/technology/biogen-could-add-1-billion-in-2017-on-muscular-dystrophy-drug-rbc/,Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC
LLY,LLY:US,BBG000BNBDC2,"Pre-Market Earnings Report for October 25, 2016 :  PG, MRK, MMM, LLY, UTX, LMT, DD, CAT, GM, MMC, BAX, S",2016-10-24 20:14:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P-auy40RuKA/pre-market-earnings-report-for-october-25-2016-pg-mrk-mmm-lly-utx-lmt-dd-cat-gm-mmc-bax-s-cm697415,The following companies are expected to report earnings prior to market open on 10 25 2016 Visit our Earnings Calendar for a full list of expected earnings releases Procter amp Gamble Company PG is reporting for the quarter ending September 30 2016
LLY,LLY:US,BBG000BNBDC2,What to Watch When Eli Lilly (LLY) Reports Q3 Results,2016-10-24 18:25:00 +0000,https://www.thestreet.com/story/13864397/1/what-to-watch-when-eli-lilly-lly-reports-q3-results.html?puc=yahoo&cm_ven=YAHOO,What to Watch When Eli Lilly (LLY) Reports Q3 Results
LLY,LLY:US,BBG000BNBDC2,What to Look for When Eli Lilly Reports Earnings,2016-10-24 16:05:23 +0000,http://finance.yahoo.com/news/look-eli-lilly-reports-earnings-160523880.html,What to Look for When Eli Lilly Reports Earnings
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More",2016-10-24 14:27:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cqpf-7ymC40/drug-stocks-q3-earnings-roster-for-oct-25-mrk-lly-more-cm697035,The third quarter earnings season has picked up pace with 116 S amp P 500 members as of Oct 21 accounting for 23 2 of the index s total market capitalization having reported results according to the Earnings Preview report While total earnings for these 116 index members were up 3 3
LLY,LLY:US,BBG000BNBDC2,"Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More",2016-10-24 12:28:12 +0000,http://finance.yahoo.com/news/drug-stocks-q3-earnings-roster-122812341.html,"Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More"
LLY,LLY:US,BBG000BNBDC2,Analyst Recommendations for Pfizer and Its Peers in 2016,2016-10-24 12:06:20 +0000,http://marketrealist.com/2016/10/analyst-recommendations-pfizer-peers-2016/?utm_source=yahoo&utm_medium=feed,Analyst Recommendations for Pfizer and Its Peers in 2016
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s Valuation Cheat Sheet 3Q16,2016-10-24 12:04:05 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-valuation-cheat-sheet-3q16/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s Valuation Cheat Sheet 3Q16
LLY,LLY:US,BBG000BNBDC2,Do Analysts Expect Negative Growth for Novartis in 3Q16?,2016-10-21 22:04:10 +0000,http://marketrealist.com/2016/10/do-analysts-expect-negative-growth-for-novartis-in-3q16/?utm_source=yahoo&utm_medium=feed,Do Analysts Expect Negative Growth for Novartis in 3Q16?
LLY,LLY:US,BBG000BNBDC2,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,2016-10-21 15:36:21 +0000,http://finance.yahoo.com/news/drugs-working-pharma-giants-eli-153621166.html,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
LLY,LLY:US,BBG000BNBDC2,"The Zacks Analyst Blog Highlights: Halliburton, Netflix, Disney, Eli Lilly and Sprint",2016-10-21 15:27:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KRk2fJfs02I/the-zacks-analyst-blog-highlights-halliburton-netflix-disney-eli-lilly-and-sprint-cm696586,For Immediate Release Chicago IL October 21 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
LLY,LLY:US,BBG000BNBDC2,Earnings ahead! What Analysts Expect for Eli Lilly and Co.,2016-10-21 15:04:08 +0000,http://marketrealist.com/2016/10/earnings-ahead-what-analysts-expect-for-eli-lilly-and-co/?utm_source=yahoo&utm_medium=feed,Earnings ahead! What Analysts Expect for Eli Lilly and Co.
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved",2016-10-21 14:04:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iHEfrrCHCpA/pharma-stock-roundup-another-strong-quarter-from-jj-lilly-cancer-drug-approved-cm696502,Earnings started on a positive note for the pharma sector with industry bellwether Johnson amp Johnson JNJ reporting better than expected results Swiss company Roche RHHBY also reported nine month sales figures this week Recap of the Week s Most Important Stories J amp J
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16: The Major Developments,2016-10-21 14:04:09 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-the-major-developments/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16: The Major Developments
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved",2016-10-21 12:28:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-another-strong-122812176.html,"Pharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16: Expectations for Elanco,2016-10-21 12:04:08 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-expectations-for-elanco/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16: Expectations for Elanco
LLY,LLY:US,BBG000BNBDC2,"Analyst Reports for Netflix, Halliburton & Disney",2016-10-20 21:26:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kq4CIHGz1Jw/analyst-reports-for-netflix-halliburton-disney-cm696202,Thursday October 20 2016 Today s Research Daily features new research reports on 16 major stocks including Halliburton HAL Netflix NFLX and Disney DIS Shares of Buy rated Halliburton have been strong performers this year handily beating the Energy sector as a whole the stock is
LLY,LLY:US,BBG000BNBDC2,"Analyst Reports for Netflix, Halliburton & Disney",2016-10-20 17:46:05 +0000,http://finance.yahoo.com/news/analyst-reports-netflix-halliburton-disney-174605240.html,"Analyst Reports for Netflix, Halliburton & Disney"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16 Estimates: Expectations for New Products,2016-10-20 15:04:15 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-estimates-expectations-for-new-products/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16 Estimates: Expectations for New Products
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16 Estimates: Oncology Franchise,2016-10-20 14:04:33 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-estimates-oncology-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16 Estimates: Oncology Franchise
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma,2016-10-20 13:51:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3CwzFCuosCg/eli-lilly-lartruvo-gets-fda-approval-for-soft-tissue-sarcoma-cm695769,Eli Lilly and Company LLY announced that the FDA has granted accelerated approval to its pipeline candidate Lartruvo olaratumab injection 10 mg mL in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma STS not amenable to curative
LLY,LLY:US,BBG000BNBDC2,The 3 Biggest Stories From Johnson & Johnson's Third-Quarter Report,2016-10-20 13:50:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OiNCD8VOikw/the-3-biggest-stories-from-johnson-johnsons-third-quarter-report-cm695772,Johnson amp Johnson CEO Alex Gorsky Image source Johnson amp Johnson The largest publicly traded healthcare company in the world Johnson amp Johnson NYSE JNJ reported its third quarter earnings results before the opening bell on Tuesday Oct 18 As has become
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16 Estimates: Cardiovascular Franchise,2016-10-20 12:04:42 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-estimates-cardiovascular-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16 Estimates: Cardiovascular Franchise
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma,2016-10-20 11:51:11 +0000,http://finance.yahoo.com/news/eli-lilly-lartruvo-gets-fda-115111984.html,Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma
LLY,LLY:US,BBG000BNBDC2,"CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides",2016-10-20 01:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yBWOilte3bA/ceru-gains-big-on-nanoparticle-deal-lly-gets-fda-nod-baby-makes-big-strides-20161020-00031,"CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides"
LLY,LLY:US,BBG000BNBDC2,FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma,2016-10-19 20:38:10 +0000,http://www.publicnow.com/view/D49C4F15B51FB528D3B6417B4A24F92734B52338,"[at noodls] - INDIANAPOLIS, Oct. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™(olaratumab injection, 10 ..."
LLY,LLY:US,BBG000BNBDC2,FDA grants accelerated approval to Lilly's soft tissue sarcoma drug,2016-10-19 19:20:06 +0000,http://finance.yahoo.com/news/fda-grants-accelerated-approval-lillys-192006358.html,"[Reuters] - The U.S. Food and Drug Administration on Wednesday granted accelerated approval to Eli Lilly and Co's drug for treating adults with advanced soft tissue sarcoma (STS). Lilly's drug, Lartruvo, is approved for use with FDA-approved chemotherapy doxorubicin in STS patients who cannot be cured with radiation or surgery or who have a type of STS for which chemotherapeutic agent anthracycline is an appropriate treatment. Soft tissue sarcoma refers to cancers that develop in muscles, fat, tendons or other soft tissues."
LLY,LLY:US,BBG000BNBDC2,Lilly's soft tissue sarcoma treatment gets U.S. approval,2016-10-19 18:18:53 +0000,http://finance.yahoo.com/news/lillys-soft-tissue-sarcoma-treatment-181853322.html,"[Reuters] - The U.S. Food and Drug Administration on Wednesday approved Eli Lilly and Co's treatment for adults with advanced soft tissue sarcoma . Lilly's drug, Lartruvo, is approved for use with chemotherapy doxorubicin ..."
LLY,LLY:US,BBG000BNBDC2,"Noteworthy ETF Inflows: VYM, PFE, WMT, LLY",2016-10-19 16:49:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tMnNh8z-kZA/noteworthy-etf-inflows-vym-pfe-wmt-lly-cm695426,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 49 8 million dollar inflow that s a 0 3 increase week over week
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Announces FDA Approval For LARTRUVO - Quick Facts,2016-10-19 16:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RIk49_B8KXE/eli-lilly-announces-fda-approval-for-lartruvo--quick-facts-20161019-00801,Eli Lilly Announces FDA Approval For LARTRUVO - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Can Eli Lilly (LLY) Pull a Surprise this Earnings Season?,2016-10-19 15:51:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/maogj0NV0yo/can-eli-lilly-lly-pull-a-surprise-this-earnings-season-cm695370,Eli Lilly and Company LLY is set to report third quarter 2016 results on Oct 25 before the market opens Last quarter the company posted a positive earnings surprise of 1 18 The company s performance has been pretty strong so far with earnings surpassing expectations in three of the
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise,2016-10-19 15:05:32 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-estimates-neuroscience-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co.’s 3Q16 Estimates: Endocrine Franchise,2016-10-19 14:06:17 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-estimates-endocrine-franchise/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16 Estimates: Endocrine Franchise
LLY,LLY:US,BBG000BNBDC2,Shire Cancer Drug Onivyde Receives EU Marketing Approval,2016-10-19 13:50:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lFWBMk5Cr9U/shire-cancer-drug-onivyde-receives-eu-marketing-approval-cm695203,Shire plc SHPG announced that the European Commission has granted marketing authorization to Onivyde in combination with fluorouracil 5 FU and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following treatment with Eli Lilly and Company
LLY,LLY:US,BBG000BNBDC2,Can Eli Lilly (LLY) Pull a Surprise this Earnings Season?,2016-10-19 13:14:01 +0000,http://finance.yahoo.com/news/eli-lilly-lly-pull-surprise-131401984.html,Can Eli Lilly (LLY) Pull a Surprise this Earnings Season?
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 3Q16 Estimates: Expect Revenue Growth!,2016-10-19 12:06:45 +0000,http://marketrealist.com/2016/10/eli-lillys-3q16-estimates-expect-revenue-growth/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s 3Q16 Estimates: Expect Revenue Growth!
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s 3Q16 Earnings: What to Expect,2016-10-18 21:21:03 +0000,http://marketrealist.com/2016/10/eli-lillys-3q16-earnings-what-to-expect/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s 3Q16 Earnings: What to Expect
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Leaps Over Patent Hurdles,2016-10-18 16:00:36 +0000,http://finance.yahoo.com/news/eli-lily-leaps-over-patent-160036308.html,Eli Lilly Leaps Over Patent Hurdles
LLY,LLY:US,BBG000BNBDC2,Lilly Announces Ambitious New Commitment to Expand Global Access to Health Care,2016-10-18 15:48:06 +0000,http://www.publicnow.com/view/3821CC8586226B2323687A95CF276AB91CB5A1DE,"[at noodls] - INDIANAPOLIS, Oct. 18, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an ambitious plan to increase access to quality health care and to improve long-term health for millions of ..."
LLY,LLY:US,BBG000BNBDC2,Alzheimer's Remains a Top Priority for Big Pharma,2016-10-18 11:37:36 +0000,http://www.fool.com/investing/2016/10/17/alzheimers-remains-a-top-priority-for-big-pharma.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Alzheimer's Remains a Top Priority for Big Pharma
LLY,LLY:US,BBG000BNBDC2,Eli Lilly announces $90M health care initiative: CEO,2016-10-18 11:33:00 +0000,http://finance.yahoo.com/video/eli-lilly-announces-90m-health-113300038.html,Eli Lilly announces $90M health care initiative: CEO
LLY,LLY:US,BBG000BNBDC2,"3 Healthcare Stocks to Buy Now, Even If Hillary Clinton Is Elected",2016-10-17 22:47:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mge8mTlB_Rs/3-healthcare-stocks-to-buy-now-even-if-hillary-clinton-is-elected-cm694476,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips This past year has been anything but remarkable for healthcare sector The S amp P 500 Healthcare Sector index is down by roughly 3 year to date That dwarfs the 4 gain that the entire S amp P 500
LLY,LLY:US,BBG000BNBDC2,Alzheimer's Remains a Top Priority for Big Pharma,2016-10-17 21:47:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpPqR__TpuM/alzheimers-remains-a-top-priority-for-big-pharma-cm694462,Alzheimer s disease AD has been a graveyard for experimental medications A recent study for instance reported that a whopping 99 6 of experimental AD drugs 160 failed to improve patient outcomes over the course of 2002 to 2012 Despite this sky high failure rate
LLY,LLY:US,BBG000BNBDC2,"Daily Dividend Report: AMGN, LLY, WY, HSY, VMC, UNM",2016-10-17 20:46:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HkEQT_Yep_8/daily-dividend-report-amgn-lly-wy-hsy-vmc-unm-cm694422,Amgen AMGN declared a 1 00 per share dividend for the fourth quarter of 2016 The dividend will be paid on Dec 8 2016 to all stockholders of record as of the close of business on Nov 16 2016 Eli Lilly and Company LLY has declared a dividend for the fourth quarter of 2016
LLY,LLY:US,BBG000BNBDC2,"Health Care Sector Update for 10/17/2016: LLY,MSTX,PHG,PTCT",2016-10-17 20:26:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v8UMAHIwB2M/health-care-sector-update-for-10172016-llymstxphgptct-cm694445,Top Health Care StocksTop Health Care Stocks JNJ 0 65 JNJ 0 65 PFE 0 41 PFE 0 41 MRK 0 42 MRK 0 42 ABT 0 98 ABT 0 98 AMGN 0 51 AMGN 0 51 Health care stocks were lower Monday afternoon with the NYSE Health Care Index posting a 0 4 retreat while shares of health care companies in
LLY,LLY:US,BBG000BNBDC2,Lilly Declares Fourth-Quarter 2016 Dividend,2016-10-17 18:53:02 +0000,http://www.publicnow.com/view/1697F0FB4BE48A0DABEB88D114F50F3DF01F8A42,"[at noodls] - INDIANAPOLIS, Oct. 17, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2016 of $0.51 per share on outstanding common stock. ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative,2016-10-17 15:53:08 +0000,http://www.publicnow.com/view/85419F7D319D3CEDEEA2A86F370A78697F8687AB,"[at noodls] - INDIANAPOLIS, Oct. 17, 2016 /PRNewswire/ -- With the global prevalence of new cancer cases expected to rise by 70 percent during the next two decades, representatives from government, academic, pharmaceutical ..."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : October 17, 2016",2016-10-17 12:51:42 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-breached-its-50-day-moving-average-in-a-bearish-manner-lly-us-october-17-2016/,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : October 17, 2016"
LLY,LLY:US,BBG000BNBDC2,"Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say",2016-10-14 18:57:00 +0000,https://www.thestreet.com/story/13854005/1/bet-on-animal-health-by-investing-in-idexx-laboratories-analysts-say.html?puc=yahoo&cm_ven=YAHOO,"Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say"
LLY,LLY:US,BBG000BNBDC2,Pfizer’s Divestment of Hospira Infusion Systems,2016-10-14 14:04:37 +0000,http://marketrealist.com/2016/10/pfizers-divestment-hospira-infusion-systems/?utm_source=yahoo&utm_medium=feed,Pfizer’s Divestment of Hospira Infusion Systems
LLY,LLY:US,BBG000BNBDC2,Can These Top 5 Biotechs Climb Q3 'Wall Of Worry'? RBC Calls For Rally,2016-10-13 20:37:53 +0000,http://www.investors.com/news/technology/can-these-top-5-biotechs-climb-q3-wall-of-worry-rbc-calls-for-rally/,Can These Top 5 Biotechs Climb Q3 'Wall Of Worry'? RBC Calls For Rally
LLY,LLY:US,BBG000BNBDC2,Prothena Slammed On Politics; Could Win Eli Lilly Or Pfizer Partnership,2016-10-13 20:09:21 +0000,http://www.investors.com/news/technology/prothena-slammed-on-politics-could-win-eli-lilly-or-pfizer-partnership/,Prothena Slammed On Politics; Could Win Eli Lilly Or Pfizer Partnership
LLY,LLY:US,BBG000BNBDC2,Does Pfizer Deserve a Better Valuation?,2016-10-13 16:30:31 +0000,http://marketrealist.com/2016/10/pfizer-deserve-better-valuation/?utm_source=yahoo&utm_medium=feed,Does Pfizer Deserve a Better Valuation?
LLY,LLY:US,BBG000BNBDC2,Top 5 Jefferies Big Pharma Stock Picks for Q4,2016-10-13 14:40:03 +0000,http://247wallst.com/healthcare-business/2016/10/13/top-5-jefferies-big-pharma-stock-picks-for-q4/,Top 5 Jefferies Big Pharma Stock Picks for Q4
LLY,LLY:US,BBG000BNBDC2,Merrimack's Onivyde Positive in Pancreatic Cancer Study,2016-10-12 14:41:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iXAepQQhcRs/merrimacks-onivyde-positive-in-pancreatic-cancer-study-cm692337,Merrimack Pharmaceuticals Inc MACK announced encouraging final data from a phase III study NAPOLI 1 on Onivyde in combination with fluorouracil 5 FU and leucovorin in the treatment of patients with metastatic pancreatic ductal adenocarcinoma mPDAC following treatment with Eli Lilly
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community",2016-10-12 13:47:10 +0000,http://www.publicnow.com/view/9AC3F0E643CBA65E79C45B39427A1A4A913BAEF0,"[at noodls] - INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with ..."
LLY,LLY:US,BBG000BNBDC2,Merrimack's Onivyde Positive in Pancreatic Cancer Study,2016-10-12 13:41:01 +0000,http://finance.yahoo.com/news/merrimacks-onivyde-positive-pancreatic-cancer-134101723.html,Merrimack's Onivyde Positive in Pancreatic Cancer Study
LLY,LLY:US,BBG000BNBDC2,HMS Holdings Corp. Announces New Appointment to its Board of Directors,2016-10-12 13:00:00 +0000,http://finance.yahoo.com/news/hms-holdings-corp-announces-appointment-130000121.html,"[GlobeNewswire] - IRVING, Texas, Oct. 12, 2016-- HMS Holdings Corp. today announced that Alex Michael Azar II has been appointed to the HMS Board of Directors, effective October 11, 2016. Azar is President, Lilly USA, LLC, ..."
LLY,LLY:US,BBG000BNBDC2,"Notable ETF Inflow Detected - VYM, JPM, LLY, DD",2016-10-11 16:18:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l3UgQTjAw8Y/notable-etf-inflow-detected-vym-jpm-lly-dd-cm691845,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 66 8 million dollar inflow that s a 0 4 increase week over week
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2016 (record date) : By the numbers : October 11, 2016",2016-10-11 15:49:53 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-lly-us-dividend-analysis-august-15th-2016-record-date-by-the-numbers-october-11-2016/,"Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2016 (record date) : By the numbers : October 11, 2016"
LLY,LLY:US,BBG000BNBDC2,Lilly to Participate in Credit Suisse 2016 Healthcare Conference,2016-10-11 14:00:00 +0000,http://finance.yahoo.com/news/lilly-participate-credit-suisse-2016-140000892.html,"[PR Newswire] - INDIANAPOLIS, Oct. 11, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 2016 Healthcare Conference on Monday, November 7, 2016. The following Lilly executives ..."
LLY,LLY:US,BBG000BNBDC2,"Leading Experts Warn Global Goal to Cure or Treat Alzheimer's Disease By 2025 is at Risk, Offer Solutions to Adjust Course",2016-10-11 12:00:00 +0000,http://finance.yahoo.com/news/leading-experts-warn-global-goal-120000363.html,"[PR Newswire] - INDIANAPOLIS, Oct. 11, 2016 /PRNewswire/ -- Alzheimer's disease (AD) has an enormous impact on the lives of patients and caregivers, in addition to placing a significant burden on health care systems around ..."
LLY,LLY:US,BBG000BNBDC2,Merck Topples Bristol-Myers On Lung Cancer Drug Win,2016-10-10 20:20:21 +0000,http://www.investors.com/research/ibd-industry-themes/esmo-2016-merck-topples-bristol-myers-on-lung-cancer-drug-win/,Merck Topples Bristol-Myers On Lung Cancer Drug Win
LLY,LLY:US,BBG000BNBDC2,S&P 500 Analyst Moves: LLY,2016-10-10 17:17:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lBF1IXQZ890/sp-500-analyst-moves-lly-cm691147,The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S amp P 500 index Eli Lilly amp Co LLY is now the 98 analyst pick moving up by 3 spots This rank is formed by averaging the analyst opinions for each component from
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Is Waiting for a Catalyst,2016-10-10 12:20:00 +0000,https://www.thestreet.com/story/13846799/1/eli-lilly-is-waiting-for-a-catalyst.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly Is Waiting for a Catalyst
LLY,LLY:US,BBG000BNBDC2,[$$] Insulin Prices Soar While Drugmakers’ Share Stays Flat,2016-10-10 04:56:34 +0000,http://www.wsj.com/articles/insulin-prices-soar-while-drugmakers-share-stays-flat-1475876764?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - Insulin prices are soaring, creating pain for patients whose life depends on the injectable drug—yet most of the revenue from the increases isn’t going to the drug manufacturers, it is largely being collected ..."
LLY,LLY:US,BBG000BNBDC2,Mindset Shifts Take Time,2016-10-09 19:30:55 +0000,http://finance.yahoo.com/tumblr/blog-mindset-shifts-take-time-193102164.html,Mindset Shifts Take Time
LLY,LLY:US,BBG000BNBDC2,Why Novo Nordisk Stock Fell 10.2% in September,2016-10-09 10:58:27 +0000,http://www.fool.com/investing/2016/10/08/why-novo-nordisk-stock-fell-102-in-september.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Novo Nordisk Stock Fell 10.2% in September
LLY,LLY:US,BBG000BNBDC2,New Data on the Combination of Lilly's ALIMTA® (pemetrexed) and Merck's KEYTRUDA® (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer,2016-10-09 07:33:02 +0000,http://www.publicnow.com/view/AAEEE6A9CB98D44D500DDEDC449090E22FD8FE7B,"[at noodls] - INDIANAPOLIS, Oct. 9, 2016 /PRNewswire/ -- Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY) ongoing immuno-oncology collaborations with Merck (known as MSD outside the U.S. ..."
LLY,LLY:US,BBG000BNBDC2,Why Novo Nordisk Stock Fell 10.2% in September,2016-10-08 12:44:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dYjgIIJH4Pg/why-novo-nordisk-stock-fell-102-in-september-cm690662,Image source Getty Images What happened Shares of Novo Nordisk A S NYSE NVO a leading diabetes care drugmaker fell 10 2 in September according to data from S amp P Global Market Intelligence Increased pressure in the U S to control prescription drug
LLY,LLY:US,BBG000BNBDC2,Bristol-Myers Squibb’s Premium Valuation,2016-10-07 22:04:18 +0000,http://marketrealist.com/2016/10/bristol-myers-squibbs-premium-valuation/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s Premium Valuation
LLY,LLY:US,BBG000BNBDC2,[$$] Insulin-Price Increases Reflect Role of Health-Care Middlemen,2016-10-07 22:02:37 +0000,http://www.wsj.com/articles/insulin-prices-soar-while-drugmakers-share-stays-flat-1475876764?mod=yahoo_hs,[$$] Insulin-Price Increases Reflect Role of Health-Care Middlemen
LLY,LLY:US,BBG000BNBDC2,Area's biggest animal health company offloads portfolio to assuage antitrust regulators,2016-10-07 21:19:37 +0000,http://www.bizjournals.com/kansascity/news/2016/10/07/boehringer-ingelheim-vetmedica-pet-vaccines-sale.html?ana=yahoo,Area's biggest animal health company offloads portfolio to assuage antitrust regulators
LLY,LLY:US,BBG000BNBDC2,[$$] BioVentures Investors Closes Fourth Fund at $87M,2016-10-07 21:10:03 +0000,http://www.wsj.com/articles/bioventures-investors-closes-fourth-fund-at-87m-1475874601?mod=yahoo_hs,[$$] BioVentures Investors Closes Fourth Fund at $87M
LLY,LLY:US,BBG000BNBDC2,Insulin List-Prices Climb Even as Drugmakers' Share Stays Flat,2016-10-07 18:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m0rUoE3GvfU/insulin-listprices-climb-even-as-drugmakers-share-stays-flat-20161007-00535,Insulin List-Prices Climb Even as Drugmakers' Share Stays Flat
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good",2016-10-06 14:47:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k9ivxzZZw6s/pharma-stock-roundup-lilly-inks-animal-health-deal-jjs-psoriasis-data-looks-good-cm689700,Once again acquisitions and deals were in focus in the pharma sector with Lilly LLY announcing a deal to boost its animal health segment and Allergan AGN and AstraZeneca AZN announcing licensing agreements Meanwhile companies like Johnson amp Johnson JNJ and Novartis NVS presented data
LLY,LLY:US,BBG000BNBDC2,5 High-Quality Stocks to Weather Any Market,2016-10-06 13:42:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ortPUW-EWm8/5-high-quality-stocks-to-weather-any-market-cm689585,Admission tickets to the all weather club aren t cheap these days Price earnings ratios for companies such as Procter amp Gamble symbol PG the ultimate safety stock are well above the average price earnings ratio of 17 for Standard amp Poor s 500 stock index Yes
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Eli Lilly Acquires Boehringer Ingelheim Pet Vaccines Unit,2016-10-06 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-eli-lilly-acquires-131500885.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / October 6, 2016 / Active Wall St. blog coverage looks at the headline from Eli Lilly and Company (NYSE: LLY ). On October 5th, 2016, Eli Lilly and Co.'s subsidiary, Elanco US, ..."
LLY,LLY:US,BBG000BNBDC2,Blog Coverage Eli Lilly Acquires Boehringer Ingelheim Pet Vaccines Unit,2016-10-06 12:57:53 +0000,http://news.investornetwork.com/2016/10/06/blog-coverage-eli-lilly-acquires-boehringer-ingelheim-pet-vaccines-unit/?1=1&1475758673,Blog Coverage Eli Lilly Acquires Boehringer Ingelheim Pet Vaccines Unit
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit,2016-10-06 12:46:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ge1xYaP_0Ow/eli-lilly-to-buy-boehringers-vetmedica-pet-vaccines-unit-cm689581,Eli Lilly and Company LLY announced that its Elanco animal health business has agreed to acquire the U S pet vaccines unit Vetmedica and a Fort Dodge IA based manufacturing site from German drugmaker Boehringer Ingelheim for 885 million The acquisition of the Vetmedica portfolio
LLY,LLY:US,BBG000BNBDC2,4 Merrill Lynch US 1 Stocks to Buy That Also Pay Solid Dividends,2016-10-06 12:20:00 +0000,http://247wallst.com/investing/2016/10/06/4-merrill-lynch-us-1-stocks-to-buy-that-also-pay-solid-dividends/,4 Merrill Lynch US 1 Stocks to Buy That Also Pay Solid Dividends
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good",2016-10-06 12:12:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-inks-121212940.html,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit,2016-10-06 10:54:10 +0000,http://finance.yahoo.com/news/eli-lilly-buy-boehringers-vetmedica-105410984.html,Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit
LLY,LLY:US,BBG000BNBDC2,Business Watch,2016-10-06 04:13:30 +0000,http://www.wsj.com/articles/business-watch-1475707703?ru=yahoo?mod=yahoo_itp,[at The Wall Street Journal] - Business Watch
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Looks To Corral More Animal-Health Business Vs. Zoetis,2016-10-05 20:04:55 +0000,http://www.investors.com/news/technology/eli-lilly-looks-to-corral-more-animal-health-business-vs-zoetis/,Eli Lilly Looks To Corral More Animal-Health Business Vs. Zoetis
LLY,LLY:US,BBG000BNBDC2,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research,2016-10-05 16:38:12 +0000,http://finance.yahoo.com/news/anavex-life-sciences-joins-club-163812803.html,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Needs Its Animal Spirits,2016-10-05 16:21:24 +0000,http://www.bloomberg.com/gadfly/articles/2016-10-05/eli-lilly-animal-health-spinoff-probably-isn-t-happening?cmpid=yhoo.headline,Eli Lilly Needs Its Animal Spirits
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Expands Pet Vaccines Portfolio With Boehringer Acquisition,2016-10-05 14:35:27 +0000,http://finance.yahoo.com/news/eli-lilly-expands-pet-vaccines-143527881.html,Eli Lilly Expands Pet Vaccines Portfolio With Boehringer Acquisition
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Stock Gains on $885 Million Boehringer Ingelheim Pet Vaccine Deal,2016-10-05 14:19:00 +0000,https://www.thestreet.com/story/13842341/1/eli-lilly-lly-stock-gains-on-885-million-boehringer-ingelheim-pet-vaccine-deal.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly (LLY) Stock Gains on $885 Million Boehringer Ingelheim Pet Vaccine Deal
LLY,LLY:US,BBG000BNBDC2,Lilly Highlights Advancements in its Oncology Portfolio with New Data at ESMO 2016,2016-10-05 12:38:07 +0000,http://www.publicnow.com/view/4900A898F1058F248CE5E1D4787929BD600F358E,"[at noodls] - INDIANAPOLIS, Oct. 5, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during ..."
LLY,LLY:US,BBG000BNBDC2,Merrill Lynch Out With 10 Top US Stock Ideas for Q4,2016-10-05 12:20:50 +0000,http://247wallst.com/investing/2016/10/05/merrill-lynch-out-with-10-top-us-stock-ideas-for-q4/,Merrill Lynch Out With 10 Top US Stock Ideas for Q4
LLY,LLY:US,BBG000BNBDC2,Lilly to buy Boehringer's U.S. pet vaccines unit,2016-10-05 12:03:12 +0000,http://finance.yahoo.com/news/lilly-buy-boehringers-u-pet-120312402.html,Lilly to buy Boehringer's U.S. pet vaccines unit
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio,2016-10-05 11:43:27 +0000,http://www.wsj.com/articles/eli-lilly-to-buy-boehringer-ingelheim-pet-vaccines-portolio-for-885-million-1475667529?mod=yahoo_hs,[$$] Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
LLY,LLY:US,BBG000BNBDC2,Eli Lilly's Elanco to acquire Boheringer Inghelheim's U.S. rabies vaccine business for $885 million,2016-10-05 11:13:13 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E1DA4168-B481-4BBE-8B85-3BB15D1FF84D&siteid=yhoof2,Eli Lilly's Elanco to acquire Boheringer Inghelheim's U.S. rabies vaccine business for $885 million
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to buy Boehringer Ingelheim's U.S. pet vaccines unit,2016-10-05 11:05:17 +0000,http://finance.yahoo.com/news/eli-lilly-buy-boehringer-ingelheims-110517520.html,Eli Lilly to buy Boehringer Ingelheim's U.S. pet vaccines unit
LLY,LLY:US,BBG000BNBDC2,"Boehringer Ingelheim Vetmedica Inc. Enters Into an Agreement to Sell U.S. Feline, Canine and Rabies Vaccines Portfolio to Elanco Animal Health",2016-10-05 11:00:00 +0000,http://finance.yahoo.com/news/boehringer-ingelheim-vetmedica-inc-enters-110000625.html,"[PR Newswire] - ST. JOSEPH, Mo., Oct. 5, 2016 /PRNewswire/ -- Boehringer Ingelheim Vetmedica Inc. (BIVI) today announced an agreement with Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), to sell ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Buys Pet Vaccines From Boehringer for $885 Million,2016-10-05 10:45:32 +0000,http://www.bloomberg.com/news/articles/2016-10-05/lilly-to-buy-animal-vaccines-from-boehringer-for-885-million?cmpid=yhoo.headline,Lilly Buys Pet Vaccines From Boehringer for $885 Million
LLY,LLY:US,BBG000BNBDC2,"Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio",2016-10-05 10:45:00 +0000,http://finance.yahoo.com/news/elanco-animal-health-enters-agreement-104500451.html,"[PR Newswire] - GREENFIELD, Ind., Oct. 5, 2016 /PRNewswire/ -- Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business; subject ..."
LLY,LLY:US,BBG000BNBDC2,U.S. Hot Stocks: Hot Stocks to Watch,2016-10-05 09:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e67b9UpbAPg/us-hot-stocks-hot-stocks-to-watch-20161005-00573,U.S. Hot Stocks: Hot Stocks to Watch
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio,2016-10-05 08:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j303XdD6gGk/eli-lilly-to-buy-boehringer-ingelheim-pet-vaccines-portfolio-20161005-00367,Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Buy Boehringer Ingelheim Pet Vaccines Portolio for $885 Million,2016-10-05 07:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dnymujw47fg/eli-lilly-to-buy-boehringer-ingelheim-pet-vaccines-portolio-for-885-million-20161005-00288,Eli Lilly To Buy Boehringer Ingelheim Pet Vaccines Portolio for $885 Million
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Unit To Buy BIVI's U.S. Feline, Canine And Rabies Vaccines Portfo",2016-10-05 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lmPMG7nr4cE/eli-lilly-unit-to-buy-bivis-us-feline-canine-and-rabies-vaccines-portfo-20161005-00236,"Eli Lilly Unit To Buy BIVI's U.S. Feline, Canine And Rabies Vaccines Portfo"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly Unit To Buy BIVI's U.S. Feline, Canine And Rabies Vaccines Portfo",2016-10-05 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLcQ5R9-Qps/eli-lilly-unit-to-buy-bivis-us-feline-canine-and-rabies-vaccines-portfo-20161005-01060,"Eli Lilly Unit To Buy BIVI's U.S. Feline, Canine And Rabies Vaccines Portfo"
LLY,LLY:US,BBG000BNBDC2,Alkermes Commences Metabolic Study on Schizophrenia Drug,2016-10-05 00:42:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NSBEUkJOFUE/alkermes-commences-metabolic-study-on-schizophrenia-drug-cm688866,Alkermes plc ALKS announced that it has initiated a phase I study to evaluate the metabolic effects of its experimental schizophrenia candidate ALKS 3831 The randomized double blind parallel group study willassess the effects of ALKS 3831 on insulin sensitivity lipid metabolism and
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date And Conference Call For Third-Quarter 2016 Financial Results Announcement,2016-10-04 19:08:05 +0000,http://www.publicnow.com/view/1FB2F69DF61337A5F1FF7E4702797DD207E90746,"[at noodls] - INDIANAPOLIS, Oct. 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2016 on Tuesday, October 25, 2016. Lilly will also conduct a conference ..."
LLY,LLY:US,BBG000BNBDC2,J&J's Psoriasis Drug Shows Superior Efficacy Over Humira,2016-10-03 21:43:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dm54KrC7b1c/jjs-psoriasis-drug-shows-superior-efficacy-over-humira-cm688124,Johnson amp Johnson JNJ subsidiary Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab over AbbVie Inc s ABBV drug Humira in the treatment of moderate to severe plaque psoriasis Data from the VOYAGE
LLY,LLY:US,BBG000BNBDC2,J&J's Psoriasis Drug Shows Superior Efficacy Over Humira,2016-10-03 19:39:07 +0000,http://finance.yahoo.com/news/j-js-psoriasis-drug-shows-193907010.html,J&J's Psoriasis Drug Shows Superior Efficacy Over Humira
LLY,LLY:US,BBG000BNBDC2,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success",2016-10-03 18:12:14 +0000,http://finance.yahoo.com/news/one-experts-view-eli-lillys-181214267.html,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success"
LLY,LLY:US,BBG000BNBDC2,What Will Drive Novo Nordisk’s Growth in Diabetes and Hemophilia?,2016-10-03 15:05:00 +0000,http://marketrealist.com/2016/09/late-stage-research-pipeline-may-drive-novo-nordisks-growth-diabetes-haemophilia-segments/?utm_source=yahoo&utm_medium=feed,What Will Drive Novo Nordisk’s Growth in Diabetes and Hemophilia?
LLY,LLY:US,BBG000BNBDC2,"Halozyme Therapeutics, Inc. (HALO) Keeping Good Company",2016-09-30 22:22:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGE-efggO9U/halozyme-therapeutics-inc-halo-keeping-good-company-cm687386,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Investing in biotech companies with continued quarterly losses is always a risky endeavor but the technical outlook and partnerships can play an important role in deciding when to get into
LLY,LLY:US,BBG000BNBDC2,Prothena Builds On Psoriasis Science For Arthritis Treatment,2016-09-30 20:54:31 +0000,http://www.investors.com/news/technology/prothena-builds-on-psoriasis-science-for-arthritis-treatment/,Prothena Builds On Psoriasis Science For Arthritis Treatment
LLY,LLY:US,BBG000BNBDC2,What Will Gilead Try Buying Next? Polls Offer Some 'Incyte',2016-09-30 20:20:31 +0000,http://www.investors.com/news/technology/post-medivation-flop-to-pfizer-what-will-gilead-try-buying-next/,What Will Gilead Try Buying Next? Polls Offer Some 'Incyte'
LLY,LLY:US,BBG000BNBDC2,SunTrust Has Large Cap Dividend Pharma Stocks to Buy Now,2016-09-30 12:25:30 +0000,http://247wallst.com/healthcare-business/2016/09/30/suntrust-has-large-cap-dividend-pharma-stocks-to-buy-now/,SunTrust Has Large Cap Dividend Pharma Stocks to Buy Now
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk Announces Job Cuts,2016-09-30 01:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0WBpbTe6AUc/novo-nordisk-announces-job-cuts-20160930-00020,Novo Nordisk Announces Job Cuts
LLY,LLY:US,BBG000BNBDC2,"Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market",2016-09-29 20:09:25 +0000,http://www.investors.com/news/technology/amgen-migraine-drug-likely-to-beat-eli-lilly-alder-teva-to-market/,"Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market"
LLY,LLY:US,BBG000BNBDC2,The Diabetes Price War Claims Casualties,2016-09-29 17:34:36 +0000,http://www.bloomberg.com/gadfly/articles/2016-09-29/novo-nordisk-job-cuts-diabetes-drug-price-war-casualties?cmpid=yhoo.headline,The Diabetes Price War Claims Casualties
LLY,LLY:US,BBG000BNBDC2,Geographic Diversification Has Helped Novo Nordisk Offset Modest US Sales,2016-09-29 17:16:39 +0000,http://marketrealist.com/2016/09/geographic-diversification-helped-novo-nordisk-partially-offset-modest-u-s-sales-2016/?utm_source=yahoo&utm_medium=feed,Geographic Diversification Has Helped Novo Nordisk Offset Modest US Sales
LLY,LLY:US,BBG000BNBDC2,7 Healthcare Stocks in Focus on World Heart Day,2016-09-29 16:24:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a05pILds2Pk/7-healthcare-stocks-in-focus-on-world-heart-day-cm686605,Every year on Sep 29 World Heart Day is observed to raise awareness about cardiovascular CV diseases including heart disease and stroke The focus is on creating heart healthy environments that will help reduce cardiovascular risk be it at work or at home According to the World
LLY,LLY:US,BBG000BNBDC2,"VYM, IBM, WMT, LLY: ETF Inflow Alert",2016-09-29 16:22:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/epYc3hed30o/vym-ibm-wmt-lly-etf-inflow-alert-cm686583,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 61 9 million dollar inflow that s a 0 4 increase week over week
LLY,LLY:US,BBG000BNBDC2,7 Healthcare Stocks in Focus on World Heart Day,2016-09-29 14:03:02 +0000,http://finance.yahoo.com/news/7-healthcare-stocks-focus-world-140302072.html,7 Healthcare Stocks in Focus on World Heart Day
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : September 28, 2016",2016-09-28 14:33:00 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-value-analysis-nyselly-september-28-2016/,"Eli Lilly & Co. – Value Analysis (NYSE:LLY) : September 28, 2016"
LLY,LLY:US,BBG000BNBDC2,Merrill Lynch Makes a Huge Change to Prestigious US 1 Portfolio,2016-09-28 14:05:02 +0000,http://247wallst.com/investing/2016/09/28/merrill-lynch-makes-a-huge-change-to-prestigious-us-1-portfolio/,Merrill Lynch Makes a Huge Change to Prestigious US 1 Portfolio
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly rises on Goldman recommendation,2016-09-27 20:41:11 +0000,"http://www.ft.com/cms/s/77d8d354-84c5-11e6-a29c-6e7d9515ad15,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Eli Lilly shares will rally by almost a fifth over the next year given the pharmaceutical group's slim reliance on drug price increases and a strong roster of treatments in its pipeline, Goldman Sachs ..."
LLY,LLY:US,BBG000BNBDC2,Biotech Lilly Upgraded On Alzheimer's Drug's $7.5 Billion Potential,2016-09-27 20:25:34 +0000,http://www.investors.com/news/technology/biotech-lilly-upgraded-on-7-5-billion-alzheimers-drug-potential/,Biotech Lilly Upgraded On Alzheimer's Drug's $7.5 Billion Potential
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Poised For an Era of Rapid Growth (LLY),2016-09-27 20:19:00 +0000,http://www.investopedia.com/news/eli-lilly-poised-era-rapid-growth-lly/?partner=YahooSA,Eli Lilly Poised For an Era of Rapid Growth (LLY)
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Upgraded at Goldman, Jim Cramer Weighs In",2016-09-27 17:48:00 +0000,https://www.thestreet.com/story/13753770/1/eli-lilly-lly-upgraded-at-goldman-jim-cramer-weighs-in.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly (LLY) Upgraded at Goldman, Jim Cramer Weighs In"
LLY,LLY:US,BBG000BNBDC2,Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast,2016-09-27 17:30:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/27/goldman-sachs-pharma-stocks-that-need-price-hikes-to-thrive-better-find-a-new-strategy-fast/?mod=yahoobarrons&ru=yahoo,Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Stock Upgraded: What You Need to Know,2016-09-27 17:21:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ebH7jEgHR-A/eli-lilly-stock-upgraded-what-you-need-to-know-cm685417,Flat across the past 52 weeks and down 3 since the year began Eli Lilly and Co NYSE LLY has had a hard time keeping up with the rest of the stock market lately But according to one analyst that s all about to change and Lilly doesn t even need a blockbuster to prove
LLY,LLY:US,BBG000BNBDC2,Lilly to Present Latest Data for Taltz® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress,2016-09-27 17:00:00 +0000,http://finance.yahoo.com/news/lilly-present-latest-data-taltz-170000559.html,[CNW Group] - Lilly to Present Latest Data for Taltz® (ixekizumab) in Psoriasis at the European Academy of Dermatology and Venereology (EADV) Annual Congress
LLY,LLY:US,BBG000BNBDC2,Pfizer (PFE) to Stay Together as a Single Company After All,2016-09-27 16:24:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iSyZA5gjw2w/pfizer-pfe-to-stay-together-as-a-single-company-after-all-cm685345,Drug maker Pfizer Inc PFE has finally decided not to split its two segments Innovative Health IH and Essential Health EH into two publicly traded companies For years the company has been facing pressure from investors and analysts alike to split into two separate companies in
LLY,LLY:US,BBG000BNBDC2,Call of the day: Eli Lilly,2016-09-27 16:24:00 +0000,http://finance.yahoo.com/video/call-day-eli-lilly-162400806.html,Call of the day: Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Stock Upgraded: What You Need to Know,2016-09-27 16:06:27 +0000,http://www.fool.com/investing/2016/09/27/eli-lilly-stock-upgraded-what-you-need-to-know.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Eli Lilly Stock Upgraded: What You Need to Know
LLY,LLY:US,BBG000BNBDC2,Array (ARRY) Hits 52-Week High on Positive Phase III Data,2016-09-27 15:24:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fAmlk8KAmqk/array-arry-hits-52-week-high-on-positive-phase-iii-data-cm685278,Array BioPharma Inc ARRY along with its partner Pierre Fabre announced positive top line data from part 1 of the phase III study COLUMBUS on a combination of encorafenib BRAF inhibitor and binimetinib MEK inhibitor for the treatment of BRAF mutant advanced unresectable or
LLY,LLY:US,BBG000BNBDC2,Pfizer (PFE) to Stay Together as a Single Company After All,2016-09-27 14:44:02 +0000,http://finance.yahoo.com/news/pfizer-pfe-stay-together-single-144402448.html,Pfizer (PFE) to Stay Together as a Single Company After All
LLY,LLY:US,BBG000BNBDC2,"Top 5 Pharma stocks by value : September 27, 2016",2016-09-27 14:29:04 +0000,http://www.capitalcube.com/blog/index.php/top-5-pharma-stocks-by-value-september-27-2016/,"Top 5 Pharma stocks by value : September 27, 2016"
LLY,LLY:US,BBG000BNBDC2,Biosimilars in Limelight on FDA Approval of Amgen Drug,2016-09-27 14:24:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yrJXyQi5CLs/biosimilars-in-limelight-on-fda-approval-of-amgen-drug-cm685240,Late last week the FDA approved yet another biosimilar product biotech giant Amgen Inc s AMGN Amjevita adalimumab atto Amjevita has been approved for use in all eligible indications of the reference product AbbVie Inc s ABBV blockbuster drug Humira adalimumab which is used for a
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: This is Gonna Be Good,2016-09-27 13:55:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/27/eli-lilly-this-is-gonna-be-good/?mod=yahoobarrons&ru=yahoo,Eli Lilly: This is Gonna Be Good
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Stock Higher, Upgraded at Goldman",2016-09-27 12:41:00 +0000,https://www.thestreet.com/story/13752857/1/eli-lilly-lly-stock-higher-upgraded-at-goldman.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly (LLY) Stock Higher, Upgraded at Goldman"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : September 27, 2016",2016-09-27 12:34:32 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-breached-its-50-day-moving-average-in-a-bearish-manner-lly-us-september-27-2016/,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : September 27, 2016"
LLY,LLY:US,BBG000BNBDC2,Lilly Expands Use of Salesforce Platform to Build More Apps and Put Patients at the Center of Their Care,2016-09-27 12:09:09 +0000,http://www.publicnow.com/view/4146C878B396ABC19A28E6FD57D6869FEDD182F1,"[at noodls] - SAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ -- Salesforce (NYSE:CRM), the Customer Success Platform and world's #1 CRM company, today announced that Eli Lilly and Company (NYSE: LLY) -- a Fortune 500 company ..."
LLY,LLY:US,BBG000BNBDC2,Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval,2016-09-26 13:22:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/krEMIMDkzoM/amgens-biosimilar-of-abbvies-humira-gets-fda-approval-cm684356,Amgen Inc AMGN today announced the approval of Amjevita adalimumab atto a biosimilar version to AbbVie Inc s ABBV rheumatoid arthritis RA drug Humira Amjevita has been approved for the same indications that Humira is being used for including rheumatoid arthritis RA
LLY,LLY:US,BBG000BNBDC2,“Don’t fire until you see the whites of their eyes”,2016-09-25 17:04:26 +0000,http://finance.yahoo.com/tumblr/blog-dont-fire-until-you-see-the-whites-of-their-170432457.html,“Don’t fire until you see the whites of their eyes”
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO",2016-09-23 14:24:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UDVTQGxu0qM/pharma-stock-roundup-allergan-acquisitions-in-focus-jj-to-buy-abbotts-amo-cm683695,Once again acquisitions and deals were in focus in the pharma sector with Allergan AGN announcing a couple of back to back deals including one worth up to 1 695 billion Meanwhile industry bellwether Johnson amp Johnson JNJ signed an agreement to acquire Abbott s ABT eye care segment
LLY,LLY:US,BBG000BNBDC2,[video]Takeover Chatter Around Clovis May Be Overdone,2016-09-23 13:28:00 +0000,https://www.thestreet.com/story/13750094/1/takeover-chatter-around-clovis-may-be-overdone.html?puc=yahoo&cm_ven=YAHOO,[video]Takeover Chatter Around Clovis May Be Overdone
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO",2016-09-23 12:00:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-allergan-acquisitions-120012919.html,"Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO"
LLY,LLY:US,BBG000BNBDC2,New Setback for Sanofi's Lantus Increases Need for M&A,2016-09-22 13:56:00 +0000,https://www.thestreet.com/story/13748866/1/new-setback-for-sanofi-s-lantus-increases-need-for-m-amp-a.html?puc=yahoo&cm_ven=YAHOO,New Setback for Sanofi's Lantus Increases Need for M&A
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Can't Put the Petal to the Metal,2016-09-21 20:03:00 +0000,http://realmoney.thestreet.com/articles/09/21/2016/eli-lilly-cant-put-petal-metal?puc=yahoo&cm_ven=YAHOO,Eli Lilly Can't Put the Petal to the Metal
LLY,LLY:US,BBG000BNBDC2,Sanofi Sues Merck Over Patent Infringement,2016-09-21 17:20:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FmXlYyXbWIk/sanofi-sues-merck-over-patent-infringement-cm682487,French pharmaceutical giant Sanofi SA SNY filed a lawsuit against Merck amp Co MRK for supposed patent infringements last Friday The company has taken action in an attempt to prevent its American rival from releasing a competing version of its best selling insulin
LLY,LLY:US,BBG000BNBDC2,Stocks Futures Buoyed by Bank of Japan Move on Long-Term Rates; Waiting For FOMC,2016-09-21 13:40:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dtJV2GLUadE/stocks-futures-buoyed-by-bank-of-japan-move-on-long-term-rates-waiting-for-fomc-cm682507,Stocks are set to open with sizable gains Wednesday as global investors react to the surprise move by the Bank of Japan to target long term interest rates and ahead of today s Federal Open Market Committee meeting Dow futures are 70 points above fair value with financial and consumer
LLY,LLY:US,BBG000BNBDC2,Sanofi Sues Merck Over Patent Infringement,2016-09-20 18:00:12 +0000,http://finance.yahoo.com/news/sanofi-sues-merck-over-patent-180012625.html,Sanofi Sues Merck Over Patent Infringement
LLY,LLY:US,BBG000BNBDC2,"VYM, IBM, WMT, LLY: Large Inflows Detected at ETF",2016-09-20 16:22:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8n72zxWy0iE/vym-ibm-wmt-lly-large-inflows-detected-at-etf-cm682021,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard High Dividend Yield ETF Symbol VYM where we have detected an approximate 82 1 million dollar inflow that s a 0 5 increase week over week
LLY,LLY:US,BBG000BNBDC2,"Teva, Eli Lilly Have Migraine Treatments in Trial Phases",2016-09-20 15:04:57 +0000,http://marketrealist.com/2016/09/teva-pharmaceutical-eli-lilly-continue-explore-opportunities-migraine-segment/?utm_source=yahoo&utm_medium=feed,"Teva, Eli Lilly Have Migraine Treatments in Trial Phases"
LLY,LLY:US,BBG000BNBDC2,A Breakdown Here In This Sector Would Not Be Healthy,2016-09-19 22:50:37 +0000,http://finance.yahoo.com/tumblr/blog-a-breakdown-here-in-this-sector-would-not-be-225043635.html,A Breakdown Here In This Sector Would Not Be Healthy
LLY,LLY:US,BBG000BNBDC2,Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?,2016-09-19 18:22:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AumUEQoW84E/could-this-alzheimers-disease-drug-really-be-worth-20-billion-cm681485,Biogen s NASDAQ BIIB 160 plaque busting Alzheimer s disease AD drug candidate aducanumab could represent a jaw dropping 20 billion peak commercial opportunity for the company and its shareholders Putting this monstrous figure into context this experimental medicine has
LLY,LLY:US,BBG000BNBDC2,"Sanofi SA (ADR) (SNY) Sues Merck & Co., Inc. (MRK) Over Multiple Patent Infringements",2016-09-19 18:21:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZvHpM-Aag5s/sanofi-sa-adr-sny-sues-merck-co-inc-mrk-over-multiple-patent-infringements-cm681465,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Sanofi SA ADR 160 NYSE SNY is suing 160 Merck amp Co Inc 160 NYSE MRK for what it claims are several 160 instances of patent
LLY,LLY:US,BBG000BNBDC2,Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?,2016-09-19 17:16:18 +0000,http://www.fool.com/investing/2016/09/19/could-this-alzheimers-disease-drug-really-be-worth.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab,2016-09-19 16:23:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cux0zgVfUvM/eli-lilly-lly-gets-favorable-chmp-opinion-for-olaratumab-cm681325,Eli Lilly and Company LLY announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has issued a positive opinion for a conditional marketing authorization of olaratumab in the treatment of advanced soft tissue sarcoma STS Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Five Dividend Stocks Billionaire Steve Cohen Really Likes,2016-09-19 15:50:48 +0000,http://www.insidermonkey.com/blog/five-dividend-stocks-billionaire-steve-cohen-really-likes-475207/,Five Dividend Stocks Billionaire Steve Cohen Really Likes
LLY,LLY:US,BBG000BNBDC2,"This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective",2016-09-19 15:24:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/annci5qomcc/this-diabetes-breakthrough-is-great-news-or-terrible-news-depending-on-your-perspective-cm681268,Image source Getty Images It may not be as deadly as cancer or heart disease but diabetes was the seventh leading cause of death in the United States as of 2014 According to the American Diabetes Association 29 1 million people in the U S had diabetes as of 2012 some 8 million
LLY,LLY:US,BBG000BNBDC2,"Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement",2016-09-19 14:47:00 +0000,https://www.thestreet.com/story/13743633/1/sanofi-fighting-a-losing-battle-sues-merck-for-alleged-patent-infrigement.html?puc=yahoo&cm_ven=YAHOO,"Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab,2016-09-19 14:25:02 +0000,http://finance.yahoo.com/news/eli-lilly-lly-gets-favorable-142502536.html,Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab
LLY,LLY:US,BBG000BNBDC2,"This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective",2016-09-19 13:45:49 +0000,http://www.fool.com/investing/2016/09/19/this-diabetes-breakthrough-is-great-news-or-terrib.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective"
LLY,LLY:US,BBG000BNBDC2,What Analysts Think about Bristol-Myers Squibb,2016-09-19 12:05:21 +0000,http://marketrealist.com/2016/09/inside-bristol-myers-squibb-analyst-recommendations-2016/?utm_source=yahoo&utm_medium=feed,What Analysts Think about Bristol-Myers Squibb
LLY,LLY:US,BBG000BNBDC2,Sanofi Files Suit Against Merck,2016-09-19 08:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/99WoS74zfzU/sanofi-files-suit-against-merck-20160919-00313,Sanofi Files Suit Against Merck
LLY,LLY:US,BBG000BNBDC2,There's something odd about the way insulin prices change,2016-09-17 19:00:00 +0000,http://finance.yahoo.com/news/theres-something-odd-way-insulin-190000509.html,There's something odd about the way insulin prices change
LLY,LLY:US,BBG000BNBDC2,What Do 2016 Valuation Multiples Say about Bristol-Myers?,2016-09-16 22:27:33 +0000,http://marketrealist.com/2016/09/valuation-multiples-tell-bristol-myers-squibb-2016/?utm_source=yahoo&utm_medium=feed,What Do 2016 Valuation Multiples Say about Bristol-Myers?
LLY,LLY:US,BBG000BNBDC2,Will Eli Lilly (LLY) Stock Be Helped by European Drug Recommendation?,2016-09-16 17:36:00 +0000,https://www.thestreet.com/story/13743032/1/will-eli-lilly-lly-stock-be-helped-by-european-drug-recommendation.html?puc=yahoo&cm_ven=YAHOO,Will Eli Lilly (LLY) Stock Be Helped by European Drug Recommendation?
LLY,LLY:US,BBG000BNBDC2,"CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma",2016-09-16 12:38:02 +0000,http://www.publicnow.com/view/B6590DEDC94C7BCD15F9C5347631FACCCF86E418,"[at noodls] - INDIANAPOLIS, Sept. 16, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued ..."
LLY,LLY:US,BBG000BNBDC2,Analyst Price Targets and Recommendations for Sanofi,2016-09-16 12:04:24 +0000,http://marketrealist.com/2016/09/analyst-price-targets-and-recommendations-for-sanofi/?utm_source=yahoo&utm_medium=feed,Analyst Price Targets and Recommendations for Sanofi
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: CHMP Issues Positive Opinion On Conditional Approval For Olaratumab,2016-09-16 07:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qxD2eO6R8hY/eli-lilly-chmp-issues-positive-opinion-on-conditional-approval-for-olaratumab-20160916-00167,Eli Lilly: CHMP Issues Positive Opinion On Conditional Approval For Olaratumab
LLY,LLY:US,BBG000BNBDC2,A 93-year-old drug that can cost more than a mortgage payment tells us everything that's wrong with American healthcare,2016-09-16 04:02:00 +0000,http://finance.yahoo.com/news/necessary-drug-costing-more-mortgage-040200672.html,A 93-year-old drug that can cost more than a mortgage payment tells us everything that's wrong with American healthcare
LLY,LLY:US,BBG000BNBDC2,Biotech bright spots,2016-09-15 21:42:00 +0000,http://finance.yahoo.com/video/biotech-bright-spots-214200999.html,Biotech bright spots
LLY,LLY:US,BBG000BNBDC2,"Boston Mayor Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter, Receive Alzheimer's Readiness Award",2016-09-15 16:15:00 +0000,http://finance.yahoo.com/news/boston-mayor-walsh-alzheimers-association-161500257.html,"[PR Newswire] - BOSTON, Sept. 15, 2016 /PRNewswire/ -- Boston Mayor Martin J. Walsh and the Alzheimer's Association, Massachusetts/New Hampshire Chapter were recognized today for their efforts to ensure the city of Boston is prepared for the fiscal and social impact of Alzheimer's disease. The Alzheimer's Readiness Award was presented to Mayor Walsh and James Wessler, CEO of the Massachusetts/New Hampshire Chapter of the Alzheimer's Association, on behalf of the Alzheimer's Readiness Project, an initiative of Eli Lilly and Company (LLY) committed to inspiring action by fostering a deeper understanding of Alzheimer's, its evolving science and the public health crisis it poses. The award recognizes their collaborative efforts to partner across government, healthcare and advocacy organizations to develop action plans that prepare the city to effectively address the growing crisis of Alzheimer's disease."
LLY,LLY:US,BBG000BNBDC2,A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare,2016-09-15 15:11:01 +0000,http://finance.yahoo.com/news/93-old-drug-children-cant-151101570.html,A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare
LLY,LLY:US,BBG000BNBDC2,How Sanofi’s Various Franchises Performed in 2Q16,2016-09-14 22:04:13 +0000,http://marketrealist.com/2016/09/how-sanofis-various-franchises-performed-in-2q16/?utm_source=yahoo&utm_medium=feed,How Sanofi’s Various Franchises Performed in 2Q16
LLY,LLY:US,BBG000BNBDC2,How Sanofi’s Franchises Could Perform into 2017,2016-09-14 20:04:31 +0000,http://marketrealist.com/2016/09/how-sanofis-franchises-could-perform-into-2017/?utm_source=yahoo&utm_medium=feed,How Sanofi’s Franchises Could Perform into 2017
LLY,LLY:US,BBG000BNBDC2,"Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career",2016-09-14 14:48:06 +0000,http://www.publicnow.com/view/4A7215E7B3151801A58E57960A99918C5ED41BFF,"[at noodls] - INDIANAPOLIS, Sept. 14, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted ..."
LLY,LLY:US,BBG000BNBDC2,"Elanco's Antibiotic Stewardship Plan Yields Innovation, Scientific Advancements",2016-09-14 10:00:00 +0000,http://finance.yahoo.com/news/elancos-antibiotic-stewardship-plan-yields-100000342.html,"[PR Newswire] - GREENFIELD, Ind., Sept. 14, 2016 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (LLY), reports on scientific and structural advancements made toward enhancing responsible antibiotic use and bringing new alternatives to decrease the need for shared-class antibiotics in livestock."
LLY,LLY:US,BBG000BNBDC2,Biotech Stocks Bounce Back in Monday Trading: 3 Picks,2016-09-13 15:49:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kjcnaOB1Djo/biotech-stocks-bounce-back-in-monday-trading-3-picks-cm678799,The healthcare sector has been choppy since the beginning of 2016 continuing the volatile trend from the second half of 2015 Media and political focus on the high prices of drugs have made things difficult for the pharma biotech sector since the past one year Democratic presidential
LLY,LLY:US,BBG000BNBDC2,Jefferies Issues Top Pharma and Biohealth Stocks to Buy,2016-09-13 14:25:04 +0000,http://247wallst.com/healthcare-business/2016/09/13/jefferies-issues-top-pharma-and-biohealth-stocks-to-buy/,Jefferies Issues Top Pharma and Biohealth Stocks to Buy
LLY,LLY:US,BBG000BNBDC2,Eli Lilly To Present At Morgan Stanley Global Conference ; Webcast At 10:35 AM,2016-09-13 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1ASeqlbyWOs/eli-lilly-to-present-at-morgan-stanley-global-conference--webcast-at-1035-am-20160913-00639,Eli Lilly To Present At Morgan Stanley Global Conference ; Webcast At 10:35 AM
LLY,LLY:US,BBG000BNBDC2,How the Tides Are Turning in Alzheimer's Research,2016-09-12 20:10:00 +0000,http://www.fool.com/investing/2016/09/12/how-the-tides-are-shifting-in-alzheimers-research.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How the Tides Are Turning in Alzheimer's Research
LLY,LLY:US,BBG000BNBDC2,What's driving biotech?,2016-09-12 19:43:00 +0000,http://finance.yahoo.com/video/whats-driving-biotech-194300495.html,What's driving biotech?
LLY,LLY:US,BBG000BNBDC2,How the Tides Are Turning in Alzheimer's Research,2016-09-12 18:32:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dq_227I0xcg/how-the-tides-are-turning-in-alzheimers-research-cm678162,Image source Getty Images Here s how James Lah the lead researcher for the Alzheimer s Research Center at Emory explains what s coming in Alzheimer s disease The baby boomers are now turning 65 at the rate of 10 000 a day And one in nine of that 10 000 is going to have
LLY,LLY:US,BBG000BNBDC2,Why Novo Nordisk Stock Dropped 18.9% in August,2016-09-12 14:33:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dKWMZ-Kp2cY/why-novo-nordisk-stock-dropped-189-in-august-cm677890,Image source Getty Images What happened Shares of Novo Nordisk NYSE NVO 160 a Danish pharma with a large presence in diabetes care fell 18 9 in August according to data from S amp P Global Market Intelligence A depressing outlook for next year because of
LLY,LLY:US,BBG000BNBDC2,Analysts Forecast 10% Gains Ahead For The Holdings of JKD,2016-09-12 14:31:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GsUte9-xDSo/analysts-forecast-10-gains-ahead-for-the-holdings-of-jkd-cm677845,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
LLY,LLY:US,BBG000BNBDC2,Why Novo Nordisk Stock Dropped 18.9% in August,2016-09-12 13:24:52 +0000,http://www.fool.com/investing/2016/09/12/why-novo-nordisk-stock-dropped-189-in-august.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Novo Nordisk Stock Dropped 18.9% in August
LLY,LLY:US,BBG000BNBDC2,4 Safe Large Cap Dividend Stocks to Buy as Market Risk Increases,2016-09-12 12:20:55 +0000,http://247wallst.com/investing/2016/09/12/4-safe-large-cap-dividend-stocks-to-buy-as-market-risk-increases/,4 Safe Large Cap Dividend Stocks to Buy as Market Risk Increases
LLY,LLY:US,BBG000BNBDC2,Sanofi-Backed Lexicon Diabetes Drug Scores In Type 1 Diabetes,2016-09-09 20:05:38 +0000,http://www.investors.com/news/technology/sanofi-backed-lexicon-diabetes-drug-scores-in-type-1-diabetes/,Sanofi-Backed Lexicon Diabetes Drug Scores In Type 1 Diabetes
LLY,LLY:US,BBG000BNBDC2,"Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree?",2016-09-09 17:50:13 +0000,http://www.insidermonkey.com/blog/inside-the-fda-eli-lilly-and-co-lly-jardiance-aims-at-proving-cardiovascular-benefit-in-diabetes-will-fda-agree-473396/,"Inside The FDA: Eli Lilly and Co (LLY) Jardiance Aims at Proving Cardiovascular Benefit in Diabetes, Will FDA Agree?"
LLY,LLY:US,BBG000BNBDC2,"Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib",2016-09-09 14:34:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gg7G3Kk_UQY/pharma-stock-roundup-drug-pricing-remains-in-focus-merck-drops-odanacatib-cm676813,While drug pricing and Mylan MYL remained in the news this week as well companies like Merck MRK Bristol Myers BMY and Novo Nordisk NVO came out with regulatory pipeline updates Recap of the Week s Most Important Stories Mylan now Being Investigated by New York AG Allergan
LLY,LLY:US,BBG000BNBDC2,How Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August,2016-09-09 13:33:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W-hx4VV7WYA/how-aratana-therapeutics-inc-clawed-its-way-to-a-17-gain-in-august-cm676703,Image source Flickr user Brad Holt What happened Shares of Aratana Therapeutics NASDAQ PETX a small cap biotech company solely focused on developing therapies to treat companion pets surged 17 during the month of August according to data from S amp P Global
LLY,LLY:US,BBG000BNBDC2,10 Must-Know Biotech Stock Events to Close Out 2016,2016-09-09 13:14:00 +0000,https://www.thestreet.com/story/13699729/1/10-must-know-biotech-stock-events-to-close-out-2016.html?puc=yahoo&cm_ven=YAHOO,10 Must-Know Biotech Stock Events to Close Out 2016
LLY,LLY:US,BBG000BNBDC2,[$$] Surge in antidepressant use by children,2016-09-08 23:01:26 +0000,"http://www.ft.com/cms/s/378743a8-75cf-11e6-bf48-b372cdb1043a,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[at Financial Times] - Antidepressant prescriptions for children and teenagers have increased by almost a third in the past decade - and the majority of new prescriptions are for a drug that is not licensed for use in young ...
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly Stock Can Cure What Ails Your Portfolio,2016-09-08 20:51:00 +0000,http://www.barrons.com/articles/eli-lilly-stock-can-cure-what-ails-your-portfolio-1473367876?mod=yahoobarrons&ru=yahoo,[$$] Eli Lilly Stock Can Cure What Ails Your Portfolio
LLY,LLY:US,BBG000BNBDC2,Lilly Upgraded On Pipeline Prospects; AbbVie Downgraded,2016-09-08 20:04:45 +0000,http://www.investors.com/news/technology/lilly-upgraded-on-pipeline-prospects-abbvie-downgraded/,Lilly Upgraded On Pipeline Prospects; AbbVie Downgraded
LLY,LLY:US,BBG000BNBDC2,"Street Talk: PIR, LLY & more",2016-09-08 18:42:00 +0000,http://finance.yahoo.com/video/street-talk-pir-lly-more-184200743.html,"Street Talk: PIR, LLY & more"
LLY,LLY:US,BBG000BNBDC2,"4 Stocks, 4 trades: TSCO, SVU & more",2016-09-08 16:39:00 +0000,http://finance.yahoo.com/video/4-stocks-4-trades-tsco-163900557.html,"4 Stocks, 4 trades: TSCO, SVU & more"
LLY,LLY:US,BBG000BNBDC2,"IXJ, MDT, LLY, BIIB: Large Outflows Detected at ETF",2016-09-08 16:17:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dDjQ0tR2BLA/ixj-mdt-lly-biib-large-outflows-detected-at-etf-cm676269,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Global Healthcare ETF Symbol IXJ where we have detected an approximate 35 7 million dollar outflow that s a 2 2 decrease week over week
LLY,LLY:US,BBG000BNBDC2,Put seller sees Eli Lilly on solid ground,2016-09-08 15:15:39 +0000,http://finance.yahoo.com/news/put-seller-sees-eli-lilly-151539013.html,Put seller sees Eli Lilly on solid ground
LLY,LLY:US,BBG000BNBDC2,Eli Lilly: The Power of the New,2016-09-08 14:55:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/08/eli-lilly-the-power-of-the-new/?mod=yahoobarrons&ru=yahoo,Eli Lilly: The Power of the New
LLY,LLY:US,BBG000BNBDC2,The EpiPen isn't the only drug that's more than doubled in price,2016-09-08 14:10:00 +0000,http://finance.yahoo.com/news/epipen-isnt-only-drug-thats-134952846.html,The EpiPen isn't the only drug that's more than doubled in price
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly (LLY) Stock Higher, Upgraded at JPMorgan",2016-09-08 12:54:00 +0000,https://www.thestreet.com/story/13698222/1/eli-lilly-lly-stock-higher-upgraded-at-jpmorgan.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly (LLY) Stock Higher, Upgraded at JPMorgan"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Posting Strong Gain After JPMorgan Chase Upgrade,2016-09-08 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/teovmey1_oY/eli-lilly-posting-strong-gain-after-jpmorgan-chase-upgrade-20160908-00877,Eli Lilly Posting Strong Gain After JPMorgan Chase Upgrade
LLY,LLY:US,BBG000BNBDC2,"Final Trade: LLY, SLW & more",2016-09-06 21:59:00 +0000,http://finance.yahoo.com/video/final-trade-lly-slw-more-215900564.html,"Final Trade: LLY, SLW & more"
LLY,LLY:US,BBG000BNBDC2,Here's Why Investors Should Steer Clear of Opioids,2016-09-06 16:37:00 +0000,https://www.thestreet.com/story/13693642/1/here-s-why-investors-should-steer-clear-of-opioids.html?puc=yahoo&cm_ven=YAHOO,Here's Why Investors Should Steer Clear of Opioids
LLY,LLY:US,BBG000BNBDC2,INVESTIndiana announces executive presentation schedule,2016-09-06 14:00:00 +0000,http://finance.yahoo.com/news/investindiana-announces-executive-presentation-schedule-140000261.html,"[GlobeNewswire] - Lineup highlights health sciences, banking, energy, high-tech and manufacturing Conference features inaugural Indiana Public Company of the Year Award Central Indiana Corporate Partnership CEO David Johnson's ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Recent Developments and Financial Guidance,2016-09-06 12:04:13 +0000,http://marketrealist.com/2016/09/eli-lillys-recent-developments-financial-guidance/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s Recent Developments and Financial Guidance
LLY,LLY:US,BBG000BNBDC2,Animal Health: Just as Important to Eli Lilly as Human Health,2016-09-05 15:04:16 +0000,http://marketrealist.com/2016/09/animal-health-just-important-eli-lilly-human-health/?utm_source=yahoo&utm_medium=feed,Animal Health: Just as Important to Eli Lilly as Human Health
LLY,LLY:US,BBG000BNBDC2,How Are Eli Lilly’s New Products Performing?,2016-09-05 14:04:15 +0000,http://marketrealist.com/2016/09/eli-lillys-new-products-performing/?utm_source=yahoo&utm_medium=feed,How Are Eli Lilly’s New Products Performing?
LLY,LLY:US,BBG000BNBDC2,Incyte’s Product Portfolio Includes Potentially Lucrative Drugs,2016-09-05 12:04:36 +0000,http://marketrealist.com/2016/09/incytes-product-portfolio-includes-potentially-lucrative-drugs/?utm_source=yahoo&utm_medium=feed,Incyte’s Product Portfolio Includes Potentially Lucrative Drugs
LLY,LLY:US,BBG000BNBDC2,How Did Eli Lilly’s Oncology Drug Sales Perform?,2016-09-05 12:04:15 +0000,http://marketrealist.com/2016/09/eli-lillys-oncology-drug-sales-perform/?utm_source=yahoo&utm_medium=feed,How Did Eli Lilly’s Oncology Drug Sales Perform?
LLY,LLY:US,BBG000BNBDC2,Understanding Incyte’s Revenue Stream in 2Q16,2016-09-02 20:04:05 +0000,http://marketrealist.com/2016/09/understanding-incytes-revenue-stream-2q16/?utm_source=yahoo&utm_medium=feed,Understanding Incyte’s Revenue Stream in 2Q16
LLY,LLY:US,BBG000BNBDC2,Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.,2016-09-02 15:22:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kan0jl6ecWc/biogen-biib-aducanumab-gets-fast-track-status-in-the-us-cm673990,Biogen Inc BIIB announced that the FDA has granted Fast Track designation for its investigational therapy aducanumab for the treatment of early stage Alzheimer s disease AD We note that the FDA grants Fast Track status to facilitate the development and expedite the review process
LLY,LLY:US,BBG000BNBDC2,Eli Lilly’s Antidepressant and Schizophrenia Drug Sales Are Down,2016-09-02 15:04:23 +0000,http://marketrealist.com/2016/09/eli-lillys-antidepressant-schizophrenia-drug-sales/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s Antidepressant and Schizophrenia Drug Sales Are Down
LLY,LLY:US,BBG000BNBDC2,Cialis Continues to Lead in Eli Lilly’s Cardiovascular Franchise,2016-09-02 14:04:27 +0000,http://marketrealist.com/2016/09/cialis-continues-lead-eli-lillys-cardiovascular-franchise/?utm_source=yahoo&utm_medium=feed,Cialis Continues to Lead in Eli Lilly’s Cardiovascular Franchise
LLY,LLY:US,BBG000BNBDC2,PFE to Enjoy Being Sole Provider of Key Breast Cancer Treatment,2016-09-02 14:04:10 +0000,http://marketrealist.com/2016/08/pfe-to-enjoy-being-sole-provider-of-key-breast-cancer-treatment/?utm_source=yahoo&utm_medium=feed,PFE to Enjoy Being Sole Provider of Key Breast Cancer Treatment
LLY,LLY:US,BBG000BNBDC2,Analyzing Eli Lilly’s Blockbuster Endocrinology Drugs,2016-09-02 12:04:38 +0000,http://marketrealist.com/2016/09/analyzing-eli-lillys-blockbuster-endocrinology-drugs/?utm_source=yahoo&utm_medium=feed,Analyzing Eli Lilly’s Blockbuster Endocrinology Drugs
LLY,LLY:US,BBG000BNBDC2,Why Are Hedge Funds In Love With Eli Lilly (LLY)?,2016-09-02 12:02:50 +0000,http://www.insidermonkey.com/blog/why-are-hedge-funds-in-love-with-eli-lilly-lly-471717/,Why Are Hedge Funds In Love With Eli Lilly (LLY)?
LLY,LLY:US,BBG000BNBDC2,Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status,2016-09-01 19:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1uoQ2hZvwsc/biogens-alzheimers-therapy-granted-fda-fasttrack-status-20160901-01261,Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status
LLY,LLY:US,BBG000BNBDC2,3 Things You Need to Know About Aratana Therapeutics Before Buying,2016-09-01 15:23:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eyobtLHwHgU/3-things-you-need-to-know-about-aratana-therapeutics-before-buying-cm673408,Image source Aratana Therapeutics Aratana Therapeutics NASDAQ PETX is a biotech company developing next generation medicine for pets Rising spending on pet health should provide tailwinds to demand for pet medicine but that doesn t necessarily mean that investors ought to
LLY,LLY:US,BBG000BNBDC2,How Are Eli Lilly’s Business Segments Performing?,2016-09-01 15:04:32 +0000,http://marketrealist.com/2016/09/eli-lillys-business-segments-performing/?utm_source=yahoo&utm_medium=feed,How Are Eli Lilly’s Business Segments Performing?
LLY,LLY:US,BBG000BNBDC2,A Look at the Drugs That Are Driving Eli Lilly’s Revenues,2016-09-01 14:05:28 +0000,http://marketrealist.com/2016/09/look-drugs-driving-eli-lillys-revenues/?utm_source=yahoo&utm_medium=feed,A Look at the Drugs That Are Driving Eli Lilly’s Revenues
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down,2016-09-01 13:45:28 +0000,http://sg.finance.yahoo.com/news/novo-nordisks-veteran-ceo-lars-134528197.html,Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down
LLY,LLY:US,BBG000BNBDC2,3 Things You Need to Know About Aratana Therapeutics Before Buying,2016-09-01 13:35:46 +0000,http://www.fool.com/investing/2016/09/01/3-things-you-need-to-know-about-artana-therapeutic.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Things You Need to Know About Aratana Therapeutics Before Buying
LLY,LLY:US,BBG000BNBDC2,Is Eli Lilly’s Valuation Higher than Its Peers?,2016-09-01 12:06:12 +0000,http://marketrealist.com/2016/09/eli-lillys-valuation-higher-peers/?utm_source=yahoo&utm_medium=feed,Is Eli Lilly’s Valuation Higher than Its Peers?
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down,2016-09-01 09:17:46 +0000,http://finance.yahoo.com/news/novo-nordisk-ceo-lars-rebien-071233806.html,Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down
LLY,LLY:US,BBG000BNBDC2,Eli Lilly and Co: LLY Dividend Growth is About to Change (LLY),2016-08-31 18:12:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p_6FQ1_y_QU/eli-lilly-and-co-lly-dividend-growth-is-about-to-change-lly-cm672931,Eli Lilly and Co ( LLY ) is a blue chip stock that has paid a consistent dividend since the early 1970s . The company's total
LLY,LLY:US,BBG000BNBDC2,[$$] Biogen predicts preventive drug for Alzheimer's disease,2016-08-31 17:00:55 +0000,"http://www.ft.com/cms/s/c1c6e708-6ef9-11e6-9ac1-1055824ca907,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - A senior scientist at Biogen, the large US biotech group, has predicted that potential Alzheimer's victims will be treated long before they develop symptoms, much as millions of people without heart problems ..."
LLY,LLY:US,BBG000BNBDC2,Express Scripts' New Program to Lower Diabetes Care Costs,2016-08-31 16:17:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MX-OQQLndeQ/express-scripts-new-program-to-lower-diabetes-care-costs-cm672899,"Pharmacy benefit manager Express Scripts Holding CompanyESRX has launched the Diabetes Care Value Program.  As part of the Express Scripts SafeGuardRx suite of pharmacy solutions, this program aims to improve pharmacy care while controlling plan costs"
LLY,LLY:US,BBG000BNBDC2,Jamere Jackson Elected to Lilly Board of Directors,2016-08-31 11:03:07 +0000,http://www.publicnow.com/view/88AA83FCAD47F128D6F035513ABF95BC7FC0D2E8,"[at noodls] - INDIANAPOLIS, Aug. 31, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly's board, ..."
LLY,LLY:US,BBG000BNBDC2,This Pharma Company Is Leading The Race For A Zika Vaccine,2016-08-30 17:30:00 +0000,http://finance.yahoo.com/news/pharma-company-leading-race-zika-173000684.html,This Pharma Company Is Leading The Race For A Zika Vaccine
LLY,LLY:US,BBG000BNBDC2,Is Johnson & Johnson’s Valuation High Compared to Its Peers?,2016-08-30 16:19:06 +0000,http://marketrealist.com/2016/08/johnson-johnsons-valuation-high-compared-peers/?utm_source=yahoo&utm_medium=feed,Is Johnson & Johnson’s Valuation High Compared to Its Peers?
LLY,LLY:US,BBG000BNBDC2,Macrocure Stock Up on Merger Deal with Leap Therapeutics,2016-08-30 14:16:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OtfTTzEXhVk/macrocure-stock-up-on-merger-deal-with-leap-therapeutics-cm672106,"Shares of Macrocure Ltd.MCUR shot up 66.1% after the company announced that it has signed a definitive merger agreement with privately held company, Leap Therapeutics, Inc.  After the completion of the deal, Leap Therapeutics will become"
LLY,LLY:US,BBG000BNBDC2,Why My Favorite Pick In Pharma Today is Eli Lilly and Co (LLY),2016-08-29 22:12:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v0xlDt8Xr7o/why-my-favorite-pick-in-pharma-today-is-eli-lilly-and-co-lly-cm671883,"Big pharma has some great long term drivers, ranging from aging demographics to a growing middle class around the world.   Few products reach"
LLY,LLY:US,BBG000BNBDC2,My Absolute Favorite Pharma Stock Right Now,2016-08-26 17:30:00 +0000,http://finance.yahoo.com/news/favorite-pick-pharma-173000305.html,My Absolute Favorite Pharma Stock Right Now
LLY,LLY:US,BBG000BNBDC2,"ETF’s with exposure to Eli Lilly & Co. : August 26, 2016",2016-08-26 14:34:58 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-eli-lilly-co-august-26-2016/,"ETF’s with exposure to Eli Lilly & Co. : August 26, 2016"
LLY,LLY:US,BBG000BNBDC2,Sell These 5 Stocks Now Before They Turn Toxic,2016-08-26 10:49:00 +0000,https://www.thestreet.com/story/13686338/1/sell-these-5-stocks-now-before-they-turn-toxic.html?puc=yahoo&cm_ven=YAHOO,Sell These 5 Stocks Now Before They Turn Toxic
LLY,LLY:US,BBG000BNBDC2,Notable Two Hundred Day Moving Average Cross - LLY,2016-08-25 21:46:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DGt2z1N9cSQ/notable-two-hundred-day-moving-average-cross-lly-cm670326,"In trading on Thursday, shares of Eli Lilly & Co. (Symbol LLY) crossed below their 200 day moving average of $78.06, changing hands as low as $77.80 per share. Eli Lilly & Co. shares are currently trading off about"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : August 25, 2016",2016-08-25 12:16:05 +0000,http://www.capitalcube.com/blog/index.php/eli-lilly-co-breached-its-50-day-moving-average-in-a-bearish-manner-lly-us-august-25-2016/,"Eli Lilly & Co. breached its 50 day moving average in a Bearish Manner : LLY-US : August 25, 2016"
LLY,LLY:US,BBG000BNBDC2,Tiffany Q2 16 Earnings Conference Call At 8:30 AM ET,2016-08-25 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IkKHPw18u9k/tiffany-q2-16-earnings-conference-call-at-830-am-et-20160825-00240,Tiffany Q2 16 Earnings Conference Call At 8:30 AM ET
LLY,LLY:US,BBG000BNBDC2,Lilly to Participate in Morgan Stanley Global Healthcare Conference,2016-08-24 15:00:00 +0000,http://finance.yahoo.com/news/lilly-participate-morgan-stanley-global-150000802.html,"[PR Newswire] - INDIANAPOLIS, Aug. 24, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016. Jeffrey Simmons, senior vice president ..."
LLY,LLY:US,BBG000BNBDC2,Acrux and Eli Lilly to appeal patent ruling on Axiron,2016-08-24 08:58:03 +0000,http://www.publicnow.com/view/5F407844F618FD878052BA82CDD4823A4D4C0625,"[at noodls] - ACRUX (ACR) - ASX ANNOUNCEMENT 24 AUGUST2016 ACRUX AND ELI LILLY TO APPEAL PATENT RULING ON AXIRON® On 23 August 2016, in the United States (24 August Melbourne AEST), Eli Lilly and Company and Acrux announced ..."
LLY,LLY:US,BBG000BNBDC2,Why AstraZeneca Reported Negative Growth in 2Q16,2016-08-23 21:04:05 +0000,http://marketrealist.com/2016/08/astrazeneca-reported-negative-growth-2q16/?utm_source=yahoo&utm_medium=feed,Why AstraZeneca Reported Negative Growth in 2Q16
LLY,LLY:US,BBG000BNBDC2,"Notable ETF Inflow Detected - VYM, IBM, WMT, LLY",2016-08-23 16:46:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LAeEZLSoyXA/notable-etf-inflow-detected-vym-ibm-wmt-lly-cm669060,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol VYM) where we have detected an approximate $82.4 million dollar"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track",2016-08-23 14:49:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P_1wsqn4mcc/eli-lilly-astrazeneca-alzheimers-drug-gets-fda-fast-track-cm668917,"Eli Lilly and CompanyLLY and AstraZeneca plcAZN gained fast track status in the U.S. for their experimental Alzheimer's disease (AD) treatment, AZD3293.  AZD3293 is a BACE inhibitor that is currently in phase III studies. In addition"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track",2016-08-23 12:59:12 +0000,http://finance.yahoo.com/news/eli-lilly-astrazeneca-alzheimers-drug-125912182.html,"Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track"
LLY,LLY:US,BBG000BNBDC2,Fundstrat's high-yield picks,2016-08-22 21:32:00 +0000,http://finance.yahoo.com/video/fundstrats-high-yield-picks-213200428.html,Fundstrat's high-yield picks
LLY,LLY:US,BBG000BNBDC2,How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16?,2016-08-22 13:06:27 +0000,http://marketrealist.com/2016/08/how-did-bristol-myers-squibbs-oncology-segment-perform-in-2q16/?utm_source=yahoo&utm_medium=feed,How Did Bristol-Myers Squibb’s Oncology Segment Perform in 2Q16?
LLY,LLY:US,BBG000BNBDC2,Can Allergan Generics Boost Teva Pharmaceutical’s 2016 Revenues?,2016-08-22 13:05:23 +0000,http://marketrealist.com/2016/08/acquisition-allergan-generics-business-expected-boost-teva-pharmaceuticals-revenues-2016/?utm_source=yahoo&utm_medium=feed,Can Allergan Generics Boost Teva Pharmaceutical’s 2016 Revenues?
LLY,LLY:US,BBG000BNBDC2,"[$$] Eli Lilly, AstraZeneca Progress With Alzheimer's Drug",2016-08-22 12:33:24 +0000,http://www.wsj.com/articles/eli-lilly-astrazeneca-get-fast-track-status-for-alzheimers-drug-1471866180?mod=yahoo_hs,"[$$] Eli Lilly, AstraZeneca Progress With Alzheimer's Drug"
LLY,LLY:US,BBG000BNBDC2,"Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease",2016-08-22 10:18:08 +0000,http://www.publicnow.com/view/0BC9EF885A26925304842538516633D79852E309,"[at noodls] - INDIANAPOLIS, Aug. 22, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease",2016-08-22 10:00:00 +0000,http://finance.yahoo.com/news/lilly-astrazeneca-receive-fda-fast-100000450.html,"[PR Newswire] - INDIANAPOLIS, Aug. 22, 2016 /PRNewswire/ -- Eli Lilly and Company (LLY) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development program in Alzheimer's disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in phase 3 clinical trials. The FDA's Fast Track program is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Progress With Alzheimer's Drug",2016-08-22 08:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tuUaQMihg6U/eli-lilly-astrazeneca-progress-with-alzheimers-drug-20160822-00296,"Eli Lilly, AstraZeneca Progress With Alzheimer's Drug"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Progress With Alzheimer''s Drug",2016-08-22 08:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/erEC0FN_2e0/eli-lilly-astrazeneca-progress-with-alzheimers-drug-20160822-00295,"Eli Lilly, AstraZeneca Progress With Alzheimer''s Drug"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Get Fast-Track Designation for Alzheimer''s Drug--Update",2016-08-22 07:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zWSuDbO0zUc/eli-lilly-astrazeneca-get-fasttrack-designation-for-alzheimers-drugupdate-20160822-00167,"Eli Lilly, AstraZeneca Get Fast-Track Designation for Alzheimer''s Drug--Update"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Get Fast Track Designation for Alzheimer''s Drug",2016-08-22 07:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bAwRmM2NfWY/eli-lilly-astrazeneca-get-fast-track-designation-for-alzheimers-drug-20160822-00122,"Eli Lilly, AstraZeneca Get Fast Track Designation for Alzheimer''s Drug"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Get Fast Track Designation for Alzheimer's Drug",2016-08-22 07:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uYFbinvCiII/eli-lilly-astrazeneca-get-fast-track-designation-for-alzheimers-drug-20160822-00128,"Eli Lilly, AstraZeneca Get Fast Track Designation for Alzheimer's Drug"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly, AstraZeneca Get Fast Track Designation For AZD3293",2016-08-22 06:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k3-se4STHaY/eli-lilly-astrazeneca-get-fast-track-designation-for-azd3293-20160822-00084,"Eli Lilly, AstraZeneca Get Fast Track Designation For AZD3293"
LLY,LLY:US,BBG000BNBDC2,[$$] Pharmaceuticals: Staying power,2016-08-21 18:20:58 +0000,"http://www.ft.com/cms/s/d7b1c59e-65fb-11e6-a08a-c7ac04ef00aa,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - It was October of last year and the pharmaceuticals industry was firefighting an explosion set off by Martin Shkreli, the enfant terrible of drug making, who sparked an international outcry by raising ..."
LLY,LLY:US,BBG000BNBDC2,[$$] US doctors waste millions on branded medicines,2016-08-21 16:04:14 +0000,"http://www.ft.com/cms/s/e2a44bf6-6647-11e6-a08a-c7ac04ef00aa,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Doctors in the US are wasting hundreds of millions of dollars a year prescribing expensive branded medicines even when cheaper generic alternatives are available, according to an analysis by the Financial ..."
LLY,LLY:US,BBG000BNBDC2,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?,2016-08-19 21:04:13 +0000,http://marketrealist.com/2016/08/how-does-bristol-myers-squibbs-valuation-compare-to-peers/?utm_source=yahoo&utm_medium=feed,How Does Bristol-Myers Squibb’s Valuation Compare to Peers?
LLY,LLY:US,BBG000BNBDC2,"No Pain, Potential for Lots of Gain",2016-08-19 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=765787&SR=Yahoo,"No Pain, Potential for Lots of Gain"
LLY,LLY:US,BBG000BNBDC2,"Thursday 8/18 Insider Buying Report: CF, LLY",2016-08-18 15:46:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qfMKuQCAwOc/thursday-818-insider-buying-report-cf-lly-cm667098,"Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard earned cash to make a"
LLY,LLY:US,BBG000BNBDC2,Better Buy: AbbVie Inc. vs. Eli Lilly & Co.,2016-08-17 21:53:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2wDI5HM59aA/better-buy-abbvie-inc-vs-eli-lilly-co-cm666755,"Image source  Getty Images.  Investors torn between income and growth appreciate Big Pharma stocks because they tend to provide both. Over the past decade, the iShares U.S. Pharmaceuticals ETF  has risen about 216%,"
LLY,LLY:US,BBG000BNBDC2,Better Buy: AbbVie Inc. vs. Eli Lilly & Co.,2016-08-17 19:06:00 +0000,http://www.fool.com/investing/2016/08/17/better-buy-abbvie-inc-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: AbbVie Inc. vs. Eli Lilly & Co.
LLY,LLY:US,BBG000BNBDC2,"Massive Insider Selling at Northrop Grumman (NOC) and Chinese Biotech, While Insider Buying Observed at 3 Other Companies",2016-08-17 15:48:33 +0000,http://www.insidermonkey.com/blog/massive-insider-selling-at-northrop-grumman-noc-and-chinese-biotech-while-insider-buying-observed-at-3-other-companies-469484/,"Massive Insider Selling at Northrop Grumman (NOC) and Chinese Biotech, While Insider Buying Observed at 3 Other Companies"
LLY,LLY:US,BBG000BNBDC2,CELG’s Otezla Continues Dominating US Inflammation and Immunology,2016-08-17 15:04:21 +0000,http://marketrealist.com/2016/08/celgenes-otezla-continues-dominate-inflammation-immunology-segment-u-s/?utm_source=yahoo&utm_medium=feed,CELG’s Otezla Continues Dominating US Inflammation and Immunology
LLY,LLY:US,BBG000BNBDC2,Health sciences and economic leader David Johnson to address INVESTIndiana Equity Conference,2016-08-17 12:30:00 +0000,http://finance.yahoo.com/news/health-sciences-economic-leader-david-123000815.html,"[GlobeNewswire] - INDIANAPOLIS, Aug. 17, 2016-- An Indiana leader who raises millions of dollars of seed money, directs a strategic partnership of CEOs, university presidents and other business VIPs, and is a prominent ..."
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk A/S Focuses on New Drugs,2016-08-16 20:36:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aorj5YHFozo/novo-nordisk-as-focuses-on-new-drugs-cm666167,"Image source  Novo Nordisk.  Novo Nordisk 's(NYSE  NVO) first half earnings weren't horrible, but the company disclosed continued pricing pressure due to competition for its older insulins, requiring the drugmaker to lower"
LLY,LLY:US,BBG000BNBDC2,Novo Nordisk A/S Focuses on New Drugs,2016-08-16 18:30:00 +0000,http://www.fool.com/investing/2016/08/16/novo-nordisk-as-focuses-on-new-drugs.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Novo Nordisk A/S Focuses on New Drugs
LLY,LLY:US,BBG000BNBDC2,Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis,2016-08-15 17:05:26 +0000,http://247wallst.com/healthcare-business/2016/08/15/credit-suisse-issues-top-pharma-picks-in-bullbear-upside-analysis/,Credit Suisse Issues Top Pharma Picks in Bull/Bear Upside Analysis
LLY,LLY:US,BBG000BNBDC2,"VYM, IBM, WMT, LLY: Large Inflows Detected at ETF",2016-08-15 16:37:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4mcNVQgWyt0/vym-ibm-wmt-lly-large-inflows-detected-at-etf-cm665407,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol VYM) where we have detected an approximate $58.5 million dollar"
LLY,LLY:US,BBG000BNBDC2,Epizyme Doses First Patient in Phase II Mesothelioma Study,2016-08-15 15:40:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qzW5HmywnEM/epizyme-doses-first-patient-in-phase-ii-mesothelioma-study-cm665323,"Epizyme, Inc.EPZM announced that it has dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss of function. The study will first evaluate the safety and pharmacokinetic"
LLY,LLY:US,BBG000BNBDC2,Jobs at these 10 companies will literally pay you for life,2016-08-15 13:30:24 +0000,http://qz.com/679808/companies-with-defined-benefit-pension-plans/?utm_source=YPL,Jobs at these 10 companies will literally pay you for life
LLY,LLY:US,BBG000BNBDC2,Epizyme Doses First Patient in Phase II Mesothelioma Study,2016-08-15 13:25:01 +0000,http://finance.yahoo.com/news/epizyme-doses-first-patient-phase-132501505.html,Epizyme Doses First Patient in Phase II Mesothelioma Study
LLY,LLY:US,BBG000BNBDC2,Is Merck’s Valuation Improving?,2016-08-12 21:17:47 +0000,http://marketrealist.com/2016/08/is-mercks-valuation-improving/?utm_source=yahoo&utm_medium=feed,Is Merck’s Valuation Improving?
LLY,LLY:US,BBG000BNBDC2,"Elanco Launches New Video Series Illustrating the Powerful Bond Between Service Dogs, Owners",2016-08-11 11:00:00 +0000,http://finance.yahoo.com/news/elanco-launches-video-series-illustrating-110000128.html,"[PR Newswire] - GREENFIELD, Ind., Aug. 11, 2016 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY) and the makers of Trifexis® (spinosad + milbemycin oxime), today launched its Celebrate the Bond video series that lets viewers share the experience of two individuals embarking on life-changing relationships. The documentary series, which can be viewed at CelebrateTheBond.com, chronicles the growing connection between two Canine Assistants dogs – Spirit and Ringer – and their recipients, Sean and Tim."
LLY,LLY:US,BBG000BNBDC2,PRESS DIGEST - Wall Street Journal - Aug 11,2016-08-11 05:09:29 +0000,http://finance.yahoo.com/news/press-digest-wall-street-journal-050929285.html,[Reuters] - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Federal prosecutors are investigating whether Valeant Pharmaceuticals ...
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly’s Investigational Cancer Drug Hits Snag in Breast Cancer Trial,2016-08-11 04:11:48 +0000,http://www.wsj.com/articles/eli-lillys-investigational-cancer-drug-hits-snag-in-breast-cancer-trial-1470835020?ru=yahoo?mod=yahoo_itp,[$$] Eli Lilly’s Investigational Cancer Drug Hits Snag in Breast Cancer Trial
LLY,LLY:US,BBG000BNBDC2,"Lilly Breast Cancer Drug Study Rolls On, Pushing Back Launch Date",2016-08-10 20:41:49 +0000,http://www.investors.com/news/technology/lilly-breast-cancer-drug-study-goes-on-pushing-back-launch-date/,"Lilly Breast Cancer Drug Study Rolls On, Pushing Back Launch Date"
LLY,LLY:US,BBG000BNBDC2,"Lilly announces Joshua Smiley, Anat Ashkenazi appointed to new roles, Thomas Grein retires",2016-08-10 15:41:03 +0000,http://www.publicnow.com/view/B1019DB377C91497ADAEF196481ECB6026887C61,"[at noodls] - INDIANAPOLIS, Aug. 10, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Joshua Smiley will be appointed to senior vice president, Finance, and treasurer effective October 1. Smiley ..."
LLY,LLY:US,BBG000BNBDC2,The chart that's proving crash-happy stock bears wrong,2016-08-10 14:31:02 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=68BB4A2E-5EB8-11E6-9329-FBF61CB89D67&siteid=yhoof2,The chart that's proving crash-happy stock bears wrong
LLY,LLY:US,BBG000BNBDC2,"Lilly breast cancer drug stumbles, but trial continues",2016-08-10 13:58:27 +0000,http://finance.yahoo.com/news/lilly-cancer-drug-hits-hurdle-115542242.html,"[Reuters] - An independent panel's interim analysis of Eli Lilly and Co's breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial. If approved, abemaciclib is expected to compete with Pfizer Inc's breast cancer drug, Ibrance, which brought in over half a billion dollars in second-quarter sales. The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 11, 2016",2016-08-10 13:29:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l2cGitfSmzU/eli-lilly-and-company-lly-ex-dividend-date-scheduled-for-august-11-2016-cm663161,"Eli Lilly and Company ( LLY ) will begin trading ex dividend on August 11, 2016. A cash dividend payment of $0.51 per share is scheduled to be paid on September 09, 2016. Shareholders who purchased LLY prior to"
LLY,LLY:US,BBG000BNBDC2,[$$] Eli Lilly's Investigational Cancer Drug Hits Snag in Breast Cancer Trial,2016-08-10 13:17:02 +0000,http://www.wsj.com/articles/eli-lillys-investigational-cancer-drug-hits-snag-in-breast-cancer-trial-1470835020?mod=yahoo_hs,[$$] Eli Lilly's Investigational Cancer Drug Hits Snag in Breast Cancer Trial
LLY,LLY:US,BBG000BNBDC2,An Update on Analyst Recommendations for Novo,2016-08-10 13:07:12 +0000,http://marketrealist.com/2016/08/update-analyst-recommendations-novo/?utm_source=yahoo&utm_medium=feed,An Update on Analyst Recommendations for Novo
LLY,LLY:US,BBG000BNBDC2,Lilly Stock Falls as Breast Cancer Drug Fails Efficacy Criteria,2016-08-10 12:15:35 +0000,http://www.bloomberg.com/news/articles/2016-08-10/lilly-falls-after-panel-recommends-breast-cancer-study-continue?cmpid=yhoo.headline,Lilly Stock Falls as Breast Cancer Drug Fails Efficacy Criteria
LLY,LLY:US,BBG000BNBDC2,Watch the $78 Level on Eli Lilly,2016-08-10 12:01:00 +0000,http://realmoney.thestreet.com/articles/08/10/2016/watch-78-level-eli-lilly?puc=yahoo&cm_ven=YAHOO,Watch the $78 Level on Eli Lilly
LLY,LLY:US,BBG000BNBDC2,Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib,2016-08-10 11:40:08 +0000,http://www.publicnow.com/view/5CF3547AC550E91EF76C9EBA498A956E94EAE54B,"[at noodls] - INDIANAPOLIS, Aug. 10, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring Committee (DMC) ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly says late-stage trial of breast cancer treatment failed to meet goals,2016-08-10 11:30:31 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=40F25B64-B8AE-45CD-BE6B-8E87EF9EFFE0&siteid=yhoof2,Eli Lilly says late-stage trial of breast cancer treatment failed to meet goals
LLY,LLY:US,BBG000BNBDC2,Panel recommends Lilly continue breast cancer drug study,2016-08-10 11:06:59 +0000,http://finance.yahoo.com/news/panel-recommends-lilly-continue-breast-110659924.html,"[Reuters] - Eli Lilly and Co said an interim analysis of a late-stage study testing its breast cancer drug abemaciclib by an independent panel showed the treatment did not meet the effectiveness criteria and recommended that the company continue the trial. The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly''s Investigational Cancer Drug Hits Snag in Breast Cancer Trial,2016-08-10 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6dYZX_5FADA/eli-lillys-investigational-cancer-drug-hits-snag-in-breast-cancer-trial-20160810-00569,Eli Lilly''s Investigational Cancer Drug Hits Snag in Breast Cancer Trial
LLY,LLY:US,BBG000BNBDC2,Lilly Updates On MONARCH 2 Phase 3 Trial Of Abemaciclib,2016-08-10 06:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-sd4dI5NVg/lilly-updates-on-monarch-2-phase-3-trial-of-abemaciclib-20160810-00162,Lilly Updates On MONARCH 2 Phase 3 Trial Of Abemaciclib
LLY,LLY:US,BBG000BNBDC2,Why Is Pfizer’s Valuation Low Compared to Its Peers?,2016-08-10 02:28:15 +0000,http://marketrealist.com/2016/08/why-is-pfizers-valuation-low-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Why Is Pfizer’s Valuation Low Compared to Its Peers?
LLY,LLY:US,BBG000BNBDC2,See Which Of The Latest 13F Filers Holds Eli Lilly & Co.,2016-08-09 17:32:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NUIq8nu1ZyM/see-which-of-the-latest-13f-filers-holds-eli-lilly-co-cm662610,"At Holdings Channel , we have reviewed the latest batch of the 24 most recent 13F filings for the 06 30 2016 reporting period, and noticed that Eli Lilly & Co. (Symbol LLY) was held by 10 of these"
LLY,LLY:US,BBG000BNBDC2,Will Eli Lilly’s Valuation Multiple Follow the Industry Trend?,2016-08-09 13:04:10 +0000,http://marketrealist.com/2016/07/will-eli-lillys-valuation-multiple-follow-the-industry-trend/?utm_source=yahoo&utm_medium=feed,Will Eli Lilly’s Valuation Multiple Follow the Industry Trend?
LLY,LLY:US,BBG000BNBDC2,Analyzing Future Estimates for Eli Lilly,2016-08-08 15:04:46 +0000,http://marketrealist.com/2016/07/analyzing-future-estimates-for-eli-lilly/?utm_source=yahoo&utm_medium=feed,Analyzing Future Estimates for Eli Lilly
LLY,LLY:US,BBG000BNBDC2,This Long-Term Cardiovascular Study Could Revolutionize the Treatment of Type 2 Diabetes,2016-08-07 04:16:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7D3K0-s8nWI/this-long-term-cardiovascular-study-could-revolutionize-the-treatment-of-type-2-diabetes-cm661486,"Image source  Getty Images.  It may not incite the same amount of fear as cancer, but diabetes is a growing problem within the United States. According to the 2014 National Diabetes Statistics Report"
LLY,LLY:US,BBG000BNBDC2,"Bristol-Myers Tanks, Buy These Two Large Cap Pharma Stocks Instead",2016-08-05 21:16:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sISeDf1_sJo/bristol-myers-tanks-buy-these-two-large-cap-pharma-stocks-instead-cm661330,Several large cap pharmaceutical stocks are making waves on Friday as shares of Bristol Myers Squibb BMY tanked more than 17% following the news that its cancer drug failed to meet targets in a late stage study. Bristol Myers
LLY,LLY:US,BBG000BNBDC2,"Notable ETF Inflow Detected - VYM, LLY, OXY, COP",2016-08-05 15:57:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fXiexByHbpI/notable-etf-inflow-detected-vym-lly-oxy-cop-cm661206,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol VYM) where we have detected an approximate $81.8 million dollar"
LLY,LLY:US,BBG000BNBDC2,Better Buy: Merck & Co. Inc. vs. Eli Lilly,2016-08-04 16:56:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vKpHWU1smYY/better-buy-merck-co-inc-vs-eli-lilly-cm660466,"Image source  Getty Images.  Over the past decade, the iShares U.S. Pharmaceuticals ETF has risen a stunning 211%, trouncing the broad market S&P 500 benchmark's gain of about 70% over the same period."
LLY,LLY:US,BBG000BNBDC2,Pharma ETFs Soaring on Solid Q2 Earnings,2016-08-03 18:53:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VE_98viaUrM/pharma-etfs-soaring-on-solid-q2-earnings-cm659847,"Like the past several quarters, the healthcare sector has impressed with strong Q2 earnings. This is especially true as total earnings for 71.9% of the sector's total market capitalization are up 5.4% on revenue growth of 10.5%. Earnings and"
LLY,LLY:US,BBG000BNBDC2,CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies,2016-08-02 19:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/veVrvXp-qXM/cvs-drops-coverage-of-2-branded-biotech-drugs-in-favor-of-copies-20160802-01620,CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies
LLY,LLY:US,BBG000BNBDC2,"Pfizer (PFE) Tops on Q2 Earnings, Revenues, Maintains View",2016-08-02 15:00:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B70Y5krz8cE/pfizer-pfe-tops-on-q2-earnings-revenues-maintains-view-cm658705,"Pfizer Inc.'sPFE second quarter earnings per share came in at 64 cents, a couple of cents above the Zacks Consensus Estimate and 14% above the year ago earnings. Pfizer Inc. (PFE) Street Actual & Estimate EPS Last 5 Quarters"
LLY,LLY:US,BBG000BNBDC2,"CVS Raises Earnings Outlook, Aided by Pharmacy Benefit Business",2016-08-02 08:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zS6HWH5w_is/cvs-raises-earnings-outlook-aided-by-pharmacy-benefit-business-20160802-01067,"CVS Raises Earnings Outlook, Aided by Pharmacy Benefit Business"
LLY,LLY:US,BBG000BNBDC2,CVS Misses Sales Expectations as Pharmacy Business Softens,2016-08-02 08:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k1cMkXmV5gY/cvs-misses-sales-expectations-as-pharmacy-business-softens-20160802-00524,CVS Misses Sales Expectations as Pharmacy Business Softens
LLY,LLY:US,BBG000BNBDC2,Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?,2016-08-02 00:52:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jF_XHcmbOiI/merrimack-mack-can-the-stock-surprise-in-q2-earnings-cm658488,"Merrimack Pharmaceuticals, Inc.MACK is scheduled to report second quarter 2016 results on Aug 4. Last quarter, Merrimack delivered an earnings surprise of +15.38%. Let's see how things are shaping up for the company this quarter.Factors Influencing This Quarter Merrimack's"
LLY,LLY:US,BBG000BNBDC2,"Top 7 Research Reports for July 29, 2016",2016-07-29 21:28:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7AQkCqiKi8M/top-7-research-reports-for-july-29-2016-cm657576,"Friday, July 29, 2016 Today's must read reports are for Amgen (AMGN), JPMorgan (JPM) and Mondelez (MDLZ). Zacks Rank # 2 (Buy) rated Amgen 's strong Q2 earnings report earlier this week it beat on the top and bottom"
LLY,LLY:US,BBG000BNBDC2,Merck (MRK) Updates Outlook Following Q2 Earnings Beat,2016-07-29 16:33:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-sXe5HTqVYY/merck-mrk-updates-outlook-following-q2-earnings-beat-cm657333,"Merck & Co.MRK  reported second quarter 2016 earnings of 93 cents per share, surpassing the Zacks Consensus Estimate by a penny and increasing 8.1% from the year ago period. Merck & Company Inc. (MRK) Street Actual & Estimate EPS"
LLY,LLY:US,BBG000BNBDC2,"AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View",2016-07-29 16:32:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XfVUMPrlTyg/abbvie-abbv-beats-on-2q-earnings-revenues-ups-view-cm657292,"AbbVie Inc.ABBV reported second quarter 2016 earnings of $1.26 per share, up 16.7% from the year ago quarter and surpassing the Zacks Consensus Estimate of $1.20 per share Abbvie Inc. (ABBV) Street Actual & Estimate EPS Last 5 Quarters"
LLY,LLY:US,BBG000BNBDC2,"Noteworthy ETF Inflows: VYM, LLY, OXY, COP",2016-07-28 17:21:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HsnuAfQW4UI/noteworthy-etf-inflows-vym-lly-oxy-cop-cm656558,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard High Dividend Yield ETF (Symbol VYM) where we have detected an approximate $97.7 million dollar"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO to Retire As New Drugs Take Off -- WSJ,2016-07-28 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cyCD17kUDK4/eli-lilly-ceo-to-retire-as-new-drugs-take-off--wsj-20160728-00090,Eli Lilly CEO to Retire As New Drugs Take Off -- WSJ
LLY,LLY:US,BBG000BNBDC2,Business Highlights,2016-07-27 22:34:04 +0000,http://sg.finance.yahoo.com/news/business-highlights-223404459.html,Business Highlights
LLY,LLY:US,BBG000BNBDC2,Long-time Lilly CEO Lechleiter to retire in December,2016-07-27 15:30:58 +0000,http://sg.finance.yahoo.com/news/long-time-lilly-ceo-lechleiter-115633777.html,Long-time Lilly CEO Lechleiter to retire in December
LLY,LLY:US,BBG000BNBDC2,Lilly Holds Press Conference to Detail Leadership Changes,2016-07-27 12:08:05 +0000,http://www.publicnow.com/view/C9BD5EBE6B0C63833AA78543F99554D872CC3D38,"[at noodls] - Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective December ..."
LLY,LLY:US,BBG000BNBDC2,John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor,2016-07-27 12:08:05 +0000,http://www.publicnow.com/view/7F02F1CEAC0FF69A7F15D1FA321A767EC17493E9,"[at noodls] - INDIANAPOLIS, July 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and ..."
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly CEO John Lechleiter to Retire, David Ricks to Replace Him -- Update",2016-07-27 11:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xA6I0IT9hjE/eli-lilly-ceo-john-lechleiter-to-retire-david-ricks-to-replace-him--update-20160727-00877,"Eli Lilly CEO John Lechleiter to Retire, David Ricks to Replace Him -- Update"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO to Retire,2016-07-27 08:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bDqDh-PIc1c/eli-lilly-ceo-to-retire-20160727-00526,Eli Lilly CEO to Retire
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly CEO Lechleiter to Retire, Ricks to Replace Him",2016-07-27 08:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o5MDcAUCpR0/eli-lilly-ceo-lechleiter-to-retire-ricks-to-replace-him-20160727-00516,"Eli Lilly CEO Lechleiter to Retire, Ricks to Replace Him"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly CEO John Lechleiter To Retire; David Ricks To Succeed - Quick Facts,2016-07-27 06:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pwwYZntIFlw/eli-lilly-ceo-john-lechleiter-to-retire-david-ricks-to-succeed--quick-facts-20160727-00254,Eli Lilly CEO John Lechleiter To Retire; David Ricks To Succeed - Quick Facts
LLY,LLY:US,BBG000BNBDC2,Lilly beats Street 2Q forecasts,2016-07-26 11:10:51 +0000,http://sg.finance.yahoo.com/news/lilly-beats-street-2q-forecasts-103331765.html,Lilly beats Street 2Q forecasts
LLY,LLY:US,BBG000BNBDC2,"Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through the Remainder of the Decade",2016-07-26 11:08:04 +0000,http://www.publicnow.com/view/B5B183CE840B5DDC17345725A15F92B3D04C8DBA,"[at noodls] - INDIANAPOLIS, July 26, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2016. ... This is an abstract of the original noodl. To continue ..."
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Q2 16 Earnings Conference Call At 9:00 AM ET,2016-07-26 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OFVT1EOKMqQ/eli-lilly-and-co-q2-16-earnings-conference-call-at-900-am-et-20160726-00149,Eli Lilly And Co. Q2 16 Earnings Conference Call At 9:00 AM ET
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Revenue Rise Helped by New Products,2016-07-26 07:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hqV6boS00cA/eli-lilly-revenue-rise-helped-by-new-products-20160726-00345,Eli Lilly Revenue Rise Helped by New Products
LLY,LLY:US,BBG000BNBDC2,Eli Lilly Revenue Helped by Sales of New Drugs,2016-07-26 07:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hVzfijnI-9E/eli-lilly-revenue-helped-by-sales-of-new-drugs-20160726-00337,Eli Lilly Revenue Helped by Sales of New Drugs
LLY,LLY:US,BBG000BNBDC2,Eli Lilly And Co. Reports 5% Drop In Q2 Bottom Line,2016-07-26 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XsOYNEYlko8/eli-lilly-and-co-reports-5-drop-in-q2-bottom-line-20160726-00151,Eli Lilly And Co. Reports 5% Drop In Q2 Bottom Line
LLY,LLY:US,BBG000BNBDC2,Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer,2016-07-13 12:33:03 +0000,http://www.publicnow.com/view/0C76EE90F1A4E800A2A6506FF491816338E4CC14,"[at noodls] - INDIANAPOLIS, July 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability ..."
LLY,LLY:US,BBG000BNBDC2,"Lilly, Boehringer Ingelheim Collaborate On Metastatic Breast Cancer Trial",2016-07-13 08:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8I2D34kOebU/lilly-boehringer-ingelheim-collaborate-on-metastatic-breast-cancer-trial-20160713-00323,"Lilly, Boehringer Ingelheim Collaborate On Metastatic Breast Cancer Trial"
LLY,LLY:US,BBG000BNBDC2,"Lilly, Boehringer Ingelheim Collaborate On Metastatic Breast Cancer Trial",2016-07-13 08:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yHcRlEiu0so/lilly-boehringer-ingelheim-collaborate-on-metastatic-breast-cancer-trial-20160713-00322,"Lilly, Boehringer Ingelheim Collaborate On Metastatic Breast Cancer Trial"
LLY,LLY:US,BBG000BNBDC2,Lilly and Howard University partner on summer Medical Scientific Fellowship,2016-07-12 13:53:01 +0000,http://www.publicnow.com/view/1D778A58D293434BBE78BCB99560580E4993A861,"[at noodls] - INDIANAPOLIS, July 12, 2016 /PRNewswire/ -- Lilly USA, LLC will partner with Howard University this summer on an inaugural Minority Fellowship program for post-graduate minority professionals embarking ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Diabetes Welcomes Acclaimed Singer/Songwriter Crystal Bowersox as Newest Spokesperson,2016-07-06 11:51:09 +0000,http://www.publicnow.com/view/4AC869847ACD66620CDF528E2F8B04A553D0F995,"[at noodls] - INDIANAPOLIS, July 6, 2016 /PRNewswire/ -- Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. Diagnosed with type 1 diabetes at ..."
LLY,LLY:US,BBG000BNBDC2,FDA Advisory Committee recommends approval of Jardiance® (empagliflozin) for cardiovascular indication in 12-11 vote,2016-06-28 23:11:25 +0000,http://www.publicnow.com/view/8DD6AFF0CD712245D59A0FB156C90FE9632495F3,"[at noodls] - RIDGEFIELD, Conn. and INDIANAPOLIS, June 28, 2016 /PRNewswire/ -- A U.S. Food and Drug Administration (FDA) Advisory Committee today voted 12-11 that substantial evidence exists to establish that Jardiance ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Confirms Date And Conference Call For Second-Quarter 2016 Financial Results Announcement,2016-06-28 18:41:01 +0000,http://www.publicnow.com/view/7650C08FAD3402EE07232EC4FB3037CE0CFF52EB,"[at noodls] - INDIANAPOLIS, June 28, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2016 on Tuesday, July 26, 2016. Lilly will also conduct a conference ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Convenes Leaders at National Mayor's Conference to Address Impact of Alzheimer's Disease on Local Communities,2016-06-27 19:21:05 +0000,http://www.publicnow.com/view/0DAC1B80FAD913B352F1579C2196628CD7355986,"[at noodls] - INDIANAPOLIS, June 27, 2016 /PRNewswire/ -- With the prevalence of Alzheimer's disease expected to triple by 2050, there is an urgent need for greater awareness of the economic and social impact of the ..."
LLY,LLY:US,BBG000BNBDC2,U.S. FDA panel to vote whether diabetes drug cuts cardiac death,2016-06-24 12:32:21 +0000,http://uk.finance.yahoo.com/news/u-fda-panel-vote-whether-123221581.html,U.S. FDA panel to vote whether diabetes drug cuts cardiac death
LLY,LLY:US,BBG000BNBDC2,Diabetes Scholars Foundation Announces 2016 Scholarship Recipients,2016-06-23 14:39:04 +0000,http://www.publicnow.com/view/510FC79FD2D93F984BD3C6B49919F740AFD8CCA4,"[at noodls] - PARK RIDGE, Ill. and INDIANAPOLIS, June 23, 2016 /PRNewswire/ -- If the caliber of students receiving a Lilly Diabetes Tomorrow's Leaders Scholarship is any indication, the future is in good hands. The ..."
LLY,LLY:US,BBG000BNBDC2,Q2 Solutions Receives 2016 Global Supplier Award from Eli Lilly and Company,2016-06-23 10:59:01 +0000,http://www.publicnow.com/view/B9AA50497E41FDFF3C343D86024A6C7048909483,"[at noodls] - http://www.businesswire.com/news/home/20160623005091/en/ Each year, the Lilly Global Supplier Award recognizes suppliers who have worked collaboratively to deliver a positive and measurable impact on Lilly's ..."
LLY,LLY:US,BBG000BNBDC2,MacroStat Receives 2016 Lilly Global Supplier Award,2016-06-22 15:51:00 +0000,http://au.finance.yahoo.com/news/macrostat-receives-2016-lilly-global-155100547.html,"[Business Wire] - SHANGHAI--(BUSINESSWIRE)-- MacroStat, a leading biometrics CRO fully owned by Tigermed (ChiNext SZ: 300347), has received the 2016 Lilly Global Supplier Award that recognizes MacroStat’s outstanding performance ..."
LLY,LLY:US,BBG000BNBDC2,Lilly Declares Third-Quarter 2016 Dividend,2016-06-20 17:59:06 +0000,http://www.publicnow.com/view/889A16FD2A4CC95BE016B214A14A393D062A0D50,"[at noodls] - INDIANAPOLIS, June 20, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2016 of $0.51 per share on outstanding common stock. ..."
LLY,LLY:US,BBG000BNBDC2,German Supreme Court Grants Lilly Appeal in Alimta® Vitamin Regimen Patent Lawsuit,2016-06-14 22:59:01 +0000,http://www.publicnow.com/view/D5CC4C22C7C245FE8325B8EB2EC6C5FE294F4D08,"[at noodls] - INDIANAPOLIS, June 14, 2016 /PRNewswire/ -- The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (NYSE: LLY) in the case of Eli Lilly and Company v. Actavis, vacating the prior ..."
LLY,LLY:US,BBG000BNBDC2,Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease,2016-06-14 15:05:00 +0000,http://au.finance.yahoo.com/news/jardiance-empagliflozin-significantly-reduced-risk-150500724.html,"[Business Wire] - INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESSWIRE)-- New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in people with type 2 diabetes with established cardiovascular disease. Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY - News) announced today that the findings have been published in The New England Journal of Medicine and also presented at the American Diabetes Association (ADA) 76th Scientific Sessions® in New Orleans. “These findings are clinically important, given that one in two people with type 2 diabetes worldwide will develop kidney disease, which can lead to kidney failure and eventually the need for dialysis,” said Prof. Christoph Wanner, Chief of the Division of Nephrology and Hypertension at the University Hospital of Würzburg, Germany."
LLY,LLY:US,BBG000BNBDC2,Aarti Shah named chief information officer,2016-06-13 18:19:05 +0000,http://www.publicnow.com/view/006067285B61DA0EBF13B44D8418AEAA36F92335,"[at noodls] - INDIANAPOLIS, June 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the promotion of Aarti Shah, Ph.D., to senior vice president and chief information officer effective July 1. ..."
LLY,LLY:US,BBG000BNBDC2,New Data Show Lilly's Once-Weekly Trulicity® (dulaglutide) in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes,2016-06-12 20:09:06 +0000,http://www.publicnow.com/view/2F59BE13A3F7E12C957C10D5E37C6E3AB6244C25,"[at noodls] - INDIANAPOLIS, June 12, 2016 /PRNewswire/ -- New data from a completed Phase 3 trial show Trulicity (dulaglutide) 1.5 mg significantly reduced hemoglobin A1c (A1C) and body weight as an add-on to insulin ..."
LLY,LLY:US,BBG000BNBDC2,New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes,2016-06-12 18:09:06 +0000,http://www.publicnow.com/view/0FBC76134D91C0B466BA9F385F449D139C949075,"[at noodls] - RIDGEFIELD, Conn. and INDIANAPOLIS, June 12, 2016 /PRNewswire/ -- New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® ..."
LLY,LLY:US,BBG000BNBDC2,Lilly misses Street 1Q forecasts,2016-04-26 10:35:34 +0000,http://sg.finance.yahoo.com/news/lilly-misses-street-1q-forecasts-103534822.html,Lilly misses Street 1Q forecasts
LLY,LLY:US,BBG000BNBDC2,Eli Lilly to widen its drug portfolio,2016-04-12 09:48:05 +0000,http://in.finance.yahoo.com/news/eli-lilly-widen-drug-portfolio-094805892.html,Eli Lilly to widen its drug portfolio
LLY,LLY:US,BBG000BNBDC2,"Asian markets mixed ahead of Fed decision, China meeting",2016-03-16 03:33:17 +0000,http://sg.finance.yahoo.com/news/us-stocks-fall-early-energy-141847606.html,"Asian markets mixed ahead of Fed decision, China meeting"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly changes outcome goals in Alzheimer's drug study,2016-03-15 21:16:27 +0000,http://sg.finance.yahoo.com/news/eli-lilly-changes-outcome-goals-203544899.html,Eli Lilly changes outcome goals in Alzheimer's drug study
LLY,LLY:US,BBG000BNBDC2,Eli Lilly loses latest round in UK drug patent battle,2016-02-12 13:30:04 +0000,http://sg.finance.yahoo.com/news/eli-lilly-loses-latest-round-133004507.html,Eli Lilly loses latest round in UK drug patent battle
LLY,LLY:US,BBG000BNBDC2,Indiana culture war over gay rights worries business leaders,2016-02-04 00:27:24 +0000,http://sg.finance.yahoo.com/news/indiana-culture-war-over-gay-231019044.html,Indiana culture war over gay rights worries business leaders
LLY,LLY:US,BBG000BNBDC2,Indiana business fears fallout from gay rights failure,2016-02-03 08:02:55 +0000,http://sg.finance.yahoo.com/news/indiana-business-fears-fallout-gay-074752065.html,Indiana business fears fallout from gay rights failure
LLY,LLY:US,BBG000BNBDC2,Lilly tops Street 4Q forecasts,2016-01-28 11:33:30 +0000,http://sg.finance.yahoo.com/news/lilly-tops-street-4q-forecasts-113931242.html,Lilly tops Street 4Q forecasts
LLY,LLY:US,BBG000BNBDC2,Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®▼ (empagliflozin) as an option for patients with type 2 diabetes in Wales,2016-01-12 11:40:00 +0000,http://uk.finance.yahoo.com/news/type-2-diabetes-wales-medicines-114000211.html,Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®▼ (empagliflozin) as an option for patients with type 2 diabetes in Wales
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly's diabetes pill takes market share from J&J, Astra",2016-01-05 23:37:48 +0000,http://in.finance.yahoo.com/news/eli-lillys-diabetes-pill-takes-233748572.html,"Eli Lilly's diabetes pill takes market share from J&J, Astra"
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly's diabetes pill takes market share from J&J, Astra",2016-01-05 23:37:48 +0000,http://sg.finance.yahoo.com/news/eli-lillys-diabetes-pill-takes-233748736.html,"Eli Lilly's diabetes pill takes market share from J&J, Astra"
LLY,LLY:US,BBG000BNBDC2,Drugmaker Lilly's 2016 forecast misses Street expectations,2016-01-05 19:53:34 +0000,http://sg.finance.yahoo.com/news/drugmaker-lillys-2016-forecast-misses-130447032.html,Drugmaker Lilly's 2016 forecast misses Street expectations
LLY,LLY:US,BBG000BNBDC2,"Europe recommends lung cancer drugs from AstraZeneca, Lilly",2015-12-18 12:48:51 +0000,http://sg.finance.yahoo.com/news/europe-recommends-lung-cancer-drugs-124851900.html,"Europe recommends lung cancer drugs from AstraZeneca, Lilly"
LLY,LLY:US,BBG000BNBDC2,FDA approves cheaper version of top-selling diabetes drug,2015-12-16 23:18:52 +0000,http://sg.finance.yahoo.com/news/fda-approves-cheaper-version-top-215708596.html,FDA approves cheaper version of top-selling diabetes drug
LLY,LLY:US,BBG000BNBDC2,Sanofi plans to reshape via $20 billion asset swap with Boehringer,2015-12-15 15:41:03 +0000,http://sg.finance.yahoo.com/news/sanofi-boehringer-talks-swap-assets-080402710.html,Sanofi plans to reshape via $20 billion asset swap with Boehringer
LLY,LLY:US,BBG000BNBDC2,"Merck, Eli Lilly probed on drug pricing",2015-11-06 20:22:50 +0000,http://uk.finance.yahoo.com/news/merck-eli-lilly-probed-drug-202250746.html,"Merck, Eli Lilly probed on drug pricing"
LLY,LLY:US,BBG000BNBDC2,Lilly plans $70M research facility expansion in Indianapolis,2015-11-02 15:05:52 +0000,http://sg.finance.yahoo.com/news/lilly-plans-70m-research-facility-150552586.html,Lilly plans $70M research facility expansion in Indianapolis
LLY,LLY:US,BBG000BNBDC2,Sanofi sees possible $109 mln hit from injector recall,2015-10-29 08:03:00 +0000,http://sg.finance.yahoo.com/news/sanofi-sees-possible-109-mln-071940276.html,Sanofi sees possible $109 mln hit from injector recall
LLY,LLY:US,BBG000BNBDC2,Pearson names pharma executive Sidney Taurel as new chairman,2015-10-26 12:27:30 +0000,http://sg.finance.yahoo.com/news/pearson-names-pharma-executive-sidney-122730894.html,Pearson names pharma executive Sidney Taurel as new chairman
LLY,LLY:US,BBG000BNBDC2,Pearson names pharma exec Sidney Taurel as new chairman,2015-10-26 12:20:14 +0000,http://uk.finance.yahoo.com/news/pearson-names-pharma-exec-sidney-122014434.html,Pearson names pharma exec Sidney Taurel as new chairman
LLY,LLY:US,BBG000BNBDC2,Lilly beats 3Q profit forecasts,2015-10-22 10:33:37 +0000,http://sg.finance.yahoo.com/news/lilly-beats-3q-profit-forecasts-103337507.html,Lilly beats 3Q profit forecasts
LLY,LLY:US,BBG000BNBDC2,"AstraZeneca, Lilly to deepen collaboration on cancer immunotherapy",2015-10-22 06:36:36 +0000,http://sg.finance.yahoo.com/news/astrazeneca-lilly-deepen-collaboration-cancer-063636155.html,"AstraZeneca, Lilly to deepen collaboration on cancer immunotherapy"
LLY,LLY:US,BBG000BNBDC2,"AstraZeneca, Lilly to deepen collaboration on cancer immunotherapy",2015-10-22 06:33:21 +0000,http://uk.finance.yahoo.com/news/astrazeneca-lilly-deepen-collaboration-cancer-063321248.html,"AstraZeneca, Lilly to deepen collaboration on cancer immunotherapy"
LLY,LLY:US,BBG000BNBDC2,AstraZeneca diabetes drug combination faces delay after FDA rebuff,2015-10-16 10:12:29 +0000,http://sg.finance.yahoo.com/news/fda-declines-approval-astrazeneca-diabetes-062759040.html,AstraZeneca diabetes drug combination faces delay after FDA rebuff
LLY,LLY:US,BBG000BNBDC2,J&J says its diabetes drug should have same survival edge as Lilly's,2015-10-13 15:42:09 +0000,http://uk.finance.yahoo.com/news/j-j-says-diabetes-drug-154209869.html,J&J says its diabetes drug should have same survival edge as Lilly's
LLY,LLY:US,BBG000BNBDC2,J&J says Jardiance survival benefit likely to be seen by Invokana,2015-10-13 14:32:05 +0000,http://sg.finance.yahoo.com/news/j-j-says-jardiance-survival-143205758.html,J&J says Jardiance survival benefit likely to be seen by Invokana
LLY,LLY:US,BBG000BNBDC2,Eli Lilly halts phase III evacetrapib heart drug trials,2015-10-12 13:41:00 +0000,http://uk.finance.yahoo.com/news/eli-lilly-halts-phase-iii-134100597.html,Eli Lilly halts phase III evacetrapib heart drug trials
LLY,LLY:US,BBG000BNBDC2,EXCLUSIVE-US insurers hold back Lilly's death-defying diabetes drug,2015-10-02 15:19:15 +0000,http://uk.finance.yahoo.com/news/exclusive-us-insurers-hold-back-151915568.html,EXCLUSIVE-US insurers hold back Lilly's death-defying diabetes drug
LLY,LLY:US,BBG000BNBDC2,Lilly diabetes drug slashes deaths in patients with heart risk,2015-09-17 22:20:20 +0000,http://uk.finance.yahoo.com/news/lilly-diabetes-drug-slashes-deaths-214300932.html,Lilly diabetes drug slashes deaths in patients with heart risk
LLY,LLY:US,BBG000BNBDC2,BUZZ-Lilly shares add to gains after diabetes drug finding,2015-09-17 17:12:57 +0000,http://uk.finance.yahoo.com/news/buzz-lilly-shares-add-gains-171257908.html,BUZZ-Lilly shares add to gains after diabetes drug finding
LLY,LLY:US,BBG000BNBDC2,New data demonstrates Jardiance®▼ (empagliflozin) showed a significant reduction in cardiovascular risk in diabetes patients in a dedicated outcome trial,2015-09-17 15:50:00 +0000,http://uk.finance.yahoo.com/news/data-demonstrates-jardiance-empagliflozin-showed-155000336.html,New data demonstrates Jardiance®▼ (empagliflozin) showed a significant reduction in cardiovascular risk in diabetes patients in a dedicated outcome trial
LLY,LLY:US,BBG000BNBDC2,"Eli Lilly wins UK Alimta drug patent case on appeal, shares jump",2015-06-25 15:37:40 +0000,http://uk.finance.yahoo.com/news/eli-lilly-wins-uk-alimta-153740973.html,"Eli Lilly wins UK Alimta drug patent case on appeal, shares jump"
LLY,LLY:US,BBG000BNBDC2,US STOCKS-Wall St falls as Greece crisis unresolved; energy shares dip,2015-06-12 20:30:02 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-falls-203002394.html,US STOCKS-Wall St falls as Greece crisis unresolved; energy shares dip
LLY,LLY:US,BBG000BNBDC2,AstraZeneca and Lilly to test new cancer drug combination,2015-05-29 06:39:51 +0000,http://uk.finance.yahoo.com/news/astrazeneca-lilly-test-cancer-drug-063951225.html,AstraZeneca and Lilly to test new cancer drug combination
LLY,LLY:US,BBG000BNBDC2,U.S. FDA warns on newer class of type 2 diabetes drugs,2015-05-15 20:53:46 +0000,http://uk.finance.yahoo.com/news/u-fda-warns-newer-class-152209270.html,U.S. FDA warns on newer class of type 2 diabetes drugs
LLY,LLY:US,BBG000BNBDC2,Takeda warns of loss after $2.4 bn diabetes drug settlements,2015-04-29 04:28:22 +0000,http://uk.finance.yahoo.com/news/takeda-warns-loss-2-4-042822526.html,Takeda warns of loss after $2.4 bn diabetes drug settlements
LLY,LLY:US,BBG000BNBDC2,Takeda agrees $2.4 bn settlement for diabetes drug suits,2015-04-28 22:50:19 +0000,http://uk.finance.yahoo.com/news/takeda-agrees-2-4-bn-225019999.html,Takeda agrees $2.4 bn settlement for diabetes drug suits
LLY,LLY:US,BBG000BNBDC2,"AstraZeneca science is on the move, one year on from Pfizer bid",2015-04-15 13:29:58 +0000,http://uk.finance.yahoo.com/news/astrazeneca-science-move-one-pfizer-132958093.html,"AstraZeneca science is on the move, one year on from Pfizer bid"
LLY,LLY:US,BBG000BNBDC2,EU MEDICINES AGENCY SAYS RECOMMENDS APPROVAL OF MERCK'S GARDASIL 9 VACCINE,2015-03-27 12:13:27 +0000,http://uk.finance.yahoo.com/news/eu-medicines-agency-says-recommends-121327139.html,EU MEDICINES AGENCY SAYS RECOMMENDS APPROVAL OF MERCK'S GARDASIL 9 VACCINE
LLY,LLY:US,BBG000BNBDC2,"Exclusive - Biogen shortens name, expands ambitions in Alzheimer's, ALS",2015-03-23 05:04:17 +0000,http://sg.finance.yahoo.com/news/exclusive-biogen-shortens-name-expands-050417968.html,"Exclusive - Biogen shortens name, expands ambitions in Alzheimer's, ALS"
LLY,LLY:US,BBG000BNBDC2,Eli Lilly loses Alimta drug patent case in Germany to Actavis,2015-03-06 14:23:58 +0000,http://uk.finance.yahoo.com/news/eli-lilly-loses-alimta-drug-142358450.html,Eli Lilly loses Alimta drug patent case in Germany to Actavis
LLY,LLY:US,BBG000BNBDC2,Drugmaker Lilly cuts revenue forecast as dollar strengthens,2015-01-30 12:54:19 +0000,http://sg.finance.yahoo.com/news/drugmaker-lilly-cuts-revenue-forecast-125419243.html,Drugmaker Lilly cuts revenue forecast as dollar strengthens
LLY,LLY:US,BBG000BNBDC2,Lilly must divest Sentinel products after FTC nod on Novartis deal,2014-12-22 16:57:21 +0000,http://sg.finance.yahoo.com/news/lilly-must-divest-sentinel-products-165721511.html,Lilly must divest Sentinel products after FTC nod on Novartis deal
LLY,LLY:US,BBG000BNBDC2,Novartis results top forecasts as new products gain momentum,2014-10-28 09:06:48 +0000,http://sg.finance.yahoo.com/news/novartis-third-quarter-results-beat-062250329.html,Novartis results top forecasts as new products gain momentum
LLY,LLY:US,BBG000BNBDC2,AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug,2014-09-16 07:23:35 +0000,http://sg.finance.yahoo.com/news/astrazeneca-gets-500-million-lilly-072335297.html,AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug
